



Effective Health Care Program

Comparative Effectiveness Review
Number 27

Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

This report is based on research conducted by the Johns Hopkins University Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0018). The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products or actions may not be stated or implied.

Comparative Effectiveness Review

Number 27

Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update

Update of Comparative Effectiveness Review No. 8, *Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes, Including New Drug Classes and Two-Drug Combinations*

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-02-0018

Prepared by:

Johns Hopkins University Evidence-based Practice Center
Baltimore, MD

Investigators:

Wendy L. Bennett, M.D., M.P.H.
Lisa M. Wilson, Sc.M.
Shari Bolen, M.D., M.P.H.
Nisa Maruthur, M.D.
Sonal Singh, M.D.
Ranee Chatterjee, M.D., M.P.H.
Spyridon S. Marinopoulos, M.D., M.B.A.
Milo A. Puhan, M.D., Ph.D.
Padmini Ranasinghe, M.D., M.P.H.
Wanda K. Nicholson, M.D., M.P.H.
Lauren Block, M.D.
Olaide Odelola, M.B.B.S., M.P.H.
Deepan S. Dalal, M.B.B.S., M.P.H.
Grace E. Ogbeche, M.B.B.S., M.P.H.
Aditya Chandrasekhar, M.B.B.S.
Susan Hutfless, Ph.D.
Eric B. Bass, M.D., M.P.H.
Jodi B. Segal, M.D., M.P.H.

**AHRQ Publication No. 11-EHC038-EF
March 2011**

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials that are clearly noted in the document. Further reproduction of those copyrighted materials is prohibited without the specific permission of copyright holders.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation: Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh, S, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Nicholson WK, Block L, Odelola O, Dalal DS, Ogbeche GE, Chandrasekhar A, Hutfless S, Bass EB, Segal JB. Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update. Comparative Effectiveness Review No. 27. (Prepared by Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018.) AHRQ Publication No. 11-EHC038-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Preface

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting Comparative Effectiveness Reviews (CERs) of medications, devices, and other relevant interventions, including strategies for how these items and services can best be organized, managed, and delivered.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about systematic reviews, see <http://effectivehealthcare.ahrq.gov/reference/purpose.cfm>.

AHRQ expects that CERs will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. In addition, AHRQ is committed to presenting information in different formats so that consumers who make decisions about their own and their family's health can benefit from the evidence.

Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an e-mail list to learn about new program products and opportunities for input. Comparative Effectiveness Reviews will be updated regularly.

We welcome comments on this CER. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by e-mail to epc@ahrq.hhs.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director
Evidence-based Practice Center Program
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Steven Fox, M.D., S.M., M.P.H.
Task Order Officer
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Acknowledgments

The Evidence-based Practice Center thanks Erica Shelton, M.D. for her management of the guideline analysis and Sachin Srinivasan, Ugonna Nwosu, and Rukeme Ake for their assistance with reviewing articles.

Technical Expert Panel

Linda Humphrey, M.D., M.P.H.
American College of Physicians
Portland, OR

Silvio Inzucchi, M.D.
Yale School of Medicine
New Haven, CT

Sue Kirkman, M.D.
American Diabetes Association
Alexandria, VA

Leonard Pogach, M.D.
Veterans Administration Health Care
System
East Orange, NJ

Helena W. Rodbard, M.D., F.A.C.P.,
M.A.C.E.
Endocrine and Metabolic Consultants
Rockville, MD

Chris Saudek, M.D.
Johns Hopkins University
Baltimore, MD

Christopher H. Schmid, Ph.D.
Tufts Medical Center
Boston, MA

Donna Sweet, M.D.
American College of Physicians
Wichita, KS

Susan Tan-Torres, M.D., M.P.H.
Blue Cross and Blue Shield
Audubon, PA

Peer Reviewers

Lloyd Axelrod, M.D.
Massachusetts General Hospital
Boston, MA

Gilad Gordon, M.D., M.B.A.
ORRA Group
Boulder, CO

Tarek Hammad, M.D.
Food and Drug Administration
Silver Spring, MD

Steven Mitchell
Consumer Union

Leonard Pogach, M.D.
Veterans Administration Health Care
System
East Orange, NJ

Helena W. Rodbard, M.D., F.A.C.P.,
M.A.C.E.
Endocrine and Metabolic Consultants
Rockville, MD

Donna Sweet, M.D.
American College of Physicians
Wichita, KS

Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update

Structured Abstract

Objectives. Given the number of medications available for type 2 diabetes mellitus, clinicians and patients need information about their effectiveness and safety to make informed choices. The objective of this review was to summarize the benefits and harms of medications (metformin, second-generation sulfonylureas, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 [DPP-4] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists), as monotherapy and in combination, for the treatment of adults with type 2 diabetes.

Data Sources. We searched the MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases from inception through April 2010 for original English-language articles and sought unpublished data from the Food and Drug Administration and others.

Review Methods. Two reviewers independently screened titles to identify studies that assessed intermediate outcomes (e.g., hemoglobin A1c [HbA1c]), long-term clinical outcomes (e.g., mortality), and harms (e.g., hypoglycemia) in head-to-head monotherapy or combination therapy comparisons. Two reviewers serially extracted data for each article using standardized protocols, assessed applicability, and independently evaluated study quality.

Results. The review included 140 randomized controlled trials and 26 observational studies. We graded evidence as low or insufficient for long-term clinical outcomes of all-cause mortality, cardiovascular disease, nephropathy, and neuropathy. Most medications lowered HbA1c on average by 1 absolute percentage point, but metformin was more efficacious than the DPP-4 inhibitors. Two-drug combinations had similar HbA1c reduction. Compared with metformin, thiazolidinediones and sulfonylureas had a more unfavorable effect on weight (mean difference of +2.6 kg). Metformin decreased low density lipoprotein cholesterol relative to pioglitazone, sulfonylureas, and DPP-4 inhibitors. Sulfonylureas had a fourfold higher risk of mild/moderate hypoglycemia compared with metformin alone, and, in combination with metformin, had more than a fivefold increased risk compared with metformin plus thiazolidinediones. Thiazolidinediones had an increased risk of congestive heart failure relative to sulfonylureas and bone fractures relative to metformin. Diarrhea occurred more often for metformin compared with thiazolidinedione users.

Conclusions. Comprehensive information comparing benefits and harms of diabetes medications can facilitate personalized treatment choices for patients. Although the long-term benefits and harms of diabetes medications remain unclear, the evidence supports use of metformin as a first-line agent. Comparisons of two-drug combinations showed little to no difference in HbA1c reduction, but some combinations increased risk for hypoglycemia and other adverse events.

Contents

Executive Summary	ES-1
Introduction	1
Background	1
Rationale for Update of Review on Comparative Effectiveness of Diabetes Medications	3
Conceptual Model	4
Scope and Key Questions	6
Key Questions	6
Methods	8
Topic Development	8
Search Strategy	8
Study Selection	9
Data Abstraction	11
Quality Assessment	11
Applicability	12
Data Analysis and Synthesis	12
Data Entry and Quality Control	14
Rating the Body of Evidence	14
Peer Review and Public Commentary	15
Results	16
Search Results	16
Key Question 1–Intermediate Outcomes	17
Key Points and Evidence Grades	17
Study Design and Population Characteristics	21
The Evidence About Hemoglobin A1c	25
The Evidence About Weight	40
The Evidence About Low-Density Lipoproteins	57
The Evidence About High-Density Lipoproteins	68
The Evidence About Triglycerides	80
Publication Bias	93
Gray Literature	93
Applicability	93
Key Question 2–Long-Term Clinical Outcomes	94
Key Points and Evidence Grades	94
Study Design and Population Characteristics	96
The Evidence About All-Cause Mortality	99
The Evidence About Cardiovascular Mortality	106
The Evidence About Cardiovascular and Cerebrovascular Disease Morbidity	108
The Evidence About Retinopathy	114
The Evidence About Nephropathy	114
The Evidence About Neuropathy	115
Summary of Results of Updated Search Through December 2010 for Long-Term Clinical Outcomes	116
Gray Literature	116
Applicability	117
Key Question 3–Adverse Events and Side Effects	117

Key Points and Evidence Grades	118
Study Design and Population Characteristics	120
The Evidence About Hypoglycemia.....	123
The Evidence About Liver Injury.....	140
The Evidence About Congestive Heart Failure	141
The Evidence About Lactic Acidosis	145
The Evidence About Cancer	145
The Evidence About Severe Allergic Reactions.....	146
The Evidence About Hip and Non-Hip Fractures.....	146
The Evidence About Acute Pancreatitis	148
The Evidence About Cholecystitis.....	148
The Evidence About Macular Edema	149
The Evidence About Gastrointestinal Effects.....	149
Publication Bias	155
Gray Literature.....	155
Applicability	157
Key Question 4–Subpopulations.....	157
Key Points.....	157
The Evidence for Comparative Effectiveness and Safety in Sub-Populations	164
Quality Assessment.....	164
Articles Reporting More Than One Study	166
Discussion	166
Key Findings and Implications	166
Intermediate Outcomes	168
Long-Term Clinical Outcomes	170
Adverse Events	171
Two-Drug Combinations, Including Addition of Insulin Preparations	172
Newer Diabetes Classes of Medications: DPP-4 Inhibitors and GLP-1 Agonists.....	173
Limitations	174
Future Research	174
Populations.....	175
Interventions and Comparators	175
Outcomes of Interest	175
Timing.....	175
Setting	175
References	177
Abbreviations	194

Tables

Table A. Priority Medication Comparisons Included for Each of the Key Questions	ES-3
Table B. Evidence of the Comparative Effectiveness and Safety of Diabetes Medications as Monotherapy and Combination Therapy on Intermediate Endpoints, Mortality, Microvascular Outcomes, Macrovascular Outcomes, and Adverse Events	ES-9
Table 1. Characteristics of Medications Included in This Report	2
Table 2. Priority Medication Comparisons Included for Each of the Key Questions	7
Table 3. Inclusion and Exclusion Criteria.....	10
Table 4. Key Findings and Strength of the Evidence Comparing Diabetes Medications as Monotherapy or Combination Therapy for Intermediate Outcomes	23
Table 5. Strength of Evidence and Key Findings Comparing Diabetes Medications as Monotherapy or Combination Therapy for Long-Term Clinical Outcomes	97
Table 6. Studies Comparing Metformin Versus Sulfonylurea for All-Cause Mortality.....	100
Table 7. Studies Comparing Metformin with Combination of Metformin and Sulfonylurea for All-Cause Mortality.....	102
Table 8. Key Findings and Strength of the Evidence Comparing Diabetes Medications as Monotherapy or Combination Therapy for Adverse Events.....	121
Table 9. Additional Randomized Controlled Trials Comparing Metformin with Sulfonylurea for Hypoglycemia	126
Table 10. Randomized Controlled Trials Comparing Metformin with a Combination of Metformin and Sulfonylurea for Hypoglycemia	126
Table 11. Randomized Controlled Trials Comparing Thiazolidinediones with Meglitinides for Hypoglycemia.....	133
Table 12. Randomized Controlled Trials Comparing Combination of Metformin and Sulfonylurea with Combination Metformin and Another Agent for Hypoglycemia.....	138
Table 13. Randomized Controlled Trials Comparing Combination of Metformin and a Basal Insulin with Combination of Metformin and Another Insulin for Hypoglycemia....	139
Table 14. Studies Comparing Metformin with Thiazolidinediones for Heart Failure Events.....	142
Table 15. Studies Comparing Thiazolidinediones with Sulfonylureas for Heart Failure Events	143
Table 16. Randomized Controlled Trials Comparing Metformin with Thiazolidinediones for Gastrointestinal Effects.....	149
Table 17. Randomized Controlled Trials Comparing Metformin with Sulfonylureas for Gastrointestinal Effects.....	150
Table 18. Randomized Controlled Trials Comparing Metformin with Meglitinides for Gastrointestinal Effects.....	151
Table 19. Randomized Controlled Trials Comparing Metformin with a Combination of Metformin and Thiazolidinediones for Gastrointestinal Effects	151
Table 20. Randomized Controlled Trials Comparing Metformin with a Combination of Metformin and DPP-4 Inhibitors for Gastrointestinal Effects.....	152
Table 21. Randomized Controlled Trials Comparing Thiazolidinediones with Sulfonylureas for Gastrointestinal Effects.....	153
Table 22. Randomized Controlled Trials Comparing a Combination of Metformin and Thiazolidinediones with a Combination of Metformin and Sulfonylureas for Gastrointestinal Effects	153
Table 23. Results from Randomized Controlled Trials Reporting Outcomes in a Subpopulation	161

Table 24. Summary of Studies Reporting on More Than One Study.....	165
--	-----

Figures

Figure 1. Conceptual Model	5
Figure 2. Summary of the Literature Search (Number of Articles).....	16
Figure 3. Mean Difference in Hba1c Comparing Metformin with Thiazolidinediones	25
Figure 4. Mean Difference in Hba1c Comparing Metformin with Sulfonylureas.....	26
Figure 5. Mean Difference in Hba1c Comparing Metformin with DPP-4 Inhibitors.....	29
Figure 6. Mean Difference in Hba1c Comparing Metformin with Combination of Metformin and Thiazolidinediones	30
Figure 7. Mean Difference in Hba1c Comparing Metformin with Combination of Metformin and Sulfonylureas.....	31
Figure 8. Mean Difference in Hba1c Comparing Metformin with Combination of Metformin and DPP-4 Inhibitors	32
Figure 9. Mean Difference in Hba1c Comparing Rosiglitazone with Pioglitazone	33
Figure 10. Mean Difference in Hba1c Comparing Thiazolidinediones with Sulfonylureas	34
Figure 11. Mean Difference in Hba1c Comparing Sulfonylureas with Meglitinides.....	35
Figure 12. Mean Difference in Hba1c Comparing Combination of Metformin and Thiazolidinediones with Combination of Metformin and Sulfonylureas	36
Figure 13. Mean Difference in Hba1c Comparing Combination of Metformin and Sulfonylureas with Combination of Thiazolidinediones and Sulfonylureas.....	39
Figure 14. Mean Difference in Hba1c Comparing Combination of Metformin and Basal Insulin with Combination of Metformin and Premixed Insulin.....	40
Figure 15. Mean Difference in Weight Comparing Metformin with Thiazolidinediones.....	41
Figure 16. Mean Difference in Weight Comparing Metformin with Sulfonylureas	42
Figure 17. Mean Difference in Weight Comparing Metformin with Sulfonylureas Among Studies Less Than 24 Weeks in Duration.....	43
Figure 18. Mean Difference in Weight Comparing Metformin with Sulfonylureas Among Studies 24 Weeks or Longer in Duration.....	44
Figure 19. Mean Difference in Weight Comparing Metformin with DPP-4 Inhibitors	45
Figure 20. Mean Difference in Weight Comparing Metformin with Combination Metformin and Thiazolidinediones	46
Figure 21. Mean Difference in Weight Comparing Metformin with Combination Metformin and Sulfonylureas.....	47
Figure 22. Mean Difference in Weight Comparing Metformin with Combination Metformin and DPP-4 Inhibitors.....	48
Figure 23. Mean Difference in Weight Comparing Rosiglitazone with Pioglitazone.....	49
Figure 24. Mean Difference in Weight Comparing Thiazolidinediones with Sulfonylureas	50
Figure 25. Mean Difference in Weight Comparing Sulfonylureas with Meglitinides	51
Figure 26. Mean Difference in Weight Comparing Sulfonylureas with GLP-1 Agonists	52
Figure 27. Mean Difference in Weight Comparing Combination Metformin and Thiazolidinediones with Combination Metformin and Sulfonylureas.....	53
Figure 28. Mean Difference in Weight Comparing Combination Metformin and Sulfonylureas with Combination Thiazolidinediones with Sulfonylureas.....	55
Figure 29. Mean Difference in Weight Comparing Combination Metformin and Basal Insulin with Combination Metformin and Premixed Insulin.....	57
Figure 30. Mean Difference in LDL Comparing Metformin with Rosiglitazone.....	58

Figure 31. Mean Difference in LDL Comparing Metformin with Pioglitazone.....	59
Figure 32. Mean Difference in LDL Comparing Metformin with Sulfonylureas	60
Figure 33. Mean Difference in LDL Comparing Metformin with DPP-4 Inhibitors	61
Figure 34. Mean Difference in LDL Comparing Metformin with Combination Metformin and Rosiglitazone.....	62
Figure 35. Mean Difference in LDL Comparing Metformin with Combination Metformin and Sulfonylureas.....	63
Figure 36. Mean Difference in LDL Comparing Metformin with Combination Metformin and DPP-4 Inhibitors.....	64
Figure 37. Mean Difference in LDL Comparing Rosiglitazone with Pioglitazone.....	65
Figure 38. Mean Difference in LDL Comparing Pioglitazone with Sulfonylureas.....	66
Figure 39. Mean Difference in LDL Comparing Combination of Metformin and Rosiglitazone with Combination of Metformin and Sulfonylureas	67
Figure 40. Mean Difference in HDL Comparing Metformin with Rosiglitazone	69
Figure 41. Mean Difference in HDL Comparing Metformin with Pioglitazone	70
Figure 42. Mean Difference in HDL Comparing Metformin with Sulfonylureas	71
Figure 43. Mean Difference in HDL Comparing Metformin with DPP-4 Inhibitors.....	72
Figure 44. Mean Difference in HDL Comparing Metformin with Combination Metformin and Rosiglitazone.....	73
Figure 45. Mean Difference in HDL Comparing Metformin with Combination Metformin and Sulfonylureas.....	74
Figure 46. Mean Difference in HDL Comparing Metformin with Combination Metformin and DPP-4 Inhibitors.....	75
Figure 47. Mean Difference in HDL Comparing Rosiglitazone with Pioglitazone	76
Figure 48. Mean Difference in HDL Comparing Pioglitazone with Sulfonylureas	77
Figure 49. Mean Difference in HDL Comparing Sulfonylureas with Meglitinides	78
Figure 50. Mean Difference in HDL Comparing Combination Metformin and Rosiglitazone with Combination Metformin and Sulfonylureas	79
Figure 51. Mean Difference in Triglycerides Comparing Metformin with Rosiglitazone	81
Figure 52. Mean Difference in Triglycerides Comparing Metformin with Pioglitazone	82
Figure 53. Mean Difference in Triglycerides Comparing Metformin with Sulfonylureas	83
Figure 54. Mean Difference in Triglycerides Comparing Metformin with DPP-4 Inhibitors.....	84
Figure 55. Mean Difference in Triglycerides Comparing Metformin with Combination Metformin and Rosiglitazone	85
Figure 56. Mean Difference in Triglycerides Comparing Metformin with Combination Metformin and Sulfonylureas	86
Figure 57. Mean Difference in Triglycerides Comparing Metformin with Combination Metformin and DPP-4 Inhibitors	87
Figure 58. Mean Difference in Triglycerides Comparing Rosiglitazone with Pioglitazone	88
Figure 59. Mean Difference in Triglycerides Comparing Pioglitazone with Sulfonylureas	89
Figure 60. Mean Difference in Triglycerides Comparing Sulfonylureas with Meglitinides	90
Figure 61. Mean Difference in Triglycerides Comparing Combination Metformin and Rosiglitazone with Combination Metformin and Sulfonylureas	91
Figure 62. Pooled Odds Ratio of Fatal and Non-Fatal Ischemic Heart Disease Comparing Metformin with Combination of Metformin and Rosiglitazone.....	111

Figure 63. Pooled Odds Ratio of Having at Least One Mild or Moderate Hypoglycemic Event Comparing Metformin with Sulfonylureas	124
Figure 64. Pooled Odds Ratio of Having at Least One Mild or Moderate Hypoglycemic Event Comparing Metformin with Meglitinides	125
Figure 65. Pooled Odds Ratio of Having at Least One Mild or Moderate Hypoglycemic Event Comparing Metformin with Metformin Plus Thiazolidinedione.....	127
Figure 66. Pooled Odds Ratio of Having at Least One Mild or Moderate Hypoglycemic Event Comparing Metformin qith Metformin Plus DPP-4 Inhibitors.....	130
Figure 67. Pooled Odds Ratio of Having t Least One Mild Or Moderate Hypoglycemic Event Comparing Metformin Qith Metformin Plus Meglitinides.....	131
Figure 68. Pooled Odds Ratio of Having at Least One Mild or Moderate Hypoglycemic Event Comparing Thiazolidinediones with Sulfonylureas.....	132
Figure 69. Pooled Odds Ratio of Having at Least One Mild or Moderate Hypoglycemic Event Comparing Sulfonylureas with Meglitinides	135
Figure 70. Pooled Odds Ratio of Having at Least One Mild o Moderate Hypoglycemic Event Comparing Combination Metformin and Thiazolidinediones with Combination Metformin and Sulfonylureas.....	136
Figure 71. Pooled Odds Ratio of Congestive Heart Failure Comparing Thiazolidinediones with Second-Generation Sulfonylureas	144

Appendixes

Appendix A. Medication Comparisons
Appendix B. Detailed Electronic Database Search Strategies
Appendix C. Hand-Searches Journals
Appendix D. Forms
Appendix E. Tallies for Comparisons Not Included in Review
Appendix F. Excluded Articles
Appendix G. Evidence Tables
Appendix H. Summary of Updated Literature Search for Long-Term Clinical Outcomes

Executive Summary

Background

Type 2 diabetes is a common chronic illness characterized by insulin resistance and eventually by decreased insulin secretion by pancreatic beta cells, leading to chronic hyperglycemia and associated long-term disease complications. In the United States, the prevalence of diabetes increased from 5.1 percent during 1988–1994 to 6.5 percent during 1999–2002.¹ Like many chronic illnesses, diabetes disproportionately affects older people. It is associated with obesity, and its prevalence is higher among racial and ethnic minority populations. The annual economic burden of diabetes is estimated to be \$132 billion and is increasing, mostly because of the costly complications of the disease.

Long-term complications of diabetes include microvascular disease, such as retinopathy and blindness, neuropathy, nephropathy, and end-stage kidney disease. In addition, the death rate from cardiovascular disease in adults with type 2 diabetes is two to four times as high as in adults without diabetes.² Management of hyperglycemia using diet and pharmacologic therapy is the cornerstone of treatment for type 2 diabetes. Results from randomized controlled trials (RCTs) have demonstrated that the risk of microvascular complications, particularly retinopathy, can be reduced by improved glycemic control in patients with type 2 diabetes. However, studies have had mixed results regarding the impact of intensive glycemic control (hemoglobin A1c [HbA1c] < 7 percent) on cardiovascular events and mortality. While older studies indicated that intensive glycemic control may reduce cardiovascular morbidity and mortality, recent studies have raised the possibility that intensive glycemic control has either no effect or a negative effect on cardiovascular morbidity and mortality. These mixed results suggest the need for further research, including investigation of the long-term safety of glucose-lowering therapies. In addition to questions about optimal glycemic control, recent studies have addressed concerns about excess cardiovascular risk associated with particular oral hypoglycemic agents, specifically the risk of rosiglitazone.

In 1995, the only drugs for treating type 2 diabetes were sulfonylureas and insulin. Since then, many new pharmacotherapy options have become available. At present, there are 11 classes of diabetes medications: biguanides (i.e., metformin), thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, glucagon-like peptide-1 (GLP-1) receptor agonists, an amylin analogue, bromocriptine, alpha-glucosidase inhibitors, colesevalam (a bile-acid sequestrant), and insulins. The newer agents are more costly than the older medications, and some are only approved as adjunctive therapies. In addition to having an increased number of medication choices, patients with type 2 diabetes often need to take more than one type of diabetes medication. In 2005–2006, 35 percent of all patients with diabetes were taking two classes of antidiabetes medications, and 14 percent were taking three or more classes, as compared to only 6 percent taking three or more classes in 1999–2000.³

In 2007, the Agency for Healthcare Research and Quality (AHRQ) published its first systematic review on the comparative effectiveness of oral medications for type 2 diabetes, *Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes* (Comparative Effectiveness Review No. 8). The review was unique because it included comparisons of all oral diabetes medications. It also had a broad scope, including intermediate outcomes such as glycemic control and clinical outcomes such as cardiovascular disease and nephropathy, as well as adverse events. The review of 216 studies concluded that most oral

diabetes medications had a similar effect on reducing HbA1c, most drugs except for metformin and acarbose caused increases in body weight, and only metformin decreased low-density lipoprotein (LDL) cholesterol. There were too few studies to make it possible to assess the differential effects of the oral diabetes medications on all-cause mortality, cardiovascular mortality and morbidity, or microvascular complications. The sulfonylurea class was associated with an increased risk of hypoglycemia, metformin with gastrointestinal problems, and the thiazolidinediones with heart failure.

In the years following publication of that review, enough studies were published to merit an update to address research gaps and integrate newer evidence. Since the first review, two new medication classes have been approved by the U.S. Food and Drug Administration (FDA). Two injectable incretin mimetics, exenatide and liraglutide, were FDA approved in 2005 and 2010, respectively. The DPP-4 inhibitors sitagliptin and saxagliptin were FDA approved in 2006 and 2009. In addition, the review needed to be updated to include evidence about combinations of medications, including combinations of an oral medication with insulin therapy.

For this update, we decided to build upon the previous evidence report by focusing on the most important issues without seeking to replicate all parts of the previous report. Thus, the current evidence report focuses on the head-to-head comparisons of medications that should be of greatest relevance to clinicians and their patients. Readers should refer to the original evidence report if they want more information about placebo-controlled trials of the medications. For the head-to-head comparisons, we conducted a comprehensive literature search that included all literature that had been searched for the first report. We expanded the scope of the review by including a few additional outcomes that were relevant to the comparisons of interest. We also included comparisons with combinations of medications. As part of the revised scope of work, we applied slightly different exclusion criteria. Therefore, this report represents both an update and an expansion of our previous comprehensive review of the evidence comparing the effectiveness and safety of oral medications used to treat type 2 diabetes.

The report addresses the following key questions for the priority medication comparisons presented in Table A:

Key Question 1. In adults age 18 or older with type 2 diabetes mellitus, what is the comparative effectiveness of these treatment options (see list of comparisons) for the intermediate outcomes of glycemic control (in terms of HbA1c), weight, or lipids?

Table A. Priority medication comparisons included for each of the key questions

	Main intervention	Comparisons
Monotherapy as main intervention	Metformin	<ul style="list-style-type: none"> • Thiazolidinedione • Sulfonylurea • DPP-4 inhibitor • Meglitinides • GLP-1 agonist • Combination of metformin plus thiazolidinedione • Combination of metformin plus sulfonylurea • Combination of metformin plus DPP-4 inhibitor • Combination of metformin plus meglitinides • Combination of metformin plus GLP-1 agonist
	Thiazolidinedione	<ul style="list-style-type: none"> • Different thiazolidinedione • Sulfonylurea • DPP-4 inhibitor • Meglitinides • GLP-1 agonist
	Sulfonylurea	<ul style="list-style-type: none"> • DPP-4 inhibitor • Meglitinides • GLP-1 agonist
	DPP-4 inhibitor	<ul style="list-style-type: none"> • Meglitinides • GLP-1 agonist
Combination therapy as main intervention	Combination of metformin plus (a thiazolidinedione or a sulfonylurea or one of the meglitinides or a DPP-4 inhibitor or a GLP-1 agonist or a basal insulin or a premixed insulin)	<ul style="list-style-type: none"> • Combination of metformin plus (a thiazolidinedione or a sulfonylurea or a meglitinides or DPP-4 inhibitor or GLP-1 agonist or a basal insulin or a premixed insulin)
	Combination of metformin plus (a thiazolidinedione or a sulfonylurea or a meglitinides or DPP-4 inhibitor or GLP-1 agonist or a basal insulin or a premixed insulin)	<ul style="list-style-type: none"> • Combination of a thiazolidinedione plus (a sulfonylurea or a meglitinides or DPP-4 inhibitor or GLP-1 agonist)

DPP-4 inhibitor = dipeptidyl peptidase-4 inhibitor; GLP-1 agonist = glucagon-like peptide-1 receptor agonist

Key Question 2. In adults age 18 or older with type 2 diabetes mellitus, what is the comparative effectiveness of the treatment options (see list of comparisons) in terms of the following long-term clinical outcomes?

- All-cause mortality
- Cardiovascular mortality
- Cardiovascular and cerebrovascular morbidity (e.g., myocardial infarction and stroke)
- Retinopathy
- Nephropathy
- Neuropathy

Key Question 3. In adults age 18 or older with type 2 diabetes mellitus, what is the comparative safety of the treatment options (see list of comparisons) in terms of the following adverse events and side effects?

- Hypoglycemia
- Liver injury
- Congestive heart failure

- Severe lactic acidosis
- Cancer
- Severe allergic reactions
- Hip and non-hip fractures
- Pancreatitis
- Cholecystitis
- Macular edema or decreased vision
- Gastrointestinal side effects

Key Question 4. Do the safety and effectiveness of these treatment options (see list of comparisons) differ across subgroups of adults with type 2 diabetes, in particular for adults age 65 or older, in terms of mortality, hypoglycemia, cardiovascular, and cerebrovascular outcomes?

Conclusions

Summary Table B presents the main conclusions and strength of evidence from published studies regarding the comparative effectiveness and safety of diabetes medications, organized by key question and outcome. Below we provide additional summary information for selected comparisons of interest by key question, with a description of key factors that influenced our grading of the strength of evidence, any important exceptions, and implications.

Key Question 1: Intermediate Outcomes

Intermediate clinical outcomes were the most frequently evaluated outcomes. We identified 121 relevant articles with data from RCTs that addressed either HbA1c, body weight, or lipids. Fifty-one of the studies had also been included in the 2007 comparative effectiveness review.

HbA1c. We found that most diabetes medications (metformin, thiazolidinediones, sulfonylureas, and repaglinide) reduced HbA1c to a similar degree, by about 1 absolute percentage point when compared with baseline values, after 3 or more months of treatment. Metformin was more effective in reducing HbA1c than the DPP-4 inhibitors as monotherapy (by about 0.4 absolute percentage points). Two-drug combination therapies with metformin (such as metformin plus thiazolidinediones, metformin plus sulfonylureas, and metformin plus DPP-4 inhibitors) were generally more effective in reducing HbA1c than was metformin monotherapy (by about 1 absolute percentage point). Most combinations of metformin, sulfonylureas, and thiazolidinediones had similar efficacies in lowering HbA1c. Although we included comparisons with the GLP-1 agonists, we graded the evidence for these comparisons as insufficient or low; therefore, we were limited in our ability to draw firm conclusions about their effectiveness.

Weight. Diabetes medications varied in terms of their effects on body weight. Notably, weight change was small to moderate, generally less than 2 kg between baseline and final values. Unlike thiazolidinediones or sulfonylureas, metformin was not associated with weight gain, with a mean difference of about -2.6 kg between metformin and the other drugs, in trials that lasted more than 3 months but generally less than 1 year. Although placebo-controlled trials of metformin were excluded from this review, we know from the 2007 evidence report that metformin was

associated with weight neutrality when compared with placebo. As compared with sulfonylureas, the GLP-1 agonists were associated with a relative weight change of about 2.5 kg.

Lipids. The effects on lipid levels varied across medication type, but most were small to moderate (changes of about 0.5 mg/dL to 16 mg/dL for LDL, 0.5 mg/dL to 4 mg/dL for high-density lipoprotein [HDL], and 0 mg/dL to 33 mg/dL for triglycerides [TG]), in studies that generally lasted between 3 and 12 months. Metformin had favorable effects on all the lipid classes: It decreased LDL more effectively than did sulfonylureas, rosiglitazone, or pioglitazone, and it decreased TG more efficiently than sulfonylureas or rosiglitazone. However, pioglitazone was more effective than metformin in decreasing TG. The addition of rosiglitazone to metformin increased LDL and HDL but also increased TG when compared to metformin monotherapy and to the combination of metformin and a sulfonylurea. The addition of pioglitazone to metformin also increased HDL but decreased TG when compared to the combination of metformin and a sulfonylurea. The addition of DPP-4 inhibitors to metformin did not have an effect on HDL in comparison with metformin monotherapy. We noted that one medication or class may have favorable effects on one lipid outcome and unfavorable effects on another lipid outcome. For instance, rosiglitazone was less effective than pioglitazone in decreasing LDL, and it increased HDL to a lesser extent than did pioglitazone, but both favorably decreased TG.

Key Question 2: Macrovascular and Microvascular Long-Term Complications of Diabetes

Although we identified 41 new studies in addition to the 25 studies included in the 2007 evidence report, the new studies were generally of short duration (less than 1 year) and had few long-term events (such as deaths and cardiovascular disease), making any estimates of risk difference very imprecise. Therefore, most comparisons for this key question had a low strength of evidence. Metformin was associated with slightly lower all-cause mortality and cardiovascular disease mortality than were sulfonylureas. However, the evidence was limited by inconsistency between the trials and observational studies and the overall low precision of the results, due to the rarity of events. Data from the 2007 evidence report also showed that treatment with metformin was associated with a decreased risk of cardiovascular mortality when compared with any other oral diabetes agent or placebo, although the results for all-cause mortality and cardiovascular morbidity were not significant.

We found few studies with the newer DPP-4 inhibitors and GLP-1 agonists, but overall the evidence on these newer agents was insufficient to allow us to make any meaningful conclusions. Few studies included insulin added to oral medications or compared other two-drug combination therapies.

Few studies addressed microvascular outcomes of nephropathy, retinopathy, or neuropathy. We found moderate strength of evidence that pioglitazone is better than metformin at reducing short-term nephropathy, based on two short-duration RCTs. Only three comparisons were included for the outcome of neuropathy, and these studies were limited by their small sample sizes and poorly defined outcomes. We did not identify any studies for the outcome of retinopathy.

Key Question 3: Adverse Events and Side Effects

This Key Question was addressed by 107 studies.

Hypoglycemia. Hypoglycemic episodes were three to seven times as frequent in people taking sulfonylureas as in those taking metformin, thiazolidinediones, or DPP-4 inhibitors. Combination therapies that included a sulfonylurea plus metformin also had an excess hypoglycemia risk when compared to metformin plus a thiazolidinedione.

Congestive heart failure. Based on a single RCT with moderate risk of bias, we found low strength of evidence that the risk of congestive heart failure (CHF) was higher with combination therapy containing rosiglitazone than with a combination of metformin and a sulfonylurea (relative risk [RR] 2.1). We also found a higher risk of CHF with thiazolidinedione monotherapy than with sulfonylurea monotherapy. We were unable to draw any useful conclusions about CHF risk from other drug comparisons of interest, either because of an absence of evidence, conflicting results, or the low quality of the studies.

Gastrointestinal side effects. Metformin was associated with higher risk of gastrointestinal side effects than were all other medications, regardless of whether the metformin was used as monotherapy or as part of combination therapy.

Other adverse events. We found reports of four types of adverse events that were not addressed in our previous evidence report: macular edema, cholecystitis, pancreatitis, and fractures. Except for fractures, the majority of the evidence was graded as low strength because the availability of only a few studies and events limited the assessment of consistency and precision of the results. We did find a high strength of evidence showing that thiazolidinediones, either in combination with another medication or as monotherapy, were associated with a 1.5-fold higher risk of bone fractures than was metformin alone or in combination with sulfonylurea.

We also found little evidence regarding liver injury and cancer, outcomes included in the 2007 evidence report. However, in agreement with other reviews, we found a moderate strength of evidence for a lack of increased risk of lactic acidosis with metformin treatment, as compared to a sulfonylurea or a combination of metformin and sulfonylurea.

Key Question 4: Differences in Subgroups

Twenty-eight studies applied to Key Question 4. We found that when compared to men, women taking rosiglitazone either as monotherapy or in combination were at higher risk for bone fractures than were those taking metformin alone or in combination with sulfonylureas. However, for the majority of comparisons, the available studies did not have sufficient power to allow for subgroup analyses, and few studies occurred exclusively in a subpopulation. We found no conclusive information to predict which subgroups of patients might differentially respond to alternative treatments.

Remaining Issues

In this review, we have synthesized the current literature about the comparative effectiveness and safety of diabetes medications when used alone or in two-drug combinations. We focused primarily on the relative differences between drugs in our analyses. However, in the figures in the main body of the report, we also included footnotes with information about the range of absolute differences from baseline to followup in the comparison arms for readers who wish to estimate the magnitude of effect in absolute terms. We identified some deficiencies in the

published literature that need to be addressed by future research in order to meet the decision making needs of patients, physicians, and policymakers. We organized these deficiencies and recommendations using the PICOTS format for specifying research questions: patient populations, interventions, comparators, outcome measures of interest, timing, and settings.

Populations

Studies often employed narrow inclusion criteria, enrolling patients at lowest risk for complications, and they commonly used run-in periods to avoid enrolling patients with adverse effects or poor adherence; all these factors may limit the applicability of these studies. We identified the following research gaps related to target patient populations:

1. The literature is deficient in studies enrolling people with varying levels of underlying cardiovascular and renal disease risk.
2. Results reported in subgroups of the population were rare, especially with regard to the elderly and people with multiple comorbid conditions, such as underlying chronic kidney disease.

Interventions and Comparators

We identified the following gaps in the literature, indicating areas where future studies could address additional medication comparisons to support clinicians in decisionmaking.

1. The published literature is deficient in studies of the comparative effectiveness of two-drug combinations that are focused on either their effectiveness or safety, and thus the interaction between the two medications.
2. The comparative effectiveness literature is sparse with regard to monotherapy and combination therapy comparisons of meglinitides, DPP-4 inhibitors, and GLP-1 agonists with other first-line diabetes medications.
3. Few studies have included comparisons with a basal or premixed insulin added to metformin or thiazolidinediones.

Outcomes of Interest

Overall, few studies contained sufficient data on event rates to make it possible to analyze major clinically important adverse events and long-term complications of diabetes.

1. We identified few published studies on long-term clinical outcomes such as cardiovascular disease, stroke, nephropathy, and neuropathy.
2. Few studies used standard measures for diabetic nephropathy and kidney function, such as estimated glomerular filtration rate, or clinical outcomes, such as time to dialysis, as outcomes in their comparisons of these medications.
3. We identified few observational studies that examined macular edema, cancer, and fractures as related to thiazolidinediones, insulin, and other medications.

Timing

We identified several key deficiencies in study timing and duration of followup:

1. The literature is relatively deficient in studies of the short-term benefits, if any, of the addition of insulin to oral agents, and the long-term effects on mortality and cardiovascular disease of the addition of insulin to a regimen, relative to the addition of another oral agent.

2. Few studies on harms lasted longer than 2 years. This is a shorter duration of exposure than is typically seen in clinical practice, in which these drugs may be prescribed for decades. Some adverse effects, such as congestive heart failure, may take years to develop, and others, such as fractures, may result from cumulative exposure. The FDA approval process focuses on short-term harms, providing less incentive for pharmaceutical companies to engage in longer term studies.

Setting

Study settings are relevant to understanding the applicability of the findings to the general population of patients with diabetes in the United States.

- Few trials reported the study setting or source for participant recruitment, such as an outpatient clinical or subspecialty clinical setting. This information is relevant because the majority of patients with diabetes are cared for by primary care physicians.

We also identified methodological problems and made recommendations to consider for future research:

1. We recommend that studies consistently report between-group comparisons of changes from baseline, as well as measures of dispersion such as standard errors, to improve the interpretation of the significance of their findings.
2. We recommend improvements in adverse event and long-term outcome reporting, with predefined outcomes and definitions and a description of methods for ascertainment.
3. We recommend that trials report the steps taken to ensure randomization and allocation concealment.
4. We recommend that observational studies of the comparative effectiveness and safety of diabetes medications report details of the treatment type, dose, timing and duration of use of the medication, when available.
5. We recommend that studies consistently report the number of deaths in each study arm, even if there were none.
6. We recommend that studies allowing use of “background” medications identify which medications were allowed and stratify their results by the combination therapy, which includes the background medication(s) plus the study drug(s).
7. We recommend conducting a network meta-analysis to assess indirect comparisons, which were not addressed in this report.

Table B. Evidence of the comparative effectiveness and safety of diabetes medications as monotherapy and combination therapy on intermediate endpoints, mortality, microvascular outcomes, macrovascular outcomes, and adverse events

Outcome	Level of Evidence*	Conclusions
Key Question 1: In adults age 18 or older with type 2 diabetes mellitus, what is the comparative effectiveness of treatment options for the intermediate outcomes of glycemic control (in terms of HbA1c), weight, or lipids?		
HbA1c	High	Metformin and second-generation sulfonylureas showed similar changes in HbA1c, with a pooled between-group difference of 0.07% (95% CI -0.12% to 0.26%) for studies lasting longer than 3 months but usually less than 1 year in duration.
	High	Combination therapies were better than monotherapy regimens at reducing HbA1c, with an absolute difference of about 1%. In comparisons of metformin versus metformin plus thiazolidinediones, and metformin versus metformin plus sulfonylureas, the combination therapy was favored for HbA1c reduction.
	Moderate	When compared with DPP-4 inhibitors, metformin had a greater reduction in HbA1c, with a pooled between-group difference of -0.4% (95% CI -0.5% to -0.2%).
	Moderate	Comparisons of metformin versus thiazolidinediones, thiazolidinediones versus sulfonylureas, sulfonylureas versus repaglinide, and pioglitazone versus rosiglitazone showed similar reductions in HbA1c, with an absolute reduction in HbA1c of around 1% as compared with baseline values, with trials lasting 1 year or less.
	Moderate	Metformin plus DPP-4 inhibitor was favored over metformin alone for HbA1c reduction.
	Moderate	The combination of metformin plus thiazolidinedione had a similar efficacy in reducing HbA1c as the combination of metformin plus sulfonylurea.
	Low	The combination of pioglitazone plus sulfonylurea was minimally favored over metformin plus pioglitazone, by an absolute difference of 0.03%.
	Low	The combination of metformin plus a premixed insulin analogue was minimally favored over metformin plus a basal insulin, by an absolute difference of 0.30% to 0.43%.

Table B. Evidence of the comparative effectiveness and safety of diabetes medications as monotherapy and combination therapy on intermediate endpoints, mortality, microvascular outcomes, macrovascular outcomes, and adverse events (continued)

Outcome	Level of Evidence*	Conclusions
Body weight	High	Metformin maintained or decreased weight to a greater extent than did thiazolidinediones (pooled between-group difference of -2.6 kg, 95% CI -4.1 kg to -1.2 kg), the combination of metformin plus a thiazolidinedione (pooled between-group difference of -2.2 kg, 95% CI -2.6 kg to -1.9 kg), or the combination of metformin plus a sulfonylurea (pooled between-group difference of -2.3 kg, 95% CI -3.3 kg to -1.2 kg). Thiazolidinediones alone or in combination were associated with weight gain.
	High	Metformin maintained or decreased weight to a greater extent than did sulfonylureas, with a pooled between-group difference of -2.7 kg (95% CI -3.5 kg to -1.9 kg).
	High	Sulfonylureas and the meglitinides had similar effects on body weight.
	Moderate	GLP-1 agonists decreased weight to a greater extent than did sulfonylureas (pooled between-group difference of -2.5 kg, 95% CI -3.8 kg to -1.1 kg).
	Moderate	Metformin plus sulfonylurea had a more favorable effect on weight than did either the combinations of a thiazolidinedione plus sulfonylurea (pooled between-group difference of -3.2 kg, 95% CI -5.2 kg to -1.1 kg) or metformin plus a thiazolidinedione (pooled between-group difference of -0.9 kg, 95% CI -1.3 kg to -0.4 kg).
	Moderate	Metformin decreased weight to a greater extent than did DPP-4 inhibitors (pooled between-group difference of -1.4 kg, 95% CI -1.8 kg to -1.0 kg).
	Moderate	Metformin had no significantly different effect on weight than did the combination of metformin plus DPP-4 inhibitors (pooled between-group difference of -0.2 kg, 95% CI -0.7 kg to 0.2 kg).
	Low	Metformin plus GLP-1 agonists decreased weight to a greater extent than did several combination therapies (metformin plus sulfonylurea, metformin plus thiazolidinedione, metformin plus basal insulin, or metformin plus DPP-4 inhibitor).
Low	Metformin plus DPP-4 inhibitors decreased weight to a greater extent than did two standard combinations, metformin plus thiazolidinedione or metformin plus sulfonylurea.	
LDL cholesterol	High	Metformin decreased LDL to a greater extent than did sulfonylureas, which generally had little effect on LDL, with a pooled between-group difference of -10.1 mg/dL (95% CI -13.3 mg/dL to -7.0 mg/dL).
	High	The combination of metformin and rosiglitazone decreased LDL to a lesser extent than did metformin monotherapy (pooled between-group difference of 14.5 mg/dL, 95% CI 13.3 mg/dL to 15.7 mg/dL).
	Moderate	Metformin decreased LDL cholesterol to a greater extent than did pioglitazone, which increased LDL cholesterol, with a pooled between-group difference in LDL of -14.2 mg/dL (95% CI -15.3 mg/dL to -13.1 mg/dL).
	Moderate	Metformin decreased LDL cholesterol to a greater extent than did rosiglitazone, with a pooled between-group difference in LDL of -12.8 mg/dL (95% CI -24.0 mg/dL to -1.6 mg/dL).
	Moderate	Metformin decreased LDL to a greater extent than did DPP-4 inhibitors, with a pooled between-group difference of -5.9 mg/dL (95% CI -9.7 mg/dL to -2.0 mg/dL).
	Moderate	The combination of metformin and rosiglitazone decreased LDL to a lesser extent than did a combination of metformin and a second-generation sulfonylurea, with a pooled between-group difference in LDL of 13.5 mg/dL (95% CI 9.1 mg/dL to 17.9 mg/dL).

Table B. Evidence of the comparative effectiveness and safety of diabetes medications as monotherapy and combination therapy on intermediate endpoints, mortality, microvascular outcomes, macrovascular outcomes, and adverse events (continued)

Outcome	Level of Evidence*	Conclusions
HDL cholesterol	High	Metformin increased HDL to a lesser extent than did pioglitazone, with a pooled between-group difference of -3.2 mg/dL (95% CI -4.3 mg/dL to -2.1 mg/dL).
	High	Sulfonylureas were similar to metformin in terms of changes in HDL.
	High	The combination of metformin and rosiglitazone increased HDL to a greater extent than did metformin monotherapy (pooled between-group difference 2.8 mg/dL, 95% CI 2.2 mg/dL to 3.5 mg/dL).
	Moderate	Rosiglitazone increased HDL to a lesser extent than did pioglitazone (pooled between-group difference of -2.3 mg/dL, 95% CI -3.5 mg/dL to -1.2 mg/dL).
	Moderate	Rosiglitazone alone was similar to metformin in terms of changes in HDL.
	Moderate	Pioglitazone increased HDL to a greater extent than did sulfonylureas (pooled between-group difference of 4.3 mg/dL, 95% CI 1.9 mg/dL to 6.6 mg/dL).
	Moderate	The combination of metformin and pioglitazone increased HDL by about 5 mg/dL relative to the combination of metformin and a sulfonylurea.
	Moderate	The combination of metformin and rosiglitazone increased HDL to a greater extent than did the combination of metformin and a sulfonylurea (pooled between-group difference 2.7 mg/dL, 95% CI 1.4 mg/dL to 4.1 mg/dL).
	Moderate	The combination of metformin and DPP-4 inhibitors had similar effect on HDL as did metformin monotherapy (pooled between-group difference was 0.5 mg/dL, 95% CI -1.5 mg/dL to 2.5 mg/dL).
Triglycerides	Low	The combination of pioglitazone with another medication was favored for the following comparisons: pioglitazone plus metformin versus metformin monotherapy, metformin plus pioglitazone versus metformin plus sulfonylurea, and pioglitazone plus sulfonylurea versus metformin plus sulfonylurea, with a range of between-group differences from 3.1 mg/dL to 10.5 mg/dL.
	High	Pioglitazone decreased TG to a greater extent than did metformin (pooled between-group difference -27.2 mg/dL, 95% CI -30.0 mg/dL to -24.4 mg/dL).
	High	Metformin monotherapy decreased TG to a greater extent than did the combination of metformin and rosiglitazone, with a pooled between-group difference in TG of -14.5 mg/dL (95% CI -15.7 mg/dL to -13.3 mg/dL).
	Moderate	Metformin decreased TG to a greater extent than did rosiglitazone, which increased TG, with a pooled between-group difference of -26.9 mg/dL (95% CI -49.3 mg/dL to -4.5 mg/dL).
	Moderate	Metformin decreased TG to a greater extent than did sulfonylureas (pooled between-group difference -8.6 mg/dL, 95% CI -15.6 mg/dL to -1.6 mg/dL).
	Moderate	The combination of metformin plus rosiglitazone and the combination of metformin plus sulfonylurea had similar effects on TG.
	Moderate	The combination of metformin and pioglitazone decreased TG to a greater extent than did the combination of metformin and a sulfonylurea, with between-group differences ranging from -10 mg/dL (p = 0.30) to -24.9 mg/dL (p = 0.045).
	Moderate	Sulfonylureas and meglitinides had similar effects on TG (pooled between-group difference 0.2 mg/dL, 95% CI -3.8 mg/dL to 4.2 mg/dL).

Table B. Evidence of the comparative effectiveness and safety of diabetes medications as monotherapy and combination therapy on intermediate endpoints, mortality, microvascular outcomes, macrovascular outcomes, and adverse events (continued)

Outcome	Level of Evidence*	Conclusions
Key Question 2: In adults age 18 or older with type 2 diabetes mellitus, what is the comparative effectiveness of the treatment options in terms of the following long-term clinical outcomes: all-cause mortality, cardiovascular mortality, cardiovascular and cerebrovascular morbidity, retinopathy, nephropathy, and neuropathy?		
All-cause mortality	Low	Compared to sulfonylureas, metformin was associated with a slightly lower risk of all-cause mortality in observational studies, but the results were inconsistent between trials and observational studies, and all had a moderate risk of bias.
	Low	Many RCTs were of short duration (less than 1 year) and had few deaths, limiting the precision of the results.
	Insufficient	No studies addressed several comparisons, including most DPP-4 inhibitor and GLP-1 agonist comparisons, pioglitazone versus rosiglitazone, comparisons with an insulin preparation, and the majority of combination therapy comparisons.
Cardiovascular disease mortality	Low	Metformin was associated with a slightly lower risk of cardiovascular mortality than was a second-generation sulfonylurea, but the results were imprecise and had a moderate risk of bias.
	Low	The risk of cardiovascular mortality was similar between metformin and each of the thiazolidinediones as monotherapy, with high imprecision of results, inconsistencies, and a moderate risk of bias.
	Low	Metformin alone was slightly favored over a combination of metformin and rosiglitazone in terms of lower risk of fatal myocardial infarction, with consistent direction of the results but high imprecision.
	Insufficient	No studies addressed several comparisons, including most DPP-4 inhibitor and GLP-1 agonist comparisons, pioglitazone versus rosiglitazone, and the majority of combination therapy comparisons.
Cardiovascular and cerebrovascular morbidity (nonfatal myocardial infarction and stroke)	Low	A comparison of the risk of cardiovascular morbidity between metformin and thiazolidinedione as monotherapy was inconclusive, with high imprecision and inconsistency in the direction of the findings.
	Low	Metformin alone was slightly favored over a combination of metformin and rosiglitazone in terms of a lower risk of non-fatal ischemic heart disease, with a consistent direction of the results but high imprecision and a failure to reach statistical significance. The pooled odds ratio (OR) for combined fatal and non-fatal ischemic heart disease events was 0.43, 95% CI 0.17 to 1.10. The range of rates for non-fatal ischemic heart disease for the comparison group, metformin, ranged from 0 to 2.9%.
	Insufficient	No studies addressed several comparisons, including most DPP-4 inhibitors and GLP-1 agonist comparisons, pioglitazone versus rosiglitazone, and the majority of combination therapy comparisons.
Microvascular outcomes (retinopathy, nephropathy, neuropathy)	Moderate	Pioglitazone was more effective than metformin in reducing the urinary albumin-to-creatinine ratio (15% and 19% decrease in 2 trials), likely indicating less nephropathy.
	Low	Three comparisons were included for the outcome of neuropathy, but studies were at high risk for bias, with low sample sizes and poorly defined outcomes.
	Insufficient	No studies addressed the outcome of retinopathy.

Table B. Evidence of the comparative effectiveness and safety of diabetes medications as monotherapy and combination therapy on intermediate endpoints, mortality, microvascular outcomes, macrovascular outcomes, and adverse events (continued)

Outcome	Level of Evidence*	Conclusions
Key Question 3: In adults age 18 or older with type 2 diabetes mellitus, what is the comparative safety of the treatment options in terms of the adverse events and side effects?		
Hypoglycemia	High	The risk of mild to moderate hypoglycemia with sulfonylureas exceeds the risk with metformin, with a pooled OR of 4.6 (95% CI 3.2 to 6.5). The range of rates for mild to moderate hypoglycemia in the metformin group was 0 to 17.7%, with a median rate of 0%.
	High	The risk of mild to moderate hypoglycemia with sulfonylureas exceeds the risk with thiazolidinediones, with a pooled OR of 3.9 (95% CI 3.0 to 4.9). The range of rates for mild to moderate hypoglycemia in the thiazolidinedione group was 0 to 92.1%, with a median rate of 4.4%.
	High	The risk of hypoglycemia with metformin plus sulfonylurea exceeds the risk of metformin plus thiazolidinediones, with a pooled OR of 5.8 (95% CI 4.3 to 7.7). The range of rates for mild to moderate hypoglycemia in the metformin plus thiazolidinediones group ranged from 0 to 9.3%, with a median rate of 1.3%.
	Moderate	The risk of hypoglycemia with sulfonylurea exceeds the risk with DPP-4 inhibitors (20 events versus none in a single study).
	Moderate	The risk of hypoglycemia was similar between metformin and thiazolidinediones.
	Moderate	The risk of hypoglycemia with metformin plus sulfonylurea exceeded the risk with metformin alone, with an OR range of 0.6 to 9.3.
	Moderate	The risk of hypoglycemia was modestly higher for meglitinides than for metformin, with an OR of 3.0 (95% CI 1.8 to 5.2). The range of rates for mild to moderate hypoglycemia in the metformin group ranged from 0 to 24%, with a median rate of 3.7%.
	Moderate	The risk of hypoglycemia was higher for metformin plus a thiazolidinedione than for metformin alone, with an OR of 1.6 (95% CI 1.0 to 2.4). The range of rates for mild to moderate hypoglycemia in the metformin group ranged from 0 to 9.1%, with a median rate of 1.4%.
	Moderate	The combination of metformin and DPP-4 inhibitor had similar risk of hypoglycemia as that of metformin alone.
	Moderate	The combination of metformin with a sulfonylurea had a higher risk of hypoglycemia than metformin with GLP-1 agonist.
Moderate	Metformin combined with a basal insulin had a modestly lower risk of hypoglycemia when compared to metformin combined with a premixed insulin, with the RR ranging from 0.34 to 0.94 in 5 trials.	
Gastrointestinal (GI) side effects	High	Metformin was associated with twice as many GI adverse events, most commonly diarrhea, nausea, and vomiting, as were thiazolidinediones.
	High	The rates of GI adverse effects were similar for thiazolidinediones and sulfonylureas.
	Moderate	Metformin was associated with more frequent GI adverse events than were DPP-4 inhibitors.
	Moderate	Metformin was associated with twice as many GI adverse event rates as were second-generation sulfonylureas.
	Moderate	Metformin monotherapy was associated with more frequent GI adverse events than were either the combination of metformin plus a sulfonylurea or metformin plus a thiazolidinedione, if the metformin component was of a lower dose than in the metformin monotherapy arm.
	Moderate	The combination of metformin and sulfonylurea was associated with slightly more frequent GI adverse events than were seen with a combination of a thiazolidinedione and a sulfonylurea.
Congestive heart failure	Moderate	The risk of CHF was higher for thiazolidinediones than for sulfonylureas (OR 1.68, 95% CI 0.99 to 2.85).
	Insufficient	No long-term trials assessed the comparative effects of the DPP-4 inhibitors and GLP-1 agonists on the risk of heart failure

Table B. Evidence of the comparative effectiveness and safety of diabetes medications as monotherapy and combination therapy on intermediate endpoints, mortality, microvascular outcomes, macrovascular outcomes, and adverse events (continued)

Outcome	Level of Evidence*	Conclusions
Cholecystitis and pancreatitis	Low	Two comparisons were included for the outcome of cholecystitis, and one comparison was included for the outcome of pancreatitis, with unclear conclusions.
Lactic acidosis	Moderate	The risk of lactic acidosis was similar for metformin and sulfonylurea alone and for the two in combination.
Macula edema	Insufficient	Only one trial reported on macular edema. The evidence was insufficient for all comparisons.
Cancer	Insufficient	Few studies addressed the outcome of cancer.
Liver injury	High	The risk of liver injury was similar for thiazolidinediones and sulfonylureas.
	Moderate	The rates of liver injury were similar between thiazolidinediones and metformin.
Fractures	High	The risk of fracture was higher for thiazolidinediones than for metformin. In one large RCT the RR was 1.57 (95% CI 1.13 to 2.17) and women in the thiazolidinedione arm had a higher fracture risk than men. The fracture rate was 4.1% in the reference (metformin) arm.
	High	The risk of fracture was higher for combination therapy with a thiazolidinedione than for metformin plus sulfonylurea, with higher risk in women than in men. In one large RCT, the RR was 1.57 (95% CI 1.26 to 1.97) for the rosiglitazone combination therapy arm, as compared to the combination of metformin plus sulfonylurea arms. The fracture rate in the reference (metformin + sulfonylurea) arm was 1.6%.

GI = gastrointestinal; HDL = high density lipoprotein; HbA1c = hemoglobin A1c; kg = kilograms; LDL = low density lipoproteins; mg/dL = milligrams per deciliter; RCT = randomized controlled trial; RR = relative risk; TG = triglycerides

* The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate.

Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

References

1. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. *Diabetes Care* 2006; 29(6):1263–1268.
2. National Institute of Diabetes and Digestive and Kidney Diseases. *National Diabetes Statistics, 2007 fact sheet*. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2008.
3. Mann DM, Woodward M, Ye F, Krousel-Wood M, Muntner P. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. *Arch Intern Med* 2009;169(18):1718–1720.

Introduction

Background

Type 2 diabetes is a common chronic illness, with an increasing prevalence that parallels the rise in obesity rates. Type 2 diabetes is characterized by insulin resistance, which is worsened by obesity and physical inactivity. Over time, the pancreatic beta cells lose their ability to maintain the high insulin levels needed to counter liver and muscle insulin resistance and beta cell failure occurs.¹ The natural history of type 2 diabetes has been described in several populations.¹

In the United States, the prevalence of diabetes has increased from 5.1 percent during 1988–1994 to 6.5 percent during 1999–2002.² Like many chronic illnesses, diabetes disproportionately affects older people, and its prevalence is higher among racial and ethnic minority populations.³ The annual economic burden of diabetes is estimated to be \$132 billion⁴ and is increasing, mostly attributable to costly complications of the disease.⁵

Complications of longstanding diabetes include the microvascular complications of retinopathy and blindness, neuropathy, nephropathy, and end-stage kidney disease. In addition, there is a twofold to fourfold increased death rate from cardiovascular disease in adults with type 2 diabetes compared to adults without diabetes.⁶ Management of hyperglycemia using diet and pharmacologic therapy is the cornerstone of treatment for type 2 diabetes, along with management of coexisting lipid abnormalities and hypertension. Results from randomized controlled trials have demonstrated that the risk of microvascular complications, particularly retinopathy, can be reduced with good glycemic control in patients with type 2 diabetes.⁷⁻⁹ However, studies have had mixed results regarding the impact of intensive glycemic control (hemoglobin A1c [HbA1c] < 7 percent) on cardiovascular events and mortality. While older studies indicated that intensive glycemic control may reduce cardiovascular morbidity and mortality,^{10,11} recent studies have raised the possibility that intensive glycemic control has either no effect or a negative effect on cardiovascular morbidity and mortality.^{12,13} These mixed results suggest the need for further research, including investigation of the long-term safety of glucose-lowering therapies.^{8,11,14}

Early data from the United Kingdom Prospective Diabetes Study suggested a protective effect of improved glucose control on cardiovascular disease morbidity and mortality. In particular, treatment with metformin compared with sulfonylureas and insulin resulted in greater cardiovascular benefit.⁸ However, in the last two years, several major trials have found no benefit from intensive glycemic control.¹²⁻¹³ In fact, the Action to Control Cardiovascular Disease in Diabetes study identified an increased risk for death from cardiovascular causes and higher total mortality among those participants treated with an intensive glucose control strategy.¹³ There have been concerns, too, about an increased risk of ischemic heart disease and congestive heart failure associated with specific oral hypoglycemic agents, specifically rosiglitazone, from the thiazolidinedione class.^{15,16} National trends in the treatment of diabetes have reflected the public's concern about this drug, with a 63 percent decrease in rosiglitazone use between 2004 and 2007.¹⁷⁻¹⁹

In 1995, the only drugs for treating diabetes were sulfonylureas and insulin. Since 1995 many new pharmacotherapy options have become available. Currently there are 11 classes of diabetes medications, including sulfonylureas, meglitinides, glucagon-like peptide-1 (GLP-1) receptor agonists, biguanides, an amylin analogue, thiazolidinediones, bromocriptine, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, colesevalam (a bile-acid sequestrant), and

insulins (Table 1).¹⁷ The newer agents are more costly than the older medications, and some are only approved as adjunctive therapies.

Table 1. Characteristics of medications included in this report

Drug	Trade name	Dosing	Cost in U.S. dollars*
ORAL AGENTS			
Biguanides			
Metformin	Glucophage, Glucophage XR	Oral: 500 to 2550 mg divided doses (qd to tid) Max dose: 2550 mg; 2000 mg for XR	Tablets 500 mg (100): \$35.57 850 mg (100): \$38.63 1000 mg (100): \$45.97 Tablet, 24-hour 750 mg (100): \$114.98
Thiazolidinediones			
Pioglitazone	Actos	Oral: 15 to 30 mg qd max dose: 45 mg qd	15 mg (30): \$144.36 30 mg (30): \$220.61 45 mg (30): \$239.29
Rosiglitazone	Avandia	Oral: 4 to 8 mg qd or 2 to 4 mg bid max dose: 8 mg qd or 4 mg qd with insulin or sulfonylurea	2 mg (60): \$158.94 4 mg (30): \$117.95 8 mg (30): \$214.31
Sulfonylureas			
Glimepiride	Amaryl	Oral: 1 to 8 mg qd max dose: 8 mg qd	1 mg (100): \$13.41 2 mg (100): \$21.74 4 mg (100): \$41.00
Glipizide	Glucotrol, Glucotrol XL or GITS	Oral: 5 to 15 mg qd or 5 to 20 mg bid max dose: 20 mg bid, 20 mg qd for XL	Tablets 5 mg (100): \$64.07 10 mg (100): \$117.58 Tablet, 24-hour 2.5 mg (30): \$19.00 5 mg (100): \$63.34 10 mg (100): \$125.52
Glyburide	Micronase, Diabeta, Glynase Prestab	Oral: 2.5-20 mg qd or bid max dose: 20 mg qd	Tablets 1.25 mg (100): \$12.44 2.5 mg (100): \$18.93 5 mg (30): \$28.31
Dipeptidyl peptidase-4 inhibitors			
Sitagliptin	Januvia	Oral: 25 to 100 mg qd recommended dose is 100 mg qd	100 mg (30): \$192.52
Saxagliptin	Onglyza	Oral: 2.5-5 mg qd	Not listed
Meglitinides			
Repaglinide	Prandin	Oral: 0.5 to 4 mg before meals max dose: 16 mg	0.5 mg (100): \$194.14 1 mg (100): \$194.14 2 mg (90): \$194.14
Nateglinide	Starlix	Oral: 60 to 120 mg before meals	60 mg (100): \$177.31 120 mg (100): \$184.22
NON-INSULIN SUBCUTANEOUS AGENTS			
GLP-1 agonists			
Exenatide injection	Byetta	SC injection: 5-10 mcg SC bid	5 mcg/0.02 mL solution 1.2 mL: \$231.20 10 mcg/0.04 mL solution 2.4 mL: \$271.32
Liraglutide injection	Victoza	SC injection: 1.6-1.8 mg SC qd	Not listed
INSULIN			
Long- or intermediate-acting insulin			
NPH insulin	Humulin N Novolin N	NA	Humulin N: 100 unit/mL suspension 10 mL vial: \$33.20 Novolin N: not listed

Table 1. Characteristics of medications included in this report (continued)

Drug	Trade name	Dosing	Cost in U.S. dollars*
Insulin detemir	Levemir	NA	100 unit/mL solution 10 mL vial: <i>\$103.18</i>
Insulin glargine	Lantus	1-80 units daily	100 unit/mL solution 10 mL vial: <i>\$103.16</i>
Premixed insulin			
50% NPH: 50% Regular	Humulin 50/50	NA	Not listed
70% NPH: 30% Regular	Humulin 70/30 Novolin 70/30	NA	Humulin: 10 mL vial: <i>\$143.34</i>
50% lispro protamine suspension: 50% lispro	Humalog Mix 50/50	NA	10 mL vial: <i>\$111.24</i>
75% lispro protamine suspension: 25% lispro	Humalog Mix 75/25	NA	10 mL vial: <i>\$111.24</i>
70% aspart protamine suspension: 30% aspart	NovoLog Mix 70/30	NA	10 mL vial: <i>\$111.20</i>

bid = twice daily; GITS = gastrointestinal therapeutic system; HCl = hydrogen chloride; max = maximum; mcg = micrograms; mg = milligram; mL = milliliter; NA = not applicable; NPH = neutral protamine Hagedorn; qd = once daily; SC = subcutaneous; tid = three-times daily; U.S. = United States; XL = extended release; XR = extended release

Used Micromedix: <http://www.thomsonhc.com/hcs/librarian> for pharmaceutical information.

*Information provided includes dose, pill count, and cost in U.S. dollars (Red Book Pharmacy's Fundamental Reference, 2009 Edition); Prices for branded medications are italicized.

With the increasing number of available medication choices for diabetes, patients are being managed with a greater number of classes of medications in combination. During 2005–2006, 35.3 percent of all patients with diabetes were taking two classes of antidiabetes medications and 14.2 percent were taking three or more classes, compared to only 5.6 percent taking three or more classes during 1999–2000.²⁰ Some experts advocate earlier use of combination therapies to prevent the progressive beta cell failure associated with diabetes, but the evidence for this protection is still not clear.¹ With newer insulin products on the market since 2001, use of insulin has started to increase. Long-acting insulin glargine and the ultra-short-acting insulin lispro are the most commonly used individual insulin therapies in 2007.¹⁷

Rationale for Update of Review on Comparative Effectiveness of Diabetes Medications

In 2007, the Agency for Healthcare Research and Quality (AHRQ) published its first systematic review on the comparative effectiveness of oral hypoglycemic medications for type 2 diabetes.²¹ This comprehensive review was unique because it included comparisons of all oral diabetes medications. It also had a broad scope, including both intermediate outcomes like glycemic control and clinical outcomes like cardiovascular disease and nephropathy, as well as adverse events. This review of 216 studies concluded that most oral diabetes medications had a similar effect on reducing HbA1c, most drugs except for metformin and acarbose caused increases in body weight, and only metformin decreased low-density lipoprotein cholesterol. There were too few studies to support any conclusions about differential effects of the oral

diabetes medications on all-cause mortality, cardiovascular mortality and morbidity, and microvascular complications. The sulfonylurea class was shown to be associated with an increased risk of hypoglycemia, metformin with gastrointestinal problems, and the thiazolidinediones with heart failure.


In the years following publication of that review, enough studies were published to merit an update to address research gaps and integrate newer evidence. Since the first review, the Food and Drug Administration (FDA) approved two new medication classes. The noninsulin injectable GLP-1 agonists, exenatide and liraglutide, were FDA-approved in 2005 and 2010, respectively. The DPP-4 inhibitors, sitagliptin and saxagliptin, were FDA-approved in 2006 and 2009. Additionally, an update of the review was needed to include evidence about combinations of medications, including combinations of an oral medication with insulin therapy. Accordingly, AHRQ requested this update to the previously published work to amalgamate and update the previously published work.

Conceptual Model

Our conceptual model describes the decisions that patients and their providers face when managing type 2 diabetes pharmacologically (Figure 1). It highlights the comparisons and outcomes of interest that correspond to each of the key questions in our review.

When beginning medical treatment, patients usually begin with one of five drug classes, (Table 1) which have all been FDA-approved for monotherapy. These include biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, meglitinides, and the GLP-1 agonists. Clinical guidelines of the American Diabetes Association recommend monitoring the HbA1c to determine the need for changing the medication dose or adding another agent to improve glycemic control.^{22,23} If the HbA1c is not adequately controlled, clinicians typically add an additional oral hypoglycemic medication, or may add insulin or a noninsulin injectable medication like a GLP-1 agonist. Both intermediate- and long-term outcomes are monitored as indicators of effectiveness. Intermediate outcomes include HbA1c, weight, and lipids. In addition, clinicians monitor short-term and long-term safety and adverse effects of the drug.

Figure 1. Conceptual model



HbA1c = hemoglobin A1c; KQ=key question; NPH = neutral protamine Hagedorn

Scope and Key Questions

AHRQ commissioned this Comparative Effectiveness Review to update Comparative Effectiveness Review No. 8, The Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults with Type 2 Diabetes.²¹ Because of the rapid advances in the field of diabetes, with new medications on the market and the increasing use of medications in combination, AHRQ recognized the need to conduct an updated review and synthesis. We conducted a topic refinement process to identify the evidence gaps specified in the prior review, to assess the utility and impact of the review in subsequent guideline development, and to refine the key questions for this update. Based on this process, there are several notable distinctions from the 2007 Review, which include:

1. A focus on priority head-to-head drug comparisons, identified a priori as clinically relevant comparisons for which there were evidence gaps;
2. The inclusion of two newly FDA-approved medication classes: GLP-1 agonists (exenatide, liraglutide) and DPP-4 inhibitors (sitagliptin, and saxagliptin);
3. The inclusion of comparisons of two-drug combinations with a focus on:
 - a. Metformin and thiazolidinediones in combination with another medication;
 - b. Basal and premixed insulin therapy in combination with an oral medication;
4. The addition of safety outcomes, including fractures and macular edema; and
5. The exclusion of the alpha-glucosidase inhibitors (e.g., acarbose) because they are less frequently prescribed in the United States, have lower efficacy for glycemic control, and have high rates of gastrointestinal side effects limiting tolerability.²¹

Key Questions

We addressed the following key questions:

Key Question 1. In adults age 18 or older with type 2 diabetes mellitus, what is the comparative effectiveness of these treatment options (Table 2 and Appendix A) for the intermediate outcomes of glycemic control (in terms of HbA1c), weight, or lipids?

Key Question 2. In adults age 18 or older with type 2 diabetes mellitus, what is the comparative effectiveness of these treatment options (Table 2) in terms of the following long-term clinical outcomes?

- All-cause mortality
- Cardiovascular mortality
- Cardiovascular and cerebrovascular morbidity (e.g., myocardial infarction and stroke)
- Retinopathy
- Nephropathy
- Neuropathy

Key Question 3. In adults age 18 or older with type 2 diabetes mellitus, what is the comparative safety of the following treatment options (Table 2) in terms of the following adverse events and side effects?

- Hypoglycemia
- Liver injury

- Congestive heart failure
- Severe lactic acidosis
- Cancer
- Severe allergic reactions
- Hip and non-hip fractures
- Pancreatitis
- Cholecystitis
- Macular edema or decreased vision
- Gastrointestinal side effects

Key Question 4. Do safety and effectiveness of these treatment options (Table 2) differ across subgroups of adults with type 2 diabetes, in particular for adults age 65 or older, in terms of mortality, hypoglycemia, and cardiovascular and cerebrovascular outcomes?

Table 2. Priority medication comparisons included for each of the key questions

	Main intervention	Comparisons
Monotherapy as main intervention	Metformin	<ul style="list-style-type: none"> • Thiazolidinedione • Sulfonylurea • DPP-4 inhibitor • Meglitinides • GLP-1 agonist • Combination of metformin plus thiazolidinedione • Combination of metformin plus sulfonylurea • Combination of metformin plus DPP-4 inhibitor • Combination of metformin plus meglitinides
	Thiazolidinedione	<ul style="list-style-type: none"> • Different thiazolidinedione • Sulfonylurea • DPP-4 inhibitor • Meglitinides • GLP-1 agonist
	Sulfonylurea	<ul style="list-style-type: none"> • DPP-4 inhibitor • Meglitinides • GLP-1 agonist
	DPP-4 inhibitors	<ul style="list-style-type: none"> • DPP-4 inhibitor • Meglitinides • GLP-1 agonist
	Meglitinides	<ul style="list-style-type: none"> • GLP-1 agonist
Combination therapy as main intervention	Combination of metformin plus (a thiazolidinedione or a sulfonylurea or a meglitinide or DPP-4 inhibitor or GLP-1 agonist or a basal insulin or a premixed insulin)	<ul style="list-style-type: none"> • Combination of metformin plus (a thiazolidinedione or a sulfonylurea or a meglitinides or DPP-4 inhibitor or GLP-1 agonist or a basal insulin or a premixed insulin)
	Combination of metformin plus (a thiazolidinedione or a sulfonylurea or a meglitinides or DPP-4 inhibitor or GLP-1 agonist or a basal insulin or a premixed insulin)	<ul style="list-style-type: none"> • Combination of a thiazolidinedione plus (a sulfonylurea or a meglitinides or DPP-4 inhibitor or GLP-1 agonist)

DPP-4 inhibitor = dipeptidyl peptidase-4 inhibitor; GLP-1 agonist = glucagon-like peptide-1 receptor agonist

Methods

The Agency for Healthcare Research and Quality (AHRQ) requested an update to Comparative Effectiveness Review No. 8, Comparative Effectiveness and Safety of Oral Diabetes Medications For Adults with Type 2 Diabetes. In addition, AHRQ requested that the scope be broadened to include a review of the comparative effectiveness and safety of combinations of medications for diabetes treatment. Our Evidence-based Practice Center (EPC) established a team and a work plan to develop the evidence report. The project involved recruiting technical experts, formulating and refining the questions, performing a comprehensive literature search, summarizing the state of the literature, constructing evidence tables, synthesizing the evidence, and submitting the report for peer review.

Topic Development

The topic for this report was nominated in a public process. At the beginning of the project, we recruited a panel of internal and external technical experts and key informants to give input on key steps including the selection and refinement of the questions to be examined. The panel included internal technical experts from the Johns Hopkins University having expertise in various aspects of the efficacy and/or safety of oral diabetes medications, and external experts who have expertise in diabetes research.

To understand some of the pressing issues concerning the use of oral diabetes medications, we analyzed the recommendations in published guidelines on the treatment of type 2 diabetes. We conducted a search of PubMed and the National Guideline Clearinghouse for all guidelines concerning oral diabetes medications published since completion of the 2007 review. Two investigators reviewed each guideline for inclusion in this process. Guidelines needed to have been written in English, published after July 2007, and included recommendations on the medical management of type 2 diabetes in nonpregnant adults. Additionally, the guideline had to have been sponsored by or authorized by an organization in the United States, United Kingdom, or Canada, and met the criteria for a guideline.²⁴ For each included guideline, two reviewers abstracted the recommendations on medical management and whether the recommendations agreed with the key findings from the 2007 review.

With the technical experts and representatives of AHRQ and the Scientific Resources Center, and with our understanding of the gaps in existing guidelines, we developed the Key Questions that are presented in the Scope and Key Questions section of the Introduction. The final Key Questions focus on the differences among oral diabetes medications, used as monotherapy and used in combination, in their ability to affect intermediate outcomes, long-term clinical outcomes, and their adverse effects.

Search Strategy

We searched the following databases for primary studies for the periods in parentheses: MEDLINE® (1966 to April 2010), Embase® (1974 to April 2010), and the Cochrane Central Register of Controlled Trials (1966 to April 2010). We updated the MEDLINE search to December 2010 for long-term clinical outcomes (i.e., all-cause mortality, cardiovascular morbidity and mortality, nephropathy and neuropathy). We developed a search strategy for MEDLINE, accessed via PubMed, based on an analysis of the medical subject headings (MeSH) terms and text words of key articles identified a priori. Our search strategy was similar to the one

used for the initial 2007 review,²¹ but it included terms for the additional medications included in this review (Appendix B).

In addition, we received the following material from the Scientific Resource Center:

- Medical reviews of rosiglitazone, pioglitazone, sitagliptin, glyburide, and metformin, combination of metformin and glipizide, combination of metformin and sitagliptin, insulin detemir, exenatide and postmarketing drug safety information on pioglitazone and insulin glargine from the FDA Web site,
- The Scientific Discussion sections of the European Public Assessment Reports for rosiglitazone, pioglitazone, sitagliptin, combination rosiglitazone and metformin, exenatide, insulin detemir, and insulin glargine,
- Health Canada Product Monographs for rosiglitazone, pioglitazone, sitagliptin, combination rosiglitazone and metformin, insulin glargine, and insulin detemir,
- Public registries of clinical trials, such as Clinical Study Results Web site (available at: www.clinicalstudyresults.org) and ClinicalTrials.gov (available at: www.clinicaltrials.gov).

We hand searched 15 journals that most likely to publish articles on this topic (see Appendix C) by scanning the table of contents of each issue for relevant citations from February 2009 through September 2009. We also reviewed the reference lists of each included article and relevant review articles.

The results of the searches were downloaded and imported into ProCite[®] version 5 (ISI ResearchSoft, Carlsbad, CA). We scanned for exact article duplicates, author/title duplicates, and title duplicates using the duplication check feature in ProCite.[®] From ProCite, the articles were uploaded to DistillerSR (Evidence Partners, Ottawa, Ontario, Canada), a Web-based software package developed for systematic review data management. This database was used to track the search results at the levels of title review, abstract review, article inclusion/exclusion, and data abstraction.

Study Selection

Two independent reviewers conducted title scans in parallel. For a title to be eliminated at this level, both reviewers had to indicate that it was ineligible. If they disagreed, the article was promoted to the next level (Appendix D, Title Review Form). The title review was designed to capture as many studies as possible that reported on the efficacy or safety of oral diabetes medications. These titles were promoted to the abstract review phase.

The abstract review phase was designed to identify studies reporting on the effects of oral diabetes medications on intermediate outcomes, long-term clinical outcomes, or adverse events and side effects (Appendix D, Abstract Review Form). Abstracts were reviewed independently by two investigators, and were excluded if both investigators agreed that the article met one or more of the exclusion criteria (see inclusion and exclusion criteria listed in Table 3). Differences between investigators regarding abstract inclusion or exclusion were resolved through consensus adjudication.

Articles promoted on the basis of abstract review underwent another independent parallel review to determine if they should be included for data abstraction (Appendix D, Article Review Form). Differences regarding article inclusion were resolved through consensus adjudication.

Table 3. Inclusion and exclusion criteria

Population and condition of interest	<input type="checkbox"/> All studies included patients with type 2 diabetes, non-insulin dependent diabetes mellitus, or adult-onset diabetes. We excluded studies that evaluated only patients with type 1 diabetes, impaired glucose tolerance, metabolic syndrome, maturity onset diabetes of youth, and gestational diabetes. <input type="checkbox"/> All studies included human subjects. <input type="checkbox"/> We excluded studies if they included only pregnant women or only subjects less than or equal to 18 years of age.
Interventions	<input type="checkbox"/> All studies must have evaluated an oral diabetes medication or drug combination of interest. <ul style="list-style-type: none"> ○ Biguanides (metformin) ○ Thiazolidinediones (rosiglitazone, pioglitazone) ○ Second-generation sulfonylureas (glyburide, glibenclamide, glipizide, glimepiride) ○ Dipeptidyl peptidase-4 inhibitor (sitagliptin, saxagliptin) ○ Meglitinides (repaglinide, nateglinide) ○ Glucagon-like peptide-1 analogs (exenatide, liraglutide) ○ Combination of metformin plus a thiazolidinedione ○ Combination of metformin plus a sulfonylurea ○ Combination of metformin plus dipeptidyl peptidase-4 inhibitor ○ Combination of metformin plus a meglitinide ○ Combination of metformin plus glucagon-like peptide-1 analog ○ Combination of metformin plus a basal insulin (insulin glargine, insulin detemir, NPH insulin) ○ Combination of metformin plus a premixed insulin (NPH/regular 50/50, NPH/regular 70/30, insulin lispro 50/50, insulin lispro 75/25, insulin aspart 70/30) ○ Combination of a thiazolidinedione and a sulfonylurea ○ Combination of a thiazolidinedione and a meglitinide <input type="checkbox"/> We excluded studies that did not specify the adjunctive medications, such as those stating use of “any oral hypoglycemic” or if the study listed possible medications without stratification of the results by treatment.
Comparisons of interest	<input type="checkbox"/> We excluded studies that did not have a comparison group. <input type="checkbox"/> Table 2 presents the diabetes medication comparisons of interest. We excluded studies that did not have one of these comparisons.
Outcomes	<input type="checkbox"/> We excluded studies that did not apply to the key questions. <input type="checkbox"/> For Key Question 1, we included the following outcomes: HgbA1c, weight, and serum lipid levels (HDL, LDL, TG). <ul style="list-style-type: none"> ○ We did not include data on total cholesterol or other measures of glycemic variability. <input type="checkbox"/> For Key Question 2, we included the following outcomes: all-cause mortality, cardiovascular disease mortality, cardiovascular and cerebrovascular disease morbidity, retinopathy, neuropathy, and nephropathy. <ul style="list-style-type: none"> ○ We excluded biologic markers of outcomes, such as vascular endothelial function or carotid intima medial thickness. <input type="checkbox"/> For Key Question 3, we included the following outcomes: hypoglycemia, liver injury, congestive heart failure, severe lactic acidosis, cancer, severe allergic reactions, hip and non-hip fractures, pancreatitis, cholecystitis, macular edema or decreased vision, and GI side effects.
Type of study	<input type="checkbox"/> We excluded articles not written in English, studies less than 3 months in duration, studies with less than 40 total subjects, articles with no original data (editorials, comments, letters). <input type="checkbox"/> For Key Question 1, we included only RCTs. <input type="checkbox"/> For Key Questions 2 and 3, we included only RCTs, non-RCTs, cohort studies with a comparison group, and case-control studies. <input type="checkbox"/> We included crossover studies for the outcomes of hypoglycemia, liver injury, and GI side effects regardless of the duration of the washout period. For all other outcomes, we included crossover studies only if the duration of the washout period was greater than 1 month.

GI = gastrointestinal; HDL = high density lipoprotein; HgbA1c = hemoglobin A1c; LDL = low density lipoprotein; NPH = neutral protamine Hagedorn; RCT = randomized controlled trial; TG = triglycerides

During both the abstract review and article review, reviewers indicated if there was a monotherapy comparison or a combination comparison of interest. For studies that were excluded because they did not involve a comparison of interest, reviewers still noted the comparison (see Appendix E for a list of the comparisons that were tallied).

The inclusion and exclusion criteria for this review differed from the initial review. First, this review includes interventions that were excluded from the initial review: dipeptidyl peptidase-4 (DPP-4) inhibitor, glucagon-like peptide-1 (GLP-1) analogs, combination metformin plus DPP-4 inhibitor, combination metformin plus a meglitinide, combination metformin plus GLP-1 analogs, combination of metformin plus a basal insulin, combination of metformin plus a premixed insulin, and combination thiazolidinedione plus a meglitinide. This review includes studies with unambiguous medication combinations but not studies in which participants were treated with unspecified adjunctive diabetes medications. We did not update the initial review on acarbose. Second, this review includes outcomes that were not included in the initial review: fractures, cholecystitis, and macular edema. We did not update the initial review on the outcomes of blood pressure, body mass index, 2-hour postprandial glucose, peripheral arterial disease, amputations, quality of life, functional status, anemia, thrombocytopenia, leucopenia, hypervolemia, and withdrawals due to adverse events.

Data Abstraction

We used a systematic approach for extracting data to minimize the risk of bias in this process. By creating standardized forms for data extraction, we sought to maximize consistency in identifying all pertinent data available for synthesis. If reviewers determined that an article addressed both efficacy and safety, multiple data abstraction forms were used.

Each article underwent double review by study investigators for data abstraction and assessment of study quality. The second reviewer confirmed the first reviewer's data abstraction for completeness and accuracy. Reviewer pairs were formed to include personnel with both clinical and methodological expertise. A third reviewer rereviewed a random sample of articles by the first two reviewers to ensure consistency in the data abstraction of the articles. Reviewers were not masked to the articles' authors, institution, or journal.²⁵ In most instances, data were directly abstracted from the article. If possible, relevant data were also abstracted from figures. Differences in opinion were resolved through consensus adjudication. For assessments of study quality, each reviewer independently judged study quality and rated items on quality assessment forms (Appendix D, Data Abstraction Review Forms).

For all articles, reviewers extracted information on general study characteristics (e.g., study design, study period, and followup), study participants (e.g., age, gender, race, weight/body mass index, hemoglobin A1c [HbA1c] levels, and duration of diabetes), eligibility criteria, interventions (e.g., initial, maximum, and mean doses, frequency of use, and duration of use), outcome measures and the method of ascertainment, and the results of each outcome, including measures of variability (Appendix D, Data Abstraction Review Forms).

All information from the article review process was entered into the DistillerSR database by the individual completing the review. Reviewers entered comments into the system whenever applicable. The DistillerSR database was used to maintain and clean the data, as well as to create detailed evidence tables and summary tables.

Quality Assessment

Article quality was assessed differently for randomized controlled trials (RCTs) and observational studies. For RCTs the dual, independent review of article quality was based on the Jadad criteria: (1) appropriateness of the randomization scheme, (2) appropriateness of the blinding, and (3) description of withdrawals and dropouts.²⁶ For the updated review, we also

included a question to evaluate the overall quality of the study, as suggested by the Guide for Conducting Comparative Effectiveness Reviews.²⁷

We developed a quality assessment tool for observational studies based on the recommendations in the Guide for Conducting Comparative Effectiveness Reviews²⁷ and quality forms previously developed by our EPC.²⁸ The quality assessment included items about the study setting, inclusion and exclusion criteria, key characteristics of enrolled subjects, details about the treatments, details about the outcomes and how they were measured, statistical analysis, losses to followup, and the overall study quality. For both the RCTs and the observational studies, the overall study quality was assessed as:

- **Good (low risk of bias).** These studies had the least bias, and the results were considered valid. These studies adhered to the commonly held concepts of high quality, including the following: a formal randomized controlled design; a clear description of the population, setting, interventions, and comparison groups; appropriate measurement of outcomes; appropriate statistical and analytic methods and reporting; no reporting errors; a low dropout rate; and clear reporting of dropouts.
- **Fair.** These studies were susceptible to some bias, but not enough to invalidate the results. They did not meet all the criteria required for a rating of good quality because they had some deficiencies, but no flaw was likely to cause major bias. The study may have been missing information, making it difficult to assess limitations and potential problems.
- **Poor (high risk of bias).** These studies had significant flaws that might have invalidated the results. They had serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.²⁷

In the initial 2007 review, we did not assess the quality of observational studies or nonrandomized trials.

We had high consistency between the primary and secondary reviewer; therefore, we report only the second reviewers' quality scores (the second reviewers generally had more research experience than the primary reviewers). We used our study quality assessment to help us understand differences in results between studies.

Applicability

Throughout the report, we discuss the applicability of studies in terms of the degree to which the study population, interventions, outcomes, and settings are typical of the treatment of individuals with type 2 diabetes who are receiving treatment in a usual care setting (conceived as outpatient treatment by internists, family physicians, and endocrinologists).

Data Analysis and Synthesis

For each Key Question, we created a set of detailed evidence tables containing all information extracted from eligible studies. We conducted meta-analyses when there were sufficient data (at least three trials) and studies were sufficiently homogenous with respect to key variables (population characteristics, study duration, and drug dose). We combined medications by class, except for the thiazolidinediones, which were considered as individual drugs (rosiglitazone and pioglitazone) due to their differences in effects.

For continuous outcomes, we recorded the mean difference between groups along with its measure of dispersion. If this was not reported, we calculated the point estimate using the mean difference from baseline for each group. If the mean difference from baseline was not reported, we calculated this from the baseline and final values for each group.²⁹ If no measure of dispersion was reported for the between-group difference, we calculated it using the sum of the variances for the mean difference from baseline for each group. If there were no measures of dispersion for the mean difference from baseline for each group, we calculated the variance using the standard deviation of the baseline and final values, assuming a correlation between baseline and final values of 0.5. If data were only presented in graphical form, we abstracted data from the graphs. For trials that had more than one dosing arm, we chose the arm that was most consistent with dosing in the other trials. When more than one followup interval was reported, we used the data from the followup most similar to the other trials. We reported the rest of the results descriptively. When data were not sufficient to combine in a meta-analysis, we summarized the outcomes by reporting the ranges of values for mean differences from baseline or mean differences between groups (when possible).

For Key Questions 2 and 3, we were unable to conduct meta-analyses on most of the outcomes due to methodologic diversity among the trials such as differences in definitions of selected outcomes or lack of sufficient numbers of trials to combine. When there were sufficient data (at least three trials) and the studies were considered to be similar with respect to important variables (population characteristics, drug comparisons, drug dosage, definition of outcome, and followup time), we performed meta-analyses.

For the outcome of hypoglycemia, we needed to generate categories for the outcomes to match those in the 2007 review. The studies included in the 2007 review had hypoglycemia outcomes categorized as total, serious, and those which led to withdrawal from the study. In order to pool these with the new studies, we categorized those outcomes as: (a) serious hypoglycemia or hypoglycemia leading to withdrawal from the study, and (b) all other. These were then combined with events categorized as: (a) severe hypoglycemia and (b) mild or moderate hypoglycemia, which were the categories for the newly abstracted studies. The categories were based on the definitions of hypoglycemia provided in the studies. Usually, severe hypoglycemia was defined as requiring assistance. In previously included studies from the 2007 review, the hypoglycemia outcomes were reported as the number of people with hypoglycemic episodes (not the number of events). Therefore, in integrating the previously and newly identified studies, we pooled the number of people with events. The number of events is reported descriptively when available. Several studies reported only the rates of events per time of followup; these, too, are described in the text. The count of individuals upon enrollment was used as the denominator for the prevalence of hypoglycemic events. For trials not amenable to pooling, the Mantel-Haenszel risk ratios were calculated with 95 percent confidence intervals surrounding the estimate (STATA Intercooled, version 9.2, StataCorp, College Station, TX).

For continuous outcomes, we used a random-effects model with the DerSimonian and Laird formula to derive pooled posttreatment weighted mean differences.³⁰ For the outcome of hypoglycemia, we calculated pooled odds ratios using the Peto method because trial arms had balanced sample sizes.³¹ Because congestive heart failure and ischemic heart disease were rare events, we calculated pooled fixed-effects odds ratios using the treatment arm continuity correction (reciprocal of the sample size in the opposite treatment group in cells with 0 events).³² Heterogeneity among the trials in all the meta-analyses was tested using a standard chi-squared test using a significance level of alpha less than or equal to 0.10. We also examined

heterogeneity among studies with an I^2 statistic, which describes the variability in effect estimates that is due to heterogeneity rather than random chance.³³ A value greater than 50 percent may be considered to have substantial variability. If heterogeneity was found, we attempted to determine potential reasons by conducting metaregression using study level characteristics such as baseline values, study duration, and dose ratio (dose ratio of drug 1 divided by dose ratio of drug 2). The dose ratio for each drug was calculated as the dose given in the study divided by the maximum approved dose of drug. We conducted sensitivity analyses by omitting one study at a time to assess the influence of any single study on the pooled estimate.

Because statistically significant findings are more likely to be published than studies without statistically significant results (publication bias), we examined whether there was evidence that smaller, negative studies appeared to be missing from the literature. We therefore conducted formal tests for publication bias using Begg's³⁴ and Eggers tests³⁵ including evaluation of the asymmetry of funnel plots for each comparison of interest for the outcomes where meta-analyses were conducted for Key Question 1. All meta-analyses were conducted using STATA (Intercooled, version 9.2, StataCorp, College Station, TX).

Unadjusted odds ratios were calculated in instances when the total number of deaths was reported for each arm, the total number of participants was reported for each arm, and when measures of association were either not calculated at all or when a comparator which was not of interest was used as the reference group. These unadjusted odds ratios and confidence intervals were calculated using SAS 9.1.3 using the PROC FREQ command.

Data Entry and Quality Control

After a second reviewer reviewed the data that had been entered into DistillerSR, adjudicated data were resubmitted into Web-based data collection forms by the second reviewer. Second reviewers were generally more experienced members of the research team. In addition, two additional investigators audited a random sample of the reviews to identify problems with data abstraction. If problems were recognized in a reviewer's data abstraction, the problems were discussed at a meeting with the reviewers. In addition, research assistants used a system of random data checks to assure data abstraction accuracy.

Rating the Body of Evidence

At the completion of our review, at least three investigators graded the quantity, quality, and consistency of the best available evidence addressing Key Questions 1, 2, and 3 by adapting an evidence grading scheme recommended by the Guide for Conducting Comparative Effectiveness Reviews.²⁷ We applied evidence grades to the bodies of evidence about each intervention comparison for each outcome. We assessed the strength of the study designs with RCTs considered best, followed by non-RCTs, and observational studies. We also assessed the quality and consistency of the best available evidence, including assessment of limitations to individual study quality (using individual quality scores), consistency, directness, precision, and the magnitude of the effect.

We classified evidence bodies pertaining to Key Questions 1, 2 and 3, into four basic categories: (1) "high" grade (indicating high confidence that the evidence reflects the true effect and further research is very unlikely to change our confidence in the estimate of the effect); (2) "moderate" grade (indicating moderate confidence that the evidence reflects the true effect and further research may change our confidence in the estimate of the effect and may change the estimate); (3) "low" grade (indicating low confidence that the evidence reflects the true effect

and further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate); and (4) “insufficient” grade (evidence is unavailable).

Peer Review and Public Commentary


A draft of the evidence report was reviewed by the peer reviewers, AHRQ representatives, and the EPC Program’s Scientific Resource Center. The draft report also was posted to a Web site for public comment. In response to the comments of the peer reviewers and the public, we revised the evidence report and submitted a summary of the comments and their disposition to AHRQ.

Results

Search Results

A summary of the search results is presented in Figure 2. From the search, we retrieved 20,748 unique citations. After a review of the titles and abstracts, 1,027 were deemed eligible for further review, and the full articles were retrieved. A total of 166 articles were included in this review.

Figure 2. Summary of the literature search (number of articles)



* Total may exceed number in corresponding box, as articles could be excluded for more than one reason at this level.

†71 studies were included in the 2007 review

CENTRAL = Central Register of Controlled Trials

Key Question 1. In adults age 18 or older with type 2 diabetes mellitus, what is the comparative effectiveness of the treatment options (see list of comparisons) for the intermediate outcomes of glycemic control (in terms of HbA1c), weight, or lipids?

Key Points and Evidence Grades

HbA1c

Monotherapy Versus Monotherapy

- Most oral diabetes medications had similar efficacy in achieving reductions in HbA1c, with absolute reduction by around 1 percent compared with baseline values. The strength of evidence was graded high for metformin versus sulfonylurea with a pooled between-group difference of 0.1 percent (95 percent confidence interval [CI] -0.1 percent to 0.3 percent). The strength of evidence was graded as moderate for the following comparisons: metformin versus thiazolidinediones, thiazolidinediones versus sulfonylureas, sulfonylureas versus repaglinide, and pioglitazone versus rosiglitazone.
- Metformin had a greater reduction in hemoglobin A1c (HbA1c) compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, with a pooled between-group difference of -0.4 percent (95 percent CI -0.5 percent to -0.2 percent), with moderate strength of evidence.

Combination Therapy Versus Monotherapy

- All combination therapies were better at reducing HbA1c than monotherapy regimens, with between-group differences of about 1 percent. The strength of evidence was graded high for metformin versus metformin plus thiazolidinediones, and metformin versus metformin plus sulfonylureas, and graded moderate for metformin versus metformin plus DPP-4 inhibitors.

Combination Therapy Versus Combination Therapy

- The combination of metformin plus thiazolidinedione had similar efficacy in reducing HbA1c compared to the combination of metformin plus sulfonylurea, with moderate strength of evidence.
- Nine other combination therapy comparisons had low strength of evidence, making it difficult to draw firm conclusions. However, the majority showed similar efficacy in reducing HbA1c.
 - Five combinations showed similar efficacy in reducing HbA1c: metformin plus repaglinide versus metformin plus thiazolidinedione, metformin plus sitagliptin versus metformin plus thiazolidinedione, metformin plus sulfonylurea versus metformin plus DPP-4 inhibitor, metformin plus thiazolidinedione versus metformin plus glucagon-like peptide-1 (GLP-1) agonist, and metformin plus GLP-1 agonist versus metformin plus basal insulin.
 - The combination of metformin plus GLP-1 agonist reduced HbA1c more than metformin plus DPP-4 inhibitors, with a pooled between-group difference of -0.6 percent (95 percent CI -0.8 percent to -0.4 percent). Two other comparisons only

minimally favored one combination over another with differences in HbA1c ranging from 0.03 percent to 0.09 percent: metformin plus sulfonylurea favored versus thiazolidinediones plus sulfonylurea, and thiazolidinediones plus sulfonylureas favored versus metformin plus thiazolidinediones.

Weight

Monotherapy Versus Monotherapy

- When compared with thiazolidinediones, metformin maintained or decreased weight with a pooled between-group difference of -2.6 kg (95 percent CI -4.1 kg to -1.2 kg). The strength of evidence was graded as high, favoring metformin.
- When compared with sulfonylureas, metformin maintained or decreased weight with a pooled between-group difference of -2.7 kg (95 percent CI -3.5 kg to -1.9 kg). The strength of evidence was graded as high, favoring metformin.
- Sulfonylureas had similar effects on body weight as the meglitinides when used as monotherapy, with a high evidence grade.
- When compared with sulfonylureas, GLP-1 agonists decreased weight (pooled between-group difference of -2.5 kg, 95 percent CI -3.8 kg to -1.1 kg). The strength of evidence was graded moderate favoring GLP-1 agonists.
- When compared with DPP-4 inhibitors, metformin had greater weight reduction (pooled between-group difference of -1.4 kg (95 percent CI -1.8 kg to -1.0 kg). The strength of evidence was graded as moderate, favoring metformin.
- Sulfonylureas caused slightly less weight gain when compared with thiazolidinediones (between-group difference of -1.2 kg, 95 percent CI -1.9 kg to -0.6 kg). While this was graded as low evidence for the monotherapy comparisons, it was strengthened by the combination comparisons (described below) which favor metformin plus sulfonylurea over metformin plus a thiazolidinedione (pooled between-group difference of -0.9 kg, 95 percent CI -1.3 kg to -0.4 kg) with a moderate grade of evidence.

Combination Therapy Versus Monotherapy

- Metformin monotherapy had a more favorable effect on weight compared with the combination of metformin plus a thiazolidinedione (between-group difference of -2.2 kg, 95 percent CI -2.6 kg to -1.9 kg) or metformin plus a sulfonylurea (pooled between-group difference of -2.3 kg, 95 percent CI -3.3 kg to -1.2 kg). The strength of evidence was graded high for these comparisons.
- Metformin monotherapy had no significant differences in weight when compared with the combination of metformin plus DPP-4 inhibitors (pooled between-group difference of -0.2 kg, 95 percent CI -0.7 kg to 0.2 kg). The strength of evidence was graded moderate for this comparison.

Combination Therapy Versus Combination Therapy

- Metformin plus sulfonylurea had a more favorable effect on weight compared with both the combinations of a thiazolidinedione plus sulfonylurea (between-group difference of -3.2 kg, 95 percent CI -5.2 kg to -1.1 kg) and metformin plus a thiazolidinedione (between-group difference of -0.9 kg, 95 percent CI -1.3 kg to -0.4 kg). Both comparisons had moderate strength of evidence.

- Several combination therapies, metformin plus sulfonylurea, metformin plus thiazolidinedione, metformin plus basal insulin, and metformin plus DPP-4 inhibitor, were compared with metformin plus GLP-1 agonists, all favoring the combination of metformin plus GLP-1 agonists which decreased weight.
 - While all the individual comparisons were graded as low evidence, the data as a whole suggested a beneficial effect on weight for the combination of metformin plus GLP-1 agonists compared with several other standard combination therapies. The range in between group differences was 1.9 kg to 12.3 kg, and all but one study had less than a 5 kg between-group difference.
- The combination of metformin plus DPP-4 inhibitors decreased weight when compared with the combinations of metformin plus thiazolidinedione or metformin plus sulfonylurea. While these individual comparisons are graded as low strength of evidence due to few studies with the same comparators, the data suggest that metformin plus DPP-4 inhibitors may have a more favorable effect on weight than the other two standard combinations. The range of between-group differences was small (1.5 kg to 2.5 kg).

Low-Density Lipoproteins.

Monotherapy Versus Monotherapy

- Metformin decreased low-density lipoproteins (LDL) while sulfonylureas generally had little effect on LDL (pooled between-group difference favoring metformin of -10.1 mg/dL, 95 percent CI -13.3 mg/dL to -7.0 mg/dL), with high strength of evidence.
- Rosiglitazone and pioglitazone increased LDL while metformin decreased LDL with moderate strength of evidence. The pooled between-group differences comparing metformin to rosiglitazone and pioglitazone were -12.8 mg/dL (95 percent CI -24.0 mg/dL to -1.6 mg/dL) and -14.2 mg/dL (95 percent CI -15.3 mg/dL to -13.1 mg/dL), respectively.
- Metformin decreased LDL compared to DPP-4 inhibitors, with a pooled between-group difference of -5.9 mg/dL (95 percent CI -9.8 mg/dL to -2.0 mg/dL), with moderate strength of evidence.

Combination Therapy Versus Monotherapy

- The combination of metformin and rosiglitazone increased LDL compared to metformin monotherapy (pooled between-group difference of 14.5 mg/dL, 95 percent CI 13.3 mg/dL to 15.7 mg/dL), with high strength of evidence.

Combination Therapy Versus Combination Therapy

- The combination of metformin and a sulfonylurea decreased LDL more than the combination of metformin and rosiglitazone (pooled between-group difference -13.5 mg/dL, 95 percent CI -17.9 mg/dL to -9.1 mg/dL), with moderate strength of evidence.

High-Density Lipoproteins

Monotherapy Versus Monotherapy

- Pioglitazone increased high-density lipoproteins (HDL) compared to metformin (pooled between-group difference of 3.2 mg/dL, 95 percent CI 2.1 mg/dL to 5.7 mg/dL) with high strength of evidence.
- Neither rosiglitazone nor sulfonylureas had an effect on HDL relative to metformin, with high strength of evidence for sulfonylureas and moderate for rosiglitazone
- Rosiglitazone increased HDL less than pioglitazone (pooled between-group difference of -2.3 mg/dL, 95 percent CI -3.5 mg/dL to -1.2 mg/dL), with moderate strength of evidence. Pioglitazone increased HDL when compared with sulfonylureas (pooled between-group difference of 4.3 mg/dL, 95 percent CI 1.9 mg/dL to 6.6 mg/dL), with moderate strength of evidence.

Combination Therapy Versus Monotherapy

- The combination of rosiglitazone and metformin increased HDL relative to metformin monotherapy (pooled between-group difference of 2.8 mg/dL, 95 percent CI 2.2 mg/dL to 3.5 mg/dL), with high strength of evidence.
- The combination of metformin and DPP-4 inhibitors did not affect HDL relative to metformin monotherapy. The pooled between-group difference in HDL for metformin compared to the combination of metformin and saxagliptin was 0.5 mg/dL (95 percent CI -1.5 mg/dL to 2.5 mg/dL) with moderate strength of evidence

Combination Therapy Versus Combination Therapy

- The combination of rosiglitazone or pioglitazone with metformin increased HDL compared to the combination of metformin and a sulfonylurea. The strength of evidence was graded as moderate for these comparisons:
 - The pooled between-group difference for the combination of metformin and rosiglitazone compared to the combination of metformin and a sulfonylurea was 2.7 mg/dL (95 percent CI 1.4 mg/dL to 4.1 mg/dL).
 - The combination of metformin and pioglitazone increased HDL by about 5 mg/dL compared to the combination of metformin and a sulfonylurea.
- The combination comparisons with pioglitazone favored the pioglitazone containing arm (range of between-group differences were 3.1 mg/dL to 10.5 mg/dL) for the following comparisons:
 - The combination of pioglitazone plus metformin versus metformin monotherapy, the combination of metformin plus pioglitazone versus the combination of metformin plus sulfonylurea, and the combination of sulfonylurea plus pioglitazone versus the combination of metformin plus sulfonylurea. The strength of evidence was graded as low for each individual comparison.

Triglycerides

Monotherapy Versus Monotherapy

- Pioglitazone decreased triglycerides (TG) more than metformin (pooled between-group difference -27.2 mg/dL, 95 percent CI -30.0 mg/dL to -24.4 mg/dL), with high strength of evidence.
- Metformin decreased TG relative to rosiglitazone which increased TG (pooled between-group difference -26.9 mg/dL, 95 percent CI -49.3 mg/dL to -4.5 mg/dL), with moderate strength of evidence.
- Metformin decreased TG compared to sulfonylureas (pooled between-group difference -8.6 mg/dL, 95 percent CI -15.6 mg/dL to -1.6 mg/dL) with moderate strength of evidence.
- Sulfonylureas and meglitinides had similar effects on TG (pooled between-group difference 0.2 mg/dL, 95 percent CI -3.8 mg/dL to 4.2 mg/dL), with moderate strength of evidence.

Combination Therapy Versus Monotherapy

- Metformin monotherapy decreased TG compared to the combination of metformin and rosiglitazone (pooled between-group difference -14.5 mg/dL, 95 percent CI -15.7 mg/dL to -13.3 mg/dL), with high strength of evidence.

Combination Therapy Versus Combination Therapy

- The combination of metformin and rosiglitazone had similar effects on TG compared to a combination of metformin and a sulfonylurea, with moderate strength of evidence.
- The combination of metformin and pioglitazone decreased TG compared to the combination of metformin and a sulfonylurea by about 15 mg/dL, with moderate strength of evidence.

See Table 4 for the evidence grades and specific conclusions for each comparison. Details of the evidence grades are in Appendix G, Table 1.

Study Design and Population Characteristics

One hundred nineteen randomized controlled trials (RCTs) (reported in 122 articles) evaluated intermediate clinical outcomes for adults with type 2 diabetes, and met our inclusion criteria (Appendix G, Tables 2 and 3). One hundred four, 79, and 74 of these RCTs reported HbA1c, weight, and lipid outcomes, respectively. All trials were parallel-arm RCTs except one, which used a crossover design.³⁶ About half the trials answering Key Question 1 occurred partly or exclusively in the United States (n = 32), Italy (n = 13), and/or were multinational (n = 28); the rest of the trials occurred in developed or newly industrialized countries. These RCTs lasted from 12 weeks to 9 years; however, most studies lasted less than a year and only three studies lasted more than 2 years (United Kingdom Prospective Diabetes Study [UKPDS], Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes [RECORD], and A Diabetes Outcome Progression Trial [ADOPT]).^{16,37,38} Only seven studies reported receiving no pharmaceutical support,³⁹⁻⁴⁵ while about one-quarter of RCTs (n = 33) did not describe whether or not they received pharmaceutical support.

Study participants were mainly middle-aged, overweight or obese adults who had diabetes between 3 to 6 years duration. The exclusion criteria were generally similar for most trials: significant renal, cardiovascular, and hepatic disease. About half the trials (58 percent) excluded older subjects (generally older than 75 to 80 years old). Almost all the studies reported a diverse gender mix among the participants. About 20 percent of the RCTs did not report race. When race was reported, most subjects were Caucasian. The mean baseline HbA1c among study subjects varied from 6 to 12 absolute percentage points, with most subjects having a mean baseline HbA1c between 7 and 9 absolute percentage points.

Table 4. Key findings and strength of the evidence comparing diabetes medications as monotherapy or combination therapy for intermediate outcomes

Comparison	HbA1c	Weight/BMI	LDL	HDL	TG
MONOTHERAPY COMPARISONS					
Metformin versus					
TZD	Neither Favored; Mod	Favors Met; High	Favors Met; Mod [†] Favors Met; High [§]	Neither Favored; Mod [†] Favors Pio; High [§]	Favors Met; Mod [†] Favors Pio; High [§]
SU	Neither Favored; High	Favors Met; High	Favors Met; High	Neither Favored; High	Favors Met; Mod
DPP-4 inhibitor	Favors Met; Mod	Favors Met; Mod	Favors Met; Mod	Neither Favored; Low	Neither Favored; Low
Meglitinides	Neither Favored; Low* Favors Met; Low [†]	Unclear; Low	Unclear; Low	Unclear; Low	Unclear; Low
GLP-1 agonist	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + TZD	Favors Met+TZD; High	Favors Met; High	Favors Met; High [†] Unclear; Low [§]	Favors Met+Rosi; High [†] Favors Met+Pio; Low [§]	Favors Met; High [†] Unclear; Low [§]
Metformin + SU	Favors Met+SU; High	Favors Met; High	Neither Favored; Low	Neither Favored; Low	Neither Favored; Low
Metformin + DPP-4 inhibitor	Favors Met+DPP-4; Mod	Neither Favored; Mod	Neither Favored; Low	Neither Favored; Mod	Favors Met+DPP-4; Low
Metformin + meglitinides	Favors Met+Meg; Low	Favors Met; Low	Unclear; Low	Neither Favored; Low	Favors Met+Meg; Low
TZD versus					
TZD	Neither Favored; Mod	Neither Favored; Low	Favors Pio; Low	Favors Pio; Mod	Neither Favored; Low
SU	Neither Favored; Mod	Favors SU; Low	Favors SU; Low ^{†§}	Favors Rosi; Low [†] Favors Pio; Mod [§]	Unclear; Low [†] Favors Pio; Low [§]
DPP-4 inhibitor	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
Meglitinides	Unclear; Low* Neither Favored; Low [†]	Unclear; Low	Unclear; Low ^{†§}	Unclear; Low [†] Favors Pio; Low [§]	Unclear; Low [†] Favors Pio; Low [§]
GLP-1 agonist	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
SU versus					
DPP-4 inhibitor	Neither Favored; Low	Unclear; Low	Neither Favored; Low	Neither Favored; Low	Neither Favored; Low
Meglitinides	Neither Favored; High* Neither Favored; Low [†]	Neither Favored; High	Neither Favored; Low	Neither Favored; High	Neither Favored; Mod
GLP-1 agonist	Unclear; Low	Favors GLP-1; Mod	Unclear; Low	Insufficient	Unclear; Low
DPP-4 inhibitor versus					
Meglitinides	Insufficient	Insufficient	Insufficient	Unclear; Low	Insufficient
GLP-1 agonist	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient

Table 4. Strength of the evidence and conclusion comparing diabetes medications as monotherapy or combination therapy for intermediate outcomes (continued)

Comparison	HbA1c	Weight/BMI	LDL	HDL	TG
COMBINATION COMPARISONS					
Metformin + TZD versus					
Metformin + SU	Neither favored; Mod	Favors Met+SU; Mod	Favors Met+SU; Mod [†] Favors Met+SU; Low [§]	Favors Met+Rosi; Mod [‡] Favors Met+Pio; Low [§]	Neither favored; Mod [†] Favors Met+Pio; Mod [§]
Metformin + meglitinides	Neither favored; Low* Insufficient [†]	Unclear; Low	Favors Met+Meg; Low [†] Insufficient [§]	Favors Met+Rosi; Low [‡] Insufficient [§]	Neither favored; Low [†] Insufficient [§]
Metformin + DPP-4 inhibitor	Neither favored; Low	Favors Met+DPP4; Low	Insufficient ^{†§}	Low; Unclear [‡] Insufficient [§]	Low; Favors Met+Sita [‡] Insufficient [§]
Metformin + GLP-1 agonist	Neither favored; Low	Favors Met+GLP1; Low	Unclear; Low ^{†§}	Favors Met+Rosi; Low [‡] Insufficient [§]	Favors Met+GLP1; Low [†] Insufficient [§]
TZD + SU	Favors TZD+SU; Low	Insufficient	Insufficient [†] Neither favored; Low [§]	Insufficient [†] Favors Met+Pio; Low [§]	Insufficient [†] Favors Met+Pio; Low [§]
Met + SU versus					
Metformin + meglitinides	Insufficient* Unclear; Low [†]	Unclear; Low	Unclear; Low	Neither favored; Low	Unclear; Low
Metformin + DPP-4 inhibitor	Neither favored; Low	Favors Met+DPP4; Low	Insufficient	Insufficient	Insufficient
Metformin + GLP-1 agonist	Unclear; Low	Favors Met+GLP1; Low	Insufficient	Insufficient	Insufficient
TZD + SU	Favors Met+SU; Low	Favors Met+SU; Mod	Unclear; Low [†] Favors Met+SU; Low [§]	Unclear; Low [†] Favors Pio+SU; Low [§]	Unclear; Low [†] Favors Pio+SU; Low [§]
Metformin + premixed insulin	Unclear; Low	Favors Met+Basal; Low	Insufficient	Insufficient	Insufficient
Met + Basal Insulin versus					
Metformin + premixed insulin	Neither favored; Low	Neither favored; Low	Insufficient	Insufficient	Insufficient
Metformin + GLP-1 agonist	Neither favored; Low	Favors Met+GLP1; Low	Insufficient	Insufficient	Insufficient
Met + DPP-4 inhibitor versus					
Met + GLP-1 agonist	Favors Met+GLP1; Low	Favors Met+GLP1; Low	Unclear; Low	Neither favored; Low	Unclear; Low

BMI = body mass index; HDL = high density lipoprotein; HbA1c = hemoglobin A1c; Meg = meglitinides; Met = metformin; LDL = low density lipoprotein; Pio = pioglitazone; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TG = triglycerides; TZD = thiazolidinedione

* For comparisons with repaglinide

† For comparisons with nateglinide

‡ For comparisons with rosiglitazone

§ For comparisons with pioglitazone


The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Mod = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

All other comparisons and intermediate outcomes were graded as insufficient since there were no studies.

The Evidence About Hemoglobin A1c (Appendix G, Table 4)

Metformin versus thiazolidinediones. Fourteen RCTs lasting around a year or less directly compared metformin versus thiazolidinedione, showing no between-group differences in HbA1c, with a pooled between-group difference of -0.1 percent (95 percent CI -0.2 percent to 0.04 percent) (Figure 3).^{39,45-57} We conducted a standard sensitivity analysis testing the relative effect of each individual study to the combined point estimate. Only removing the study by Lawrence et al. affected the combined point estimate resulting in a pooled mean difference of -0.1 percent (95 percent CI -0.2 percent to -0.003 percent) which minimally favored metformin. However, we have no reason to exclude this small comparably dosed RCT, especially given the unlikely clinical relevance of such a minimal difference. No substantial heterogeneity was noted.

Figure 3. Mean difference in HbA1c comparing metformin with thiazolidinediones



CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 14.47$ with 13 degrees of freedom ($p = 0.34$)

I-squared statistic = 10%


The range in change scores for HbA1c for the comparison group, thiazolidinediones, was -2.6% to -0.3%. The median change was -1.0%.

We excluded two studies from the meta-analysis, one with a median study duration of 4 years³⁸ and one which reported median HbA1c instead of means.⁵⁸ The 4-year double-blind RCT (known as the ADOPT study) was designed to compare long-term glycemic control between metformin, rosiglitazone, and glyburide monotherapy as initial treatment for type 2 diabetic adults.³⁸ While they found a statistically significant difference between groups favoring rosiglitazone (mean difference between groups 0.1 percent, 95 percent CI 0.05 percent to 0.2 percent), the clinical relevance of this difference is less clear. Of note, the HbA1c decreased

in all groups for the first 6 months, and then increased in all groups over the rest of the study. The other short-duration RCT excluded from the meta-analysis was consistent with the pooled results, reporting no between-group differences in median HbA1c.⁵⁸

Metformin versus sulfonylureas. We combined 17 studies comparing metformin with a second-generation sulfonylurea and showed similar changes in HbA1c in both groups, with a pooled between-group difference of 0.1 percent (95 percent CI -0.1 percent to 0.3 percent) (Figure 4).^{36,50,51,53,59-71} Removing the 1-year study by DeFronzo et al. changed the results of the meta-analysis, favoring second-generation sulfonylureas slightly with a pooled between-group difference of 0.2 percent (95 percent CI 0.02 percent to 0.3 percent);⁷⁰ which may reflect the slightly longer study duration.

Figure 4. Mean difference in HbA1c comparing metformin with sulfonylureas



CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 43.22$ with 16 degrees of freedom ($p = 0.003$)
 I-squared statistic = 63%
 The range in change scores for HbA1c for the comparison group, sulfonylureas, was -2.5% to 0.5%. The median change was -1.2%.

While most of the point estimates were close to zero, substantial heterogeneity was found. Metaregression suggested that study duration may explain some of the heterogeneity ($p = 0.09$). Studies lasting less than 6 months seemed to favor sulfonylureas slightly (pooled between-group difference of 0.2 percent, 95 percent CI 0.01 percent to 0.3 percent), while those lasting 6 months to a year showed no between-group differences in medications (pooled between-group difference of -0.1 percent, 95 percent CI -0.5 percent to 0.3 percent). The small possible difference of 0.18

percent seen with studies lasting less than 6 months has questionable clinical relevance. Baseline HbA1c and dosing ratio did not explain the heterogeneity.

The two long-term studies excluded from the meta-analysis (ADOPT and UKPDS) lasting longer than 4 years have conflicting results related to glycemic control. ADOPT favored metformin over sulfonylurea after a median followup of 4 years.³⁸ UKPDS appeared to favor sulfonylurea over metformin in overweight individuals on monotherapy after 9 years of followup, while showing no between-group differences in mean HbA1c after 10 years of followup for those subjects where other diabetes medications were added to their monotherapy regimen.⁸ These differences could be due to different types of sulfonylureas between studies, study duration, or study design components such as double-blind versus open label.

The ADOPT study was excluded from the meta-analysis since the median followup was 4 years compared with the other shorter duration studies lasting less than 1 year.³⁸ As mentioned previously, this double-blind RCT evaluated the long-term glycemic control between metformin, rosiglitazone, and glyburide monotherapy as initial treatment for type 2 diabetic adults. The between-group difference between metformin and glyburide favored metformin after 4 years (mean difference between-groups of -0.3 percent, 95 percent CI -0.2 percent to -0.4 percent). Of note, the glyburide group reduced HbA1c more than metformin initially, but then the HbA1c started to rise after about 6 months in all groups. The HbA1c rose more in the glyburide arm compared with the metformin arm by 1.5 years after treatment was started.

One of the UKPDS studies was included in this report since the article evaluated only those overweight individuals assigned metformin or sulfonylurea who did not have a second medication added over time.³⁷ They compared the proportion of subjects who achieved a target HbA1c less than 7 percent after 9 years of followup between metformin and sulfonylurea, and appeared to favor sulfonylurea slightly (13 percent versus 21 percent respectively with nonoverlapping confidence intervals). However, only 25 percent of subjects were able to achieve a target HbA1c after 9 years on monotherapy alone.


The rest of the UKPDS⁷²⁻⁷⁴ studies were excluded from this section of the report since they were allowed to add other diabetes medications to their initial monotherapy groups, making it impossible to discern comparative drug effects. We describe it here briefly since it is a well known study with the longest followup (up to 10 years). The UKPDS was a multicenter trial conducted in the United Kingdom comparing different types of treatment for type 2 diabetes. Patients were recruited starting in 1977, and initially put on a diet with 50 percent carbohydrates, high fiber, reduced calories if obese, and low saturated fat. After 3 months, subjects were randomized to treatment arms or diet based on the fasting plasma glucose. If subjects had very high serum glucose values and symptoms of hyperglycemia prior to the 3-month main randomization, they were randomized to treatment early without a diet arm (the primary diet failure group). Both groups (the main randomization and the primary diet failure groups) were randomized to medications stratified by weight. If subjects were overweight based on ideal body weight, they could be randomized to insulin, chlorpropamide, glibenclamide, metformin, or diet. If they were not overweight, they could be randomized to insulin, diet, chlorpropamide, or glibenclamide. No metformin arm was available if the patient was not overweight. Metformin, glibenclamide, and insulin could be added to any of the groups if a participant was still hyperglycemic based on study protocols. Losses to followup were less than or equal to 5 percent in both the primary diet failure and main randomization groups.

The 1-year, 3-year, 6-year, and 10-year data all showed similar changes in HbA1c between groups.^{8,72-74} After 10 years, the change in median HbA1c from baseline was similar in both the

metformin and glibenclamide arms for the main randomization group as reported in a figure (+1.3 percent versus +1.0 percent).⁸ The median HbA1c results were not broken down by medication type in the primary diet failure group at 10 years. After 6 years, the reported 95 percent CI for the mean final HbA1c was 7.1 percent to 9.4 percent for metformin and 6.8 percent to 9.7 percent for glibenclamide/chlorpropamide in overweight patients in the primary diet failure group.⁷² Of note, the main randomization group of UKPDS demonstrated that HbA1c was reduced within the first few years of the study for patients on either glibenclamide or metformin then began to rise again for all medications.⁸

Metformin versus DPP-4 inhibitors. Three short-duration RCTs (reported in four articles) compared metformin with DPP-4 inhibitors, reporting greater reductions in HbA1c by metformin, with a pooled between-group difference of -0.4 percent (95 percent CI -0.5 percent to -0.2 percent) (Figure 5).⁷⁵⁻⁷⁸ Two studies used metformin compared with sitagliptin,^{76,77} and one study compared metformin with saxagliptin.⁷⁸ One RCT was reported in two articles.^{75,76} The first article was a 24-week RCT,⁷⁵ while the second article was the 30-week continuation study with a higher loss to followup.⁷⁶ The between-group difference in HbA1c of -0.5 percent favored metformin over sitagliptin at both 24 and 54 weeks of followup. We included the 24-week study in the meta-analysis since the other two studies in the meta-analysis were both 24 weeks long. No substantial heterogeneity was found in the meta-analysis. A standard sensitivity analysis was conducted to determine if any one study strongly influenced the results. The removal of the study by Goldstein et al.⁷⁵ changed the pooled between-group difference to -0.2 percent (95 percent CI -0.5 percent to 0.008 percent), showing no significant differences between-groups. There would be no reason to exclude this trial compared to the other trials, however. In fact, one study used an underdosed metformin arm compared to the maximum dose DPP-4 inhibitor, thereby strengthening the result that favors metformin.⁷⁸

Figure 5. Mean difference in HbA1c comparing metformin with DPP-4 inhibitors



CI = confidence interval; diff = difference; DPP-4 inhibitors = dipeptidyl peptidase-4 inhibitors; HbA1c = hemoglobin A1c
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 1.87$ with 2 degrees of freedom ($p = 0.39$)


I-squared statistic = 0%

The range in change scores for HbA1c for the comparison group, DPP-4 inhibitors, was -1.7% to -0.4%. The median change was -0.7%.

Metformin versus meglitinides. Three RCTs (reported in four articles) lasting 3 months to 1 year compared metformin with meglitinides, showing similar effects on HbA1c.⁷⁹⁻⁸² One study favored the slightly underdosed metformin arm compared with the nateglinide arm (-0.3 percent between-group difference).⁷⁹ This same study reported in a second article showed no between-group differences in HbA1c; however, they evaluated only the subset of patients who were treatment naïve.⁸⁰ The other two studies evaluated metformin and repaglinide at comparable doses showing non-meaningful between-group differences of 0.1 percent and 0.05 percent.^{81,82}

Metformin versus a combination of metformin and thiazolidinediones. Eleven studies compared metformin with the combination of metformin plus a thiazolidinedione (most rosiglitazone except for four studies with pioglitazone),^{46,49,56,83-90} showing a greater improvement in HbA1c with the combination in all the studies. The pooled between-group difference was 0.7 percent (95 percent CI 0.5 percent to 0.9 percent) (Figure 6). No single study markedly affected the results. Despite the substantial heterogeneity reported, all studies favored the combination arm. Metaregression showed that baseline HbA1c was a significant source of heterogeneity ($p = 0.01$) while study duration and dosing ratio were not. Studies with higher baseline HbA1c (HbA1c > 8 percent) had greater between-group differences (pooled between-group difference of 0.9 percent (95 percent CI 0.7 percent to 1.1 percent) than studies with lower baseline HbA1c (HbA1c < 8 percent; pooled between-group difference of 0.4 percent, 95 percent CI 0.2 percent to 0.7 percent).

Figure 6. Mean difference in HbA1c comparing metformin with combination of metformin and thiazolidinediones



CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 63.83$ with 10 degrees of freedom ($p = 0.0000$)


I-squared statistic = 84%

The range in change scores for HbA1c for the comparison group, a combination of metformin and thiazolidinediones, was -2.3% to -0.33%. The median change was -0.83%.

Metformin versus a combination of metformin and sulfonylureas. Fourteen RCTs compared metformin with the combination of metformin plus a second-generation sulfonylurea with all of the studies favoring the combination arm over monotherapy (pooled between-group difference of 1.0 percent, 95 percent CI 0.8 percent to 1.3 percent) (Figure 7).^{36,46,59,61-65,68-71,91,92}

No single study markedly influenced the results. Metaregression was conducted due to substantial heterogeneity, showing that higher dose combinations had greater between-group effects and lower dose combinations had smaller between-group effects ($p = 0.002$). The study by Blonde et al. showed the greatest between-group differences since this study used a high-dose combination and started with the highest baseline HbA1c compared with other studies.⁶³ Three of the six dose-response studies showed a dose-response gradient favoring greater reductions in HbA1c with a higher dose combination than with a lower dose combination.^{63,64,68} One crossover study initially showed a difference between groups at the first crossover and then a negative rebound effect when changing the combination to monotherapy.³⁶

Figure 7. Mean difference in HbA1c comparing metformin with combination of metformin and sulfonylureas



CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.


Test for heterogeneity: $Q = 81.30$ with 13 degrees of freedom ($p = 0.0000$)

I-squared statistic = 84%

The range in change scores for HbA1c for the comparison group, a combination metformin and sulfonylurea, was -2.3% to -0.7%. The median change was -1.6%.

Metformin versus a combination of metformin and DPP-4 inhibitors. Six RCTs directly compared metformin with the combination of metformin plus a DPP-4 inhibitor—all favoring the combination arm, with a pooled between-group difference of 0.7 percent (95 percent CI 0.6 percent to 0.8 percent) (Figure 8).^{75,78,85,93-95} No single study markedly influenced the results, and no substantial heterogeneity was found. One RCT was published twice, first with the 24-week RCT results⁷⁵ and second as a 30-week continuation⁷⁶ to that same study. We included the shorter duration results in the meta-analysis since the study duration was more homogenous with the rest of the studies, plus had less loss to followup.⁷⁵ The 54-week results also favored the combination arm over the monotherapy arm, with a between-group difference of 0.8 percent.⁷⁶ They also showed a small dose-response effect in the combination arms, with the 2,000 mg metformin and 100 mg sitagliptin arm reducing HbA1c more than the 1,000 mg metformin plus 100 mg sitagliptin arm (mean change from baseline -1.8 percent versus -1.4 percent respectively).

Figure 8. Mean difference in HbA1c comparing metformin with combination of metformin and DPP-4 inhibitors



CI = confidence interval; diff = difference; DPP-4 inhibitors = dipeptidyl peptidase-4 inhibitors; HbA1c = hemoglobin A1c
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 179.59$ with 5 degrees of freedom ($p = 0.00$)
 I-squared statistic = 97%
 The range in change scores for HbA1c for the comparison group, a combination of metformin and DPP-4 inhibitor, was -2.5% to -0.7%. The median change was -0.9%.

Metformin versus a combination of metformin and meglitinides. Three RCTs compared metformin with combination of metformin plus meglitinides, all favoring the combination arm (range in between-group differences of -0.5 percent to -1.08 percent). We separated out nateglinide from repaglinide combinations since indirect monotherapy comparisons suggest nateglinide has less effect on HbA1c than repaglinide.²¹


Two similarly dosed 24-week studies reported in three articles compared metformin versus metformin plus nateglinide, showing greater reductions in HbA1c in the combination arms compared with the monotherapy arms (range in between-group differences of -0.5 percent to -0.8 percent).^{79,80,96} Only one of these RCTs reported that this between-group difference was also statistically significant,⁹⁶ while the other study did not report on the between-group statistical significance in either article.^{79,80}

One additional short duration study compared metformin versus metformin plus repaglinide, which also favored the combination therapy over monotherapy (between-group difference of -1.1 percent, 95 percent CI -1.8 percent to -0.3 percent).⁸²

Rosiglitazone versus pioglitazone. Three RCTs with similar dosing of the medications compared rosiglitazone with pioglitazone, and showed no significant between-group differences in HbA1c, with a pooled between-group difference of 0.1 percent (95 percent CI -0.2 percent to

0.3 percent) (Figure 9).⁹⁷⁻⁹⁹ No one study significantly influenced the results, and no substantial heterogeneity was found.

Figure 9. Mean difference in HbA1c comparing rosiglitazone with pioglitazone




CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 0.16$ with 2 degrees of freedom ($p = 0.92$)
 I-squared statistic = 0%
 The range in change scores for HbA1c for the comparison group, pioglitazone, was -1.3% to -0.2%. The median change was -0.7%.

Thiazolidinediones versus sulfonylureas. Both thiazolidinediones (TZDs) (pioglitazone and rosiglitazone) and second-generation sulfonylureas (glibenclamide, glimepiride, and glyburide) had similar effects on HbA1c, with a pooled mean difference between-groups of -0.1 percent (95 percent CI -0.2 percent to 0.01 percent) (Figure 10).^{41,50,51,53,100-108} When we combined the 3 out of 13 studies with comparable dosing,^{53,100,107} the results were similar with a weighted mean difference of -0.1 percent (95 percent CI -0.4 percent to 0.2 percent). In a standard sensitivity analysis which tests the relative influence of each individual study on the combined point estimate, we found that removal of one study influenced the pooled results. When the study by Hanefeld et al.¹⁰⁰ was removed from the main meta-analysis, the pooled mean difference favored TZDs slightly, with a pooled mean difference between-groups of -0.1 percent (95 percent CI -0.2 percent to -0.004 percent). However, the study by Hanefeld et al.¹⁰⁰ is similar to the other studies, and should not be removed from the overall meta-analysis. No other single study influenced the results, and no substantial heterogeneity was found. Glipizide was the only second-generation sulfonylurea that was not evaluated in head-to-head trials with the thiazolidinediones.

We excluded the ADOPT study from the meta-analysis due to the longer study duration (median followup of 4 years).³⁸ As mentioned previously, this double-blind RCT evaluated the long-term glycemic control between metformin, rosiglitazone, and glyburide monotherapy as initial treatment for type 2 diabetic adults. The between-group difference between rosiglitazone and glyburide favored rosiglitazone after 4 years (mean difference between-groups of -0.4, 95 percent CI -0.5 percent to -0.3 percent). Of note, glyburide reduced HbA1c more than

rosiglitazone initially. The HbA1c then rose higher in the glyburide arm compared with the rosiglitazone arm after 1.5 years.

Figure 10. Mean difference in HbA1c comparing thiazolidinediones with sulfonylureas



CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 7.07$ with 12 degrees of freedom ($p = 0.85$)
 I-squared statistic = 0%
 The range in change scores for HbA1c for the comparison group, sulfonylureas, was -2.5% to 1.5%. The median change was -0.9%.


Thiazolidinediones versus meglitinides. Two 24-week similar quality head-to-head trials compared thiazolidinediones with repaglinide specifically, and showed no consistent effects favoring one of the medications.^{109,110} These inconsistent results may be due to different thiazolidinediones, or different dosing. One study with slightly lower doses of pioglitazone (30 mg fixed dose) versus upward titration of repaglinide to a maximum of 12 mg per day favored repaglinide monotherapy (between-group difference of 0.5 percent).¹¹⁰ The other study with more comparable dosing between rosiglitazone and repaglinide favored rosiglitazone with a between-group difference of 0.39 percent.¹⁰⁹

A one-year RCT compared pioglitazone with nateglinide at comparable doses, and reported similar reductions in HbA1c in each arm (-1.6 percent and -1.4 percent respectively).¹⁰⁸

Sulfonylureas versus DPP-4 inhibitors. One double-blind moderately sized RCT directly compared four doses of sitagliptin to glipizide upward titrated to 20 mg daily.¹¹¹ After 12 weeks, both high dose sitagliptin (100 mg per day) and glipizide (maximum dose of 20 mg per day) similarly reduced HbA1c (-0.77 percent versus -1.00 percent respectively), with overlapping confidence intervals for the placebo-subtracted change from baseline in each group. A small absolute dose-response relationship was reported but it was not statistically significant.

Sulfonylureas versus meglitinides. Seven RCTs compared a second-generation sulfonylurea with repaglinide, showing a pooled between-group difference of 0.1 percent (95 percent CI -0.2 percent to 0.3 percent) (Figure 11).¹¹²⁻¹¹⁸ No single study markedly influenced these results nor was there substantial heterogeneity among the studies. There were no differences in results when only evaluating the studies using comparable doses.^{113,117,118}

Figure 11. Mean difference in HbA1c comparing sulfonylureas with meglitinides



CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 10.548$ with 6 degrees of freedom ($p = 0.10$)

I-squared statistic = 43%


The range in change scores for HbA1c for the comparison group, meglitinides, was -1.2% to 0.58%. The median change was -0.2%.

Two short-duration RCTs compared a slightly under-dosed glibenclamide arm with nateglinide at somewhat higher doses, showing no significant differences between groups (range in non-significant between-group differences of -0.5 percent to -0.2 percent).^{108,119} We did not include these studies in a meta-analysis due to potential differences in glycemic control between nateglinide and repaglinide.

Sulfonylurea versus GLP-1 agonists. Three RCTs compared sulfonylureas directly with liraglutide with conflicting results. We did not combine these trials in a meta-analysis due to dosing differences within and between studies. One comparably dosed small RCT reported no statistically significant differences between the two arms.¹²⁰ The two other larger RCTs favored the liraglutide arm,^{121,122} yet one of these studies underdosed the sulfonylurea arm compared with the liraglutide arm making it difficult to discern true drug differences versus dosing differences.¹²¹

Combination of metformin and thiazolidinediones versus combination of metformin and sulfonylureas. Six comparably dosed shorter duration RCTs directly compared the combination of metformin plus a thiazolidinedione with metformin plus a sulfonylurea, showing a pooled mean difference in HbA1c between groups of -0.1 percent (95 percent CI -0.2 percent to 0.1 percent) (Figure 12).¹²³⁻¹²⁸ No single study markedly influenced the results, and no substantial heterogeneity was found. We excluded two studies due to inconsistent dosing within arms of the study and therefore between them and the rest of the studies.^{46,129} Both studies underdosed the metformin in the metformin plus sulfonylurea arms, and found between-group differences in HbA1c favoring the metformin plus thiazolidinedione arms (-0.3 percent in both studies). A sensitivity analysis including both these studies in the meta-analysis showed no differences between-groups but increases the heterogeneity between studies markedly.

Figure 12. Mean difference in HbA1c comparing combination of metformin and thiazolidinediones with combination of metformin and sulfonylureas



CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c; Met = metformin; SU = sulfonylurea; TZD = thiazolidinedione
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 7.45$ with 5 degrees of freedom ($p = 0.19$)
 I-squared statistic = 33%
 The range in change scores for HbA1c for the comparison group, a combination of metformin and sulfonylurea, was -1.5% to 0.9%. The median change was -0.9%.

In the meta-analysis, we included the shorter duration RECORD study since the study duration was more comparable to the other included studies.¹²⁴ The RECORD study was a multicenter open label RCT evaluating 4447 patients with type 2 diabetes and uncontrolled glycemia already on metformin or sulfonylurea monotherapy.^{16,124} They randomly assigned subjects to addition of rosiglitazone or to a combination of metformin and sulfonylurea, and the primary endpoint was cardiovascular hospitalization or cardiovascular death. They reported glycemic control at a mean of 18 months and 5.5 years after study start.^{16,124} The between-group difference in HbA1c of -0.07 percent was small and not significant in the 516 subjects with 18-month followup.¹²⁴ In the article reporting on the mean followup of 5.5 years in 2,222 subjects,

the between-group difference in HbA1c of -0.29 percent significantly favored metformin plus rosiglitazone over metformin plus sulfonylurea.¹⁶ However, it is unclear whether these mild differences in glycemic control affect cardiovascular outcomes. While the RECORD study reported cardiovascular outcomes in the rosiglitazone arm versus active control showing no statistically significant differences between groups, they did not break it out further into specific drug combination comparisons.¹⁶

Combination of metformin and thiazolidinediones versus combination of metformin and DPP-4 inhibitors. Two short-duration RCTs compared metformin plus rosiglitazone with the combination of metformin plus sitagliptin, showing similar reductions in HbA1c in each arm. One double-blind study with comparable dosing of the medications showed no between-group differences in HbA1c (mean difference of -0.1 percent, 95 percent CI -0.3 percent to 0.1 percent).⁸⁵ The other RCT compared a submaximally dosed metformin plus rosiglitazone arm to a maximally dosed metformin plus sitagliptin arm, and showed similar reductions in HbA1c after 16 weeks (-0.6 percent in rosiglitazone combination arm versus -0.4 percent in sitagliptin combination arm).¹³⁰

Combination of metformin and thiazolidinediones versus combination of metformin and meglitinides. One RCT lasting 26 weeks compared metformin plus rosiglitazone twice daily with the combination of metformin plus repaglinide twice daily and three times daily, showing no significant between-group differences.¹³¹

Combination of metformin and thiazolidinediones versus combination of metformin and GLP-1 agonists. One 20-week RCT with comparable dosing of medications compared the combination of metformin and rosiglitazone with the combination of metformin and exenatide, showing no significant between-group differences in HbA1c (between-group difference of -0.1 percent, $p = 0.7$).¹³²

Combination of metformin and thiazolidinediones versus combination of thiazolidinediones and sulfonylureas. One small RCT conducted a post hoc analysis comparing the combination of pioglitazone added to either existing metformin or existing sulfonylurea, favoring the pioglitazone plus sulfonylurea combination arm by 0.03 percent ($p = 0.04$).¹²⁹

Combination of metformin and sulfonylureas versus combination of metformin and DPP-4 inhibitors. One double-blinded moderately sized RCT compared fixed dose metformin plus sulfonylurea (mean dose of sulfonylurea was 10 mg) with the combination of fixed dose metformin plus fixed dose sitagliptin (100 mg), showing no between group-differences in HbA1c after 1 year (mean between-group difference of -0.01 percent, 95 percent CI -0.1 percent to 0.1 percent).¹³³ This RCT was extended a second year and continued to show no statistically significant between-group differences in HbA1c.¹³⁴

Combination of metformin and sulfonylureas versus combination of metformin and meglitinides. Two moderately sized double-blinded RCTs lasting 1 to 2 years directly compared the combination of metformin plus sulfonylurea with metformin plus nateglinide showing conflicting results.^{135,136} These differences may reflect differences in dosing. The first RCT compared the combination of metformin (mean dose 2,500 mg) plus glibenclamide (mean dose

12.5 mg) with metformin (mean dose 2,500 mg) plus nateglinide (mean dose 300 mg), and significantly favored the slightly higher dosed metformin plus nateglinide combination arm, with a between-group difference of 0.8 percent.¹³⁵ The second RCT showed no significant difference between groups (between-group difference of -0.3 percent) despite the higher dosed metformin plus nateglinide arm.¹³⁶

Combination of metformin and sulfonylureas versus combination of metformin and GLP-1 agonists. Two RCTs compared metformin plus sulfonylurea with metformin plus a GLP-1 agonist with conflicting results. One small comparably dosed RCT lasting a year compared the combination of metformin and glibenclamide with the combination of metformin and exenatide, reporting no significant between-group differences in HbA1c (between-group difference of -0.3 percent, $p > 0.05$).⁴⁴ A second comparably dosed medium-sized RCT directly compared the combination of metformin and glimepiride with two different dosing arms of the combination of metformin and liraglutide (titrated to a maximum dose of 1.2 mg of liraglutide in one combination arm and 1.8 mg in a second liraglutide combination arm).⁹² Both dosing comparisons showed greater reductions in HbA1c in the metformin plus liraglutide arms (between-group differences of -1.1 percent, 95 percent CI -1.3 percent to -0.9 percent for both arms). No dose-response gradient was reported. It is unclear whether the differences were due to differences in study medications, study duration, or other study characteristics.

Combination of metformin and sulfonylureas versus combination of metformin and premixed insulin. Two 16-week RCTs compared metformin plus glibenclamide with the combination of metformin plus a premixed insulin analogue-insulin aspart 70/30 in one study and insulin lispro 75/25 in the other study, showing different results.^{137,138} These differences may have been due to differences in dosing of the medications. The RCT¹³⁷ that showed no significant between-group differences in HbA1c (-0.11 percent, $p = 0.238$) reported their mean total dose for each combination arm, while the other RCT which significantly favored the metformin plus premixed insulin analogue (insulin aspart 70/30) arm over the metformin plus sulfonylurea arm (between-group difference of 0.46 percent, $p = 0.027$) did not clearly report mean total or maximum doses.¹³⁸ Another possible difference may have been the type of premixed insulin analogue.


Combination of metformin and sulfonylureas versus combination of thiazolidinediones and sulfonylureas. Six similar RCTs directly compared the combination of metformin and sulfonylurea with the combination of thiazolidinediones and sulfonylurea, showing no between-group differences in HbA1c (pooled between-group difference of -0.1 percent, 95 percent CI -0.2 percent to 0.01 percent) (Figure 13).^{42,124,129,139-141} No one study markedly influenced the results, and these studies showed no significant heterogeneity.

We excluded two articles from the meta-analysis with longer study durations^{16,142} since both studies had other articles in the meta-analysis that presented the shorter term glycemic results^{124,140} which were more comparable to the other RCTs. The RECORD study was a multicenter open label RCT evaluating 4,447 patients with type 2 diabetes and uncontrolled glycemia already on metformin or sulfonylurea monotherapy.^{16,124} They randomly assigned subjects to addition of rosiglitazone or to a combination of metformin and sulfonylurea, with a primary endpoint of cardiovascular hospitalization or cardiovascular death. They reported glycemic control at a mean of 18 months and 5.5 years after study start.^{16,124} The between-group

difference in HbA1c of -0.06 percent was small and not significant in the 573 subjects with 18-month followup.¹²⁴ In the article reporting on the mean followup of 5.5 years in 2,225 subjects, the between-group difference in HbA1c of 0.26 percent significantly favored rosiglitazone plus sulfonylurea over metformin plus sulfonylurea.¹⁶ However, it is unclear whether these mild differences in glycemic control affect cardiovascular outcomes. While the RECORD study reported cardiovascular outcomes in the rosiglitazone arm versus active control showing no statistically significant differences between-groups, they did not break it out further into specific drug-drug combination comparisons.¹⁶

The second RCT excluded was a 2-year followup¹⁴² of the 1-year study¹⁴⁰ presented in the meta-analysis. Both articles presented similar between-group differences in HbA1c between the combination of thiazolidinedione plus sulfonylurea and metformin plus sulfonylurea (nonsignificant between-group differences of -0.16 percent and -0.13 percent).

Figure 13. Mean difference in HbA1c comparing combination of metformin and sulfonylureas with combination of thiazolidinediones and sulfonylureas



CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c; Met = metformin; SU = sulfonylurea; TZD = thiazolidinedione

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 1.37$ with 5 degrees of freedom ($p = 0.93$)

I-squared statistic = 0%


The range in change scores for HbA1c for the comparison group, a combination of thiazolidinediones and sulfonylureas, was -1.3% to 0.6%. The median change was -1.1%.

Combination of metformin and DPP-4 inhibitors versus combination of metformin and GLP-1 agonists. One 26-week RCT with comparable dosing of medications directly compared the combination of metformin and sitagliptin with the combination of metformin and liraglutide in 2 dosing arms (maximum dose liraglutide 1.2 mg in one arm and 1.8 mg in the second combination arm), showing statistically significant greater reductions in HbA1c in the metformin and liraglutide combination arms.¹⁴³ The between-group differences in HbA1c ranged from -0.34 percent when compared with the lower dosed liraglutide combination arm to -0.60 percent when compared with the higher dosed liraglutide combination arm.¹⁴³

Combination of metformin and GLP-1 agonists versus combination of metformin and basal insulin. One small 56-week RCT compared the combination of metformin and exenatide with the combination of metformin and glargine insulin, showing similar reductions in HbA1c (between-group difference of -0.1 percent).¹⁴⁴ The exenatide combination arm had about 25 percent of their subjects on higher than the maximum recommended dose of exenatide.

Combination of metformin and basal insulin versus combination of metformin and premixed insulin. Three RCTs directly compared the combination of metformin plus basal insulin with the combination of metformin plus premixed insulin, showing no between-group differences in HbA1c (pooled between-group difference of 0.3 percent, 95 percent CI -0.3 percent to 0.9 percent) (Figure 14).¹⁴⁵⁻¹⁴⁷ No single study strongly influenced the results, and no substantial heterogeneity was found.

Figure 14. Mean difference in HbA1c comparing combination of metformin and basal insulin with combination of metformin and premixed insulin




CI = confidence interval; diff = difference; HbA1c = hemoglobin A1c; Met = metformin
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 0.003$ with 2 degrees of freedom ($p = 0.99$)
 I-squared statistic = 0%
 The range in change scores for HbA1c for the comparison group, combination metformin and premixed insulin, was -2.9% to 0.7%. The median change was -1.1%.

The Evidence About Weight (Appendix G, Table 4)

Metformin versus thiazolidinediones. Eight RCTs lasting around a year or less directly compared metformin versus thiazolidinedione favoring metformin, with a pooled mean between group difference of -2.6 kg (95 percent CI -4.1 kg to -1.2 kg) (see Figure 15).^{47-49,51,52,54,55,148} All the metformin arms had small decreases in weight while the thiazolidinedione arms had mild increases in weight except for two studies.^{48,51} No single study markedly influenced the results. There was significant heterogeneity, yet we felt comfortable combining these studies since almost all the point estimates favored metformin. Meta-regression suggested that differences in baseline weight between studies ($p = 0.07$) may have contributed to the heterogeneity. We

excluded two studies from the meta-analysis that had consistent results favoring metformin, since the median study duration was 4 years for one study³⁸ and no measure of variability was reported for the second study.⁵⁶ The 4-year double-blind RCT (known as the ADOPT study) was designed to compare long-term glycemic control between metformin, rosiglitazone, and glyburide monotherapy as initial treatment for diabetic adults, where weight was evaluated as a secondary outcome. The between-group difference in weight was -6.9 kg (95 percent CI -6.3 kg to -7.4 kg) favoring metformin. The second shorter duration RCT reported weight gain (1.6 kg) with pioglitazone and weight loss (-1.3 kg) with metformin, but no measures of variability.⁵⁶

Figure 15. Mean difference in weight comparing metformin with thiazolidinediones



CI = confidence interval; diff = difference; kg = kilogram

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 46.51$ with 7 degrees of freedom ($p = 0.0000$)


I-squared statistic = 85%

The range in change scores for weight for the comparison group, thiazolidinediones, was -2 kg to 2.4 kg. The median change was -0.3 kg.

Metformin versus sulfonylureas. We combined 12 studies comparing metformin with a second-generation sulfonylurea, with a pooled mean difference of -2.7 kg (95 percent CI -3.5 kg to -1.9 kg) favoring metformin (Figure 16).^{51,61-71} We stratified the meta-analyses based on study duration (less than 24 weeks and more than 24 weeks) since this may have been a source of the heterogeneity between studies. The longer studies had slightly larger between-group differences in weight. In eight studies with less than 24 weeks duration, studies favored metformin with a pooled between-group difference of -1.9 kg (95 percent CI -2.5 kg to -1.4 kg) (Figure 17).^{51,61-66,71} Four studies lasting 24 weeks or longer were combined and favored metformin, with a

pooled between-group difference of -3.6 kg (95 percent CI -4.1 kg to -3.1 kg) (Figure 18).⁶⁷⁻⁷⁰ Heterogeneity tests were not significant once we stratified the meta-analyses by study duration.


Figure 16. Mean difference in weight comparing metformin with sulfonylureas



CI = confidence interval; diff = difference; kg = kilogram
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 22.64$ with 11 degrees of freedom ($p = 0.02$)
 I-squared statistic = 51%
 The range in change scores for weight for the comparison group, sulfonylureas, was -0.3 kg to 2.67 kg. The median change was 1.6 kg.

The ADOPT study was excluded from the meta-analysis since the median followup was 4 years compared with the other shorter duration studies lasting less than a year, yet showed consistent results favoring metformin over glyburide (mean between-group difference in weight of -2.5 kg; 95 percent CI -2.0 kg to -3.1 kg).³⁸ This double-blind RCT evaluated long-term glycemic control between metformin, rosiglitazone, and glyburide monotherapy as initial treatment for type 2 diabetic adults, where weight was a secondary end point. Metformin decreased weight over the study duration while glyburide increased weight in the first year followed by weight maintenance for the rest of the study.

Figure 17. Mean difference in weight comparing metformin with sulfonylureas among studies less than 24 weeks in duration



CI = confidence interval; diff = difference; kg = kilogram

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.


Test for heterogeneity: $Q = 2.51$ with 7 degrees of freedom ($p = 0.93$)

I-squared statistic = 0%

The range in change scores for weight for the comparison group, sulfonylureas, was -0.3 kg to 1.7 kg. The median change was 0.9 kg.

The UKPDS,^{8,72,74} while consistent with the above meta-analysis, was excluded from this section of the report since they were allowed to add other diabetes medications to their initial monotherapy groups. We describe it here briefly since it is a well known study with the longest followup (up to 10 years). In the 3-year followup of UKPDS in the obese subjects from the primary diet failure and main randomization groups combined, the between-group difference was -2 kg, favoring metformin.⁷⁴ In the 6-year followup in the primary diet failure group only, the between-group difference was -5 kg comparing obese subjects taking metformin with obese and nonobese subjects taking glibenclamide.⁷² In the 10-year followup comparing obese subjects on metformin with obese and nonobese subjects on glibenclamide, the between-group difference still favored metformin at -2 kg.⁸ None of these papers reported the statistical significance of these differences except as it relates to diet or insulin. Of note, most of the weight gain in the glibenclamide group occurred in the first 2 years, while metformin maintained weight in the first 2 years and then had some weight gain after that.⁸

Figure 18. Mean difference in weight comparing metformin with sulfonylureas among studies 24 weeks or longer in duration



CI = confidence interval; diff = difference; kg = kilogram

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 1.04$ with 3 degrees of freedom ($p = 0.79$)


I-squared statistic = 0%

The range in change scores for weight for the comparison group, sulfonylureas, was -0.3 kg to 3.3 kg. The median change was 2.7 kg.

Metformin versus DPP-4 inhibitors. Three short duration RCTs (reported in four articles) compared metformin with DPP-4 inhibitors, reporting greater reductions in weight with metformin (pooled between-group difference of -1.4 kg, 95 percent CI -1.8 kg to -1.0 kg) (Figure 19).⁷⁵⁻⁷⁸ No substantial heterogeneity was found in the meta-analysis, and no single study markedly influenced the results. Two studies used metformin compared with sitagliptin,^{76,77} and one study compared metformin with saxagliptin.⁷⁸ One RCT was reported in two articles.^{75,76} The first article was a 24-week RCT,⁷⁵ while the second article was the 30-week continuation study with a higher loss to followup.⁷⁶ The higher dosed metformin arm had greater weight loss from baseline compared with the lower dose metformin arm. We included the 24-week study in the meta-analysis since the other two studies in the meta-analysis were both 24 weeks long.

Metformin versus meglitinides. Two small comparably-dosed RCTs lasting about a year compared metformin with repaglinide, suggesting metformin may reduce weight compared with repaglinide (range in between-group differences from -2.0 kg to -3.4 kg).^{81,82} One study reported this difference as nonsignificant,⁸¹ and one reported only that there were significant differences from baseline in both arms.⁸² The small number of subjects may have precluded the ability to detect significant differences between groups.

Figure 19. Mean difference in weight comparing metformin with DPP-4 inhibitors



CI = confidence interval; diff = difference; DPP-4 inhibitor = dipeptidyl peptidase-4 inhibitor; kg = kilogram

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.


Test for heterogeneity: $Q = 2.10$ with 2 degrees of freedom ($p = 0.35$)

I-squared statistic = 5%

The range in change scores for weight for the comparison group, DPP-4 inhibitors, was -1.1 kg to 0.6 kg. The median change was -0.6 kg.

Metformin versus a combination of metformin and thiazolidinediones. We combined five studies that directly compared metformin monotherapy with the combination of metformin plus a thiazolidinedione (mostly rosiglitazone), showing a pooled between-group difference in weight of -2.2 kg (95 percent CI -2.6 kg to -1.9 kg) favoring metformin (Figure 20).^{49,84,85,87,90} There was no significant heterogeneity between studies, and no single study markedly affected the results. All five studies showed that the metformin arms had weight loss while the combination arms had weight gain. One study reported only qualitatively that the metformin arm had relatively no weight change while the combination therapy arm had a significant increase in weight of 1.6 kg reported quantitatively.⁸³ While consistent with the meta-analysis results, we did not have sufficient quantitative data to include it with the other studies. Another study was excluded from the meta-analysis since no measures of variability were reported; however, this study was consistent with the meta-analysis findings.⁵⁶ The 24-week RCT reported weight gain (0.7 kg) with combination metformin and pioglitazone and weight loss (-1.3 kg) with metformin monotherapy.⁵⁶

Figure 20. Mean difference in weight comparing metformin with combination metformin and thiazolidinediones



CI = confidence interval; diff = difference; kg = kilogram

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.


Test for heterogeneity: $Q = 1.35$ with 4 degrees of freedom ($p = 0.85$)

I-squared statistic = 0%

The range in change scores for weight for the comparison group, a combination of metformin and thiazolidinedione, was 0.7 kg to 1.7 kg. The median change was 1.5 kg.

Metformin versus a combination of metformin and sulfonylureas. Ten RCTs compared metformin with the combination of metformin plus a second-generation sulfonylurea favoring metformin monotherapy, with a pooled between-group difference of -2.3 kg (95 percent CI -3.3 kg to -1.2 kg) (Figure 21).^{61,62,64,65,68-71,91,92} No single study markedly influenced the results. While heterogeneity existed, all studies favored the metformin arm over the combination arm with minimal between-group differences among the studies. Studies with lower baseline weight appeared to have somewhat smaller between-group differences than studies with higher baseline weight.

Figure 21. Mean difference in weight comparing metformin with combination metformin and sulfonylureas



CI = confidence interval; diff = difference; kg = kilogram

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.


Test for heterogeneity: $Q = 52.88$ with 9 degrees of freedom ($p = 0.0000$)

I-squared statistic = 83%

The range in change scores for weight for the comparison group, a combination of metformin and sulfonylureas, was -0.3 kg to 1.9 kg. The median change was 0.7 kg.

Metformin versus a combination of metformin and DPP-4 inhibitors. Three RCTs directly compared metformin with the combination of metformin plus a DPP-4 inhibitor, with a pooled between-group difference of -0.2 kg (95 percent CI -0.7 kg to 0.2 kg) (Figure 22).^{75,78,85} No single study markedly influenced the results, and no substantial heterogeneity was found. Only three out of six studies had sufficient quantitative data to combine in a meta-analysis. The other three studies reported results that were consistent with the meta-analysis.^{85,94,95} One RCT was published twice, first with the 24-week RCT results⁷⁵ and second as a 30-week continuation study.⁷⁶ The 24-week study was included in the meta-analysis since the study duration was more similar to the other included studies. The 54-week results were consistent with the 24-week results, reporting a significant weight loss from baseline in both groups with overlapping confidence intervals or a non-significant between-group difference of 0.2 kg.⁷⁶ They also showed a small dose-response effect in the combination arms, with the 2000 mg metformin and 100 mg sitagliptin arm reducing weight more than the 1000 mg metformin plus 100 mg sitagliptin arm (mean change from baseline -1.7 kg versus -0.7 kg respectively).

Figure 22. Mean difference in weight comparing metformin with combination metformin and DPP-4 inhibitors




CI = confidence interval; diff = difference; DPP-4 inhibitor = dipeptidyl peptidase-4 inhibitor; kg = kilogram
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 1.16$ with 2 degrees of freedom ($p = 0.56$)
 I-squared statistic = 0%
 The range in change scores for weight for the comparison group, a combination of metformin and DPP-4 inhibitors, was -1.1 kg to 0.6 kg. The median change was -0.4 kg.

Metformin versus a combination of metformin and meglitinides. Two RCTs compared metformin with combination of metformin plus meglitinides; both slightly favoring the monotherapy metformin arms.⁸²⁻⁹⁶ One small 3-month RCT compared metformin (mean dose 1800 mg) versus metformin (mean dose 1,800 mg) plus repaglinide (maximum titrated dose of 4 mg before meals), and reported qualitatively that weight remained stable in the metformin arm while increasing from baseline in the metformin plus repaglinide arm ($3.0 \text{ kg} \pm 0.5 \text{ kg}$, $p < 0.05$).⁸² The second 24-week moderately sized study compared metformin with metformin plus nateglinide at two different doses, showing a statistically significant between-group difference in weight of 0.9 kg favoring metformin monotherapy when compared with the higher dosed metformin plus nateglinide arm (120 mg three times daily). No significant difference was reported when metformin was compared with the metformin plus lower dose nateglinide (60 mg three times daily).⁹⁶

Rosiglitazone versus pioglitazone. Three RCTs with similar dosing of medications compared rosiglitazone with pioglitazone, and showed no significant between-group differences in weight, with a pooled between-group difference of -0.4 kg (95 percent CI -0.8 kg to 0.0 kg) (Figure 23).⁹⁷⁻⁹⁹ No one study significantly influenced the results, and no substantial heterogeneity was found. All three short-duration studies showed an increase in weight from baseline, ranging from 0.7 kg to 2 kg for both thiazolidinediones.

Figure 23. Mean difference in weight comparing rosiglitazone with pioglitazone



CI = confidence interval; diff = difference; kg = kilogram

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 0.02$ with 2 degrees of freedom ($p = 0.99$)


I-squared statistic = 0%

The range in change scores for weight for the comparison group, pioglitazone, was 1.2 kg to 2.0 kg. The median change was 2.0 kg.

Thiazolidinediones versus sulfonylureas. Five studies lasting a year or less compared a thiazolidinedione to a second-generation sulfonylurea, showing higher weight gain in the thiazolidinedione arms, with a pooled between-group difference of 1.2 kg (95 percent CI 0.6 kg to 1.9 kg) (Figure 24).^{51,100,101,106,149} One study showed a dose response relationship between rosiglitazone and weight; patients treated with rosiglitazone (4 mg per day) gained 1.8 kg and those treated with 8 mg per day gained 3.0 kg over 52 weeks compared with the glibenclamide arm which gained 1.9 kg.¹⁰⁰ No single study markedly influenced the results, and no substantial heterogeneity was found.

We excluded two RCTs from the meta-analysis due to the longer study duration of 3 to 4 years.^{38,150} Both RCTs had results that were consistent with the meta-analysis. As mentioned previously, the ADOPT study was a double-blind RCT evaluating the long-term glycemic control between metformin, rosiglitazone, and glyburide monotherapy as initial treatment for type 2 diabetic adults, with weight as a secondary outcome.³⁸ The between-group difference between rosiglitazone and glyburide was consistent with the results of the meta-analysis of the shorter duration studies favoring sulfonylureas after an estimated 5 years of followup (mean difference between-groups of 2.5 kg, 95 percent CI 2.0 kg to 3.1 kg). Of note, the glyburide arm showed increased weight over the first year when weight began to stabilize, while the rosiglitazone arm had continued weight gain over the course of the study. The second large 3-year multicenter study comparing pioglitazone and glibenclamide showed a 5.2 kg weight gain in the pioglitazone-treated group and a 0.9 kg weight gain in the glibenclamide-treated group.¹⁵⁰

Figure 24. Mean difference in weight comparing thiazolidinediones with sulfonylureas



CI = confidence interval; diff = difference; kg = kilogram

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 3.16$ with 4 degrees of freedom ($p = 0.53$)

I-squared statistic = 0%


The range in change scores for weight for the comparison group, sulfonylureas, was 1.1 kg to 3.4 kg. The median change was 1.9 kg.

Thiazolidinediones versus meglitinides. Two 24-week non-blinded RCTs compared thiazolidinediones with repaglinide specifically, and both reported slightly greater weight gain in the thiazolidinedione groups (range in between-group differences of 0.7 to 1.7 kg, no measures of variability reported).^{109,110}

Sulfonylureas versus DPP-4 inhibitors. One double-blind moderately sized RCT directly compared four doses of sitagliptin to glipizide, showing a potential benefit in weight of sitagliptin over glipizide.¹¹¹ After 12 weeks, the high dose sitagliptin arm (100 mg a day) showed a nonsignificant between-group difference comparing sitagliptin with placebo of 0.4 kg (95 percent CI -0.2 kg to 0.9 kg) while the glipizide (maximum dose: 20 mg a day) arm showed a significant between-group difference compared with placebo of 1.3 kg (95 percent CI 0.8 kg to 1.8 kg). The study did not report the direct between-group differences in weight.

Sulfonylureas versus meglitinides. Six RCTs compared weight between a second-generation sulfonylurea and repaglinide showing no differences between groups, with a pooled between-group difference of 0.01 kg (95 percent CI -1.0 kg to 1.0 kg) (Figure 25).^{112,113,115-118} Heterogeneity tests were not significant, and no single study markedly influenced this result. Most studies showed no change in weight in both treatment arms.

Figure 25. Mean difference in weight comparing sulfonylureas with meglitinides



CI = confidence interval; diff = difference; kg = kilogram

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.


Test for heterogeneity: $Q = 1.15$ with 5 degrees of freedom ($p = 0.95$)

I-squared statistic = 0%

The range in change scores for weight for the comparison group, meglitinides, was -1.7 kg to 0.2 kg. The median change was -0.1 kg.

Sulfonylureas versus GLP-1 agonists. Three RCTs comparing sulfonylureas directly with liraglutide showed greater weight gain with sulfonylurea (pooled between-group difference of 2.5 kg, 95 percent CI 1.2 kg to 3.8 kg) (Figure 26).¹²⁰⁻¹²² No single study strongly influenced the results. Substantial heterogeneity was found. Metaregression found statistically significant differences due to drug dosing ($p = 0.017$). Given the low power of metaregression when only 3 studies are evaluated, other characteristics such as study duration may have partly explained the heterogeneity ($p = 0.15$). The one study with the largest between-group difference in weight¹²² lasted at least 24 weeks longer than the other two studies. Additionally, one of the two studies with a lower between-group difference under-dosed the sulfonylurea arm¹²¹ while the study with more comparable and higher drug doses had a larger between-group difference. All three studies however showed weight gain with sulfonylureas and weight loss with liraglutide when compared with baseline weight.

Figure 26. Mean difference in weight comparing sulfonylureas with GLP-1 agonists




CI = confidence interval; diff = difference; GLP-1 agonists = glucagon-like peptide-1 agonists; kg = kilogram
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 28.23$ with 2 degrees of freedom ($p = 0.00$)
 I-squared statistic = 93%
 The range in change scores for weight for the comparison group, GLP-1 agonist, was -2.5 kg to 1.0 kg. The median change was -0.7 kg.

Combination of metformin and thiazolidinediones versus combination of metformin and sulfonylureas. We combined five studies that directly compared metformin plus a thiazolidinedione to metformin plus a sulfonylurea favoring the combination of metformin plus sulfonylurea, with a pooled between-group difference of 0.9 kg (95 percent CI 0.4 kg to 1.3 kg) (Figure 27).^{123-126,151} No one study markedly influenced the results, and no substantial heterogeneity was found.

In the meta-analysis, we included the shorter duration RECORD study since the study duration was more comparable to the other included studies.¹²⁴ The RECORD study was a multicenter open label RCT evaluating 4447 patients with type 2 diabetes and uncontrolled glycemia already on metformin or sulfonylurea monotherapy.^{16,124} Body weight was increased significantly with rosiglitazone plus metformin compared to sulfonylurea plus metformin, with a mean difference between-groups of 1.2 kg (95 percent CI 0.4 kg to 2.0 kg) after 18 months¹²⁴ which increased to 3.8 kg after 5 years of followup.¹⁶

We excluded one short duration RCT from the meta-analysis since the dosing was not comparable to the other studies, which likely explains its conflicting results.¹²⁸ This RCT used a lower dose of metformin in the metformin plus sulfonylurea arm compared with a higher dose of metformin in the metformin plus thiazolidinedione arm. Since metformin has been shown to reduce or maintain weight compared with most other monotherapy diabetes medications, a higher dose of metformin in the thiazolidinedione combination arm would bias the results in favor of that combination.

Figure 27. Mean difference in weight comparing combination metformin and thiazolidinediones with combination metformin and sulfonylureas



CI = confidence interval; diff = difference; kg = kilogram; Met = metformin; SU = sulfonylureas; TZD = thiazolidinediones
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 3.41$ with 4 degrees of freedom ($p = 0.49$)
 I-squared statistic = 0%

The range in change scores for weight for the comparison group, a combination of metformin and sulfonylureas, was -4.5 kg to 1.7 kg. The median change was 1.5 kg.

Combination of metformin and thiazolidinediones versus combination of metformin and DPP-4 inhibitors. Two short duration RCTs compared metformin plus rosiglitazone with the combination of metformin plus sitagliptin, showing weight loss in the metformin plus sitagliptin arms and weight gain in the metformin plus thiazolidinedione arms. Neither study reported on the between-group difference in weight, only on the difference from baseline for each arm. In one study, the metformin plus rosiglitazone arm had an increase in weight from baseline of 1.5 kg (95 percent CI 1.0 kg to 1.9 kg) while the metformin plus sitagliptin arm had a decrease in weight from baseline of -0.4 kg (95 percent CI -0.8 kg to 0.0 kg).⁸⁵ The nonoverlapping confidence intervals suggest that this difference between groups is statistically significant. The other open label 16-week RCT showed a statistically significant weight loss from baseline with the metformin plus sitagliptin arm (-1.2 kg, $p = 0.0008$) and a nonsignificant small weight gain with the metformin plus rosiglitazone arm (0.3 kg, $p = 0.59$).¹³⁰

Combination of metformin and thiazolidinediones versus combination of metformin and meglitinides. One RCT with 568 patients lasting 26 weeks compared metformin plus rosiglitazone twice daily with the combination of metformin plus repaglinide twice daily and three times daily; they reported qualitatively no significant between-group differences in weight but did not report any quantitative numbers.¹³¹

Combination of metformin and thiazolidinediones versus combination of metformin and GLP-1 agonists. One 20-week RCT with comparable dosing of medications compared the combination of metformin and rosiglitazone with the combination of metformin and exenatide, favoring the combination of metformin and exenatide with a between-group difference of 2.7 kg ($p < 0.001$).¹³² The metformin and rosiglitazone arm showed weight gain from baseline (+1.5 kg) while the metformin and exenatide arm showed weight loss from baseline (-1.2 kg).¹³²

Combination of metformin and sulfonylureas versus combination of metformin and DPP-4 inhibitors. One double-blinded moderately sized RCT compared fixed-dose metformin plus sulfonylurea (mean dose of sulfonylurea was 10 mg) with the combination of fixed dose metformin plus fixed dose sitagliptin (100 mg), showing body weight was significantly reduced in the metformin plus sitagliptin arm compared with an increase in body weight from baseline in the metformin plus sulfonylurea arm (mean difference between-groups of -2.5 kg, 95 percent CI -3.1 kg to -2.0 kg).¹³³ This RCT was extended a second year and continued to show weight loss in the metformin plus sitagliptin arm (-1.6 kg) and weight gain in the metformin plus glipizide arm (+0.7 kg) with a between-group mean difference of -2.3 kg (95 percent CI -3.0 kg to -1.6 kg).¹³⁴

Combination of metformin and sulfonylureas versus combination of metformin and meglitinides. Two moderately sized double-blinded RCTs lasting 2 years directly compared the combination of metformin plus sulfonylurea with metformin plus nateglinide showing slightly different results.^{136,152} One study showed a small but significant between-group difference of -1.2 kg favoring the metformin plus nateglinide arm ($p = 0.01$).¹³⁶ The other comparable study did not report quantitative data, only stating no clinically relevant changes in weight were found in either group.¹⁵²


Combination of metformin and sulfonylurea versus combination of metformin and GLP-1 agonists. Two RCTs compared metformin plus sulfonylurea with metformin plus a GLP-1 agonist, favoring the combination of metformin and GLP-1 agonist (between-group differences of 3.8 kg and 12.3 kg).^{44,92} Both RCTs showed weight loss with the combination of metformin and GLP-1 agonists and weight gain with the combination of metformin and sulfonylurea. One RCT with comparable dosing of medications lasting a year compared the combination of metformin and glibenclamide with the combination of metformin and exenatide, reporting weight loss with metformin and exenatide (-8 kg, $p < 0.001$) and weight gain with metformin and glibenclamide (4.3 kg, $p < 0.05$).⁴⁴ This article did not report on the between-group difference in weight.⁴⁴ Another short-duration RCT with comparable dosing of medications directly compared the combination of metformin and glimepiride with three different dosing arms of the combination of metformin and liraglutide (0.6 mg, 1.2 mg and 1.8 mg).⁹² All three dosing comparisons showed a dose response effect on weight in the metformin plus liraglutide arms (range in weight loss of -1.8 kg to -2.8 kg with greater weight loss using higher doses) and a weight gain in metformin and glimepiride arm (1 kg). The between-group differences in weight were statistically significant for this study.⁹²

Combination of metformin and sulfonylureas versus combination of metformin and premixed insulin. Two short-duration RCTS compared metformin plus glibenclamide with the combination of metformin plus a premixed insulin analogue-insulin aspart 70/30 in one study

and insulin lispro 75/25 in the other study; both studies nonsignificantly favored the metformin plus sulfonylurea arms (range in between-group differences of -0.7 kg to -0.5 kg).^{137,138} None of the study arms decreased weight from baseline.

Combination of metformin and sulfonylureas versus combination of thiazolidinediones and sulfonylureas. Four RCTs compared the combination of metformin plus a sulfonylurea with a combination of a thiazolidinedione plus a sulfonylurea, favoring the metformin plus sulfonylurea arms with a pooled between-group difference of -3.2 kg (95 percent CI -5.2 kg to -1.1 kg) (Figure 28).^{124,126,140,142} Heterogeneity was significant but all between-group point estimates are in the same direction with minimal differences between studies. No single study markedly influenced these results.

Figure 28. Mean difference in weight comparing combination metformin and sulfonylureas with combination thiazolidinediones with sulfonylureas



CI = confidence interval; diff = difference; kg = kilogram; Met = metformin; SU = sulfonylureas; TZD = thiazolidinediones
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 21.67$ with 3 degrees of freedom ($p = 0.0001$)

I-squared statistic = 86%

The range in change scores for weight for the comparison group, a combination of thiazolidinedione and sulfonylureas, was -1 kg to 3 kg. The median change was 2.2 kg.

We included only the shorter duration results for the RECORD study¹²⁴ in the meta-analysis since all other studies were shorter duration. However, the longer duration results were consistent with the shorter duration studies favoring the metformin plus sulfonylurea arm.¹⁶ The RECORD study was a multicenter open label RCT evaluating 4,447 patients with type 2 diabetes and uncontrolled glycemia already on metformin or sulfonylurea monotherapy.^{16,124} They randomly assigned subjects to addition of rosiglitazone or metformin to existing sulfonylurea, with a primary endpoint of cardiovascular hospitalization or cardiovascular death. These two studies showed a significant increase in weight for the thiazolidinedione plus sulfonylurea arm compared with a slight decrease in weight from baseline in the metformin plus sulfonylurea arm


(significant between-group differences of 4.3 kg in the 18-month followup and 5.9 kg in the estimated 5-year followup).

Combination of metformin and DPP-4 inhibitors versus combination of metformin and GLP-1 agonists. One 26-week RCT with comparable dosing of medications directly compared the combination of metformin and sitagliptin with the combination of metformin and liraglutide in 2 dosing arms (maximum dose liraglutide 1.2 mg in one arm and 1.8 mg in the second combination arm), showing a significantly greater weight loss in the metformin and liraglutide arms compared to the metformin and sitagliptin arm. The mean difference between groups in weight was -2.4 kg (95 percent CI -3.1 kg to -1.7 kg) for the liraglutide (1.8 mg) plus metformin arm versus the combination of metformin plus sitagliptin and -1.9 kg (95 percent CI -2.6 kg to -1.2 kg) for the liraglutide (1.2 mg) plus metformin arm versus the combination of metformin plus sitagliptin.¹⁴³

Combination of metformin and GLP-1 agonists versus combination of metformin and basal insulin. One small 56-week RCT compared the combination of metformin and exenatide with the combination of metformin and glargine insulin, showing statistically significant weight loss with the metformin plus exenatide treated group compared to the metformin plus glargine insulin treated group (between group difference of -4.6 kg, $p < 0.0001$).¹⁴⁴ Of note, the exenatide combination arm had about 25 percent of their subjects on higher than the maximum recommended dose of exenatide. Weight returned to baseline 12 weeks after discontinuation of treatment in both arms.

Combination of metformin and basal insulin versus combination of metformin and premixed insulin. Three RCTs directly compared the combination of metformin plus basal insulin with the combination of metformin plus premixed insulin, showing no between-group differences in weight (pooled mean difference of -1.8 kg, 95 percent CI -7.8 kg to 4.2 kg) (Figure 29).¹⁴⁵⁻¹⁴⁷ No single study strongly influenced the results, and no substantial heterogeneity was found.

Figure 29. Mean difference in weight comparing combination metformin and basal insulin with combination metformin and premixed insulin




CI = confidence interval; diff = difference; kg = kilogram; Met = metformin
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 21.67$ with 3 degrees of freedom ($p = 0.0001$)
 I-squared statistic = 86%
 The range in change scores for weight for the comparison group, combination metformin and premixed insulin, was 0.9 kg to 5.6 kg. The median change was 2.2 kg.

The Evidence About Low-Density Lipoproteins (Appendix G, Table 4)

Metformin versus rosiglitazone. Six RCTs compared metformin to rosiglitazone and favored metformin (pooled between-group difference -12.8 mg/dL, 95 percent CI -24.0 mg/dL to -1.6 mg/dL) (Figure 30).^{45,48,49,148,153,154} Removal of any of three studies resulted in point estimates which still favored metformin but loss of the statistical significance of those pooled between-group differences in LDL.^{49,148,153} While there was statistical evidence of heterogeneity, all studies reported between-group differences consistent with the pooled estimate. Another study reported that median LDL decreased by 31.2 mg/dL in the metformin arm and by 15.6 mg/dL in the rosiglitazone arm but was not included the meta-analysis because it reported medians and not means.⁵⁸


Figure 30. Mean difference in LDL comparing metformin with rosiglitazone



CI = confidence interval; diff = difference; LDL = low density lipoprotein; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 11.38$ with 5 degrees of freedom ($p = 0.04$)
 I-squared statistic = 56%
 The range in change scores for LDL for the comparison group, rosiglitazone, was -3.9 mg/dL to 23.4 mg/dL. The median change was 5.1 mg/dL.

Metformin versus pioglitazone. Six studies compared metformin to pioglitazone favoring metformin (pooled between-group difference in LDL -14.2 mg/dL, 95 percent CI -15.3 mg/dL to -13.1 mg/dL) (Figure 31).^{39,47,52-54,57} No one study significantly influenced results, and there was no evidence of heterogeneity.


Figure 31. Mean difference in LDL comparing metformin with pioglitazone



CI = confidence interval; diff = difference; LDL = low density lipoprotein; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 4.13$ with 5 degrees of freedom ($p = 0.53$)
 I-squared statistic = 0%
 The range in change scores for LDL for the comparison group, pioglitazone, was -4.0 mg/dL to 10.5 mg/dL. The median change was 7.2 mg/dL.

Metformin versus sulfonylureas. Eight RCTs compared metformin with sulfonylureas with a pooled between-group difference in LDL of -10.1 mg/dL (95 percent CI -13.3 mg/dL to -7.0 mg/dL) which favored metformin (Figure 32).^{60-62,64,67,68,70,155} No one study significantly influenced results. While there was statistical evidence of heterogeneity, point estimates from all studies favored metformin. Another study reported no difference in overall lipid levels between groups but did not provide quantitative results.⁶³

Figure 32. Mean difference in LDL comparing metformin with sulfonylureas




CI = confidence interval; diff = difference; LDL = low density lipoprotein; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 46.42$ with 7 degrees of freedom ($p = 0.0000$)
 I-squared statistic = 85%
 The range in change scores for LDL for the comparison group, sulfonylurea, was -3.9 mg/dL to 5.1 mg/dL. The median change was 1.4 mg/dL.

Metformin versus DPP-4 inhibitors. Three RCTs compared metformin with DPP-4 inhibitors with a pooled between-group difference in LDL of -5.9 mg/dL (95 percent CI -9.7 mg/dL to -2.0 mg/dL) favoring metformin (Figure 33).⁷⁶⁻⁷⁸ No one study significantly influenced results, and there was no evidence of heterogeneity.

Metformin versus meglitinides. As seen in the previous report,²¹ in a single RCT, the between-group difference in LDL (-3.12 mg/dL) favored metformin over repaglinide, but this difference was not statistically significant ($p > 0.05$).⁸¹

Metformin versus a combination of metformin and rosiglitazone. Seven RCTs favored metformin over the combination of metformin and rosiglitazone (pooled between-group difference in LDL -14.5 mg/dL, 95 percent CI -15.7 mg/dL to -13.3 mg/dL) (Figure 34).^{49,85-88,90,156} No one study significantly affected results, and there was no evidence of statistical heterogeneity.

Figure 33. Mean difference in LDL comparing metformin with DPP-4 inhibitors



CI = confidence interval; diff = difference; DPP-4 inhibitors = dipeptidyl peptidase-4 inhibitors; LDL = low density lipoprotein; mg/dL = milligrams per deciliter


Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 2.77$ with 2 degrees of freedom ($p = 0.25$)

I-squared statistic = 28%

The range in change scores for LDL for the comparison group, DPP-4 inhibitors, was -1.6 mg/dL to 11.2 mg/dL. The median change was -0.5 mg/dL.

Figure 34. Mean difference in LDL comparing metformin with combination metformin and rosiglitazone



CI = confidence interval; diff = difference; LDL = low density lipoprotein; mg/dL = milligrams per deciliter
Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 1.83$ with 6 degrees of freedom ($p = 0.93$)


I-squared statistic = 0%

The range in change scores for LDL for the comparison group, a combination of metformin and rosiglitazone, was -0.3 mg/dL to 20.4 mg/dL. The median change was 16.4 mg/dL.

Metformin versus a combination of metformin and pioglitazone. Two RCTs compared the effect of metformin to the combination of metformin and pioglitazone on LDL. One RCT found a between-group difference of -2.6 mg/dL,⁸⁴ and the other reported a between-group difference in percentage change from baseline of 4.2 percentage points.⁸⁹ Statistical significance was not reported.

Metformin versus a combination of metformin and sulfonylureas. Six RCTs found no between-group difference in LDL (pooled between-group difference -0.2 mg/dL, 95 percent CI -5.6 mg/dL to 5.2 mg/dL) for metformin compared to the combination of metformin and a sulfonylurea (Figure 35).^{61 62 64 68 70 155} No one study significantly affected results. Meta-regression revealed study duration as a potential source of heterogeneity. Shorter duration studies (16 to 18 weeks) tended to favor the combination of metformin and a sulfonylurea,^{68 70 155} and longer duration studies (24 to 26 weeks) tended to favor metformin.^{61 62 64} Another study reported no changes in lipid values between groups but did not provide quantitative results.⁶³

Figure 35. Mean difference in LDL comparing metformin with combination metformin and sulfonylureas




CI = confidence interval; diff = difference; LDL = low density lipoprotein; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 112.04$ with 5 degrees of freedom ($p = 0.0000$)
 I-squared statistic = 96%

The range in change scores for LDL for the comparison group, a combination of metformin and sulfonylureas, was -7.8 mg/dL to 4.5 mg/dL. The median change was -4.5 mg/dL.

Metformin versus a combination of metformin and DPP-4 inhibitors. Four RCTs found no between-group difference in LDL for metformin compared to the combination of metformin and a DPP-4 inhibitor (pooled between-group difference -0.4 mg/dL, 95 percent CI -5.4 mg/dL to 6.2 mg/dL) (Figure 36).^{76,78,85,94} There was no statistical evidence of heterogeneity, and no one study significantly influenced results. One study evaluated LDL at 24 weeks and after a continuation (at 54 weeks).⁷⁶ We included the shorter duration results in the meta-analysis since the study duration was more homogenous with the rest of the studies and had less loss to followup.⁷⁶ The 54-week results were similar to those at 24-weeks; significance of the between-group difference was not reported, but the 95 percent CIs for percentage change in LDL from baseline were overlapping.⁷⁶ There was a possible dose-response relationship with the 2000 mg metformin and 100 mg sitagliptin arm reducing LDL (mean change from baseline -1.1 percent at 24 weeks and -4.1 percent at 54 weeks) compared to the 1000 mg metformin plus 100 mg sitagliptin arm (mean change in LDL from baseline 1.4 percent at 24 weeks and -0.3 percent at 54 weeks). Another study studied two combination arms: metformin plus saxagliptin 5 mg once daily and metformin plus saxagliptin 10 mg once daily.⁷⁸ We included the arm with saxagliptin dosing of 5 mg per day in the meta-analysis since this is the FDA-approved dose.⁷⁸ However, percent changes in LDL were similar in both arms, -4.6 mg/dL and -3.8 mg/dL for the 5- and 10-mg saxagliptin arms, respectively.⁷⁸

Figure 36. Mean difference in LDL comparing metformin with combination metformin and DPP-4 inhibitors



CI = confidence interval; diff = difference; DPP-4 inhibitors = dipeptidyl peptidase-4 inhibitors; LDL = low density lipoprotein; mg/dL = milligrams per deciliter

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 0.61$ with 3 degrees of freedom ($p = 0.90$)


I-squared statistic = 0%

The range in change scores for LDL for the comparison group, a combination of metformin and DPP-4 inhibitors, was -4.6 mg/dL to 9.2 mg/dL. The median change was -0.9 mg/dL.

Metformin versus a combination of metformin and meglitinides. A single 24-week RCT directly compared the combination of metformin and nateglinide at two different doses (60 mg and 120 mg) to the combination of metformin and placebo and showed no between-group difference in LDL (0 mg/dL) over the course of the study.⁹⁶

Rosiglitazone versus pioglitazone. Three RCTs comparing rosiglitazone directly with pioglitazone showed a greater increase in LDL with rosiglitazone, (pooled between-group difference of 14.3 mg/dL, 95 percent CI 5.8 mg/dL to 22.7 mg/dL) (Figure 37).⁹⁷⁻⁹⁹ No one study significantly influenced results. While there was statistical evidence of heterogeneity, point estimates from all studies favored pioglitazone. Due to these differences, pioglitazone and rosiglitazone were not combined for comparisons including these thiazolidinediones for the LDL section.

Figure 37. Mean difference in LDL comparing rosiglitazone with pioglitazone



CI = confidence interval; diff = difference; LDL = low density lipoprotein; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 9.65$ with 2 degrees of freedom ($p = 0.008$)
 I-squared statistic = 79%
 The range in change scores for LDL for the comparison group, pioglitazone, was -18 to 12.3 mg/dL. The median change was -13.7 mg/dL.


Rosiglitazone versus sulfonylureas. Two RCTs compared rosiglitazone to a sulfonylurea, and in both studies, rosiglitazone (8 mg daily) increased median LDL relative to a sulfonylurea (range in median between-group difference 15.2 mg/dL to 19.5 mg/dL).^{100,149} Statistical significance of between-group differences were not reported. There was suggestion of a dose-response given that a lower dose rosiglitazone (4 mg daily) was associated with a smaller median between-group difference (11.7 mg/dL) in one study.¹⁰⁰

Pioglitazone versus sulfonylureas. Three RCTs compared pioglitazone to a sulfonylurea (pooled between-group difference in LDL 7.1 mg/dL, 95 percent CI 5.3 mg/dL to 9.0 mg/dL) (Figure 38).^{41,105,106} No one study affected results, and there was no significant heterogeneity.
Rosiglitazone versus meglitinides. As seen in the previous evidence report,²¹ a single RCT compared rosiglitazone to repaglinide and found a between-group difference in LDL of 15 mg/dL.¹⁰⁹

Pioglitazone versus meglitinides. As seen in the previous report,²¹ a single RCT compared pioglitazone to repaglinide and found a between-group difference in LDL of -16 mg/dL.¹¹⁰

Sulfonylureas versus DPP-4 inhibitors. One double-blind moderately sized RCT directly compared four doses of sitagliptin to glipizide upward titrated to 20 mg daily.¹¹¹ After 12 weeks, both high dose sitagliptin (100 mg a day) and glipizide (maximum dose 20 mg a day) increased LDL (5.5 percent versus 2.2 percent respectively) with overlapping confidence intervals for the placebo-subtracted change from baseline in each group.¹¹¹

Figure 38. Mean difference in LDL comparing pioglitazone with sulfonylureas




CI = confidence interval; diff = difference; LDL = low density lipoprotein; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 2.08$ with 2 degrees of freedom ($p = 0.35$)
 I-squared statistic = 4%
 The range in change scores for LDL for the comparison group, sulfonylureas, was -8 mg/dL to -1.2 mg/dL. The median change was -1.4 mg/dL.

Sulfonylureas versus meglitinides. As seen in the previous evidence report,²¹ two RCTs compared a sulfonylurea with repaglinide and showed no significant between-group differences in LDL (range in between-group differences of -1.5 mg/dL to 1 mg/dL).^{113,117} An additional RCT reported no difference between nateglinide and glibenclamide in LDL, but no quantitative results were provided.¹¹⁹

Sulfonylurea versus GLP-1 agonists. A single RCT compared a sulfonylurea to liraglutide and found a non-significant between-group difference in LDL: 2.7 mg/dL (95 percent CI -1.5 mg/dL to 6.6 mg/dL).¹²¹ Of note, the dose used in the sulfonylurea arm was low relative to that used in the liraglutide arm.¹²¹

Combination of metformin and rosiglitazone versus combination of metformin and sulfonylureas. Four RCTs compared the combination of metformin and rosiglitazone to metformin and a sulfonylurea. The pooled between-group difference in LDL was 13.5 mg/dL (95 percent CI 9.1 mg/dL to 17.9 mg/dL) comparing metformin and rosiglitazone with metformin and a sulfonylurea (Figure 39).^{123,124,128,157} There was no statistical evidence of heterogeneity, and no single study significantly influenced results. We included results from the 18-month analysis of RECORD in the meta-analysis since this duration was more comparable to the other studies included in the meta-analysis.¹²⁴ At 5.5 years, the combination of metformin and rosiglitazone decreased LDL less than the combination of metformin and a sulfonylurea (between-group difference 6.6 mg/dL ($p = 0.0001$)).¹⁶

Figure 39. Mean difference in LDL comparing combination of metformin and rosiglitazone with combination of metformin and sulfonylureas



CI = confidence interval; diff = difference; LDL = low density lipoprotein; Met = metformin; mg/dL = milligrams per deciliter; Rosi = rosiglitazone; SU = sulfonylurea

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 2.16$ with 3 degrees of freedom ($p = 0.54$)

I-squared statistic = 0%

The range in change scores for LDL for the comparison group, a combination of metformin and sulfonylureas, was -16 mg/dL to -4 mg/dL. The median change was -8.2 mg/dL.

Combination of metformin and pioglitazone versus combination of metformin and sulfonylureas. A single RCT compared the combination of metformin and pioglitazone to the combination of metformin and glimepiride at 26 weeks and reported a between-group difference of 8.5 mg/dL ($p = 0.03$) favoring the combination of metformin and glimepiride.¹²⁶

Combination of metformin and rosiglitazone versus combination of metformin and DPP-4 inhibitors. Two RCTs compared metformin plus rosiglitazone with the combination of metformin plus sitagliptin showing between-group differences in percentage change in LDL from baseline of 14.8 percentage points (95 percent CI 5.7 percent to 23.9 percent)⁸⁵ and 0.1 percent.¹³⁰

Combination of metformin and rosiglitazone versus combination of metformin and meglitinides. One RCT lasting 26 weeks compared metformin plus rosiglitazone twice daily with the combination of metformin plus repaglinide twice daily and three times daily, showing a significant between-group difference in LDL of 12.2 mg/dL ($p = 0.0002$).¹³¹

Combination of metformin and rosiglitazone versus combination of metformin and GLP-1 agonists. A single RCT 20 weeks in duration compared the combination of metformin and rosiglitazone to the combination of metformin and exenatide yielding a between-group difference in LDL of 14.7 mg/dL.¹³² Significance was not reported.¹³²

Combination of metformin and pioglitazone versus combination of pioglitazone and sulfonylureas. A single RCT found no difference in LDL for pioglitazone added to either metformin or a sulfonylurea ($p = 0.28$) in a post-hoc analysis at 6 months.¹⁵⁸

Combination of metformin and sulfonylureas versus combination of metformin and meglitinides. Two moderately sized double-blinded RCTs lasting 1 to 2 years directly compared the combination of metformin plus sulfonylurea with metformin plus nateglinide.¹³⁵⁻¹³⁶ One study reported that LDL decreased by less than 5 percent in both groups.¹³⁶ The other study reported a decrease in LDL which was greater in the metformin plus sulfonylurea arm compared with the metformin plus nateglinide arm (between group difference -7 mg/dL).¹³⁵

Combination of metformin and sulfonylureas versus combination of rosiglitazone and sulfonylureas. One RCT lasting only 12 weeks reported less of a decrease in LDL in the metformin plus sulfonylurea arm compared to the rosiglitazone plus sulfonylurea arm (between-group difference 2.7 mg/dL, $p = 0.005$).⁴² At 18 months, the RECORD trial reported a between-group difference in LDL of -18.7 mg/dL ($p < 0.001$)¹²⁴ and -12.1 mg/dL ($p < 0.0001$) at 5.5 years¹²⁴ comparing metformin plus sulfonylurea to rosiglitazone plus sulfonylurea.

Combination of metformin and sulfonylureas versus combination of pioglitazone and sulfonylureas. Two RCTs found that the combination of metformin and sulfonylurea decreased LDL relative to the combination of pioglitazone and sulfonylurea. One study reported a median between-group difference of -11.7 mg/dL ($p = 0.11$), and the other a mean between-group difference of -9.4 mg/dL ($p = 0.0002$).^{140,141}


Combination of metformin and DPP-4 inhibitors versus combination of metformin and GLP-1 agonists. A single RCT lasting 26 weeks compared the combination of metformin and sitagliptin with the combination of metformin and one of 2 doses of liraglutide.¹⁴³ LDL increased in all arms, and the dose of liraglutide did not affect this change: mean between-group difference in LDL 1.9 mg/dL (95 percent CI -6.6 mg/dL to 2.7 mg/dL, daily dose of liraglutide 1.2 mg) and 3.1 mg/dL (95 percent CI -7.7 mg/dL to 1.5 mg/dL, daily dose of liraglutide 1.8 mg) for the metformin plus sitagliptin arm compared with the metformin plus liraglutide arms.¹⁴³

The Evidence About High-Density Lipoproteins (Appendix G, Table 4)

Metformin versus rosiglitazone. Six RCTs reported no between-group difference in HDL for metformin compared to rosiglitazone (pooled between-group difference -0.5 mg/dL, 95 percent CI -2.3 mg/dL to 1.4 mg/dL) (Figure 40).^{45,48,49,148,153,154} No one study significantly affected results, and there was no statistical evidence of heterogeneity.

Metformin versus pioglitazone. Eight RCTs favored pioglitazone over metformin with a pooled between-group difference in HDL of -3.2 mg/dL (95 percent CI -4.3 mg/dL to -2.1 mg/dL) (Figure 41).^{39,47,50-54,57} No one study significantly affected results. While there was statistical evidence of heterogeneity, point estimates from all studies favored pioglitazone.


Figure 40. Mean difference in HDL comparing metformin with rosiglitazone



CI = confidence interval; diff = difference; HDL = high density lipoproteins; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 3.65$ with 5 degrees of freedom ($p = 0.60$)
 I-squared statistic = 0%

The range in change scores for HDL for the comparison group, rosiglitazone, was 0.8 mg/dL to 7.8 mg/dL. The median change was 3.5 mg/dL.


Figure 41. Mean difference in HDL comparing metformin with pioglitazone



CI = confidence interval; diff = difference; HDL = high density lipoproteins; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 100.55$ with 7 degrees of freedom ($p = 0.0000$)
 I-squared statistic = 93%
 The range in change scores for HDL for the comparison group, pioglitazone, was -1.9 mg/dL to 9.4 mg/dL. The median change was 4.5 mg/dL.

Metformin versus sulfonylureas. Eleven studies found no significant change in HDL for metformin compared to a sulfonylurea (pooled between-group difference 0.2 mg/dL, 95 percent CI -0.4 mg/dL to 0.8 mg/dL) (Figure 42).^{50,51,60-52,64,66-68,70,71} No one study significantly affected results. There was no obvious source of the observed heterogeneity on metaregression. Another study reported no changes in lipid values between groups but did not provide quantitative results.⁶³


Figure 42. Mean difference in HDL comparing metformin with sulfonylureas



CI = confidence interval; diff = difference; HDL = high density lipoproteins; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 175.80$ with 10 degrees of freedom ($p = 0.0000$)
 I-squared statistic = 94%
 The range in change scores for HDL for the comparison group, sulfonylureas, was -0.4 mg/dL to 5.9 mg/dL. The median change was 0.5 mg/dL.

Metformin versus DPP-4 inhibitors. Three RCTs compared metformin with DPP-4 inhibitors on HDL with a pooled between-group difference of 2.3 mg/dL (95 percent CI -0.28 mg/dL to 4.9 mg/dL) (Figure 43).⁷⁶⁻⁷⁸ Removal of the largest study⁷⁷ led to a statistically significant pooled between-group difference in HDL favoring metformin. Only 3 studies were included in this meta-analysis making it difficult to understand the significance of this. There was no statistical evidence of heterogeneity.

Figure 43. Mean difference in HDL comparing metformin with DPP-4 inhibitors



CI = confidence interval; diff = difference; DPP-4 inhibitors = dipeptidyl peptidase-4 inhibitors; HDL = high density lipoproteins; mg/dL = milligrams per deciliter

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 3.90$ with 2 degrees of freedom ($p = 0.14$)


I-squared statistic = 49%

The range in change scores for HDL for the comparison group, DPP-4 inhibitors, was 0.5 mg/dL to 6.2 mg/dL. The median change was 3.9 mg/dL.

Metformin versus meglitinides. As seen in the previous evidence report,²¹ in a single RCT, the between-group difference in HDL (-4.3 mg/dL) favored repaglinide over metformin, but this difference was not statistically significant.⁸¹

Metformin versus a combination of metformin and rosiglitazone. Seven RCTs compared metformin to the combination of metformin and rosiglitazone (pooled between-group difference in HDL -2.8 mg/dL, 95 percent CI -3.5 mg/dL to -2.2 mg/dL) (Figure 44).^{49,85-88,90,156} No one study significantly affected results. While there was evidence of substantial heterogeneity, point estimates from each study were consistent with the pooled results.

Figure 44. Mean difference in HDL comparing metformin with combination metformin and rosiglitazone




CI = confidence interval; diff = difference; HDL = high density lipoproteins; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 34.57$ with 6 degrees of freedom ($p = 0.0000$)
 I-squared statistic = 83%

The range in change scores for HDL for the comparison group, a combination of metformin and rosiglitazone, was 1.8 mg/dL to 6.4 mg/dL. The median change was 3.5 mg/dL.

Metformin versus a combination of metformin and pioglitazone. Two RCTs favored the combination of metformin and pioglitazone over metformin on the change in HDL.^{84,89} One reported a between-group difference of 6.4 mg/dL (significance not reported),⁸⁴ and the other found a statistically significant percentage difference in percentage change from baseline (8.7 percent).⁸⁹

Metformin versus a combination of metformin and sulfonylureas. Five RCTs found no between-group difference in HDL (pooled between-group difference 0.3 mg/dL, 95 percent CI -1.6 mg/dL to 2.1 mg/dL) for metformin compared to the combination of metformin and a sulfonylurea (Figure 45).^{61,62,64,68,71,91} There was substantial evidence of heterogeneity, and meta-regression suggested medication dose as a potential source of heterogeneity ($p = 0.072$). In particular, the study with the lowest relative dose of metformin monotherapy compared to the combination of metformin and sulfonylurea reported the largest point estimate (between-group difference 3.1 mg/dL).⁷¹ Removal of this study from the meta-analysis led to a significant pooled between-group difference of -0.75 mg/dL (95 percent CI -1.3 mg/dL to -0.2 mg/dL).⁷¹ Another study reported no changes in lipid values between groups but did not provide quantitative results.⁶³

Figure 45. Mean difference in HDL comparing metformin with combination metformin and sulfonylureas




CI = confidence interval; diff = difference; HDL = high density lipoproteins; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 282.15$ with 4 degrees of freedom ($p = 0.0000$)
 I-squared statistic = 99%

The range in change scores for HDL for the comparison group, a combination of metformin and sulfonylurea, was -1.2 mg/dL to 1.6 mg/dL. The median change was 0.8 mg/dL.

Metformin versus a combination of metformin and DPP-4 inhibitors. Four RCTs found no between-group difference in HDL for metformin compared to the combination of metformin and sitagliptin (pooled between-group difference 0.5 mg/dL, 95 percent CI -1.5 mg/dL to 2.5 mg/dL) (Figure 46).^{76,78,85,94} There was no statistical evidence of heterogeneity, and no one study significantly influenced results. One study evaluated HDL at 24 weeks and after a continuation (at 54 weeks).⁷⁶ We included the shorter duration results in the meta-analysis since the study duration was more homogenous with the rest of the studies and had less loss to followup.⁷⁶ The 54-week results were similar to those at 24 weeks; significance of the between-group difference was not reported, but the 95 percent CIs for percentage change in HDL from baseline were overlapping.⁷⁶ There was a possible dose-response relationship with the 2000 mg metformin and 100 mg sitagliptin arm increasing HDL (mean change from baseline 5.8 percent at 24 weeks and 7.2 percent at 54 weeks) compared to the 1,000 mg metformin plus 100 mg sitagliptin arm (mean change in HDL from baseline 3.6 percent at 24 weeks and 5.1 percent at 54 weeks). Another study varied the dose of saxagliptin (5 mg and 10 mg daily) in two separate combination arms.⁷⁸ We included the lower-dose arm in the meta-analysis since this is the FDA-approved dose. HDL increased similarly in the lower and higher dose combination arms.⁷⁸

Figure 46. Mean difference in HDL comparing metformin with combination metformin and DPP-4 inhibitors



CI = confidence interval; diff = difference; DPP-4 inhibitors = dipeptidyl peptidase-4 inhibitors; HDL = high density lipoproteins; mg/dL = milligrams per deciliter

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 1.42$ with 3 degrees of freedom ($p = 0.70$)

I-squared statistic = 0%


The range in change scores for HDL for the comparison group, a combination of metformin and DPP-4 inhibitors, was -4.8 mg/dL to 6.7 mg/dL. The median change was 1.2 mg/dL.

Metformin versus a combination of metformin and meglitinides. A single 24-week RCT directly compared the combination of metformin and nateglinide at two different doses (60 mg and 120 mg) to the combination of metformin and placebo and showed no between-group difference in HDL (0 mg/dL) over the course of the study.⁹⁶

Rosiglitazone versus pioglitazone. Three RCTs directly comparing rosiglitazone with pioglitazone showed that pioglitazone increased HDL more than rosiglitazone (pooled between-group difference of -2.3 mg/dL, 95 percent CI -3.5 mg/dL to -1.2 mg/dL) (Figure 47).⁹⁷⁻⁹⁹ No one study significantly influenced results. While there was statistical evidence of heterogeneity, point estimates from all studies favored pioglitazone. Due to these differences, pioglitazone and rosiglitazone were not combined for comparisons including these thiazolidinediones for the HDL section. Removal of the largest study led to loss of significance of the pooled estimate, but the pooled estimate still favored pioglitazone.

Rosiglitazone versus sulfonylureas. Two RCTs compared rosiglitazone to a sulfonylurea, and in both studies, rosiglitazone (8 mg daily) increased median HDL relative to a sulfonylurea (range in median between-group difference 3.5 mg/dL to 7.7 mg/dL).^{100,149} The statistical significance of between-group differences was not reported. There was suggestion of a dose-response relationship given that a lower dose rosiglitazone (4 mg daily) was associated with a smaller median between-group difference (1.6 mg/dL) in one study.¹⁰⁰

Figure 47. Mean difference in HDL comparing rosiglitazone with pioglitazone



CI = confidence interval; diff = difference; HDL = high density lipoproteins; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 1.35$ with 2 degrees of freedom ($p = 0.51$)
 I-squared statistic = 0%
 The range in change scores for HDL for the comparison group, pioglitazone, was 2 mg/dL to 5.2 mg/dL. The median change was 4.7 mg/dL.

Pioglitazone versus sulfonylureas. Six RCTs favored pioglitazone over a sulfonylurea (pooled between-group difference in HDL 4.3 mg/dL, 95 percent CI 1.9 mg/dL to 6.6 mg/dL) (Figure 48).^{41,50,51,105,106,108} Removal of either of the 2 largest studies^{50,106} resulted in pooled between-group differences (3.8 mg/dL and 4.7 mg/dL) that were nonsignificant. Meta-regression suggested that study duration was a potential source of heterogeneity ($p = 0.04$). Increased study duration was associated with an increase in between-group differences in HDL.

Rosiglitazone versus meglitinides. As seen in the previous evidence report,²¹ a single RCT compared rosiglitazone to repaglinide and found a between-group difference in HDL of 1.3 mg/dL.¹⁰⁹


Pioglitazone versus meglitinides. Two RCTs compared pioglitazone with a meglitinide and found a between-group difference in HDL of 7 mg/dL in both studies.^{108,110} Neither study commented on the statistical significance of this difference.

Sulfonylureas versus DPP-4 inhibitors. One double-blind moderately sized RCT directly compared four doses of sitagliptin to glipizide upward titrated to 20 mg daily.¹¹¹ After 12 weeks, both high dose sitagliptin (100 mg per day) and glipizide (maximum dose of 20 mg per day) increased HDL (4.6 percent versus 2.8 percent respectively) with overlapping confidence intervals for the placebo-subtracted change from baseline in each group.¹¹¹

Sulfonylureas versus meglitinides. Six RCTs compared a sulfonylurea to a meglitinide and found no significant difference in HDL (pooled between-group difference -0.7 mg/dL, 95 percent


CI -2.1 mg/dL to 0.7 mg/dL) (Figure 49).^{108,113-117} Removal of one of the larger studies resulted in a statistically significant pooled between-group difference (-1.2 mg/dL, 95 percent CI -1.9 mg/dL to -0.4 mg/dL).¹¹⁴ This study did not appear to be different from the other studies and was therefore kept in the meta-analysis. No source of heterogeneity was found on meta-regression. One additional RCT reported no difference between nateglinide and glibenclamide in HDL consistent with the results of the meta-analysis, but no quantitative results were provided.¹¹⁹

Figure 48. Mean difference in HDL comparing pioglitazone with sulfonylureas



CI = confidence interval; diff = difference; HDL = high density lipoproteins; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 485.49$ with 5 degrees of freedom ($p = 0.0000$)
 I-squared statistic = 99%
 The range in change scores for HDL for the comparison group, sulfonylureas was -4.5 mg/dL to 5.9 mg/dL. The median change was 0.5 mg/dL.

Figure 49. Mean difference in HDL comparing sulfonylureas with meglitinides




CI = confidence interval; diff = difference; HDL = high density lipoproteins; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 92.38$ with 5 degrees of freedom ($p = 0.0000$)
 I-squared statistic = 95%
 The range in change scores for HDL for the comparison group, meglitinides was -0.8 mg/dL to 1.2 mg/dL. The median change was 1.1 mg/dL.

Sulfonylureas versus GLP-1 agonists. A single RCT compared a sulfonylurea with liraglutide and found a non-significant between-group difference in HDL: -0.4 mg/dL (95 percent CI -1.2 mg/dL to 1.9 mg/dL).¹²¹ Of note, the dose used in the sulfonylurea arm was low relative to that used in the liraglutide arm.¹²¹

Combination of metformin and rosiglitazone versus combination of metformin and sulfonylureas. Four RCTs compared the combination of metformin and rosiglitazone with the combination of metformin and a sulfonylurea. The pooled between-group difference in HDL was 2.7 mg/dL (95 percent CI 1.4 mg/dL to 4.1 mg/dL) comparing combination metformin and rosiglitazone with combination metformin and a sulfonylurea (Figure 50).^{123,124,128,157} There was no statistical evidence of heterogeneity, and no one study significantly influenced results. We included results from the 18-month analysis of RECORD in the meta-analysis since this duration was more comparable to the other included studies.¹²⁴ At 5.5 years, the combination of metformin and rosiglitazone increased HDL more than the combination of metformin and a sulfonylurea (between-group difference 3.1 mg/dL, $p < 0.0001$).¹⁶

Figure 50. Mean difference in HDL comparing combination metformin and rosiglitazone with combination metformin and sulfonylureas



CI = confidence interval; diff = difference; HDL = high density lipoproteins; Met = metformin; mg/dL = milligrams per deciliter; Rosi = rosiglitazone; SU = sulfonylureas

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 1.25$ with 3 degrees of freedom ($p = 0.74$)

I-squared statistic = 0%

The range in change scores for HDL for the comparison group, a combination of metformin and sulfonylureas, was -2 mg/dL to 1.2 mg/dL. The median change was 0.4 mg/dL.

Combination of metformin and pioglitazone versus combination of metformin and sulfonylureas.

Two RCTs compared the combination of metformin and pioglitazone to metformin and a sulfonylurea.^{126,158} In both studies, HDL increased in the metformin and pioglitazone arm and decreased in the metformin and sulfonylurea arm; between-group differences ranged from 5.1 mg/dL ($p < 0.001$) to 5.8 mg/dL ($p = 0.0001$).^{126,158}

Combination of metformin and rosiglitazone versus combination of metformin and DPP-4 inhibitors.

One double-blind small RCT lasting 18 weeks compared maximum dose metformin plus rosiglitazone to the combination of maximum dose metformin plus sitagliptin showing a significant between-group difference in HDL (mean difference in percentage change from baseline of 4.9 percent, 95 percent CI 0.6 percent to 9.2 percent).⁸⁵ Another small RCT 16 weeks in duration found that the mean percent decrease in HDL from baseline was slightly greater in the metformin plus rosiglitazone arm compared with the metformin plus sitagliptin arm (mean difference in percentage change from baseline of -1 percent, significance not reported).¹³⁰

Combination of metformin and rosiglitazone versus combination of metformin and meglitinides.

One RCT lasting 26 weeks compared metformin plus rosiglitazone twice daily with the combination of metformin plus repaglinide twice daily and three times daily, showing a significant between-group difference in HDL of 4.6 mg/dL ($p < 0.0001$).¹³¹

Combination of metformin and rosiglitazone versus combination of metformin and GLP-1 agonists. A single small RCT 20 weeks in duration compared metformin plus rosiglitazone with metformin plus exenatide and found a between-group mean difference in HDL of 0.8 mg/dL (significance not reported).¹³²

Combination of metformin and pioglitazone versus combination of pioglitazone and sulfonylureas. In a post hoc analysis in a single RCT, metformin plus pioglitazone increased HDL (2.3 mg/dL, $p = 0.009$) over pioglitazone plus sulfonylurea (0.4 mg/dL, $p = 0.62$) at 6 months.¹⁵⁸

Combination of metformin and sulfonylureas versus combination of metformin and meglitinides. Two moderately sized double-blinded RCTs lasting 1 to 2 years directly compared the combination of metformin plus sulfonylurea with metformin plus nateglinide.^{135,136} One study reported that HDL increased by approximately 5 percent in both groups.¹³⁶ The other study showed no between-group difference (0 mg/dL) in HDL as well.¹³⁵

Combination of metformin and sulfonylureas versus combination of metformin and premixed insulin. A single RCT lasting 4 months compared the combination of metformin and premixed insulin with the combination of metformin and a sulfonylurea, and HDL increased more in the metformin and premixed insulin group relative to the metformin plus sulfonylurea group (between-group difference 2.0 mg/dL), but this difference was not statistically significant.¹³⁸

Combination of metformin and sulfonylureas versus combination of rosiglitazone and sulfonylureas. One RCT lasting only 12 weeks reported less of a decrease in HDL in the metformin plus sulfonylurea arm compared to the rosiglitazone plus sulfonylurea arm (between-group difference 2.7 mg/dL, $p = 0.87$).⁴² At 18 months, the RECORD trial reported a between-group difference in HDL of -0.4 mg/dL ($p > 0.05$)¹²⁴ and -1.6 mg/dL ($p < 0.0001$) at 5.5 years¹²⁴ comparing metformin plus sulfonylurea to rosiglitazone plus sulfonylurea.

Combination of metformin and sulfonylureas versus combination of pioglitazone and sulfonylureas. Three RCTs found that the combination of pioglitazone and sulfonylurea increased HDL relative to the combination of metformin and sulfonylurea.^{140,141,158} In one study, the between-group difference in median HDL was 3.1 mg/dL ($p = 0.009$),¹⁴¹ and two other RCTs found a range of between-group differences of 5.5 mg/dL ($p = 0.20$) to 10.5 mg/dL ($p < 0.0001$).^{140,158}


Combination of metformin and DPP-4 inhibitors versus combination of metformin and GLP-1 agonists. A single RCT lasting 26 weeks compared the combination of metformin and sitagliptin with the combination of metformin and one of 2 doses of liraglutide.¹⁴³ HDL did not change in any arm, and thus there was no between-group difference in HDL change regardless of liraglutide dose.¹⁴³

The Evidence About Triglycerides (Appendix G, Table 4)

Metformin versus rosiglitazone. Six RCTs favored metformin over rosiglitazone in terms of lowering TG levels (pooled between-group difference -26.9 mg/dL, 95 percent CI -49.3 mg/dL

to -4.5 mg/dL) (Figure 51).^{45,48,49,148,153,154} When either of the largest studies was excluded from the meta-analysis, the point estimate still favored metformin but the confidence interval included 0.^{48,148} We performed meta-regression because of substantial heterogeneity. Study duration and dose were possible sources of heterogeneity with longer study duration and higher relative dose of metformin associated with a greater pooled between-group difference in TG. Another study reported that median TG decreased by 81 mg/dL in the metformin arm and increased by 9.8 mg/dL in the rosiglitazone arm. This study was not included in the meta-analysis because it only provided medians for point estimates, but the results were consistent with the meta-analysis.⁵⁸


Figure 51. Mean difference in triglycerides comparing metformin with rosiglitazone



CI = confidence interval; diff = difference; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.
 Test for heterogeneity: $Q = 16.38$ with 5 degrees of freedom ($p = 0.006$)
 I-squared statistic = 70%
 The range in change scores for triglycerides for the comparison group, rosiglitazone, was -44 mg/dL to 22 mg/dL. The median change was -4.2 mg/dL.

Metformin versus pioglitazone. Eight RCTs compared metformin to pioglitazone and found a pooled between-group difference in TG of 27.2 mg/dL (95 percent CI 24.4 mg/dL to 30.0 mg/dL) (Figure 52).^{39,47,50-54,57} No one study significantly affected results, and there was no statistical evidence of heterogeneity.

Figure 52. Mean difference in triglycerides comparing metformin with pioglitazone



CI = confidence interval; diff = difference; mg/dL = milligrams per deciliter

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 4.34$ with 7 degrees of freedom ($p = 0.74$)

I-squared statistic = 0%

The range in change scores for triglycerides for the comparison group, pioglitazone, was -155.6 mg/dL to -8.0 mg/dL. The median change was -26.6 mg/dL.


Metformin versus sulfonylureas. Eleven RCTs favored metformin over sulfonylurea (pooled between-group difference in TG -8.6 mg/dL, 95 percent CI -15.6 mg/dL to -1.6 mg/dL) (Figure 53).^{50,51,60-62,64,66-68,70,71} Removal of one study resulted in loss of statistical significance (pooled between-group difference -6.9 mg/dL (95 percent CI -13.9 mg/dL to 0.1 mg/dL).⁶⁴ There was no obvious source of the observed heterogeneity on meta-regression. Another study reported no changes in lipid values between groups but did not provide quantitative results.⁶³

Metformin versus DPP-4 inhibitors. Three RCTs found that sitagliptin decreased TG more than metformin, but the pooled between-group difference was not significant (3.4 mg/dL, 95 percent CI -0.4 mg/dL to 7.2 mg/dL) (Figure 54).⁷⁶⁻⁷⁸ No one study significantly influenced results, and there was no evidence of heterogeneity.

Metformin versus meglitinides. As seen in the previous evidence report,²¹ in a single RCT, the between-group difference in triglycerides (-8.01 mg/dL) favored metformin over repaglinide, but this difference was not statistically significant.⁸¹

Metformin versus a combination of metformin and rosiglitazone. Seven RCTs compared metformin to the combination of metformin and rosiglitazone (pooled between-group difference in TG -14.5 mg/dL, 95 percent CI -15.7 mg/dL to -13.3 mg/dL) (Figure 55).^{49,85-88,90,156} No one study significantly affected results, and there was no statistical evidence of heterogeneity.

Figure 53. Mean difference in triglycerides comparing metformin with sulfonylureas



CI = confidence interval; diff = difference; mg/dL = milligrams per deciliter


Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 122.78$ with 10 degrees of freedom ($p = 0.0000$)

I-squared statistic = 92%

The range in change scores for triglycerides for the comparison group, sulfonylureas, was -44.5 mg/dL to 59.8 mg/dL. The median change was 0 mg/dL.

Figure 54. Mean difference in triglycerides comparing metformin with DPP-4 inhibitors




CI = confidence interval; diff = difference; DPP-4 inhibitors = dipeptidyl peptidase-4 inhibitors; mg/dL = milligrams per deciliter
 Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 0.97$ with 2 degrees of freedom ($p = 0.62$)

I-squared statistic = 0%

The range in change scores for triglycerides for the comparison group, DPP-4 inhibitors, was -3.7 mg/dL to 6 mg/dL. The median change was -3 mg/dL.

Figure 55. Mean difference in triglycerides comparing metformin with combination metformin and rosiglitazone



CI = confidence interval; diff = difference; mg/dL = milligrams per deciliter

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 3.66$ with 6 degrees of freedom ($p = 0.72$)


I-squared statistic = 0%

The range in change scores for triglycerides for the comparison group, a combination of metformin and rosiglitazone, was -33.7 mg/dL to 11.8 mg/dL. The median change was 0 mg/dL.

Metformin versus a combination of metformin and pioglitazone. Two RCTs compared metformin to the combination of metformin and pioglitazone.^{84,89} One RCT found a between-group difference of -6.1 mg/dL (significance not reported),⁸⁴ and the other reported statistically significant between-group percentage change in percentage change from baseline of 18.2 percent.⁸⁹

Metformin versus a combination of metformin and sulfonylureas. As seen in the previous evidence report,²¹ six RCTs found no between-group difference in TG (pooled between-group difference 6.9 mg/dL, 95 percent CI -1.1 mg/dL to 14.9 mg/dL) for metformin compared to the combination of metformin and a sulfonylurea (Figure 56).^{61,62,64,68,70,71} Meta-regression did not reveal a source of the observed statistical heterogeneity. Removal of one study from the meta-analysis resulted in a significant pooled between-group difference of 8.9 mg/dL (95 percent CI 0.2 mg/dL to 17.7 mg/dL).⁶⁴ Two studies reported no changes in lipid values between groups but did not provide quantitative results.^{63,91}

Figure 56. Mean difference in triglycerides comparing metformin with combination metformin and sulfonylureas



CI = confidence interval; diff = difference; mg/dL = milligrams per deciliter

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.


Test for heterogeneity: $Q = 57.40$ with 5 degrees of freedom ($p = 0.0000$)

I-squared statistic = 91%

The range in change scores for triglycerides for the comparison group, a combination of metformin and sulfonylureas, was -17.8 mg/dL to 18.5 mg/dL. The median change was -10.2 mg/dL.

Metformin versus a combination of metformin and DPP-4 inhibitors. Four RCTs compared metformin to the combination of metformin and sitagliptin and found that metformin decreased TG less than the combination with a pooled between-group difference of 20.7 mg/dL (95 percent CI -0.8 mg/dL to 42.1 mg/dL) (Figure 57).^{76,78,85,94} Removal of the largest study led to a significant pooled between-group difference (34.8 mg/dL, 95 percent CI 11.3 mg/dL to 58.3 mg/dL). There was no statistical evidence of heterogeneity. One study evaluated TG at 24 weeks and after a continuation (at 54 weeks).⁷⁶ We included the shorter duration results in the meta-analysis since the study duration was more homogenous with the rest of the studies and had less loss to followup.⁷⁶ The 54-week results were similar to those at 24 weeks.⁷⁶ Results suggested a dose-response relationship with the 2000 mg metformin and 100 mg sitagliptin arm decreasing TG (mean change from baseline -10.1 percent at 24 weeks ($p < 0.05$) and -7.1 percent at 54 weeks ($p < 0.05$)) compared to the 1000 mg metformin plus 100 mg sitagliptin arm (mean change in TG from baseline -3.7 percent at 24 weeks ($p > 0.05$) and -4.6 percent at 54 weeks ($p > 0.05$)).⁷⁶ Another study evaluated two combination arms: metformin plus saxagliptin 5 mg once daily and metformin plus saxagliptin 10 mg once daily.⁷⁸ We included the arm with saxagliptin at 5 mg per day in the meta-analysis since this is the FDA-approved dose.⁷⁸ However, percent changes in TG were similar in both arms, -5.8 percent and -4.5 percent for the 5 and 10 mg saxagliptin arms, respectively.⁷⁸

Figure 57. Mean difference in triglycerides comparing metformin with combination metformin and DPP-4 inhibitors



CI = confidence interval; diff = difference; DPP-4 inhibitors = dipeptidyl peptidase-4 inhibitors; mg/dL = milligrams per deciliter. Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 6.03$ with 3 degrees of freedom ($p = 0.11$)


I-squared statistic = 50%

The range in change scores for triglycerides for the comparison group, a combination of metformin and DPP-4 inhibitors, was -16 mg/dL to 7.7 mg/dL. The median change was -10.2 mg/dL.

Metformin versus a combination of metformin and meglitinides. A single 24-week RCT directly compared the combination of metformin and nateglinide at two different doses (60 mg and 120 mg) to the combination of metformin and placebo and showed a small reduction in triglycerides in the combination arms compared to the monotherapy arm (range in between-group differences in triglycerides -17.8 mg/dL to 8.9 mg/dL). This difference was statistically significant ($p < 0.05$) for the higher-dose nateglinide (120 mg) arm.⁹⁶

Rosiglitazone versus pioglitazone. Three RCTs compared rosiglitazone with pioglitazone and demonstrated a favorable effect of pioglitazone on TG relative to rosiglitazone (pooled between-group difference 33.2 mg/dL, 95 percent CI -16.7 mg/dL to 83.1 mg/dL comparing rosiglitazone to pioglitazone) (Figure 58).⁹⁷⁻⁹⁹ Removal of either of the largest studies led to a statistically significant difference which still favored pioglitazone (pooled between-group difference 63.3 mg/dL, 95 percent CI 42.1 mg/dL to 84.5 mg/dL and pooled between-group difference 7.7 mg/dL, 95 percent CI 2.2 mg/dL to 13.2 mg/dL).^{98,99} While there was statistical evidence of heterogeneity, point estimates from all studies favored pioglitazone. Due to these differences, pioglitazone and rosiglitazone were not combined for comparisons including these thiazolidinediones for the TG section.

Figure 58. Mean difference in triglycerides comparing rosiglitazone with pioglitazone



CI = confidence interval; diff = difference; mg/dL = milligrams per deciliter

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 25.37$ with 2 degrees of freedom ($p = 0.0000$)

I-squared statistic = 92%

The range in change scores for triglycerides for the comparison group, pioglitazone, was -51 mg/dL to -15 mg/dL. The median change was -33.0 mg/dL.


Rosiglitazone versus sulfonylureas. In one RCT, rosiglitazone (8 mg/day) and a sulfonylurea both decreased TG at 52 weeks (mean between-group difference 11 mg/dL for rosiglitazone relative to sulfonylurea) which was reported to be nonsignificant.¹⁴⁹ Another RCT found that at 4 mg/day, rosiglitazone decreased TG relative to a sulfonylurea (mean between-group difference -7 mg/dL), but at 8 mg/day rosiglitazone increased TG relative to a sulfonylurea (mean between-group difference 15 mg/dL) at 52 weeks; statistical significance was not reported.¹⁰⁰

Pioglitazone versus sulfonylureas. Six RCTs favored pioglitazone over a sulfonylurea (pooled between-group difference -31.6 mg/dL, 95 percent CI -49.1 mg/dL to -14.1 mg/dL) (Figure 59).^{41,50,51,105,106,108} While there was statistical evidence of heterogeneity, point estimates from all studies favored pioglitazone. No one study significantly influenced results.

Rosiglitazone versus meglitinides. As seen in the previous evidence report,²¹ one RCT found that compared to repaglinide, rosiglitazone caused a greater absolute increase in TG (between-group difference 23 mg/dL), but statistical significance was not reported.¹⁰⁹

Pioglitazone versus meglitinides. As seen in the previous evidence report,²¹ one RCT found that compared with repaglinide, pioglitazone caused a greater absolute reduction in TG (between-group difference -96 mg/dL), but statistical significance was not reported.¹¹⁰ A small RCT comparing pioglitazone to nateglinide found a between-group difference in TG of -32 mg/dL favoring pioglitazone, but statistical significance was not reported.¹⁰⁸

Figure 59. Mean difference in triglycerides comparing pioglitazone with sulfonylureas



CI = confidence interval; diff = difference; mg/dL = milligrams per deciliter

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 57.26$ with 5 degrees of freedom ($p = 0.0000$)


I-squared statistic = 91%

The range in change scores for triglycerides for the comparison group, sulfonylureas, was -44 mg/dL to 7.3 mg/dL. The median change was -3.6 mg/dL.

Sulfonylureas versus DPP-4 inhibitors. One double-blind moderately sized RCT directly compared four doses of sitagliptin to glipizide upward titrated to 20 mg daily.¹¹¹ After 12 weeks, both high dose sitagliptin (100 mg per day) and glipizide (maximum dose of 20 mg a day) increased TG (3.6 percent versus 7.0 percent respectively) with overlapping confidence intervals for the placebo-subtracted change from baseline in each group.¹¹¹

Sulfonylureas versus meglitinides. Four RCTs compared sulfonylureas with a meglitinide and found no difference in TG (pooled between-group difference of 0.2 mg/dL, 95 percent CI -3.8 mg/dL to 4.2 mg/dL) (Figure 60).^{108,113,114,117} There was no statistical evidence of heterogeneity, and no one study markedly influenced the results. Two additional RCTs also reported no significant differences in TG between sulfonylureas and meglitinides; one study did not report a measure of variance (e.g., standard error), and the other study did not provide quantitative results.^{116,119}

Figure 60. Mean difference in triglycerides comparing sulfonylureas with meglitinides



CI = confidence interval; diff = difference; mg/dL = milligrams per deciliter

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 0.54$ with 3 degrees of freedom ($p = 0.91$)


I-squared statistic = 0%

The range in change scores for triglycerides for the comparison group, meglitinides, was -18 mg/dL to 6.57 mg/dL. The median change was 1.0 mg/dL.

Sulfonylureas versus GLP-1 agonists. A single RCT compared a sulfonylurea with liraglutide and found a nonsignificant between-group difference in TG: 4.4 mg/dL (95 percent CI -9.7 mg/dL to 8.0 mg/dL).¹²¹ Of note, the dose used in the sulfonylurea arm was low relative to that used in the liraglutide arm.¹²¹

Combination of metformin and rosiglitazone versus combination of metformin and sulfonylureas. Four RCTs compared the combination of metformin and rosiglitazone with the combination of metformin and a sulfonylurea and found a pooled between-group difference in TG of 4.6 mg/dL (95 percent CI -16.5 mg/dL to 25.8 mg/dL) (Figure 61).^{123,124,128,159} Removal of one study¹⁵⁹ from the meta-analysis led to statistical significance of the between-group difference (16.5 mg/dL, 95 percent CI 2.2 mg/dL to 30.8 mg/dL); this study did not seem different from the other studies in terms of dosing, duration, or baseline TG and was left in the meta-analysis. No source of heterogeneity was found on metaregression. We included results from the 18-month analysis of RECORD in the meta-analysis since this duration was more comparable to the other included studies.¹²⁴ At 5.5 years, the combination of metformin and rosiglitazone decreased TG more than the combination of metformin and a sulfonylurea (between-group difference -10.7 mg/dL, $p = 0.046$).¹⁶

Figure 61. Mean difference in triglycerides comparing combination metformin and rosiglitazone with combination metformin and sulfonylureas



CI = confidence interval; diff = difference; Met = metformin; mg/dL = milligrams per deciliter; Rosi = rosiglitazone; SU = sulfonylureas

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 10.28$ with 3 degrees of freedom ($p = 0.02$)

I-squared statistic = 71%

The range in change scores for triglycerides for the comparison group, combination metformin and sulfonylureas, was -41 mg/dL to 13.4 mg/dL. The median change was -5.6 mg/dL.

Combination of metformin and pioglitazone versus combination of metformin and sulfonylureas. Two RCTs compared the combination of metformin and pioglitazone to metformin and a sulfonylurea.^{126,158} In both studies, TG decreased in the metformin and pioglitazone arm. TG decreased in the metformin and sulfonylurea arm in one study¹²⁶ and increased slightly in another.¹⁵⁸ Between-group differences ranged from -10 mg/dL ($p = 0.30$) to -24.9 mg/dL ($p = 0.045$) for the combination of metformin and pioglitazone relative to the combination of metformin and a sulfonylurea.^{126,158}

Combination of metformin and rosiglitazone versus combination of metformin and DPP-4 inhibitors. One double-blind small RCT lasting 18 weeks compared maximum dose metformin plus rosiglitazone to the combination of maximum dose metformin plus sitagliptin showing a significant between-group difference in TG (mean difference in percentage change from baseline of 17.9 percent, 95 percent CI 6.7 percent to 29.2 percent).⁸⁵ Another small RCT 16 weeks in duration found that the mean percent decrease in TG from baseline was greater in the metformin plus rosiglitazone arm compared with the metformin plus sitagliptin arm (mean difference in percentage change from baseline of 25.4 percent, significance not reported).¹³⁰

Combination of metformin and rosiglitazone versus combination of metformin and repaglinide. One RCT lasting 26 weeks compared metformin plus rosiglitazone twice daily with the combination of metformin plus repaglinide twice daily and three times daily, showing no significant between-group difference in TG (7.4 mg/dL, $p = 0.60$).¹³¹

Combination of metformin and rosiglitazone versus combination of metformin and GLP-1 agonists. A single small RCT 20 weeks in duration compared metformin plus rosiglitazone with metformin plus exenatide and found a between-group mean difference in TG of 36.3 mg/dL (significance not reported).¹³²

Combination of metformin and pioglitazone versus combination of pioglitazone and sulfonylureas. On a post hoc analysis in a single RCT, addition of pioglitazone to a sulfonylurea decreased TG (-28.5 mg/dL, $p = 0.017$) relative to the addition of pioglitazone to metformin (-17.8 mg/dL, $p = 0.07$) at 6 months.¹⁵⁸

Combination of metformin and sulfonylureas versus combination of metformin and meglitinides. Two moderately sized double-blinded RCTs lasting 1 to 2 years directly compared the combination of metformin plus sulfonylurea with metformin plus nateglinide.^{135,136} One study reported that TG decreased by approximately 10 percent in both groups.¹³⁶ The other study reported a decrease in TG in each arm which was greater in the metformin plus sulfonylurea arm compared to the metformin plus nateglinide arm (between group difference -6 mg/dL).

Combination of metformin and sulfonylureas versus combination of metformin and premixed insulin. A single RCT lasting 4 months compared the combination of metformin and 70/30 insulin aspart with the combination of metformin and a sulfonylurea, and TG decreased less in the metformin and premixed insulin group relative to the metformin plus sulfonylurea group (between-group difference 13.3 mg/dL), but this difference was not statistically significant.¹³⁸

Combination of metformin and sulfonylurea versus combination of rosiglitazone and sulfonylureas. One RCT lasting only 12 weeks reported less of a decrease in TG in the metformin plus sulfonylurea compared with the rosiglitazone plus sulfonylurea arm (between-group difference 20.5 mg/dL, $p = 0.63$).⁴² The RECORD trial reported a between-group difference in HDL of -0.4 mg/dL ($p > 0.05$) at 18 months¹²⁴ and -1.6 mg/dL ($p < 0.0001$) at 5.5 years¹⁶ comparing metformin plus sulfonylurea to rosiglitazone plus sulfonylurea.

Combination of metformin and sulfonylurea versus combination of pioglitazone and sulfonylureas. One RCT reported that median TG increased by 17.8 mg/dL ($p = 0.60$) in the metformin plus sulfonylurea group relative to the pioglitazone plus sulfonylurea group at 24 weeks.¹⁴¹ Another 24-week study reported that mean TG increased by 31.1 mg/dL ($p < 0.05$) in the metformin plus sulfonylurea group relative to the pioglitazone plus sulfonylurea group.¹⁵⁸ A longer RCT (52 weeks) reported that TG decreased in both arms but less so in the metformin plus sulfonylurea arm (between-group difference -12.5 mg/dL, $p = 0.008$).¹⁴⁰ Another small RCT reported median TG at baseline and 24 weeks and found that median TG increased by 17.7 mg/dL in the metformin plus sulfonylurea arm compared with the pioglitazone and sulfonylurea arm (significance not reported).¹⁶⁰

Combination of metformin and DPP-4 inhibitors versus combination of metformin and GLP-1 agonists. A single RCT lasting 26 weeks compared the combination of metformin and sitagliptin with the combination of metformin and one of 2 doses of liraglutide.¹⁴³ TG decreased

in all arms. Compared with metformin plus sitagliptin, TG decreased less in the metformin plus 1.2 mg liraglutide arm (between group difference -18.6 mg/dL, 95 percent CI -40.7 mg/dL to 3.5 mg/dL) but decreased more in the metformin plus 1.8 mg liraglutide arm (between-group difference 2.7 mg/dL, 95 percent CI -18.6 mg/dL to 24.8 mg/dL).¹⁴³

Publication Bias

Overall, we did not find strong evidence for publication bias in this literature. Across all analyses of intermediate outcomes, there were only two statistically significant comparisons ($p < 0.05$) by the less conservative Egger's test. Metformin versus rosiglitazone for the TG outcome was one of the comparisons ($p = 0.02$, number of studies (N) = 6). Based on the funnel plot, this comparison was missing one or two large studies with smaller between-group differences and missing a few smaller studies with larger between-group differences. Including a few larger studies with smaller between-group differences and smaller studies with larger between-group differences may have slightly changed the effect size, but would have been unlikely to change the overall conclusions showing that metformin reduces triglycerides compared with rosiglitazone. The second comparison with significant publication bias was metformin versus metformin plus thiazolidinedione for HbA1c outcome ($p = 0.002$, number of studies (N) = 11). Few to no small studies with smaller between-group differences were included based on the funnel plot. This may have led to a slight overestimation of effect; however, including these types of studies would likely not have changed the overall conclusion. For all other comparisons, the funnel plots appeared roughly symmetrical and the Begg's and Egger's tests were not significant. In most cases, the number of studies in each comparison was small and was unlikely to have had high power to detect moderate publication bias.

Gray Literature

After reviewing the data from the FDA and clinical trials registry, we found this data to be consistent with the published peer-reviewed literature included in this report on the intermediate outcomes.

Applicability

The applicability of these studies to the question of comparable efficacy and effectiveness of the drugs will depend largely on the comparability of the drug interventions, duration of exposure to the drug, and how similar the trial populations are to the U.S. population with type 2 diabetes. The studies had generally applicable populations, interventions, outcomes, and settings to adults with type 2 diabetes in the United States with a few exceptions: less comorbidity, less older populations, less racial diversity, and shorter duration of drug exposure.

Study population differences are the most pronounced threat to applicability for this section. As mentioned under study population characteristics, study participants were mainly middle-aged, overweight or obese adults who had diabetes between 3 to 6 years duration. This is similar to the general U.S. population of type 2 diabetes.¹⁶¹ However, most of the studies excluded older people over the age of 75 or 80 years and excluded people with significant renal, hepatic, cardiovascular disease, and other significant comorbidity, making these studies less applicable to type 2 diabetic adults with comorbidity and older adults with diabetes. When race was reported, most subjects were Caucasian. These studies are therefore less applicable to people of different

racess, some of whom have greater diabetes disease burden than Caucasians (i.e., African Americans, Hispanics, and Pima Indians).^{2,162,163}

While comparability of interventions could impact applicability, most studies used comparable dosing, frequency, and monitoring to usual care. One possible threat to applicability relates to the duration of drug exposure, especially for glycemic control. All but four studies lasted 2 years or less. Longer exposure to certain diabetes medications may begin to show differences in glycemic control later than most of these trials, especially since insulin sensitivity may allow insulin sensitizers to work longer as monotherapy than non-insulin sensitizers. In usual care, diabetes subjects are kept on medications for over 10 years and are on multiple medications which impacts adherence and side effects. If we were able to determine comparable effectiveness in glycemic control over a longer time frame, we might be able to reduce the number of medications a person takes for a longer period of time after diagnosis (assuming there were differences in glycemic control over longer time frames, and that these differences impacted longer term clinical outcomes).

We had few concerns regarding applicability of the trial settings to usual care. While many trials did not take place exclusively in the United States, they did occur in similar settings. About half the trials occurred partly or exclusively in the United States (n = 32), Italy (n = 13), and/or were multinational (n = 28); the rest of the trials occurred in developed or newly industrialized countries. However, few of the trials (about 10 percent) reported on the setting for recruitment such as outpatient versus inpatient or primary care versus specialty care.

Key Question 2. In adults age 18 or older with type 2 diabetes mellitus, what is the comparative effectiveness of the treatment options (see list of comparisons) in terms of the following long-term clinical outcomes?

- All-cause mortality
- Cardiovascular mortality
- Cardiovascular and cerebrovascular disease morbidity (e.g., myocardial infarction and stroke)
- Retinopathy
- Nephropathy
- Neuropathy

Key Points and Evidence Grades

All-Cause Mortality

- The majority of comparisons were graded with low strength of evidence because many RCTs had short duration (less than 1 year) and had few deaths, limiting the precision of results.
- Metformin was associated with lower risk of all-cause mortality compared with a sulfonylurea, with low strength of evidence because of moderate risk of bias from primarily observational studies, and inconsistent results when compared to a 4-year RCT.
- We found insufficient evidence for several comparisons, including: most DPP-4 inhibitor and GLP-1 agonist comparisons; rosiglitazone versus pioglitazone; comparisons involving insulin in combination with an oral agent; and the majority of other combination therapy comparisons, including those using insulin.

Cardiovascular Mortality

- Only one RCT, the RECORD trial, had cardiovascular disease mortality as its primary outcome, and the completeness of its outcome ascertainment has been a source of concern.
- The majority of studied comparisons were graded with low strength of evidence because many RCTs had short duration (less than 1 year) and had few deaths, limiting the precision of results.
- Metformin was associated with slightly lower risk of cardiovascular mortality compared with a sulfonylurea, with low strength of evidence because of high imprecision and moderate risk of bias, with the majority of studies being observational.
- Risk of cardiovascular mortality was similar between metformin and thiazolidinediones as monotherapy, with low strength of evidence because of high imprecision and moderate risk of bias.
- Metformin alone was slightly favored over a combination of metformin and rosiglitazone for lower risk of fatal myocardial infarction, with consistent direction of results, but high imprecision.
- We found insufficient evidence for several comparisons, including: most DPP-4 inhibitor and GLP-1 agonist comparisons; rosiglitazone versus pioglitazone; and the majority of combination therapy comparisons, including those using insulin.

Cardiovascular and Cerebrovascular Morbidity

- Only six studies reported any cerebrovascular morbidity outcomes (stroke, transient ischemic attack).
- The majority of these comparisons were graded with low strength of evidence because many RCTs had short duration (less than 1 year) and had few cardiovascular or cerebrovascular events, limiting the precision of results.
- Risk of cardiovascular and cerebrovascular morbidity between metformin and thiazolidinedione as monotherapy was inconclusive, with low strength of evidence because of high imprecision and inconsistency in direction of findings.
- Metformin alone was slightly favored over a combination of metformin and rosiglitazone for lower risk of combined fatal and non-fatal ischemic heart disease, with consistent direction of results but high imprecision, which did not reach the level of statistical significance. The pooled odds ratio (OR) for combined fatal and nonfatal ischemic heart disease events was 0.463, 95 percent CI 0.17 to 1.10.
- We found insufficient evidence for several comparisons, including: most DPP-4 inhibitor and GLP-1 agonist comparisons; rosiglitazone versus pioglitazone; and the majority of combination therapy comparisons, including those using insulin.

Retinopathy

- We found insufficient evidence for the outcome of retinopathy.

Nephropathy

- For most comparisons addressed in this review, there was insufficient evidence about nephropathy. Where evidence was available, it was mostly of low strength because the

studies were at moderate to high risk for bias, provided imprecise results, or used surrogate outcomes that provided indirect evidence only.

- The only comparison with moderately strong evidence showed that pioglitazone has favorable effects on renal function compared to metformin over a treatment period of 1 year. It is unclear whether the statistically significant reductions in urinary albumin-to-creatinine ratio translate into lower rates of nephropathy.

Neuropathy

- For most comparisons addressed in this review, there was insufficient evidence about neuropathy.
- We found low strength of evidence for three comparisons for the outcome of neuropathy: metformin versus metformin plus a thiazolidinedione; metformin versus metformin plus DPP-4 inhibitors; and metformin plus a thiazolidinedione versus metformin plus a sulfonylurea. Where evidence was available, it was graded as low strength because studies were at high risk for bias, had low sample sizes, and had poorly defined outcomes. As a consequence, we could not draw any conclusions regarding the comparative effects of oral diabetes drugs on neuropathy.

See Table 5 for the evidence grades and specific conclusions for each comparison. Details of the evidence grades are in Appendix G, Table 5.

Study Design and Population Characteristics

Sixty-six studies (totaling 67 publications) reported on the comparative effectiveness of oral diabetes medications on long-term outcomes (Appendix G, Tables 6 and 7). Twenty-three studies occurred in North America, approximately 16 in Europe, and several were multicontinent studies.

Forty-eight studies were RCTs, with the study duration ranging from 12 weeks to 6 years. Fifteen of the RCTs lasted 1 year or more in duration. Only one RCT had a long-term outcome as the primary outcome;¹⁶ the others had intermediate outcomes (see Key Question 1), but then also reported the incidence of one or more long-term outcomes (e.g., mortality), usually as an adverse event. Two studies used a crossover design.^{164,165} Thirty-seven RCTs reported support from a pharmaceutical company.

There were 16 cohort studies and 1 case-control cohort study with duration of followup ranging from 6 months to 8 years, which analyzed data from twelve unique cohorts, with four studies coming from the Saskatchewan Health databases¹⁶⁶⁻¹⁶⁹ and three studies coming from the U.K. General Practice Research Database (GPRD).¹⁷⁰⁻¹⁷² Two observational studies reported support from a pharmaceutical company.

The mean age of participants ranged from approximately 48 years to 75 years, with the majority of studies reporting a mean age in the mid-50s. Participants were about 50 percent female and the majority Caucasian. Two RCTs reported greater than 25 percent African American participants;^{85,131} two studies reported 70 percent to 80 percent Hispanic participants;^{88,130} and four studies were based in Asia.^{59,108,121,173} Most trials excluded people with coexisting illness, such as renal, cardiovascular, or liver disease.

Table 5. Strength of evidence and key findings comparing diabetes medications as monotherapy or combination therapy for long-term clinical outcomes

Comparison	All-cause mortality	CVD mortality	CVD and cerebrovascular morbidity	Nephropathy, neuropathy
MONOTHERAPY COMPARISONS				
Metformin versus				
TZD	Neither favored; Low	Neither favored; Low	Unclear; Low	Favors Pio*; Mod
SU	Favors Met; Low	Favors Met; Low	Unclear; Low	Unclear*; Low Insufficient†
DPP-4 inhibitor	Unclear; Low	Insufficient	Insufficient	Insufficient
Meglitinide	Unclear; Low	Unclear; Low	Unclear; Low	Insufficient
GLP-1 agonist	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + TZD	Unclear; Low	Unclear; Low	Unclear; Low	Insufficient* Unclear†; Low
Metformin + SU	Neither favored; Low	Unclear; Low	Favors Met; Low	Insufficient
Metformin + DPP-4 inhibitor	Unclear; Low	Unclear; Low	Unclear; Low	Insufficient* Unclear†; Low
Metformin + meglitinide	Unclear; Low	Unclear; Low	Unclear; Low	Insufficient
TZD versus				
TZD	Insufficient	Insufficient	Unclear; Low	Insufficient
SU	Neither favored; Low	Unclear; Low	Unclear; Low	Unclear*; Low
DPP-4 inhibitor	Insufficient	Insufficient	Insufficient	Insufficient
Meglitinide	Insufficient	Insufficient	Insufficient	Unclear*; Low
GLP-1 agonist	Unclear; Low	Insufficient	Unclear; Low	Insufficient
SU versus				
DPP-4 inhibitor	Insufficient	Insufficient	Insufficient	Insufficient
Meglitinide	Unclear; Low	Unclear; Low	Unclear; Low	Insufficient
GLP-1 agonist	Insufficient	Insufficient	Insufficient	Insufficient
DPP-4 inhibitor versus				
Meglitinide	Insufficient	Insufficient	Insufficient	Insufficient
GLP-1 agonist	Insufficient	Insufficient	Insufficient	Insufficient

Table 5. Strength of evidence and key findings comparing diabetes medications as monotherapy or combination therapy for long-term clinical outcomes (continued)

Comparison	All-cause mortality	CVD mortality	CVD and cerebrovascular morbidity	Nephropathy, neuropathy
COMBINATION COMPARISONS				
Metformin + another agent versus				
Metformin + TZD	Unclear; Low	Unclear; Low	Unclear; Low	Low. Conclusion unclear for nephropathy and neuropathy.
Metformin + SU	Unclear; Low	Unclear; Low	Unclear; Low	Insufficient
Metformin + meglitinide	Unclear; Low	Insufficient	Insufficient	Insufficient
Metformin + DPP-4 inhibitor	Unclear; Low	Unclear; Low	Unclear; Low	Insufficient
Metformin + GLP-1 agonist	Insufficient	Unclear; Low	Insufficient	Insufficient
Metformin + basal insulin	Insufficient	Unclear; Low	Unclear; Low	Insufficient
Metformin + premixed insulin	Unclear; Low	Unclear; Low	Insufficient	Insufficient
TZD + another agent versus				
Metformin + TZD	Insufficient	Insufficient	Unclear; Low	Insufficient
Metformin + SU	Unclear; Low	Insufficient	Unclear; Low	Insufficient
Metformin + meglitinide	Unclear; Low	Insufficient	Insufficient	Insufficient
Metformin + DPP-4 inhibitor	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + GLP-1 agonist	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + basal insulin	Unclear; Low	Insufficient	Insufficient	Insufficient
Metformin + premixed insulin	Unclear; Low	Insufficient	Unclear; Low	Insufficient

CVD = cardiovascular disease; DPP-4 inhibitor = dipeptidyl peptidase-4 inhibitor; GLP-1 agonist = glucagon-like peptide 1 agonist; Met = metformin; Pio = pioglitazone; SU = sulfonylurea; TZD = thiazolidinedione

Data presented here are strength of the evidence and main conclusion. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

* Key finding for nephropathy.

† Key finding for neuropathy.

The Evidence About All-Cause Mortality (Appendix G, Table 8)

Forty four studies reported the number of deaths by treatment group. Thirty-one studies were RCTs, and 13 studies were observational studies based on data from 7 unique cohorts. Most of the RCTs were of short duration and had no deaths in at least one of the treatment arms. Twenty-nine of the 31 RCTs had support from a pharmaceutical company.

Metformin Versus Thiazolidinediones

Randomized controlled trials. Four RCTs compared the effects of metformin versus a thiazolidinedione. A Diabetes Outcome Progression Trial (ADOPT) trial was the largest of these trials and had the longest duration. This study, which recruited participants from 488 different centers in the United States, Canada, and Europe, randomized participants to treatments with rosiglitazone, metformin, or glyburide for a median duration of 4 years.³⁸ There were 1,454 participants in the metformin arm and 1,456 in the rosiglitazone arm, and there was a similar number of deaths in each of these two arms with 31 (2.1 percent) and 34 (2.3 percent) deaths during followup respectively. Another trial comparing metformin and rosiglitazone of 32 weeks duration reported no deaths in either arm.⁴⁹ The other two trials compared metformin and pioglitazone.^{52,53} The larger of these trials, which lasted 52 weeks, also had a similar number of deaths in each arm: two in the metformin arm and three in the pioglitazone arm.⁵²

Observational studies. Two cohort studies compared the effects of thiazolidinediones and metformin. One cohort study using data from the U.K. GPRD found no significant difference in all-cause mortality between users of rosiglitazone as monotherapy (n = 8,442) and users of metformin as monotherapy (n = 68,181) with users of rosiglitazone having an adjusted hazard ratio (HR) of 1.07 (95 percent CI 0.77 to 1.49) compared to metformin users over a mean followup period of 7.1 years.¹⁷¹ Another cohort study used data from the Cleveland Clinic electronic health record system (EHR) on people with newly and previously diagnosed diabetes from 1998 to 2006.¹⁷⁴ It also found no significant difference in all-cause mortality between users of rosiglitazone as monotherapy for their initial treatment of diabetes compared with users of metformin as initial monotherapy (adjusted HR 1.33, 95 percent CI 0.93 to 1.91) or between users of pioglitazone as monotherapy for their initial treatment of diabetes compared to users of metformin as initial monotherapy (adjusted HR 1.08, 95 percent CI 0.78 to 1.51). This study, however, did not describe the followup time of participants, nor did it describe what, how many, or when other medications might have been added on to these initial regimens during the study period.

Metformin versus sulfonylureas. Five RCTs and 11 observational studies, reporting findings from 5 unique cohorts, evaluated the effect of metformin versus a sulfonylurea (Table 6).

Randomized controlled trials. Of the RCTs, four trials lasted less than 30 weeks. Described above, the ADOPT trial was the largest and with the longest duration; 1,454 participants were randomized to metformin and 1,441 to glyburide. There were equal number of deaths from any cause, with 31 deaths in each arm.³⁸ Three smaller trials were of short duration (16 to 18 weeks) and reported no deaths in either treatment arm.^{59,61,62} One 29-week study had a single death in the metformin arm and no deaths in the sulfonylurea arm.⁷⁰

Observational studies. Three observational studies^{166,168,169} reported all-cause mortality from the cohort based on the Saskatchewan Health registry, which maintains health records for people in the province with prescription drug benefits, and compared metformin versus a sulfonylurea as monotherapy. One study reported an adjusted OR of all-cause mortality of 0.60 (95 percent CI 0.49 to 0.74) for those on metformin compared with sulfonylurea monotherapy, adjusted for age, sex, chronic disease score, and nitrate use.¹⁶⁸ Similar results were found in another study which found that higher doses of sulfonylurea were associated with even higher risk of death.¹⁶⁶

Table 6. Studies comparing metformin versus sulfonylurea for all-cause mortality

Author, year	Number of deaths: metformin versus sulfonylurea	Measure of association	Estimate of the measure of association (95% CI) (sulfonylurea as reference group)
Randomized controlled trials			
Chien, 2007 ⁵⁹	0/17 versus 0/17	NR	NR
Kahn, 2006 ³⁸	31/1454 versus 31/1441	NR	NR
Garber, 2003 ⁶¹	0/164 versus 0/151	NR	NR
Goldstein, 2003 ⁶²	0/76 versus 0/84	NR	NR
DeFronzo, 1995 ⁷⁰	1/210 versus 0/209	NR	NR
Cohort studies			
Kahler, 2007 ¹⁷⁵	82/2988 versus 1005/19053	Adjusted OR	0.87 (0.68 to 1.10)
Simpson, 2006 ¹⁶⁶	39.6/1000 person-years versus 61.4/1000 person-years	Unadjusted OR*	0.55 (0.47 to 0.63)
Johnson, 2002 ¹⁶⁸	159/1150 versus 750/3033	Adjusted OR	0.60 (0.49 to 0.74)
Eurich, 2005 ¹⁶⁹	69/208 versus 404/773	Adjusted HR	0.70 (0.54 to 0.91)
Evans, 2006 ¹⁷⁶	4.7% versus 17.9%	NR	NR
Gulliford, 2004 ¹⁷⁰	144/2232 versus 1030/6620	Unadjusted OR*	0.35 (0.29 to 0.42)
Fisman, 2001 ¹⁷⁷	25/79 versus 324/953	Unadjusted OR*	0.90 (0.56 to 1.47)
Fisman, 1999 ¹⁷⁸	20/78 versus 234/1041	NR	NR
Tzoulaki, 2009 ¹⁷¹	NR	Adjusted HR*	0.81 (0.74 to 0.88)
Pantalone, 2008 ¹⁷⁴	NR	Adjusted HR	0.54 (0.46 to 0.64)

* Calculated for this report from values published in study

CI = confidence interval; HR = hazard ratio; NR= not reported; OR = odds ratio

Another study from this cohort examined people with incident heart failure who were then initiated on either sulfonylurea or metformin monotherapy with a mean followup time of 2.5 years.¹⁶⁹ This study reported a higher number of deaths among those on a sulfonylurea alone. The sulfonylurea group had 404 deaths out of 773 people (52 percent) compared with 69 deaths out of 208 people in the metformin group (33 percent). Adjusted multivariate analyses confirmed these findings, with a lower HR of death among those on metformin of 0.70 (95 percent CI 0.54 to 0.91) compared with those on sulfonylurea monotherapy, after adjusting for age, sex, chronic disease score, medications, and number of physician visits before diagnosis of heart failure.

A cohort study that followed people receiving care through the U.K. National Health Service in Tayside, Scotland for about 8 years also reported a higher risk of overall mortality among those on sulfonylurea compared with metformin monotherapy, with an adjusted risk ratio of mortality of 1.43 (95 percent CI 1.15 to 1.77).¹⁷⁶

Three observational studies¹⁷⁰⁻¹⁷² reported all-cause mortality from the cohort based on the UK GPRD, which maintains de-identified health records of about 5 million people, and compared metformin versus a sulfonylurea as monotherapy. One of these studies, with patient data from 1992 to 1998 and with a mean duration of followup of 1.7 to 3.5 years, described a higher rate of death among users of sulfonylurea alone compared with metformin. The crude mortality rate was 58.6 per 1000 person-years in the sulfonylurea group compared with a crude

mortality rate of 25.5 per 1000 person-years in the metformin group, with an unadjusted OR of 0.35 (95 percent CI 0.29 to 0.42) among those on metformin compared to sulfonylurea.¹⁷⁰ A study using the same database but extending the “enrollment period” from 1990 to 2005 with a longer mean followup period of 7.1 years per person also found a significantly lower risk of mortality in those using metformin as monotherapy compared to sulfonylureas with an adjusted HR of 0.81 (95 percent CI 0.74 to 0.88).¹⁷¹ A nested case-control study using this data drew the same conclusions and found that, over a median followup period of 3.5 years, those on metformin monotherapy had an adjusted relative risk (RR) of death from any cause of 0.70 (95 percent CI 0.64 to 0.75) compared with users of sulfonylurea monotherapy. This lower risk of death persisted among metformin users regardless of the duration of metformin use, which was categorized as less than 4 months, 4 to 8 months, or at least 8 months.¹⁷²

In a smaller Israeli cohort of people with known coronary artery disease, mortality was similar but slightly higher among those on glyburide compared with metformin.¹⁷⁷

A large cohort, the Veterans’ Health Administrations’ Diabetes Epidemiology Cohort, includes all veterans with diabetes who have received care at the Department of Veterans Affairs (VA) centers since October 1996. In that cohort, analysis showed a higher number of deaths among subjects taking sulfonylureas (1,005 deaths of 19,053 people [5.3 percent]) compared with subjects taking metformin only (82 deaths out of 2,988 people (2.7 percent)).¹⁷⁵ The adjusted OR for death for metformin versus sulfonylurea was 0.87 (95 percent CI 0.68 to 1.10), after adjusting for propensity score plus age, diabetes duration, HbA1c, serum creatinine, number of physician visits related to diabetes, and use of medications for dyslipidemia and hypertension.¹⁷⁵

Finally, the cohort study based on data from the Cleveland Clinic EHR found a lower risk of all-cause mortality among users of metformin as initial monotherapy compared with users of sulfonylureas, with an adjusted HR of 0.54 (95 percent CI 0.46 to 0.64); however, limitations of this study include its lack of description of followup time and lack of description or adjustment for addition of other diabetes medications during the study period.¹⁷⁴

Metformin versus meglitinides. Only one 24-week trial assessed the mortality of participants on metformin compared to a meglitinide and reported one death in the metformin arm and no deaths in the nateglinide arm.⁷⁹

Metformin versus DPP-4 inhibitors. Two short-term RCTs compared the effects of metformin as monotherapy compared to sitagliptin as monotherapy and reported deaths during the study period. One multinational trial over 24 weeks, with 328 participants on metformin monotherapy and 335 participants on sitagliptin monotherapy, reported 3 deaths in the metformin arm and no deaths in the sitagliptin arm.⁷⁸ The second trial, also multinational and lasting 24 weeks, with 439 participants on metformin monotherapy and 455 participants on sitagliptin monotherapy, reported 1 death in the sitagliptin arm due to metastatic lung cancer, thought not to be related to the study medication.⁷⁷

Metformin versus a combination of metformin and thiazolidinediones. Four RCTs of relatively short duration, ranging from 24 to 32 weeks, and one article describing post hoc pooled data from two different RCTs lasting 6 months each, compared the effects of metformin as monotherapy versus a combination of metformin plus rosiglitazone. Overall, there were very few deaths in these studies. In one RCT, there were no deaths in either arm.⁴⁹ For three other

RCTs, each reported one death in the combination therapy arm and no deaths in the metformin monotherapy arm.^{86,87,90} One death was due to sudden death, one was due to an acute myocardial infarction, and one death was due to unknown causes. In the article that describes data from two RCTs in a post hoc fashion, there was one death in the combination therapy arm due to fatal myocardial infarction and no deaths in the metformin monotherapy arm.¹⁷⁹

Metformin versus a combination of metformin and sulfonylureas. Four RCTs and four unique cohort studies (published in five articles) assessed the effect of metformin monotherapy versus a combination of metformin plus a sulfonylurea (Table 7). All of these studies had also examined the effect of metformin versus a sulfonylurea, each as monotherapy, and are referred to above.

Table 7. Studies comparing metformin with combination of metformin and sulfonylurea for all-cause mortality

Author, year	Number of deaths: metformin versus combination of metformin and sulfonylurea	Measure of association	Measurement of association (95% CI) (combination therapy as reference group)
Randomized controlled trials			
Chien, 2007 ⁵⁹	0/14 versus 0/42	NR	NR
Garber, 2003 ⁶¹	0/164 versus 2/171	NR	NR
Goldstein, 2003 ⁶²	0/76 versus 0/87	NR	NR
DeFronzo, 1995 ⁷⁰	1/210 versus 0/213	NR	NR
Cohort studies			
Kahler, 2007 ¹⁷⁵	82/2988 versus 468/13820	Unadjusted OR*	0.81 (0.63 to 1.02)
Gulliford, 2004 ¹⁷⁰	144/3099 versus 159/2735	Unadjusted OR*	0.79 (0.63 to 1.00)
Johnson, 2002 ¹⁶⁸	159/1150 versus 635/4683	NR	NR
Eurich, 2005 ¹⁶⁹	69/208 versus 263/852	NR	NR
Fisman, 2001 ¹⁷⁷	25/79 versus 111/253	Unadjusted OR*	0.59 (0.35 to 1.01)
Fisman, 1999 ¹⁷⁸	20/78 versus 84/266	NR	NR

* Calculated for this report from values published in study
CI = confidence interval; NR= not reported; OR = odds ratio

Randomized controlled trials. All four RCTs were of short duration, ranging from 16 to 29 weeks. Again, there were few deaths in any of these trials. Two trials reported no deaths^{59,62} and one study reported two deaths in the combination arm and no deaths in the metformin monotherapy arm.⁶¹ Another study reported one death in the metformin as monotherapy arm and no deaths in the combination therapy arm.⁷⁰

Observational studies. The Veterans' Health Administrations' Diabetes Epidemiology Cohort and the UK's GPRD cohorts found similar numbers of deaths between the metformin monotherapy group and the combination treatment groups, with only slightly higher rates of death among the combination therapy group. In the VA cohort, which followed people for about 2 years, 3.4 percent of those in the combination treatment arm died compared to 2.7 percent in the metformin treatment arm, with an unadjusted OR of death of metformin compared to combination therapy of 0.81 (95 percent CI 0.63 to 1.02).¹⁷⁵ In the U.K. GPRD cohort, which followed people for about 6 years, 5.8 percent of people in the combination treatment groups (reported as those who were treated with metformin first then sulfonylurea combined with those treated with sulfonylurea first then metformin) died compared to 4.6 percent in the metformin monotherapy group, with an unadjusted OR of mortality of 0.79 (95 percent CI 0.63 to 1.00) for those on metformin alone compared to those on combination therapy.¹⁷⁰

Data from the Saskatchewan Health database also showed similar results with no clear difference in mortality rates for metformin as monotherapy compared with metformin plus a sulfonylurea (13.8 percent versus 13.6 percent, respectively).¹⁶⁸ Even among the subgroup of people with heart failure, there was a similar rate of death between these two treatment groups, 33 percent for those on metformin alone and 31 percent for those on the metformin plus sulfonylurea combination therapy.¹⁶⁹

Unlike the cohorts described above, the Israeli cohort included only people with known heart disease. There was a higher rate of death among those people who were on metformin plus sulfonylurea combination therapy compared with metformin alone, with a mortality rate of 43.9 percent for those on combination therapy compared to a mortality rate of 31.6 percent for those on metformin alone, with an unadjusted OR of 0.59 (95 percent CI 0.35 to 1.01) of mortality for those in metformin compared to combination therapy, over a mean period of 7.7 years.¹⁷⁷

Metformin versus a combination of metformin and DPP-4 inhibitors. Three RCTs looked at the effect of metformin as monotherapy versus metformin combined with sitagliptin. One was a multinational study of 190 participants over approximately 30 weeks. In this study, there was one death due to a myocardial infarction in the metformin group and no deaths in the combination treatment group.⁹³ The second was a 24-week multinational RCT which reported three deaths in the metformin monotherapy arm (n = 328) and no deaths in the combination treatment groups (n = 643).⁷⁸ The third was a 54-week multinational trial of 1,091 patients, which reported one death in each arm.⁷⁶

Metformin versus a combination of metformin and meglitinides. Only one RCT looked at the comparison of effects between metformin as monotherapy and metformin combined with a meglitinide agent. This study had one death due to heart disease in the metformin arm and no deaths in the combination arm over a 24-week period.⁷⁹

Rosiglitazone versus pioglitazone. One cohort study used the Cleveland Clinic EHR to compare the effects of rosiglitazone and pioglitazone on all-cause mortality. This cohort of people with newly and previously diagnosed diabetes from 1998 to 2006 found that those on initial pioglitazone monotherapy had no significant difference in risk of death compared with those on initial rosiglitazone monotherapy, with an adjusted HR of 0.81 (95 percent CI 0.52 to 1.27). This study, however, did not describe the followup time of participants, nor did it describe what, how many, or when other medications might have been added on to these initial regimens.¹⁷⁴

Thiazolidinediones versus sulfonylureas. Three RCTs and one cohort study compared the effect of a thiazolidinedione and a sulfonylurea.

Randomized clinical trials. The largest and longest duration of these trials was the ADOPT trial, which reported a similar number of deaths in the rosiglitazone arm compared with the glyburide arm (2.3 percent versus 2.2 percent, respectively).³⁸ A smaller trial lasting 56 weeks reported two deaths in the glyburide arm and no deaths in the pioglitazone arm.¹⁰¹ Another trial reported no deaths in either the thiazolidinedione or sulfonylurea arms.¹⁰⁰

Observational study. The cohort from the Cleveland Clinic EHR compared risk of all-cause mortality between initial users of pioglitazone monotherapy versus initial users of sulfonylurea monotherapy as well as between users of rosiglitazone monotherapy versus initial users of sulfonylurea monotherapy. This study found that those in the pioglitazone group had a significantly lower risk of death compared with the sulfonylurea group, with an adjusted HR of 0.59 (95 percent CI 0.43 to 0.81). Those in the rosiglitazone did not have a statistically significant difference in risk of death compared with those in the sulfonylurea group, with an adjusted HR of 0.73 (95 percent CI 0.51 to 1.02). Again, followup time was not specified, and participants could have changed medication regimens during the study period.¹⁷⁴

Sulfonylureas versus meglitinides. One RCT compared the effects of a sulfonylurea with a meglitinide. This 1-year U.S. study reported three deaths among the 362 participants randomized to the repaglinide group and one death among the 182 randomized to glyburide.¹¹⁷

Sulfonylureas versus GLP-1 agonists. One 24-week RCT from Japan compared the effects of use of glibenclamide and liraglutide as monotherapy and reported on deaths. This short-term study reported one death in the liraglutide arm due to gastroenteritis, which required hospitalization and subsequent cardio-respiratory arrest, and no deaths in the sulfonylurea arm.¹²¹

Combination of metformin and thiazolidinediones versus combination of metformin and sulfonylureas. Two RCTs^{123,125} directly compared the effect of the combination of metformin plus a thiazolidinedione with the combination of metformin plus a sulfonylurea. One multinational study recruited about 600 participants and randomized them to treatment with metformin plus a sulfonylurea (either glibenclamide or gliclazide) or metformin plus rosiglitazone. This study reported two deaths in each arm over the 52-week treatment period.¹²³ The second trial was also multinational and randomized participants to treatment with metformin combined with glyburide or metformin with rosiglitazone. This trial had one death due to a fatal myocardial infarction in the metformin plus rosiglitazone combination arm and no deaths in the metformin plus sulfonylurea combination arm.¹²⁵

Combination of metformin and thiazolidinediones versus combination of metformin and meglitinides. One U.S. RCT compared the effect of the combination of metformin with a thiazolidinedione (rosiglitazone) versus the combination of metformin with a meglitinide (repaglinide). This study of 26 weeks reported one death in the metformin plus meglitinide combination arm and no deaths in the metformin plus thiazolidinedione combination arm.¹³¹

Combination of metformin and sulfonylureas versus combination of metformin and DPP-4 inhibitors. One multinational RCT compared the effect of the combination of metformin plus a sulfonylurea (glipizide) with the combination of metformin plus sitagliptin. This study randomized 1,172 participants to the 2 treatment arms. At 52 weeks, they reported two deaths in the metformin plus sulfonylurea combination arm and one death in the metformin plus sitagliptin combination arm.¹³³ At 2 years of followup, they had 519 participants and reported 8 deaths in the metformin plus sulfonylurea arm due to various causes including sudden cardiac death, myocardial infarction, cancer, sepsis, and suicide, and still only one death in the metformin plus sitagliptin arm, which was due to trauma.¹³⁴

Combination of metformin and sulfonylureas versus combination of metformin and meglitinides. Two U.S. RCTs^{136,152} and one Italian cohort study¹⁸⁰ compared the effect of the combination of metformin with a sulfonylurea with the combination of metformin with a meglitinide (nateglinide).

The larger of the RCTs compared metformin plus glyburide versus metformin plus nateglinide over 2 years and reported one death in each arm.¹³⁶ Another study of similar duration looked at the effect of the same combinations of medications among a subpopulation of its RCT study population (66 participants that were 65 years of age or older) and reported a single death in the metformin plus sulfonylurea combination arm and no deaths in the metformin plus nateglinide combination arm.¹⁵²

The main purpose of the cohort study that looked at the effect of these combinations of medications was to assess the mortality of people on combinations of secretagogues and biguanides among people with and without ischemic heart disease. Among those with and without ischemic heart disease on a combination of metformin and any sulfonylurea, there were 35 deaths over 6,344 person-months. Among those with and without heart disease who were on metformin and repaglinide, there was a slightly lower mortality rate: 5 deaths over 2,013 person-months.¹⁸⁰

Combination of metformin and sulfonylureas versus combination of metformin or sulfonylureas and thiazolidinediones. One large multinational RCT, the RECORD trial, randomized about 4,450 participants to the following four treatments: combination of metformin plus rosiglitazone, combination of metformin plus sulfonylurea, combination of rosiglitazone plus sulfonylurea, and combination of metformin plus sulfonylurea. For analyses for the outcome of all-cause mortality, the two groups assigned to rosiglitazone were combined and compared to the combination of metformin and sulfonylurea. Over a mean of 5.5 years of treatment and followup, there were a similar number of deaths in the two groups with 136 deaths out of 2,220 in the rosiglitazone group and 157 deaths out of 2,227 in the metformin plus sulfonylurea combination group with an HR of mortality of 0.86 (95 percent CI 0.68 to 1.08) for those on rosiglitazone compared to those not on rosiglitazone.¹⁶

Combination of metformin and sulfonylureas versus combination of metformin and biphasic insulin. Two multinational RCTs compared the effect of the combination of metformin plus a sulfonylurea with the combination of metformin plus a form of biphasic insulin (insulin aspart 70/30 in one study and insulin lispro 75/25 in the other). Both studies reported one death each in the metformin combined with biphasic insulin arms and no deaths in the metformin combined with sulfonylurea arms during the trial period.^{137,138}

Combination of metformin and sulfonylureas versus combination of thiazolidinediones and sulfonylureas. One RCT directly compared the effect of the combination of metformin plus a sulfonylurea with the combination of a thiazolidinedione plus a sulfonylurea. This study recruited 639 participants from European countries and Canada, who were already on a sulfonylurea, and randomized them to the addition of either metformin or pioglitazone with a mean treatment duration of 11 months. This study reported that there were two deaths in the metformin plus sulfonylurea combination arm and one death in the pioglitazone plus sulfonylurea combination arm.¹⁴⁰

The Evidence About Cardiovascular Mortality (Appendix G, Table 8)

Twelve trials and 4 cohort studies contained 14 head-to-head comparisons of interest for the outcome of cardiovascular mortality.

Metformin versus thiazolidinediones. The ADOPT trial was a large double-blind RCT involving 4,360 patients followed for a median of 4 years, with patients randomly assigned to metformin, rosiglitazone, or glyburide. There were equal rates of cardiovascular mortality in the metformin and rosiglitazone arms, each with two fatal myocardial infarctions (0.1 percent).³⁸ A smaller 24-week RCT of metformin versus pioglitazone did not report any cardiovascular deaths in either arm.⁵³

Metformin versus sulfonylureas. The ADOPT trial also compared metformin with glyburide, and reported slightly higher incidence of cardiovascular mortality in the glyburide arm versus the metformin arm, with two fatal myocardial infarctions in the metformin arm and three in the sulfonylurea arm (0.2 percent versus 0.1 percent), without report of a statistical test.³⁸

In addition, four cohort studies compared metformin with a second-generation sulfonylurea.^{167,168,176,177} Two of these studies were from the Saskatchewan Health databases, a longitudinal cohort of the residents of this Canadian province. They identified more than 4,000 residents with type 2 diabetes between 1991 and 1999 and grouped them by their first dispensation of an oral diabetes medication. Metformin was associated with lower risk for cardiovascular mortality than any sulfonylurea (HR 0.64, 95 percent CI 0.49 to 0.84), after adjusting for age, sex, chronic disease score, and nitrate use.¹⁶⁸ This result was confirmed in another analysis in this same cohort after additional adjustment for a calculated propensity score to adjust for between-group differences (HR 0.76, 95 percent CI 0.58 to 1.00).¹⁶⁷ A different 5-year retrospective cohort study of 5,730 Scottish subjects also reported higher mortality from cardiovascular disease in the second-generation sulfonylurea group versus metformin group, after adjustment for potential confounders, including prior cardiovascular disease-related hospital admission (RR 1.70, 95 percent CI 1.18 to 2.45).¹⁷⁶

In contrast, a prospective cohort study of 2,275 Israeli patients with type 2 diabetes and prior coronary artery disease showed slightly higher age-adjusted mortality from coronary artery disease in the metformin versus the glyburide groups (30 per 1,000 person-years versus 24.5 per 1,000 person-years, respectively).¹⁷⁷

Metformin versus meglitinides. One 24-week RCT with 701 participants reported no cardiovascular deaths in the nateglinide arm and one death in the metformin arm.⁷⁹

Metformin versus a combination of metformin and thiazolidinediones. Two large RCTs^{87,90} and one study that reported the combined results of two smaller RCTs¹⁷⁹ compared metformin versus metformin with the addition of rosiglitazone. Bailey et al. reported no deaths from cardiovascular disease in the metformin arm. In the metformin plus rosiglitazone arm there was one sudden death in sleep, which may have been sudden cardiac death, and one death related to a myocardial infarction.⁸⁷ Fonseca et al. was a trial of 348 participants, with 119 randomized to metformin plus 4 mg per day of rosiglitazone, 113 to metformin plus 8 mg per day of rosiglitazone, and 116 to metformin alone. In this study there was one death due to myocardial infarction in the metformin plus 4 mg per day of rosiglitazone arm and none in the other arms.⁹⁰ The study that pooled the results of two RCTs reported one fatal myocardial infarction out of 126

participants in the metformin plus rosiglitazone arms and no events in the 121 participants in the metformin arms.¹⁷⁹ We pooled these three RCTs with four RCTs reporting nonfatal ischemic heart disease events (Figure 62).

Metformin versus a combination of metformin and sulfonylureas. Two of the cohort studies described above (under comparison of metformin versus sulfonylurea) showed decreased cardiovascular mortality in the group taking metformin alone as compared to subjects taking the combination of metformin and sulfonylurea.^{176,177}

Compared with those on metformin monotherapy, one cohort study reported a risk ratio of 1.94 (95 percent CI 1.25 to 3.01) in subjects who were started on metformin, with sulfonylurea subsequently added-on and 2.50 (95 percent CI 1.69 to 3.71) in those started on sulfonylurea with metformin subsequently added-on, but the numbers in these groups were small.¹⁷⁶ Risk ratios were adjusted multiple confounding variables, including sociodemographics, cardiovascular risk factors, prior cardiovascular disease admission and use of cardiovascular medications, making confounding by indication less likely.

A second cohort study examined 2,275 Israeli patients with type 2 diabetes and known prior coronary artery disease. Among subjects on metformin alone, the age-adjusted mortality rate for ischemic heart disease per 1,000 person-years was slightly lower compared to the combination of metformin plus sulfonylurea group (30.0 versus 31.2), but these estimates were not adjusted for cardiovascular disease severity.¹⁷⁷

Metformin versus a combination of metformin and DPP-4 inhibitors. We identified two RCTs. One was a 30-week RCT in 190 participants on metformin randomized to the addition of sitagliptin or placebo, which reported one fatal myocardial infarction in the metformin plus placebo arm and no cardiovascular deaths in the metformin plus sitagliptin arm.⁹³ The second RCT was a multinational trial with 1,091 participants, and reported one sudden cardiovascular death in the metformin arm in the first 24-weeks of the trial, which was prior to starting metformin treatment, and no cardiovascular deaths in the combination arm.⁷⁶

Metformin versus a combination of metformin and meglitinides. Horton et al. (described above under metformin versus meglitinides) also contained a metformin plus nateglinide arm, enabling an additional comparison with metformin alone.⁷⁹ In all arms, there was a single death attributed to cardiovascular disease and it occurred in the metformin alone arm.

Thiazolidinediones versus sulfonylureas. The ADOPT trial also contained a comparison of rosiglitazone with glyburide. As described above, there were two myocardial infarctions in the rosiglitazone arm and three myocardial infarctions in the glyburide arm, but no statistical test of this difference.³⁸

Sulfonylureas versus meglitinides. A 1-year RCT with 576 participants reported one cardiovascular death in the glyburide arm and one in the repaglinide arm.¹¹⁷

Combination of metformin and thiazolidinediones versus combination of metformin and meglitinides. One 26-week RCT comparing metformin plus rosiglitazone versus metformin plus repaglinide reported one death likely attributable to sudden cardiac death in the metformin plus repaglinide arm.¹³¹

Combination of metformin and sulfonylureas versus combination of metformin or sulfonylureas and thiazolidinediones. The RECORD study was an open-label noninferiority multicenter RCT with 4,447 participants with type 2 diabetes taking either metformin or a sulfonylurea randomly assigned to one of three arms, metformin plus rosiglitazone, sulfonylurea plus rosiglitazone, or metformin plus sulfonylurea, with time to first cardiovascular hospitalization or death as its primary outcome.¹⁶ For analyses of the primary endpoint at a mean of 5.5 years, they combined the two rosiglitazone arms (metformin or sulfonylurea plus rosiglitazone) and compared rosiglitazone with the active control of metformin plus sulfonylurea and showed non-inferiority for cardiovascular mortality (HR 0.84, 95 percent CI 0.59 to 1.18).

Combination of metformin and sulfonylureas versus combination of metformin and DPP-4 inhibitors. One RCT reported in two articles, providing 52-week¹³³ and 2-year data,¹³⁴ compared metformin plus the sulfonylurea, glipizide, versus metformin plus sitagliptin. After 52 weeks, there were two deaths from cardiovascular disease (one from sudden cardiac death and one from myocardial infarction) in the metformin plus glipizide arm and none in the metformin plus sitagliptin arm.¹³³ No additional cardiovascular mortality was reported during the second year of the trial.¹³⁴

Combination of metformin and DPP-4 inhibitors versus combination of metformin plus GLP-1 agonists. One 26-week open-label RCT randomized 665 patients with poorly controlled diabetes on metformin alone to the addition of oral sitagliptin (100 mg), or one of two doses of daily subcutaneous injections of liraglutide (1.2 mg or 1.8 mg). It reported one fatal cardiac arrest in the metformin plus sitagliptin arm and none in the metformin plus liraglutide arms.¹⁴³

Combination of metformin and sulfonylureas versus combination of metformin and premixed insulin. In a 16-week open-label RCT, 341 participants with poorly controlled type 2 diabetes on metformin alone were randomly assigned to metformin plus glibenclamide or metformin plus twice daily insulin aspart 70/30, a premixed insulin analog containing 30 percent soluble, rapid-acting insulin aspart and 70 percent intermediate-acting protamine-bound aspart in each injection.¹³⁸ There was one death from myocardial infarction in the metformin plus premixed insulin arm and none in the metformin plus glibenclamide arm.

Combination of metformin and basal insulin versus combination of metformin and premixed insulin. A 32-week open-label crossover study randomized 97 patients to metformin plus insulin glargine versus metformin plus insulin lispro 75/25 twice daily. It reported one fatal myocardial infarction in the metformin plus insulin lispro arm and no such events in the metformin plus glargine arm.¹⁶⁵

The Evidence About Cardiovascular and Cerebrovascular Disease Morbidity (Appendix G, Table 8)

Seventeen trials and seven cohort studies contained eighteen head-to-head comparisons of interest for the outcome of cardiovascular disease morbidity. We identified six studies that reported one of the cerebrovascular disease morbidity outcomes.

Metformin versus thiazolidinediones. Three RCTs^{38,49,55} and five retrospective cohort studies^{171,173,174,181,182} compared metformin versus rosiglitazone. One small 24-week RCT⁵³ and four cohort studies^{171,173,174,182} compared metformin versus pioglitazone.

Among the RCTs, the ADOPT trial was the largest (total N = 4360 for three study arms) and had the longest duration of treatment (median 4 years). The study reported minimal differences between the metformin and rosiglitazone arms for nonfatal myocardial infarction and stroke (1.4 percent versus 1.7 percent for nonfatal myocardial infarction, 1.3 percent versus 1.1 percent for stroke, respectively), without a statistical test.³⁸ The other smaller RCTs did not show any difference in event rates.^{49,55} Among the cohort studies, three reported no increased risk of ischemic heart disease for rosiglitazone compared with metformin.^{171,174,181}

Two cohort studies comparing metformin with rosiglitazone showed increased risk of cardiovascular disease associated with rosiglitazone.^{173,182} A 6-year retrospective cohort study of newly diagnosed patients with diabetes used Taiwan's National Health Insurance, and reported higher risk for myocardial infarction (HR 2.09, 95 percent CI 1.36 to 3.24), angina pectoris (adjusted HR 1.79, 95 percent CI 1.39 to 2.30), and transient ischemic attack (adjusted HR 2.57, 95 percent CI 1.33 to 4.96), but not stroke (adjusted HR 1.61, 95 percent CI 0.72 to 3.62) for rosiglitazone compared with metformin. A higher proportion of patients prescribed thiazolidinediones as monotherapy had previous cardiovascular disease compared with the metformin group.¹⁷³

One 24-week RCT of 60 patients compared metformin with pioglitazone in two of three of its arms and reported no cardiovascular events in either group.⁵³ Four cohort studies comparing metformin and pioglitazone^{171,173,174,182} showed no significant difference in cardiovascular disease risk between groups.

Metformin versus sulfonylureas. Two RCTs^{38,68} and five cohort studies^{167,171,173,174,181} reported outcomes for metformin versus a second-generation sulfonylurea

The ADOPT trial, described above, also contained a glyburide arm. Incidences of nonfatal myocardial infarction and stroke in the glyburide arm were 1.0 percent and 1.2 percent, respectively, showing minimal difference compared with the metformin arm (1.4 percent and 1.3 percent, respectively), without a statistical test.³⁸ Two large cohort studies did not show significant differences in cardiovascular events.^{171,174} Tzoulaki et al. reported the results of a large cohort study of 91,521 people with diabetes in the United Kingdom general practice research database and described no increase in the risk of incident myocardial infarction in its fully adjusted model for users of second-generation sulfonylureas compared with metformin users (adjusted HR 1.09, 95 percent CI 0.94 to 1.27).¹⁷¹

Conversely, two cohort studies described higher risk of cardiovascular disease morbidity for a sulfonylurea versus metformin.^{167,181} In the retrospective cohort study from Saskatchewan health databases, metformin was associated with a decreased risk of nonfatal cardiovascular hospitalization as compared with unspecified sulfonylurea (HR 0.78, 95 percent CI 0.63 to 0.97) in the fully adjusted model.¹⁶⁷ McAfee et al. reported a 23 percent risk reduction of the composite outcome of acute myocardial infarction or coronary revascularization for metformin as compared with sulfonylurea monotherapy (HR 0.77, 95 percent CI 0.62 to 0.96), in a propensity score matched cohort study.¹⁸¹ Hsaio et al. only reported crude cardiovascular event rates for this comparison.¹⁷³

Metformin versus meglitinides. Only one 24-week RCT with 701 participants compared metformin with nateglinide and reported low rates of study-related electrocardiogram abnormalities in both arms.⁷⁹

Metformin versus a combination of metformin and thiazolidinediones. Six RCTs^{49,85-88,156} and two cohort studies^{173,181} compared metformin with a combination of metformin plus rosiglitazone and reported the incidence of ischemic cardiac events. One of the cohorts also reported metformin versus metformin plus pioglitazone.¹⁷³ The six RCTs were similar in study duration (range 18 to 32 weeks) and used doses of rosiglitazone ranging from 2 mg to 8 mg. Scott et al. reported no cardiovascular events in either the metformin or metformin plus rosiglitazone arms.⁸⁵ The five RCTs that had at least one event in were pooled with the three RCTs reporting nonfatal ischemic heart disease events (totaling seven studies because one study contributed one fatal and one nonfatal event) in a meta-analysis.^{49,86-88,90,156,179} In a fixed effects model using treatment arm continuity correction for arms with zero events, the pooled odds ratio of ischemic heart disease events was 0.43 (95 percent CI 0.17 to 1.10) for metformin compared with metformin plus thiazolidinedione, which was not statistically significant (Figure 62). Neither Begg's nor Egger's tests for publication bias were statistically significant, and the funnel plot for these seven studies was fairly symmetrical, indicating a low likelihood of publication bias.


McAfee et al., a large retrospective cohort study, showed minimal difference in incidence rate ratios (IRR) for the composite outcome of hospitalization for myocardial infarction or coronary revascularization between subjects treated with metformin (IRR 13.90, 95 percent CI 11.80 to 16.27) compared with metformin plus rosiglitazone (IRR 14.26, 95 percent CI 9.37 to 20.86).¹⁸¹ Hsaio et al. only reported crude cardiovascular event rates for this comparison.¹⁷³

Metformin versus a combination of metformin and sulfonylureas. One RCT⁶⁸ and one cohort study¹⁸¹ assessed this comparison for cardiovascular morbidity. In a 6-month RCT, Hermann et al. reported a 5 percent versus 14 percent rate of unspecified cardiovascular adverse events in the metformin versus combination metformin plus sulfonylurea arms, respectively.⁶⁸ In a 36-month retrospective cohort study using claims data, the adjusted incidence rates for the composite outcome of hospitalization for myocardial infarction or coronary revascularization between subjects was lower in subjects started on metformin compared with metformin plus sulfonylurea (adjusted incidence rate of 13.90 versus 19.44, respectively per 1,000 person-years).¹⁸¹ Hsaio et al. did not report adjusted analyses for this comparison.¹⁷³

Metformin versus a combination of metformin and DPP-4 inhibitors. One 30-week RCT in 190 participants reported three cases (3.1 percent) of angina pectoris in the metformin plus sitagliptin arm and none in the metformin alone arm.⁹³ A shorter 18-week study also reported two coronary artery disease events in the metformin plus sitagliptin arm and none in the metformin alone arm.⁸⁵

Metformin versus a combination of metformin and meglitinides. Horton et al. (described above under metformin versus meglitinides) also contained an arm of the combination of metformin plus nateglinide arm and reported two study-related electrocardiogram abnormalities in the combination arm and one in the metformin arm.⁷⁹

Figure 62. Pooled odds ratio of fatal and nonfatal ischemic heart disease comparing metformin with combination of metformin and rosiglitazone



CI = confidence interval; Met = metformin; Rosi = rosiglitazone

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 2.80$ with 6 degrees of freedom ($p = 0.83$)

I-squared statistic = 0%

Rosiglitazone versus pioglitazone. No RCTs directly compared rosiglitazone with pioglitazone for cardiovascular outcomes, but we identified three cohort studies that included this comparison.^{171,173,174} Tzoulaki et al. (described under the rosiglitazone versus sulfonylurea comparison) and Pantalone et al. did not show any significant risk difference for ischemic heart disease in rosiglitazone versus pioglitazone users.^{171,174} Hsiao et al. reported a higher incidence of composite cardiovascular events (which included angina pectoris and myocardial infarction) in rosiglitazone versus pioglitazone users, but no adjusted statistical analyses was presented and there was evidence of differences in previous cardiovascular disease rates between the two groups.¹⁷³

Thiazolidinediones versus sulfonylureas. Two RCTs^{38,149} and three retrospective cohort studies^{173,181,182} compared rosiglitazone with a sulfonylurea. One RCT¹⁰¹ and two cohort studies^{173,174} compared pioglitazone with a sulfonylurea. The ADOPT trial (described in detail under metformin versus thiazolidinedione) reported minimal differences between the rosiglitazone arms and sulfonylurea arms for non-fatal myocardial infarction and stroke (1.7 percent versus 1.0 percent for non-fatal myocardial infarction, 1.3 percent versus 1.2 percent for stroke, respectively).³⁸ A 52-week RCT with 351 participants reported a higher incidence of “cardiac-related” adverse events in the rosiglitazone versus glyburide groups (15.4 percent versus 12.1 percent, respectively). These events included mitral insufficiency, tachycardia, myocardial infarction, and palpitations.¹⁴⁹

Results from the three cohort studies comparing rosiglitazone with second-generation sulfonylureas were not consistent. One 36-month retrospective cohort study reported a lower adjusted incidence rate for the composite outcome of hospitalization for myocardial infarction or coronary revascularization for rosiglitazone compared with sulfonylureas (adjusted incidence rate of 15.71 versus 19.55 per 1,000 person-years).¹⁸¹ Another cohort study showed no significant differences in risk for myocardial infarction or stroke, but elevated risk for transient ischemic attack (adjusted HR 1.90, 95 percent CI 1.02 to 3.57) and angina pectoris (adjusted HR 1.45, 95 percent CI 1.15 to 1.85) for rosiglitazone versus sulfonylurea.¹⁷³ Brownstein et al. reported an elevated adjusted risk for myocardial infarction for rosiglitazone compared with a sulfonylurea (RR 1.4, 95 percent CI 1.0 to 2.0).

A 56-week RCT with 502 participants randomly assigned participants to glyburide or pioglitazone. It reported fewer cardiovascular adverse events, defined as coronary artery disease, myocardial infarction, and chest pain, in the pioglitazone arm compared with the glyburide arm (1 percent versus 3 percent).¹⁰¹ One cohort study reported no significant difference in coronary artery disease between pioglitazone and sulfonylurea users.¹⁷⁴

Sulfonylureas versus meglitinides. Two 1-year RCTs compared glyburide with repaglinide.^{116,117} One RCT with over 500 participants reported 5 percent cardiovascular adverse events in the repaglinide arm and 2 percent in the glyburide arm without a statistical test.¹¹⁷ The other RCT had 242 participants and stated that cardiac events occurred with similar frequencies between treatment arms.¹¹⁶

Sulfonylureas versus GLP-1 agonists. One 24-week double-blind RCT of 411 patients randomized to oral glibenclamide versus once-daily subcutaneous liraglutide reported one acute myocardial infarction in the liraglutide arm and none in the glibenclamide arm.¹²¹

Combination of metformin and rosiglitazone versus combination of metformin and pioglitazone. One cohort study reported a higher risk of myocardial infarction for metformin plus pioglitazone compared with metformin plus rosiglitazone (HR 6.34, 95 percent CI 1.80 to 22.31), although the estimated precision was very low, with a wide confidence interval. There was no difference in risk of stroke, angina pectoris, and transient ischemic attack for this same comparison.¹⁷³

Combination of metformin and thiazolidinediones versus combination of metformin and sulfonylureas. One open-label RCT of 250 participants reported one acute myocardial infarction in the metformin plus pioglitazone arm versus no events on the metformin plus sulfonylurea arm.¹²⁹

Combination of metformin and thiazolidinediones versus combination of metformin and meglitinides. One 26-week RCT comparing metformin plus rosiglitazone versus metformin plus repaglinide reported one subject with ventricular fibrillation and one with non-cardiac chest pain in the metformin plus rosiglitazone arm, and one transient ischemic attack in the metformin plus repaglinide arm.¹³¹

Combination of metformin and thiazolidinediones versus combination of metformin and DPP-4 inhibitors. Another 18-week trial reported no cardiovascular events in the 87 participants in the metformin plus rosiglitazone arm, and two coronary artery disease events in the 94 participants in the metformin plus sitagliptin arm.⁸⁵

Combination of metformin and sulfonylureas versus combination of metformin or sulfonylureas and thiazolidinediones. The RECORD study, a 5.5-year RCT of 4,447 subjects, combined the two rosiglitazone arms (metformin or sulfonylurea plus rosiglitazone) and compared results with the active control of metformin plus sulfonylurea to assess cardiovascular outcomes. Fatal and nonfatal myocardial infarctions were combined and showed no difference between the two combined rosiglitazone arms and metformin plus sulfonylurea arm (HR 1.14, 95 percent CI 0.80 to 1.63). Fatal and nonfatal stroke were also combined and showed no difference between the two combined rosiglitazone arms and metformin plus sulfonylurea (HR 0.72, 95 percent CI 0.49 to 1.06).¹⁶

Combination of metformin and thiazolidinediones versus combination of metformin and DPP-4 inhibitors. One 16-week open-label trial randomized 169 patients with inadequate glycemic control on metformin alone to rosiglitazone versus sitagliptin and reported one transient ischemic attack each in the rosiglitazone and sitagliptin arms.¹³⁰

Combination of metformin and sulfonylureas versus combination of metformin and DPP-4 inhibitors. In a 52-week trial with 1,172 participants, there was one myocardial infarction in the metformin plus glipizide arm compared with none in the metformin plus sitagliptin arm.¹³³ There were no additional events reported at 2 years of followup.¹³⁴

Combination of metformin and DPP-4 inhibitors versus combination of metformin plus GLP-1 agonists. One 26-week open-label RCT randomized 665 patients on metformin alone to the addition of oral sitagliptin (100 mg), or one of two doses of daily subcutaneous injections of

liraglutide (1.2 mg or 1.8 mg). It reported the occurrence of “cardiac disorders” in one patient on metformin plus 1.8 mg liraglutide and in one patient on metformin plus sitagliptin.¹⁴³

Combination of metformin and basal insulin versus combination of metformin and premixed insulin. In a 16-week cross-over study, 105 patients with newly diagnosed type 2 diabetes were randomly assigned to metformin plus insulin glargine versus metformin plus insulin lispro 75/25 twice daily.¹⁶⁴ In addition, there was an 8-week lead-in period when patients received neutral protamine Hagedorn at night and the metformin dose was titrated. During the lead-in period, one patient experienced a myocardial infarction, and during treatment with the premixed insulin there was one case of chest pain, but it was not reported whether these events occurred before or after the crossover.¹⁶⁴

Combination of metformin and thiazolidinediones versus combination of thiazolidinediones and sulfonylureas. Rosak et al. was a 6-month observational study of over 22,000 patients in Germany. Fewer myocardial infarctions and strokes occurred in the group with rosiglitazone added onto metformin therapy compared with the rosiglitazone plus sulfonylurea combination (incidence of 0.04 percent versus 0.11 percent for myocardial infarction and 0.01 percent versus 0.18 percent for stroke, respectively).¹⁸³

A limitation of the RECORD study was that it contained separate metformin plus thiazolidinedione and sulfonylurea plus thiazolidinedione arms to make this comparison, but did not report these analyses for cardiovascular disease morbidity.¹⁶

Combination of metformin and sulfonylureas versus combination of thiazolidinediones and sulfonylureas. One 52-week trial with 639 participants compared metformin plus a sulfonylurea versus pioglitazone plus a sulfonylurea and reported no difference in the incidence of “cardiac disorders” between the two groups (4.1 percent versus 3.1 percent respectively) but no statistical test results were provided.¹⁴⁰

The Evidence About Retinopathy

There were no studies included in the report that evaluated the outcome of diabetic retinopathy.

The Evidence About Nephropathy (Appendix G, Table 8)

For the nephropathy analyses, we included studies where changes in renal function was described for each treatment group, which could have included the number of patients developing nephropathy or changes in urinary albumin-to-creatinine ratio or glomerular filtration rate. There were nine trials reporting on nephropathy as an outcome.^{52,66,102-104,108,125,140,184} In none of the studies was nephropathy a primary outcome. It was either a secondary outcome or reported under adverse effects.

Metformin versus thiazolidinediones. Two larger trials (total n = 1,176⁵² and n = 639¹⁴⁰) compared the effects of metformin and pioglitazone on renal function. In both trials, the urinary albumin-to-creatinine ratio declined in patients receiving pioglitazone by 15 percent¹⁴⁰ and 19 percent,⁵² respectively but remained unchanged in patients with metformin with statistically significant differences between groups in both trials.

Metformin versus sulfonylureas. One small trial of 3 months duration compared metformin with sulfonylurea (glibenclamide).⁶⁶ Microalbuminuria decreased significantly in patients with metformin while it increased with glibenclamide. Also, glomerular filtration rate remained stable in patients receiving metformin while it increased significantly in patients with glibenclamide. However, no formal between-group comparisons were reported.

Thiazolidinediones versus sulfonylureas. Five small trials compared a thiazolidinedione (pioglitazone or rosiglitazone) with a sulfonylurea.^{102-104,108,184} One trial found significantly less albuminuria in patients receiving pioglitazone compared with glibenclamide.¹⁰² Two other trials also reported reductions in albuminuria with pioglitazone but the differences compared with patients receiving a sulfonylurea were either not significant¹⁸⁴ or not reported.¹⁰³ Another small trial included patients with longstanding diabetes and microalbuminuria and reported reduced urinary albumin excretion with pioglitazone compared to glibenclamide, but no formal statistical comparisons between groups were shown.¹⁰⁸

One trial compared 12-month treatment with rosiglitazone and glyburide¹⁰⁴ and found no statistically significant difference in the urinary albumin-to-creatinine ratio. Similarly, there was no difference in the proportion of patients with progression to microalbuminuria.

Thiazolidinediones versus meglitinides. One small trial of patients with longstanding diabetes and microalbuminuria compared pioglitazone and nateglinide and reported reduced urinary albumin excretion with pioglitazone as compared with nateglinide. No formal statistical comparisons between groups were shown.¹⁰⁸

Combination of metformin and thiazolidinediones versus combination of metformin and sulfonylureas. One trial¹²⁵ compared metformin plus a thiazolidinedione (rosiglitazone) and metformin plus a sulfonylurea (glyburide) and found a greater reduction of the urinary albumin:creatinine ratio with the combination of metformin plus a thiazolidinedione but the difference to the group with metformin plus a sulfonylurea was not statistically significantly different.

The Evidence About Neuropathy (Appendix G, Table 8)

For the neuropathy analyses, we included studies where newly developed neuropathy was reported for each treatment group. Three small short-term trials reported on neuropathy as an adverse outcome.^{88,93,129} In all three studies, neuropathy was reported under adverse effects.

Metformin versus a combination of metformin and thiazolidinediones. One trial⁸⁸ comparing metformin (n = 34) and metformin plus a thiazolidinedione (rosiglitazone) at 2 different dosages (n = 35 and n = 36, respectively) reported on one withdrawal due to undefined neuropathy in the metformin alone group but did not provide any formal between-group comparison.

Metformin versus a combination of metformin and DPP-4 inhibitors. The other trial⁹³ reported on the incidence of (undefined) diabetic neuropathy with metformin alone (n = 2, 2.1 percent) and metformin plus sitagliptin (n = 4, 4.2 percent) but did not provide a statistical comparison.

Combination of metformin and thiazolidinediones versus combination of metformin and sulfonylureas. In a 6-month trial¹²⁹ neuropathy was not a prespecified primary or secondary outcome but there was one patient (n = 103) who developed neuropathy in the group with combination metformin plus thiazolidinedione whereas none of the patients with combination metformin plus sulfonylurea (n = 80) developed neuropathy.

Summary of Results of Updated Search Through December 2010 for Long-Term Clinical Outcomes

We screened 805 records and identified 4 articles that addressed Key Question 2's long term clinical outcomes (Appendix H). Two were RCT's;^{185,186} one¹⁸⁵ trial was a 50-week extension of a previously included 54-week study.⁷⁶ The other two articles were observational studies.^{187,188} Results of these four studies were consistent with our review's findings and did not change the conclusions or strength of evidence grades.

Gray Literature

We found eight unpublished reports from clinicaltrials.gov and the Food and Drug Administration (FDA) Web site that reported on long-term clinical outcomes for our comparisons of interest. These results were generally consistent with the results from the published studies included in the review.

Metformin versus thiazolidinediones. One unpublished study had 2,902 subjects in the rosiglitazone group and 225 subjects in the metformin group, and reported myocardial infarction in nine subjects in the rosiglitazone group and one subject in the metformin group.¹⁸⁹ This study also reported the occurrence of a cerebrovascular disorder in four subjects in the rosiglitazone group and one in the metformin group.

Metformin versus sulfonylureas. One unpublished study had 160 subjects in the metformin group and 157 in the sulfonylurea group and reported one death due to myocardial infarction in each arm.¹⁹⁰ Another unpublished study had 225 subjects in the metformin group and 626 subjects in the sulfonylurea group, and reported myocardial infarction in two subjects in the sulfonylurea group and one in the metformin group.¹⁸⁹ An unpublished study had 225 subjects in the metformin group and 626 subjects in the sulfonylurea group, and reported a cerebrovascular disorder in one subject in the metformin group and none in the sulfonylurea group.¹⁸⁹

Metformin versus DPP-4 inhibitors. One unpublished 54-week RCT, with 364 subjects in the metformin group and 179 subjects in the sitagliptin group, reported myocardial infarction in one subject in the sitagliptin group and none in the metformin group.¹⁹¹

Metformin versus a combination of metformin and sulfonylureas. One unpublished study had 160 subjects in the metformin arm and 315 subjects on the combination of metformin plus sulfonylurea, and reported one death from myocardial infarction in the metformin group and two deaths in the combination therapy group.¹⁹²

A 24-week double-blind active-controlled trial, with 521 subjects on metformin plus sulfonylurea and 177 subjects on metformin alone, reported one death in the combination therapy group and none in the metformin group.¹⁹³

Combination of metformin and sulfonylureas versus combination of metformin and DPP-4 inhibitors. An unpublished 52-week RCT had 559 subjects in the metformin plus glipizide group and 576 subjects in the metformin plus sitagliptin group, and reported one death in the metformin plus sitagliptin combination group and three in the metformin plus glipizide combination group. There were two myocardial infarctions in the metformin plus glipizide combination group, and none in the metformin plus sitagliptin combination group.¹⁹¹

Applicability

The majority of studies included for Key Question 2 had a short duration limiting their applicability to the assessment of long-term outcomes and complications of diabetes in patients with type 2 diabetes in the U.S. Among the RCTs, the two with the longest study duration were 6 years³⁸ and 7.5 years,¹⁶ but the majority were less than 6 months long.

Most trials did not report the source for participant recruitment, such as an outpatient clinical or subspecialty clinical setting, which is relevant because most patients with diabetes are cared for by primary care physicians. In the 29 trials identified since the 2007 report, four reported recruitment from outpatient primary care settings.^{16,78,131,184} Six studies reported excluding greater than 10 percent of participants following a run-in period, which may limit their generalizability to outpatient settings with varying degrees of medication adherence.^{49,123,125,133,156,164}

Overall, participants were middle-aged, which is fairly representative of the U.S. population with type 2 diabetes, but most studies excluded people greater than age 74. Participants were about 50 percent female and the majority was identified as Caucasian. Notably, two RCTs reported greater than 25 percent African American participants,^{85,131} although many studies did not report any racial-ethnic breakdown of the participants. Two RCTs took place in Mexico,^{66,88} and one in both Mexico and Colombia,¹³⁰ with 70 percent to 80 percent Hispanic participants.⁸⁸ Most trials had similar exclusion criteria for coexisting illnesses, such as renal, cardiovascular, and hepatic disease, with the implication that participants were overall less complicated, and thus at lower risk for long-term complications of diabetes.

A majority of studies were conducted in the United States or multinational Europe, where the practice of medicine related to the treatment of diabetes is fairly similar. Most studies received pharmaceutical company support.

Key Question 3. In adults age 18 or older with type 2 diabetes mellitus, what is the comparative safety of the treatment options (see list of comparisons) in terms of the following adverse events and side effects?

- Hypoglycemia
- Liver injury
- Congestive heart failure
- Severe lactic acidosis
- Cancer
- Severe allergic reactions
- Hip and non-hip fractures
- Pancreatitis
- Cholecystitis

- Macular edema or decreased vision
- Gastrointestinal side effects

Key Points and Evidence Grades

Hypoglycemia

- There was high strength of evidence to conclude that the risk of hypoglycemia with sulfonylureas exceeds the risk with metformin with a pooled OR for mild to moderate hypoglycemic events of 4.6 (95 percent CI 3.2 to 6.5) for sulfonylurea versus metformin.
- There was high strength of evidence to conclude that the risk of hypoglycemia with sulfonylureas exceeds the risk with thiazolidinediones with a pooled OR of 3.9, 95 percent CI 3.0 to 4.9 for mild to moderate hypoglycemia for sulfonylurea versus thiazolidinediones.
- There was high strength of evidence to conclude that the risk of hypoglycemia with metformin plus sulfonylurea is about six times as high as the risk of metformin plus thiazolidinediones.
- Moderate grade evidence showed that the risk of hypoglycemia with metformin is comparable to the risk with thiazolidinediones.
- Moderate grade evidence showed that the risk of hypoglycemia with metformin plus sulfonylurea is higher than the risk with metformin alone.
- Moderate grade evidence showed that the risk of hypoglycemia with sulfonylurea exceeds the risk with DPP-4 inhibitors.
- Moderate grade evidence showed a modest increase (OR 3.0, 95 percent CI 1.8 to 5.2) in risk of hypoglycemia with meglitinides over metformin.
- Moderate grade evidence showed a modest increase in risk of hypoglycemia with metformin plus a thiazolidinedione over metformin alone (OR 1.6, 95 percent CI 1.0 to 2.4).
- Moderate grade evidence showed that metformin with a DPP-4 inhibitor has similar risk of hypoglycemia as metformin alone.
- Moderate grade evidence showed that metformin with a sulfonylurea has a higher risk of hypoglycemia than metformin with liraglutide.
- Moderate grade evidence showed a modestly lower risk of hypoglycemia when metformin is combined with a basal insulin rather than a premixed insulin.
- The evidence about hypoglycemia for the other comparisons had low strength or was insufficient.
- No monotherapy or combination therapy convincingly demonstrated more occurrences of severe hypoglycemia than another.

Liver Injury

- High grade evidence showed that rates of liver injury are similar between thiazolidinediones and sulfonylureas.
- Moderate grade evidence showed that the rates of liver injury are similar between thiazolidinediones and metformin.

Congestive Heart Failure

- Moderate evidence showed that thiazolidinediones increase the risk of heart failure when compared to sulfonylureas.
- There were no long-term trials that provide a robust assessment of the comparative safety of the DPP-4 inhibitors and GLP-1 agonists on the risk of heart failure.

Severe Lactic Acidosis

- Moderate strength of evidence indicated that there is no increased risk of lactic acidosis in metformin users compared to those using a sulfonylurea or a combination of metformin and a sulfonylurea.

Cancer

- The evidence had low strength and did not allow definitive conclusions about the risk of cancer with any of the antidiabetic medication comparisons.

Severe Allergic Reactions

- No studies addressed the outcome of severe allergic reactions, and therefore insufficient evidence.

Hip and Non-Hip Fractures

- High grade evidence showed that thiazolidinediones, either in combination with another medication or as monotherapy, are associated with a higher risk of bone fractures compared with metformin alone or in combination with sulfonylurea.

Pancreatitis

- The evidence had low strength and did not allow definitive conclusions about the comparative safety of oral antidiabetic agents on the outcome of acute pancreatitis.

Cholecystitis

- The evidence had low strength and did not allow definitive conclusions about the comparative safety of diabetes medications regarding the outcome of cholecystitis.

Macular Edema or Decreased Vision

- The evidence had low strength and did not allow definitive conclusions about the comparative safety of oral antidiabetic agents on the outcome of macular edema.

Gastrointestinal (GI) Side Effects

- High grade evidence showed that metformin was associated with more frequent GI adverse events compared with thiazolidinediones.
- High strength of evidence demonstrated that the rates of GI adverse effects were similar between thiazolidinediones and sulfonylureas.
- Moderate strength of evidence showed that metformin was associated with more frequent GI adverse events compared with second-generation sulfonylureas.
- Moderate strength of evidence showed that metformin monotherapy was associated with more frequent GI adverse events than the combination of metformin plus a second-

generation sulfonylurea or metformin plus thiazolidinediones if the metformin component was a lower dose than the metformin monotherapy arm.

- Moderate strength of evidence suggested that a combination of metformin and sulfonylurea is associated with more frequent GI adverse events compared with a combination of a thiazolidinedione and a sulfonylurea.
- Moderate strength of evidence showed that metformin was associated with more frequent GI adverse events compared with DPP-4 inhibitors.

See Table 8 for the evidence grades and specific conclusions for each comparison. Details of the evidence grades are in Appendix G, Table 9.

Study Design and Population Characteristics

One hundred thirteen studies are included for Key Question 3 describing adverse effects during treatment (Appendix G, Tables 10 and 11). We included 38 articles from the Comparative Effectiveness Review (CER) published in 2007 that described adverse events for our comparisons of interest and identified an additional 74 studies describing adverse events since completion of that review for this update. The majority of the studies were RCTs. None of the studies was designed explicitly to evaluate adverse events from these medications and medication combinations.

Table 8. Key findings and strength of the evidence comparing diabetes medications as monotherapy or combination therapy for adverse events

Comparison	Hypoglycemia	Liver Injury	GI adverse events	CHF	Macular edema	Pancreatitis and cholecystitis	Fractures
MONOTHERAPY COMPARISONS							
Metformin versus							
TZD	Neither favored; Mod	Neither favored; Mod	Favors TZD; High	Neither favored; Mod	Insufficient	Favors Met*; Low Insufficient†	Favors Met; High
SU	Favored Met; High	Unclear; Low	Favors SU; Mod	Favors Met; Mod	Insufficient	Insufficient	Unclear; Low
DPP-4 inhibitor	Neither favored; High	Insufficient	Favors DPP-4; Mod	Insufficient	Insufficient	Insufficient	Insufficient
Meglitinides	Favors Met; Mod	Insufficient	Favors Meg‡; Low	Insufficient	Insufficient	Insufficient	Insufficient
GLP-1 agonists	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + TZD	Favors Met; Mod	Insufficient	Favors Met+TZD‡; Mod	Insufficient	Insufficient	Favors Met+TZD*; Low Insufficient†	Favors Met; Low
Metformin + SU	Favors Met; Mod	Insufficient	Favors Met+SU§; Mod	Insufficient	Insufficient	Insufficient* Favors Met†; Low	Unclear; Low
Metformin + DPP-4 inhibitor	Neither favored; Mod	Insufficient	Unclear; Low	Insufficient	Insufficient	Insufficient	Unclear; Low
Metformin + meglitinides	Favors Met; Low	Insufficient	Unclear; Low	Insufficient	Insufficient	Insufficient	Insufficient
TZD versus							
TZD	Favors Rosi; Low	Unclear; Low	Insufficient	Unclear; Low	Insufficient	Insufficient	Insufficient
SU	Favors TZD; High	Neither favored; High	Neither favored; High	Favors SU; Mod	Insufficient	Neither favored*; Low Insufficient†	Favors SU; High
DPP-4 inhibitors	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
Meglitinides	Favors TZD; Low	Insufficient	Unclear; Low	Insufficient	Insufficient	Insufficient	Insufficient
GLP-1 agonists	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
SU versus							
DPP-4 inhibitors	Favors DPP4; Mod	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
Meglitinides	Favors Meg; Low	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
GLP-1 agonist	Favors GLP1; High	Insufficient	Favors SU; Low	Insufficient	Insufficient	Insufficient	Insufficient
DPP-4 inhibitor versus							
Meglitinides	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
GLP-1 agonists	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient* Neither favored†; Low	Insufficient

Table 8. Key findings and strength of the evidence comparing diabetes medications as monotherapy or combination therapy for adverse events (continued)

Comparison	Hypoglycemia	Liver Injury	GI adverse events	CHF	Macular edema	Pancreatitis and cholecystitis	Fractures
COMBINATION COMPARISONS							
Metformin + another agent versus							
Metformin + TZD	Favors Met+TZD; High	Neither favored; Low	Neither favored; Low	Insufficient	Favors Met+ other; Low	Insufficient	Favors Met+ other; High
Metformin + SU	Unclear; Low	Insufficient	Unclear; Low	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + meglitinides	Insufficient	Insufficient	Favors Met+SU [¶] ; Low	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + DPP-4	Insufficient	Insufficient	Neither favored; Low	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + GLP-1	Insufficient	Insufficient	Unclear; Low	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + basal insulin	Favors Met+Basal Insulin; Mod	Insufficient	Unclear; Low	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + premixed insulin	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
TZD + another agent versus							
Metformin + TZD	Favors Met+TZD; Low	Insufficient	Insufficient	Favors Met+ TZD; Low	Insufficient	Insufficient	Insufficient
Metformin + SU	Favors TZD+SU; Low	Neither favored; Low	Favors TZD combination; Mod	Favors Met+SU; Low	Insufficient	Insufficient	Favors Met+SU; High
Metformin + meglitinides	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + DPP-4	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + GLP-1	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + basal insulin	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient
Metformin + premixed insulin	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient	Insufficient

CHF = congestive heart failure; GI = gastrointestinal; Met = metformin; Rosi = rosiglitazone; SU = sulfonylurea; TZD = thiazolidinedione

* Key finding and evidence grade for cholecystitis.

† Key finding and evidence grade for pancreatitis.

‡ For diarrhea only.

§ When lower dose of metformin.

¶ For dyspepsia.

The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Mod = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

All other comparisons and intermediate outcomes were graded as insufficient since there were no studies.

The Evidence About Hypoglycemia (Appendix G, Table 12)

From the 2007 CER²¹ we included 29 RCTs,^{36,50,60,61,63-65,68,70,71,79,81,86,87,89-91,106,109,110,114-119,128,140,149} and 3 cohort studies that reported hypoglycemia.¹⁹⁴⁻¹⁹⁶ Of the newly identified studies, 51 were RCTs,^{38,44,49,59,75-78,80,82,84,85,92-96,100,101,111,112,120-123,125,126,129-134,136-138,142,144-147,150,152,156,164,165,179,184,197,198} one was a nonrandomized trial¹⁹⁹ and four were cohort studies.^{183,200-202} The high-quality study from by Home, et al. (RECORD), was not used to look at hypoglycemic events because the authors did not report the number of affected people stratified by the therapy accompanying the thiazolidinedione (e.g., rosiglitazone plus sulfonylurea or rosiglitazone plus metformin).¹⁶

Metformin versus thiazolidinediones. This comparison was addressed by a single, large trial.³⁸ The trial was the ADOPT study, a high-quality trial comparing metformin, rosiglitazone, and glyburide. There was no significant difference in the number of self-reported hypoglycemic events among individuals receiving rosiglitazone and those receiving metformin (141/1456 versus 167/1454, RR 0.90, 95 percent CI 0.80 to 1.0) with just a single serious event in each group.³⁸


Metformin versus sulfonylureas. Nine RCTs were eligible for pooling,^{50,59-61,63-65,70,71} although two studies had no events in either arm.⁵⁹ There was moderate statistical heterogeneity between these studies with an I-squared of 68 percent. The pooled odds ratio having at least one mild or moderate hypoglycemic event was 4.6 (95 percent CI 3.2 to 6.5) with use of sulfonylurea relative to metformin (Figure 63). Only one study reported on severe hypoglycemia and found no significant difference between arms ($p = 0.18$).⁶⁸

Two additional RCTs could not be pooled and had results in the same direction as those in the pooled analysis (Table 9).^{38,198}

Metformin versus DPP-4 inhibitors. Three studies looked at this comparison for hypoglycemic outcomes.⁷⁶⁻⁷⁸ The first study of sitagliptin was a continuation of that by Goldstein et al.⁷⁵ Two of 182 patients randomized to metformin and two of 179 randomized to sitagliptin had mild or moderate hypoglycemic symptoms.⁷⁶ A more recent study reported that 3.3 percent of the 522 patients treated with metformin had mild or moderate hypoglycemic symptoms while 1.7 percent of the 528 treated with 100 mg daily of sitagliptin did ($p = 0.12$). There were no patients with severe hypoglycemia in the metformin group and two patients in the sitagliptin group.⁷⁷ The other study reported 13 patients of 328 treated with metformin and five patients of 335 treated with 10 mg of saxagliptin with mild hypoglycemia and no patient in either group with severe symptoms.⁷⁸

Metformin versus meglitinides. Five RCTs reported mild or moderate hypoglycemia for this comparison.^{79-82,197} One had no events in either arm.⁸¹ There was minimal statistical heterogeneity between these studies (I-squared = 0.0 percent). The odds ratio for hypoglycemia was 3.0 (95 percent CI 1.8 to 5.2) for meglitinides compared to metformin (Figure 64). No additional trials or observational studies reported this outcome.

Figure 63. Pooled odds ratio of having at least one mild or moderate hypoglycemic event comparing metformin with sulfonylureas



CI = confidence interval; Met = metformin; SU = sulfonylurea


Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 18.68$ with 6 degrees of freedom ($p = 0.005$)

I-squared statistic = 67.9%

The range of rates for mild to moderate hypoglycemia for the comparison group, sulfonylureas, was 0% to 64.9%. The median rate was 2.8%.

Figure 64. Pooled odds ratio of having at least one mild or moderate hypoglycemic event comparing metformin with meglitinides



CI = confidence interval; Meg = meglitinides; Met = metformin

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 0.18$ with 3 degrees of freedom ($p = 0.98$)

I-squared statistic = 0%

The range of rates for mild to moderate hypoglycemia for comparison group, meglitinides, was 0 to 50%. The median rate was 1.9%.

Table 9. Additional randomized controlled trials comparing metformin with sulfonylurea for hypoglycemia

Author, year	Outcome	Results	Comments
Kahn, 2006 ³⁸	Self-report hypoglycemia, severity unspecified	168/1451 in metformin arm versus 557/1441 events in sulfonylurea arm	High quality trial, Individuals with short duration of disease, HbA1c = 7.3% at baseline
Wright, 2006 ¹⁹⁸	Mild to severe (not just transient symptoms)	Mean annual percentage 0.30% in 290 patients in metformin arm versus 1.20% in 1418 patients in sulfonylurea arm	Part of UKPDS study, open-label, HbA1c 6.9% at baseline, mostly non-obese participants

HbA1c = hemoglobin A1c; UKPDS = United Kingdom Prospective Diabetes Study

Metformin versus a combination of metformin and thiazolidinediones. Eight RCTs were acceptable for pooling for the outcome of mild or moderate hypoglycemia (Figure 65).^{49,84-87,89,90,156} There was minimal statistical heterogeneity. The odds ratio from the fixed effects model was 1.6 (95 percent CI 1.0 to 2.4) favoring metformin alone for the outcome of hypoglycemia. No additional trials or observational studies reported this outcome.


Metformin versus a combination of metformin and sulfonylureas. There were nine RCTs of this comparison (Table 10).^{59,61,63,64,68,70,71,91,92} Seven reported mild or moderate hypoglycemia and were pooled, but there was substantial statistical heterogeneity (I-squared of 73 percent) so this pooled outcome is not reported.

Table 10. Randomized controlled trials comparing metformin with a combination of metformin and sulfonylurea for hypoglycemia

Author, year	Outcome	Results (metformin versus metformin + sulfonylurea)	Comments (metformin as the reference group)
DeFronzo, 1995 ⁷⁰	Individuals with mild or moderate hypoglycemia	4/210 versus 38/213	RR = 9.3 (95% CI 3.4 to 26)
Charpentier, 2001 ⁷¹	Individuals with mild or moderate hypoglycemia	8/75 versus 30/147	RR = 2 (95% CI 0.9 to 4)
Blonde, 2002 ⁶³	Individuals with mild or moderate hypoglycemia	1/153 versus 22/162	RR = 20.8 (95% CI 3 to 152) Definition of hypoglycemia required symptoms with a measured glucose < 60 mg/dl
Marre, 2002 ⁶⁴	Individuals with mild or moderate hypoglycemia	0/104 versus 12/103	RR = 25 (95% CI 1.5 to 421)
Garber, 2003 ⁶¹	Individuals with mild or moderate hypoglycemia	29/164 versus 59/171	RR = 2 (95% CI 1.3 to 2.9)
Feinglos, 2005 ⁹¹	Individuals with mild or moderate hypoglycemia	2/56 versus 9/56	RR = 4.5 (95% CI 1.0 to 20)
Chien, 2007 ⁵⁹	Individuals with mild or moderate hypoglycemia	0/25 versus 0/26	Most subjects had been on both medications before the trial began.
Hermann, 1994 ⁶⁸	Individuals with severe hypoglycemia	8/38 versus 24/72	RR = 1.6 (95% CI 0.8 to 3.2)
Nauk, 2009 ⁹²	Individuals with severe hypoglycemia	0/122 versus 0/244	Not a significant difference

CI = confidence interval; mg/dL = milligrams per deciliter; RR = relative risk

Figure 65. Pooled odds ratio of having at least one mild or moderate hypoglycemic event comparing metformin with metformin plus thiazolidinedione



Pooled odds of mild to moderate hypoglycemia

CI = confidence interval; Met = metformin; TZD = thiazolidinediones

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate. Test for heterogeneity: $Q = 2.93$ with 7 degrees of freedom ($p = 0.89$)

I-squared statistic = 0% The range of rates for mild to moderate hypoglycemia for comparison group, a combination of metformin and thiazolidinedione, was 0.6% to 12.2%. The median rate was 1.1%.

Metformin versus a combination of metformin and DPP-4 inhibitors. Five articles, describing four trials, examined hypoglycemia with metformin compared to metformin with sitagliptin.^{75,76,85,93,94} Williams-Herman et al,⁷⁶ is an extension of the Goldstein et al. trial.⁷⁵ There was minimal heterogeneity between these studies. The addition of sitagliptin to metformin does not raise the risk of mild or moderate hypoglycemia (odds ratio [OR] = 0.9, 95 percent CI 0.4 to 2.3) (Figure 66). No additional trials or observational studies reported this outcome.

Two trials examined metformin compared to metformin plus saxagliptin at doses ranging from 2.5 mg to 10 mg.^{78,95} In one, 13 of 328 patients treated with metformin had mild hypoglycemia while 11 of 320 patients in the 5 mg saxagliptin plus metformin group had hypoglycemia and 16 of 323 in the 10 mg saxagliptin plus metformin group did. Two patients in the higher dose arm had severe hypoglycemia defined as serum glucose < 50 mg/dl with symptoms.⁷⁸ In the other trial, 9 of 170 metformin-treated patients had mild hypoglycemia; when saxagliptin was added the counts were 15 of 192, 10 of 191, and 7 of 181 in the groups receiving 2.5 mg, 5 mg, and 10 mg, respectively. One patient in each arm had severe symptoms, including the metformin only arm.⁹⁵

Metformin versus a combination of metformin and meglitinides. Three studies reported mild or moderate hypoglycemia for this comparison.^{80,92,96} There was minimal statistical heterogeneity between the studies. One high-quality study had very few affected individuals and used a low dose of nateglinide.⁹⁶ Results are unclear but suggest possibly an increased risk of hypoglycemia with the combination (Figure 67). No additional trials or observational studies reported this outcome.

Rosiglitazone versus pioglitazone. This was addressed by a single, retrospective cohort study.²⁰² The subjects had poor glycemic control at cohort entry with a mean HbA1c of 9.5 percent in the rosiglitazone group and 9.6 percent in the pioglitazone group. The prevalence of hypoglycemia did not differ significantly between groups (11 out of 96 in the rosiglitazone-treated group and 18 out of 106 in the pioglitazone group).


Thiazolidinediones versus sulfonylureas. Nine studies examined hypoglycemic outcomes for this comparison.^{38,50,100,101,106,149,150,184,200} Two looked at counts of events rather than individuals,^{38,184} and one described only the severe events in both arms.¹⁴⁹ The pooled results for mild or moderate hypoglycemia for the five studies reporting affected individuals showed a higher risk of hypoglycemia among those on a sulfonylurea than on any thiazolidinedione (OR = 3.9, 95 percent CI 3.1 to 4.9) (Figure 68).

However, the large multicentred RCT (ADOPT) reported no significant difference in the number of events in each group (1,341 out of 1,456 in the group on rosiglitazone and 1338 out of 1,441 in the sulfonylurea group, $p = 0.44$).³⁸ This high number of events suggests that even very minor events were included in this count. One additional trial reported two events of hypoglycemia in the pioglitazone arm among 22 randomized participants and one event among 22 randomized participants receiving sulfonylurea (glipizide).¹⁸⁴ A cohort study evaluating a population over age 65 years reported that 2.6 percent of recipients of sulfonylurea reported hypoglycemia and 2.2 percent of thiazolidinedione recipients, which are not significantly different percentages.²⁰⁰

There were very few patients affected by severe hypoglycemia. Only a single individual treated with a thiazolidinedione in the four studies reporting this outcome had an event (this was

in the ADOPT trial³⁸); 0 to 3 percent of the sulfonylurea-treated patients had severe events.^{38,50,100,149}

Figure 66. Pooled odds ratio of having at least one mild or moderate hypoglycemic event comparing metformin with metformin plus DPP-4 inhibitors



CI = confidence interval; DPP4 inhibitors = dipeptidyl peptidase-4 inhibitors; Met = metformin


Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 2.59$ with 3 degrees of freedom ($p = 0.46$)

I-squared statistic = 0%

The range of rates for mild to moderate hypoglycemia for comparison group, a combination of metformin and DPP-4 inhibitors, was 0 to 2.1%. The median rate was 1.5%.

Figure 67. Pooled odds ratio of having at least one mild or moderate hypoglycemic event comparing metformin with metformin plus meglitinides



CI = confidence interval; Meg = meglitinides; Met = metformin


Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 2.52$ with 2 degrees of freedom ($p = 0.28$)

I-squared statistic = 20.7%

The range of rates for mild to moderate hypoglycemia for comparison group, a combination of metformin and meglitinides, was 0 to 33%. The median rate was 3.4%.

Figure 68. Pooled odds ratio of having at least one mild or moderate hypoglycemic event comparing thiazolidinediones with sulfonylureas



CI = confidence interval; SU = sulfonylureas; TZD = thiazolidinediones

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 6.78$ with 4 degrees of freedom ($p = 0.15$)

I-squared statistic = 41%

The range of rates for mild to moderate hypoglycemia for comparison group, sulfonylureas, was 2.7% to 29.4%. The median rate was 12.1%.

Thiazolidinediones versus meglitinides. Two RCTs reported hypoglycemic outcomes for this comparison (Table 11).^{109,110}

Table 11. Randomized controlled trials comparing thiazolidinediones with meglitinides for hypoglycemia

Author, year	Outcome	Results (thiazolidinediones versus meglitinides)	RR and comments (thiazolidinediones as reference group)
Jovanovic, 2004 ¹¹⁰	Individuals with mild or moderate hypoglycemia	4/62 versus 8/61	RR = 1.2 (95% CI 0.8 to 1.8)
Raskin, 2004 ¹⁰⁹	Individuals with mild or moderate hypoglycemia Severe hypoglycemia	1/62 versus 4/63 None	RR = 1.6 (95% CI 1.0 to 2.6) NA

CI = confidence interval; NA = not applicable; RR = relative risk

Sulfonylureas versus DPP-4 inhibitors. A single high-quality RCT examined hypoglycemia with this comparison.¹¹¹ Subjects had a mean HbA1c of 7.9 percent upon enrollment. Twenty-one of 123 patients treated with a sulfonylurea had mild or moderate hypoglycemia while none did among the 122 patients treated with sitagliptin.

Sulfonylureas versus meglitinides. Eight studies reported hypoglycemia with this comparison.^{112,114-119,203} One looked only at severe events,¹¹⁴ and one trial focused on the comparison while patients were fasting in observance of Ramadan.²⁰³ The other six had similar outcomes and were amenable to pooling. Fewer patients receiving meglitinides had hypoglycemia than those receiving sulfonylurea although the pooled risk ratio was not statistically significant (OR = 0.8, 95 percent CI 0.6 to 1.1) (Figure 69).

In the trial by Madsbad et al., there were no severe hypoglycemic events in either treatment group.¹¹⁴ The high quality trial by Mafauzy et al. randomized patients to repaglinide or glibenclamide during the period of Ramadan.²⁰³ The number of hypoglycemic events with midday blood glucose less than 81 mg/dL was significantly lower in the meglitinide group (2.8 percent) than in the sulfonylurea group (7.9 percent) ($p < 0.001$).

Sulfonylureas versus GLP-1 agonists. Three trials compared a sulfonylurea (glibenclamide or glimepiride) to liraglutide.¹²⁰⁻¹²² One was a small 12-week dose-finding study that reported a single episode of mild hypoglycemia among the 30 individuals receiving 0.6 mg of liraglutide daily and no episodes in the higher dose group (0.75 mg). Four of 26 patients in the glimepiride group had mild hypoglycemic episodes.¹²⁰ The larger trial which also used glimepiride found 12 of 251 (1.2 mg of liraglutide) and 8 of 247 (1.8 mg of liraglutide) episodes of mild hypoglycemia, compared to 26 of 248 in the sulfonylurea group, which is significantly higher in the sulfonylurea group. The number of episodes was comparable in the 1.2 mg of liraglutide group and the 1.8 mg of liraglutide group.²⁰⁴ The other trial used glibenclamide and compared it to 0.9 mg of liraglutide.¹²¹ There were 45 of 132 individuals with symptomatic hyperglycemia in the glibenclamide group (and 228 events) compared to 36 individuals of 268 in the liraglutide group (and 61 events), significantly favoring the liraglutide arm. There were also more episodes of measured low blood sugar among the glibenclamide treated individuals ($p < 0.0001$). There was no severe hypoglycemia in this trial.


Combination of metformin and thiazolidinediones versus combination of metformin and sulfonylureas. Five trials examined hypoglycemic outcomes,^{123,125,126,128,129} as did one

nonrandomized interventional study.²⁰¹ Among those reporting mild or moderate hypoglycemia, there was minimal heterogeneity between studies (Figure 70). The trial by Hamann et al. was designed so that patients were withdrawn from the study if they did not reach an efficacy target after 8 weeks of treatment.¹²³ The rates of hypoglycemia were high as medications were titrated up to efficacy, although the relative risk of hypoglycemia in the two arms was comparable to the other studies.

In the studies that reported severe hypoglycemia, the rates were higher in the combination of metformin and sulfonylurea arms than the combination of metformin and thiazolidinedione arms. In Garber et al., 7 of 159 patients had severe hypoglycemic events in the metformin with sulfonylurea arm and none in the metformin with thiazolidinedione group.¹²⁸ This study included patients with high HbA1c upon enrollment and had a higher proportion of Asian patients than most studies (12 percent Asian).

One nonrandomized trial compared addition of pioglitazone with addition of glibenclamide in patients taking metformin, with a mean followup of 42 months.²⁰¹ More patients receiving glibenclamide had hypoglycemic events than those who received pioglitazone (34 out of 250 compared to five out of 250, respectively).

Figure 69. Pooled odds ratio of having at least one mild or moderate hypoglycemic event comparing sulfonylureas with meglitinides



CI = confidence interval; Meg = meglitinides; SU = sulfonylureas


Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 4.89$ with 4 degrees of freedom ($p = 0.30$)

I-squared statistic = 18.2%

The range of rates for mild to moderate hypoglycemia for comparison group, meglitinides was 0% to 14.1%. The median rate was 4.6%.

Figure 70. Pooled odds ratio of having at least one mild or moderate hypoglycemic event comparing combination metformin and thiazolidinediones with combination metformin and sulfonylureas



CI = confidence interval; Met = metformin; SU = sulfonylureas; TZD = thiazolidinediones

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 3.79$ with 4 degrees of freedom ($p = 0.44$)

I-squared statistic = 0%

The range of rates for the comparison group, a combination of metformin and sulfonylureas, was 1.3% to 33.3%. The median rate was 29.9%.

Combination of metformin and thiazolidinediones versus combination of metformin and meglitinides. A single RCT reported hypoglycemia for this comparison.¹³¹ This study compared meglitinide plus metformin to two different intensities of metformin plus thiazolidinedione (twice-daily or three-times daily dosing). The combination of metformin plus meglitinide was associated with more hypoglycemia than the combination of metformin plus thiazolidinedione. In the repaglinide plus metformin twice-daily group, 8 of 187 randomized participants had 162 events and in the rosiglitazone plus metformin twice-daily group, one of the 187 randomized participants had 11 events (RR = 1.8, 95 percent CI 1.4 to 2.3 comparing the number of affected participants). There were no episodes of severe hypoglycemia in either group.

Combination of metformin and thiazolidinediones versus combination of metformin and another agent. One study randomized 56 patients to metformin and rosiglitazone and 56 to metformin and sitagliptin. One patient in the rosiglitazone group withdrew for hypoglycemia but it is not clearly reported how many in each group experienced hypoglycemia.²⁰⁵ The other study randomized 45 patients to metformin and rosiglitazone and 45 to metformin and exenatide. No patients receiving rosiglitazone described hypoglycemia while two receiving exenatide did, although this difference was not statistically significant.¹³² There were no severe hypoglycemic events in the latter study.

Combination of metformin and sulfonylureas versus combination of metformin and another agent. Nine trials examined hypoglycemia for metformin plus sulfonylurea compared to metformin plus another drug (Table 12).^{44,92,133,134,136-138,152,199}

Combination of metformin and exenatide versus metformin and a basal insulin. A single small study evaluated this comparison.¹⁴⁴ More patients receiving insulin had hypoglycemic events than patients receiving exenatide. Of the 33 patients receiving insulin, 24 percent had hypoglycemia while 8 percent of the 36 receiving exenatide with their metformin had hypoglycemia. There was no severe hypoglycemia in either arm.

Combination of metformin and a basal insulin versus combination of metformin and another insulin. Five trials examined the comparison of metformin plus insulin glargine to metformin plus another insulin preparation (Table 13).^{145-147,164,165}

Table 12. Randomized controlled trials comparing combination of metformin and sulfonylurea with combination metformin and another agent for hypoglycemia

Author, year	Comparison	Outcome	Results	RR and comments (combination metformin and another agent as reference)
Gerich, 2005 ¹³⁶	Metformin + sulfonylurea versus metformin + meglitinides	Mild or moderate	38/209 versus 18/219	RR = 2.2 (95% CI 1.3 to 3.8)
		Severe	2/209 versus 0/219	No significant difference
Schwarz, 2008 ¹⁵²	Metformin + sulfonylurea versus metformin + meglitinides	Severe	1/40 versus 0/35	No significant difference
Nauck, 2007 ¹³³	Metformin + sulfonylurea versus metformin + sitagliptin	Severe	7/584 versus 1/588	RR = 7.0 (95% CI 0.9 to 57)
Malone, 2003 ¹³⁷	Metformin + sulfonylurea versus metformin + insulin	Nocturnal	(N = 597 in trial) Greater number of participants with nocturnal hypoglycemia (p < 0.01) with metformin plus sulfonylurea than metformin plus insulin.	NA
		Severe	Comparable number with severe hypoglycemia	p = 1.0
Kvapil, 2006 ¹³⁸	Metformin + sulfonylurea versus metformin + insulin	Mild or moderate	9/114 versus 13/108	RR = 1.5 (95% CI 0.7 to 3.4)
Nauck, 2009 ⁹²	Metformin + sulfonylurea versus metformin + liraglutide	Mild and separately reports severe	17% versus 3% of patients	Same in low dose and high dose groups receiving liraglutide; no severe episodes in any arm
Seck, 2010 ^{134†}	Metformin + sulfonylurea versus metformin + sitagliptin	Severe	18/584 versus 2/588	RR = 9.1 (95% CI 2.1 to 39)
Derosa, 2010 ⁴⁴	Metformin + sulfonylurea versus metformin + exenatide	Withdrawal from study for hypoglycemia	3/65 versus 0/63	Not calculable
Dimic, 2009 ^{199*}	Metformin + sulfonylurea versus metformin + repaglinide	Moderate	7/30 versus 5/30, patients each with one episode	RR = 1.4 (95% CI 0.5 to 3.9)

CI = confidence interval; NA = not available; RR = relative risk

* patients assigned a treatment, not clearly randomized

† Continuation of Nauck, 2007¹³³

Table 13. Randomized controlled trials comparing combination of metformin and a basal insulin with combination of metformin and another insulin for hypoglycemia

Author, year	Comparison	Outcome	Results	RR and comments (combination metformin and another insulin as reference group)
Malone, 2004 ¹⁶⁴	Metformin + glargine versus metformin + lispro 75/25	Mild or moderate Severe	40/101 versus 57/100 (87 versus 181 events) None	RR = 0.69 (95% CI 0.5 to 0.9), both arms of cross-over pooled NA
Malone, 2005 ¹⁶⁵	Metformin + glargine versus metformin + lispro 75/25	Mild or moderate Severe	0.44 versus 0.61 events/patient/30 days None	P = 0.47; more daytime hypoglycemia with lispro 75/25 but less nocturnal hypoglycemia NA
Raskin, 2007 ¹⁴⁶	Metformin + glargine versus metformin + aspart 70/30	Mild or moderate	11/78 versus 33/79 (23 versus 121 events)	RR = 0.34 (95% CI 0.2 to 0.6)
Robbins, 2007 ¹⁴⁵	Metformin + glargine versus metformin + lispro 50/50	Mild or moderate Severe	75/158 versus 79/157 2/158 versus 3/157	RR = 0.94 (95% CI 0.8 to 1) RR = 0.66 (95% CI 0.1 to 4)
Davies, 2007 ¹⁴⁷	Metformin + NPH versus metformin + NPH/regular 70/30	Mild or moderate	7/29 versus 8/27	RR = 0.81 (95% CI 0.34 to 1.9); a poorly conducted trial

CI = confidence interval; NA = not available; NPH = neutral protamine Hagedorn; RR = relative risk

Combination of metformin and thiazolidinediones versus combination of thiazolidinediones and sulfonylureas. A single large cohort study examined this comparison.¹⁸³ This prospective cohort study enrolled 22,808 patients in Germany who were treated with rosiglitazone and observed their outcomes as their own clinicians prescribed additional medications. Hypoglycemic events occurred at a rate of 0.05 per 100 person-years of followup in the metformin plus thiazolidinedione group and 0.47 per 100 person-years of followup in the thiazolidinedione plus sulfonylurea group.

Combination of metformin and sulfonylureas versus combination of thiazolidinediones and sulfonylureas. A single study compared metformin plus sulfonylurea to a thiazolidinedione plus sulfonylurea.¹⁴² This was the longer term followup on the patients enrolled in the study first reported by Hanefeld et al.¹⁴⁰ There was a 10 percent withdrawal rate from adverse events and an 8 percent withdrawal rate for lack of efficacy. Fifty of 224 subjects receiving metformin plus sulfonylurea had mild or moderate hypoglycemic symptoms while 36 of 217 receiving thiazolidinedione plus sulfonylurea had symptoms (RR 1.3, 95 percent CI 0.9 to 2).

Severe hypoglycemia. As noted above, relatively few studies separately described severe hypoglycemia.^{38,44,68,78,92,95,114,133,134,136,137,145,152,164,165} The definitions differed across studies, but it was most commonly defined as hypoglycemia requiring assistance for resolution. The studies that compared metformin with a sulfonylurea to metformin with another agent were the studies that most commonly reported this outcome. In the seven studies reporting, only one found a higher rate of severe hypoglycemia in the arm with a sulfonylurea than in the arm with sitagliptin. Otherwise, none of the comparisons reporting this outcome found more severe

hypoglycemia in one arm relative to the other. Many of the studies were underpowered to demonstrate differences for this infrequent outcome.

The Evidence About Liver Injury (Appendix G, Table 12)

Metformin versus thiazolidinediones. One 52-week trial compared metformin and pioglitazone and reported on changes in liver enzymes.⁵² There were 3 instances of hepatotoxicity leading to drug discontinuation—1 patient of 597 treated with metformin and 2 of 597 treated with pioglitazone. Liver enzyme abnormalities were more frequent. In the metformin group, 2.2 percent of participants had an increase in alanine transaminase to 3 times the upper limit of normal as did 0.9 percent of pioglitazone-treated patients ($p = 0.06$). In both groups, the mean alanine transaminase, gamma-glutamyltransferase concentrations, and alkaline phosphatase concentrations decreased during the trial. Additionally, a single cohort study assessed liver injury with metformin as compared with pioglitazone, using propensity scores to match subjects based on disease severity.²⁰⁶ The incidence of liver failure or hepatitis was defined using claims data. For the 1,847 subjects in each group for the metformin versus pioglitazone comparison, the rate of liver failure or hepatitis was 0.8 percent and 0.4 percent, respectively, which was not statistically different in Cox proportional hazard models.

Metformin versus sulfonylureas. The ADOPT study, a large 6-year parallel-arm RCT, compared metformin with glyburide, with over 1,400 subjects in each arm.³⁸ The average age in the metformin group was 57.9 (standard deviation [SD] 9.9). Average age in the glyburide group was 56.4 (SD 10.4). The percentage of individuals with liver injury was 1.1 percent among the 1,341 individuals in the metformin group and 0.8 percent among the individuals in the glyburide group. Mean alanine aminotransferase (ALT) levels were slightly higher in the glyburide group (27.2 international units [IU]/liter; 95 percent CI 26.3 IU/liter to 28.1 IU/liter) compared to the metformin group (24.9 IU/liter; 95 percent CI 24.1 IU/liter to 25.8 IU/liter), but the clinical significance of this slight difference is not clear and there was no statistical test performed.

Rosiglitazone versus pioglitazone. This comparison was addressed by a single, cohort study conducted in the US using a pharmacy database.²⁰⁶ As mentioned above, the diagnosis of liver failure or hepatitis was based on claims data. There was no difference in the incidence of liver injury between the two treatment groups. The incidence of hepatitis was 0.4 percent among the 1,847 people treated with rosiglitazone and 0.5 percent among the 1,847 treated with pioglitazone.

Thiazolidinediones versus sulfonylureas. This comparison was addressed with the ADOPT study, described above, which compared rosiglitazone with glyburide.³⁸ The average age of participants in the rosiglitazone and glyburide groups was 57.9 (SD 9.9) and 56.4 (SD 10.4), respectively. The outcome of liver injury was based on elevated liver enzymes. There were no cases of liver injury among the 1,456 people randomized to rosiglitazone or the 1,441 people randomized to glyburide. The cohort study discussed above also compared pioglitazone versus any sulfonylurea and assessed rates of liver failure and hepatitis.²⁰⁶ The incidence of hepatitis, defined with claims data, was 0.6 percent among the 1,474 individuals treated with pioglitazone and 1 percent in the 1,474 individuals treated with any sulfonylurea, which was not significant. One additional large trial reported this outcome.¹⁵⁰ None of the 1,051 patients receiving

pioglitazone had liver enzyme abnormalities while four of the 1,046 individuals receiving glyburide did ($p = 0.06$).

Combination of metformin and thiazolidinediones versus combination of metformin and sulfonylureas. One RCT examined liver injury as an adverse event for this comparison.¹²⁷ Liver injury was defined as an ALT or aspartate aminotransferase value more than 3 times the upper limit of normal. There were no cases of liver injury reported in the 48 patients in the combination metformin plus rosiglitazone arm and none in the 47 patients in the combination metformin plus glimepiride arm.

Combination of metformin and sulfonylureas versus combination of thiazolidinediones and sulfonylureas. A single parallel arm 12-week RCT in 198 participants, conducted in China, examined this comparison.¹³⁹ Individuals with poor glucose control were randomized to receive metformin plus an sulfonylurea or rosiglitazone plus a sulfonylurea. There were no cases of liver injury reported in either group in this short trial. One additional trial describing liver enzyme changes reported this as an outcome (rather than as an adverse event) and saw improvement in gamma-glutamyl transpeptidase, alanine aminotransferase, and alkaline phosphatase in both groups over the 52-week trial.¹⁴⁰

The Evidence About Congestive Heart Failure (Appendix G, Table 12)

Seven trials^{38,83,141,149,150,164,184} and 11 observational studies^{171,173,174,183,195,200,202,207-210} reported on the outcome of heart failure for our comparisons of interest.

Metformin versus thiazolidinediones. Three trials^{38,83,141} and four observational studies^{171,173,174,200} examined heart failure for this comparison (Table 14). Low grade evidence showed that thiazolidinediones increase the risk of heart failure when compared to metformin. The ADOPT study, a large long-term RCT of median duration of treatment of 4 years, which compared metformin with rosiglitazone, with over 1,400 subjects in each arm. There was no difference between the incidences of investigator reported heart failure in these two arms.³⁸

Table 14. Studies comparing metformin with thiazolidinediones for heart failure events

Author, year	Study design	Comparison	Heart failure incidence (metformin as reference group)
Kahn, 2006 ³⁸	RCT	Rosiglitazone versus metformin	22/1456 versus 19/1454 versus
Leiter, 2005 ⁸³	RCT	Rosiglitazone versus metformin	3/405 versus 0/78
Van der Meer, 2009 ¹⁴¹	RCT	Pioglitazone versus metformin	No events reported in either arm
Asche, 2008 ²⁰⁰	Observational study	Thiazolidinedione versus metformin	19/889 versus 0/2326
Pantalone, 2009 ¹⁷⁴	Observational study	Rosiglitazone versus metformin	HR 1.16 (95% CI 0.78 to 1.73)
		Pioglitazone versus metformin	HR 1.38 (95% CI 1.00 to 1.90)
Hsiao, 2009 ¹⁷³	Observational study	Rosiglitazone versus metformin	HR 1.30 (95% CI 0.89 to 1.89)
		Pioglitazone versus metformin	HR 1.54 (95% CI 0.65 to 3.64)
Tzoulaki, 2009 ¹⁷¹	Observational study	Rosiglitazone versus metformin	HR 0.61 (95% CI 0.33 to 1.15)
		Pioglitazone versus metformin	HR 1.17 (95% CI 0.77 to 1.77)

CI = confidence interval; HR = hazard ratio for TZDs with metformin as references group; RCT = randomized controlled trial

Metformin versus sulfonylureas. Five observational studies reported on the risk of heart failure events with the sulfonylureas compared to metformin.^{174,195,207,208,211}

A retrospective cohort study from Canada reported a higher rate of heart failure with a sulfonylurea (96 percent of SU users used glyburide) compared to metformin (adjusted HR 1.2, 95 percent CI 1.0 to 1.5). The risk of heart failure associated with sulfonylureas was dose-responsive with increasing risk with higher doses.²⁰⁸ Another retrospective cohort study of nearly 30,000 patients using the General Practitioner Research Database in the U.K. reported a higher incidence of heart failure with sulfonylurea monotherapy (27/1000 person-years) compared to metformin monotherapy (19/1000 person-years).¹⁹⁵ A short observational study of around 10 months reported a lower risk of incident heart failure hospitalization among metformin users (HR 0.7, 95 percent CI 0.5 to 1.0, $p = 0.05$) compared to sulfonylurea users.²⁰⁷ Another observational study reported a lower risk of congestive heart failure with metformin compared with sulfonylureas (HR 0.76, 95 percent CI 0.64 to 0.91, $p = 0.003$).¹⁷⁴ Yet another observational study reported a higher risk of congestive heart failure with second-generation sulfonylureas compared with metformin (HR 1.18, 95 percent CI 1.04 to 1.34, $p = 0.011$).¹⁷¹

Rosiglitazone versus pioglitazone. Four observational studies reported on this comparison.^{173,174,202,210} A prospective observational study from Ontario reported a statistically significant lower risk of congestive heart failure among patients on pioglitazone compared to rosiglitazone (HR 0.77, 95 percent CI 0.69 to 0.87).²¹⁰ Another observational study reported 66 cases of congestive heart failure among 2,093 participants exposed to rosiglitazone monotherapy compared with 13 cases of heart failure among 495 participants exposed to pioglitazone monotherapy (3.33 percent versus 2.66 percent).¹⁷³ Another observational study reported no difference in the risk of congestive heart failure with pioglitazone compared with rosiglitazone (HR 1.19, 95 percent CI 0.74 to 1.91, $p = 0.48$).¹⁷⁴ One prospective observational study in Australia reported nearly similar rates of pulmonary edema when pioglitazone (2/107) was compared to rosiglitazone (3/96).²⁰²


Thiazolidinediones versus sulfonylureas. Four trials^{38,149,150,184} and four observational studies^{173,174,200,207,208} examined outcomes for this comparison (Table 15). A meta-analysis of the 4 RCTs^{38,149,150,184} showed an increased risk of congestive heart failure with thiazolidinediones compared with second-generation sulfonylureas which did not reach statistical significance but could not rule out a clinically significant excess associated with the thiazolidinediones (RR 1.68, 95 percent CI 0.99 to 2.85) (Figure 71). There was no evidence of statistical heterogeneity among the included studies ($I^2 = 0$ percent). Moderate grade evidence showed that thiazolidinediones increase the risk of heart failure when compared with sulfonylureas.

Table 15. Studies comparing thiazolidinediones with sulfonylureas for heart failure events

Author, year	Study design	Comparison	Heart failure incidence (sulfonylurea as reference)
Asche, 2008 ²⁰⁰	Observational study	Thiazolidinedione versus sulfonylurea	19/889 and 0/2223
Karter, 2005 ²⁰⁷	Observational study	Pioglitazone versus sulfonylurea	HR = 1.3 (95% CI 0.85 to 1.92) for incident hospitalization for heart failure
Pantalone, 2009 ¹⁷⁴	Observational study	Rosiglitazone versus sulfonylurea	HR = 0.88 (95% CI 0.60 to 1.31), p = 0.55
		Pioglitazone versus sulfonylurea	HR = 1.05 (95% CI 0.77 to 1.43), p = 0.76
Hsiao, 2009 ¹⁷³	Observational study	Rosiglitazone versus sulfonylurea	HR = 1.22 (95% CI 0.86 to 1.74), p = 0.26
		Pioglitazone versus sulfonylurea	HR = 1.37 (95% CI 0.58 to 3.20), p = 0.46

CI = confidence interval; HR = hazard ratio

Figure 71. Pooled odds ratio of congestive heart failure comparing thiazolidinediones with second-generation sulfonylureas



Pooled odds ratio of congestive heart failure

CI = confidence interval; RR = relative risk

Boxes indicate individual study point estimates. The box size denotes the weight of the study, with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95 percent confidence intervals for each study. The diamond at the bottom of the graph indicates the 95 percent confidence interval for the random-effects pooled estimate.

Test for heterogeneity: $Q = 2.37$ with 3 degrees of freedom ($p = 0.50$)

I-squared statistic = 0%

Combination of metformin and sulfonylureas versus combination of metformin or sulfonylureas and thiazolidinediones. The RECORD trial was a long-term open-label noninferiority trial designed to assess cardiovascular outcomes with rosiglitazone. Low grade evidence from the RECORD showed that the combination of thiazolidinediones and another agent (second or third generation sulfonylurea or metformin) was associated with a significant doubling in the risk of heart failure in comparison to combination of sulfonylurea and metformin (61/2220 versus 29/2227, RR 2.1, 95 percent CI 1.35 to 3.27).¹⁶

Combination of metformin and a basal insulin versus combination of metformin and another insulin. In an RCT that compared a combination of insulin glargine daily plus metformin with combination of insulin lispro 75/25 plus metformin, hospitalization due to heart failure was reported in a single patient on the insulin lispro 75/25 and metformin combination.¹⁶⁴

Combination of metformin and thiazolidinediones versus combination of thiazolidinediones and sulfonylureas. A 6-month observational study from Germany reported rates of heart failure that were higher with a thiazolidinedione and sulfonylurea (0.47/100 person-years) relative to a thiazolidinedione and metformin combination (0.13/100 person-years).¹⁸³

The Evidence for Lactic Acidosis (Appendix G, Table 12)

We identified two double-blind RCTs comparing the rates of lactic acidosis between metformin, second-generation sulfonylurea, and metformin in combination with a second-generation sulfonylurea.^{62,63} Both the trials were conducted in the United States and lasted only 16 to 18 weeks. The average age of individuals participating in both these trials was greater than 50 years and individuals with significant renal or liver diseases were excluded. There were no cases of lactic acidosis reported in any of the treatment arms in either of the two trials.

The Evidence About Cancer (Appendix G, Table 12)

We found four RCTs^{93,101,143,197} and one observational study²¹² which reported on cancer outcomes.

Metformin versus sulfonylureas. A retrospective cohort study of 62,089 patients reported on cancer outcomes in the U.K. in The Health Information Network in U.K. General Practices.²¹² Compared with those using metformin alone, users of sulfonylureas reported a higher risk of cancer (HR 1.36, 95 percent CI 1.19 to 1.54, $p < 0.001$).

Metformin versus meglitinides. Additionally, we identified a single crossover RCT reporting cancer outcomes that compared metformin to meglitinides.¹⁹⁷ The study was conducted in 96 individuals with two 4-month treatment periods with a 1-month washout period in between. Two cancers (one cancer of the vocal plicae and one lung cancer) were reported in patients on metformin, while none were reported among patients on meglitinides.

Metformin versus a combination of metformin and sulfonylureas. In the same study, compared with metformin alone, users of both metformin and sulfonylureas reported no difference in the risk of cancer (HR 1.08, 95 percent CI 0.96 to 1.21, $p = 0.21$).²¹²

Metformin versus a combination of metformin and DPP-4 inhibitors. The second trial was a 30-week trial conducted among 190 individuals randomly assigned to sitagliptin or placebo as an add-on to ongoing metformin therapy.⁹³ Three cases of cancer were reported in the metformin only group while none were reported in the combination metformin and sitagliptin group.

Thiazolidinediones versus sulfonylureas. In a 56-week, multicenter trial in the United States and Puerto Rico conducted among 502 individuals randomly assigned to pioglitazone (n = 251) or second-generation sulfonylurea, glyburide (n = 251),¹⁰¹ two events of stage 4 colon cancer (0.8 percent) were reported in the sulfonylurea group while none were reported in the thiazolidinedione group.

Combination of metformin and DPP-4 inhibitors versus combination of metformin and GLP-1 agonists. One case of cancer was reported in each group in another 26-week open label RCT that compared 221 participants randomized to the liraglutide and metformin group, compared with 219 participants in the sitagliptin and metformin combination group.¹⁴³

The Evidence About Severe Allergic Reactions

None of the studies included in the report evaluated the outcome of severe allergic reactions.

The Evidence About Hip and Non-Hip Fractures (Appendix G, Table 12)

Metformin versus thiazolidinediones. The ADOPT study was a large RCT comparing rosiglitazone, metformin, and glyburide for a median of 4 years duration. They reported a separate analysis examining time to first fracture, rates of occurrence, and fracture site. The estimated hazard ratio for risk of fracture with rosiglitazone versus metformin was 1.57 (95 percent CI 1.13 to 2.17). They also included a subgroup analysis to examine fracture risk by sex (see Key Question 4). Among the 1,840 women, there were 111 fractures, 60 (9.3 percent) in the rosiglitazone arm, 30 (5.1 percent) in the metformin arm, and 21 (3.5 percent) in the glyburide arm. This represented an increased HR for risk of fracture for rosiglitazone versus metformin (HR 1.81, 95 percent CI 1.17 to 2.80, p = 0.008) among women. There was no excess risk among men.²¹³ A 24-week RCT reported on one wrist fracture in the metformin monotherapy group (wrist fracture in males (n = 210) without any fractures reported in the pioglitazone group (n = 189).⁵⁶ A retrospective study in the U.K. GPRD reported no statistically significant difference in the risk of fractures when rosiglitazone was compared with metformin (HR 1.09, 95 percent CI 0.72 to 1.68, p = 0.69) or when pioglitazone was compared with metformin (HR 1.28, 95 percent CI 0.93 to 1.77, p = 0.127).¹⁷¹

Metformin versus sulfonylureas. Two RCTs reported on fractures for the comparison of metformin and second-generation sulfonylureas.^{59,213} In the ADOPT subanalysis described above,²¹³ there were slightly more fractures in the metformin arm (59 out of 1,454, 4.1 percent) compared with the glyburide arm (49 out of 1441, 3.4 percent) but no statistical test was performed. A small 16-week trial, conducted in Taiwan, compared glyburide (n = 17) and metformin (n = 17) as monotherapy and in combination. This study reported one fracture of the right metacarpal bone of the hand in a single subject in the glyburide arm.⁵⁹

The risk of fractures associated with second-generation sulfonylureas was not statistically different when compared with metformin alone (HR 1.09, 95 percent CI 0.97 to 1.23, $p = 0.129$) in a retrospective study in the U.K. general practice research database.¹⁷¹

Metformin versus a combination of metformin and thiazolidinediones. A 24-week RCT reported one wrist fracture in a male patient in the metformin monotherapy group ($n = 210$) compared with one wrist fracture in a female in the combination of metformin and pioglitazone group ($n = 201$).⁵⁶ A retrospective study in the U.K. GPRD reported a higher risk of non-hip fractures with rosiglitazone combination therapy compared with metformin alone after adjusting for potential confounders (HR 1.53, 95 percent CI 1.25 to 1.88, $p < 0.01$).¹⁷¹ A cross-sectional study of males having diabetes reported a higher risk of fractures among those treated with rosiglitazone plus metformin compared with metformin alone (66.7 percent versus 27.3 percent, $p = 0.01$), with a significantly higher odds of fractures in the combination arm (OR 6.5, 95 percent CI 1.3 to 38.1, $p = 0.03$) after adjusting for age and body mass index.²¹⁴

Metformin versus a combination of metformin and sulfonylureas. The above 16-week trial only reported a single fracture in the glyburide monotherapy group as compared with no fractures in the two combination metformin plus glyburide groups ($n = 42$).⁵⁹

Metformin versus a combination of metformin and DPP-4 inhibitors. One 30-week multicenter, parallel-arm RCT randomized 190 subjects to metformin or metformin plus sitagliptin.⁹³ They reported one case of osteoporotic limb fracture among the 94 individuals in the metformin group and no fractures in the metformin plus sitagliptin group.

Thiazolidinediones versus sulfonylureas. This comparison was assessed by two RCTs^{101,213} and one observational study.²¹⁵ In the ADOPT subanalysis on fracture risk, there was an increased HR (2.13, 95 percent CI 1.30 to 3.51) for rosiglitazone as compared with glyburide.²¹³ A second trial randomized subjects to pioglitazone or glyburide.¹⁰¹ There were no reported cases of ankle fracture among the 251 individuals in the pioglitazone arm. Two ankle fractures (incidence of 0.2 percent) were reported among the 251 participants in the glyburide group, without a statistical test.

Another prospective study reported on the comparison between thiazolidinediones and first- and second-generation sulfonylureas acetohexamide, chlorpropamide, gliclazide, glimepiride, glyburide, and tolbutamide for fractures among men and women.²¹⁵ Thiazolidinediones were associated with an increased risk of all fractures compared with sulfonylureas (HR 1.28, 95 percent CI 1.12 to 1.45, $p < 0.001$) after adjusting for various confounders. Compared with the sulfonylureas, the hazard ratios for any fractures with the thiazolidinediones did not reach statistical significance for men (HR 1.15, 95 percent CI 0.95 to 1.40, $p = 0.14$) but was statistically significantly higher for women (HR 1.40, 95 percent CI 1.18 to 1.67, $p < 0.001$). Among women, both pioglitazone (HR 1.70, 95 percent CI 1.30 to 2.23, $p < 0.001$) and rosiglitazone (HR 1.29, 95 percent CI 1.04 to 1.59, $p = 0.02$) were significantly associated with an increased risk of fractures compared with the sulfonylureas.

Combination of metformin and sulfonylureas versus combination of metformin or sulfonylureas and thiazolidinediones. The RECORD study was an open-label noninferiority multicenter RCT with 4,447 participants with type 2 diabetes taking either metformin or a

second- or third-generation sulfonylurea, glyburide/glibenclamide (normal or micronized), glimepiride or glimepiride randomly assigned to one of three arms, metformin plus rosiglitazone, sulfonylurea plus rosiglitazone, or metformin plus sulfonylurea.¹⁶ The incidence of participant-reported bone fractures was higher in the combined metformin plus rosiglitazone and sulfonylurea plus rosiglitazone arms, with 49 events out of 2,220 participants (2.3 percent) versus 36 out of 2227 participants (1.6 percent) in the metformin plus sulfonylurea arms. The risk ratio was 1.57 (95 percent CI 1.26 to 1.97, $p < 0.0001$) for the rosiglitazone combination therapy arms compared with the combination metformin plus sulfonylurea arms. Consistent with the ADOPT trial reporting metformin versus rosiglitazone monotherapy, the RR was higher for women compared with men (RR 1.82, 95 percent CI 1.37 to 2.41 versus 1.23, 95 percent CI 0.85 to 1.77). The fractures occurred predominantly in the upper limb, distal lower limb, and not hip or femur fractures.¹⁶

The Evidence About Acute Pancreatitis (Appendix G, Table 12)

We identified five trials that reported on the rates of acute pancreatitis with the specific drug comparisons.^{92,121,122,143,144}

Metformin versus a combination of metformin and sulfonylureas. The Liraglutide Effect and Action in Diabetes (LEAD) 2 trial reported one patient with acute pancreatitis in the metformin plus glimepiride arm among 242 exposed patients compared with none in the metformin arm among 121 exposed patients.⁹²

Sulfonylureas versus GLP-1 agonists. The Liraglutide Versus Glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono) trial also reported two participants with pancreatitis in the liraglutide arm ($n = 498$) compared with none having pancreatitis in the glimepiride arm, ($n = 248$)¹²² for 52 weeks. Another 24-week trial that compared liraglutide ($n = 272$) to glibenclamide ($n = 139$) also reported no episodes of pancreatitis.²¹⁶

DPP-4 inhibitors versus GLP-1 agonists. Another 26-week trial that compared liraglutide ($n = 446$) with sitagliptin ($n = 219$) reported no episodes of pancreatitis.¹⁴³

Combination of metformin and GLP-1 agonist versus combination of metformin and basal insulin. One patient on metformin plus exenatide developed pancreatitis ($n = 36$) compared with none in the metformin plus insulin glargine arm ($n = 33$) in another RCT.¹⁴⁴

The Evidence About Cholecystitis (Appendix G, Table 12)

Three RCTs reported on the outcome of cholecystitis.^{54,87,150}

Metformin versus thiazolidinediones. One trial identified a single participant with cholecystitis among 105 treated with a thiazolidinedione; none of the 100 patients treated with metformin suffered from cholecystitis.⁵⁴

Metformin versus combination of metformin and thiazolidinediones. In an RCT, one patient had cholecystitis ($n = 280$) in the metformin arm compared with none ($n = 288$) in the metformin plus rosiglitazone arm.⁸⁷

Thiazolidinediones versus sulfonylureas. A 3-year RCT reported that four participants developed cholecystitis NOS (not otherwise specified) and zero participants developed acute cholecystitis NOS among 1,051 patients randomized to pioglitazone, compared with 3 patients developing cholecystitis NOS and 1 participant developing acute cholecystitis NOS among 1,046 patients randomized to glyburide.¹⁵⁰

The Evidence About Macular Edema (Appendix G, Table 12)

In one trial, macular edema was reported in two subjects with metformin plus thiazolidinedione compared to none in the metformin plus meglitinide arm.¹³¹

The Evidence About Gastrointestinal Effects (Appendix G, Table 12)

Fifty-one studies examined GI adverse events, which included nausea, abdominal pain, diarrhea, or a composite outcome. We included 21 studies^{36,52,54,60-63,65,66,68,70,71,79,81,86-88,110,128,140,159} from the 2007 CER²¹ and identified 30 additional studies^{38,44,49,56,59,76-78,80,84,85,92-95,100,101,121-123,126,132,133,142,145,150,152,156,197,200} for the update that reported GI adverse events for comparisons of interest.

Metformin versus thiazolidinediones. Five RCTs compared GI adverse events between metformin and either rosiglitazone or pioglitazone (Table 16).^{38,49,52,54,56} GI adverse event rates were consistently higher in the metformin arm compared with a thiazolidinedione.

Metformin versus sulfonylureas. Eleven RCTs examined GI adverse events between metformin and a second-generation sulfonylurea.^{38,59-53,65,66,68,70,71} GI adverse events rates were consistently higher in the metformin arm compared with a sulfonylurea (Table 17).

One retrospective cohort study compared the risk of adverse events associated with the use of metformin, sulfonylureas, and thiazolidinediones among geriatric patients in an outpatient settings.²⁰⁰ Consistent with the results from the trials, this cohort reported higher GI adverse events with the use of metformin. However, the incidence of metformin-associated diarrhea in this study was much lower than in the clinical trials and the authors suggested that it may be a result of pre-therapy screening or effective patient self-management.

Table 16. Randomized controlled trials comparing metformin with thiazolidinediones for gastrointestinal effects

Author, year	Outcome	Event rates (metformin versus thiazolidinediones)
Kahn, 2006 ³⁸	Combined GI events	38% (557/1454) versus 23% (335/1456)
	Nausea	11.7% (170/1454) versus 7.7% (112/1456)
	Vomiting	5.8% (84/1454) versus 4% (58/1456)
	Diarrhea	23.7% (345/1454) versus 8.9% (129/1456)
	Abdominal discomfort	15.4% (224/1454) versus 11.1% (161/1456)
Rosenstock, 2006 ⁴⁹	Nausea/vomiting	13% (20/154) versus 8% (13/159)
	Diarrhea	21% (32/154) versus 7% (11/159)
	Dyspepsia	8% (12/154) versus 9% (14/159)
Scherthaner, 2004 ⁵²	Diarrhea	11.1% (66/597) versus 3.2% (19/597)
	Nausea	4.2% (25/597) versus 2.3% (14/597)
Pavo, 2003 ⁵⁴	Diarrhea	16% (16/100) versus 3% (4/105)
Perez, 2009 ⁵⁶	Diarrhea	15.3% (32/210) versus 2.6% (5/189)

GI = gastrointestinal

Metformin versus DDP-4 inhibitors. Two RCTs compared metformin and sitagliptin. The first assessed the incidence of total GI adverse events, including abdominal pain, diarrhea, nausea, and vomiting.⁷⁶ Compared with the arm with highest dose of metformin, the sitagliptin arm had fewer GI adverse events overall (31 percent versus 20 percent), and less diarrhea (12 percent versus 4 percent), nausea (10 percent versus 1 percent), and vomiting (3 percent versus 1 percent). There was no reported difference between groups for abdominal pain. The second RCT also compared metformin with sitagliptin for the combined outcomes of diarrhea, nausea, abdominal pain, and vomiting and found a higher incidence in the metformin group (20.7 percent versus 11.6 percent). When each outcome was looked at individually, it became evident that diarrhea accounted for most of this difference (incidence 10.9 percent versus 3.6 percent) followed by nausea (3.1 percent versus 1.1 percent) and vomiting (1.3 percent versus 0.4 percent).⁷⁷

One RCT compared metformin with saxagliptin and found a higher incidence of diarrhea in the metformin arm (24 percent versus 10 percent).⁷⁸

Metformin versus meglitinides. Four RCTs compared GI adverse events between metformin and a meglitinide (Table 18).^{79-81,197} Composite GI adverse events rates were generally higher in the metformin arm compared with a meglitinide, but one trial⁸⁰ reported higher diarrhea rates, but similar rates for abdominal pain and dyspepsia.

Table 17. Randomized controlled trials comparing metformin with sulfonylureas for gastrointestinal effects

Author, year	Outcome	Event rates (metformin versus sulfonylureas)
Chien, 2007 ⁵⁹	Combined GI events	32% (8/25) versus 13% (3/23)
Kahn, 2006 ³⁸	Combined GI events	38% (557/1454) versus 22% (316/1441)
	Nausea	11.7% (170/1454) versus 6.9% (99/1441)
	Vomiting	5.8% (84/1454) versus 3.1% (45/1441)
	Diarrhea	23.7% (345/1454) versus 9.9% (142/1441)
	Abdominal discomfort	15.4% (224/1454) versus 11.3% (163/1441)
Garber, 2003 ⁶¹	Nausea/vomiting	10.4% (17/164) versus 6.6% (10/151)
	Abdominal pain	6.1% (10/164) versus 4% (6/151)
	Diarrhea	18% (30/164) versus 5.3% (18/151)
Blonde, 2002 ⁶³	Nausea and vomiting	12.4% (19/153) versus 5.5% (9/164)
	Dyspepsia/heartburn	4.6% (7/153) versus 3% (5/164)
	Flatulence	2% (3/153) versus 0% (0/164)
Hermann, 1994 ⁶⁸	Any GI outcome	63% (24/38) versus 32% (11/34)
	Abdominal pain	18% (7/38) versus 6% (2/34)
	Diarrhea	50% (19/38) versus 0 (0/34)
	Nausea	24% (9/38) versus 9% (3/34)
	Withdrawal for GI symptoms	14% versus 0%
Goldstein, 2003 ⁶²	Diarrhea	17.3% (13/75) versus 13.1% (11/84)
Derosa, 2004 ⁶⁰	Nausea and diarrhea	2.4% (2/75) versus 0% (0/73)
Charpentier, 2001 ⁷¹	Diarrhea	7% (5/75) versus 1% (1/150)
DeFronzo, 1995 ⁷⁰	Nausea and diarrhea	1.4% (3/210) versus 1.0% (2/209)
Amador-Licona, 2000 ⁶⁶	Diarrhea and abdominal pain	14.3% (4/28) for metformin; event rates are not reported for sulfonylurea
Garber, 2002 ⁶⁵		metformin (n = 159); glyburide (n = 160)
	Any GI outcome	43% versus 24%
	Diarrhea	15.1% versus 4.4%
	Nausea/Vomiting	6.3% versus 0.6%
	Abdominal pain	5% versus 3.1%
	Dyspepsia	5% versus 2.5%

GI = gastrointestinal

Table 18. Randomized controlled trials comparing metformin with meglitinides for gastrointestinal effects

Author, year	Outcome	Event rates (metformin versus meglitinides)
Lund, 2007 ¹⁹⁷	Combined GI events	70% (65/83) versus 47% (47/82)
Horton, 2004 ⁸⁰	Diarrhea	20.2% (21/104) versus 3.8% (4/104)
	Abdominal pain	6.7% (7/104) versus 6.7% (7/104)
	Dyspepsia	7.7% (8/104) versus 9.6% (10/104)
Derosa, 2003 ⁸¹	Withdrawal for GI symptoms	3.6% (2/56) versus 0% (0/56)
Horton, 2000 ⁷⁹	Withdrawal for GI symptoms	3.4% (6/178) versus 0.6% (1/179)

GI = gastrointestinal

Metformin versus a combination of metformin and thiazolidinediones. Eight RCTs compared the rates of GI adverse events between metformin and a combination of metformin and a thiazolidinedione, generally showing similar rates between the two groups (Table 19).^{49,56,84-88,156}

In studies that showed lower rates of diarrhea in the combination arm, the dose of metformin was lower when used in combination than when used as monotherapy.

Table 19. Randomized controlled trials comparing metformin with a combination of metformin and thiazolidinediones for gastrointestinal effects

Author, year	Outcome	Event rates (metformin versus metformin plus thiazolidinediones)
Kaku, 2009 ⁸⁴	Constipation & Abdominal Pain	2.3% (2/86) versus 2.4% (2/83)
Scott, 2008 ⁸⁵	Combined GI events	9% (8/91) versus 7% (6/87)
Rosenstock, 2006 ⁴⁹	Diarrhea	51% (79/154) versus 47% (73/155) (Minimal difference in rates of nausea, vomiting and dyspepsia)
Stewart, 2006 ¹⁵⁶	Diarrhea	18% (49/272) versus 8% (20/254)
Bailey, 2005 ⁸⁷	Withdrawal due to GI events	5.4% (15/280) versus 3% (9/288)
Weissman, 2005 ⁸⁶	Withdrawal due to GI events	6.8% (26/384) versus 3.1% (12/382)
Gomez-Perez, 2002 ⁸⁸	Combined GI events	OR 1.6 (95% CI 1.2 to 2.2)
	Combined GI events	15.4% (5/35) versus 16.8% (6/35) for low dose combination and 16.8% (6/36) for high dose combination
Perez, 2009 ⁵⁶	Diarrhea	15.3% (32/210) versus 9% (18/201)

CI = confidence interval; GI = gastrointestinal; OR = odds ratio

Metformin versus a combination of metformin and sulfonylureas. Ten RCTs examined GI adverse events comparing metformin and metformin plus a second-generation sulfonylurea.^{36,59,61-63,65,68,70,71,92} One RCT compared subjects with GI adverse events between metformin and a combination of metformin plus glyburide and favored the combination arm.⁵⁹ It reported an incidence of 32 percent for metformin alone versus 7.69 percent in the metformin/lowest dose glyburide combination ($p = 0.021$).⁵⁹ The combination arm had a lower dose of metformin than the metformin monotherapy arm, which may account for this difference.

Six studies that were included from the 2007 CER²¹ compared GI events between metformin versus metformin plus glyburide or glibenclamide.^{36,61,63,65,68,70} Three studies did not significantly favor either arm,^{62,70,92} the others found fewer events in the combination arm for at least one GI adverse event, most commonly diarrhea.^{36,61,63,65,68,71} In general, the combination arm was favored if the doses of metformin in the combination was lower than in the monotherapy arm.

Metformin versus a combination of metformin and DPP-4 inhibitors. Four RCTs compared the incidence of GI adverse events between metformin and metformin plus sitagliptin and there was no clear difference between the two groups (Table 20).^{76,85,93,94} Two RCTs compared the incidence of diarrhea between metformin and metformin plus saxagliptin (Table 20).^{78,95} One RCT reported a higher incidence of diarrhea in the group receiving metformin and high dose saxagliptin than in the group receiving metformin alone or the group receiving metformin and low dose saxagliptin.⁷⁸ A second RCT found a higher incidence of diarrhea in the metformin only group than in the two groups receiving saxagliptin and metformin.⁹⁵

Metformin versus a combination of metformin and meglitinides. One RCT compared diarrhea, abdominal pain, dyspepsia, and nausea between metformin and metformin plus nateglinide.⁸⁰ The incidence of diarrhea and dyspepsia were similar between the treatment groups, but the incidence of abdominal pain was 6.7 percent in the metformin arm compared with 12.4 percent in the combination arm.

Thiazolidinediones versus sulfonylureas. Three RCTs compared diarrhea between pioglitazone or rosiglitazone and either glyburide or its chemical equivalent, glibenclamide, and showed no consistent difference between the groups (Table 21).^{38,100,101,150}

Table 20. Randomized controlled trials comparing metformin with a combination of metformin and DPP-4 inhibitors for gastrointestinal effects

Author, year	Outcome	Event rates (metformin versus combination of metformin and DPP-4 inhibitor)
Williams-Herman, 2009 ⁷⁶	Combined GI events	31% (57/182) versus 29% (53/182) (no difference)
	Diarrhea	7% versus 13% (high dose combination) and 9% (low dose combination)
	Abdominal Pain	4% versus 3% (high dose combination) and 4% (low dose combination)
	Vomiting	0% versus 2% (high dose combination) and 4% (low dose combination)
Scott, 2008 ⁸⁵	Combined GI events	9% (8/91) versus 1% (1/94)
Raz, 2008 ⁹³	Abdominal Pain	7.4% (7/94) versus 10.4% (10/96)
	Gastritis	3.2% (3/94) versus 2.1% (2/96)
	Upper GI Hemorrhage	1 case in metformin versus 0 in combination group
Charbonnel, 2006 ⁹⁴	Combined GI events	10.5% (25/237) versus 11.9% (55/464) (no difference)
Jadzinsky, 2009 ⁷⁸	Diarrhea	7.3% (24/328) versus 9.6% (31/323) versus 6.9% (22/320); metformin versus higher dose saxagliptin combination versus lower dose saxagliptin combination
DeFronzo, 2009 ⁹⁵	Diarrhea	11.2% (20/179) versus 5.5% (10/181) versus 5.8% (11/191) versus 9.9% (19/192); metformin versus higher dose versus intermediate dose versus lower dose saxagliptin combination

GI = gastrointestinal

Table 21. Randomized controlled trials comparing thiazolidinediones with sulfonylureas for gastrointestinal effects

Author, year	Outcome	Event rates (thiazolidinediones versus sulfonylureas)
Jain, 2006 ¹⁰¹	Diarrhea	6.0% (15/251) versus 6.4% (16/251) (no difference)
Hanefeld, 2007 ¹⁰⁰	Combined GI events	5.5% versus 3.4% (no difference) (4mg dose of rosiglitazone)
Kahn, 2006 ³⁸	Any GI outcome	23% (335/1456) versus 21.9% (316/1441)
	Nausea	8% (112/1456) versus 7% (99/1441)
	Vomiting	4% (58/1456) versus 3% (45/1441)
	Diarrhea	9% (129/1456) versus 10% (142/1441)
	Abdominal discomfort	11% (161/1456) versus 11% (163/1441)
Tolman, 2009 ¹⁵⁰	Diarrhea	8.8% (93/1051) versus 7.6% (80/1046)

GI = gastrointestinal; mg = milligram

Thiazolidinediones versus meglitinides. A single RCT compared diarrhea incidence between pioglitazone and repaglinide and reported slightly fewer events in the pioglitazone arm (3 percent versus 5 percent).¹¹⁰

Sulfonylureas versus GLP-1 agonists. One RCT compared constipation between glibenclamide and liraglutide and found a similar incidence: 5/132 versus 15/268 (3.8 percent versus 5.6 percent). The same study also compared diarrhea and found an incidence of 5/132 versus 17/268 (3.8 percent versus 6.3 percent).¹²¹

One RCT compared GI adverse events between glimepiride and liraglutide and found significantly more events in the liraglutide group.¹²² Overall, the incidence of participants with GI adverse events was 49 percent and 51 percent in the liraglutide groups (at 1.2 mg and 1.8 mg respectively) and 26 percent in the glimepiride arm. Nausea was reported by 27.5 percent and 29.3 percent of participants in the liraglutide groups (at 1.2 mg and 1.8 mg respectively) compared with 8.5 percent in the glimepiride group ($p < 0.0001$ for both comparisons). Vomiting was seen in 9.3 percent and 12.4 percent of patients in the liraglutide groups versus 3.6 percent of patients on glimepiride. Diarrhea was seen in 15.5 percent (liraglutide 1.2 mg, $p = 0.0283$), 18.7 percent (liraglutide 1.8 mg, $p = 0.0017$) and 8.9 percent (glimepiride group).

Combination of metformin and thiazolidinediones versus combination of metformin and sulfonylureas. Four RCTs examined GI adverse events between metformin plus a thiazolidinedione and metformin plus a sulfonylurea with inconsistent results (Table 22).^{123,126,128,159}

Table 22. Randomized controlled trials comparing a combination of metformin and thiazolidinediones with a combination of metformin and sulfonylureas for gastrointestinal effects

Author, year	Outcome	Event rates (metformin plus thiazolidinedione versus metformin plus sulfonylurea)
Umpierrez, 2006 ¹²⁶	Diarrhea	4.7% (5/104) versus 6% (6/96) (no difference)
Hamann, 2008 ¹²³	Combined GI events	13% (38/294) versus 18% (54/301)
Derosa, 2005 ¹⁵⁹	Flatulence	4.2% (2/48) versus 2.1% (1/47)
Garber, 2006 ¹²⁸	Combined GI events	10% (16/155) versus 11% (18/159) (no difference)
	Diarrhea	3% (5/155) versus 6% (10/159)
	Abdominal pain	4% (6/155) versus 6% (10/159)

GI = gastrointestinal

Combination of metformin and thiazolidinediones versus combination of metformin and GLP-1 agonists. One RCT compared metformin and rosiglitazone to metformin and exenatide for the individual outcomes of diarrhea and vomiting and found a higher incidence for both outcomes in the exenatide group (diarrhea: 4 percent versus 7 percent; vomiting: 0 percent versus 22 percent, respectively).¹³²

Combination of metformin and thiazolidinediones versus combination of metformin and DPP-4 inhibitors. One RCT compared GI adverse events in the combination of metformin plus rosiglitazone versus the combination metformin plus sitagliptin and did not favor either arm for total GI events or for the specific events of diarrhea, nausea, abdominal pain, and vomiting.⁸⁵

Combination of metformin and sulfonylureas versus combination of metformin and DPP-4 inhibitors. One RCT compared diarrhea, abdominal pain, nausea, and vomiting between metformin with glipizide and metformin with sitagliptin and did not favor either arm.¹³³

Combination of metformin and sulfonylureas versus combination of metformin and meglitinides. One RCT compared diarrhea and constipation between metformin with glyburide and metformin with nateglinide and did not show an overall difference between arms, but did report more dyspepsia in the metformin with glyburide arm (13 percent versus 3 percent).¹⁵²

Combination of metformin and sulfonylureas versus combination of metformin and GLP-1 agonists. One RCT compared metformin and glibenclamide versus metformin and exenatide for vomiting and diarrhea with a similar incidence of adverse events in both groups (vomiting: 1/65 versus 1/63; diarrhea: 1/65 versus 2/63).⁴⁴

Another RCT compared metformin and glimepiride versus metformin and liraglutide for the combined outcomes of nausea, vomiting, and diarrhea and found a higher incidence in the liraglutide group (17 percent versus 40 percent and 44 percent respectively as the total dose of liraglutide increased from 1.2 mg to 1.8 mg).⁹²

Combination of metformin and a basal insulin versus combination of metformin and another insulin. One RCT compared diarrhea incidence between metformin in a combination regimen with either insulin glargine or lispro and neither arm was favored.¹⁴⁵

Combination of metformin and sulfonylureas versus combination of thiazolidinediones and sulfonylureas. Two RCTs compared GI adverse events between a combination of metformin and a sulfonylurea versus a combination of a thiazolidinedione and a sulfonylurea.^{140,142} One RCT compared diarrhea incidence and reported a higher incidence of diarrhea in the metformin combination arm (14.4 percent versus 3.4 percent). A second RCT had consistent results, favoring the thiazolidinedione combination arm compared with the metformin combination arm. It reported higher rates of diarrhea and withdrawals due to diarrhea in the metformin combination arm (diarrhea: 12 percent in the metformin combination arm versus 3 percent in the thiazolidinedione combination arm; withdrawals: 23 percent in the metformin combination arm versus 12 percent in the thiazolidinedione combination arm, respectively).¹⁴⁰

Publication Bias

For each meta-analysis, we examined graphical displays of publication bias and found little. We appreciate the insensitivity of these methods when the number of studies is low. We think it is more relevant to KQ3 to recognize the selective reporting of outcomes. The body of literature about adverse events is smaller than that for efficacy outcomes suggesting selective reporting of adverse event outcomes. Additionally, it is hard to know in the literature where the absence of a statement about an adverse event is evidence that it did not occur, or that it just was not reported in the publication. We conservatively opted to assume that it was just not reported and drew no conclusions from the absence of statements about adverse events.

Gray Literature

Metformin versus sulfonylureas. One study evaluated the safety profile of metformin versus sulfonylurea.¹⁹³ The study reported a higher incidence of GI adverse drug effects in the metformin group (20.3 percent) compared to the sulfonylurea groups (12.9 percent). Hypoglycemia (defined as finger stick glucose < 50 mg/dl) was reported in 3 percent of those treated with sulfonylurea but none in those treated with metformin.

Metformin versus DPP-4 inhibitors. In a pre-approval trial, sitagliptin was tested against metformin in a 24-week trial. Adverse events were very similar except for gastrointestinal side effects which were much higher with metformin (54/364 versus 11/179). The rates of hypoglycemia, cancer, fractures, and cholecystitis were very low in both groups.¹⁹¹ This is likely to be the same data as was published by Williams-Herman.⁷⁶

Metformin versus a combination of metformin and thiazolidinediones. In a pre-approval trial, the addition of a thiazolidinedione to metformin resulted in no increased rate of hypoglycemia when compared to rates with metformin alone.²¹⁷ This differs from the published data which suggests that patients treated with the combination have slightly more hypoglycemia.

In another study, metformin was compared to metformin with rosiglitazone (4 mg and 8 mg) in a 26-week trial in the United States. Hypoglycemia requiring assistance was reported in one patient on 4 mg rosiglitazone, one patient on 8 mg rosiglitazone and no patients in the metformin arm.¹⁸⁹

Metformin versus a combination of metformin and sulfonylureas. The combination of metformin and sulfonylurea was evaluated against metformin in a 28-week trial. Hypoglycemia was reported in 3 percent of patients on metformin, 11 percent of patients on a fixed combination of 250 mg/1.25 mg and 38 percent of patients on 500 mg/2.5 mg. While no patient on metformin had hypoglycemia below 50 mg/dL, 8 of 158 patients in the low-dose combination group and 26 of 168 in the high-dose combination group reported hypoglycemia less than 50 mg/dL. In the same study the frequency of GI adverse events was 43.4 percent with metformin monotherapy, 31.6 percent with the low dose combination ($p = 0.037$) and 38.3 percent with the higher dose combination (difference with metformin not significant).¹⁹⁰ One study evaluated metformin 500 mg and a low-dose combination and a high-dose combination with approximately 160 participants in each group. One patient on metformin reported symptoms of hypoglycemia compared to 22 patients on combination therapy. There were no reports of serious hypoglycemia.

GI adverse events occurred in 39 percent of metformin recipients versus 35 percent of metformin with sulfonylurea recipients.¹⁹²

One study evaluated the safety profile of combination of metformin plus sulfonylurea versus metformin (500 mg).¹⁹³ The study reported a higher incidence of GI adverse effects in metformin group (20.3 percent) compared to in any of the three combination groups (15.9 percent, 12.2 percent and 11.6 percent respectively). Hypoglycemia (defined as finger stick glucose less than 50 mg/dL) was reported in 5 percent, 8 percent and 9 percent of those treated with the combination but none in those treated with metformin.

Metformin versus a combination of metformin and DPP-4 inhibitors. One trial for FDA approval of the combination of metformin and sitagliptin reported on the adverse outcomes of this combination (two dose levels) compared to metformin alone (two dose levels). The rates of hypoglycemia were low in the subjects treated in the combination group (6/372) and similar to that in the metformin groups (3/364). There was a single report of congestive heart failure in the combination group. Cancers were rare and equivalent in the groups as were fractures. Similarly, GI adverse events were reported in 49 participants in the combination groups and 54 in the metformin groups.¹⁹¹ This is probably the same data as was published by Williams-Herman.⁷⁶

Thiazolidinediones versus sulfonylureas. This was a 52-week active-controlled study at different centers in Europe which compared two dosing levels of rosiglitazone to glyburide. Hypoglycemia was reported in 25/207 patients on glyburide compared to 1/200 patients on 2 mg rosiglitazone and 3/191 on 4 mg rosiglitazone. Nearly half of the events in the glyburide arm occurred in the first 14 days of treatment.¹⁸⁹

Another trial evaluated rosiglitazone 2mg twice daily versus glyburide 10 mg twice daily for 26 weeks. No hypoglycemia was reported in the thiazolidinedione group versus 6 of 106 patients in sulfonylurea group. Hypoglycemia requiring assistance was reported by one patient in the sulfonylurea group.²¹⁸ One additional study was double-blind placebo-controlled in which patients were randomized to rosiglitazone 1 mg or rosiglitazone 2mg or placebo and continued concurrent sulfonylurea therapy for 60 weeks in Europe. Hypoglycemia was reported in 2 percent of patients on sulfonylurea alone compared to 3.4 percent and 5.3 percent on low dose thiazolidinedione with sulfonylurea and high-dose thiazolidinedione with sulfonylurea, respectively.²¹⁸

A 52-week, double-blind RCT assessed the risk of hypoglycemia in those treated with a thiazolidinedione and those treated with a sulfonylurea.²¹⁹ A higher incidence of hypoglycemia was reported in patients treated with glyburide (12.1 percent) compared to those treated with rosiglitazone, 2 mg twice daily (0.5 percent) or rosiglitazone 4 mg twice daily (1.6 percent).

Sulfonylureas versus DPP-4 inhibitors. One preapproval trial of sitagliptin compared to glipizide showed markedly higher rates of hypoglycemia with glipizide when compared to sitagliptin (187/584 versus 29/588). The rates of congestive heart failure were low and similar (1 versus 1), as were GI sides effects (69 versus 74), cancer (7 versus 5) and cholecystitis (2 versus 0).¹⁹¹ This is consistent with the published literature.

Applicability

The applicability of this body of studies to the question of harm depends largely on the characteristics of the participants enrolled in the trials and how different the enrolled subjects are from the population of patients with diabetes who may experience harms when treated with these drugs. Additionally, the evidence can only be considered highly applicable if the doses of the drugs administered are comparable to that which is used in practice and the treated patients are monitored at a frequency comparable to that used in practice. We have no concerns about the applicability of these studies regarding the latter two criteria—the tested drug regimens are quite comparable by dose, frequency and monitoring to those used in a usual care setting.

The majority of the evidence about harms of these drugs comes from trials lasting 2 years or less. This duration of exposure of the subjects to the drug is shorter than would typically be seen in practice where these drugs may be prescribed for decades. Nonetheless, for the majority of the harms from the drugs, such as hypoglycemia or lactic acidosis, the incidence rate per year is not expected to increase with the duration of exposure to the drug. It is less clear with other harms like congestive heart failure whether this may be dependent on the duration of exposure. If the harms do increase with exposure time, these relatively short trials are not entirely applicable to addressing this question.

The most pronounced threat to the applicability of these studies to addressing the question about harm is the enrolled population. The vast majority of studies had a mean age of participants in their 50s. Fewer than 10 studies enrolled older participants and these had a mean age in the low 60s. The prevalence of diabetes increases with age and these trials of harms from hypoglycemic agents are not necessarily applicable to older adults in their 70s and 80s or older. Further, the trials were very restrictive in their inclusion criteria, as is necessary for the safety of the participants. Thus, these studies are not necessarily applicable to the broader patient population with diabetes, many of whom have some renal insufficiency and coronary artery disease. The studies' populations were primarily Caucasian, although some of the trials in Asia enrolled only Asian patients. The proportion of participants of African descent was uniformly low (nearly always less than 10 percent), so the applicability of these results to that large patient population cannot be assured.

Key Question 4. Do safety and effectiveness of these treatment options (see list of comparisons) differ across subgroups of adults with type 2 diabetes, in particular for adults age 65 or older, in terms of mortality, hypoglycemia, cardiovascular and cerebrovascular outcomes?

Key Points

- Few studies had sufficient power to assess comparative effectiveness or safety by subgroup. The evidence favoring one medication over another across subgroups is unclear.

Twenty-eight studies reported comparative effectiveness and safety for subpopulations relevant to Key Question 4. Three studies^{179,180,213} focused on a specific population for the study and the others conducted subgroup analyses of larger clinical trials or cohorts.

We included 21 RCTs and 7 cohort studies that addressed this key question. The majority of trials evaluated differences in the outcome of glycemic control by baseline HbA1c.^{75,78,85,93,96,133,136,138,220} Other trial outcomes included weight gain,^{179,221,222} nephropathy,¹⁸⁴ fractures,²¹³ and congestive heart failure.²²³ The cohort study outcomes focused on mortality^{166,169,180,224} and congestive heart failure.^{195,207} None of the studies conducted subgroup analyses on adverse events or mortality by age. We were unable to draw conclusions based on subgroup analyses and studies conducted in population subgroups because of the small number of studies available for each comparison of interest for each subgroup.

The Evidence for Comparative Effectiveness and Safety in Subpopulations

Subpopulations by baseline glycemic control. The majority of studies with subgroup analyses examined differences by baseline HbA1c.^{75-78,85,93,96,133,136,138,220} One RCT of metformin plus nateglinide versus metformin plus glyburide found that in both treatment arms, patients with higher baseline HbA1c had a greater mean decrease in HbA1c than patients with lower baseline HbA1c.¹³⁶ Ten other trials similarly found that among all treatment arms, patients with higher HbA1c had greater HbA1c reduction (see Table 23). One study of metformin versus glibenclamide found that the percent of patients achieving target glucose control did not vary by baseline HbA1c.²²⁵ A study of patients treated with nateglinide plus metformin versus metformin alone found that the subgroup of patients with lower baseline HbA1c treated with high-dose nateglinide plus metformin had increased rates of hypoglycemic symptoms compared with patients with higher baseline HbA1c.⁹⁶ One study investigated the efficacy of sitagliptin versus metformin in terms of HbA1c lowering by baseline HbA1c.⁷⁷

Subpopulations by age, sex or race. Five studies examined the impact of age on glycemic control, but we were unable to draw conclusions regarding comparative medication effectiveness in older adults with diabetes. Five found no difference in the effect on HbA1c,^{75,77,85,93,136} one found that patients over age 46 were more likely to require combination therapy to reach target glucose control than younger patients.²²² One study of the impact of diabetes treatment on congestive heart failure hospitalizations and cardiovascular mortality in patients with baseline New York class II or III heart failure found that among patients over age 64 years, higher rates of heart failure progression were noted in the pioglitazone users compared with glyburide users whereas no significant difference was seen in younger patients.²²³

Six studies examined the impact of sex on glycemic control, and found no differences in the effect on HbA1c.^{75,77,85,93,136,222} However, a retrospective analysis of the ADOPT trial by sex found that women treated with rosiglitazone were at increased risk of fracture relative to those treated with metformin or glyburide (HR 1.57 and 1.61, respectively)²¹³ over a median followup of 4 years. Consistent with the ADOPT trial, the RECORD study reported higher fracture risk in women compared with men (RR 1.82, 95 percent CI 1.37 to 2.41 versus 1.23, 95 percent CI 0.85 to 1.77) in the rosiglitazone plus metformin or sulfonylurea arm, as compared to the metformin plus sulfonylurea active control arm. The fractures occurred predominantly in the upper limb, distal lower limb, and were not hip fractures.¹⁶

Two studies examined the impact of race on HbA1c reduction, and found no impact on glycemic control.^{77,136} A retrospective study of all-cause mortality among patients treated with hypoglycemic agents found that in women, metformin use was associated with lower mortality rate at 1 year than use of sulfonylureas, whereas in men mortality was increased in metformin

users compared to sulfonylurea users.²²⁴ Higher rates of heart failure progression in patients with baseline congestive heart failure were found among men treated with pioglitazone compared with glyburide, but rates were similar among women.²²³ A retrospective study of heart failure development among patients with diabetes treated with metformin, insulin, or sulfonylurea found that women were less likely to develop heart failure than men across all treatment modalities.¹⁹⁵

None of the studies we included assessed the impact of socioeconomic status or education level on glycemic control or outcomes.

Subpopulations by obesity, duration of diabetes, or geographical region. Five studies found no effect of body mass index on HbA1c reduction or glycemic control.^{75,77,85,136,222} A study evaluating rosiglitazone plus metformin combination therapy versus metformin monotherapy found that among patients treated with metformin monotherapy fewer obese patients had at least one adverse event than non-obese patients, most commonly diarrhea and headache.¹⁷⁹ Another study of efficacy at achieving an HbA1c less than 7 percent found that obese patients treated with metformin had greater chance of achieving the targeted HbA1c level without additional agents than patients treated with sulfonylurea or insulin.³⁷ An important consideration in obese patients is medication impact on weight control, and a prospective study found that obese patients allocated to insulin had a greater mean increase in body weight than those allocated to sulfonylurea, and those allocated to metformin, on average, lost weight.²²²

Four studies found no impact of the duration of diabetes on glycemic control.^{75,77,85,93} One study found that among patients treated with glibenclamide, the percent of patients achieving targeted glycemic control varied inversely with duration of diabetes.²²⁵

One RCT compared sitagliptin and metformin and found that glycemic control did not differ by “geographical region” (regions not specified).⁷⁷

Subpopulations by required medication dosage. Two retrospective studies examined outcomes among patients who required higher than median doses of sulfonylurea and metformin and found that high-dose sulfonylurea users (chlorpropamide, tolbutamide, glipizide, and glyburide) had higher risk of heart failure²⁰⁸ and increased mortality¹⁶⁶ than those treated with lower doses of these medications. Notably, high-dose users of metformin were not at elevated risk of heart failure or increased mortality.^{166,208} These findings were from observational studies so there was likely to be residual confounding, related to the patients’ need for higher doses.

Subpopulations by prior comorbid conditions. A retrospective cohort study concluded that patients with a prior diagnosis of ischemic heart disease treated with either sulfonylurea or repaglinide had higher all-cause mortality than those treated with metformin alone after adjusting for age, sex, and comorbidity.¹⁸⁰ A retrospective cohort study of patients with heart failure treated with metformin monotherapy, sulfonylurea monotherapy, or combination therapy found that use of metformin, alone or in combination, was associated with reduced all-cause 1-year mortality compared with sulfonylurea monotherapy (adjusted HR 0.66, 95 percent CI 0.44 to 0.97 and 0.54, 95 percent CI 0.42 to 0.70, respectively). This mortality benefit persisted after mean followup of 2.5 years.¹⁶⁹ No studies in our review specifically reported the comparative effectiveness of medications in patients with other underlying cardiovascular disease risk factors, such as hypertension.

A trial of rosiglitazone versus glyburide for reduction of urinary albumin excretion found that among patients with baseline microalbuminuria (baseline urine albumin to creatinine ratio ≥ 30

ug/mg) there was a correlation between reduction in mean blood pressure and reduction in albumin excretion ($r = 0.875$) for patients treated with rosiglitazone but not glyburide. There was no significant difference in reduction of baseline microalbuminuria between the two groups.¹⁰⁴ No studies included in our review compared the safety and efficacy of diabetes medications by patients' renal function.

Observational studies. Seven cohort studies reported on subpopulations.^{166,169,180,195,207,215,224} Three studies only reported analyses adjusted for several key patient characteristics but did not specifically report differences by group.^{166,169,207}

Two observational studies reported on mortality in subpopulations. One retrospective cohort study included 8,494 participants in a nationwide population-based followup study of Danish patients with a myocardial infarction. Among women, the use of metformin was associated with a lower mortality rate than the use of sulfonylureas (adjusted 1-year HR 0.49, 95 percent CI 0.30 to 0.79), whereas among men the risk appeared to be increased (adjusted 1-year HR 1.82, 95 percent CI 1.25 to 2.64).²²⁴ Another study favored metformin over sulfonylurea or repaglinide for all-cause age-adjusted mortality in people with prior ischemic heart disease.¹⁸⁰

One study supported the finding from a RCT²²³ that men were more likely to develop congestive heart failure than women regardless of pharmacologic treatments, which included various monotherapy and combination therapies for the cohort study.¹⁹⁵

One cohort study of 84,339 patients from British Columbia, Canada, compared fracture rates in users of pioglitazone, rosiglitazone and sulfonylureas in men and women. In women, the overall fracture rate among users of any thiazolidinedione was greater than sulfonylureas (adjusted HR 1.34, 95 percent CI 1.10 to 1.64), but this was not the case for men. For both women and men, pioglitazone use was associated with higher risk of peripheral fracture (defined by the International Classification of Diseases, 9th Edition [ICD-9] codes) compared with sulfonylurea (adjusted HR for women 1.77, 95 percent CI 1.32 to 2.38 and adjusted HR for men 1.61; 95 percent CI 1.18 to 2.20). Rosiglitazone use was not associated with increased fracture risk in men or women.²¹⁵

Table 23. Results from randomized controlled trials reporting outcomes in a subpopulation

Subgroup	Outcome				
	HbA1c	Weight	CHF	Fractures	Nephropathy
Elevated baseline HbA1c	<p>Met vs. met + sita:^{75,93} Favors met + sita</p> <p>Met vs. sita:⁷⁷ Conclusion unclear</p> <p>Met vs. met + saxa:⁷⁸ Favors met + saxa</p> <p>Met vs. met + meg:⁹⁶ Favors met + meg</p> <p>Met + rosi vs. met + sita:⁸⁵ Favors met + rosi</p> <p>Met + SU vs. met + meg:¹³⁶ Conclusion unclear</p> <p>Met + glipizide vs. met + sita:¹³³ Favors met + glipizide</p> <p>Met + SU vs. met + premixed:¹³⁸ Favors met + premixed</p>	No evidence	No evidence	No evidence	No evidence
Age	<p>Met vs. sita:⁷⁷ Conclusion unclear</p> <p>Met vs. met + sita:^{75,93} Favors met + sita across age groups</p> <p>Met + rosi vs. met + sita:⁸⁵ Conclusion unclear</p> <p>Met + SU vs. met + meg:¹³⁶ Conclusion unclear</p>	No evidence	TZD vs. SU: ²²³ Favors SU over pio in patients over age 64 with baseline CHF	No evidence	No evidence

Table 23. Results from randomized controlled trials reporting outcomes in a subpopulation (continued)

Subgroup	Outcome				
	HbA1c	Weight	CHF	Fractures	Nephropathy
Sex	<p>Met vs. met + sita:^{75,93} Favors met + sita regardless of sex</p> <p>Met + TZD vs. met + sita:⁸⁵ Conclusion unclear</p> <p>Met + SU vs. met + meg:¹³⁶ Conclusion unclear</p> <p>Met vs. sita:⁷⁷ Conclusion unclear</p>	<p>Met vs. met + pio:²²¹ Favors met + pio for weight control regardless of gender</p>	<p>TZD vs. SU:²²³ Favors SU over pio in men with baseline CHF; Women less likely to develop heart failure than men across all treatment modalities</p>	<p>Met vs. TZD vs. SU:^{213,215} Glyburide and met favored over rosi in pre- and post-menopausal women; difference in men unclear</p>	No evidence
Duration of diabetes	<p>Met vs. met + sita:^{75,93} Favors met + sita regardless of duration</p> <p>Met + TZD vs. met + sita:⁸⁵ Conclusion unclear</p> <p>Met vs. sita:⁷⁷ Conclusion unclear</p>	No evidence	No evidence	No evidence	No evidence
Prior treatment	<p>Met vs. met + SU:⁹² Favors met + SU regardless of prior treatment.</p> <p>Met + insulin glargine vs. met + premixed:¹⁴⁵ Favors met + premixed regardless of prior number of injections</p> <p>Met + TZD vs. met + meg:¹³¹ Conclusion unclear</p> <p>Met vs. sita:⁷⁷ Conclusion unclear</p>	No evidence	<p>TZD vs. SU:²²³ Favors SU over pio in patients with baseline CHF and insulin use.</p>	No evidence	No evidence

Table 23. Results from randomized controlled trials reporting outcomes in a subpopulation (continued)

Subgroup	Outcome				
	HbA1c	Weight	CHF	Fractures	Nephropathy
Obesity	<p>Met vs. SU:³⁷ Favors SU among obese patients in long-term treatment (over 9 years)</p> <p>Met vs. met + rosi:¹⁷⁹ Favors met + rosi among overweight and obese patients</p> <p>Met vs. met + sita:^{75,93} Favors met + sita across BMI groups</p> <p>Met + rosi vs. met + sita:⁸⁵ Conclusion unclear</p> <p>Met + SU vs. met + nateglinide:¹³⁶ Conclusion unclear</p> <p>Met vs. sita:⁷⁷ Conclusion unclear</p>	<p>Met vs. SU:²²² Obese patients lost more weight with met</p> <p>Met vs. met + rosi:¹⁷⁹ Favors met for weight loss among obese patients</p>	No evidence	No evidence	No evidence
Geo-graphic region	<p>Met vs. sita:⁷⁷ Conclusion unclear</p>				
Elevated DBP	No evidence	No evidence	No evidence	No evidence	Pio vs. SU: ¹⁸⁴ Conclusion unclear
Race	<p>Met + SU vs. met + nateglinide:¹³⁶ Conclusion unclear</p>	No evidence	No evidence	No evidence	
Baseline proteinuria	No evidence	No evidence	No evidence	No evidence	<p>Pio vs. SU:¹⁸⁴ Conclusion unclear</p> <p>Rosi vs. SU:¹⁰⁴ Conclusion unclear</p>

BMI = body mass index; CHF = congestive heart failure; DBP=diastolic blood pressure; HbA1c = hemoglobin A1c; Meg = meglitinides; Met = metformin; Pio = pioglitazone; Premixed = premixed insulin; Rosi = rosiglitazone; Saxa = saxagliptin; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione

Quality Assessment

Quality assessment of trials. Out of the 143 trials included in this report, only six were described as non-randomized trials and two were a crossover study (Appendix G, Table 13). Among the 136 RCTs, 35 percent described their randomization scheme and another 58 percent were described as being double-blinded. About one-third of all double-blinded RCTs also described the steps taken to ensure blinding. The majority of trials (74 percent) described the withdrawals and dropouts. Although we evaluated the quality of the studies included in our 2007 CER, we used a different approach for the additional articles identified for this update. Among the 55 trials included from the 2007 review, only about one third of them received the highest two quality scores (4 or 5) on the five-point scale used in our update. Among the 88 trials identified for the update, 37 percent were rated as “good” quality, 46 percent as “fair” quality and 17 percent as “poor” quality.

Quality assessment of observational studies. We assessed the quality of the 26 observational studies newly identified for the update (Appendix G, Table 14). In the 2007 review, we did not assess the quality of observational studies. Of the newly identified studies, 42 percent reported the study setting or study population from which the study sample was drawn, 88 percent described inclusion/exclusion criteria, and 73 percent provided at least some description of key characteristics of the study population. Thirty-one percent of the studies provided details about treatment, which included treatment type, dose, timing and duration of medication. Seventy-seven percent of studies described and objectively measured the outcomes of interest. The majority of studies conducted appropriate statistical analyses and presented results adjusted or stratified for differences in groups or stated that the groups were comparable at baseline. Only five of the prospective cohort studies described the number of participants who were lost to followup after the start of the period of observation. Twenty-five of 26 observational studies were rated as having fair or good overall quality.

Articles Reporting More Than One Study

Nine studies reported on more than one study (see Table 24).²²⁶⁻²³⁴ Since many of these studies pooled data from studies already included in our review, we did not abstract that data. For articles that pooled data from studies not included in our review, we abstracted and reported the results. The results from these studies are consistent with the findings from our review.

Table 24. Summary of studies reporting on more than one study

Author, year	Results of pooled studies if not duplicated or already in our report
Belcher, 2004 ²²⁶	Mean blood pressure was slightly reduced by all treatments, with pioglitazone treatment resulting in the largest falls (approximately 1.5 mmHg). Hospitalizations for cardiac or cerebrovascular events were similar with the different treatments. Overall mortality was 7 of 1857 for pioglitazone and 10 of 1856 for non-pioglitazone treatments, of which 3 and 6 were cardiac deaths, respectively. The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments.
Khan, 2004 ²²⁷	Pioglitazone, alone or combined with metformin or sulfonylurea, resulted in mean decreases in triglycerides (9 to 11%), and mean increases in HDL cholesterol (17 to 20%).
Davidson, 2004 ²²⁸	Individual studies were included in the report
Perez, 2004 ²²⁹	This study mostly discusses subfractionations of lipids. They do state that pioglitazone in combination with metformin or sulfonylurea was significantly associated with an increase in HDL after 24 weeks. For pioglitazone plus metformin only, LDL increased from baseline significantly.
Belcher, 2005 ²³⁰	Individual studies were included in the report
Belcher, 2005 ²³¹	Individual studies were included in the report
Charbonnel, 2005 ²³²	Individual studies were included in the report
Ceriello, 2005 ²³³	Individual studies were included in the report
Rendell, 2003 ²³⁴	Individual studies were included in the report

HDL = high density lipoprotein; LDL = low density lipoprotein; mmHg = millimeters of mercury

Discussion

This systematic review addresses the comparative effectiveness and safety of diabetes medications used most frequently in the United States as monotherapy and in combination therapy with each other and with insulin preparations. This review updates and adds to a previous comparative effectiveness review (CER)²¹ published in 2007 comparing the effectiveness and safety of oral diabetes medications, mainly as monotherapy.

Prior to beginning this update, we conducted an extensive preliminary literature review and assessed evidence gaps identified in the 2007 review. We built upon the prior systematic review by focusing on the head-to-head comparisons of medications that should be of greatest relevance to clinicians and their patients (Table 2). We broadened the scope by including two newer medication classes, namely the Glucagon-like peptide-1 (GLP-1) receptor agonists and the Dipeptidyl peptidase-4 (DPP-4) inhibitors and two-drug combinations of medications. We identified 166 articles, which included 75 trials and 19 observational studies that have been published since we completed our 2007 review. We included 19 articles with newer medication class comparisons, 77 articles that contained either metformin or a thiazolidinedione in combination with another medication, and 8 articles with comparisons that included insulin preparations in combination with oral medications (Table 2). Our comprehensive review of the newer medications classes in comparison to other medications and comparisons of combination therapies is an important contribution to the literature because it is the first to address this many comparisons for a wide range of outcomes in patients with type 2 diabetes mellitus.

We defined our key questions similarly to the 2007 review, focusing on intermediate outcomes (Key Question 1), long-term clinical outcomes (Key Question 2), adverse events (Key Question 3) and subpopulations (Key Question 4). As expected, intermediate clinical outcomes such as hemoglobin A1c (HbA1c) levels were studied more frequently in randomized controlled trials (RCTs) than long-term clinical outcomes of diabetes, with 121 RCTs included in Key Question 1 about glycemic control and other intermediate outcomes, 66 articles that applied to Key Question 2 on long-term clinical outcomes, 107 articles for Key Question 3 on adverse events, and 28 articles that contained information for Key Question 4, addressing medication effectiveness and safety in subpopulations.

Key Findings and Implications

Overall, we were unable to definitively support one drug or combination of drugs over another for mortality, macrovascular and microvascular complications of diabetes. Compared with other medications, metformin alone and in combination, had the highest benefit to risk ratio for intermediate outcomes, with similar efficacy for HbA1c reduction as other drugs, but less weight gain and less risk of hypoglycemia.

Intermediate Outcomes

Hemoglobin A1c (HbA1c). Most diabetes medications (metformin, thiazolidinediones, sulfonylureas, and repaglinide) reduced HbA1c to a similar degree by about 1 absolute percentage point when compared with baseline values. Metformin reduced HbA1c more than the DPP-4 inhibitors as monotherapy by about 0.4 absolute percentage points. Combination therapies with metformin (such as metformin plus thiazolidinediones, metformin plus sulfonylureas, and metformin plus DPP-4 inhibitors) generally were more effective at reducing

HbA1c compared with metformin monotherapy by about 1 absolute percentage point. These results were consistent with the 2007 systematic review,²¹ except that we did not have any data on the DPP-4 inhibitors at that time because they were not yet Food and Drug Administration (FDA)-approved. Although we included comparisons with the GLP-1 agonists, evidence for these comparisons was graded as insufficient or low, limiting our ability to draw firm conclusions. Although we could not draw firm conclusions on the comparative effectiveness of 2-drug combinations due to few head to head studies, we did find that most combination therapies showed similar reductions in HbA1c.

Two other recent systematic reviews compared HbA1c with add-on treatments to metformin.^{235,236} One review identified 16 placebo-controlled trials and 11 comparisons with active comparators of metformin combination therapy and concluded that sulfonylureas were superior to thiazolidinediones in reducing HbA1c in combination with metformin.²³⁵ In our pooled analysis of direct comparisons, we did not detect a significant difference in these combinations, which was confirmed in a recent network meta analysis.²³⁶ Our review adds to these recently published reviews by including add-on therapies to thiazolidinediones, including more articles and additional meta-analyses.

Weight. Diabetes medications varied in their effects on body weight. Notably, weight gain was small to moderate, even in the longer duration RCTs such as U.K. Prospective Diabetes Study (UKPDS)⁸ and A Diabetes Outcome Progression Trial (ADOPT)³⁸ (less than 5 kg). However, even small amounts of weight gain (5 percent to 10 percent of body weight) may be associated with increased insulin resistance.²³⁷

Metformin consistently had a more favorable effect on weight when compared with other diabetes medications such as thiazolidinediones, sulfonylureas, and DPP-4 inhibitors. As monotherapy, metformin was associated with between-group differences of -2.6 kg when compared with thiazolidinediones, -2.7 kg when compared with sulfonylureas and -1.4 kg when compared with DPP-4 inhibitors. Our results on weight related to comparisons among thiazolidinediones, metformin, and sulfonylureas were consistent with the 2007 review, which showed weight gain for thiazolidinediones and sulfonylureas when compared with placebo, and weight neutrality when metformin was compared with placebo.²¹ The findings on the GLP-1 agonists and their associated weight loss were similar with another systematic review.²³⁸

We also found high strength of evidence for some combination therapies. For example, metformin plus sulfonylurea had a slightly more favorable effect on weight than either metformin plus a thiazolidinedione or a thiazolidinedione plus a sulfonylurea. Drug effects on weight may impact the choice of drug added for second line combination therapy in a patient not well controlled on a single agent. One explanation for metformin's favorable effect on weight is that it was due to the removal of pretrial medications that increased weight in the run-in period. This suggests that a beneficial effect on weight is seen in direct comparisons between medications only when the other medication has a clearly adverse effect on weight. The mechanism of weight loss for the GLP-1 agonists is not yet well understood, but animal studies suggest a centrally mediated anorectic effect of GLP-1.^{239,240}

Lipids. Effects on lipid levels varied across medication type, but most effects were small to moderate. For instance, pooled analyses showed between-group differences of around 5 to 10 mg/dL in low-density lipoproteins (LDL), 10 to 30 mg/dL in triglycerides (TG), and 3 to 5 mg/dL in high-density lipoproteins (HDL).

In general, we found that metformin had favorable effects on all the lipid classes; it decreased LDL and TG, and modestly increased HDL. Metformin decreased LDL relative to sulfonylureas, rosiglitazone and pioglitazone, and decreased TG relative to sulfonylureas and rosiglitazone. However, pioglitazone decreased TG more than metformin. Compared with metformin alone, the combination of rosiglitazone and metformin increased LDL and HDL, but also increased TG. The addition of pioglitazone to metformin also increased HDL but decreased TG over the combination of metformin and a sulfonylurea. The addition of DPP-4 inhibitors to metformin did not have an effect on HDL relative to metformin monotherapy. Our updated review contributes to the literature by including DPP-4 inhibitors and GLP-1 agonists for lipid outcomes. However, we found insufficient or low strength of evidence for most of these comparisons because of the limited number of studies. Similar to our 2007 review,²¹ we noted that one medication or class may have favorable effects on one lipid outcome and unfavorable effects on another lipid outcome. For instance, rosiglitazone increased LDL more than pioglitazone, and increased HDL less than pioglitazone, but both favorably decreased TG. Varying effects on lipid fractions such as these may account for differences in cardiovascular risk between medications. Decisions regarding medications that may adversely affect lipids are important because of the importance of cardiovascular disease risk reduction in patients with diabetes.²⁴¹

Long-Term Clinical Outcomes

Despite the inclusion of two additional large RCTs^{16,38} and 39 other studies since the 2007 systematic review, we found, overall, low or insufficient strength of evidence to support conclusions about the comparative effectiveness of diabetes medications, either in monotherapy and combination therapy, on all-cause mortality, or macrovascular and microvascular long-term diabetes complications. Compared with the 2007 review, we have additional trials for each drug-drug comparison specifically for metformin versus a thiazolidinedione, metformin versus a sulfonylurea, and comparisons with meglitinides.

Using the trials identified in the 2007 review, Selvin et al. conducted meta-analyses of each drug versus any other drug comparators.²⁴² Treatment with metformin was associated with a decreased risk of ischemic heart disease (pooled OR 0.74; 95 percent CI 0.62 to 0.89) compared with any other oral diabetes agent or placebo, although the results for all-cause mortality and cardiovascular morbidity were not significant. Rosiglitazone was the only diabetes agent associated with an increased risk of cardiovascular morbidity or mortality when compared to any other comparator or placebo, but this result was not statistically significant and had a wide confidence interval.²⁴²

In September 2010, the FDA placed restrictions on the use of rosiglitazone, through a Risk Evaluation and Mitigation Strategy, which in part, will require clinicians to attest to and document that the drug's benefits outweigh the cardiovascular risks. This decision was made after a federal medical advisory panel concluded that rosiglitazone was associated with myocardial ischemia, but voted to keep it on the market.²⁴³ Their conclusion was based on recent observational data^{18,210} and meta-analyses by Nissen and Wolski,^{15,19} as well as increased understanding of the pharmacology of rosiglitazone.²⁴⁴ Although the FDA acknowledged the limitations of the study designs, there was little evidence to clearly disprove the concerns.²⁴⁵ Other analyses including the original 2007 review^{21,242,246,247} have not shown an elevated risk of myocardial ischemia, but had very imprecise point estimates.

A notable addition to this update was the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial, which reported that the combined arms of

rosiglitazone plus metformin and rosiglitazone plus sulfonylurea were noninferior to metformin plus sulfonylurea for the primary endpoint of hospitalization or death from cardiovascular disease.¹⁶ However, these findings were inconclusive for myocardial infarction, for which there was a nonsignificant slightly increased risk in the two arms that included rosiglitazone (combined with metformin or sulfonylurea).¹⁶ As the FDA acknowledged, the RECORD trial was open label with a noninferiority design which may have limited its ability to ascertain the cardiovascular effects of rosiglitazone.²⁴⁵

Our updated review informs the debate around rosiglitazone by providing a comprehensive comparative risk and benefit assessment in relation to all other hypoglycemic agents on a wide range of outcomes, not only cardiovascular ischemic risk. We followed a prespecified protocol and engaged a research team that was not invested in either side of the rosiglitazone debate. Other than the risk of heart failure associated with the thiazolidinediones, we found no conclusive evidence of excess ischemic cardiovascular risk associated with rosiglitazone, consistent with the original review. However, the methods for this review differed from those by Nissen and Wolski.^{15,19} We included studies that occurred only in people with type 2 diabetes and had active comparators, while Nissen et al. included studies in people with other chronic diseases and placebo-controlled trials. In light of the potential ischemic risk of rosiglitazone and the multiple other available medications to treat diabetes, clinicians will need to determine when the benefits of rosiglitazone outweigh the potential risk for individual patients, in keeping with the FDA's recommendations.

In addition to comparisons with the controversial drug, rosiglitazone, we included other drugs and comparisons of high clinical interest for long-term clinical outcomes. Several large, well-done cohort studies concluded that the risk of all-cause mortality and cardiovascular disease morbidity and mortality was decreased for metformin compared with sulfonylureas, either alone or in combination with other medications, consistent with the analysis by Selvin et al.²⁴² However, the large A Diabetes Outcome Progression Trial (ADOPT),³⁸ which followed participants for a median of 4 years, did not identify any difference in risk between the sulfonylurea and metformin arms. The cohort studies are subject to confounding by indication, as sicker patients may be more likely to take sulfonylureas, and use them in combination. However, trials like ADOPT³⁸ often exclude patients with comorbidities who are at highest risk for long-term complications.

Unfortunately, no studies reporting the outcome of retinopathy met our inclusion criteria. In the 2007 review, six studies reported this outcome, which were all excluded from this updated review because participants were either taking additional background medications or because there was no comparison of interest (e.g., gliclazide versus glibenclamide). In the 2007 review, three studies reported on the outcome of retinopathy. The most notable study was the U.K. PDS, which reported no difference in progression to retinopathy between a sulfonylurea and metformin at 12 years of followup.⁸ Unfortunately, we found no additional studies examining this clinically important outcome.

Also, few studies reported on the outcomes of nephropathy or neuropathy. We found pioglitazone had greater reductions in the albumin-to-creatinine ratio as compared with metformin, with unclear implications for long-term effects on diabetic nephropathy or chronic kidney disease progression. We were unable to make conclusions about neuropathy because of small sample sizes and inconsistent definitions of the outcome. Because few studies have considered neuropathy and its profound implications for patient quality of life, this will be an important area for future research.

The paucity of robust evidence on cardiovascular outcomes and other important clinical outcomes for diabetes medications may reflect the emphasis of most studies on glycemic control, a surrogate marker, for drug approval. Future research and longer studies will be needed to address this evidence gap.

Adverse Events

We focused our review on the comparative safety of diabetes medications as monotherapy and in combination therapy, and refer readers to our 2007 review for additional details about specific adverse effects reported in placebo-controlled trials. In this update, we confirmed the elevated risk of hypoglycemia associated with sulfonylureas, either alone or in combination, compared with the other hypoglycemic agents. For example, we showed a more than four-fold higher risk of hypoglycemia associated with sulfonylureas compared with metformin alone, and an almost 6-fold higher risk of hypoglycemia for metformin plus a sulfonylurea compared with metformin plus a thiazolidinedione. We also demonstrated that the newer drug class, DPP-4 inhibitors had a lower risk of hypoglycemia than sulfonylureas, and a risk comparable to that of metformin.

We confirmed a doubling of the risk of heart failure with the thiazolidinedione class of medications, particularly compared with sulfonylureas, which was also reported in two recent meta-analyses.^{248,249} In fact, both the thiazolidinediones, rosiglitazone and pioglitazone, are contraindicated in patients with serious or severe heart failure (Stage 3 or Stage 4) according to the FDA boxed warnings on the thiazolidinediones.^{250,251} The excess deaths and hospitalizations associated with heart failure with the thiazolidinediones in RECORD¹⁶ indicates that heart failure induced by thiazolidinediones is clinically important.

We included four new safety outcomes in addition to the others we addressed in the 2007 review: macular edema, cholecystitis, pancreatitis, and fractures, because of safety concerns that emerged after the review. The 2007 review reported an increased risk of cholecystitis with pioglitazone in an unpublished pooled analysis from the FDA.²¹ However, in this updated review we found no additional evidence on this outcome for the comparisons of interest. Several case reports and case series have reported spontaneous macular edema associated with the thiazolidinedione class.²⁵²⁻²⁵³ However, clinical trials are underpowered to detect rare adverse events and hence we did not detect any significant difference in the rates of macular edema, as we only identified one trial reporting on this outcome. A recently published prospective cohort study in the Kaiser Permanente database of over 17,000 users of the thiazolidinediones reported an increased odds of macular edema with the thiazolidinediones (OR 2.6; 95 percent CI 2.4 to 3.0) compared to nonusers, significant even after adjustment for age and glycemic control. Notably, this cohort study also reported an increased risk of macular edema with insulin and meglitinides.²⁵⁴

Patients with diabetes may have an increased baseline risk of acute pancreatitis.²⁵⁵ The current drug labels for exenatide and sitagliptin have been strengthened with information from spontaneous post-marketing reports of severe pancreatitis including hemorrhagic pancreatitis occurring after exenatide therapy.²⁵⁶ The clinical trials with the GLP-1 agonists may have been underpowered to detect these rare occurrences of pancreatitis. However, a recent claims database study failed to show any significant relationship between the GLP-1 agonists, DPP-4 inhibitors and pancreatitis.²⁵⁷

Our results for lactic acidosis support the results from the 2007 review, as well as the Cochrane systematic review on this topic²⁵⁸ showing no increased risk of lactic acidosis among

metformin users. The Cochrane review reported similar rates between metformin users (5.1 cases per 100,000 patient-years) and those on other oral hypoglycemic agents or placebo (5.8 cases per 100,000 patient-years). Further, there was no statistically significant difference in the net change of lactate levels from baseline in metformin users compared to those on other oral hypoglycemic agents or placebo suggesting no increased risk of lactic acidosis with metformin compared to other oral hypoglycemic agents or placebo.²⁵⁸

As with the 2007 systematic review, we evaluated cancer as an outcome. We included four trials with inconclusive results. One retrospective cohort study not included for this outcome, because of uneven use of insulin, evaluated cancer mortality among the sulfonylurea cohort compared to the metformin cohort using the administrative data from Saskatchewan Health, Canada.²⁵⁹ The mortality from cancer was higher in the sulfonylurea cohort (9.7 per 1000 person-years) than the metformin cohort (6.3 per 1000 person-years), with a hazard ratio for cancer mortality of 1.3 (95 percent CI 1.1 to 1.6), adjusted for age, sex, insulin use, and comorbidities. This study was limited by the use of administrative data and high risk for residual confounding. Although we did not identify additional evidence about diabetes medications and cancer risk, several recent studies have highlighted that this is an area of active research.^{260,261} In particular, a large German cohort study published in 2009 showed a positive association between cancer incidence and insulin for all insulin types. Another study suggested a relationship between cancer risk and treatment with insulin glargine compared with human insulin,²⁶⁰ while another study did not observe the association.²⁶² A recent study extracted cancer diagnosis information from ADOPT and RECORD, with nearly 39,000 person-years of drug exposure, and showed no advantage of metformin over rosiglitazone and sulfonylureas in terms of cancer rates.²⁶³

We found high strength of evidence for comparative safety in terms of fracture risk. The RECORD study reported significantly increased risk of upper and lower limb fractures in women randomized to rosiglitazone combination therapy arms compared with metformin plus sulfonylureas. A prior systematic review that included ten studies evaluating the long-term effect of thiazolidinediones on fracture risk showed a significant increase in fracture risk, most apparent in women.²⁶⁴ Fractures reported with the thiazolidinediones have been mainly those of the upper and lower limb and not hip fractures. Several recent observational studies have also reported an increased risk of fractures with the thiazolidinediones among men as well, but the risk appears to be higher among women and those of advanced age.²⁶⁵

We confirmed the results of our 2007 review showing more frequent gastrointestinal adverse events for metformin compared with thiazolidinediones and sulfonylureas.²¹ We also reported higher gastrointestinal side effects with metformin compared with the newer DPP-4 inhibitors, but graded the strength of evidence as low because of inconsistency of effects.

Two-Drug Combinations, Including Addition of Insulin Preparations

In this update, we included comparisons of two-drug combinations of medications that contained either metformin or a thiazolidinedione in combination with another medication, two-drug combinations compared to metformin alone, and combinations of a medication with either basal or premixed insulin preparations compared with non-insulin two-drug combinations (Table 2). Overall, we found that most combinations of two drugs when compared to monotherapy had additive effects, both in terms of improved glycemic control, but also risk for adverse events and weight gain, confirming the 2007 review and other reviews.²¹

Comparative benefit of a two-drug combination over another was less clear, and several combinations had evidence of similar effects on glycemic control. Our conclusion is similar to a recent network meta-analysis of the effect of non-insulin medications added to metformin.²³⁶ One combination comparison favored metformin plus GLP-1 analogs over metformin plus DPP-4 inhibitors, showing a 0.6 absolute percentage point greater reduction in HbA1c. The clinical meaning of this small between-group difference is unclear. Despite little to no difference in HbA1c among the combination therapies, we found that some combinations clearly had increased risk for adverse events and weight gain. Thiazolidinediones in combination with either metformin or sulfonylureas increased weight gain compared with metformin plus sulfonylurea. In contrast, metformin plus a GLP-1 agonist decreased weight compared with several other two-drug combinations, but we found low strength of evidence because of the paucity of studies using the same comparators (see below).

Although this review does not provide a comprehensive review of the addition of insulin preparations to oral medications, we did include several clinically relevant comparisons. We were unable to draw any firm conclusions about the use of premixed insulin preparations compared with basal insulin, in combination with oral agents, with regard to glycemic control or long term clinical outcomes. There was a modestly lower risk of hypoglycemia when metformin was combined with a basal insulin rather than a premixed insulin preparation, confirming a recent CER on premixed insulin analogues, also commissioned by AHRQ.²⁶⁶ In addition, two recent systematic reviews compared NPH insulin with longer-acting synthetic insulins, glargine or detemir. Most studies had combined insulin with oral medications. They reported no difference in glycemic control between the two insulin products, and also found slightly lower hypoglycemia with the longer-acting insulins.^{267,268}

Newer Diabetes Classes of Medications: DPP-4 Inhibitors and GLP-1 Agonists

Eight articles contained comparisons with the new GLP-1 receptor agonists, exenatide or liraglutide, and 12 articles contained comparisons with the DPP-4 inhibitors, sitagliptin or saxagliptin, either as monotherapy or combination therapy. The American Diabetes Association Consensus/European Association for the Study of Diabetes consensus statement has suggested the use of a GLP-1 receptor agonist as an add-on treatment to metformin,²² a comparison of interest we included for this updated review, but did not have explicit recommendations for the DPP-4 inhibitor class. The American Association of Clinical Endocrinologists/American College of Endocrinology's consensus algorithm recommends consideration of a DPP-4 inhibitor either as initial monotherapy or second line therapy, and a GLP-1 agonist as initial combination therapy with metformin when the HbA1c is greater than or equal to 7.6 percent.²³

We found that the DPP-4 inhibitors improved HbA1c to a lesser extent than metformin as monotherapy, but that when added to metformin there was improved HbA1c without additional hypoglycemia risk. These findings are consistent with a Cochrane systematic review²⁶⁹ and another recent systematic review.²⁷⁰

The majority of comparisons with the GLP-1 agonists for the intermediate outcomes (KQ1) were graded with low strength of evidence because of few studies within each comparison, and evidence was insufficient for the long-term outcomes and most safety outcomes. Despite this limitation, the GLP-1 agonists combined with metformin showed similar HbA1c reduction, when compared to metformin plus basal insulin or metformin plus a thiazolidinedione. In addition, the GLP-1 agonists showed decreases in weight compared with sulfonylureas alone, as well as in

combination with metformin compared with other standard combination therapies. The largest recent systematic review of the GLP-1 agonists identified 21 RCTs (six unpublished) and showed a reduction in HbA1c by one absolute percentage point in comparison with placebo, with weight loss, as well as a low risk of hypoglycemia.²³⁸ Since exenatide's release, the FDA published alerts about postmarketing case reports of pancreatitis²⁷¹ and acute renal failure and insufficiency.²⁷² In the studies we included, the event rates for these complications were too low to draw any conclusions.

Limitations

Several important limitations to our updated systematic review deserve mention. Because this was an update of a comprehensive review published in 2007, we focused our update a priori on studies with active control comparators, which are most relevant for clinical practice. Placebo-controlled trials had been included in the original 2007 review. However, the majority of placebo-controlled trials are short-term and lacking long-term outcomes. However, the exclusion of placebo-controlled trials has implications for the review, including missed rare adverse events, such as macular edema and acute pancreatitis. To conclude from an active-control study that one medication is more effective than another requires prior knowledge that the active-control drug has been studied previously and is known to be more effective than placebo. Because this was an update of the 2007 review that had included placebo controlled trials, for most drug comparisons this was probably true.²⁷³ However, this assumption may be less valid for the newer medications of saxagliptin, sitagliptin, nateglinide, exenatide and liraglutide, where evidence from other systematic reviews, such as Cochrane Reviews, will be also be helpful in making conclusions, and further studies will be needed.

In addition, our inclusion criteria required that all studies fit into one or more of the prespecified comparisons of interest (Table 2), which identified specific drug-drug or two-drug comparisons. For example, studies that included any number of “background medications” were excluded. Our rationale was to avoid contamination by use of background medications with unclear interactions with the intervention medications. This was especially important because of our goal of evaluating two-drug combinations. Applying the inclusion criteria, which required prespecified comparisons of interest, had several implications. This criteria required the exclusion of several large trials,^{8,9,12,72-74,274-277} some of which compared HbA1c lowering strategies, not individual medications, as well as some smaller trials and observational studies. Of note, the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study was included in the 2007 systematic review but excluded from this updated review.²⁷⁴ Another unintended consequence of requiring these prespecified comparisons of interest was that some of the recent studies of exenatide²⁷⁸⁻²⁸¹ as add-on therapy to oral medications did not fit our inclusion criteria.

Another implication of the requirement of specific medication comparisons was the exclusion of several case-control studies that did not report outcomes of interest by drug comparison. Although we applied very broad search terms and did not exclude studies by study design, we only identified seven case control studies and six of these were subsequently excluded from the review because they did not report their results to fit with the prespecified drug comparisons of interest for this review. For example, five studies²⁸²⁻²⁸⁶ compared a drug of interest with any other unspecified drug for an adverse event outcome, and this was not a comparison of interest.

We selected key questions focused on intermediate and long-term clinical outcomes through an extensive topic refinement process at the beginning of this process, which involved input from stakeholders on the Technical Expert Panel. Diabetes care is a rapidly growing and very extensive field, and we note the omission of key outcomes. For example, we did not collect information about several patient-reported outcomes, such as medication adherence and barriers to adherence, or health-related quality of life. These outcomes are important because they may mediate the efficacy of treatment outcome, and also have significant value to patients and clinicians. Future reviews with methodologies designed to capture many different study designs, including qualitative studies, and use of a wide range of measures, are most needed to address these outcomes. Although we assessed the mean difference in HbA1c between intervention groups in Key Question 1, we did not include the durability of HbA1c changes over time as an outcome, which may best be addressed using long-term well-designed observational studies.

Limitations within the included studies have presented challenges to how we reported their outcomes and our ability to combine them in meta-analyses. For example, several studies failed to report the significance of between-group differences and the measures of dispersion, thereby hindering efforts to estimate effect size across trials. Some trials underdosed comparison medications, limiting our ability to draw conclusions about efficacy. In addition, because of our interest in the comparative effectiveness of drugs, we focused primarily on the relative differences between drugs in our forest plots. In the forest plots, however, we also included footnotes with information about the range of absolute differences from baseline to followup in the comparison arms for readers who wish to estimate the magnitude of effect in absolute terms. Finally, many included trials were industry-sponsored, raising the possibility of publication bias and other forms of bias, such as selective reporting of outcomes. While publication bias generally was not found, these analyses have limited power due to small numbers of studies for many comparisons.

Future Research

In this updated systematic review, we synthesized current literature about the comparative effectiveness and safety of diabetes medications when used as monotherapy and in two-drug combinations. We identified some deficiencies in the published literature that need to be addressed by future research to meet the decision making needs of patients, providers, and policy makers. We organized these deficiencies and recommendations using the PICOTS format for specifying research questions: patient populations, interventions, comparators, outcome measures of interest, timing, and settings.

Populations

Studies often employed narrow inclusion criteria, enrolling patients at lowest risk for complications, and commonly used run-in periods to avoid enrolling patients with adverse effects or poor adherence, which may limit applicability. We identified the following research gaps related to target patient populations:

1. The literature is deficient in studies enrolling people with varying levels of underlying cardiovascular and renal disease risk.
2. Results reported in subgroups of the population were rare, especially the elderly and people with multiple comorbid conditions, such as underlying chronic kidney disease.

Interventions and Comparators

We identified the following gaps in the literature, where future studies could address additional medication comparisons to support clinicians in decision making.

1. The published literature is deficient in studies of the comparative effectiveness of two-drug combinations, focused either on their effectiveness or the safety and thus, interaction between two medications.
2. The comparative effectiveness literature is sparse on monotherapy and combination therapy comparisons of meglitinides, DPP-4 inhibitors, and GLP-1 agonists, with other first line diabetes medications.
3. Few studies used comparisons with a basal or premixed insulin added to metformin or thiazolidinediones.

Outcomes of Interest

Overall, few studies contained sufficient data on event rates for major clinically important adverse events and long-term complications of diabetes.

1. We identified few published studies on long-term clinical outcomes such as cardiovascular disease, stroke, nephropathy, and neuropathy.
2. Few studies used standard measures for diabetic nephropathy and kidney function, such as estimated glomerular filtration rate, or clinical outcomes like time to dialysis, as outcomes in the comparison of these medications.
3. We identified few observational studies that examined macular edema, cancer and fractures for thiazolidinediones, insulin, and other medications.

Timing

We identified several key deficiencies in study timing and duration of followup.

1. The literature is relatively deficient in studies of the short-term benefits, if any, of the addition of insulin to oral agents, and the long-term effects on mortality and cardiovascular disease, from the addition of insulin to a regimen relative to the addition of another oral agent.
2. Few studies on harms lasted greater than 2 years, a shorter duration of exposure than typically seen in clinical practice, where these drugs may be prescribed for decades. Some adverse effects, like congestive heart failure, may take years to develop, and others like fractures, may be due to cumulative exposure. The FDA approval process focuses on short-term harms, providing less incentive for pharmaceutical companies to engage in longer term trials.

Setting

Study settings are relevant to understanding the applicability of the findings to the general U.S. population of patients with diabetes.

- Few trials reported the study setting or source for participant recruitment, such as an outpatient clinical or subspecialty clinical setting, which is relevant because the majority of patients with diabetes are cared for by primary care physicians.

We also identified methodological problems and made recommendations to consider for future research:

1. We recommend studies consistently report between-group comparisons of changes from baseline, as well as measures of dispersion such as standard errors, to improve interpretation of the significance of their findings.
2. We recommend improved adverse event and long-term outcome reporting, with pre-defined outcomes and definitions, and a description of methods for ascertainment.
3. We recommend trials report the steps taken to ensure randomization and allocation concealment.
4. We recommend that observational studies of the comparative effectiveness and safety of diabetes medications report details of the treatment type, dose, timing and duration of use of the medication, when available.
5. We recommend that studies consistently report the number of deaths in each study arm, even if there were none.
6. We recommend that studies allowing use of “background” medications report which medications were allowed and stratify results by the combination therapy, which includes the background medication(s) plus the study drug(s).
7. We recommend conducting a network meta-analysis to assess indirect comparisons, which were not addressed in this report.

References

1. DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes* 2009;58(4):773-795.
2. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. *Diabetes Care* 2006;29(6):1263-1268.
3. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. *Diabetes Care* 2009;32(2):287-294.
4. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. *Diabetes Care* 2003;26(3):917-932.
5. Skyler JS, Oddo C. Diabetes trends in the USA. *Diabetes Metab Res Rev* 2002;18(Suppl 3):S21-S26.
6. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2007 fact sheet. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2008.
7. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 1995;28(2):103-117.
8. Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352(9131):854-865.
9. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352(9131):837-853.
10. Anonymous. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med* 1993;329(14):977-986.
11. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359(15):1577-1589.
12. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;360(2):129-139.
13. Gerstein HC, Miller ME. Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. *N Engl J Med* 2008;358(24):2545-2559.
14. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* 2000;23(Suppl 2):B21-B29.
15. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med* 2007;356(24):2457-2471.
16. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 2009.
17. Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 1994-2007. *Arch Intern Med* 2008;168(19):2088-2094.
18. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. *JAMA* 2010;304(4):411-418.

19. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. *Arch Intern Med* 2010.
20. Mann DM, Woodward M, Ye F, et al. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. *Arch Intern Med* 2009;169(18):1718-1720.
21. Bolen S, Wilson L, Vassy J, et al. Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults with Type 2 Diabetes. Comparative Effectiveness Review No. 8. (Prepared by the Johns Hopkins Evidence-based Practice Center under Contract No. 290-02-0018). Rockville, MD: Agency for Healthcare Research and Quality, 2007.
22. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009;32(1):193-203.
23. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract* 2009;15(6):540-559.
24. Institute of Medicine. *Clinical Practice Guidelines: Directions for a New Program*. Washington, DC: National Academy Press, 1990.
25. Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. *Lancet* 1997;350(9072):185-186.
26. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17(1):1-12.
27. *Guide for Conducting Comparative Effectiveness Reviews*. Rockville, MD: Agency for Healthcare Research and Quality, 2007.
28. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism. Evidence Report No. 180. AHRQ Publication No. 09-E011 edition. Rockville, MD: Agency for Healthcare Research and Quality, 2009.
29. Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews for Interventions Version 5.0.2 [updated September 2009]*. The Cochrane Collaboration [Web page].
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7(3):177-188.
31. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Prog Cardiovasc Dis* 1985;27(5):335-371.
32. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med* 2004;23(9):1351-1375.
33. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557-60.
34. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50(4):1088-1101.
35. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7109):629-634.
36. Tosi F, Muggeo M, Brun E, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. *Metabolism* 2003;52(7):862-867.
37. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. *JAMA* 1999;281(21):2005-2012.

38. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 2006;355(23):2427-2443.
39. Erdem G, Dogru T, Tasci I, et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2008;82(2):214-218.
40. Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. *Hypertens Res* 2007;30(5):387-394.
41. Teramoto T, Yamada N, Shirai K, et al. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. *J Atheroscler Thromb* 2007;14(2):86-93.
42. Kim HJ, Kang ES, Kim DJ, et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. *Clin Endocrinol (Oxf)* 2007;66(2):282-289.
43. Nagasaka S, Aiso Y, Yoshizawa K, et al. Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. *Diabet Med* 2004;21(2):136-141.
44. Derosa G, Maffioli P, Salvadeo SA, et al. Exenatide versus glibenclamide in patients with diabetes. *Diabetes Technol Ther* 2010;12(3):233-240.
45. Kiyici S, Ersoy C, Kaderli A, et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. *Diabetes Res Clin Pract* 2009;86(1):44-50.
46. Derosa G, Maffioli P, Salvadeo SA, et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. *Metabolism* 2009.
47. Gupta AK, Smith SR, Greenway FL, Bray GA. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. *Diabetes Obes Metab* 2009;11(4):330-337.
48. Iliadis F, Kadoglou NP, Hatzitolios A, et al. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes. *In Vivo* 2007;21(6):1107-1114.
49. Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. *Diabetes Obes Metab* 2006;8(6):650-660.
50. Yamanouchi T, Sakai T, Igarashi K, et al. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. *Diabet Med* 2005;22(8):980-985.
51. Ramachandran A, Snehalatha C, Salini J, et al. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. *J Assoc Physicians India* 2004;52:459-463.
52. Scherthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. *J Clin Endocrinol Metab* 2004;89(12):6068-6076.
53. Lawrence JM, Reid J, Taylor GJ, et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. *Diabetes Care* 2004;27(1):41-46.
54. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. *J Clin Endocrinol Metab* 2003;88(4):1637-1645.

55. Hallsten K, Virtanen KA, Lonqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. *Diabetes* 2002;51(12):3479-3485.
56. Perez A, Zhao Z, Jacks R, et al. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. *Curr Med Res Opin* 2009;25(12):2915-2923.
57. Kato T, Sawai Y, Kanayama H, et al. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. *Exp Clin Endocrinol Diabetes* 2009;117(10):593-599.
58. Turkmen Kemal Y, Guvener Demirag N, Yildirim A, et al. Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus. *Acta Diabetol* 2007;44(3):149-156.
59. Chien HH, Chang CT, Chu NF, et al. Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. *J Chin Med Assoc* 2007;70(11):473-480.
60. Derosa G, Franzetti I, Gadaleta G, et al. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. *Diabetes Nutr Metab* 2004;17(3):143-150.
61. Garber AJ, Donovan Jr DS, Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. *J Clin Endocrinol Metab* 2003;88(8):3598-3604.
62. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. *Clin Ther* 2003;25(3):890-903.
63. Blonde L, Rosenstock J, Mooradian AD, et al. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. *Diabetes Obes Metab* 2002;4(6):368-375.
64. Marre M, Howlett H, Lehert P, et al. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. *Diabet Med* 2002;19(8):673-680.
65. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. *Diabetes Obes Metab* 2002;4(3):201-208.
66. Amador-Licona N, Guizar-Mendoza J, Vargas E, et al. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. *Arch Med Res* 2000;31(6):571-575.
67. Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. *Diabetes Metab* 1994;20(4):394-400.
68. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. *Diabetes Care* 1994;17(10):1100-1109.
69. Hermann LS, Bitzen PO, Kjellstrom T, et al. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. *Diabetes Metab* 1991;17(1 Pt 2):201-208.
70. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. *N Engl J Med* 1995;333(9):541-549.
71. Charpentier G, Fleury F, Kabir M, et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. *Diabet Med* 2001;18(10):828-834.
72. Turner R, Murchison L, Wright AD, et al. United Kingdom prospective diabetes study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. *Ann Intern Med* 1998;128(3):165-175.

73. U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study. *Diabetes* 1985;34(8):793-798.
74. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. *BMJ* 1995;310(6972):83-88.
75. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2007;30(8):1979-1987.
76. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. *Curr Med Res Opin* 2009;25(3):569-583.
77. Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. *Diabetes Obes Metab* 2010;12(3):252-261.
78. Jadzinsky M, Pftzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. *Diabetes Obes Metab* 2009;11(6):611-622.
79. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. *Diabetes Care* 2000;23(11):1660-1665.
80. Horton ES, Foley JE, Shen SG, et al. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. *Curr Med Res Opin* 2004;20(6):883-889.
81. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. *Diabetes Res Clin Pract* 2003;60(3):161-169.
82. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* 1999;22(1):119-124.
83. Leiter LA, Harris SB, Chiasson J-L, et al. Efficacy and safety of Rosiglitazone as monotherapy or in combination with metformin in primary care settings. *Can J Diabetes* 2005;29(4):384-392.
84. Kaku K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. *Curr Med Res Opin* 2009;25(5):1111-1119.
85. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2008;10(10):959-969.
86. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. *Curr Med Res Opin* 2005;21(12):2029-2035.
87. Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. *Clin Ther* 2005;27(10):1548-1561.
88. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. *Diabetes Metab Res Rev* 2002;18(2):127-134.
89. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. *Clin Ther* 2000;22(12):1395-1409.

90. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. *JAMA* 2000;283(13):1695-1702.
91. Feinglos M, Dailey G, Cefalu W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. *Diabetes Res Clin Pract* 2005;68(2):167-175.
92. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care* 2009;32(1):84-90.
93. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. *Curr Med Res Opin* 2008;24(2):537-550.
94. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care* 2006;29(12):2638-2643.
95. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care* 2009;32(9):1649-1655.
96. Marre M, Van Gaal L, Usadel KH, et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. *Diabetes Obes Metab* 2002;4(3):177-186.
97. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. *Diabetes Care* 2002;25(4):708-711.
98. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. *Diabetes Care* 2005;28(7):1547-1554.
99. Vijay SK, Mishra M, Kumar H, et al. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. *Acta Diabetol* 2009;46(1):27-33.
100. Hanefeld M, Patwardhan R, Jones NP. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. *Nutr Metab Cardiovasc Dis* 2007;17(1):13-23.
101. Jain R, Osei K, Kupfer S, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. *Pharmacotherapy* 2006;26(10):1388-1395.
102. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. *Metabolism* 2004;53(10):1382-1386.
103. Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. *J Diabetes Complications* 2000;14(5):250-254.
104. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. *J Hum Hypertens* 2003;17(1):7-12.
105. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. *J Am Coll Cardiol* 2005;45(12):1925-1931.
106. Tan MH, Johns D, Strand J, et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. *Diabet Med* 2004;21(8):859-866.

107. Tan M, Johns D, Gonzalez Galvez G, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. *Clin Ther* 2004;26(5):680-693.
108. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. *Diabetes Metab Res Rev* 2006;22(5):385-389.
109. Raskin P, McGill J, Saad MF, et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. *Diabet Med* 2004;21(4):329-335.
110. Jovanovic L, Hassman DR, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. *Diabetes Res Clin Pract* 2004;63(2):127-134.
111. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. *Int J Clin Pract* 2007;61(1):171-180.
112. Jibrán R, Suliman MI, Qureshi F, et al. Safety and efficacy of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients. *Pak. J. Med. Sci.* 2006;22(4):385-390.
113. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. *Clin Ther* 2003;25(2):472-484.
114. Madsbad S, Kilhovd B, Lager I, et al. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. *Diabet Med* 2001;18(5):395-401.
115. Landgraf R, Bilo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. *Eur J Clin Pharmacol* 1999;55(3):165-171.
116. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. *Diabetes Care* 1999;22(3):463-467.
117. Marbury T, Huang WC, Strange P, et al. Repaglinide versus glyburide: a one-year comparison trial. *Diabetes Res Clin Pract* 1999;43(3):155-166.
118. Wolffenbuttel BH, Nijst L, Sels JP, et al. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. *Eur J Clin Pharmacol* 1993;45(2):113-116.
119. Vakkilainen J, Mero N, Schweizer A, et al. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. *Diabetes Metab Res Rev* 2002;18(6):484-490.
120. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. *Diabetes Care* 2004;27(6):1335-1342.
121. Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. *Curr Med Res Opin* 2010.
122. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. *Lancet* 2009;373(9662):473-481.
123. Hamann A, Garcia-Puig J, Paul G, et al. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. *Exp Clin Endocrinol Diabetes* 2008;116(1):6-13.
124. Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. *Diabet Med* 2007;24(6):626-634.

125. Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. *J Hypertens* 2006;24(10):2047-2055.
126. Umpierrez G, Issa M, Vlahjanic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. *Curr Med Res Opin* 2006;22(4):751-759.
127. Derosa G, Gaddi AV, Piccinni MN, et al. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. *Pharmacotherapy* 2005;25(5):637-645.
128. Garber A, Klein E, Bruce S, et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. *Diabetes Obes Metab* 2006;8(2):156-163.
129. Comaschi M, Demicheli A, Di Pietro C, et al. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. *Diabetes Technol Ther* 2007;9(4):387-398.
130. Rigby SP, Handelsman Y, Lai YL, et al. Effects of Colesevelam HCl, Rosiglitazone, or Sitagliptin on Glycemic Control and the Lipid Profile in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy. *Endocr Pract* 2009;1-34.
131. Raskin P, Lewin A, Reinhardt R, et al. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. *Diabetes Obes Metab* 2009.
132. Defronzo RA, Triplitt C, Qu Y, et al. Effects Of Exenatide Plus Rosiglitazone On Beta Cell Function And Insulin Sensitivity In Subjects With Type 2 Diabetes On Metformin. *Diabetes Care* 2010.
133. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes Obes Metab* 2007;9(2):194-205.
134. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. *International Journal of Clinical Practice: Int. J. Clin. Pract.* 2010;64(5):562-576.
135. Derosa G, D'Angelo A, Fogari E, et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. *J Clin Pharm Ther* 2009;34(1):13-23.
136. Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. *Diabetes Care* 2005;28(9):2093-2099.
137. Malone JK, Beattie SD, Campaigne BN, et al. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? *Diabetes Res Clin Pract* 2003;62(3):187-195.
138. Kvapil M, Swatko A, Hilberg C, et al. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. *Diabetes Obes Metab* 2006;8(1):39-48.
139. Yang J, Di F, He R, et al. Effect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients. *Chin Med J (Engl)* 2003;116(5):785-787.
140. Hanefeld M, Brunetti P, Scherthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. *Diabetes Care* 2004;27(1):141-147.

141. van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. *Circulation* 2009;119(15):2069-2077.
142. Seufert J, Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. *Diabetes Res Clin Pract* 2008;79(3):453-460.
143. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet* 2010;375(9724):1447-1456.
144. Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. *Diabetes Care* 2009;32(5):762-768.
145. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. *Clin Ther* 2007;29(11):2349-2364.
146. Raskin PR, Hollander PA, Lewin A, et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. *Eur J Intern Med* 2007;18(1):56-62.
147. Davies MJ, Thaware PK, Tringham JR, et al. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. *Diabet Med* 2007;24(7):714-719.
148. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. *Diabetes Care* 2004;27(6):1349-1357.
149. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. *Diabetes Care* 2002;25(11):2058-2064.
150. Tolman KG, Freston JW, Kupfer S, et al. Liver safety in patients with type 2 diabetes treated with pioglitazone: Results from a 3-year, randomized, comparator-controlled study in the US. *Drug Saf.* 2009;32(9):787-800.
151. Derosa G, Cicero AF, Gaddi AV, et al. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. *Clin Ther* 2005;27(9):1383-1391.
152. Schwarz SL, Gerich JE, Marcellari A, et al. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. *Diabetes Obes Metab* 2008;10(8):652-660.
153. Hallsten K, Virtanen KA, Lonnqvist F, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. *Diabet Med* 2004;21(12):1280-1287.
154. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. *Diabetes* 2003;52(2):283-290.
155. Hermann LS, Kjellstrom T, Nilsson-Ehle P. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus. *Diabetes Metab* 1991;17(1 Pt 2):174-179.
156. Stewart MW, Cirkel DT, Furuseth K, et al. Effect of metformin plus rosiglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. *Diabet Med* 2006;23(10):1069-1078.

157. Derosa G, Gaddi AV, Piccinni MN, et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. *Diabetes Obes Metab* 2006;8(2):197-205.
158. Comaschi M, Corsi A, Di Pietro C, et al. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. *Nutr Metab Cardiovasc Dis* 2008;18(5):373-379.
159. Derosa G, Gaddi AV, Ciccarelli L, et al. Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. *J Int Med Res* 2005;33(3):284-294.
160. Jonker JT, Lamb HJ, van der Meer RW, et al. Pioglitazone Compared with Metformin Increases Pericardial Fat Volume in Patients with Type 2 Diabetes Mellitus. *J Clin Endocrinol Metab* 2009.
161. Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes in the United States. *Am J Epidemiol* 2002;156(8):714-719.
162. Kirk JK, D'Agostino Jr RB, Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. *Diabetes Care* 2006;29(9):2130-2136.
163. Saydah S, Cowie C, Eberhardt MS, et al. Race and ethnic differences in glycemic control among adults with diagnosed diabetes in the United States. *Ethn Dis* 2007;17(3):529-535.
164. Malone JK, Kerr LF, Campaigne BN, et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. *Clin Ther* 2004;26(12):2034-2044.
165. Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. *Diabet Med* 2005;22(4):374-381.
166. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulphonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. *CMAJ* 2006;174(2):169-174.
167. Johnson JA, Simpson SH, Toth EL, et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. *Diabet Med* 2005;22(4):497-502.
168. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulphonylurea monotherapy in type 2 diabetes. *Diabetes Care* 2002;25(12):2244-2248.
169. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. *Diabetes Care* 2005;28(10):2345-2351.
170. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. *Diabetes Metab Res Rev* 2004;20(3):239-245.
171. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. *BMJ* 2009;339:1-9.
172. Azoulay L, Schneider-Lindner V, Dell'aniello S, et al. Combination therapy with sulphonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. *Pharmacoepidemiol Drug Saf* 2010;19(4):335-342.

173. Hsiao FY, Huang WF, Wen YW, et al. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. *Drug Saf* 2009;32(8):675-690.
174. Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. *Acta Diabetol* 2009;46(2):145-154.
175. Kahler KH, Rajan M, Rhoads GG, et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. *Diabetes Care* 2007;30(7):1689-1693.
176. Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. *Diabetologia* 2006;49(5):930-936.
177. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. *Clin Cardiol* 2001;24(2):151-158.
178. Fisman EZ, Tenenbaum A, Benderly M, et al. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. *Cardiology* 1999;91(3):195-202.
179. Jones TA, Sautter M, Van Gaal LF, et al. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. *Diabetes Obes Metab* 2003;5(3):163-70.
180. Monami M, Marchionni N, Masotti G, et al. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. *Int J Cardiol* 2008;126(2):247-251.
181. McAfee AT, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. *Pharmacoepidemiol Drug Saf* 2007;16(7):711-725.
182. Brownstein JS, Murphy SN, Goldfine AB, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. *Diabetes Care* 2010;33(3):526-531.
183. Rosak C, Standl E, Reblin T, et al. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. *Int J Clin Pract* 2006;60(9):1040-1047.
184. Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. *Kidney Int* 2005;68(1):285-292.
185. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. *Diabetes Obes Metab* 2010;12(5):442-451.
186. Hu YY, Ye SD, Zhao LL, et al. Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes. *Clin Endocrinol (Oxf)* 2010;73(6):739-743.
187. Sillars B, Davis WA, Hirsch IB, et al. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. *Diabetes Obes Metab* 2010;12(9):757-765.
188. Loebstein R, Dushinat M, Vesterman-Landes J, et al. Database Evaluation of the Effects of Long-Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes. *J Clin Pharmacol* 2010.
189. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review for Avandia. Application number 021071. 1999.
190. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review for Glucovance. Application number 21-178. 2000.
191. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review for Janumet. Application number 22-044. 2007.

192. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Supplemental Medical Officer Review for Metformin/Glyburide. Application number 21-178. 2002.
193. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review for Metformin/Glipizide. Application Number 21-460. 2002.
194. Rajagopalan R, Iyer S, Khan M. Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. *Curr Med Res Opin* 2005;21(1):163-172.
195. Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. *Diabetes Care* 2005;28(1):20-26.
196. Nichols GA, Koro CE, Gullion CM, et al. The incidence of congestive heart failure associated with antidiabetic therapies. *Diabetes Metab Res Rev* 2005;21(1):51-57.
197. Lund SS, Tarnow L, Stehouwer CD, et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. *Diabetes Obes Metab* 2007;9(3):394-407.
198. Wright AD, Cull CA, Macleod KM, et al. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. *J Diabetes Complications* 2006;20(6):395-401.
199. Dimic D, Velojic Golubovic M, Antic S, et al. Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metformin administration. *Bratislava Med J* 2009;110(6):335-339.
200. Asche CV, McAdam-Marx C, Shane-McWhorter L, et al. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. *Drugs Aging* 2008;25(7):611-622.
201. Hanefeld M, Pfitzner A, Forst T, et al. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. *Curr Med Res Opin* 2006;22(6):1211-1215.
202. Hussein Z, Wentworth JM, Nankervis AJ, et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. *Med J Aust* 2004;181(10):536-539.
203. Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. *Diabetes Res Clin Pract* 2002;58(1):45-53.
204. Blevins T. Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. *Postgrad Med* 2010;122(1):172-183.
205. Mourad C, Chevalier S, Morais JA, et al. Antihyperglycaemic medication modifies factors of postprandial satiety in type 2 diabetes. *Diabetes Obes. Metab.* 2009;11(8):819-822.
206. Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. *Diabetes Obes Metab* 2005;7(2):161-169.
207. Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. *Diabet Med* 2005;22(8):986-993.
208. McAlister FA, Eurich DT, Majumdar SR, et al. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. *Eur J Heart Fail* 2008;10(7):703-708.
209. Hartung DM, Touchette DR, Bultemeier NC, et al. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicare claims-based case-control study. *Pharmacotherapy* 2005;25(10):1329-1336.
210. Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. *BMJ* 2009;339:b2942.

211. Singh S, Mukherjee KK, Gill KD, et al. Lead-induced peripheral neuropathy following ayurvedic medication. *Indian J Med Sci* 2009;63(9):408-410.
212. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. *Diabetologia* 2009;52(9):1766-1777.
213. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care* 2008;31(5):845-851.
214. Mancini T, Mazziotti G, Doga M, et al. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. *Bone* 2009;45(4):784-788.
215. Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. *Arch Intern Med* 2009;169(15):1395-1402.
216. Mathieu C. The scientific evidence: vildagliptin and the benefits of islet enhancement. *Diabetes Obes Metab* 2009;11 (Suppl 2):9-17.
217. European Medicines Agency. Scientific Discussion for Actos. 2004.
218. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review for Rosiglitazone. Application Number 21-071/001. 2000.
219. GlaxoSmithKline I. Product Monograph for Avandia. Submission Control No. 119390. 2009.
220. Chou HS, Palmer JP, Jones, AR et al. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. *Diabetes Obes Metab* 2008;10(8):626-637.
221. Kawai T, Funae O, Shimada A, et al. Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. *Intern Med* 2008;47(13):1181-1188.
222. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. *Ann Intern Med* 1998;128(3):165-175.
223. Giles TD, Miller AB, Elkayam U, et al. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. *J Card Fail* 2008;14(6):445-452.
224. Horsdal HT, Johnsen SP, Sondergaard F, et al. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. *Diabetologia* 2008;51(4):567-574.
225. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. *Diabet Med* 1994;11(10):953-960.
226. Belcher G, Lambert C, Goh KL, et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. *Int J Clin Pract* 2004;58(9):833-837.
227. Khan M, Xu Y, Edwards G, et al. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies. *Int J Clin Pract* 2004;58(10):907-912.
228. Lester JW, Fernandes AW. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. *Int J Clin Pract* 2005;59(2):134-142.
229. Perez A, Khan M, Johnson T, et al. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. *Diab Vasc Dis Res* 2004;1(1):44-50.
230. Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. *Diabet Med* 2005;22(8):973-979.

231. Belcher G, Lambert C, Edwards G, et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. *Diabetes Res Clin Pract* 2005;70(1):53-62.
232. Charbonnel B, Scherthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. *Diabetologia* 2005;48(6):1093-1104.
233. Ceriello A, Johns D, Widel M, et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. *Diabetes Care* 2005;28(2):266-272.
234. Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. *J Diabetes Complications* 2003;17(4):211-217.
235. Monami M, Lamanna C, Marchionni N, et al. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. *Diabetes Res Clin Pract* 2008;79(2):196-203.
236. Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. *JAMA* 2010;303(14):1410-1418.
237. Kahn BB, Flier JS. Obesity and insulin resistance. *J. Clin. Invest.* 2000;106(4):473-481.
238. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. *Eur J Endocrinol* 2009;160(6):909-917.
239. Barrera JG, D'Alessio DA, Drucker DJ, et al. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. *Diabetes* 2009;58(12):2820-2827.
240. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. *Diabetes* 2006;55(12):3387-3393.
241. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. *Arch Intern Med* 2001;161(14):1717-1723.
242. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. *Arch Intern Med* 2008;168(19):2070-2080.
243. Food and Drug Administration. Briefing document: July 13-14, 2010 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. [Web Page]. Accessed October 27, 2010).
244. Rosen CJ. Revisiting the rosiglitazone story—lessons learned. *N Engl J Med* 2010;363(9):803-806.
245. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. *N Engl J Med* 2010;363(16):1489-1491.
246. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2007;(3):CD006063.
247. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med* 2007;147(6):386-399.
248. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet* 2007;370(9593):1129-1136.
249. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. *JAMA* 2007;298(10):1189-1195.
250. GlaxoSmithKline. AVANDIA package insert. Available at: http://us.gsk.com/products/assets/us_avandia.pdf. Accessed December 9, 2009.

251. Takeda Pharmaceutical America, I. ACTOS package insert. Available at: <http://general.takedapharm.com/content/file/pi.pdf?applicationcode=8a9c4571-a123-4477-91de-b9cafe7d07e3&filetypecode=actospi>. Accessed December 14, 2009.
252. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. *Arch Ophthalmol* 2005;123(9):1273-1275.
253. Ryan Jr EH, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. *Retina* 2006;26(5):562-570.
254. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. *Am J Ophthalmol* 2009;147(4):583-6.e1.
255. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. *Diabetes Care* 2009;32(5):834-838.
256. U.S. Food and Drug Administration. Exenatide (marketed as Byetta) Information. Available at: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113705.htm>. Accessed December 14, 2009).
257. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. *Curr Med Res Opin* 2009;25(4):1019-1027.
258. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2006;(1):CD002967.
259. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. *Diabetes Care* 2006;29(2):254-258.
260. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. *Diabetologia* 2009;52(9):1732-1744.
261. Bodmer M, Meier C, Krahenbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. *Diabetes Care* 2010.
262. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. *Diabetologia* 2009;52(9):1755-1765.
263. Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. *Diabetologia* 2010;53(9):1838-1845.
264. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. *CMAJ* 2009;180(1):32-39.
265. Hsiao FY, Mullins CD. The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study. *Diabetologia* 2009.
266. Qayyum R, Wilson LM, Bolen S, et al. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults with Type 2 Diabetes. Comparative Effectiveness Review No. 14 edition. Rockville, MD: Agency for Healthcare Research and Quality, 2008.
267. Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: A meta-analysis of randomized controlled trials. *Diabetic Med*. 2008;25(8):924-932.
268. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. *Diabetes Res Clin Pract* 2008;81(2):184-189.
269. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2008;(2):CD006739.

270. Wani JH, John-Kalarickal J, Fonseca VA. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. *Cardiol Clin* 2008;26(4):639-648.
271. U.S. Food and Drug Administration. Byetta (exenatide). Available at: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079781.htm>. Accessed December 14, 2009.
272. U.S. Food and Drug Administration. Byetta (exenatide)—Renal Failure. Available at: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm>. Accessed December 14, 2009.
273. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. *Ann Intern Med* 2000;133(6):455-463.
274. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005;366(9493):1279-1289.
275. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358(24):2545-2559.
276. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *New Engl. J. Med.* 2008;358(24):2560-2572.
277. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA* 2008;299(13):1561-1573.
278. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. *Diabetes Obes Metab* 2006;8(4):436-447.
279. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2007;146(7):477-485.
280. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 2004;27(11):2628-2635.
281. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2005;28(5):1092-1100.
282. Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. *Acta Diabetol* 2008.
283. Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. *Diabetes Res Clin Pract* 2008;82(3):391-395.
284. Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. *Diabetes Care* 2008;31(11):2086-2091.
285. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. *Arch Intern Med* 2008;168(8):820-825.
286. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. *Diabetologia* 2005;48(7):1292-1299.
287. Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. *Pediatr Nephrol* 2010.
288. Derosa G, D'Angelo A, Fogari E, et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. *Intern Med* 2007;46(22):1837-1846.

289. Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. *Diabetologia* 2005;48(12):2477-2481.
290. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. *Circulation* 2005;111(19):2525-2531.
291. Smith SA, Porter LE, Biswas N, et al. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. *J Clin Endocrinol Metab* 2004;89(12):6048-6053.
292. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. *Eur Heart J* 2010;31(7):824-831.

Abbreviations

ACCORD	Action to Control Cardiovascular Disease in Diabetes
ADOPT	A Diabetes Outcome Progression Trial
AHRQ	Agency for Healthcare Research and Quality
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
CI	Confidence interval
DPP-4	Dipeptidyl peptidase-4
EPC	Evidence-based Practice Center
FDA	Food and Drug Administration
GI	Gastrointestinal
GLP-1	Glucagon-like peptide-1
GPRD	General Practice Research Database
HDL	High density lipoproteins
HbA1c	Hemoglobin A1c
HR	Hazard ratio
HR	Hazard ratio
IRR	Incidence rate ratios
IU	International units
kg	Kilograms
LDL	Low density lipoproteins
mg/dL	Milligrams per deciliter
MI	Myocardial infarction
NPH	Neutral protamine Hagedorn
OR	Odds ratio
PROactive	PROspective pioglitAzone Clinical Trial in macroVascular Events
RCT	Randomized controlled trial
RECORD	Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes
RR	Relative risk
TG	Triglycerides
U.K.	United Kingdom
UKPDS	United Kingdom Prospective Diabetes Study
U.S.	United States
VA	Department of Veterans Affairs

Appendix A. Medication Comparisons

Table 1. Monotherapy comparisons considered for review

	MET	TZD	SU	DPP4	MEG	AGI	BROMO	COL	any insulin	non-drug	MET/TZD	MET/SU	MET/DPP4	MET/MEG	MET/EX	Met/Insulin
MET																
TZD																
SU																
DPP4																
MEG																
AGI																
BROMO																
COL																

Black boxes indicate comparisons that were included in the review; light gray boxes indicate comparisons that were not included, but tallied; and dark gray boxes indicate comparisons that were excluded from the review.
 AGI = alpha-glucosidase inhibitors; BROMO – bromocriptine; COL = colesevalam; DPP4 = dipeptidyl peptidase-4 inhibitors; MEG = meglitinides; MET = metformin; SU = sulfonylurea; TZD = thiazolidinedione

Table 2. Combination comparisons considered for review

	MET+SU	MET+MEG	MET+DPP4	MET+EX	MET+Basal	MET+premixed	TZD+SU	TZD+MEG	TZD+DPP4	TZD+EX	TZD+basal	TZD+premixed	SU+MEG	SU+DPP4	SU+EX	SU+Basal	SU+premixed	MEG+DPP4	MEG+EX	MEG+Basal	MEG+premixed	DPP4+EX	DPP4+basal ins	DPP4+premixed	EX+basal ins	EX+premixed		
MET + TZD																												
MET + SU																												
MET + MEG																												
MET+DPP4																												
MET + EX																												
MET + Basal																												
MET + premixed																												
TZD+SU																												
TZD+MEG																												
TZD+DPP4																												
TZD+EX																												
TZD+basal																												
TZD+premixed																												
SU+MEG																												
SU+DPP4																												
SU+EX																												
SU+basal																												
SU+premixed																												
MEG+DPP4																												
MEG+ EX																												
MEG+basal																												
MEG+premixed																												
DPP4+EX																												
DPP4+basal																												
DPP4+premixed																												
EX+basal																												

Black boxes indicate comparisons that were included in the review; light gray boxes indicate comparisons that were not included, but tallied; and dark gray boxes indicate comparisons that were excluded from the review.

AGI = alpha-glucosidase inhibitors; basal = basal insulin; BROMO = bromocriptine; COL = colesevalam; DPP4 = dipeptidyl peptidase-4 inhibitors; EX = exenatide; MEG = meglitinides; MET = metformin; premixed = premixed insulin; SU = sulfonylurea; TZD = thiazolidinedione

Appendix B. Detailed Electronic Database Search Strategies

MEDLINE Strategy

Terms	Returns
("diabetes mellitus, type 2"[mh] or (diabet*[tiab] and ("non-insulin dependent"[tiab] or type-2[tiab] or "type II"[tiab] or "type 2"[tiab]))) AND ("thiazolidinediones"[mh] or "glipizide"[mh] or "glyburide"[mh] or "metformin"[mh] or "acarbose"[mh] or thiazolidinedione*[tiab] or pioglitazone[tiab] or rosiglitazone[tiab] or sulfonylurea*[tiab] or sulphonylurea*[tiab] or glipizide[tiab] or glyburide[tiab] or glimepiride[tiab] or glibenclamide[tiab] or biguanide*[tiab] or metformin[tiab] or "insulin secretagogues"[tiab] or meglitinide*[tiab] or repaglinide[tiab] or nateglinide[tiab] or "alpha-glucosidase inhibitors"[tiab] or "alpha-glucosidase inhibitor"[tiab] or acarbose[tiab] or "Dipeptidyl-Peptidase IV Inhibitors"[mh] or sitagliptin*[tiab] or saxagliptin*[tiab] or dpp-4[tiab] or dpp-iv[tiab] or bromocriptine[mh] or bromocriptine[tiab] or colesevelam[tiab] or "Glucagon-Like Peptide 1"[mh] or liraglutide[tiab] or exenatide[tiab]) AND English[lang] NOT (animal[mh] NOT human[mh]) NOT (letter[pt] or comment[pt] or editorial[pt])	7927

Embase Strategy

('non insulin dependent diabetes mellitus'/exp OR 'non insulin dependent diabetes mellitus' or (diabet*:ti,ab and ('non-insulin dependent':ti,ab or type-2:ti,ab or 'type II':ti,ab or 'type 2':ti,ab))) AND ('thiazolidinedione'/exp or 'rosiglitazone'/exp or 'pioglitazone'/exp or 'glipizide'/exp or 'glyburide'/exp or 'glimepiride'/exp or 'metformin'/exp or 'alpha glucosidase inhibitor'/exp or 'acarbose'/exp or 'sitagliptin'/exp or 'colesevelam'/exp or thiazolidinedione*:ti,ab or pioglitazone:ti,ab or rosiglitazone:ti,ab or sulfonylurea*:ti,ab or sulphonylurea*:ti,ab or glipizide:ti,ab or glyburide:ti,ab or glimepiride:ti,ab or glibenclamide:ti,ab or biguanide*:ti,ab or metformin:ti,ab or 'insulin secretagogues':ti,ab or meglitinide*:ti,ab or repaglinide:ti,ab or nateglinide:ti,ab or 'alpha-glucosidase inhibitors':ti,ab or 'alpha-glucosidase inhibitor':ti,ab or acarbose:ti,ab or 'Dipeptidyl-Peptidase IV Inhibitor'/exp or saxagliptin/exp or saxagliptin*:ti,ab or sitagliptin/exp or sitagliptin*:ti,ab or dpp-4:ti,ab or dpp-iv:ti,ab or 'bromocriptine mesilate'/exp or bromocriptine:ti,ab or colesevelam:ti,ab or exenatide/exp or exenatide:ti,ab or liraglutide/exp or liraglutide:ti,ab) AND [english]/lim NOT ([animals]/lim NOT [humans]/lim) NOT (letter:it or comment:it or editorial:it)	16093
--	-------

The Cochrane Central Register of Controlled Trials (CENTRAL)

(diabetes near type-2) or (diabet*:ti,ab,kw and ("non-insulin dependent":ti,ab,kw or type-2:ti,ab,kw or "type II":ti,ab,kw or "type 2":ti,ab,kw)) AND (thiazolidinedione*:ti,ab,kw or pioglitazone:ti,ab,kw or rosiglitazone:ti,ab,kw or sulfonylurea*:ti,ab,kw or sulphonylurea*:ti,ab,kw or glipizide:ti,ab,kw or glyburide:ti,ab,kw or glimepiride:ti,ab,kw or glibenclamide:ti,ab,kw or biguanide*:ti,ab,kw or metformin:ti,ab,kw or "insulin secretagogues":ti,ab,kw or meglitinide*:ti,ab,kw or repaglinide:ti,ab,kw or nateglinide:ti,ab,kw or "alpha-glucosidase inhibitors":ti,ab,kw or "alpha-glucosidase inhibitor":ti,ab,kw or acarbose:ti,ab,kw or "Dipeptidyl-Peptidase IV Inhibitors":ti,ab,kw or saxagliptin*:ti,ab,kw or sitagliptin*:ti,ab,kw or liraglutide:ti,ab,kw or exenatide:ti,ab,kw or bromocriptine:ti,ab,kw or colesevelam:ti,ab,kw)	6507
--	------

Appendix C. Hand-Searched Journals

All Journals Hand Searched

February 2009–September 2009

American Journal of Medicine

Clinical Therapeutics

Diabetic Medicine

Diabetes and Metabolism

Diabetes

Diabetes Care

Diabetes, Obesity & Metabolism

Diabetes Research and Clinical Practice

Diabetologia

Hormone and Metabolic Research

Journal of Clinical Endocrinology and Metabolism

Lancet

Metabolism: Clinical and Experimental

Practical Diabetes International

Appendix D. Forms

Project Diabetes Medications (Switch) **User** lisa.wilson (My Settings)
Messages **1 new**



Review | Datarama | Reports | References | Edit Forms | Manage Levels | Manage Users
Logout

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.
Rethnam U, Yesupalan RS, Sinha A.

and go to Does this article POTENTIALLY apply to any of our key questions? [Click here to see drug matrix.](#) Yes No

and go to



Project Diabetes Medications (Switch) User lisa.wilson (My Settings)
 Messages 1 new

- Review
- Datarama
- Reports
- References
- Edit Forms
- Manage Levels
- Manage Users
- Logout

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.
 Rethnam U, Yesupalan RS, Sinha A.

BACKGROUND: Skateboarding has been a popular sport among teenagers even with its attendant associated risks. The literature is packed with articles regarding the perils of skateboards. Is the skateboard as dangerous as has been portrayed?

METHODS: This was a retrospective study conducted over a 5 year period. All skateboard related injuries seen in the Orthopaedic unit were identified and data collated on patient demographics, mechanism & location of injury, annual incidence, type of injury, treatment needed including hospitalisation.

RESULTS: We encountered 50 patients with skateboard related injuries. Most patients were males and under the age of 15. The annual incidence has remained low at about 10. The upper limb was predominantly involved with most injuries being fractures. Most injuries occurred during summer. The commonest treatment modality was plaster immobilisation. The distal radius was the commonest bone to be fractured. There were no head & neck injuries.

Submit Form and go to
Diabetes Medications Abstract Review Form

1. Exclude article because (check all that apply) :
- Exclude, but pull for handsearching (e.g. systematic review article that applies to key question)
 - Does not apply to any of the key questions
 - No original data (e.g. Review article, commentary or editorial)
 - No concurrent control or comparison group (e.g. case series or case report or pre-post design; note that case-control studies should be included)
 - Does not have a drug comparison of interest (see list below)
 - No subjects with type 2 diabetes mellitus, non-insulin dependent diabetes mellitus (NIDDM), or adult-onset diabetes
 - Only applies to KQ1 and is not a RCT - DO NOT USE
 - Number of subjects in study < 40
 - Study participants on drug < 30 days or 1 month
 - No human data reported (e.g. evaluates outcomes in animals only)
 - Not written in English
 - No subjects > or = 18 years old
 - Other reason for exclusion:

2. Unclear
- Unclear — pull for full article review
- To see the drug matrix, click here.
 To see the list of drug names, click here. To see the key questions, click here.

3. Article includes the following comparisons of medications (check all that apply; drugs/combinations are listed in order of priority):

Monotherapy - Green	Main intervention (select one) <input checked="" type="radio"/> Metformin alone <input type="radio"/> TZD alone <input type="radio"/> Sulfonylurea alone <input type="radio"/> Sitagliptin alone (DPP-4 inhibitor) Clear Response	Comparison (select all that apply) <input type="checkbox"/> TZD alone <input type="checkbox"/> Sulfonylurea alone <input type="checkbox"/> Sitagliptin alone (DPP-4 inhibitor) <input type="checkbox"/> Meglitinides alone <input type="checkbox"/> Metformin + TZD (only vs. metformin alone) <input type="checkbox"/> Metformin + SU (only vs. metformin alone) <input type="checkbox"/> Metformin + sitagliptin (only vs. metformin alone) <input type="checkbox"/> Metformin + meglitinides (only vs. metformin alone)
Combination - Green	Main intervention (select one) <input checked="" type="radio"/> Metformin + TZD <input type="radio"/> Metformin + SU <input type="radio"/> Metformin + meglitinides <input type="radio"/> Metformin + sitagliptin <input type="radio"/> Metformin + exenatide <input type="radio"/> Metformin + any HG <input type="radio"/> Metformin + basal insulin <input type="radio"/> Metformin + premixed insulin Clear Response	Comparison (select all that apply) <input type="checkbox"/> Metformin + TZD <input type="checkbox"/> Metformin + SU <input type="checkbox"/> Metformin + meglitinides <input type="checkbox"/> Metformin + sitagliptin <input type="checkbox"/> Metformin + exenatide <input type="checkbox"/> Metformin + any HG <input type="checkbox"/> Metformin + basal insulin <input type="checkbox"/> Metformin + premixed insulin <input type="checkbox"/> TZD + SU <input type="checkbox"/> TZD + meglitinides

4. TALLY - Article includes the following comparisons of medications (check all that apply; drugs/combinations are listed in order of priority):

Monotherapy - Yellow	Main intervention (select one) <input checked="" type="radio"/> Metformin alone <input type="radio"/> TZD alone <input type="radio"/> Sulfonylurea alone <input type="radio"/> Sitagliptin alone (DPP-4 inhibitor) <input type="radio"/> Meglitinides alone Clear Response	Comparison (select all that apply) <input type="checkbox"/> Acarbose alone <input type="checkbox"/> Bromocriptine (cycloset) alone (only vs. metformin alone) <input type="checkbox"/> Colesevalam (alone) (only vs. metformin alone) <input type="checkbox"/> Any insulin (only vs. metformin alone) <input type="checkbox"/> Non-drug or placebo <input type="checkbox"/> Metformin + exenatide (only vs. metformin alone) <input type="checkbox"/> Metformin + insulin (only vs. metformin alone)
Combination - Yellow	Main intervention (select one) <input checked="" type="radio"/> Metformin + TZD	Comparison (select all that apply) <input type="checkbox"/> TZD + meglitinides

12/17/2009

DistillerSR

open fractures or injuries requiring surgical intervention.

CONCLUSION: Despite its negative image among the medical fraternity, the skateboard does not appear to be a dangerous sport with a low incidence and injuries encountered being not severe.

Skateboarding should be restricted to supervised skateboard parks and skateboarders should wear protective gear.

These measures would reduce the number of skateboarders injured in motor vehicle collisions, reduce the personal injuries among skateboarders, and reduce the number of pedestrians injured in collisions with skateboarders.

- Metformin + SU
 - Metformin + meglitinides
 - Metformin + sitagliptin
 - Metformin + exenatide
 - Metformin + any HG
 - Metformin + basal insulin
 - Metformin + premixed insulin
 - TZD + SU
 - TZD + meglitinides
 - TZD + sitagliptin
 - TZD + exenatide
 - SU + meglitinides
 - SU + sitagliptin
 - SU + exenatide
 - Meglitinides + sitagliptin
 - Meglitinides + exenatide
 - Sitagliptin + exenatide
 - [Clear Response](#)
- TZD + sitagliptin
 - TZD + exenatide
 - TZD + basal insulin
 - TZD + premixed insulin
 - SU + meglitinides
 - SU + sitagliptin
 - SU + exenatide
 - SU + basal insulin
 - SU + premixed insulin
 - Meglitinides + sitagliptin
 - Meglitinides + exenatide
 - Meglitinides + basal insulin
 - Meglitinides + premixed insulin
 - Sitagliptin + exenatide
 - Sitagliptin + basal insulin
 - Sitagliptin + premixed insulin

11. Comments (limit: 250 characters)

and go to



Refid 12, Skateboards: Are they really perky? A retrospective study from a district hospital. Rethnam U, Yesupalan RS, Sinha A.

Submit Form and go to Diabetes Medication

Article Review Form

Table with 3 columns: Key Question, Study Design Criteria, Study Duration Criteria. Contains criteria for key questions regarding comparative effectiveness and safety of treatment options in adults with type 2 diabetes mellitus.

- 1. Exclude article because (check all that apply).
- Does not apply to any of the key questions
- Does not meet the study design criteria for any of the corresponding questions (see above)
- Study duration < 3-months or 90-days
- No original data (e.g. Review article, commentary or editorial)
- No comparison group (e.g. case series or case report or pre/post design; note: case-control studies should be included)
- Does not have a drug comparison of interest (see list of comparisons) (Exclude if additional medications are not specified, such as "any oral hypoglycemic" or "any of the following.", or if study lists possible medications without stratification by arm)
- No subjects with type 2 diabetes mellitus, non-insulin dependent diabetes mellitus (NIDDM), or adult-onset diabetes (e.g. Exclude if it only evaluates people with impaired glucose tolerance, impaired fasting glucose, metabolic syndrome, gestational diabetes)
- Only includes pregnant women with diabetes
- Number of type 2 diabetes patients in study < 40
- No human data reported (e.g. evaluates outcomes in animals only)
- Not written in English
- No subjects > or = 18 years old
- Exclude, but pull for handsearching (e.g. systematic review article that applies to key question)
- Other reason for exclusion:

- 2. Exclude, but tally, studies that evaluate adverse outcomes and are 1-3 months long
- Evaluates adverse outcomes and is 1-3 months long

If not excluded in Q1, then please answer Q3.

3. Comparisons of Interest

A. Green Comparisons

Table with 3 columns: Comparison, Main intervention, Comparison. Lists green comparison options for Monotherapy and Combination treatments.

B. Yellow Comparisons

If article does NOT include one of the green comparisons, please check off which of the following other comparisons it addresses (check all that apply). If article includes both a green and a yellow comparison, mark the green comparison in Q3A and skip to the end. The yellow comparison will be captured during data abstraction. Do NOT mark the yellow comparison here.

Table with 3 columns: Comparison, Main intervention, Comparison. Lists yellow comparison options for Monotherapy and Combination treatments.

12/17/2009

- SU + exenatide
- Meglitinides + sitagliptin
- Meglitinides + exenatide
- Sitagliptin + exenatide

[Clear Response](#)

DistillerSR

- Meglitinides + premixed insulin
- Sitagliptin + exenatide
- Sitagliptin + basal insulin
- Sitagliptin + premixed insulin

3. Comments (limit 250 characters)

and go to

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.

Rethnam U, Yesupalan RS, Sinha A.

Submit Form and go to

Diabetes Medications Study Design Form

Fill out this form for all included studies.

1. In what country does the study occur? **(check all that apply)**

- United States
 Canada
 United Kingdom
 Japan
 Multinational Europe
 Multi-continent
 Other (specify):
 Not reported

2. What study design is used? **(check only one response)**

- Randomized controlled trial
 Non-randomized trial
 Prospective or retrospective cohort
 Cross-sectional study
 Case-control
 Other (specify):

3. Select trial type **(check all that apply)**

- Parallel arms
 Factorial design
 Crossover design
 Other (specify):
 None of the above apply to the trial/Not applicable (not a trial)

4. Was there a run-in period in which >10% of participants were excluded? **(check only one response)**

- Yes
 Fewer than 10% of participants were excluded during run-in
 Run-in period but number of participants excluded was not reported
 No run-in period
 Not applicable

5. Was there a washout period? **(check only one response)**

- Yes (specify how long in days):
 No
 Not reported
 Not applicable/Not a crossover trial

6. Was there pharmaceutical support (funding or drug given for free) of the study? **(check only one response)**

- Yes
 No
 Not reported

7. Study enrollment period (years of medical record collection for cohort inception) **Enter 4-digit year for start, end or both years**

systematic-review.net/.../RenderForm....

- Start year:
- End year:
- Neither year reported

<p>8. What was the total intended followup duration or maximum possible followup?</p> <p><input type="radio"/> Duration: <input type="text"/></p> <p><input type="radio"/> Not reported</p>	<p>9. Specify units: (check only one response)</p> <p><input type="radio"/> Weeks</p> <p><input type="radio"/> Months</p> <p><input type="radio"/> Years</p> <p><input type="radio"/> Not applicable</p>
---	--

10. What was the planned interval for any contact with the study participants after study drug was titrated (e.g. monitoring)? (check only one response)

- < 6 months
- >= 6 months
- Not reported
- Not applicable

11. Which subgroup analyses were conducted? (check all that apply)

- Age
- Baseline HbA1c
- Comorbid conditions
- Gender
- Obesity
- Prior treatment
- Other (specify):
- No subgroup analyses were conducted

Study Population Questions

12. What was the source(s) of the population from which subjects were enrolled in the study? (check all that apply)

- Inpatient/hospital
- Outpatient: primary care
- Outpatient: subspecialty care setting
- Community
- Other (specify):
- Not reported

13. What was the total number of patients screened?

- N:
- Not reported
- Not applicable (for cohort studies, claims data, etc)

14. What was the total number at enrollment or cohort inception?

- N:
- Not reported

15. Please select and specify the exclusion criteria. Any inclusion criteria should be entered as exclusion criteria e.g. if the inclusion criteria is type 2 diabetes, the exclusion criteria would be no type 2 diabetes.

- Age (specify):
- Male
- Female
- Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT))
- Any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance)
- History of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina)
- Poorly controlled on prior treatments (e.g. "failed initial treatment")
- Contraindication or history of intolerance to metformin
- Neuropathy
- Retinopathy

12/17/2009

DistillerSR

HbA1c > (specify):
 HbA1c < (specify):
 BM or weight (specify):
 Pregnant
 Nursing
 Not using adequate contraception
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Other (specify):
 Not reported

TALLY - Article includes the following comparisons of medications (check all that apply; drugs/combinations are listed in order of priority):

Monotherapy - Yellow	Main intervention (select one) <input type="radio"/> Metformine alone <input type="radio"/> TZD alone <input type="radio"/> Sulfonylurea alone <input type="radio"/> Sitagliptin alone (DPP-4 inhibitor) <input type="radio"/> Meglitinides alone Clear Response	Comparison (select all that apply) <input type="checkbox"/> Acarbose alone <input type="checkbox"/> Bromocriptine (cycloset) alone (only vs. metformin alone) <input type="checkbox"/> Colesevalam (alone) (only vs. metformin alone) <input type="checkbox"/> Any insulin (only vs. metformin alone) <input type="checkbox"/> Non-drug or placebo <input type="checkbox"/> Metformin + exenatide (only vs. metformin alone) <input type="checkbox"/> Metformin + insulin (only vs. metformin alone)
Monotherapy - Yellow	Main intervention (select one) <input type="radio"/> Metformine alone <input type="radio"/> TZD alone <input type="radio"/> Sulfonylurea alone <input type="radio"/> Sitagliptin alone (DPP-4 inhibitor) <input type="radio"/> Meglitinides alone Clear Response	Comparison (select all that apply) <input type="checkbox"/> Acarbose alone <input type="checkbox"/> Bromocriptine (cycloset) alone (only vs. metformin alone) <input type="checkbox"/> Colesevalam (alone) (only vs. metformin alone) <input type="checkbox"/> Any insulin (only vs. metformin alone) <input type="checkbox"/> Non-drug or placebo <input type="checkbox"/> Metformin + exenatide (only vs. metformin alone) <input type="checkbox"/> Metformin + insulin (only vs. metformin alone)
Combination - Yellow	Main intervention (select one) <input type="radio"/> Metformin + TZD <input type="radio"/> Metformin + SU <input type="radio"/> Metformin + meglitinides <input type="radio"/> Metformin + sitagliptin <input type="radio"/> Metformin + exenatide <input type="radio"/> Metformin + any HG <input type="radio"/> Metformin + basal insulin <input type="radio"/> Metformin + premixed insulin <input type="radio"/> TZD + SU <input type="radio"/> TZD + meglitinides <input type="radio"/> TZD + sitagliptin <input type="radio"/> TZD + exenatide <input type="radio"/> SU + meglitinides <input type="radio"/> SU + sitagliptin <input type="radio"/> SU + exenatide	Comparison (select all that apply) <input type="checkbox"/> TZD + meglitinides <input type="checkbox"/> TZD + sitagliptin <input type="checkbox"/> TZD + exenatide <input type="checkbox"/> TZD + basal insulin <input type="checkbox"/> TZD + premixed insulin <input type="checkbox"/> SU + meglitinides <input type="checkbox"/> SU + sitagliptin <input type="checkbox"/> SU + exenatide <input type="checkbox"/> SU + basal insulin <input type="checkbox"/> SU + premixed insulin <input type="checkbox"/> Meglitinides + sitagliptin <input type="checkbox"/> Meglitinides + exenatide <input type="checkbox"/> Meglitinides + basal insulin <input type="checkbox"/> Meglitinides + premixed insulin <input type="checkbox"/> Sitagliptin + exenatide

12/17/2009

DistillerSR

	<input type="radio"/> Meglitinides + sitagliptin <input type="radio"/> Meglitinides + exenatide <input type="radio"/> Sitagliptin + exenatide Clear Response	<input type="checkbox"/> Sitagliptin + basal insulin <input type="checkbox"/> Sitagliptin + premixed insulin
Combination - Yellow	Main intervention (select one) <input type="radio"/> Metformin + TZD <input type="radio"/> Metformin + SU <input type="radio"/> Metformin + meglitinides <input type="radio"/> Metformin + sitagliptin <input type="radio"/> Metformin + exenatide <input type="radio"/> Metformin + anyHG <input type="radio"/> Metformin + basal insulin <input type="radio"/> Metformin + premixed insulin <input type="radio"/> TZD + SU <input type="radio"/> TZD + meglitinides <input type="radio"/> TZD + sitagliptin <input type="radio"/> TZD + exenatide <input type="radio"/> SU + meglitinides <input type="radio"/> SU + sitagliptin <input type="radio"/> SU + exenatide <input type="radio"/> Meglitinides + sitagliptin <input type="radio"/> Meglitinides + exenatide <input type="radio"/> Sitagliptin + exenatide Clear Response	Comparison (select all that apply) <input type="checkbox"/> TZD + meglitinides <input type="checkbox"/> TZD + sitagliptin <input type="checkbox"/> TZD + exenatide <input type="checkbox"/> TZD + basal insulin <input type="checkbox"/> TZD + premixed insulin <input type="checkbox"/> SU + meglitinides <input type="checkbox"/> SU + sitagliptin <input type="checkbox"/> SU + exenatide <input type="checkbox"/> SU + basal insulin <input type="checkbox"/> SU + premixed insulin <input type="checkbox"/> Meglitinides + sitagliptin <input type="checkbox"/> Meglitinides + exenatide <input type="checkbox"/> Meglitinides + basal insulin <input type="checkbox"/> Meglitinides + premixed insulin <input type="checkbox"/> Sitagliptin + exenatide <input type="checkbox"/> Sitagliptin + basal insulin <input type="checkbox"/> Sitagliptin + premixed insulin

24.

Comments (limit 250 characters)

25. Comments (limit 250 characters)

26. Comments (limit 250 characters)

and go to



Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital. Rethnam U, Yesupalan RS, Sinha A.

Submit Form and go to

Oral Diabetes Medications Update Intervention Form

- Instructions: 1) Complete this form for all RCTs, cohort studies, and cross-over studies. 2) For cross-over studies, please record each portion of the crossover as a separate comparison. 3) Do not use this form for case-control studies. Please use "Case Control Intervention and Outcomes Form."

1. Indicate the following: (Mandatory question; please check one)

Main Intervention Comparison A Comparison B Comparison C Comparison D Comparison E Total Other (specify):

For monotherapy comparisons where the main intervention is using a single drug, complete the first row only. For combination comparisons, complete the first row for metformin or a TZD, and complete the second row for the additional drug. For metformin and TZD combinations, use the first row for metformin and the second row for TZD.

Table with 4 columns: Intervention (Please select one; interventions listed in order of priority), Dosing, Total daily dose after run-in (include units; OK to calculate if not explicitly stated), and Duration of dose titration. It contains two rows for drug selection and dosing details.

Please complete the baseline characteristics for this study group: Total N at enrollment for this intervention group, Age (Mean/Range), Report age categories in addition to mean or range if provided, Age category (specify/n/%).

12/17/2009

DistillerSR

Age category specify n %

Age category specify n %

Age category specify n %

Age category specify n %

Age category specify n %

Age not reported

Male

n % Gender not reported

Race/Ethnicity

African American n %

Asian or Asian American n %

Caucasian n %

Hispanic or Latino n %

Other race/ethnicity specify n %

Other race/ethnicity specify n %

Other race/ethnicity specify n %

Other race/ethnicity specify n %

Other race/ethnicity specify n %

Other race/ethnicity specify n %

Race/ethnicity not reported

BMI/Weight

Mean weight (include units) Mean BMI

Only report other measures if mean weight or BMI is not reported

Other measures specify measure: value:

Other measures specify measure: value:

Other measures specify measure: value:

Other measures specify measure: value:

BMI/weight not reported

HgbA1c

Mean HgbA1c

Only report other measures if mean HgbA1c is not reported

Other measures specify measure: value:

Other measures specify measure: value:

Other measures specify measure: value:

Other measures specify measure: value:

HgbA1c not reported

Duration of diabetes

Mean (years)

Only report other measures if mean duration of diabetes is not reported

Other measures specify measure: value:

Other measures specify measure: value:

Other measures specify measure: value:

Other measures specify measure: value:

Duration of diabetes not reported

Number of withdrawals

Comments (limit 250 characters)

61. Comments (limit 250 characters)

62. Comments (limit 250 characters)

and go to



- Review
- Datarama
- Reports
- References
- Edit Forms
- Manage Levels
- Manage Users
- Logout

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital. Rethnam U, Yesupalan RS, Sinha A.

Submit Form and go to

Diabetes Medications Outcomes Form

Fill out this form for all included studies

Outcome of interest being reported on this form (check only one outcome under KO1, KO2, or KO3 on this form):

Key Question 1

Outcome	Units
<input type="checkbox"/> HgbA1c	<input type="checkbox"/> % <input type="checkbox"/> Cut-point (only if mean or median not reported; specify):
<input type="checkbox"/> LDL	<input type="checkbox"/> mmol/L <input type="checkbox"/> umol/L <input type="checkbox"/> mg/dL
<input type="checkbox"/> HDL	<input type="checkbox"/> mmol/L <input type="checkbox"/> umol/L <input type="checkbox"/> mg/dL
<input type="checkbox"/> Triglycerides	<input type="checkbox"/> mmol/L <input type="checkbox"/> umol/L <input type="checkbox"/> mg/dL
<input type="checkbox"/> Weight	<input type="checkbox"/> kg <input type="checkbox"/> lbs
<input type="checkbox"/> BMI (only if weight is not reported)	<input type="checkbox"/> kg/m ²

Key Question 2

All cause mortality

Cardiovascular Mortality

Fatal myocardial infarction

Other (e.g., sudden cardiac death) (specify):

Composite outcome (list if specified):

Unspecified

Cardiovascular Morbidity

Non-fatal myocardial infarction (specify how defined):

Other (e.g., acute coronary syndrome, arrhythmia, cardiac procedures, like percutaneous coronary intervention (PCI)) (congestive heart failure will be captured under Key Question 3) (specify):

Composite outcome (list if specified):

Unspecified

Cerebrovascular Mortality/Disease

Fatal stroke

Non-fatal stroke (specify how defined):

Other (e.g., transient ischemic attack) (specify):

Incident diabetic retinopathy (macular edema will be captured under Key Question 3)

Incident diabetic retinopathy (specify):

Not specified

Incident diabetic nephropathy (e.g., changes in proteinuria or microalbuminuria, ESRD, dialysis outcomes, etc.)

Incident diabetic nephropathy (specify):

Not specified

Incident diabetic neuropathy

Incident diabetic neuropathy (specify):

Not specified

Key Question 3

Adverse event or side effect

Hypoglycemia - mild/minor (specify):

Hypoglycemia - moderate (specify):

Hypoglycemia - severe/major (specify):

Liver failure (specify):

Congestive heart failure (specify):

Severe lactic acidosis (specify):

Cancer (specify):

Severe allergic reaction (specify):

Hip fracture (specify):

Non-hip fracture (specify):

Pancreatitis (specify):

Cholecystitis (specify):

Macular edema (specify):

Decreased vision (specify):

Gastrointestinal side effects (specify):

Other severe adverse event (specify):

If applies to Key Question 3 (adverse events and/or safety outcomes), please answer questions 21-23.

21. Was the mode of Adverse Event collection Active or Passive?

- Active (Active ascertainment of harms indicates (a) that participants are asked about the occurrence of specific harms in structured questionnaires or interviews or pre-defined laboratory or diagnostic tests, usually performed at pre-specified time intervals and/or (b) that the potential occurrence of harmful events are collected at pre-specified intervals; for example, the occurrence of post-operative complications were evaluated on a daily basis within 30 days of the surgery. These events are potentially expected harms as a result of the intervention.)
- Passive (Passive ascertainment of harms occurs when study participants spontaneously report (on their own initiative) or are allowed to report harmful events not probed with active ascertainment. In some studies, laboratory or diagnostic tests are only ordered if a particular event is suspected. For example, a study participant is suspected of having a stroke based on clinical presentation; the authors would indicate that brain imaging tests would then be ordered to confirm the presence or absence of the stroke.)
- Not reported

22. Did the study specify frequency and timing of adverse event collection?

- Yes
- No
- Not applicable

23. Was the analysis for this outcome 'intention-to-treat' (i.e., not per-protocol or 'on treatment analysis')?

- Yes
- No
- Not reported

Please report results for outcome specified above

Dichotomous Outcomes (Most of outcomes for Key Questions 2 and 3)

Table I. Incidence of the outcome by intervention group

Intervention group (Please be consistent with the labeling in the intervention form)	N for analysis (use a number enrolled in each group)	Outcome measure	Denominator (specify): <input type="checkbox"/> Days <input type="checkbox"/> Weeks <input type="checkbox"/> Months <input type="checkbox"/> Years <input type="checkbox"/> Persons <input type="checkbox"/> Person-years <input type="checkbox"/> Other (specify): _____ <input type="checkbox"/> Not applicable	p-value (Record exact p-value)	Indicate reference group
Main intervention		<input type="checkbox"/> # of patients with one or more events _____ <input type="checkbox"/> % of patients with one or more events _____ <input type="checkbox"/> # of events _____ <input type="checkbox"/> specify other numerator type _____ <input type="checkbox"/> specify other numerator value _____			<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison A		<input type="checkbox"/> # of patients with one or more events _____ <input type="checkbox"/> % of patients with one or more events _____ <input type="checkbox"/> # of events _____ <input type="checkbox"/> specify other numerator type _____ <input type="checkbox"/> specify other numerator value _____			<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison B		<input type="checkbox"/> # of patients with one or more events _____ <input type="checkbox"/> % of patients with one or more events _____ <input type="checkbox"/> # of events _____ <input type="checkbox"/> specify other numerator type _____ <input type="checkbox"/> specify other numerator value _____			<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison C		<input type="checkbox"/> # of patients with one or more events _____ <input type="checkbox"/> % of patients with one or more events _____ <input type="checkbox"/> # of events _____ <input type="checkbox"/> specify other numerator type _____ <input type="checkbox"/> specify other numerator value _____			<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison D		<input type="checkbox"/> # of patients with one or more events _____ <input type="checkbox"/> % of patients with one or more events _____ <input type="checkbox"/> # of events _____ <input type="checkbox"/> specify other numerator type _____ <input type="checkbox"/> specify other numerator value _____			<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison E		<input type="checkbox"/> # of patients with one or more events _____ <input type="checkbox"/> % of patients with one or more events _____ <input type="checkbox"/> # of events _____ <input type="checkbox"/> specify other numerator type _____ <input type="checkbox"/> specify other numerator value _____			<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____

Table II. Measure of association for comparison of outcome between intervention groups

Intervention group (Please be consistent with the labeling in the intervention form)	N for analysis	Point estimate <input type="checkbox"/> Relative risk (RR) <input type="checkbox"/> Relative hazard (HR) <input type="checkbox"/> Odds ratio (OR) <input type="checkbox"/> Risk difference <input type="checkbox"/> Other (specify): _____	Measure of variability <input type="checkbox"/> SE <input type="checkbox"/> SD <input type="checkbox"/> Other (specify): _____	95% Confidence Interval	p-value (Record exact p-value)	Indicate reference group
Main						<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____

12/17/2009

DistillerSR

Intervention				<input type="checkbox"/> Lower limit <input type="checkbox"/> Upper limit		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify):
Comparison A				<input type="checkbox"/> Lower limit <input type="checkbox"/> Upper limit		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify):
Comparison B				<input type="checkbox"/> Lower limit <input type="checkbox"/> Upper limit		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify):
Comparison C				<input type="checkbox"/> Lower limit <input type="checkbox"/> Upper limit		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify):
Comparison D				<input type="checkbox"/> Lower limit <input type="checkbox"/> Upper limit		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify):
Comparison E				<input type="checkbox"/> Lower limit <input type="checkbox"/> Upper limit		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify):

What were the results adjusted for in the final model?

- Age
- Sex
- Race
- BMI or weight
- Glycemic control
- Comorbidities
- Duration of diabetes
- Other (specify):
- Other (specify):
- Other (specify):
- Other (specify):
- Other (specify):
- Other (specify):
- Other (specify):
- Other (specify):
- Other (specify):
- Results are not adjusted
- RCT that did not adjust for any baseline difference

Continuous outcomes (Most of outcomes for Key Question 1)

Table III. Mean difference from other intervention group measures of outcome

Intervention group (Please be consistent with the labeling in the intervention form)	N for analysis	Point estimate (please specify negative/positive sign) <input type="checkbox"/> Mean <input type="checkbox"/> Median <input type="checkbox"/> Other (specify):	Measure of variability <input type="checkbox"/> SE <input type="checkbox"/> SD <input type="checkbox"/> Other (specify):	<input type="checkbox"/> 95% Confidence interval <input type="checkbox"/> ICR	p-value (Record exact p-value)	Indicate reference group
Main intervention				<input type="checkbox"/> Lower limit <input type="checkbox"/> Upper limit		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify):
Comparison A				<input type="checkbox"/> Lower limit <input type="checkbox"/> Upper limit		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D

<https://systematic-review.net/Submit/RenderForm.php...>

3/6

12/17/2009

DistillerSR

						<input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison B	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>	<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison C	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>	<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison D	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>	<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison E	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>	<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____

Table IV. Mean difference from baseline to final measures of outcome (If values decrease, be sure to indicate with a negative sign (-)).

Intervention group (Please be consistent with the labeling in the intervention form)	N for analysis	Point estimate (please specify negative/positive sign) <input type="checkbox"/> Mean <input type="checkbox"/> Median <input type="checkbox"/> Other (specify): _____	Measure of variability <input type="checkbox"/> SE <input type="checkbox"/> SD <input type="checkbox"/> Other (specify): _____	<input type="checkbox"/> 95% Confidence interval <input type="checkbox"/> IQR	p-value (Record exact p-value)
Main intervention	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison A	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison B	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison C	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison D	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison E	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>

Complete tables V and VI only if the point estimate AND measure of variability in tables III and IV are not reported.

Table V. Baseline measure of outcome

Intervention group (Please be consistent with the labeling in the intervention form)	N for analysis	Point estimate (please specify negative/positive sign) <input type="checkbox"/> Mean <input type="checkbox"/> Median <input type="checkbox"/> Other (specify): _____	Measure of variability <input type="checkbox"/> SE <input type="checkbox"/> SD <input type="checkbox"/> Other (specify): _____	<input type="checkbox"/> 95% Confidence interval <input type="checkbox"/> IQR	p-value (Record exact p-value)
Main intervention	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison A	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison B	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison C	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison D	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>
Comparison E	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Lower limit <input type="text"/> <input type="checkbox"/> Upper limit <input type="text"/>	<input type="text"/>

Table VI. Final measures of outcome

Intervention	N for analysis	Point estimate (please specify)	Measure of variability		p-value (Record exact p-)	Indicate reference group
--------------	----------------	---------------------------------	------------------------	--	---------------------------	--------------------------

<https://systematic-review.net/Submit/RenderForm.php...>

12/17/2009

DistillerSR

Intervention group (Please be consistent with the labeling in the intervention form)	negative/positive sign <input type="checkbox"/> Mean <input type="checkbox"/> Median <input type="checkbox"/> Other (specify): _____	SE SD Other (specify): _____	95% Confidence Interval IGR	value	
Main intervention			<input type="checkbox"/> Lower limit _____ <input type="checkbox"/> Upper limit _____		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Baseline <input type="checkbox"/> Other (specify): _____
Comparison A			<input type="checkbox"/> Lower limit _____ <input type="checkbox"/> Upper limit _____		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Baseline <input type="checkbox"/> Other (specify): _____
Comparison B			<input type="checkbox"/> Lower limit _____ <input type="checkbox"/> Upper limit _____		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Baseline <input type="checkbox"/> Other (specify): _____
Comparison C			<input type="checkbox"/> Lower limit _____ <input type="checkbox"/> Upper limit _____		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Baseline <input type="checkbox"/> Other (specify): _____
Comparison D			<input type="checkbox"/> Lower limit _____ <input type="checkbox"/> Upper limit _____		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Baseline <input type="checkbox"/> Other (specify): _____
Comparison E			<input type="checkbox"/> Lower limit _____ <input type="checkbox"/> Upper limit _____		<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Baseline <input type="checkbox"/> Other (specify): _____

Table VII. Other measures

Intervention group (Please be consistent with the labeling in the intervention form)	N for analysis	Other measure	Other measure	p-value (Record exact p-value)	Indicate reference group
Main intervention					<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison A					<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison B					<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): _____
Comparison C					<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E

<https://systematic-review.net/Submit/RenderForm.php...>

12/17/2009

DistillerSR

				<input type="checkbox"/> Other (specify): <input type="text"/>
Comparison D	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): <input type="text"/>
Comparison E	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/> Main intervention <input type="checkbox"/> Comparison A <input type="checkbox"/> Comparison B <input type="checkbox"/> Comparison C <input type="checkbox"/> Comparison D <input type="checkbox"/> Comparison E <input type="checkbox"/> Other (specify): <input type="text"/>

Comments (limit 250 characters)

Comments (limit 250 characters)

Comments (limit 250 characters)

and go to

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.

Rethnam U, Yesupalan RS, Sinha A.

and go to

Diabetes Medications

Quality Form for Trials

1. Was the study described as randomized (this includes the use of words such as randomly, random and randomization)?

- Yes
 No
 Not reported

2. If yes to Q1, was the randomization scheme described AND appropriate?

- Yes: Appropriate randomization is if each study participant is allowed to have the same chance of receiving study drug
 No: Randomization described and inappropriate (e.g. allocation using date of birth)
 No: not described

3. Was the study described as double blind?

- Yes
 No
 Not reported/Can't tell

4. If yes to Q3, was the method of double blinding described AND appropriate?

- Yes: appropriate double blinding is if neither the person doing the assessments nor the study participant could identify the intervention being assessed OR if the use of active placebos, identical placebos or dummies is mentioned
 No: the study was described as double blind AND inappropriate (e.g. comparison of tablet vs. lifestyle)
 No: no description of double blinding available and unable to tell if appropriate or not

5. Was there a description of withdrawals and dropouts?

- Yes: the number and the reasons for withdrawals in each group was stated or it was stated that there were no withdrawals (if subjects were not included in the analysis, they must state the number and reasons for not including them in the analysis)
 No

6. Please rate the overall quality of the study

- Good (low risk of bias). These studies have the least bias and results are considered valid. A study that adheres mostly to the commonly held concepts of high quality including the following: a formal randomized controlled study; clear description of the population, setting, interventions, and comparison groups; appropriate measurement of outcomes; appropriate statistical and analytic methods and reporting; no reporting errors; low dropout rate; and clear reporting of dropouts.
 Fair. These studies are susceptible to some bias, but it is not sufficient to invalidate the results. They do not meet all the criteria required for a rating of good quality because they have some deficiencies, but no flaw is likely to cause major bias. The study may be missing information, making it difficult to assess limitations and potential problems.
 Poor (high risk of bias). These studies have significant flaws that imply biases of various types that may invalidate the results. They have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.
[Clear Response](#)

7. Comments (limit 250 characters)

8. Comments (limit 250 characters)

12/17/2009

DistillerSR

9. Comments (limit 250 characters)

and go to

Refid: 12, Skateboards: Are they really perilous? A retrospective study from a district hospital.

Rethnam U, Yesupalan RS, Sinha A.

and go to

Diabetes Medications Quality Form for Observational Trials

- Did the study describe the setting or population from which the study sample was drawn?
 - Yes, complete description including an appropriate sampling scheme (consecutive, random)
 - Yes, but without description of sampling scheme or used a scheme that could bias results (convenience)
 - No or insufficient to replicate
- Were the inclusion and exclusion criteria for subjects described?
 - Yes
 - No
- Is there description of key characteristics of the enrolled subjects that could affect outcomes?
 - Yes with detailed description of covariates expected to affect outcomes (e.g. age, duration of diabetes, other therapies)
 - Some description of covariates (e.g., age, sex)
 - No
- Is there sufficient detail about the treatment?
 - Yes, describes the treatment type, dose, timing and duration of medications AND the results for all subjects who took medication
 - No, Either omits relevant information on treatment and intensity (dose or duration) OR does not report the results for all subjects exposed to the medication
 - No, does neither
- Is there sufficient detail about one or more outcomes and are they objectively measured?
 - Yes
 - Some description of outcomes but poorly detailed
 - No
- Is the statistical analysis described and appropriate for the primary comparison?
 - Yes
 - No
- Are the results presented adjusted or stratified for differences in groups or stated that the groups were comparable at baseline?
 - Yes
 - No
 - Not applicable
- Does the study describe the number of participants who were lost to follow-up after the start of the period of observation?
 - Yes
 - No
 - Not applicable (e.g. cross-sectional study)
 - Unclear
- What percentage of patients was lost to follow-up?
 - <10% in any group
 - 10-20% in any group
 - >20%
 - Not reported

10. Please rate the overall quality of the study.

- Good (low risk of bias). These studies have the least bias and results are considered valid. A study that adheres mostly to the commonly held concepts of high quality including the following: a formal randomized controlled study; clear description of the population, setting, interventions, and comparison groups; appropriate measurement of outcomes; appropriate statistical and analytic methods and reporting; no reporting errors; low dropout rate; and clear reporting of dropouts.
- Fair. These studies are susceptible to some bias, but it is not sufficient to invalidate the results. They do not meet all the criteria required for a rating of good quality because they have some deficiencies, but no flaw is likely to cause major bias. The study may be missing information, making it difficult to assess limitations and potential problems.
- Poor (high risk of bias). These studies have significant flaws that imply biases of various types that may invalidate the results. They have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.

11. Comments (limit 250 characters)

12. Comments (limit 250 characters)

13. Comments (limit 250 characters)

and go to

Appendix E. Tallies for Comparisons Not Included in Review

Main intervention	Comparator	Number of studies
Metformin	Acarbose	3
Metformin	Any insulin	3
Metformin	Placebo or any non-drug intervention	21
Metformin	Metformin + GLP-1 agonist	5
Metformin	Metformin + insulin	3
Thiazolidinedione	Acarbose	1
Thiazolidinedione	Placebo or any non-drug intervention	38
Sulfonylurea	Acarbose	6
Sulfonylurea	Placebo or any non-drug intervention	18
DPP-4 inhibitor	Placebo or any non-drug intervention	9
Meglitinides	Placebo or any non-drug intervention	10
GLP-1 agonist	Placebo or any non-drug intervention	1
Metformin + thiazolidinedione	Thiazolidinedione + DPP-4 inhibitor	3
Metformin + thiazolidinedione	Thiazolidinedione + GLP-1 agonist	1
Metformin + thiazolidinedione	Sulfonylurea + meglitinides	1
Metformin + sulfonylurea	Thiazolidinedione + basal insulin	1
Metformin + sulfonylurea	Sulfonylurea + basal insulin	2
Metformin + GLP-1 agonist	Thiazolidinedione + GLP-1 agonist	1
Metformin + GLP-1 agonist	Sulfonylurea + GLP-1 agonist	1
Metformin + basal insulin	Sulfonylurea + basal insulin	2
Metformin + premixed insulin	Sulfonylurea + premixed insulin	1
Metformin + premixed insulin	Meglitinides + premixed insulin	1

Additionally, our team attempted to tally, but found no studies evaluating the following comparisons:

- metformin versus bromocriptine
- metformin versus colesevalam
- sitagliptin versus acarbose
- meglitinides versus acarbose
- combination of metformin and either thiazolidinediones, meglitinides, sitagliptin, or premixed insulin versus combinations of thiazolidinedione and either sitagliptin, exenatide, basal insulin, or premixed insulin
- combination of metformin and thiazolidinedione versus a combination that contains either a sulfonylurea, meglitinides, or sitagliptin and either a meglitinides, sitagliptin, exenatide, basal insulin, or premixed insulin
- combination of metformin and sulfonylurea versus combinations of thiazolidinedione and either sitagliptin, exenatide, or premixed insulin
- combination of metformin and sulfonylurea versus a combination of sulfonylurea and either meglitinides, sitagliptin, exenatide, or premixed insulin
- combination of metformin and sulfonylurea versus a combination that contains either a meglitinides or sitagliptin and either a sitagliptin, exenatide, or premixed insulin
- combination of metformin and a basal insulin versus a combination of thiazolidinedione and either sitagliptin, exenatide, basal insulin, or premixed insulin
- combination of metformin and basal insulin versus a combination that contains either a meglitinides or sitagliptin and either a sitagliptin, exenatide, or premixed insulin

- combination of thiazolidinedione and either sulfonylurea, meglitinides, sitagliptin, or exenatide versus a combination of thiazolidinediones and either meglitinides, sitagliptin, exenatide, basal insulin, or premixed insulin
- combination of sulfonylurea and either meglitinides, sitagliptin, or exenatide versus a combination of sulfonylureas and either sitagliptin, exenatide, basal insulin, or premixed insulin
- combination of meglitinides and either sitagliptin or exenatide versus a combination of meglitinides and either exenatide, basal insulin, or premixed insulin
- combination of sitagliptin and exenatide versus a combination of sitagliptin and either basal insulin or premixed insulin

Appendix F. Excluded Articles

Aaboe K, Knop FK, Vilsboll T et al. Twelve weeks treatment with the DPP-4 inhibitor sitagliptin improves glycaemic control, but does not improve GLP-1 secretion, in patients with type 2 diabetes - A randomised trial. *Diabetologia*: *Diabetologia* 2009; 52(S1):S294. Other reason

Abbasi AA, Kasmikha R, Sotingeanu DG. Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. *Endocr Pract* 2000; 6(6):442-6. Does not have a drug comparison of interest

Abbatecola AM, Paolisso G. Rosiglitazone and cognitive stability in older persons with type 2 diabetes and mild cognitive impairment. *Diabetologia*: *Diabetologia* 2009; 52(S1):S67. Does not meet the study design criteria

Abbatecola AM, Rizzo MR, Barbieri M et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. *Neurology* 2006; 67(2):235-40. Does not apply

Abe M, Okada K, Kikuchi F, Matsumoto K. Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. *Clin Nephrol* 2008; 70(3):220-8. Does not apply

Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. *Diabetes Obes Metab* 2009; 11(2):150-6. No original data

Agarwal R. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. *Am J Physiol Renal Physiol* 2006; 290(3):F600-5. Does not apply

Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. *Clin Ther* 2003; 25(11):2754-64. Does not have a drug comparison of interest

Aguilar C, Reza A, Garcia JE, Rull JA. Biguanide related lactic acidosis: incidence and risk factors. *Arch Med Res* 1992; 23(1):19-24. Does not have a drug comparison of interest

Ahren B, Lundquist I, Schersten B. Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes. *Diabetes Res* 1986; 3(6):293-300. Less than 40 subjects with type 2 diabetes

Ahren B, Simonsson E, Larsson H et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. *Diabetes Care* 2002; 25(5):869-75. Study duration less than 3 months

Akanuma Y, Kosaka K, Kanazawa Y, Kasuga M, Fukuda M, Aoki S. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. *Diabetes Res Clin Pract* 1988; 5(2):81-90. Does not have a drug comparison of interest

Alba M, Ahren B, Inzucchi SE et al. Initial combination therapy with sitagliptin and pioglitazone: Complementary effects on postprandial glucose and islet cell function. *Can J Diabetes* 2009; 33(3):319-20. Does not meet the study design criteria

Albertini JP, McMorn SO, Chen H, Mather RA, Valensi P. Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. *Atherosclerosis* 2007; 195(1):e159-66. Does not have a drug comparison of interest

Alfonso A, Koops MK, Mong DP, Vigersky RA. Glycemic control with regular versus lispro insulin sliding scales in hospitalized Type 2 diabetics. *J. Diabetes Complications* 2006; 20(3):153-7. Does not have a drug comparison of interest

Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. *Am J Med* 2004; 116(4):230-5. Does not have a drug comparison of interest

Allen KV, McAulay V, Sommerfield AJ, Frier BM. Hypoglycaemia is uncommon with a combination of antidiabetic drugs and bedtime NPH insulin for type 2 diabetes. *Pract. Diabetes Int.* 2004; 21(5):179-82. Does not meet the study design criteria

Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. *Diabetes Obes Metab* 2008; 10 Suppl 1:8-15. Does not apply

Ambrosius WT, Danis RP, Goff DC Jr et al. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. *Arch Ophthalmol* 2010; 128(3):312-8. Does not have a drug comparison of interest

Anon. "PROactive" study shows Takeda's ACTOS® (pioglitazone HCl) reduces heart attacks, strokes and deaths in patients with type 2 diabetes. *Publ. Takeda Res. Lab.* 2005. Other reason

Anon. A randomised, multi-centre, phase IV, double-blind, parallel group study comparing the effects of 52 weeks' administration of AVANDAMET and metformin plus sulphonylurea on change in HbA1c from baseline in overweight type 2 diabetics poorly controlled on metformin. Other reason

Anon. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (*Diabetes Care* (1999) 22 (960-964)). *Diabetes Care* 1999; 22(11):1922. No original data

Anon. Clinical news updates from the 2005 AHA Scientific Sessions. *Formulary* 2006; 41(1):18-26. No original data

Anon. Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs. *ClinicalTrials.gov* identifier: NCT00819741. Other reason

Anon. Diabetes drugs may cause heart-failure hazard. *Health News* 2004; 10(1):15. Does not meet the study design criteria

Anon. DPP-IV inhibitor better tolerated than metformin. *Pharm. J.* 2005; 275(7370):436. No original data

Anon. Drugs for type 2 diabetes. *Treat Guidel Med Lett* 2008; 6(71):47-54. No original data

Anon. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes. *Geriatrics* 2005; 60(8):12. No original data

Anon. Effect of AC2993 (synthetic exendin-4) compared with insulin glargine in patients with type 2 diabetes also using combination therapy with sulfonylurea and metformin. Eli Lilly Clinical Trial Registry Summary 2007. Does not have a drug comparison of interest

Anon. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; 352(9131):854-65. Does not have a drug comparison of interest

Anon. Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes. ClinicalTrials.gov identifier: NCT00399711. Other reason

Anon. Effects of metformin or repaglinide therapy for diabetes on serum markers for CVD. *Nat Clin. Pract Endocrinol Metab* 2008; 4(8):427. No original data

Anon. Efficacy and safety of pioglitazone. *Aust J. Pharm* 2008; 89(1064):62-3. No original data

Anon. Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on OAD. ClinicalTrials.gov identifier: NCT00491725. Other reason

Anon. Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes. ClinicalTrials.gov identifier: NCT00491725. Other reason

Anon. Efficacy of exenatide [AC2993, synthetic exendin-4, LY2148568] compared with twice-daily biphasic insulin aspart in patients with type 2 diabetes using sulfonylurea and metformin. Eli Lilly Clinical Trial Registry Summary 2007. 2007. Other reason

Anon. Erratum: Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial (*International Journal of Clinical Practice* (2009) 63 (1395-1406)). *Int J Clin Pract* 2010; 64(2):277. Other reason

Anon. Exenatide (Byetta) for type 2 diabetes. *Med Lett Drugs Ther* 2005; 47(1210):45-6. No original data

Anon. First reports of serious adverse drug reactions in recent weeks. *Drugs Ther Perspect* 2006; 22(3):20-1. No original data

Anon. Improved risk profile with pioglitazone. *Br J Diabetes Vasc Dis* 2003; 3(6):446. No original data

Anon. Inhaled insulin superior to rosiglitazone in patients with uncontrolled type 2 diabetes. *Formulary* 2003; 38(7):408. No original data

Anon. Insulin sensitizer affects lipids. *Health News* 2005; 11(1):2. No original data

Anon. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; 352(9131):837-53. Does not have a drug comparison of interest

Anon. Janumet. *JAAPA* 2007; 20(6):14. No original data

Anon. Landmark PROactive trial investigates effect of ACTOS (pioglitazone HCl) on cardiovascular disease progression: More than 5,000 patients with type 2 diabetes studied. Publ. Takeda Res. Lab. 2004; 2004(-). Other reason

Anon. New data shows Takeda's ACTOS(registered trademark) (pioglitazone HCl) reduced heart attacks by 28 percent in people with type 2 diabetes. Publ. Takeda Res. Lab. 2005; 2005(-). Other reason

Anon. Oral agents for type 2 diabetes reduce HbA1c, are weight neutral. Geriatrics: Geriatrics 2006; 61(9):2 p following 13. No original data

Anon. PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes. Cardiovasc J Afr 2008; 19(3):159-62. No original data

Anon. Pre-meal inhaled insulin lowers HbA1c levels more effectively than rosiglitazone. Formulary 2005; 40(11):396. No original data

Anon. Primary prevention of cerebrovascular and cardiovascular events with an oral antidiabetic agent in patients with type 2 diabetes at high risk for cerebral infarction. UMIN CTR [Https://Center.Umin.Ac.Jp] 2009. Not written in English

Anon. PROactive study shows reduced heart attacks and strokes in type 2 diabetics on pioglitazone HCl (Actos) therapy. Cardiovasc J S Afr 2005; 16(5):286-7; discussion 287. No original data

Anon. Rosiglitazone decreases coronary restenosis. Cardiol Rev 2003; 20(8):11. No original data

Anon. Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis. Evid.-Based Med. 2007; 12(6):170. No original data

Anon. Rosiglitazone plus metformin combination improves glycaemic control in diabetes. Pharm J 2004; 273(7317):375. No comparison group

Anon. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable. Prescrire Int 2009; 18(99):14-5. No original data

Anon. Summaries for patients. A comparison of three insulin regimens (morning glargine, bedtime glargine, or bedtime neutral protamine Hagedorn) in addition to a pill for treating type 2 diabetes. Ann Intern Med 2003; 138(12):I33. No original data

Anon. Summaries for patients. Comparison of two types of insulin added to diabetes pills in poorly controlled type 2 diabetes. Ann Intern Med 2008; 149(8):I-46. No original data

Anon. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial (Annals of Internal Medicine (2007) 146 (477-485)). Ann Intern Med. 2007; 146(12):896. No original data

Anon. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005; 28(2):421-2. No comparison group

Anon. Thiazolidinediones could exacerbate BMD loss in elderly women. Nat. Clin. Pract. Endocrinol. Metab. 2006; 2(12):654-5. No original data

Anonymous. RAS - Rosiglitazone and Atherosclerosis Study: a 1 year randomised, double-blind, parallel group, placebo controlled study to evaluate the efficacy of rosiglitazone on the progression of intima-media thickness in the carotid artery in subjects with insulin resistance syndrome and/or type 2 diabetes mellitus.

[Http://Ctr.Gsk.Co.Uk/Summary/Rosiglitazone/IV_049653_334.Pdf](http://Ctr.Gsk.Co.Uk/Summary/Rosiglitazone/IV_049653_334.Pdf) 2004. No original data

Anwar A, Azmi KN, Hamidon BB, Khalid BA. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. *Med J Malaysia* 2006; 61(1):28-35. Other reason

Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P. Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. *Am J Med* 1990; 89(6):811-3. Does not meet the study design criteria

Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. *Diabetes Care* 2000; 23(11):1605-11. Does not have a drug comparison of interest

Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA. Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. *Diabetes Obes Metab* 2008; 10(8):638-45. Does not have a drug comparison of interest

Asic-Buturovic B. The effects of combined insulin and metformin therapy in obese patients with diabetes mellitus type 2 in the early stage of the disease. *Bosn J Basic Med Sci* 2006; 6(2):54-8. Does not meet the study design criteria

Avery MA, Chittiboyina A, Patny A. Novel Tricyclic (alpha)-Alkoxyphenyl Propanoic Acid Derivatives: Dual PPAR(alpha)/(gamma) Agonists with Hypolipidemic and Antidiabetic Activity. *Chemtracts* 2003; 16(11):653-9. No original data

Baba S, Nakagawa S, Takebe K et al. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. *Tohoku J Exp Med* 1983; 141 Suppl:693-706. Does not have a drug comparison of interest

Babich MM, Pike I, Shiffman ML. Metformin-induced acute hepatitis. *Am J Med* 1998; 104(5):490-2. No comparison group

Bachmann W, Sieger C, Haslbeck M, Lotz N. Combination of insulin and glibenclamide (gl) in the treatment of adult-onset diabetes (type 2). *Diabetologia* 1981; 21(3):21. Less than 40 subjects with type 2 diabetes

Bahadori B, Trinker M, Wallner SJ, Yazdani-Biuki B, Wascher TC. Diabetes mellitus and weight control: Differences of respiratory quotient in type 2 diabetic obese subjects receiving sulfonylureas and non-diabetic obese controls. *Nutrition* 2003; 19(2):159-60. Does not have a drug comparison of interest

Bain SC, Stella P, Cao A. Significantly reduced body mass index with liraglutide 1.2 mg treatment versus glimepiride may have an impact on cardiovascular risk in patients with type 2 diabetes. *Diabetic Medicine: Diabet. Med.* 2010; 27(Suppl 1):79. No original data

Baksi A, James RE, Zhou B, Nolan JJ. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. *Acta Diabetol* 2004; 41(2):63-9. Does not have a drug comparison of interest

Balkrishnan R, Rajagopalan R, Shenolikar RA, Camacho FT, Anderson RT. Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis. *Curr Med Res Opin* 2006; 22(3):551-9. Does not have a drug comparison of interest

Ballani P, Tran MT, Navar MD, Davidson MB. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. *Diabetes Care* 2006; 29(11):2504-5. Less than 40 subjects with type 2 diabetes

Ballary C, Desai A. Efficacy and safety of a combination of metformin and rosiglitazone in patients with type 2 diabetes mellitus--a postmarketing study. *J Indian Med Assoc* 2003; 101(2):113-4, 123. No comparison group

Barnes DJ et al. Microalbuminuria in type 2 diabetic patients: a cross sectional study. *Ann Clin Biochem* 1994; 31 (Pt 6):588-9. No original data

Barnett AH et al. Multicentre study to assess quality of life and glycaemic control of Type 2 diabetic patients treated with insulin compared with oval hypoglycaemic agents. *Practical Diabetes International*. 1996; 13(6):179-83. Does not have a drug comparison of interest

Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulphonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. *Clin Ther* 2007; 29(11):2333-48. Does not have a drug comparison of interest

Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulphonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. *Clin Ther* 2007; 29(11):2333-48. Does not have a drug comparison of interest

Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. *Diabetes Care* 2006; 29(8):1818-25. Does not have a drug comparison of interest

Barnett AH, Grant PJ, Hitman GA et al. Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. *Diabet Med* 2003; 20(5):387-93. Does not have a drug comparison of interest

Barranco C. Pioglitazone improves cardiovascular risk markers for patients with diabetes. *Nat. Clin. Pract. Cardiovasc. Med.* 2005; 2(9):438. No original data

Barzilay JI et al. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > or = 65 years (report from the Coronary Artery Surgery Study [CASS] Registry). *Am J Cardiol* 1994; 74(4):334-9. Does not apply

Baynes C, Feher MD, Elkeles RS. The effect of treatment of non-insulin-dependent diabetes mellitus (NIDDM) on serum lipids and lipoproteins. *Q. J. MED.* 1989; 72(267):579-87. No original data

Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naive Type 2 diabetes: a placebo-controlled, multicentre study. *Qual Life Res* 2003; 12(4):413-25. Does not have a drug comparison of interest

Beck-Nielsen H, Lindskov HO, Richelsen B. Mechanism of action of glibenclamide in type 2 (non-insulin dependent) diabetes during long-term treatment. *Diabetologia* 1982; 23(2):No. 16. Does not apply

Belcher G, Matthews DR. Safety and tolerability of pioglitazone. *Exp Clin Endocrinol Diabetes* 2000; 108(Suppl 2):267-73. Does not meet the study design criteria

Belden H. First in DPP-4 inhibitor class cleared for diabetes. *Drug Topics* 2006; 150(22). No original data

Belden H. New diabetes treatment combines two drugs into one. *Drug Topics* 2006; 150(17). No original data

Bell DS, Mayo MS. Improved glycaemic control with use of oral hypoglycaemic therapy with or without insulin. *Endocr Pract* 1998; 4(2):82-5. Does not apply

Bell DS, Mayo MS. Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus. *Endocr Pract* 1997; 3(2):73-6. Does not apply

Bell DS, Mayo MS. Weight loss in patients with diabetes treated with a metformin-sulfonylurea combination in comparison with twice-daily mixed insulin. *Endocr Pract* 1998; 4(6):360-4. Does not meet the study design criteria

Bell DS, Yumuk V. Frequency of severe hypoglycaemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. *Endocr Pract* 1997; 3(5):281-3. Does not apply

Bell DSH, Wyne KL. Use of fixed-dose oral combinations. *Postgrad. Med.* 2006; 119(2). No original data

Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y. Drug-induced hypoglycaemic coma in 102 diabetic patients. *Arch Intern Med* 1999; 159(3):281-4. Does not apply

Bengel FM, Abletshauer C, Nerverve J et al. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography. *Diabet Med* 2005; 22(2):158-63. Does not have a drug comparison of interest

Bergental R, Wysham C, Yan P, MacConell L, Malloy J, Porter L. Duration-2: Exenatide once weekly demonstrated significant glycaemic control and weight reduction compared to sitagliptin or pioglitazone after 26 weeks of treatment. *Diabetic Medicine: Diabet. Med.* 2010; 27(2):5. No original data

Berger W. Incidence of severe sideeffects during therapy with sulfonylureas and biguanides. *Horm Metab Res Suppl* 1985; 15:111-5. No original data

Berghout LM, Gorter KJ, Rutten GEHM. Course of glycaemia in poorly controlled type 2 diabetes patients 2.5 years after optimizing oral treatment in general practice. *Eur. J. Gen. Pract.* 2006; 12(2):80-2. Does not apply

Bergman AJ, Cote J, Yi B et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. *Diabetes Care* 2007; 30(7):1862-4. No subjects with type 2 diabetes

Bermudez-Pirela VJ, Cano C, Medina MT et al. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus. *Am J Ther* 2007; 14(2):194-202. Does not have a drug comparison of interest

Berria R, Rosenstock J, Silberman C, Davis KL, Horton ES. Weight loss and associated changes in glycaemic control and cardiovascular biomarkers in patients with type 2 diabetes mellitus receiving incretin therapies in a large cohort database. *Diabetologia: Diabetologia* 2009; 52(S1):S297. No original data

Best JD, Drury P, Davis T, Taskinen M-R, Kesaniemi A, Keech A. Metformin, sulphonylurea and insulin therapies maintain glycaemic control over five years in 4900 people with type 2 diabetes. *Diabetologia: Diabetologia* 2009; 52(S1):S93. No original data

Best JH, Yan P, Malloy J. DURATION 2: Weight-related quality of life, psychological well-being, and satisfaction with exenatide once weekly compared to sitagliptin or piaglitazone after 26 weeks of treatment. *Diabetologia: Diabetologia* 2009; 52(S1):S292-S293. Other reason

Bhansali A, Masoodi SR. Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus. *J Assoc Physicians India* 2005; 53:441-5. Does not have a drug comparison of interest

Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O. Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. *Diabetes Technol. Ther.* 2009; 11(6):353-9. No comparison group

Biesenbach G, Bodlaj G, Pieringer H. Weight gain and metabolic control in newly insulin-treated patients with type 2 diabetes with different insulin regimens. *Can. J. Diabetes* 2006; 30(4):384-9. Does not have a drug comparison of interest

Birkeland KI, Furuseth K, Melander A, Mowinckel P, Vaaler S. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. *Diabetes Care* 1994; 17(1):45-9. Does not have a drug comparison of interest

Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. *Diabetes Obes Metab* 2006; 8(4):436-47. Does not have a drug comparison of interest

Blonde L, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett Jeal. Liraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in Type 2 diabetes. *Can J Diabetes* 2008; 32:Abstract 107. No original data

Bloomgarden ZT. Pharmacologic treatment of type 2 diabetes. *Diabetes Care* 2003; 26(2):526-33. No original data

Bloomgren G, Dore D, Patterson R, Noel R, Braun D, Seeger J. Incidence of acute pancreatitis in exenatide initiators compared to other antidiabetic drug initiators: A retrospective, cohort study. *Diabetologia*: *Diabetologia* 2009; 52(S1):S9. No original data

Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. *Diabetes Care* 2008; 31(11):2086-91. Does not have a drug comparison of interest

Bokhari SU, Gopal UM, Duckworth WC. Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus. *Am J Med Sci* 2003; 325(2):66-9. Does not meet the study design criteria

Boord JB, Graber AL, Christman JW, Powers AC. Practical management of diabetes in critically III patients. *Am. J. Respir. Crit. Care Med.* 2001; 164(10 I):1763-7. No original data

Boucher M, McAuley L, Brown A, Keely E, Skidmore B. Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents. Ottawa: Canadian Coordinating Office for Health Technology Assessment 2003; Technology overview no. 9. No original data

Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. *Diabetes Care* 2006; 29(2):254-8. Does not have a drug comparison of interest

Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden DR. Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. *Diabetes Res* 1992; 19(2):69-76. Less than 40 subjects with type 2 diabetes

Boyle J, Fisher M. The addition of insulin to metformin and sulphonylureas: Results of the 4-T study. *Practical Diabetes International: Pract. Diabetes Int.* 2010; 27(1):5-6. No original data

Boyle PJ, King AB, Olansky L et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. *Clin Ther* 2002; 24(3):378-96. Does not meet the study design criteria

Brewer D. Are alpha-glucosidase inhibitors effective for control of type 2 diabetes? *Am Fam Physician* 2006; 73(3):433-4. No original data

Brixner D, McAdam-Marx C, Ye X, Misurski D, Wintle M, Fabunmi R. 18 Month A1C and weight outcomes of exenatide therapy in patients with type-2 diabetes in a real-world study. *Value Health* 2009; 12(3):A97. Other reason

Brodows R, Milton D, Ridge TDeal. Exenatide monotherapy improves glycemic control and is well tolerated over 24 weeks in drug-naïve patients with type 2 diabetes. *Diabetes* 2008; 57(Suppl 1):A145 (abstr 485-P). No original data

Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. *Diabetes Care* 2004; 27(7):1535-40. Does not apply

Brown JB, Pedula KL. Metformin as secondary therapy in a defined population with type 2 diabetes. *Clin Ther* 1999; 21(10):1678-87. Does not have a drug comparison of interest

Brown RR. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes. *Am J Health Syst Pharm* 1998; 55(24 Suppl 4):S24-7. Does not have a drug comparison of interest

Brunelli SM, Thadhani R, Ikizler TA, Feldman HI. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. *Kidney Int* 2009; 75(9):961-8. Does not meet the study design criteria

Bruns W et al. Treatment of type II diabetics (non-insulin-dependent) for sulphonylurea secondary failure - combined therapy, using glibenclamid and insulin. *Zeitschrift Für Klinische Medizin* 1990; 45(11):983-6. Does not apply

Bu S et al. [Evaluation of the efficacy and safety of once daily injection of glargine combined with glipizide GITS in the treatment of type 2 diabetes mellitus]. *Chinese Journal of Evidence-Based Medicine* 2004; 4(7):464-7. Not written in English

Bunck MC, Mari A, Comer A et al. One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks discontinuation of treatment. *Diabetologia: Diabetologia* 2009; 52(S1):S7. No original data

Buse J, Sesti G, Schmidt WE et al. A switch from twice-daily exenatide to once-daily liraglutide further improves glycaemic control in patients with type 2 diabetes on oral agents. *Diabetologia: Diabetologia* 2009; 52(S1):S7-S8. Other reason

Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet* 2009; 374(9683):39-47. Other reason

Buse JB, Sesti G, Schmidt WE et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. *Diabetes Care* 2010. Does not have a drug comparison of interest

Buyschaert M, Hermans MP. Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes. *Acta Clin Belg* 1999; 54(6):328-33. Does not have a drug comparison of interest

Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. *Aliment Pharmacol Ther* 2001; 15(1):137-42. Does not have a drug comparison of interest

Calle-Pascual A et al. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. *Diabetes & Metabolism* 1996; 22(3):201-2. Does not have a drug comparison of interest

Calvert MJ, McManus RJ, Freemantle N. The management of people with type 2 diabetes with hypoglycaemic agents in primary care: retrospective cohort study. *Fam Pract* 2007; 24(3):224-9. Does not meet the study design criteria

Campbell IW, Chalmers J, Herlihy OM. Sulphonylurea-induced hypoglycaemia in elderly people with diabetes. *Pract Diabetes* 1994; 11(3):102-3. No original data

Campbell IW, Menzies DG, McBain AM, Brown IRF. Effects of metformin on blood pressure and microalbuminuria in diabetes mellitus. *Diabete & Metabolism* 1988; 14:613-7. Other reason

Campbell IW. Metformin and glibenclamide: comparative risks. *Br Med J (Clin Res Ed)* 1984; 289(6440):289. No original data

Cardiovascular risk reduction with pioglitazone. *Cardiovasc J S Afr* 2002; 13(4):218. No original data

Carlson RF, Isley WL, Ogrinc FG, Klobucar TR. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. *Clin Ther* 1993; 15(5):788-96. Does not have a drug comparison of interest

Casscells SW, Granger E, Swedorske J et al. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006. *Am J Ther* 2008; 15(3):198-205. Other reason

Cathelineau G et al. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study. *Metabolism* 1997; 46(12 Suppl 1):31-4. No comparison group

Cefalu WT, Schneider DJ, Carlson HE et al. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. *Diabetes Care* 2002; 25(12):2123-8. No comparison group

Cesur M, Corapcioglu D, Gursoy A et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. *Diabetes Res Clin Pract* 2007; 75(2):141-7. Study duration less than 3 months

Chalasanani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. *Am J Gastroenterol* 2005; 100(6):1317-21. No comparison group

Chalmers J, Hunter JE, Robertson SJ et al. Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes. *Curr Med Res Opin* 2007; 23(8):1775-81. Does not meet the study design criteria

Chalmers J, McBain AM, Brown IRF, Campbell IW. Metformin: Is its use contraindicated in the elderly? *Pract Diabetes* 1992; 9(2):51-3. Does not have a drug comparison of interest

Chan JC, Scott R, Arjona Ferreira JC et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. *Diabetes Obes Metab* 2008; 10(7):545-55. Does not have a drug comparison of interest

Chan JC, Scott R, Arjona Ferreira JC et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. *Diabetes Obes Metab* 2008; 10(7):545-55. Does not have a drug comparison of interest

Chan KA, Truman A, Gurwitz JH et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. *Arch Intern Med* 2003; 163(6):728-34. Does not have a drug comparison of interest

Chan NN, Feher MD, Bridges NA. Metformin therapy for diabetes in Prader-Willi syndrome. *J R Soc Med* 1998; 91(11):598. No comparison group

Chandalia HB, Lamba PS, Chandalia SH, Singh DK, Modi SV, Shaikh SA. Weight gain in type 2 diabetics with different treatment modalities. *Metab Syndr Relat Disord* 2005; 3(2):130-6. Does not have a drug comparison of interest

Chandrasekharan S, Rao PP, Jayaram S, Jain SD, Ganesan R, Desai A. Efficacy and safety of nateglinide in the treatment of type II diabetes mellitus. *J Indian Med Assoc* 2002; 100(7):467-8. No comparison group

Charbonnel B, Roden M, Urquhart R et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. *Diabetologia* 2005; 48(3):553-60. Does not have a drug comparison of interest

Charbonnel B. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes. *Int J Clin Pract Suppl* 2007; (153):1-2. No original data

Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. *Diabet Med* 2005; 22(4):399-405. Does not have a drug comparison of interest

Charpentier G, Vaur L, Halimi S et al. Predictors of response to glimepiride in patients with type 2 diabetes mellitus. *Diabetes Metab* 2001; 27(5 Pt 1):563-71. No comparison group

Chen HS et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. *Diabetes Care* 2008; 31(10):1927-32. Does not have a drug comparison of interest

Chen R, Xu Z, Duan Y, Apanovitch A. Reaching HbA1c goals with saxagliptin in combination with metformin or sulfonylurea. *Diabetologia: Diabetologia* 2009; 52(S1):S296. No original data

Chiasson JL, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. *Ann Intern Med* 1994; 121(12):928-35. Does not have a drug comparison of interest

Chogtu B, Singh NP, Chawla S, Gupta U. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus. *Singapore Med J* 2009; 50(4):395-9. Does not have a drug comparison of interest

Choi D, Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. *Diabetes Care* 2004; 27(11):2654-60. Does not have a drug comparison of interest

Chokrungvaranon N, Chentanez T, Arakaki RF. Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes. *Endocrine* 2007; 32(3):311-6. Does not apply

Chou HS, Palmer JP, Jones AR et al. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. *Diabetes Obes Metab* 2008; 10(8):626-37. Does not have a drug comparison of interest

Chu JW, Abbasi F, McLaughlin TL et al. Lipoprotein risk factors for cardiovascular disease in patients with type 2 diabetes mellitus treated with oral antihyperglycaemic agents. *Diabetes Obes Metab* 2003; 5(5):333-7. Does not meet the study design criteria

Chuang L-M, Lu C, Su R-J, Wu H-P, Tai T-Y, Lin BJ. Bedtime intermediate-acting insulin in the treatment of secondary failure to oral hypoglycemic agents. *J. FORMOS. MED. ASSOC.* 1992; 91(2):185-9. Less than 40 subjects with type 2 diabetes

Ciardullo AV, Brunetti M, Daghighi MM et al. Characteristics of type 2 diabetic patients cared for by general practitioners either with medical nutrition therapy alone or with hypoglycaemic drugs. *Diabetes Nutr. Metab. Clin. Exp.* 2004; 17(2):120-3. Does not meet the study design criteria

Cohen M, Crosbie C, Cusworth L, Zimmet P. Insulin - not always a life sentence: Withdrawal of insulin therapy in non-insulin dependent diabetes. *DIABETES RES.* 1984; 1(1):31-4. Does not apply

Cohen O, Norymberg C, Neumann E, Dekel H. Weight gain in type 2 diabetes mellitus-Not all uphill. *Diabetes Res. Clin. Pract.* 2008; 79(1):128-32. Does not have a drug comparison of interest

Coppack SW, Lant AF, McIntosh CS, Rodgers AV. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. *Br J Clin Pharmacol* 1990; 29(6):673-84. Less than 40 subjects with type 2 diabetes

Corsonello A, Pedone C, Corica F et al. Concealed renal failure and adverse drug reactions in older patients with type 2 diabetes mellitus. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* 2005; 60(9):1147-51. Does not apply

Courreges JP, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Vilsbøll T. Liraglutide treatment improves glycaemic control, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes. *Diabetologia* 2006; 49(Suppl. 1):A0003. Other reason

Courreges JP, Vilsbøll T, Zdravkovic M et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. *Diabetic Medicine : a Journal of the British Diabetic Association* 2008; 25(9):1129-31. Does not have a drug comparison of interest

Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. *Diabetes Care* 2005; 28(3):539-43. Does not have a drug comparison of interest

Dailey G et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. *Diabetes Care* 2004; 27(10):2363-8. Does not have a drug comparison of interest

Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. *Diabetes Care* 1983; 6(5):472-4. Study duration less than 3 months

Dargie HJ, Hildebrandt PR, Riegger GA et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. *J Am Coll Cardiol* 2007; 49(16):1696-704. Does not have a drug comparison of interest

Davidson J, Howlett H. New prolonged-release metformin improves gastrointestinal tolerability. *Br. J. Diabetes Vasc. Dis.* 2004; 4(4):273-7. No original data

Davidson J, Koro C, Arondekar B, Lee BH, Fedder D. A retrospective analysis of the fasting plasma glucose and glycosylated hemoglobin and pharmacotherapy change patterns among type 2 diabetes mellitus patients. *Clin Ther* 2008; 30(2):287-93. Does not apply

Davidson JA, Scheen AJ, Hewlett HCS. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance(registered trademark)): A new treatment for the management of type 2 diabetes mellitus. *Drug Saf*. 2004; 27(15):1205-16. No original data

Davidson JK, Vander Zwaag R, Cox CL. The Memphis and Atlanta continuing care programs for diabetes. II. Comparative analyses of demographic characteristics, treatment methods, and outcomes over a 9-10-year follow-up period. *Diabetes Care* 1984; 7(1):25-31. No comparison group

Davies M, Nauck M, Bailey T et al. Better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analogue, compared with sitagliptin, a DPP-4 inhibitor, both in combination with metformin in type 2 diabetes. *Diabetic Medicine: Diabet. Med.* 2010; 27(Suppl 1):4-5. No original data

Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes Obes Metab* 2009; 11(12):1153-62. Does not have a drug comparison of interest

Davis PJ, Davis FB. Control of blood sugar level in elderly diabetic patients. *PRIM. CARE CLIN. OFF. PRACT.* 1982; 9(1):45-51. No original data

Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. *Diabetes Care* 2007; 30(11):2767-72. Does not have a drug comparison of interest

Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55). *Diabetes Care* 2001; 24(7):1167-74. Does not have a drug comparison of interest

Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. *Br J Clin Pharmacol* 2001; 52(2):137-44. Does not apply

de Fine Olivarius N, Andreasen AH, Siersma V, Richelsen B, Beck-Nielsen H. Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus. *Diabetologia* 2006; 49(9):2058-67. Does not meet the study design criteria

De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. *J Intern Med* 2005; 257(1):100-9. Does not have a drug comparison of interest

De Luis DA, Cuellar L, Terroba C et al. Effect of metformin on cardiovascular risk factors in obese type 2 diabetic patients. *Endocrinologia Nutr.* 2001; 48(4):110-3. Does not have a drug comparison of interest

Deeg MA, Buse JB, Goldberg RB et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. *Diabetes Care* 2007; 30(10):2458-64. Other reason

Dejgaard A, Madshad S, Kilhovd B, Langer I, Mustajoki P. Repaglinide compared to glipizide in the treatment of type 2 diabetic patients. *Diabetologia* 1998; 41(1):A236. Other reason

Del Prato S, Erkelens DW, Leutenegger M. Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. *Acta Diabetol* 2003; 40(1):20-7. Does not have a drug comparison of interest

Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. *Diabetes Care* 2003; 26(11):2983-9. Does not have a drug comparison of interest

Dembe K, Pieniqzek A, Niebisz A, Karnafel W. An evaluation of hypoglycaemia in patients with diabetes mellitus hospitalised at the Department of Gastroenterology and Metabolic Diseases, Medical University of Warsaw, Poland. *Diabetol. Dosw. Klin.* 2008; 8(4):169-72. Other reason

Derosa G, Cicero AF, Dangelo A et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. *Hypertens Res* 2005; 28(11):917-24. Does not have a drug comparison of interest

Derosa G, Cicero AF, Gaddi A et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. *Diabetes Res Clin Pract* 2005; 69(1):5-13. Does not have a drug comparison of interest

Derosa G, Cicero AF, Gaddi A et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. *Clin Ther* 2004; 26(5):744-54. Does not have a drug comparison of interest

Derosa G, Salvadeo SA, D'Angelo A et al. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. *Arch Med Res* 2008; 39(4):412-9. Does not meet the study design criteria

Desouza C, Fonseca VA. Insulin sensitizer combination therapy for type 2 diabetes. *Cardiol. Rev.* 2001; 18(1):11-5. Other reason

Deutsch JC, Santhosh-Kumar CR, Kolhouse JF. Efficacy of metformin in non-insulin-dependent diabetes mellitus. *N Engl J Med* 1996; 334(4):269; discussion 269-270. No original data

Diamant M et al. Long-term treatment with pioglitazone improves markers of liver function in patients with type 2 diabetes: results from PROactive. 42nd Annual Meeting of the European Association for the Study of Diabetes 2006 2006. Other reason

Dickinson PJ, Dornhorst A, Frost GS. A retrospective case-control study of initiating insulin therapy in type 2 diabetes. *Pract. Diabetes Int.* 2002; 19(3):67-70. Does not have a drug comparison of interest

Diez JJ. Perioperative management of type 2 diabetes mellitus by two techniques of insulin infusion. A randomized clinical study. *Endocrinologia* 1991; 38(4):108-12. Less than 40 subjects with type 2 diabetes

Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. *Horm Metab Res* 1996; 28(9):426-9. Does not have a drug comparison of interest

Doering PL, Boothby LA. CE: New drug update 2005-Part 2. *Drug Topics* 2006; 150(4). No original data

Doggrell SA. Is liraglutide or exenatide better in type 2 diabetes? *Expert Opinion on Pharmacotherapy: Expert Opin. Pharmacother.* 2009; 10(16):2769-72. Other reason

Doggrell SA. Recent evidence of sustained benefit with exenatide in Type 2 diabetes. *Expert Opin Pharmacother* 2006; 7(14):2003-6. No original data

Donadon V, Balbi M, Ghersetti M et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. *World J Gastroenterol* 2009; 15(20):2506-11. Does not apply

Donatelli M, Verga S, Terrizzi C, Vaccaro M, Bompiani GD. Long-term clinical experience with antidiabetic drugs in the treatment of noninsulin-dependent diabetes mellitus. *Curr Ther Res Clin Exp* 1987; 42(6):1166-70. Does not have a drug comparison of interest

Donnan PT, Steinke DT, Newton RW, Morris AD. Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population-based study. *Diabet Med* 2002; 19(7):606-10. Other reason

Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. *Diabet Med* 2006; 23(2):128-33. Does not meet the study design criteria

Dore DD, Seeger JD, Chan KA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. *Curr. Med. Res. Opin.* 2009; 25(4):1019-27. Does not have a drug comparison of interest

Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. *Drug Saf* 2009; 32(3):187-202. Does not have a drug comparison of interest

Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L. Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). *Atherosclerosis* 2009; 202(1):272-81. Does not have a drug comparison of interest

Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Roskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. *Horm Metab Res* 1996; 28(9):419-25. Does not have a drug comparison of interest

Drown DJ. Metformin: effective in the prevention of new-onset type 2 diabetes? *Prog Cardiovasc Nurs* 2008; 23(2):93-4. No original data

Drzewoski J, Czupryniak L. Long-term efficacy of steady-dose metformin in type 2 diabetes mellitus: a retrospective study. *Med Sci Monit* 2003; 9(6):CR240-3. Does not meet the study design criteria

Duane J, Conway W. Weight change in intensive insulin therapy for type 2 diabetes mellitus as a function of glycosylated hemoglobin (A1C) level achieved: The deep south diabetes program. *Insulin* 2008; 3(4):219-31. Does not have a drug comparison of interest

Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009; 360(2):129-39. Does not have a drug comparison of interest

Duncan AI, Koch CG, Xu M et al. Recent metformin ingestion does not increase in-hospital morbidity or mortality after cardiac surgery. *Anesth Analg* 2007; 104(1):42-50. Does not have a drug comparison of interest

Dworacka M, Abramczyk M, Winiarska H, Kuczynski S, Borowska M, Szczawinska K. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea. *Int J Clin Pharmacol Ther* 2006; 44(1):14-21. Does not meet the study design criteria

Ebell MH. Insulin monotherapy vs. combination therapy. *Am Fam Physician* 2005; 71(5):899. No original data

Eeley EA, Stratton IM, Hadden DR, Turner RC, Holman RR. UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group. *Diabet Med* 1996; 13(7):656-62. Does not have a drug comparison of interest

Emanuele N, Azad N, Abraira C et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. *Arch. Intern. Med.* 1998; 158(22):2485-90. Does not have a drug comparison of interest

Engel-Nitz NM, Martin S, Sun P, Buesching D, Fonseca V. Cardiovascular events and insulin therapy: A retrospective cohort analysis. *Diabetes Res. Clin. Pract.* 2008; 81(1):97-104. Does not have a drug comparison of interest

Erdmann E et al. Pioglitazone treatment in patients with type 2 diabetes and a history of MI: subgroup analysis from PROactive stratified by gender, age and duration of diabetes. 42nd Annual Meeting of the European Association for the Study of Diabetes 2006 2006. Other reason

Erdmann E, Charbonnel B, Wilcox RG et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). *Diabetes Care* 2007; 30(11):2773-8. Does not have a drug comparison of interest

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. *J Am Coll Cardiol* 2007; 49(17):1772-80. Does not have a drug comparison of interest

Erle G, Lovise S, Stocchiero C et al. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. *Acta Diabetol* 1999; 36(1-2):61-5. Does not have a drug comparison of interest

Esposito K, Ciotola M, Maiorino MI et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. *Ann Intern Med* 2008; 149(8):531-9. Does not meet the study design criteria

Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. *Pharmacotherapy* 2005; 25(6):810-6. Does not apply

Ezenwaka CE. Metabolic control of type-2 diabetic patients commonly treated with sulphonylureas in a developing country. *East Afr Med J* 2003; 80(4):175-80. Does not have a drug comparison of interest

Fabunmi R, Nielsen LL, Quimbo R et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine *. *Curr Med Res Opin* 2009. Does not have a drug comparison of interest

Fabunmi R, Wade R, Quimbo RA, Hou L, Pawaskar MD, Misurski D. Administrative claims analysis of patients with type-2 diabetes initiating sitagliptin therapy. *Value Health* 2009; 12(3):A98. Other reason

Fakhoury W, Lockhart I, Kotchie RW, Aagren M, LeReun C. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. *Pharmacology* 2008; 82(2):156-63. Does not apply

Famuyiwa OO, Sulimani RA, Laajam MA, Al-Jasser SJ, Mekki MO. Diabetes mellitus in Saudi Arabia: The clinical pattern and complications in 1,000 patients. *Ann Saudi Med* 1992; 12(2):140-51. Does not meet the study design criteria

Fang CC, Ng Jao YT, Yi-Chen, Yu CL, Chen CL, Wang SP. Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience. *Angiology* 2007; 58(5):523-34. Does not have a drug comparison of interest

Farquhar D. A new option in oral hypoglycemic therapy for type 2 diabetes mellitus. *Can. Med. Assoc. J.* 2000; 163(9):1186. Other reason

Feinbock C, Luger A, Klingler A et al. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. *Diabetes Nutr Metab* 2003; 16(4):214-21. Does not have a drug comparison of interest

Feldman L, Shani M, Efrati S et al. Association between rosiglitazone use and decline in renal function in patients with type 2 diabetes mellitus. *J Nephrol* 2010. Does not have a drug comparison of interest

Finn AV, Oh JS, Hendricks M et al. Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. *Am Heart J* 2009; 157(2):383.e1-8. Does not have a drug comparison of interest

Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline corrected postprandial glucose levels. *Diabetes* 2008; 57(Suppl 1):A165. No original data

Flores-Murrieta FJ, Aguilar-Cota ME, Camacho A, Reyes-Garcia G, Herrera JE, Medina-Santillan R. Comparative bioavailability of two oral formulations manufactured in Mexico containing glyburide and metformin in diabetic patients. *Proc West Pharmacol Soc* 2003; 46:82-4. Less than 40 subjects with type 2 diabetes

Florkowski CM, Scott RS, Coope PA, Moir CL. Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study. *Diabetes Res Clin Pract* 2001; 53(2):113-20. Does not have a drug comparison of interest

Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. *Am J Ophthalmol* 2009; 147(4):583-6.e1. Does not have a drug comparison of interest

Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. *Diabetes Care* 2003; 26(6):1685-90. Does not have a drug comparison of interest

Fonseca VA, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry RR. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. *J Diabetes Complications* 2006; 20(1):14-20. Does not have a drug comparison of interest

Forst T, Lubben G, Hohberg C et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. *Microcirculation* 2005; 12(7):543-50. Other reason

Fowler MJ. Diabetes treatment, Part 2: Oral agents for glycemic management. *Clin Diabetes* 2007; 25(4):131-4. No original data

Frenchman IB. Treatment and treatment-related adverse events of type 2 diabetes mellitus in residents of long-term care facilities: A retrospective study. *Curr Ther Res Clin Exp* 2003; 64(1):1-9. Other reason

Fresco C. Pioglitazone vs glimepiride in the PERISCOPE trial. *JAMA* 2008; 300(7):787; author reply 788. No original data

Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. *Clin Ther* 2003; 25(2):515-29. Does not have a drug comparison of interest

Furlong NJ, McNulty SJ, O'Brien SV, Hardy KJ. Comparison of metformin versus sulphonylurea in combination with daily NPH insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycaemic agents; Median follow-up 29 months. *Pract. Diabetes Int.* 2002; 19(8):245-9. Does not have a drug comparison of interest

Gaede P et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *Lancet* 1999; 353(9153):617-22. Does not have a drug comparison of interest

Gaede P, Parving HH, Pedersen O. PROactive study. *Lancet* 2006; 367(9504):23, 24; author reply 26-27. No original data

Galeone F, Saba P, Saponati G. Gliquidone (Glurenor) in long-term treatment of type II diabetes mellitus. *CLIN. TRIALS J.* 1989; 26(2):108-18. Does not have a drug comparison of interest

Gallwitz B, Dotta F, Kazda C et al. Changes in adipokines in type 2 diabetic patients treated with exenatide versus glimepiride on metformin background - Results of a prospective, randomized controlled study over 9 months. *Diabetologia: Diabetologia* 2009; 52(S1):S313. Other reason

Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. *Int J Clin Pract* 2010; 64(2):267-76. Other reason

Garber A, Henry R, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a human GLP-1 analogue, offers sustained and greater reduction in HbA1c, fasting plasma glucose and weight compared with glimepiride over 2 years, with lower hypoglycaemic risk, in patients with Type 2 diabetes: LEAD-3 extension study. *Diabetic Medicine: Diabet. Med.* 2010; 27(Suppl 1):78. No original data

Garber A, Henry R, Ratner RE, Hae P, Chang CT, Bode B. Two years of treatment with liraglutide, a human GLP-1 analogue, offers sustained and greater reduction with HbA1c, FPG, PPG and weight compared with glimepiride, with lower glycaemic risk, in patients with type 2 diabetes: LEAD-3 extension study. *Canadian Journal of Diabetes: Can. J. Diabetes* 2009; 33(3):289. Other reason

Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. *Am J Med* 1997; 103(6):491-7. Does not have a drug comparison of interest

Garber AJ, Henry R, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a human GLP-1 analogue, maintains greater reductions in HbA1c, FPG and weight than glimepiride over 2 years in patients with type 2 diabetes: LEAD-3 extension study. *Diabetologia: Diabetologia* 2009; 52(S1):S287-S288. Other reason

Garber AJ. Benefits of combination therapy of insulin and oral hypoglycemic agents. *Arch. Intern. Med.* 2003; 163(15):1781-2+1785. No original data

Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1999; 33(1):119-24. Does not have a drug comparison of interest

Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. *Am J Physiol Endocrinol Metab* 2007; 292(3):E871-83. Does not meet the study design criteria

Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. *Endocr Pract* 2001; 7(3):162-9. Does not have a drug comparison of interest

Gegick CG, Altheimer MD. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. *Curr Med Res Opin* 2004; 20(6):919-30. Does not meet the study design criteria

Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. *Pharmacoepidemiol Drug Saf* 2007; 16(10):1065-71. Does not have a drug comparison of interest

Gerstein HC, Garon J, Joyce C, Rolfe A, Walter CM. Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. *Diabet Med* 2004; 21(11):1200-3. Does not apply

Gerstein HC, Ratner RE, Cannon CP et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. *Circulation* 2010; 121(10):1176-87. Does not have a drug comparison of interest

Gerstein HC, Riddle MC, Kendall DM et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007; 99(12A):34i-43i. No original data

Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. *Diabet Med* 2006; 23(7):736-42. Does not have a drug comparison of interest

Gerstein HC, Miller ME. Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. *N Engl J Med* 2008; 358(24):2545-59. Does not apply

Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. *J Card Fail* 2008; 14(6):445-52. Does not have a drug comparison of interest

Gill GV, Huddle KR. Hypoglycaemic admissions among diabetic patients in Soweto, South Africa. *Diabet Med* 1993; 10(2):181-3. Does not have a drug comparison of interest

Glass LC, Qu Y, Lenox S et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. *Curr Med Res Opin* 2008; 24(3):639-44. Does not have a drug comparison of interest

Glass LC, Triplitt C, Lewis MS et al. Effects of exenatide plus rosiglitazone on measures of beta cell function and insulin sensitivity in subjects with type 2 diabetes previously treated with metformin. *Diabetologia: Diabetologia* 2009; 52(S1):S286. Other reason

GlaxoSmithKline: Study no 049653/211: a 52-week double blind study of the effect of rosiglitazone on cardiovascular structure and function in subjects with type 2 diabetes and congestive heart failure [article online]. Does not have a drug comparison of interest

Glimepiride--well tolerated in daily practice. *Cardiovasc J S Afr* 2002; 13(4):214-5. No original data

Glitazones linked to heart failure. *Pharm. J.* 2003; 271(7266):312. No original data

Glyburide/metformin (Glucovance) for type 2 diabetes. *Med Lett Drugs Ther* 2000; 42(1092):105-6. No original data

Go EH, Kyriakidou-Himonas M, Berelowitz M. Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes. *Diabetes Metab Res Rev* 2004; 20(3):225-31. Does not have a drug comparison of interest

Goke B. Improved glyceamic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. *Treat Endocrinol* 2002; 1(5):329-36. Does not have a drug comparison of interest

Goldberg RB, Einhorn D, Lucas CP et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. *Diabetes Care* 1998; 21(11):1897-903. Does not have a drug comparison of interest

Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. *Diabetes Care* 1996; 19(8):849-56. Does not have a drug comparison of interest

Goldstein BJ, Weissman PN, Wooddell MJ, Waterhouse BR, Cobitz AR. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. *Curr Med Res Opin* 2006; 22(9):1715-23. Does not apply

Gonzalez-Ortiz M et al. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy]. *Revista De Investigaci3n Cl3nica; Organo Del Hospital De Enfermedades De La Nutrici3n* 2004; 56(3):327-33. Not written in English

Gore MO, McGuire DK. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): Cardiovascular observations in context. *Diabetes Vasc Dis Res* 2009; 6(1):53-5. No original data

Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus. *Am J Med Sci* 2008; 336(3):241-7. Does not have a drug comparison of interest

Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. *Diabetes Care* 2007; 30(4):790-4. No subjects >18 years old

Goudswaard AN, Stolk RP, Zuithoff P, de Valk HW, Rutten GE. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. *J Fam Pract* 2004; 53(5):393-9. Does not have a drug comparison of interest

Gough S, Zinman B, Falahati A, Toft A. The proportion of patients reaching the composite outcome of HbA1c <7.0%, no hypoglycaemia and no weight gain with different Type 2 diabetes therapies in the Liraglutide Effect and Action in Diabetes (LEAD) programme. *Diabetic Medicine: Diabet. Med.* 2010; 27(Suppl 1):77. No original data

Govindarajan R, Ratnasinghe L, Simmons DL et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. *J Clin Oncol* 2007; 25(12):1476-81. Does not apply

Goyal A, Crook ED. Thiazolidinediones and progression of renal disease in patients with diabetes. *J Investig Med* 2006; 54(2):56-61. Does not have a drug comparison of interest

Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. *Diabetes Care* 1996; 19(1):64-6. Does not have a drug comparison of interest

Grant PJ. The effects of metformin on cardiovascular risk factors. *Diabetes Metab Rev* 1995; 11 Suppl 1:S43-50. No original data

Greco D, Angileri G. Drug-induced severe hypoglycaemia in Type 2 diabetic patients aged 80 years or older. *Diabetes Nutr Metab* 2004; 17(1):23-6. Does not meet the study design criteria

Gregorio F et al. [Body mass index, blood lactate and therapeutic effectiveness of metformin in type II diabetes mellitus]. *Medicina (Florence, Italy)* 1989; 9(2):200-4. Not written in English

Gregorio F et al. Metformin-sulphonylurea combination therapy: the influence of regional adiposity on biguanide-induced haemostatic improvement. Balance in type II diabetic patients. *Annals of Experimental and Clinical Medicine* 1994; 2:136-45. Other reason

Gregorio F, Ambrosi F, Filipponi P, Manfrini S, Testa I. Is metformin safe enough for ageing type 2 diabetic patients? *Diabetes Metab* 1996; 22(1):43-50. No comparison group

Gregorio F, Ambrosi F, Manfrini S et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. *Diabet Med* 1999; 16(12):1016-24. Does not have a drug comparison of interest

Gregorio F, Manfrini S, Testa I, Filipponi P. Metformin treatment in elderly type II diabetic patients. *Arch Gerontol Geriatr* 1996; 22 Suppl 1:261-70. Does not have a drug comparison of interest

Groop L, Widen E, Franssila-Kallunki A, Ekstrand A. Sulphonylureas and/or insulin in Type 2 diabetes. Less than 40 subjects with type 2 diabetes

Groop PH, Groop L, Totterman KJ, Pelkonen R. Metabolic effects of glibenclamide and glipizide in patients with type 2 diabetes. *ACTA ENDOCRINOL. SUPPL.* 1982; 100(Suppl. 247):25. No subjects >18 years old

Grossman E. Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al. *J. Hum. Hypertens.* 2003; 17(1):5-6. No original data

Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. *Clin Ther* 2009; 31(1):74-88. Does not have a drug comparison of interest

Guillausseau PJ. PROactive study. *Lancet* 2006; 367(9504):23; author reply 26-27. No original data

Guler S, Cakir B, Demirbas B, Gursoy G, Serter R, Aral Y. Leptin concentrations are related to glycaemic control, but do not change with short-term oral antidiabetic therapy in female patients with type 2 diabetes mellitus. *Diabetes Obes Metab* 2000; 2(5):313-6. Study duration less than 3 months

Guler S, Sharma SK, Almustafa M et al. Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. *Arch Drug Inf* 2009; 2(2):23-33. Does not have a drug comparison of interest

Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. *J Diabetes Complications* 2009. Other reason

Gupta M, Braga MB, Verma S. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. *Can J Cardiol* 2008; 24(10):e65-9. Other reason

Habib SS, Aslam M, Naveed AK, Razi MS. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy. *Saudi Med J* 2006; 27(2):174-80. Does not meet the study design criteria

Habib ZA, Tzogias L, Havstad SL et al. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. *Pharmacoepidemiol Drug Saf* 2009; 18(6):437-47. Does not have a drug comparison of interest

Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. *Circulation* 2002; 106(6):679-84. Does not have a drug comparison of interest

Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. *Int. J. Clin. Pract.* 2007; 61(12):2009-18. No comparison group

Hanefeld M et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. *Diabetologia* 1996; 39(12):1577-83. Does not have a drug comparison of interest

Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. *Diabetes Care* 2000; 23(2):202-7. Does not have a drug comparison of interest

Hanefeld M, Goke B. Combining pioglitazone with a sulphonylurea or mefformin in the management of type 2 diabetes. *Exp Clin Endocrinol Diabetes* 2000; 108(Suppl 2):256-66. No original data

Hanefeld M, Herman G, Mickel C. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-4) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. *Diabetologia* 2005; 48(Suppl 1):287-8. Other reason

Hanefeld M, Temelkova-Kurktschiev T, Kohler C. Effect of oral antidiabetics and insulin on lipids and coronary heart disease in non-insulin-dependent diabetes mellitus. *ANN. NEW YORK ACAD. SCI.* 1997; 827(-):246-68. No original data

Hao Y et al. [Effects of pioglitazone on elderly patients with type 2 diabetes mellitus]. *Medical Journal of Wuhan University* 2006; 27(1):104-7. Not written in English

Harashima K, Hayashi J, Miwa T, Tsunoda T. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. *Metabolism* 2009; 58(6):739-45. Does not meet the study design criteria

Harris S, Yale J-F, Dempsey E, Gerstein H. Can family physicians help patients initiate basal insulin therapy successfully?: Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: Lessons for family practice from the Canadian INSIGHT trial. *Can. Fam. Phys.* 2008; 54(4):550-8. Does not apply

Harrower AD. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. *Curr Med Res Opin* 1985; 9(10):676-80. Does not have a drug comparison of interest

Hartung DM, Touchette DR, Bultemeier NC, Haxby DG. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. *Pharmacotherapy* 2005; 25(10):1329-36. Does not have a drug comparison of interest

Hasche H, Mertes G, Bruns C et al. Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. *Diabetes Nutr Metab* 1999; 12(4):277-85. Does not have a drug comparison of interest

Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. *Diabetes Care* 2003; 26(3):886-91. No comparison group

Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. *Diabete Metab* 1991; 17(1 Pt 2):224-31. No comparison group

Hays JH, Gorman RT, Shakir KM. Results of use of metformin and replacement of starch with saturated fat in diets of patients with type 2 diabetes. *Endocr Pract* 2002; 8(3):177-83. Does not apply

Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. *JAMA* 1997; 278(20):1663-9. Does not have a drug comparison of interest

Hegele RA et al. Differential response of plasma lipoprotein(a) and apolipoprotein B in NIDDM subjects treated with acarbose. *Diabetes Care* 1995; 18(2):272-3. Does not have a drug comparison of interest

Heine R, Van Gaal L, Johns D et al. Exenatide achieved equivalent glycaemic control to insulin glargine in metformin and sulphonylurea -treated type 2 diabetics: blood pressure results. *JEI* 2006; 29(Suppl. 4):28. Other reason

Heine RJ, Van Gaal LF, Johns. D. Exenatide achieved equivalent glycaemic control to insulin glargine with weight reduction, independently from baseline BMI, in metformin and sulphonylurea -treated type 2 diabetes. *JEI* 2007; 30 (Suppl. 4):105. Other reason

Heliovaara MK, Herz M, Teppo AM, Leinonen E, Ebeling P. Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes. *J Endocrinol Invest* 2007; 30(4):292-7. Other reason

Hellgren M, Melander A, Ostgren CJ, Rastam L, Lindblad U. Inverse association between plasma homocysteine, sulphonylurea exposure and physical activity: a community-based sample of type 2 diabetes patients in the Skaraborg hypertension and diabetes project. *Diabetes Obes Metab* 2005; 7(4):421-9. Does not apply

Hendra TJ TC. A randomised trial of insulin on well-being and carer strain in elderly type 2 diabetic subjects. *J Diabetes Complications* 2004; 18(3):148-54. Does not apply

Henriksen JH, Ring-Larsen H. Rosiglitazone: Possible complications and treatment of non-alcoholic steatohepatitis (NASH). *J. Hepatol.* 2008; 48(1):174-6. No original data

Hermann LS, Lindberg G, Lindblad U, Melander A. Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2002; 4(5):296-304. No original data

Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. *Diabet Med* 1994; 11(10):953-60. Other reason

Hermansen K, Davies M, Dereziński T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-Naive people with type 2 diabetes. *Diabetes Care* 2006; 29(6):1269-74. Does not have a drug comparison of interest

Herz M, Johns D, Reviriego J et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. *Clin Ther* 2003; 25(4):1074-95. Does not have a drug comparison of interest

Hettihewa LM et al. Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy. *International Journal of Diabetes in Developing Countries* 2008; 28(1):26-30. Does not meet the study design criteria

Higginbotham L, Martin FIR. Double-blind trial of metformin in the therapy of non-ketotic diabetics. *Med J Aust* 1979; 2:154-6. Less than 40 subjects with type 2 diabetes

Hinke SA, McIntosh CH, Hoffmann T et al. On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors. *Diabetes Care* 2002; 25(8):1490-1; author reply 1491. No original data

Hiralal R, Koo KK, Gerstein HC. Does pioglitazone prevent macrovascular events in patients with type 2 diabetes? *CMAJ* 2006; 174(8):1090-1. No original data

Hoffmann JK. Adjustment of metabolism and eating behaviour of type II diabetics. Results of a six-months treatment with glibenclamide, respectively with acarbose. *Zeitschrift Für Allgemeinmedizin* 1992; 68(29):970-7. Not written in English

Hohberg C, Pfutzner A, Forst T et al. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study. *Diabetes Obes Metab* 2009; 11(5):464-71. No comparison group

Hollander PA, Schwartz SL, Gatlin MR et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. *Diabetes Care* 2001; 24(6):983-8. Does not have a drug comparison of interest

Holleman F et al. Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence. *Ned Tijdschr Geneesk* 2006; 150(7):358-60. Not written in English

Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemetic control over 3 years (U.K. Prospective Diabetes Study 44). *Diabetes Care* 1999; 22(6):960-4. Does not have a drug comparison of interest

Holman RR, Farmer AJ, Davies MJ et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. *N Engl J Med* 2009; 361(18):1736-47. Does not have a drug comparison of interest

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008; 359(15):1577-89. Does not have a drug comparison of interest

Holman RR, Retnakaran R, Farmer A, Stevens R. PROactive study. *Lancet* 2006; 367(9504):25, 26; author reply 26-27. No original data

Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. *N Engl J Med* 2007; 357(17):1716-30. Does not apply

Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. *Diabetes Metab Res Rev* 2001; 17(6):467-73. Does not have a drug comparison of interest

Home P, Gubb J. Rosiglitazone evaluated for cardiac outcomes and regulation of glycemia in diabetes (RECORD): a long-term cardiovascular outcome study. *Diabetes* 2002; 51(Suppl 2):A487. Other reason

Home P, Komajada M, Beck-Nielsen H, Curtis P, Zambanini A, Dargie H. Twelve months sustained efficacy of rosiglitazone combination therapy on ambulatory blood pressure (ABP) in people with type 2 diabetes mellitus. *Diabetes* 2005; 54(Suppl. 1):A134. Other reason

Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. *N Engl J Med* 2007; 357(1):28-38. Does not have a drug comparison of interest

Honisett S et al. Rosiglitazone improves vascular function in postmenopausal women with Type 2 diabetes mellitus and hormonal therapy attenuates this improvement. The 6th Australasian Menopause Society Congress 2002. Other reason

Hoogeveen EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? *J Intern Med* 1997; 242(5):389-94. Does not meet the study design criteria

Horowitz M, Vilsboll T, Zdravkovic M, Hammer M, Madsbad S. Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. *Diabetes, Obesity and Metabolism: Diabestes Obes Metab* 2008; 10(7):593-6. Does not have a drug comparison of interest

Horsdal HT, Johnsen SP, Sondergaard F, Rungby J. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. *Diabetologia* 2008; 51(4):567-74. Does not have a drug comparison of interest

Hotta N et al. Diabetic neuropathy: effects of intensified glycaemic control with multiple insulin injections. *Diabetic Medicine: a Journal of the British Diabetic Association* 1993; 10 Suppl 2:91S-4S. Other reason

Houlden R, Ross S, Harris S, Yale J-F, Sauriol L, Gerstein HC. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study. *Diabetes Res Clin Pract.* 2007; 78(2):254-8. Does not apply

Howes LG. Cardiovascular effects of sulphonylureas: role of K(ATP) channels. *Diabetes Obes Metab* 2000; 2(2):67-73. No original data

Hristov V, Sheinkova G, Simeonov S, Botushanov N, Valkov Y, Tzinlikov I. Clinical assessment of glimepiride (Amaril(registered trademark)) in the treatment of type 2 diabetes mellitus patients (results of a multicenter study). *Endocrinologia (Bulgaria)* 2002; 7(1):30-5. Not written in English

Hsiao FY, Mullins CD. The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study. *Diabetologia* 2009. Does not have a drug comparison of interest

Huang Z et al. Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed Type 2 diabetic patients. *Zhong Nan Da Xue Xue Bao Yi Xue Ban (Journal of Central South University Medical Sciences)* 2006; 31(3):367-72. Not written in English

Hulisz DT, Bonfiglio MF, Murray RD. Metformin-associated lactic acidosis. *J Am Board Fam Pract* 1998; 11(3):233-6. No comparison group

Iavicoli M, Cucinotta D, De Mattia G et al. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents. *Diabetic Med* 1988; 5(9):849-55. Does not have a drug comparison of interest

Inukai K, Watanabe M, Nakashima Y et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects. *Diabetes Res Clin Pract* 2005; 68(3):250-7. Does not have a drug comparison of interest

Inzucchi S, Leiter LA, Rosenstock J. Type 2 diabetes and TZDs (thiazolidinediones): Diabetes de tipo 2 y las TZD (tiazolidinedionas). *J. Clin. Endocrinol. Metab.* 2009; 94(11). No original data

Inzucchi SE, Masoudi FA, Wang Y et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: Insights from the national heart care project. *Diabetes Care* 2005; 28(7):1680-9. Does not have a drug comparison of interest

Iozzo P, Hallsten K, Oikonen V et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. *Diabetes Care* 2003; 26(7):2069-74. Less than 40 subjects with type 2 diabetes

Isley WL, Oki JC. Hepatotoxicity of thiazolidinediones. *Diab. Obesity Metabol* 2001; 3(6):389-92. No original data

Ito H. [Japanese Elderly Diabetes Intervention Trial (J-EDIT)]. *Nippon Rinsho* 2006; 64(1):21-6. Not written in English

Jackson M, Nussey S, Mudan S. Metformin induced lactic acidosis. *Clin. Intensive Care* 2000; 11(4):209-13. No comparison group

Janssen PG et al. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. *The British Journal of General Practice : the Journal of the Royal College of General Practitioners* 2009; 59(558):43-8. Does not apply

Jendle J, Nauck MA, Matthews DR et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. *Diabetes Obes Metab* 2009; 11(12):1163-72. Other reason

Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. *Diabetes Care* 1989; 12(3):203-8. Does not meet the study design criteria

Jermendy G, Erdesz D, Nagy L et al. Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary. *Health Qual Life Outcomes* 2008; 6:88. Does not meet the study design criteria

Jerums G, Murray RML, Seeman E. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: A two-year controlled study. *Diabetes Res Clin Pract* 1987; 3(2):71-80. Does not have a drug comparison of interest

Jialal I, Joubert SM. The effect of oral hypoglycaemic agents on lipid levels in non-insulin-dependent diabetes in the young. *S. AFR. MED. J.* 1982; 62(11):348-9. No original data

Johnsen SP, Monster TB, Olsen ML et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. *Am J Ther* 2006; 13(2):134-40. Does not have a drug comparison of interest

Jones N, Jones T, Menci L. Rosiglitazone in combination with glimeclamide plus metformin is effective and well tolerated in type 2 diabetes patients. *Diabetologia* 2001; 44(Suppl 1):A235. Other reason

Jonsson A, Hallengren B, Rydberg T, Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. *Diabetes Obes Metab* 2001; 3(6):403-9. Less than 40 subjects with type 2 diabetes

Josse RG. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. *Diabetes Res Clin Pract* 1995; 28 Suppl:S167-72. Does not have a drug comparison of interest

Jovanovic L, Dailey G 3rd, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. *J Clin Pharmacol* 2000; 40(1):49-57. Does not have a drug comparison of interest

Jun JK, Gong WC, Mathur R. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. *Am J Health Syst Pharm* 2003; 60(5):469-73. No comparison group

Jung W, Jung S. Effects of pioglitazone and insulin on tight glycaemic control assessed by the continuous glucose monitoring system: A monocentric, parallel-cohort study. *Clin. Drug Invest.* 2005; 25(5):347-52. Less than 40 subjects with type 2 diabetes

Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. *Ann Pharmacother* 2003; 37(11):1572-6. Does not have a drug comparison of interest

Kacerovsky-Bielesz G, Dressler A, Freunsch R. Long-term glycaemic control with insulin glargine in Type 2 diabetes. *Diabetes Res Clin Pract* 2006; 71(2):184-91. No comparison group

Kadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. *Diabetes Care* 2007; 30(9):2242-4. Does not have a drug comparison of interest

Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. *J Clin Invest* 2000; 106(11):1305-7. No original data

Kahn SE, Haffner SM, Viberti G et al. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care* 2010; 33(1):177-83. Does not have a drug comparison of interest

Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes. *Diabetes Care* 2008; 31(5):845-51. Other reason

Kamber N, Davis WA, Bruce DG, Davis TM. Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. *Med J Aust* 2008; 188(8):446-9. No comparison group

Kanazawa I, Yamaguchi T, Yano S et al. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. *Osteoporos Int* 2010. Does not have a drug comparison of interest

Kane MP, Busch RS, Bakst G, Hamilton RA. Substitution of pioglitazone for troglitazone in patients with type 2 diabetes. *Endocr Pract* 2004; 10(1):18-23. Does not have a drug comparison of interest

Kanzer-Lewis G. Early combination therapy with a thiazolidinedione for the treatment of type 2 diabetes. *Diabetes Educ* 2003; 29(6):954-8, 961. No original data

Karagiannis E, Pfozner A, Forst T et al. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. *Diabetes Technol Ther* 2008; 10(3):206-12. No comparison group

Karalliedde J, Smith A, Viberti G. Determinants of response to insulin therapy following failure of oral agents in type 2 diabetes. *Diabetes Care* 2005; 28(10):2589-90. No comparison group

Karasik A, Wu M, Williams-Herman D. Sitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycaemia and weight loss. *American Diabetes Association Congress* 2007; P05:23. Other reason

Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). *Diabetes Obes Metab* 2005; 7(6):722-8. Does not have a drug comparison of interest

Karter AJ, Moffet HH, Liu J et al. Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry. *Am J Manag Care* 2005; 11(4):262-70. Does not meet the study design criteria

Karter AJ, Moffet HH, Liu J et al. Glycemic response to newly initiated diabetes therapies. *Am J Manag Care* 2007; 13(11):598-606. Does not meet the study design criteria

Kasliwal R, Wilton LV, Shakir SA. Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England. *Drug Saf* 2008; 31(10):839-50. Does not apply

Kaur RH et al. Management of type 2 diabetes mellitus : Gliclazide v/s glimepride [abstract no:16]. *J Assoc Physicians India* 2002; 50. Other reason

Kaushal S, Chopra SC, Arora S. Exenatide: An incretin-mimetic agent. *Indian J Pharmacol*. 2006; 38(1):76-8. No original data

Kawamori R et al. Determination of the glycemic threshold for the regression or prevention of diabetic microangiopathies, and the insulin injection regimen to establish strict glycemic control in NIDDM. *Jpn J Med* 1991; 30(6):618-21. Does not have a drug comparison of interest

Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y. Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. *Diabetes Res Clin Pract* 2007; 76(2):229-35. Does not meet the study design criteria

Kennedy L, Herman WH. Renal status among patients using metformin in a primary care setting. *Diabetes Care* 2005; 28(4):922-4. No comparison group

Kerenyi Z, Samer H, James R, Yan Y, Stewart M. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2004; 63(3):213-23. Does not have a drug comparison of interest

Khandekar S, Sethi BK, Dash RJ. Effect of sulphonylurea therapy on insulin sensitivity in non insulin dependent diabetics. *J Assoc Physicians India* 1990; 38(7):469-71. Study duration less than 3 months

Kiayias JA, Vlachou ED, Theodosopoulou E, Lakka-Papadodima E. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. *Diabetes Care* 2002; 25(7):1251-2. Less than 40 subjects with type 2 diabetes

Kilo C, Williamson JR. The controversial American University Group Diabetes Study--a look at sulfonylurea and biguanide therapy. *Horm Metab Res Suppl* 1985; 15:102-4. No original data

Kilo C. Multicenter comparison of glyburide and glipizide in the treatment of non-insulin-dependent diabetes mellitus. *Clin Ther* 1988; 10(3):294-302. Does not have a drug comparison of interest

Kim YM, Cha BS, Kim DJ et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2005; 67(1):43-52. Does not have a drug comparison of interest

King AB, Armstrong DU, Chinnapongse S. Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes. *Diabetes Care* 2003; 26(1):245-6. Does not meet the study design criteria

King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. *Diabetes Care* 2000; 23(4):557. Does not have a drug comparison of interest

King KA, Levi VE. Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione. *Am. J. Health-Syst. Pharm.* 2004; 61(4):390-3. Does not apply

Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. *Am J Med* 2001; 111(1):10-7. Does not have a drug comparison of interest

Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). *Eur Heart J* 2000; 21(3):220-9. Does not apply

Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. *Curr Med Res Opin* 2008; 24(1):275-86. Does not have a drug comparison of interest

Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. *Curr Med Res Opin* 2008; 24(1):275-86. Does not have a drug comparison of interest

Knight PV, Semple CG, Kesson CM. The use of metformin in the older patient. *J Clin Exp. Gerontol* 1986; 8(1-2):51-8. Does not have a drug comparison of interest

Ko GT, Chan WB, Chan JC, Tsang LW, Cockram CS. Gastrointestinal symptoms in Chinese patients with Type 2 diabetes mellitus. *Diabet Med* 1999; 16(8):670-4. Does not have a drug comparison of interest

Ko GT, Tsang PC, Wai HP, Kan EC, Chan HC. Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial. *Adv Ther* 2006; 23(5):799-808. Does not have a drug comparison of interest

Ko SH, Song KH, Ahn YB et al. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. *Metabolism* 2003; 52(6):731-4. Does not have a drug comparison of interest

Kolterman OG, Scarlett JA, Gray RS. The effect of glyburide treatment on insulin binding, insulin responsiveness, and insulin secretion in type II diabetes mellitus (NIDDM). *Clin Re* 1982; 30(2):397A. No subjects >18 years old

Komajda M, Curtis P, Hanefeld M et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). *Cardiovasc Diabetol* 2008; 7:10. Does not apply

Konrad T, Lubben G, Franzen C. Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus: an open, multicentre, observational study. *Clin Drug Investig* 2005; 25(5):337-40. Does not apply

Koppel H et al. Observations on the effect of glibenclamide on noninvasive clinical parameters of myocardial ischemia. *Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy* 1998; 12(4):383-5. Less than 40 subjects with type 2 diabetes

Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. *Pharmacoepidemiol Drug Saf* 2007; 16(5):485-92. Does not apply

Koro CE, Bowlin SJ, Weiss SR. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. *Pharmacoepidemiol Drug Saf* 2005; 14(10):697-703. Other reason

Koro CE, Fu Q, Stender M. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. *Pharmacoepidemiol Drug Saf* 2008; 17(10):989-96. Does not have a drug comparison of interest

Kosachunhanun N, Benjasuratwong Y, Mongkolsomlit S et al. Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. *J Med Assoc Thai* 2006; 89 Suppl 1:S66-71. Does not meet the study design criteria

Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. *J Clin Endocrinol Metab* 2001; 86(7):3452-6. Does not have a drug comparison of interest

Kreider M, Heise M. Rosiglitazone in the management of older patients with type 2 diabetes mellitus. *Int J Clin Pract* 2002; 56(7):538-41. Does not have a drug comparison of interest

Kristensen JS, Clauson P, Bayer T, Frandsen KB. The frequency of severe hypoglycaemia is reduced with repaglinide treatment compared with sulphonylurea treatment. *Eur J Endocrinology* 1999; 140(Suppl 1):19. Other reason

Ksela U, Zemljic E, Rakusa M, Cokolic M. Glycemic control before and after starting insulin therapy in obese and other type 2 diabetics. *Diabetol. Croat.* 2007; 35(3):59-62. No comparison group

Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. *Endocr J* 2002; 49(3):323-8. Does not have a drug comparison of interest

Kudva YC, Basu A. Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitus. *Evid-Based Med* 2006; 11(6):176. No original data

Kunte H, Schmidt S, Eliasziw M et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. *Stroke* 2007; 38(9):2526-30. Does not have a drug comparison of interest

Kure J. Glipizide and glyburide. *N C Med J* 1986; 47(3):149-53. No original data

Kuusi T, Yki-Jarvinen H, Kauppinen-Makelin R et al. Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes. *Eur J Clin Invest* 1995; 25(3):194-200. Does not meet the study design criteria

Labrousse-Lhermine F, Cazals L, Ruidavets JB, Hanaire H. Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes. *Diabetes Metab* 2007; 33(4):253-60. Does not have a drug comparison of interest

Lacknauth S, Patel R, Rappa L, Branch III E. Metformin/glyburide combination therapy for 2 type diabetes. *P T* 2001; 26(5):268-72. No original data

Lalau JD, Race JM. Metformin and lactic acidosis in diabetic humans. *Diabetes Obes Metab* 2000; 2(3):131-7. No original data

Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes (ZODIAC-16). *Diabetes Care* 2009. Does not have a drug comparison of interest

Lapina IuV et al. [Efficacy and safety of the use of metformin in patients with chronic heart failure and type 2 diabetes mellitus. results of the study Not written in English

Lautamaki R, Airaksinen KEJ, Seppanen M et al. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease. *Diabetes* 2006; 55(2):511-6. Does not apply

Lautamaki R, Nuutila P, Airaksinen KE et al. The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease. *Rev Diabet Stud* 2006; 3(1):31-8. Does not have a drug comparison of interest

Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. *J Clin Endocrinol Metab* 2001; 86(1):280-8. Does not have a drug comparison of interest

Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. *Diabetes Care* 2002; 25(5):815-21. Does not have a drug comparison of interest

Leese GP, Wang J, Broomhall J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. *Diabetes Care* 2003; 26(4):1176-80. Does not have a drug comparison of interest

Levin F, Kazim M, Smith TJ, Marcovici E. Rosiglitazone-induced proptosis. *Arch Ophthalmol* 2005; 123(1):119-21. No comparison group

Lewis JD, Capra AM, Achacoso NS et al. Medical therapy for diabetes is associated with increased use of lower endoscopy. *Pharmacoepidemiol Drug Saf* 2007; 16(11):1195-202. Does not apply

Li H, Li W, Gu Y et al. Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-secretagogue administration. *Diabetes Res Clin Pract* 2009; 84(2):158-62. Does not have a drug comparison of interest

Li K, Li L, Yang M, Zong H, Liu H, Yang G. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. *Eur J Endocrinol* 2009; 161(3):391-5. Does not apply

Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. *Diabetes Care* 2009; 32(9):1620-5. Does not have a drug comparison of interest

Lin KD, Chang YH, Wang CL et al. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea. *Transl Res* 2008; 151(6):309-14. No comparison group

Lindner J et al. [Presentation of an insulin-treated patient group within the scope of a 5-year study of the Diabetes Intervention Study (DIS)]. *Zeitschrift Für Die Gesamte Innere Medizin Und Ihre Grenzgebiete* 1987; 42(7):198-200. Not written in English

Lipid effects of pioglitazone studied. *Br. J. Diabetes Vasc. Dis.* 2004; 4(3):209. No original data

Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. *JAMA* 2007; 298(22):2634-43. Does not have a drug comparison of interest

Loebstein R, Vasterman-Landes J, Silverman B et al. Database evaluation of adverse cardiovascular outcomes, related to rosiglitazone (RSG), in the treatment of type 2 diabetes mellitus (T2DM) patients in the community. *Clinical Pharmacology and Therapeutics: Clin Pharmacol Ther* 2009; 85:S7. No original data

Lomuscio A, Fiorentini C. Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction. *Diabetes Res Clin Pract* 1996; 31 Suppl:S21-6. Does not have a drug comparison of interest

Lopez-Garcia F, Borrás J, Verdu C et al. Cholestatic hepatitis associated with repaglinide. *Diabetes Care* 2005; 28(3):752-3. No comparison group

Lowry, F. S., Bevivino, M. V., Salzman, A., Yan, Y., Patwardhan, R. Rosiglitazone: BRL 49653: a 26-week randomized, double-blind, double dummy, multicenter study to evaluate the efficacy, safety and tolerability of rosiglitazone 4 mg bd when administered to patients with non-insulin dependent diabetes mellitus (NIDDM) who are inadequately controlled on a maintenance dose (2.5g/day) of metformin: report 093 phase IIIA: final clinical report. *The Clinical Effectiveness and Cost-Effectiveness of Rosiglitazone for Type 2 Diabetes Mellitus*. National Institute for Clinical Excellence. London, England. August 2000. Other reason

Luis Bautista J, Bugos C, Dirnberger G, Atherton T. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. *Clin Ther* 2003; 25(1):194-209. Does not have a drug comparison of interest

Lund SS, Tarnow L, Frandsen M et al. Erratum: Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes (*European Journal of Endocrinology* vol. 158 (1) (35-46)). *Eur. J. Endocrinol.* 2008; 158(3):443-5. No original data

Lund SS, Tarnow L, Stehouwer CD et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. *Eur J Endocrinol* 2008; 158(5):631-41. Does not apply

Lundquist I, Ahren B, Schersten B. Insulin secretagogues. Possible modulators of glucose and non-glucose stimuli. *Acta Endocrinol Suppl* 1984; 105(262):51-9. No original data

Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. *Am J Gastroenterol* 1999; 94(8):2165-70. No comparison group

Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. *Diabetes Res Clin Pract* 2002; 58(1):45-53. Study duration less than 3 months

Maheux P, Doucet J, Allen E et al. Efficacy and safety of saxagliptin 5 mg once-daily therapy in elderly patients with type 2 diabetes mellitus. *Diabetologia: Diabetologia* 2009; 52(S1):S302. Other reason

Manalo Jr. GG, Villareal DT, Anel-Quimpo J, Go RT, Litonjua AD. Body weight as a predictor of response to sulfonylurea therapy. *Philipp J Intern Med* 1993; 31(3):135-43. Other reason

Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. *Pharmacotherapy* 2003; 23(7):861-5. Does not have a drug comparison of interest

Mannucci E, Monami M, Masotti G, Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. *Diabetes Metab Res Rev* 2004; 20(1):44-7. Does not have a drug comparison of interest

Mansour AA, Habib OS. Metformin discontinuation rate among patients with type-2 diabetes mellitus in Basrah, Iraq. *Saudi Med J* 2007; 28(12):1919-21. No comparison group

Manzato E, Zambon A, Lapolla A et al. Lipoprotein abnormalities in well-treated type II diabetic patients. *Diabetes Care* 1993; 16(2):469-75. Does not have a drug comparison of interest

Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. *Am J Hypertens* 2004; 17(3):223-7. Does not have a drug comparison of interest

Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. *Horm Metab Res* 2006; 38(12):838-44. Does not apply

Marks JB. How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus? *Nat. Clin. Pract. Endocrinol. Metab.* 2008; 4(9):490-1. No original data

Marrett E, Zhang Q, Radican L. The impact of frequency and severity of self-reported hypoglycemia on quality of life in patients with type 2 diabetes mellitus treated with oral anti-hyperglycemic agents. *Value Health* 2009; 12(3):A104. Other reason

Marshall SM. Oral hypoglycaemic agents. *Pract. Diabetes Int.* 2003; 20(7):S1-S4. No original data

Marx N. PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes. *Diab Vasc Dis Res* 2008; 5(4):345-6. No original data

Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. *Circulation* 2005; 111(5):583-90. Does not have a drug comparison of interest

Massi Benedetti M, Humburg E, Dressler A, Ziemer M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with Type 2 diabetes. *Horm Metab Res* 2003; 35(3):189-96. Does not have a drug comparison of interest

Masud F, Abaidullah S, Rehman AU, Hasan M. Insulin sparing effect of glibenclamide in poorly controlled type-II diabetics and its effect on the Body Mass Index (BMI). *SPECIALIST* 1993; 9(2):105-8. Does not have a drug comparison of interest

Masud F, Hasan M, Abaidullah S, Intekhab. Assessment of metabolic profile and body mass index (BMI) in type II diabetics treated with metformin and insulin. *Specialist* 1992; 9(1):29-34. Less than 40 subjects with type 2 diabetes

Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. *Diabetes Res Clin Pract* 2004; 64(3):225-8. Less than 40 subjects with type 2 diabetes

Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. *Diabetes Metab Res Rev* 2005; 21(2):167-74. Does not have a drug comparison of interest

Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. *JAMA* 2006; 296(21):2572-81. Other reason

McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. *Diabetes Technol Ther* 2009; 11(6):339-44. No comparison group

McCall T, Bron M, Liu J, Manthena S, Spanheimer R. High-density lipoprotein cholesterol effects of pioglitazone compared with non-TZD oral medications in a US managed care cohort. *Diabetologia: Diabetologia* 2009; 52(S1):S495. No original data

McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. *Clin Ther* 2004; 26(11):1783-90. Does not have a drug comparison of interest

McEwen J, Durnin CJ, Moreland TA, Qureshi MZ, Kai PL, McEwan SR. Improved glucose control with pre-prandial glipizide: Differences between patients and healthy volunteers. *Eur J Pharmacol* 1990; 183(3):1017. Less than 40 subjects with type 2 diabetes

McNally PG et al. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. *Diabetes Care* 2007; 30(5):1044-8. Does not have a drug comparison of interest

Medina Santillan R, Reyes-Garcia G, Mateos-Garcia E. Metformin plus glyburide combination as therapy in failure to monotherapy in type 2 diabetic patients: one month follow-up. *Proc West Pharmacol Soc* 2002; 45:139-40. No comparison group

Medina Santillan R, Reyes-Garcia G, Mateos-Garcia E. Metformin plus glyburide combination as initial therapy in type 2 diabetes: one month follow-up. *Proc West Pharmacol Soc* 2002; 45:137-8. Study duration less than 3 months

Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. *Arch Intern Med* 2008; 168(8):820-5. Does not have a drug comparison of interest

Meier JJ, Deifuss S, Klamann A, Schmiegel W, Nauck MA. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). *Exp Clin Endocrinol Diabetes* 2003; 111(6):344-50. Does not have a drug comparison of interest

Meigs JB, Singer DE, Sullivan LM et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcome Research Team. *Am J Med* 1997; 102(1):38-47. Does not apply

Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. *Eur Heart J* 2008; 29(2):166-76. Does not have a drug comparison of interest

Memisogullari R, Turkeli M, Bakan E, Akcay F. Effect of metformin or gliclazide on lipid peroxidation and antioxidant levels in patients with diabetes mellitus. *Turk. J. Med. Sci.* 2008; 38(6):545-8. Does not meet the study design criteria

Menard J, Payette H, Baillargeon JP et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. *CMAJ* 2005; 173(12):1457-66. Does not apply

Meneghini L et al. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study. *Diabetes, Obesity & Metabolism* 2007; 9(6):902-13. Does not apply

Meneghini LF, Traylor L, Schwartz S. Improved Glycemic Control with Insulin Glargine Vs Pioglitazone as ADD-ON Therapy to Sulfonylurea or Metformin in Patients with Uncontrolled Type 2 Diabetes. *Endocr Pract* 2010; 1-6. Does not have a drug comparison of interest

Mercker SK, Maier C, Neumann G, Wulf H. Lactic acidosis as a serious perioperative complication of antidiabetic biguanide medication with metformin. *Anesthesiology* 1997; 87(4):1003-5. No comparison group

Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. *Diabetes Res Clin Pract* 2001; 52(3):193-204. Does not have a drug comparison of interest

Metformin less effective than sensible diet. *J. Endocrinol. Metab. Diabetes S. Afr.* 2001; 6(3):82. No original data

Mewborne JD, Ricci PE, Appel RG. Cranial CT findings in metformin (Glucophage)-induced lactic acidosis. *J Comput Assist Tomogr* 1998; 22(4):528-9. No comparison group

Meymeh RH, Woollorton E. Diabetes drug pioglitazone (Actos): risk of fracture. *CMAJ* 2007; 177(7):723-4. No original data

Migdalis IN, Iliopoulou V, Kalogeropoulou K, Koutoulidis K, Samartzis M. Correlation between high density lipoprotein cholesterol and C-peptide in sulfonylurea-treated diabetic patients. *J Med* 1989; 20(5-6):349-55. Does not have a drug comparison of interest

Mikhail N, Wali S. Insulin combination therapy in type 2 diabetes mellitus. *Ann Intern Med* 2004; 140(8):666-7; author reply 667. No original data

Milenkovic T, Percan V, Vesov G. 20-week multicentre, prospective, open-label study of the efficacy, safety and applicability of repaglinide as a first line therapy in treating type 2 diabetes patients in Diabetes Centres in Macedonia. *Endocrinologia* 2005; 10:28-34. No comparison group

Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. *Diabetes Obes Metab* 2008; 10(12):1204-11. Does not have a drug comparison of interest

Mohan V, Yang W, Son HY et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. *Diabetes Res Clin Pract* 2009; 83(1):106-16. Does not have a drug comparison of interest

Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. *Acta Diabetol* 2008. Does not have a drug comparison of interest

Monami M, Lamanna C, Pala L et al. Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. *Exp Clin Endocrinol Diabetes* 2008; 116(3):184-9. Does not have a drug comparison of interest

Monami M, Luzzi C, Lamanna C et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. *Diabetes Metab Res Rev* 2006; 22(6):477-82. Other reason

Monnier L, Grimaldi A, Charbonnel B et al. Management of French patients with type 2 diabetes mellitus in medical general practice: Report of the Mediab observatory. *Diabetes Metab.* 2004; 30(1):35-42. Does not apply

Montanana CF, Herrero CH, Fernandez MR. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients - The PREDICTIVE(trademark) BMI clinical trial. *Diabetic Med* 2008; 25(8):916-23. Does not have a drug comparison of interest

Moon JH, Kim HJ, Kim SK et al. Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. *Metabolism* 2010. Does not apply

Moran, E. G., Salzman, A., Yan, Y., and Patwardhan, R. Rosiglitazone. BRL 49653. A 26-week Randomized, Double-blind, Double-Dummy, Multicentered Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone When Administered to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Who Are Inadequately Controlled on a Maximal Dose (20-mg/day) of Glyburide. Report 079 Phase IIIA. Final Clinical Report. SB Document Number: BRL-049653/RSD-100SLN/2. 23-9-1998. SmithKline Beecham. Other reason

Moses R. Repaglinide in combination therapy with metformin in Type 2 diabetes. *Exp Clin Endocrinol Diabetes* 1999; 107 Suppl 4:S136-9. Other reason

Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. *Diabetes Care* 2001; 24(1):11-5. Does not have a drug comparison of interest

Mozersky RP, Patel H, Bahl VK, Bahl S, Mook W. Efficacy of combination therapy with insulin and oral hypoglycemic agents in patients with type II diabetes during a 1-year period. *J Am Osteopath Assoc* 1996; 96(6):346-51. Does not meet the study design criteria

Mukhtar R, Reckless JP. Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. *Diabet Med* 2005; 22 Suppl 3:6-10. No original data

Naderi N, May HT, Horne BD et al. Association of rosiglitazone and pioglitazone to death and myocardial infarction among diabetic patients with coronary artery disease. *Journal of the American College of Cardiology: J. Am. Coll. Cardiol.* 2009; 53(10):A377. No original data

Nagasaka S, Taniguchi A, Aiso Y et al. Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. *Diabetes Care* 2003; 26(7):2215-6. Less than 40 subjects with type 2 diabetes

Nakamura T et al. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes. *Ren Fail* 2001; 23(6):863-4. Less than 40 subjects with type 2 diabetes

Nakano K, Hasegawa G, Fukui M et al. Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. *Endocr J* 2010. Does not have a drug comparison of interest

Narain VS, Puri A, Ahuja A. 10 Years of clinical trials in diabetic patient with coronary artery disease. *J. Intern. Med. India* 2006; 9(1):20-6. No original data

Narce M, Poisson J-P. Novel PPAR(γ)-dependent and independent effects for thiazolidinediones. *Curr Opin Lipidology* 2003; 14(6):651-2. No original data

Nateglinide improves postprandial glucose as monotherapy or in combination with metformin. *Geriatrics* 2002; 57(8):35. No original data

Nauck M, Duran S, Kim D, Johns D, Festa A, Trautman M. Effects of exenatide compared with twice-daily biphasic insulin aspart in patients with type 2 diabetes using metformin and a sulphonylurea. *Diabetologia* 2006; 49 (Suppl. 1)(3):Abstract 0001. Other reason

Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. *Postgrad Med* 2009; 121(3):5-15. Other reason

Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. *Int J Clin Pract* 2009; 63(1):46-55. Does not have a drug comparison of interest

Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. *Exp Clin Endocrinol Diabetes* 2006; 114(8):417-23. Study duration less than 3 months

Neeser K, Lubben G, Siebert U, Schramm W. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. *Pharmacoeconomics* 2004; 22(5):321-41. No original data

Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. *Minerva Endocrinol* 2004; 29(1):11-7. Study duration less than 3 months

Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. *Diabetes Technol Ther* 2007; 9(4):317-26. No comparison group

Ng JM, Ramlall M, Mellor D, Allan BJ. Severe hypoglycaemia: Are patients correctly selected for sulphonylurea therapy? *Diabetologia*: *Diabetologia* 2009; 52(S1):S353. No original data

Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. *Diabetes Care* 2006; 29(3):504-9. Does not apply

Nichols GA, Glauber HS, Javor K, Brown JB. Achieving further glycemic control in type 2 diabetes mellitus. *West J Med* 2000; 173(3):175-9. Does not have a drug comparison of interest

Nichols GA, Gomez-Camirero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. *Diabetes Obes Metab* 2007; 9(1):96-102. Other reason

Nishio K, Sakurai M, Kusuyama T et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. *Diabetes Care* 2006; 29(1):101-6. Does not have a drug comparison of interest

Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA* 2008; 299(13):1561-73. Does not have a drug comparison of interest

Noh J-H, Kim S-K, Cho Y-J et al. Current status of diabetes management in elderly Koreans with diabetes. *Diabetes Res Clin Pract.* 2007; 77(3 SUPPL.):S71-S75. Does not apply

Nonaka K, Kakikawa T, Sato A et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract* 2008; 79(2):291-8. Does not have a drug comparison of interest

Nonaka K, Kakikawa T, Sato A. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV (DPP4) inhibitor, in Japanese patients with T2DM. *Diabetes* 2006; 55(Suppl 1):A128. Other reason

Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDDM. *Diabete Metab* 1991; 17(1 Pt 2):209-12. Does not have a drug comparison of interest

Novials A, Gomis R, Coves MJ, Conget I, Malaisse WJ. Improvement by insulin treatment of the early phase of glucose-stimulated insulin release in non-insulindependent diabetics explored after restoration of hyperglycemia. *Med Sci Res* 1989; 17(8):381-2. Less than 40 subjects with type 2 diabetes

Noyon R, Pagano Mirani-Oostdijk C, van Gent CM, Frolich M, Hillebrand I, Terpstra J. Long-term effect of acarbose on diurnal serum triglyceride, glucose, insulin and adipose tissue lipoprotein lipase levels in patients with primary endogenous hypertriglyceridaemia, with or without type II diabetes. *Neth J Med* 1986; 29(5):157-64. Less than 40 subjects with type 2 diabetes

Odom J, Williamson B, Carter L. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus. *Am J Health Syst Pharm* 2008; 65(19):1846-50. No original data

Okura H, Takagi T, Toda I. Pioglitazone affects left ventricular filling pressure in patients with ischemic heart disease and type 2 diabetes who underwent coronary intervention: An echo doppler sub-analysis from the prevention of in-stent neointimal proliferation by pioglitazone study (POPPS). *J Am Coll Cardiol* 2010; 55(10):A16.E150. Does not apply

Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. *Clin Ther* 2003; 25 Suppl B:B64-80. Does not meet the study design criteria

Olansky L, Reasner CA, Seck T et al. A strategy implementing initial therapy with a fixed-dose combination tablet of sitagliptin and metformin in patients with type 2 diabetes provides superior glycaemic control compared with a strategy using initial metformin monotherapy over 44 weeks. *Can J Diabetes* 2009; 33(3):208-9. Other reason

Olsson J, Lindberg G, Gottsater M et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. *Diabetologia* 2000; 43(5):558-60. Does not have a drug comparison of interest

O'Meara NM, Shapiro ET, Van Cauter E, Polonsky KS. Effect of glyburide on beta cell responsiveness to glucose in non-insulin-dependent diabetes mellitus. *Am J Med* 1990; 89(2A):11S-6S; discussion 51S-53S. Does not have a drug comparison of interest

Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. *Diabetes Care* 2006; 29(11):2361-4. Other reason

Oz Gul O, Tuncel E, Yilmaz Y et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. *Metabolism* 2010; 59(1):64-9. Less than 40 subjects with type 2 diabetes

Ozbek M, Erdogan M, Karadeniz M et al. Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment. *Acta Diabetol* 2006; 43(4):148-51. Does not have a drug comparison of interest

Pala L, Monami M, Lamanna C et al. Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. *Acta Diabetol* 2009. Does not meet the study design criteria

Palmer AJ, Roze S, Lammert M et al. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. *Curr Med Res Opin* 2004; 20 Suppl 1:S41-51. Study duration less than 3 months

Pan CY, Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. *Clin Drug Investig* 2007; 27(6):397-405. No comparison group

Panelo A, Wing JR. Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin. *Diabetes Care* 2005; 28(7):1789-90. Does not have a drug comparison of interest

Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1987; 30(3):123-31. No original data

Papa G, Fedele V, Chiavetta A et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. *Acta Diabetol* 2008; 45(1):53-9. Does not have a drug comparison of interest

Papa G, Fedele V, Rizzo MR et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial. *Diabetes Care* 2006; 29(8):1918-20. Other reason

Park JS, Cho MH, Lee KY et al. The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus. *Metabolism* 2007; 56(8):1081-6. Does not have a drug comparison of interest

Pastromas S, Koulouris S. Thiazolidinediones: Antidiabetic drugs with cardiovascular effects. *Hell J Cardiol* 2006; 47(6):352-60. No original data

Patasi B, MacNair D, Marble RJ, Conway JR. Rosiglitazone in Canada: experience in clinical practice. *Expert Opin Drug Metab Toxicol* 2009; 5(4):441-8. No comparison group

Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. *Diabetes Obes Metab* 1999; 1(3):165-72. Does not have a drug comparison of interest

Pawaskar MD, Anderson J, Zagar AJ. A retrospective analysis of medication use, resource utilization, and clinical effectiveness of exenatide compared to glargine in patients with type 2 diabetes. *Value Health* 2009; 12(7):A414. Other reason

Perciaccante A, Mas MD, Balbi M. Relevance of diabetes mellitus and antidiabetic therapy in patients with cirrhosis and hepatocellular carcinoma. *Hepatol Int* 2009; 3(1):148. No original data

Perez A, Zhao Z, Spanheimer R. Effect of pioglitazone and metformin fixed-dose combination on biomarkers of inflammation and dyslipidemia in patients with type 2 diabetes. *Canadian Journal of Diabetes: Can J Diabetes* 2009; 33(3):246. No original data

Perez A, Zhao Z, Spanheimer R. Effect of pioglitazone and metformin fixed-dose combination on hs-CRP and adiponectin in patients with type 2 diabetes. *Diabetologia: Diabetologia* 2009; 52(S1):S339-S340. No original data

Perfetti R. Nateglinide. *Drugs* 2000; 60(3):616. No original data

Perriello G, Pampanelli S, Brunetti P, di Pietro C, Mariz S. Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes. *Diab Vasc Dis Res* 2007; 4(3):226-30. Does not have a drug comparison of interest

Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. *Curr Med Res Opin* 2004; 20(2):215-23. Other reason

Petersen KU. Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2. *Arzneimittelforschung* 2004; 54(1):20-30. No original data

Petzholdt R, Rosak C, Stammer H. Rosiglitazone plus metformin is effective and safe in daily practise [Abstract]. *Diabetes* 2004; 53(9 Suppl 2):A 142. Other reason

Pfutzner A, Lubben G, Forst T. Pioglitazone decreases carotid intima-media thickness in diabetes mellitus. *Cardiol Rev* 2005; 22(10):30-3. Other reason

Pfutzner A, Schondorf T, Seidel D et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. *Metabolism* 2006; 55(1):20-5. Does not have a drug comparison of interest

Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes. *Clin Ther* 2006; 28(10):1569-81. Does not have a drug comparison of interest

Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. *Diabetes Care* 2001; 24(2):308-15. Does not have a drug comparison of interest

Pioglitazone ineffective in secondary prevention of macrovascular complications (PROactive). *J. Natl. Med. Assoc.* 2006; 98(1):102-3. No original data

Pioglitazone of benefit in high-risk diabetes patients. *Pharm J* 2005; 275(7367):330. No original data

Pioglitazone reduces stroke, MI, and death but increases HF. *Geriatr Aging* 2006; 9(1):48. No original data

Pioglitazone shows anti-atherosclerotic effect in type 2 diabetes. *Geriatrics* 2007; 62(2):14. No original data

Pioglitazone/glimepiride (Duetact) for diabetes. *Med Lett Drugs Ther* 2007; 49(1253):9-11. No original data

Pioglitazone: Fractures in women. *WHO Drug Inf* 2007; 21(3):207. No original data

Pisu E, Marena S, Arcari R et al. Depressed insulin secretion in response to different stimuli is a feature of secondary failure in normal-weight non-insulin dependent diabetics on sulphonylureas. *Diabetes Nutr Metab Clin Exp* 1996; 9(1):22-8. Less than 40 subjects with type 2 diabetes

Pogatsa G, Koltai MZ, Jermendy G, Simon J, Aranyi Z, Ballagi-Pordany G. The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients. *Acta Med Hung* 1992-1993; 49(1-2):39-51. Does not have a drug comparison of interest

Polonsky WH et al. Integrating medical management with diabetes self-management training: a randomized control trial of the Diabetes Outpatient Intensive Treatment program. *Diabetes Care* 2003; 26(11):3048-53. Does not apply

Ponchner M, Taylor R, Heine R, Alberti KG. The effect of sulphonylurea therapy on in vivo insulin sensitivity in non-insulin dependent diabetics. *Horm Metab Res* 1984; 16(4):208. Less than 40 subjects with type 2 diabetes

Pongchaidecha M, Srikusalanukul V, Chattananon A, Tanjariyaporn S. Effect of metformin on plasma homocysteine, vitamin B12 and folic acid: a cross-sectional study in patients with type 2 diabetes mellitus. *J Med Assoc Thai* 2004; 87(7):780-7. Does not apply

Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. *JAMA* 2009; 302(11):1186-94. Does not have a drug comparison of interest

Prager R, Schernthaner G, Matha R. Metformin does not alter insulin receptor binding in non insulin dependent diabetes mellitus. *ACTA Endocrinol Suppl* 1983; 102(253):76-7. Less than 40 subjects with type 2 diabetes

Prando R, Buzzo P, Cheli V, Melga PL, Accoto S, Rebaudo S. A short period of insulin therapy can restore the sensitivity to hypoglycaemic agents in poorly controlled type 2 diabetes. *Med Sci Res* 1988; 16(23):1245. No original data

Qu S et al. [The efficacy of glipizide XL in the treatment of type 2 diabetic patients unresponding to sulfaurea drugs]. *Pharmaceutical Care & Research (Yaoxue Fuwu Yu Yanjiu)* 2005; 5(1):32-4. Not written in English

Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. *Eur J Intern Med* 2002; 13(7):428. Does not apply

Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. *Drugs Aging* 2004; 21(4):259-71. Does not have a drug comparison of interest

Rajagopalan R, Xu Y, Abbadessa M. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials. *Am J Geriatr Pharmacother* 2006; 4(2):123-33. No original data

Rajeswaran C, Scott EM. Thiazolidinedione induced gross scrotal oedema? *Pract. Diabetes Int.* 2006; 23(7):286. No comparison group

Ramachandran A, Mohan V, Snehalatha MC, Chinnikrishnudu M, Viswanathan M. Use of metformin in selected cases of NIDDM. A clinical trial. *J Diabetic Assoc India* 1988; 28(4):137-9. No comparison group

Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. *BMC Med* 2007; 5:17. Does not apply

Raptis AE, Tountas N, Yalouris AG et al. Comparative study of the therapeutic effects of glibenclamide or the fixed combination of glibenclamide-phenformin with those of gliclazide or chlorpropamide. *Acta Diabetol Lat* 1990; 27(1):11-22. Does not have a drug comparison of interest

Raskin P, Lewin A, Reinhardt R, Lyness W. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. *Diabetes Obes Metab* 2009; 11(10):947-52. Does not apply

Ratner RE, Maggs D, Nielsen LL et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. *Diabetes Obes Metab* 2006; 8(4):419-28. Does not have a drug comparison of interest

Ravichandran S, DeFronzo R, Garber AJ et al. Once-daily saxagliptin added to metformin is well tolerated and provides sustained glycaemic control over 102 weeks in patients with type 2 diabetes. *Diabetologia: Diabetologia* 2009; 52(S1):S60. Other reason

Raz I, Gilhar D, Hoffman A. Prolonged response to glibenclamide in NIDDM patients in a normoglycemic state. *Isr J Med Sci* 1994; 30(10):775-8. Less than 40 subjects with type 2 diabetes

Reasner CA, Olansky L, Seck T et al. Initial therapy with the Fixed-Dose Combination (FDC) of sitagliptin and metformin (JANUMET(trademark)) in patients with type 2 diabetes mellitus provides superior glycaemic control and HbA1c goal attainment with lower rates of abdominal pain and diarrhea vs metformin alone. *Diabetologia: Diabetologia* 2009; 52(S1):S295. Other reason

Reblin T. Thiazolidinedione use and the risk of fractures. *CMAJ* 2009; 180(8):841. No original data

Repaglinide improves blood glucose control in patients with type 2 diabetes. *Formulary* 2004; 39(11):528. No original data

Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. *Lancet* 2009. Study duration less than 3 months

Ribowsky J, Covino J. Do thiazolidinediones increase the risk of cardiovascular events? *JAAPA* 2008; 21(8):53-4. No original data

Riddle MC, Henry RR, Poon TH et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. *Diabetes Metab Res Rev* 2006; 22(6):483-91. No original data

Riddle MC. Combined insulin and sulfonylurea therapy for type 2 diabetes mellitus. *Diabetes Res Clin Pract* 1991; 11(1):3-8. No original data

Riddle MC. The Treat-to-Target trial and related studies. *Endocr Pract* 2006; 12(SUPPL. 1):71-9. No original data

Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. *Pharmacotherapy* 2007; 27(8):1102-10. Does not meet the study design criteria

Riedel AA, Heien H, Wogen J, Plauschinat CA. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. *Am J Manag Care* 2007; 13(8):457-63. Does not meet the study design criteria

Rijzewijk LJ, Van Der Meer RW, Lubberink M et al. Differential action of pioglitazone and metformin on hepatic fat, substrate metabolism and perfusion in type 2 diabetic patients. *Diabetologia*: *Diabetologia* 2009; 52(S1):S336. No original data

Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher E. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. *Diabetes Obes Metab* 2007; 9(4):506-11. Does not have a drug comparison of interest

Ristic S, Collober-Maugeais C, Pecher E, Cressier F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. *Diabet Med* 2006; 23(7):757-62. Does not have a drug comparison of interest

Robb GH, Lowe SM. Lack of weight gain with gliclazide treatment for 30 months in Type II diabetes. *CURR. MED. RES. OPIN.* 1984; 9(1):7-9. No comparison group

Roden M, Laakso M, Johns D et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. *Diabet Med* 2005; 22(8):1101-6. Does not apply

Roden M, Mariz S, Brazzale AR, Pacini G. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. *J Intern Med* 2009; 265(4):476-87. Other reason

Rogowicz A, Litwinowicz M, Pilacinski S, Zozulinska D, Wierusz-Wysocka B. Does early insulin treatment decrease the risk of microangiopathy in non-obese adults with diabetes? *Arch Med Sci* 2007; 3(2):129-35. Does not have a drug comparison of interest

Rosenbaum P, Peres RB, Zanella MT, Ferreira SR. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. *Braz J Med Biol Res* 2002; 35(8):877-84. Does not have a drug comparison of interest

Rosenblatt J. Combination sulfonylurea-insulin therapy in the treatment of noninsulin-dependent diabetes mellitus. *Conn Med* 1991; 55(11):634-6. No original data

Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. *Coron Artery Dis* 2001; 12(5):413-23. Does not have a drug comparison of interest

Rosenstock J, Corrao PJ, Goldberg RB, Kilo C. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. *Clin Ther* 1993; 15(6):1031-40. Does not have a drug comparison of interest

Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetologia* 2008; 51(3):408-16. Does not have a drug comparison of interest

Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. *Int J Clin Pract* 2002; 56(4):251-7. Does not have a drug comparison of interest

Rosenstock J, Goldstein BJ, Vinik AI et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. Sulphonylurea Titration (RESULT) study. *Diabetes Obes Metab* 2006; 8(1):49-57. Does not have a drug comparison of interest

Rosenstock J, Hassman DR, Madder RD et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. *Diabetes Care* 2004; 27(6):1265-70. Does not have a drug comparison of interest

Rosenstock J, Meisel A, Raskin P. Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus. *Am J Med* 1987; 83(3A):10-5. No comparison group

Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. *Diabetes Care* 1996; 19(11):1194-9. Does not have a drug comparison of interest

Roskamp R. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. *Diabetic Med.* 2003; 20(7):545-51. Does not have a drug comparison of interest

Roy R, Navar M, Palomeno G, Davidson MB. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulphonylurea agent: a systematic evaluation of triple oral therapy in a minority population. *Diabetes Care* 2004; 27(7):1741-2. Does not apply

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic NM, Antic Seal. Significantly better glycaemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin + sulphonylurea in Type 2 diabetes. *Diabetologia* 2008; 51:S68. No original data

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic SSeal. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulphonylurea in Type 2 diabetes. *Diabetes* 2008; 57:P536. No original data

Russell-Jones D, Vaag A, Schmitz Oeal. Significantly better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analogue, compared with insulin glargine: all as add-on to metformin and a sulphonylurea in type 2 diabetes. *Diabetes* 2008; 57(Suppl 1):A159. No original data

Ryan EH Jr, Han DP, Ramsay RC et al. Diabetic macular edema associated with glitazone use. *Retina* 2006; 26(5):562-70. No comparison group

Saad MF, Greco S, Osei K et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. *Diabetes Care* 2004; 27(6):1324-9. Does not have a drug comparison of interest

Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. *Diabetes Res Clin Pract* 2008; 82(3):391-5. Does not have a drug comparison of interest

SAKAMOTO Nobuo et al. Usefulness of Prolonged Administration of BAY g 5421 (Acarbose) in Patients with Non-Insulin-Dependent Diabetes Mellitus: A Double-Blind Placebo-Controlled Study. *Rinsho to Kenkyu (The Japanese Journal of Clinical and Experimental Medicine)* 1990; 67(1):219-33. Not written in English

Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. *J Clin Endocrinol Metab* 2002; 87(9):4171-6. Does not have a drug comparison of interest

Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2006; (1):CD002967. No original data

Salsali A, Pratley RE. Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus? *Nat Clin Pract Endocrinol Metab* 2007; 3(6):450-1. No original data

Sari R, Balci MK, Akbas SH, Avci B. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. *Endocr Res* 2004; 30(2):169-77. Study duration less than 3 months

Satoh N, Ogawa Y, Usui T et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. *Diabetes Care* 2003; 26(9):2493-9. Does not have a drug comparison of interest

Savage S et al. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study. *Proc Assoc Am Physicians* 1997; 109(2):181-9. Does not apply

Scemons D. Are you up-to-date on diabetes medications? *Nursing (Lond)* 2007; 37(7):45-9; quiz 49-50. Does not meet the study design criteria

Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. *J Clin Pharmacol* 1998; 38(7):636-41. Does not have a drug comparison of interest

Schatz H, Schoppel K, Lehwalder D, Schandry R. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions. *Exp Clin Endocrinol Diabetes* 2003; 111(5):262-6. No comparison group

Scheen A et al. Reduced insulin requirements and improved glycaemic control with pioglitazone in insulin-treated patients with type 2 diabetes: Results from PROactive. 19th World Diabetes Conference 2006 2006. Other reason

Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B. Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). *Diabet Med* 2009; 26(12):1242-9. Does not have a drug comparison of interest

Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. *Horm Metab Res* 2002; 34(10):589-95. Does not have a drug comparison of interest

Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. *Eur J Clin Invest* 2004; 34(8):535-42. Does not have a drug comparison of interest

Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse J. Patient reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared to exenatide, when added to metformin, sulfonylurea or both. *Value in Health: Value Health* 2009; 12(3):A105. Other reason

Schmitz O et al. Pioglitazone reduces insulin requirements and improves glycaemic control in insulin-treated patients with type 2 diabetes: results from PROactive. 42nd Annual Meeting of the European Association for the Study of Diabetes 2006 2006. Other reason

Schofl C, Lubben G. Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice. *Clin Drug Investig* 2003; 23(11):725-34. Does not have a drug comparison of interest

Schofl C, Luebben G. Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy. *Clin Drug Investig* 2005; 25(5):341-5. Does not meet the study design criteria

Scholz GH, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: A non-interventional observational cohort study. *Clin Drug Invest* 2001; 21(9):597-604. Study duration less than 3 months

Schondorf T, Forst T, Seidel D. Impact of rosiglitazone on metabolic control of B-cell function and insulin resistance-results from a double-blind oral combination study. *Diabetes* 2005; 54(Suppl 1):A150. Other reason

Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. *J Clin Endocrinol Metab* 2006; 91(9):3349-54. Does not apply

Schwartz AV, Vittinghoff E, Sellmeyer DE et al. Diabetes-related complications, glycemic control, and falls in older adults. *Diabetes Care* 2008; 31(3):391-6. Does not apply

Scorpiglione N, Belfiglio M, Carinci F et al. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence. *Eur J Clin Pharmacol* 1999; 55(4):239-49. Does not have a drug comparison of interest

Seino Y, Rasmussen MF, Katayama Y, Kaku K. The human GLP-1 analogue liraglutide given once daily provides excellent metabolic control in Japanese patients either as monotherapy or in combination with SU during 52 weeks of treatment. *Diabetologia* 2009; 52(S1):S292. No original data

Selby JV, Ettinger B, Swain BE, Brown JB. First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. *Diabetes Care* 1999; 22(1):38-44. Does not have a drug comparison of interest

Seshiah V, Harinarayana CV, Venkataraman S et al. Platelet aggregation study in diabetes mellitus; effect of antidiabetic therapy - A preliminary study. *J Diabetic Assoc India* 1990; 30(3):62-5. Does not apply

Sevinc A. Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide? *Arch. Intern. Med.* 2003; 163(14):1741. No comparison group

Shah M, Kolandaivelu A, Fearon WF. Pioglitazone-induced heart failure despite normal left ventricular function. *Am J Med* 2004; 117(12):973-4. No comparison group

Shah R. Pioglitazone vs glimepiride in the PERISCOPE trial. *JAMA* 2008; 300(7):787-8; author reply 788. No original data

Shargorodsky M, Michaelova K, Boaz M, Gavish D, Zimlichman R. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study. *Diabet Med* 2007; 24(11):1254-60. Does not have a drug comparison of interest

Shargorodsky M, Wainstein J, Gavish D, Leibovitz E, Matas Z, Zimlichman R. Erratum: Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus (*American Journal of Hypertension* (2003) 16 (617-622)). *Am. J. Hypertens.* 2003; 16(10):894. Does not have a drug comparison of interest

Shaw KM. Medical treatment of non-insulin-dependent diabetes. *Pract Diabetes* 1986; 3(6):277-8. No original data

Shaya FT, Lu Z, Sohn K, Weir MR. Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents. *P T* 2009; 34(9):490-501. Does not have a drug comparison of interest

Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. *Arch Ophthalmol* 2008; 126(6):793-9. Does not have a drug comparison of interest

Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). *Diabetes Care* 2007; 30(6):1581-3. Does not apply

Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. *J Am Geriatr Soc* 1996; 44(7):751-5. Does not have a drug comparison of interest

Shoukry M, Jayyab AK. Plasma HDL in non-insulin-dependent diabetes and the effect of various types of treatment. *Atherosclerosis* 1983; 49(3):333-8. Does not have a drug comparison of interest

Signorini AM, Fondelli C, Renzoni E, Puccetti C, Gragnoli G, Giorgi G. Antioxidant effects of gliclazide, glibenclamide, and metformin in patients with type 2 diabetes mellitus. *Curr. Ther. Res. Clin. Exp.* 2002; 63(7):411-20. Does not apply

Simon S, Stephenson S, Whyte K et al. Prevalence of chronic renal failure in the diabetic population at the University Hospital of the West Indies. *West Indian Med. J.* 2004; 53(2):85-8. Does not apply

Simons WR, Vinod HD, Gerber RA, Bolinder B. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study. *Exp Clin Endocrinol Diabetes* 2006; 114(9):520-6. Does not apply

Simonson D, Smith D, Ferrannini E. Effect of glyburide (GLY) on insulin-mediated glucose metabolism and insulin secretion in non-insulin dependent diabetics (NIDD) and controls. *Clin Res* 1982; 30(2):404A. Does not apply

Simonson DC, Kourides IA, Feinglos M, Shamoan H, Fischette CT. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. *Diabetes Care* 1997; 20(4):597-606. Does not have a drug comparison of interest

Simonson DC. Glyburide improves glycemic control and reduces insulin requirement in insulin-treated NIDDM patients. *Adv Ther* 1987; 4(4):204. Less than 40 subjects with type 2 diabetes

Sinagra D, Scarpitta AM, Amato M. Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes. *Eur. Rev. Med. Pharmacol. Sci.* 1998; 2(5-6):175-9. Does not meet the study design criteria

Singhal P, Caumo A, Cobelli C, Taylor R. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. *Metabolism* 2005; 54(1):79-84. Does not have a drug comparison of interest

Sitprija S, Vajanamurhute C, Bunnag S. Blood lactate and pyruvate levels in diabetic patients treated with sulphonylureas with and without biguanides. *J Med Assoc Thailand* 1982; 65(2):63-71. Does not apply

Sivitz WI, Wayson SM, Bayless ML et al. Leptin and body fat in type 2 diabetes and monodrug therapy. *J Clin Endocrinol Metab* 2003; 88(4):1543-53. Less than 40 subjects with type 2 diabetes

Smith NL, Heckbert SR, Bittner VA et al. Antidiabetic treatment trends in a cohort of elderly people with diabetes: The Cardiovascular Health Study, 1989-1997. *Diabetes Care* 1999; 22(5):736-42. Does not apply

Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. *Metabolism* 2005; 54(1):24-32. Does not have a drug comparison of interest

Smits P. Cardiovascular effects of sulphonylurea derivatives. *Diabetologia* 1997; 40 Suppl 2:S160-1. No original data

Sonnenberg GE, Garg DC, Weidler DJ et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. *Ann Pharmacother* 1997; 31(6):671-6. Does not have a drug comparison of interest

Southwell A, Eckland D. Limitations of treatments available for the management of Type 2 diabetes: Results from an international survey of physicians. *Pract. Diabetes Int.* 1998; 15(4):112-6. Does not meet the study design criteria

Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). *Am J Cardiol* 2009; 104(2):234-9. Does not have a drug comparison of interest

Spanheimer R, Zhao Z, Perez A. Evaluating effect of insulin resistance and beta cell function in a pioglitazone and metformin fixed-dose combination study. *Diabetologia: Diabetologia* 2009; 52(S1):S212. No original data

Spanheimer R, Zhao Z, Perez A. Improvement of glycaemic control via reducing insulin resistance with pioglitazone and metformin fixed-dose combination therapy. *Canadian Journal of Diabetes: Can. J. Diabetes* 2009; 33(3):273. Does not meet the study design criteria

Stades AM, Heikens JT, Holleman F, Hoekstra JB. Effect of metformin on glycaemic control in type 2 diabetes in daily practice: a retrospective study. *Neth J Med* 2000; 56(3):86-90. Does not meet the study design criteria

Stalhammar J, Bergman U, Boman K, Dahlen M. Metabolic control in diabetic subjects in three Swedish areas with high, medium, and low sales of antidiabetic drugs. *Diabetes Care* 1991; 14(1):12-9. Does not meet the study design criteria

Standl E, Maxeiner S, Raptis S, Karimi-Anderesi Z, Schweitzer MA. Good glycaemic control with flexibility in timing of basal insulin supply: A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. *Diabetes Care* 2005; 28(2):419-20. Does not have a drug comparison of interest

Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. *Diabetes Care* 1999; 22(6):925-7. No comparison group

Stargardt T, Yin DD, Alexander CM. Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus. *Diabetes Obes Metab* 2009; 11(5):491-7. Does not meet the study design criteria

Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. *J Manag Care Pharm* 2008; 14(6):523-31. Does not apply

Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. *Am Heart J* 2007; 153(3):445.e1-6. Does not have a drug comparison of interest

Stockl KM, Le L, Zhang S, Harada AS. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications. *Pharmacoepidemiol Drug Saf* 2009; 18(2):166-74. Does not have a drug comparison of interest

Strock E, Mazze RS, Cuddihy R, Idrogo M, Wesley D, Morgan B. Multinational study examining the association between diabetes therapy and glycaemic control in patients with type 2 diabetes. *Canadian Journal of Diabetes: Can. J. Diabetes* 2009; 33(3):316. No original data

Strojek K, Bebakar WM, Khutsoane DT et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. *Curr Med Res Opin* 2009; 25(12):2887-94. Does not have a drug comparison of interest

Stroup J, Kane MP, Busch RS, Bakst G, Hamilton RA. The utility of insulin glargine in the treatment of diabetes mellitus. *Pharmacotherapy* 2004; 24(6):736-42. Does not have a drug comparison of interest

Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. *Diabetes Care* 2002; 25(10):1691-8. Does not have a drug comparison of interest

Sugihara S, Sasaki N, Kohno H, Amemiya S, Tanaka T, Matsuura N. Survey of current medical treatments for childhood-onset type 2 diabetes mellitus in Japan. *Clin Pediatr Endocrinol* 2005; 14(2):65-75. Does not meet the study design criteria

Sultan A, Avignon A, Galtier F et al. Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients. *Diabetes Care* 2008; 31(3):593-5. Does not apply

Sundar PS. Short term hypoglycemic response of 'Minidiab'(R) (glipizide) in 40 type II diabetics. *J. DIABETIC ASSOC. INDIA* 1982; 22(3):73-7. Does not meet the study design criteria

Suzuki M, Takamisawa I, Yoshimasa Y, Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. *Diabetes Res Clin Pract* 2007; 76(1):12-7. No comparison group

Svobodova H, Stulc T, Kasalova Z et al. The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus. *Physiol Res* 2008. Does not meet the study design criteria

Swislocki AL, Khuu Q, Liao E et al. Safety and efficacy of metformin in a restricted formulary. *Am J Manag Care* 1999; 5(1):62-8. No comparison group

Tahrani AA, Varughese GI, Scarpello JH, Hanna FW. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? *BMJ* 2007; 335(7618):508-12. No original data

Takagi T, Yamamuro A, Tamita K et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. *Am Heart J* 2003; 146(2):E5. Does not have a drug comparison of interest

Takagi T, Yamamuro A, Tamita K, Katayama M, Morioka S. Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study. *J Cardiol* 2005; 45(4):139-47. Does not have a drug comparison of interest

Takeda Pharmaceuticals North America, Inc. Observation of an increased risk of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type II diabetes mellitus. Deerfield, Illinois: Takeda Pharmaceuticals North America, Inc. 2007. No original data

Tan MH, Baksi A, Krahulec B et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. *Diabetes Care* 2005; 28(3):544-50. Does not have a drug comparison of interest

Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. *Clin Chem* 2004; 50(7):1184-8. Does not apply

Tankova T, Koev D, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. *Diabetes Res Clin Pract* 2003; 59(1):43-9. Does not have a drug comparison of interest

Taylor KG, Wright AD, John WG. A prospective study of sulphonylurea therapy and serum HDL-cholesterol in type 2 (insulin independent) diabetics. *Diabetologia* 1981; 21(5):514-5. Less than 40 subjects with type 2 diabetes

Taylor R, Isles TE, MacLaren S. Comparison of metabolic profiles in non obese, non insulin dependent diabetics receiving glipizide and glibenclamide. *Diabetol Croat.* 1983; 12(4):279-92. Less than 40 subjects with type 2 diabetes

Taylor R, Isles TE, McLaren S, Newton RW. A comparison of the metabolic profiles in type 2 diabetics during glipizide and glibenclamide treatment. *Diabetologia* 1981; 21(3):518. Less than 40 subjects with type 2 diabetes

Taylor R, Isles TE, McLaren S. A comparison of the metabolic profiles in type 2 (insulin independent) diabetics during glipizide and glibenclamide treatment. *Diabetologia* 1981; 21(5). Does not have a drug comparison of interest

Tentolouris N, Matsagura M, Psallas M et al. Relationship between antidiabetic treatment with QT dispersion during acute coronary syndromes in type 2 diabetes: comparison between patients receiving sulfonylureas and insulin. *Exp Clin Endocrinol Diabetes* 2005; 113(5):298-301. Does not apply

Teranishi T, Ohara T, Maeda K et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. *Metabolism* 2007; 56(10):1418-24. Does not meet the study design criteria

Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. *JAMA* 1998; 280(17):1490-6. Does not have a drug comparison of interest

Teupe B, Bergis K. Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. *Diabete Metab* 1991; 17(1 Pt 2):213-7. Does not have a drug comparison of interest

Thai AC, Husband DJ, Gill GV, Alberti KGMM. Management of diabetes during surgery. A retrospective study of 112 cases. *Diabete Metabol* 1984; 10(2):65-70. Does not apply

Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a Fixed-Dose Combination of Rosiglitazone/Glimepiride in Subjects Switching from Monotherapy or Dual Therapy with a Thiazolidinedione and/or a Sulfonylurea(May). *Ann Pharmacother* 2010. Does not have a drug comparison of interest

Tholakanahalli VN, Potti A, Heyworth MF. Glibenclamide-induced cholestasis. *West J Med* 1998; 168(4):274-7. Does not meet the study design criteria

Tildesley HD, Aydin CM, Ignaszewski A, Strelzow JA, Yu E, Bondy G. Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes. *Int J Cardiol* 2007; 115(3):312-7. Does not meet the study design criteria

Tomioka S, Ogata H, Tamura Y et al. Clinical characteristics influencing the effectiveness of metformin on Japanese type 2 diabetes receiving sulfonylureas. *Endocr J* 2007; 54(2):247-53. No comparison group

Tong PC, Chow CC, Jorgensen LN, Cockram CS. The contribution of metformin to glycaemic control in patients with Type 2 diabetes mellitus receiving combination therapy with insulin. *Diabetes Res Clin Pract* 2002; 57(2):93-8. Does not have a drug comparison of interest

Tong PCY, Ko GTC, So W-Y et al. Use of anti-diabetic drugs and glycaemic control in type 2 diabetes-The Hong Kong Diabetes Registry. *Diabetes Res. Clin. Pract.* 2008; 82(3):346-52. Does not meet the study design criteria

Tovi J, Theobald H, Engfeldt P. Effect of metabolic control on 24-h ambulatory blood pressure in elderly non-insulin-dependent diabetic patients. *J Hum Hypertens* 1996; 10(9):589-94. Less than 40 subjects with type 2 diabetes

Trischitta V, Italia S, Mazzarino S, Riddle MC. Addition of insulin or metformin after secondary failure to glyburide. *Ann Intern Med* 1992; 117(SUPPL. 2):46. Less than 40 subjects with type 2 diabetes

Trischitta V, Italia S, Raimondo M et al. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable? *J Endocrinol Invest* 1998; 21(11):744-7. Does not have a drug comparison of interest

Trovati M, Burzacca S, Mularoni E et al. A comparison of the predictive power for overall blood glucose control of a 'good' fasting level in type 2 diabetic patients on diet alone or with oral agents. *Diabet Med* 1992; 9(2):134-7. Does not have a drug comparison of interest

Tseng CH, Huang TS. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients. *Diabetes Res Clin Pract* 2005; 70(2):193-4. No original data

Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. *Ann Intern Med* 1996; 124(1 Pt 2):136-45. Does not have a drug comparison of interest

Turner R, Murchison L, Wright AD et al. United Kingdom prospective diabetes study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. *Ann. Intern. Med.* 1998; 128(3):165-75. Does not have a drug comparison of interest

Turner R, Rachman J, Holman R. UK Prospective Diabetes Study. *Diabetes Stoffwechsel* 1996; 5(3 SUPPL.):77-80. Other reason

Turner RC, Cull C, Frighi V, Holman R. UK Prospective Diabetes Study (UKPDS) Group, Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. *JAMA* 1999; 281. Other reason

Turner RC, Holman RR, Cull CA et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; 352(9131):837-53. Does not have a drug comparison of interest

Turner RC, Holman RR, Stratton IM et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998; 352(9131):854-65. Does not have a drug comparison of interest

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. *Diabetes* 1995; 44(11):1249-58. Does not have a drug comparison of interest

U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study. *Diabetes* 1985; 34(8):793-8. Does not have a drug comparison of interest

UKPDS Group. UK Prospective Diabetes Study 24: relative efficacy of sulfonylurea, insulin and metformin therapy in newly diagnosed non-insulin dependent diabetes with primary diet failure followed for six years. *Ann Intern Med* 1998; 128:165-75. Other reason

United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. *BMJ* 1995; 310(6972):83-8. Does not have a drug comparison of interest

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. *Ann Intern Med* 1998; 128(3):165-75. Does not have a drug comparison of interest

Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2005; (2):CD003639. No original data

van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. *Diabetes Care* 2005; 28(1):154-63. Does not apply

Van der Does FE BLHR. Glycemic control and complications in type II diabetes. *Diabetes Care* 1993; 16(6):952-3. No original data

Van Hooland S, Boey O, Van der Niepen P, Van den Branden C, Verbeelen D. Effect of short-term rosiglitazone therapy in peritoneal dialysis patients. *Perit Dial Int* 2009; 29(1):108-11. Less than 40 subjects with type 2 diabetes

Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. *J Clin Epidemiol* 1997; 50(6):735-41. Does not have a drug comparison of interest

Varghese P, Gleason V, Sorokin R, Senholzi C, Jabbour S, Gottlieb JE. Hypoglycemia in hospitalized patients treated with antihyperglycemic agents. *J. Hosp. Med.* 2007; 2(4):234-40. Does not meet the study design criteria

Variation in diabetes response. *Pharm. J.* 2003; 271(7272):572. No original data

Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. *Diabetologia* 2005; 48(7):1292-9. Does not have a drug comparison of interest

VilSBoll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. *Diabetes Care* 2007; 30(6):1608-10. Does not have a drug comparison of interest

Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. *Drug Saf* 2009; 32(5):409-18. Does not have a drug comparison of interest

Vongthavaravat V, Wajchenberg BL, Waitman JN et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. *Curr Med Res Opin* 2002; 18(8):456-61. Does not have a drug comparison of interest

Vray M, Attali JR. Randomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. Chinese-French Scientific Committee for the Study of Diabetes. *Diabetes Metab* 1995; 21(6):433-9. Does not have a drug comparison of interest

Wade R, Pawaskar MD, Quimbo RA, Hou L. Real world clinical effectiveness of sitagliptin therapy for management of type 2 diabetes: A retrospective database analysis. *Value Health* 2009; 12(7):A401. Other reason

Wajchenberg BL, Lerario AC, El-Andere W. The insulin receptor and the effect of sulfonylureas in non-insulin dependent diabetes mellitus. *Arq Bras Endocrinol Metabol* 1984; 28(4):107-10. Does not apply

Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. *Pharmacoepidemiol Drug Saf* 2008; 17(8):760-8. Does not have a drug comparison of interest

Wallace TM, Matthews DR. Assessment of the effects of insulin secretagogues in humans. *Diabetes Obes Metab* 2000; 2(5):271-83. No original data

Wang F, Vergara C, Carabino J, Desilets A, Vasquez R. Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms. *Am J Health Syst Pharm* 2004; 61(15):1604-8. Does not meet the study design criteria

Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. *Health Technol. Assess.* 2004; 8(45):iii-41. Does not apply

Waters AK, Morgan DB, Wales JK. Blood lactate and pyruvate levels in diabetic patients treated with biguanides with and without sulphonylureas. *Diabetologia* 1978; 14(2):95-8. Study duration less than 3 months

Wiholm BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. *Eur J Clin Pharmacol* 1993; 44(6):589-91. No comparison group

Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). *Stroke* 2007; 38(3):865-73. Does not have a drug comparison of interest

Wilcox R. An analysis from PROactive on the effects of pioglitazone on myocardial infarction and major adverse cardiovascular events (MACE) in patients with type 2 diabetes. World Congress of Cardiology 2006 2006. Other reason

Williams-Herman D, Johnson J, Lunceford J. Initial combination therapy with sitagliptin and metformin provides effective and durable glycaemic control over 1 year in patients with type 2 diabetes: a pivotal phase III clinical trial . *Diabetologia* 2007; 50(Suppl 1):52-3. Other reason

Williams-Herman D, Seck T, Golm G et al. Long-term efficacy with sitagliptin as monotherapy or add-on therapy to metformin: Improvement in glycaemic control over 2 years in patients with type 2 diabetes. *Diabetologia* 2009; 52(S1):S296. No original data

Willms B, Ruge D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. *Diabet Med* 1999; 16(9):755-61. Does not have a drug comparison of interest

Woerle HJ, Neumann C, Zschau S et al. Impact of fasting and postprandial glycemia on overall glycaemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. *Diabetes Res Clin Pract* 2007; 77(2):280-5. Does not apply

Wolever TM, Chiasson JL, Josse RG et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. *Int J Obes Relat Metab Disord* 1997; 21(9):756-63. Does not have a drug comparison of interest

Wolever TMS, Assiff L, Basu T et al. Miglitol, an (alpha)-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. *Nutr. Res.* 2000; 20(10):1447-56. Does not have a drug comparison of interest

Wolffenbittel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. *Diabet Med* 2000; 17(1):40-7. Does not have a drug comparison of interest

Wright AD, Cull CA, Holman RR, Turner RC. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulphonylurea-treated type 2 diabetes. *Diabetes Care* 1998; 21(1):87-92. Does not have a drug comparison of interest

Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. *Cancer Causes Control* 2009; 20(9):1617-22. Does not have a drug comparison of interest

Wroe CD. 66th Annual Scientific Sessions of the American Diabetes Association: The 66th Annual Scientific Sessions of the American Diabetes Association were held in Washington DC, 9-13 June 2006. *Pract. Diabetes Int.* 2006; 23(9):424-6. No original data

Wu Y-T, Gau C-S. The cardiovascular risk of sulphonylureas on newly diagnosed type ii diabetes mellitus patients. *Drug Saf.* 2009; 32(10):945-6. Other reason

Wyne KL, Bell DSH, Braunstein S, Drexler AJ, Miller JL, Nuckolls JG. Trends in management of type 2 diabetes: Role of thiazolidinediones. *Endocrinologist* 2003; 13(SUPPL. 1):i, ii+S1-S21. No original data

Wysham C, Bergenstal R, Yan P, MacConell L, Malloy J, Porter L. DURATION-2: Exenatide once weekly demonstrated superior glycaemic control and weight reduction compared to sitagliptin or pioglitazone after 26 weeks of treatment. *Diabetologia*: Diabetologia 2009; 52(S1):S290. No original data

Xu L, Williams-Herman D. Initial combination therapy with sitagliptin, a selective DPP-4 inhibitor, and metformin leads to marked improvement in cell function in patients with type 2 diabetes. *Diabetologia* 2007; 50 (Suppl 1):365. Other reason

Yamagishi S, Nakamura K, Inoue H. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH). *Med Hypotheses* 2005; 65(2):377-9. No original data

Yanagawa T, Araki A, Sasamoto K, Shirabe S, Yamanouchi T. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. *Metabolism* 2004; 53(3):353-7. Does not have a drug comparison of interest

Yang JK et al. Clinical study on rosiglitazone monotherapy of early type 2 diabetes. *China Pharmacy* 2002; 13(10):608-10. Other reason

Yang W et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetic drugs. *Diabetes Care* 2008; 31(5):852-6. Does not have a drug comparison of interest

Yang WY, Ji QH, Zhu DL et al. Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents. *Chin Med J (Engl)* 2009; 122(14):1704-8. Does not have a drug comparison of interest

Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. *Diabetes Care* 2007; 30(6):1574-6. Does not have a drug comparison of interest

Yegnanarayan R, Suryavanshi M, Singh M, Desai S. A comparative study of the glycaemic control of various antidiabetic agents and the role of homocysteine in the therapy of type 2 diabetes mellitus. *J Diabetes Complications* 2008; 22(2):104-11. Does not meet the study design criteria

Yener S, Comlekci A, Akinci B et al. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. *Med Princ Pract* 2009; 18(4):266-71. Does not have a drug comparison of interest

Yki-Jarvinen H, Kauppila M, Kujansuu E et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. *New Engl J Med* 1992; 327(20):1426-33. Does not have a drug comparison of interest

Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. *Ann Intern Med* 1999; 130(5):389-96. Does not have a drug comparison of interest

Yki-Jarvinen H, Ryysy L, Nikkila K. Bedtime insulin plus metformin was effective and did not cause weight gain in patients with poorly controlled type 2 diabetes mellitus. *Evid.-Based Med.* 1999; 4(4):108. No original data

Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. *Diabetes Care* 2001; 24(4):758-67. No original data

Yosefy C, Magen E, Kiselevich A et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. *J Cardiovasc Pharmacol* 2004; 44(2):215-22. Study duration less than 3 months

Yu AP, Wu EQ, Birnbaum HG et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: Analysis using claims, laboratory, and medical record data. *Curr Med Res Opin* 2007; 23(9):2157-69. Does not apply

Yudkin JS, Freemantle N. PROactive study. *Lancet* 2006; 367(9504):24, 25; author reply 26-27. No original data

Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemetic control in German patients with type 2 diabetes mellitus: a retrospective database study. *Clin Ther* 2007; 29(2):316-25. Does not meet the study design criteria

Zhao Z, Spanheimer R, Perez A. Effect of pioglitazone and metformin fixed-dose combination on glycaemic control in untreated patients. *Diabetologia* 2009; 52(S1):S335. Does not meet the study design criteria

Zhu XX, Pan CY, Li GW et al. Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. *Diabetes Technol Ther* 2003; 5(1):33-42. Does not have a drug comparison of interest

Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (*Diabetes Care* (2009) 32, (1224-1230)). *Diabetes Care: Diabetes Care* 2010; 33(3):692. No original data

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database. *Clin Ther* 2009; 31(11):2665-77. Does not apply

Zurlinden J. New treatment for adult-onset diabetes. *Nurs Spectr (Wash D C)* 1997; 7(16):8. No original data

Appendix G. Evidence Tables

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence (KQ1). Outcome: Hemoglobin A1c

# of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met vs. TZD							
16	5592	Medium	Consistent for short-duration studies. One long-term study Inconsistent.	Direct	Precise	No effect; Neither drug favored	Moderate
Met vs. SU							
19	6936	Low	Consistent	Direct	Precise	No effect; Neither drug favored	High
Met vs. DPP-4 Inhibitors							
3	1908	Medium	Consistent	Direct	Precise	Small; Favored Met	Moderate
Met vs. Nateg							
1	267	Medium	NA	Direct	Imprecise	Small; Favored Met	Low
Met vs. Repag							
2	167	Medium	Consistent	Direct	Imprecise	No effect; Neither drug favored	Low
Met vs. Met + TZD							
11	3495	Low	Consistent	Direct	Precise	Small; Favored Met + TZD	High
Met vs. Met + SU							
14	3619	Low	Consistent	Direct	Precise	Small; Favored Met + SU	High
Met vs. Met + DPP-4 Inhibitors							
6	4263	Medium	Consistent	Direct	Precise	Small; Favored Met + DPP-4 Inhibitor	Moderate
Met vs. Met + Nateg							
2	969	Low	Consistent	Direct	Imprecise	Small; Favored Met + Nateg	Low
Met vs. Met + Repag							
1	54	Low	NA	Direct	Precise	Small; Favored Met + Repag	Low
Rosi vs. Pio							
3	886	Medium	Consistent	Direct	Precise	No effect; Neither drug favored	Moderate
TZD vs. SU							
14	5578	Medium	Consistent	Direct	Precise	No effect; Neither drug favored	Moderate
TZD vs. Repag							
2	225	High	Inconsistent	Direct	Precise	Small; Unable to determine which drug favored	Low
TZD vs. Nateg							
1	34	Medium	NA	Direct	Imprecise	No effect; Neither drug favored	Low

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence (KQ1). Outcome: Hemoglobin A1c (continued)

# of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
SU vs. DPP-4 Inhibitors							
1	618	Low	NA	Direct	Imprecise	No effect; Neither drug favored	Low
SU vs. Repag							
7	1543	Low	Consistent	Direct	Precise	No effect; Neither drug favored	High
SU vs. Nateg							
2	82	Medium	Consistent	Direct	Imprecise	No effect; Neither drug favored	Low
SU vs. GLP-1 Agonists							
3	1310	Medium	Inconsistent	Direct	Precise	Unable to determine	Low
Met + TZD vs. Met + SU							
8	2729	Low	Consistent for short-term trials. One long-term study Inconsistent.	Direct	Precise	No effect; Neither drug combination favored in the short term	Moderate
Met + TZD vs. Met + DPP-4 Inhibitors							
2	293	Medium	Consistent	Direct	Precise	No effect; Neither drug combination favored	Low
Met + TZD vs. Met + Repag							
1	561	Medium	NA	Direct	Precise	No effect; Neither drug combination favored	Low
Met + TZD vs. Met + GLP-1 Agonists							
1	90	Medium	NA	Direct	Imprecise	No effect; Neither drug combination favored	Low
Met + TZD vs. TZD + SU							
1	170	Medium	NA	Direct	Imprecise	Small; Favored combination of TZD + SU	Low
Met + SU vs. Met + DPP-4 Inhibitors							
1	1172	Low	NA	Direct	Precise	No effect; Neither drug combination favored	Low
Met + SU vs. Met + Nateg							
2	661	Low	Inconsistent	Direct	Imprecise	Unable to determine	Low
Met + SU vs. Met + GLP-1 Agonists							
2	1215	Medium	Inconsistent	Direct	Imprecise	Unable to determine	Low
Met + SU vs. Met + Premixed Insulin							
2	827	Medium	Inconsistent	Direct	Imprecise	Unable to determine	Low

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence (KQ1).Outcome: Hemoglobin A1c (continued)

# of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met + SU vs. TZD + SU							
6	1844	Medium	Consistent for short term trials. One longer study Inconsistent.	Direct	Precise	No effect; Neither drug combination favored	Moderate
Met + DPP-4 Inhibitors vs. Met + GLP-1 Agonists							
1	661	Medium	NA	Direct	Precise	Small; Favored combination of Met + GLP-1 Agonist	Low
Met + GLP-1 Agonists vs. Met + Basal Insulin							
1	69	High	NA	Direct	Imprecise	No effect; Neither drug favored	Low
Met + Basal Insulin vs. Met + Premixed Insulin							
3	530	Medium	Consistent	Direct	Precise	No effect; Neither drug combination favored	Low

DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; Meg = meglitinides; Met = metformin; NA = not applicable; Nateg = nateglinide; Pio = pioglitazone; RCT = randomized controlled trial; Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione.

All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

* Directness was graded based on how well the evidence for a particular comparison related to the outcome of hemoglobin A1c.

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Weight

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/ Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met vs. TZD							
10	5239	Low	Consistent	Direct	Precise	Small; Favored Met	High
Met vs. SU							
13	5067	Medium	Consistent	Direct	Precise	Small; Favored Met	High
Met vs. DPP-4 Inhibitors							
3	1908	Medium	Consistent	Direct	Precise	Small; Favored Met	Moderate
Met vs. Meg (both Repag)							
2	166	High	Possibly Inconsistent	Direct	Imprecise	Unable to determine	Low
Met vs. Met + TZD							
7	2647	Low	Consistent	Direct	Precise	Small; Favored Met monotherapy	High
Met vs. Met + SU							
10	2510	Low	Consistent	Direct	Precise	Small; Favored Met monotherapy	High
Met vs. Met + DPP-4 Inhibitors							
6	4263	Medium	Consistent	Direct	Precise	No effect; Neither drug favored	Moderate
Met vs. Met + Meg							
2	521	Low	Consistent	Direct	Imprecise	Small; Favored Met monotherapy	Low
TZD vs. TZD							
3	886	Medium	Consistent	Direct	Precise	No effect; Neither drug favored	Low
TZD vs. SU							
7	6226	High	Consistent	Direct	Precise	Small; Favored SU	Low
TZD vs. Meg							
2	198	High	Consistent	Direct	Imprecise	Unable to determine	Low
SU vs. DPP-4 Inhibitors							
1	618	Low	NA	Direct	Imprecise	Unable to determine	Low
SU vs. Meg (all Repag)							
6	1326	Low	Consistent	Direct	Precise	No effect; Neither drug favored	High
SU vs. GLP-1 Agonists							
3	1310	Medium	Consistent	Direct	Imprecise	Small; Favored GLP-1 Agonist	Moderate
Met + TZD vs. Met + SU							
6	2407	Low	Consistent	Direct	Precise	Small; Favored Met + SU	Moderate
Met + TZD vs. Met + DPP-4 Inhibitors							
2	293	Medium	Consistent	Direct	Imprecise	Small; Favored Met + DPP-4 Inhibitor	Low
Met + TZD vs. Met + Meg							
1	561	Medium	NA	Direct	Imprecise	Unable to determine	Low
Met + TZD vs. Met + GLP-1 Agonists							
1	90	Low	NA	Direct	Precise	Small; Favored Met + GLP-1 Agonist	Low

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Weight (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/ Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met + SU vs. Met + DPP-4 Inhibitors							
1	1172	Low	NA	Direct	Precise	Small; Favored Met + DPP-4 Inhibitor	Low
Met + SU vs. Met + Meg							
2	494	Low	Inconsistent	Direct	Imprecise	Unable to determine	Low
Met + SU vs. Met + GLP-1 Agonists							
2	1215	Medium	Consistent	Direct	Imprecise	Small; Favored Met + GLP-1 Agonist	Low
Met + SU vs. Met + Premixed Insulin							
2	819	Low	Consistent	Direct	Precise	No effect; Neither drug combination favored	Low
Met + SU vs. TZD + SU							
4	2341	Low	Consistent	Direct	Imprecise	Small; Favored Met + SU	Moderate
Met + DPP-4 Inhibitors vs. Met + GLP-1 Agonists							
1	661	Medium	NA	Direct	Precise	Small; Favored Met + GLP-1 Agonist	Low
Met + GLP-1 Agonists vs. Met + Basal Insulin							
1	69	High	NA	Direct	Imprecise	Small; Favored Met + GLP-1 Agonist	Low
Met + Basal Insulin vs. Met + Premixed Insulin							
3	530	Medium	Consistent	Direct	Imprecise	No effect; Neither drug combination favored	Low

DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; Meg = meglitinides; Met = metformin; NA = not applicable; Nateg = nateglinide; Pio = pioglitazone; RCT = randomized controlled trial; Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

* Directness was graded based on how well the evidence for a particular comparison related to the outcome of weight.

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Low density lipoprotein

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met vs. Rosi							
7	511	Low	Consistent	Direct	Imprecise	Large; Favored Met	Moderate
Met vs. Pio							
6	1526	Low	Consistent	Direct	Precise	Large; Favored Met	High
Met vs. SU							
9	1774	Medium	Consistent	Direct	Precise	Large; Favored Met	High
Met vs. DPP-4 Inhibitors							
3	663	Medium	Consistent	Direct	Imprecise	Small; Favored Met	Moderate
Met vs. Meg							
1	112	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
Met vs. Met + Rosi							
7	2445	Low	Consistent	Direct	Precise	Large; Favored Met	High
Met vs. Met + Pio							
2	423	Medium	Inconsistent	Direct	Imprecise	Unable to determine, unable to determine	Low
Met vs. Met + SU							
7	1845	Medium	Inconsistent	Direct	Imprecise	No effect; Neither favored	Low
Met vs. Met + DPP-4 Inhibitors							
4	1943	Medium	Inconsistent	Direct	Imprecise	No effect; Neither favored	Low
Met vs. Met + Meg							
1	467	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
TZD vs. TZD							
2	846	High	Consistent	Direct	Imprecise	Small; Favored Pio	Low
Rosi vs. SU							
2	716	Medium	Consistent	Direct	Imprecise	Large; Favored SU	Low
Pio vs. SU							
3	465	High	Consistent	Direct	Precise	Small; Favored SU	Low
TZD vs. DPP-4 Inhibitors							
0		NA	NA	NA	NA	NA	Insufficient
Rosi vs. Meg							
1	54	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
Pio vs. Meg							
1	56	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Low density lipoprotein (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
SU vs. DPP-4 Inhibitors							
1	618	Low	NA	Direct	Imprecise	No effect; Neither favored	Low
SU vs. Meg							
2	668	Medium	Consistent	Direct	Imprecise	No effect; Neither favored	Low
SU vs. GLP-1 Agonists							
1	400	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
DPP-4 Inhibitors vs. Meg							
0		NA	NA	NA	NA	NA	Insufficient
Met + Rosi vs. Met + SU							
4	1708	Low	Consistent	Direct	Imprecise	Large; Favored Met + SU	Moderate
Met + Pio vs. Met + SU							
1	205	Low	NA	Direct	Imprecise	Small; Favored Met + SU	Low
Met + Rosi vs. Met + DPP-4 Inhibitors							
2	293	Medium	Consistent	Direct	Imprecise	Unable to determine, Favored Met + DPP-4 Inhibitor	Low
Met + Rosi vs. Met + Meg							
1	561		NA	Direct	Precise	Large; Favored Met + Meg	Low
Met + Rosi vs. Met + GLP-1 Agonists							
1	90	Medium	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
Met + Pio vs. Pio + SU							
1	170	Medium	NA	Direct	Imprecise	No effect; Neither favored	Low
Met + SU vs. Met + Meg							
3	661	Low	Inconsistent	Direct	Imprecise	Unable to determine, unable to determine	Low
Met + SU vs. Rosi + SU							
2	696	Medium	Inconsistent	Direct	Imprecise	Unable to determine, unable to determine	Low
Met + SU vs. Pio + SU							
2	717	Medium	Consistent	Direct	Imprecise	Small; Favored Met + SU	Low
Met + DPP-4 Inhibitors vs. Met + GLP-1 Agonists							
1	661	Low	NA	Direct	Imprecise	Unable to determine, unable to determine	Low

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Low density lipoprotein (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met + DPP-4 Inhibitors vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Meg vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Meg vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + GLP-1 Agonists vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + GLP-1 Agonists vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Basal Insulin vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Basal Insulin vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Premixed Insulin vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Premixed Insulin vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient

DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; Meg = meglitinides; Met = metformin; NA = not applicable; Nateg = nateglinide; Pio = pioglitazone; RCT = randomized controlled trial; Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

* Directness was graded based on how well the evidence for a particular comparison related to the outcome of low density lipoprotein

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: High density lipoprotein

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met vs. Rosi							
6	393	Medium	Consistent	Direct	Precise	No effect; Neither favored	Moderate
Met vs. Pio							
8	506	Medium	Consistent	Direct	Precise	Small; Favored Pio	High
Met vs. SU							
12	1953	Medium	Consistent	Direct	Precise	No effect; Neither favored	High
Met vs. DPP-4 Inhibitors							
3	2100	Medium	Inconsistent	Direct	Imprecise	No effect; Neither favored	Low
Met vs. Meg							
1	112	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
Met vs. Met + Rosi							
7	2689	Low	Consistent	Direct	Precise	Small; Favored Rosi	High
Met vs. Met + Pio							
2	470	Medium	Consistent	Direct	Imprecise	Large; Favored Met + Pio	Low
Met vs. Met + SU							
7	1841	Medium	Inconsistent	Direct	Imprecise	No effect; Neither favored	Low
Met vs. Met + DPP-4 Inhibitors							
4	2271	Medium	Inconsistent	Direct	Precise	No effect; Neither favored	Moderate
Met vs. Met + Meg							
1	467	Low	NA	Direct	Imprecise	No effect; Neither favored	Low
TZD vs. TZD							
3	886	High	Consistent	Direct	Precise	Small; Favored Pio	Moderate
Rosi vs. SU							
2	790	Medium	Consistent	Direct	Imprecise	Large; Favored Rosi	Low
Pio vs. SU							
5	616	Medium	Consistent	Direct	Imprecise	Small; Favored Pio	Moderate
TZD vs. DPP-4 Inhibitors							
0		NA	NA	NA	NA	NA	Insufficient
Rosi vs. Meg							
1	74	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
Pio vs. Meg							
2	94	High	Consistent	Direct	Imprecise	Small; Favored Pio	Low

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: High density lipoprotein (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
SU vs. DPP-4 Inhibitors							
1	618	Low	NA	Direct	Imprecise	No effect; Neither favored	Low
SU vs. Meg							
6	1108	Low	Consistent	Direct	Precise	No effect; Neither favored	High
DPP-4 Inhibitors vs. Meg							
0		NA	NA	NA	NA	NA	Insufficient
DPP-4 Inhibitors vs. GLP-1 Agonists							
1	400	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
Met + Rosi vs. Met + SU							
4	1738	Low	Consistent	Direct	Imprecise	Small; Favored Met + Rosi	Moderate
Met + Pio vs. Met + SU							
2	388	Medium	Consistent	Direct	Precise	Large; Favored Met + Pio	Low
Met + Rosi vs. Met + DPP-4 Inhibitors							
2	181	Medium	Inconsistent	Direct	Imprecise	Unable to determine, unable to determine	Low
Met + Rosi vs. Met + Meg							
1	561	?	NA	Direct	Precise	Small; Favored Met + Rosi	Low
Met + Rosi vs. Met + GLP-1 Agonists							
1	90	Medium	NA	Direct	Imprecise	Small; Favored Met + Rosi	Low
Met + Pio vs. Pio + SU							
1	170	Medium	NA	Direct	Imprecise	Small; Favored Met + Pio	Low
Met + TZD vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + SU vs. Met + Meg							
2	661	Low	Consistent	Direct	imprecise	No effect; Neither favored	Low
Met + SU vs. Met + Premixed Insulin							
1	230	Low	NA	Direct	imprecise	No effect; Neither favored	Low
Met + SU vs. Rosi + SU							
2	980	Medium	Inconsistent	Direct	imprecise	Unable to determine, unable to determine	Low
Met + SU vs. Pio + SU							
3	864	Medium	Consistent	Direct	imprecise	Small; Favored Pio + SU	Low
Met + SU vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: High density lipoprotein (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met + DPP-4 Inhibitors vs. Met + liraglutide							
1	661	Medium	NA	Direct	Precise	No effect; Neither favored	Low
Met + DPP-4 Inhibitors vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + DPP-4 Inhibitors vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Meg vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Meg vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + GLP-1 Agonists vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + GLP-1 Agonists vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Basal Insulin vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Basal Insulin vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Premixed Insulin vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient

DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; Meg = meglitinides; Met = metformin; NA = not applicable; Nateg = nateglinide; Pio = pioglitazone; RCT = randomized controlled trial; Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

* Directness was graded based on how well the evidence for a particular comparison related to the outcome of high density lipoprotein.

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Triglycerides

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met vs. Rosi							
7	459	Medium	Inconsistent	Direct	imprecise	Large; Favored Met	Moderate
Met vs. Pio							
8	506	Medium	Consistent	Direct	Precise	Large; Favored Pio	High
Met vs. SU							
12	1531	Medium	Consistent	Direct	Imprecise	Small; Favored Met	Moderate
Met vs. DPP-4 Inhibitors							
3	2100	Medium	Consistent	Direct	Imprecise	No effect; Neither favored	Low
Met vs. Meg							
1	112	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
Met vs. Met + Rosi							
7	2470	Low	Consistent	Direct	Precise	Large; Favored Met	High
Met vs. Met + Pio							
2	479	Medium	Inconsistent	Direct	Imprecise	Unable to determine, unable to determine	Low
Met vs. Met + SU							
8	1584	Medium	Inconsistent	Direct	Imprecise	No effect; Neither favored	Low
Met vs. Met + DPP-4 Inhibitors							
4	2594	Medium	Consistent	Direct	Imprecise	Large; Favored Met + DPP-4 Inhibitor	Low
Met vs. Met + Meg							
1	467	Low	NA	Direct	Imprecise	Small; Favored Met + Meg	Low
TZD vs. TZD							
3	886	High	Consistent	Direct	Imprecise	No effect; Neither favored	Low
Rosi vs. SU							
2	716	Medium	Inconsistent	Direct	Imprecise	Unable to determine, unable to determine	Low
Pio vs. SU							
6	616	High	Consistent	Direct	Imprecise	Large; Favored Pio	Low
TZD vs. DPP-4 Inhibitors							
0		NA	NA	NA	NA	NA	Insufficient
Rosi vs. Meg							
1	74	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
Pio vs. Meg							
2	94	High	Consistent	Direct	Imprecise	Large; Favored Pio	Low

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Triglycerides (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
SU vs. DPP-4 Inhibitors							
1	618	Low	NA	Direct	Imprecise	No effect; Neither favored	Low
SU vs. Meg							
6	1113	Medium	Consistent	Direct	Precise	No effect; Neither favored	Moderate
SU vs. GLP-1 Agonists							
1	400	High	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
DPP-4 Inhibitors vs. Meg							
0		NA	NA	NA	NA	NA	Insufficient
Met + Rosi vs. Met + SU							
4	1735	Low	Consistent	Direct	Imprecise	No effect; Neither favored	Moderate
Met + Pio vs. Met + SU							
2	388	Medium	Consistent	Direct	Precise	Large; Favored Met + Pio	Moderate
Met + Rosi vs. Met + DPP-4 Inhibitors							
2	673	Medium	Consistent	Direct	Imprecise	Unable to determine, Favored Met + DPP-4 Inhibitor	Low
Met + Rosi vs. Met + Meg							
1	181		NA	Direct	Imprecise	No effect; Neither favored	Low
Met + Rosi vs. Met + GLP-1 Agonists							
1	90	Medium	NA	Direct	Imprecise	Large; Favored Met + GLP-1 Agonist	Low
Met + Pio vs. Pio + SU							
1	170	Medium	NA	Direct	Imprecise	Small; Favored Pio + SU	Low
Met + TZD vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + SU vs. Met + Meg							
2	661	Low	Inconsistent	Direct	Imprecise	Unable to determine, unable to determine	Insufficient
Met + SU vs. Met + Premixed Insulin							
1	230	Low	NA	Direct	Unable to determine	No effect; Neither favored	Low
Met + SU vs. Rosi + SU							
2	3390	Medium	Inconsistent	Direct	Imprecise	Unable to determine, unable to determine	Insufficient
Met + SU vs. Pio + SU							
4	942	Medium	Inconsistent	Direct	Imprecise	Unable to determine, Favored Pio + SU	Low

Table 1. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Triglycerides (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met + SU vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + DPP-4 Inhibitors vs. Met + GLP-1 Agonists							
1	661	Low	NA	Direct	Imprecise	Unable to determine, unable to determine	Low
Met + DPP-4 Inhibitors vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + DPP-4 Inhibitors vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Meg vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Meg vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + GLP-1 Agonists vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + GLP-1 Agonists vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Basal Insulin vs. Met + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Basal Insulin vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient
Met + Premixed Insulin vs. TZD + Another agent							
0		NA	NA	NA	NA	NA	Insufficient

DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; Meg = meglitinides; Met = metformin; NA = not applicable; Nateg = nateglinide; Pio = pioglitazone; RCT = randomized controlled trial; Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

* Directness was graded based on how well the evidence for a particular comparison related to the outcome of triglycerides.

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Seino, 2010 ¹²¹	Neither year reported	Yes	< 6 months	Yes	NR/464	Age <20 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), retinopathy, HbA1c <7% or >10%, BMI >35 kg/m ² , treated with insulin within 12 weeks of the start of the study, receiving or expecting to receive systemic corticosteroids, known hypoglycemia unawareness or recurrent major hypoglycemia unawareness or recurrent major hypoglycemia, no Type 2 DM, treated with diet therapy for less than 8 weeks, on more than 1/2 of the recommended maximum dose of an SU (e.g., on more than 2.5 mg of glibenclamide)
Japan	24 weeks				NR	
Derosa, 2010 ⁴⁴	Neither year reported	No run-in period	< 6 months	No	128/128	Age <18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, retinopathy, HbA1c < 8%, BMI <25 kg/m ² or ≥30 kg/m ² , pregnant, nursing, not using adequate contraception, history of ketoacidosis, severe anemia, not intolerant to metformin at maximum dosage (3,000 mg/day), not on metformin, diabetic neuropathy
Italy	12 months				patients identified from case notes and clinical registers	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
DeFronzo, 2010 ²⁸⁷	Start Year 2006 End Year 2008	No run-in period	< 6 months	Yes	NR/137	Age <18 or >75 years, HbA1c <6.8% or >10%, BMI <25 kg/m ² or >40 kg/m ² , not on stable dose of metformin for at least 6 weeks, body weight stable for past 6 months, islet cell auto-antibodies, treatment with any other ODM (other than metformin)
U.S.	20 weeks				NR	
Aschner, 2010 ⁷⁷	Neither year reported	Run-in period but number of participants excluded was NR	NR	Yes	2068/1050	Age <18 or >78 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <6.5% or >9%, treatment naive, no Type 2 DM, FPG <120 or >250 mg/dL, triglycerides >600 mg/dL, CK > 2x upper limit normal
Multicontinent	24 weeks				NR	
Seck, 2010 ¹³⁴	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	2141/1172	Age <17 or >78 years
NR	2 years				NR	
Pratley, 2010 ¹⁴³	Start year 2008 End year 2009	No run-in period	>= 6months	Yes	1302/665	Age <18 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c >7.5% or <10%, BMI >45 kg/m ² , no Type 2 DM, cancer, contraindication to trial drugs, recurrent hypoglycemic or hypoglycemia unawareness, not on metformin for at least 3 months, on any non-metformin anti-hypoglycemic in past 3 months
Multicontinent Europe, U.S., and Canada	26 months				"Office-based"-possibly out patient	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Home, 2009 ¹⁶	Start year 2001 End year 2003	Run-in period but number of participants excluded was NR	>= 6 months	Yes	7428/4458	Age <40 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), contraindication or history of intolerance to metformin, history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c < 7% or >9%, BMI <25 kg/m ² , pregnant, nursing, not using adequate contraception
Multinational Europe	7.5 Years				Outpatient primary care	
Raskin, 2009 ¹³¹	Neither year reported	No run-in period	< 6 months	Yes	1093/383	Age <18 years, pregnant, nursing, currently not under monotherapy at least 2 months or dual therapy, FBG >260 mg/dL, any disease or abnormality as judged by the investigator, treatment with the investigational drug for 4 weeks, allergy to study drugs or related compounds, history of hypoglycemia unawareness or recurrent severe hyperglycemia
NR	26 Weeks				Outpatient primary care	
Derosa, 2009 ⁴⁶	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	NR	271/252	Age <18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, retinopathy, HbA1c <6.5%, BMI <25 kg/m ² or >30 kg/m ² , pregnant, nursing, not using adequate contraception, no Type 2 DM, history of ketoacidosis, severe anemia
Italy	15 Months				Outpatient primary care, computerized clinic registry	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Van der Meer, 2009 ¹⁴¹	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	173/80	Age <45 or >65 years, female, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <6.5% or >8.5%, BMI <25 kg/m ² or >32 kg/m ² , SBP <150 mmHg, DBP <85 mmHg, prior TZD or insulin use
Netherlands	24 Weeks				NR	
Kaku, 2009 ⁸⁴	Start year 2005	Yes	< 6 months	Yes	NR/236	Age ≤ 20 and ≥65 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., failed initial treatment), HbA1c <6.5% or >10%, other pre-existing conditions that potentially require hospitalization such as cancer, severe lung, gastrointestinal, pancreatic and hematological disorders, history of lactic acidosis, ketoacidosis, diabetic coma, or pre-coma within the preceding 26 weeks, if on any medications that might affect glycemic control, drug or alcohol dependency
Japan	40 Weeks				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Gupta, 2009 ⁴⁷	Neither year reported	No run-in period	< 6 months	Yes	247/51	Age <35 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), pregnant, not using adequate contraception, FPG >200 mg/dL, individuals using orlistat, sibutramine, ephedrine, steroids, significant lung diseases, significant neurologic diseases, baseline BP>140/90 mmHg, prior use of TZD, beta blockers, smokers, alcohol abuse and using drugs, patients using metal objects precluding required scans
NR	16 Weeks				NR	
Williams-Herman, 2009 ⁷⁶	Neither year reported	Run-in period but number of participants excluded was NR	NR	Yes	3544/1091	Age <18 or >78 years, HbA1c <7.5% or >11% after screening diet/exercise run-in (which included a wash-out period), lack of adequate compliance (>=75% by tablet count) during 2-week single-blind placebo run-in period, no Type 2 DM
NR	54 Weeks				NR	
Derosa, 2009 ¹³⁵	Neither year reported	Fewer than 10% of participants were excluded during run-in	>= 6 months	NR	NR/248	Age >18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, retinopathy, HbA1c < 7%, BMI <25 kg/m ² OR >28 kg/m ² , pregnant, nursing, not using adequate contraception, no Type 2 DM, history of ketoacidosis, severe anemia, no hypertension
Italy	12 Months				Inpatient/hospital	
Nauck, 2009 ⁹²	Neither year reported	Run-in period but number of participants excluded was NR	>= 6 months	Yes	1662/1087	Age <18 or >80 years, HbA1c <7% or >11% if on monotherapy; 10% if on combination therapy (both greater than 3 months), BMI >40 kg/m ² , used insulin in last 3 months
Multicontinent	26 Weeks				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Vijay, 2009 ⁹⁹	Neither year reported	No run-in period	< 6 months	NR	NR/40	Age <30 or >70 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <8%, BMI >36 kg/m ² , unstable weight for at least 3 months before study, pre-existing chronic diseases, any amount of smoking during previous 6 months, previous use of insulin or any TZDs, on medications such as glucocorticoids or other drugs that affect glucose metabolism, lipid lowering drugs or psychoactive substances and alcohol
India	4 months				Outpatient subspecialty care setting	
Kiyici, 2009 ⁴⁵	Neither year reported	No run-in period	< 6 months	No	NR/50	Age <30 or >65 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c >8%, BMI >40 kg/m ² , gastrointestinal disease, rheumatological, or neoplastic, infectious diseases, history of using anti-diabetic medications, any endocrine disease except diabetes or hyperlipidemia, smoking, microvascular complications of diabetes, history of substance abuse
Turkey	52 weeks				Outpatient subspecialty care setting	
Jonker, 2009 ¹⁶⁰	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	173/78	Age <45 or >65 years, female, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, retinopathy, HbA1c <6.5% or >8.5%, BMI <25 kg/m ² or >32 kg/m ² , no Type 2 DM, prior use of TZD/insulin, BP >150/85 mm Hg
Netherlands	24 weeks				Outpatient Primary care setting	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Perez, 2009 ⁵⁶	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	1436/600	Age <18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., "failed initial treatment"), contraindication or history of intolerance to metformin, HbA1c <7.5% or >10%, BMI >45 kg/m ² , pregnant, nursing, triglycerides >500 mg/dL, discontinued metformin and TZD therapy due to lack of efficacy
U.S., multinational Europe	24 weeks				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Rigby, 2009 ¹³⁰	Start year 2007 End year 2008	No run-in period	< 6 months	Yes	356/169	Age <18 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <7% (6.5% if on metformin combination therapy) or >10% (9.5% if on metformin combination therapy), BMI > 40 kg/m ² , LDL <50 mg/dL or triglycerides ≥500 mg/dL, weight loss program with ongoing weight loss or starting an intensive exercise program within 4 weeks of screening, need for oral corticosteroids, bile acid sequestrants, or any antidiabetes medications other than metformin, >2months insulin, not on metformin for ≥3 months (1500-2550 mg/day), Type 1 DM and/or ketoacidosis, dysphagia/swallowing disorders, intestinal motility disorders, pancreatitis, HIV/AIDS, drug/alcohol abuse within 2 years, any serious disorder including pulmonary, hepatic, gastrointestinal, uncontrolled endocrine/metabolic, hematologic/oncologic (within 5 years), neurologic, or psychiatric diseases, current treatment with TZD/combo with metformin/colesevelam/fixed-dose combination product including metformin, hospitalization within 14 days of screening
U.S., multicontinent	16 months				NR	
Tolman, 2009 ¹⁵⁰	Start year 2000 End Year 2005	No run-in period	< 6 months	Yes	NR/2120	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <7%, BMI <20kg/m ² or >48 kg/m ² , not taking metformin and/or SU, history of ketoacidosis, history of TZD use other than troglitazone before 4/00
U.S.	3 years				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Jadzinsky, 2009 ⁷⁸	Start year 2006 End year 2008	Fewer than 10% participants excluded during run-in period	< 6 months	Yes	2936/1394	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., "failed initial treatment"), HbA1c <8% or >12%, BMI >40 kg/m ² , prior treatment, diabetic ketoacidosis or nonketotic hyperosmolar coma, CV events 6 months prior, LVEF <40%, psychiatric history, alcohol or drug abuse, abnormal metabolic or hematologic test
Multicontinent	24 weeks				Outpatient Primary care setting	
DeFronzo, 2009 ⁹⁵	Neither year reported	Yes	< 6 months	Yes	1462/743	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., "failed initial treatment"), contraindication or history of intolerance to metformin, neuropathy, retinopathy, HbA1c < 7% or >10%, BMI >40 kg/m ² , pregnant, nursing, alcohol or drug abuse, NYHA III and IV, LVEF <40%
NR	24 weeks				NR	
Bunck, 2009 ¹⁴⁴	Start year 2004 End year 2007	No run-in period	< 6 months	Yes	150/69	Age <30 or >75 years, HbA1c <6.5% or >9.5%, BMI <25 kg/m ² or >40 kg/m ² , metformin treatment not at a stable dose for at least 2 months, no other blood glucose lowering medications allowed in 3 months prior to study, no changes in other medications known to affect beta cell function (ACEI, beta blockers)
Sweden, Finland, and Netherlands	56 weeks				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Garber, 2009 ¹²²	Start year 2006 End year 2007	Fewer than 10 % participants excluded during run-in period	< 6 months	Yes	NR/746	Age <18 or >80 years, HbA1c <7% or >11% if prior treatment was diet; >10% if prior treatment was drug, BMI >45 kg/m ² , either not treated with diet and exercise or up to half the highest dose of oral antidiabetic drug monotherapy for at least 2 months prior to trial, insulin treatment during the previous 3 months (except short-term treatment for intercurrent illness), treatment with systemic corticosteroids, hypoglycemia unawareness or recurrent severe hypoglycemia, impaired liver function (aspartate aminotransferase or alanine aminotransferase concentrations 5 times upper normal range)
U.S., Mexico	52 weeks				NR	
Kato, 2009 ⁵⁷	Neither year reported	No run-in period	NR	NR	NR/50	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, retinopathy, no Type 2 DM, no metabolic syndrome, not on continuous diet/exercise therapy, no anemia, no history of heart failure
Multinational Europe	12 weeks				NR	
Erdem, 2008 ³⁹	Neither year reported	No run-in period	< 6 months	No	53/44	Age <30 or >70 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), BMI >35 kg/m ² , other chronic disease as detected by history and physical
Turkey	12 weeks				outpatient department of internal medicine clinic	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Scott, 2008 ⁸⁵	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	486/273	Age <18 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), HbA1c <7% or >11%, not on 10 weeks on stable dose of metformin, insulin use, Type 1 DM, glucose >270 mg/dL
Multi-continent	18 weeks				NR	
Seufert, 2008 ¹⁴²	Neither year reported	No run-in period	NR	Yes	NR/1269	Age <35 or >75 years, history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., failed initial treatment), HbA1c <7.5% or >11%, pregnant, nursing, fasting C-peptide >1.5 ng/mL, ketoacidosis, symptomatic heart failure, acute malabsorption, chronic pancreatitis, familial polyposis coli, malignant disease in the previous 10 years
Multicontinent	104 weeks				NR	
Hamann, 2008 ¹²³	Neither year reported	Yes	< 6 months	NR	818/596	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <7% or >10%, BMI <25 kg/m ² , used any oral antidiabetic drug other than metformin in the prior 12 weeks, or insulin at any time other than during pregnancy or for emergency treatment, history of metabolic acidosis, edema requiring pharmacological treatment (either ongoing or within the prior 12 months), anemia (hemoglobin <11.0 g/dl for men and <10.0 g/dl for women), C-peptide <0.5nmol/L, SBP >170mmHg, DBP >100mmHg
Multinational Europe, Mexico	52 weeks				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Schwarz, 2008 ¹⁵²	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	75/69	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), contraindication or history of intolerance to metformin, HbA1c <7.0% or >11.0%, BMI <22 kg/m ² or >45 kg/m ² , FBG >270 mg/dL, history of lactic acidosis, congestive cardiac failure requiring pharmacologic treatment, Type 1 DM or secondary forms of DM
U.S.	104 weeks				NR	
Comaschi, 2008 ¹⁵⁸	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	398/250	Age <35 years, HbA1c <7.5% or >11%, fasting C-peptide <0.33 nmol/L, had not received treatment with a stable dose of either metformin or an SU as a monotherapy for at least 3 months before study entry, on other oral hypoglycemic agents, insulin, benzoic acid, long treatments with beta-blockers, or corticosteroids
Italy	6 Months				NR	
Iliadis, 2007 ⁴⁸	Neither year reported	Run-in period but number of participants excluded was NR	NR	NR	NR/48	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), diagnosis of Type 2 DM >3 years, use of any diabetes medication, no Type 2 DM, any heart failure
Greece	18 weeks				Outpatient subspecialty care setting	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Robbins, 2007 ¹⁴⁵	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	433/317	Age <35 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), HbA1c <6.5% or >11%, pregnant, nursing, not using adequate contraception, patients who were receiving continuous SC insulin injections or a total daily insulin of >2.0 U/kg or who had a change in type or dose of lipid-altering medications or TZD use up to 3 months before the study, fasting triglyceride level >4.5 mmol/L, serum creatinine >134 micromol/L (men) or >109 micromol/L (women)
U.S., Multinational Europe, multi-continent, India, Australia	24 weeks				NR	
Chien, 2007 ⁵⁹	Neither year reported	No run-in period	< 6 months	Yes	166/100	Age <30 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), contraindication or history of intolerance to metformin, retinopathy, HbA1c > 12% and FPG>250 mg/dL at screening visit, HbA1c < 7% and FPG<140 mg/dL at screening visit, BMI <18.5 kg/m ² or >35 kg/m ² , current significant GI disorder, hyperglycemic hyperosmolar non-ketotic coma, hypersensitivity to glyburide or metformin, current infection, treatment with insulin in last 6 months, surgery in past 4 weeks, history of cancer in 5 yr, on concurrent drugs affect sugar metabolism, FPG < 140 mg/dl at second visit, not on a stable dose of SU at baseline or dose of metformin>1000mg/day or SU dose too low (glyburide or gliclazide<10 mg/day, glimepiride<4mg/d, gliclazide<160mg/d)
Taiwan	16 weeks				5 medical centers. Does not specify inpatient or outpatient	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Derosa, 2007 ²⁸⁸	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	No	NR/248	Age <18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, retinopathy, HbA1c <7.0%, BMI <25 kg/m ² or >28 kg/m ² , pregnant, nursing, not using adequate contraception, history of ketoacidosis, severe anemia, non-Caucasians, SBP <130 mm Hg, DBP <85 mm Hg
Italy	12 months				NR	
Turkmen Kemal, 2007 ⁵⁸	Start year 2005	No run-in period	< 6 months	NR	46/46	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), patient on diuretics, uncontrolled hypertension
Turkey	6 months				Outpatient subspecialty care setting	
Comaschi, 2007 ¹²⁹	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	398/250	Age <35 years, HbA1c < 7.5% or >11%, had not received SU or metformin as a monotherapy at a stable dose for at least 3months, fasting C-peptide <0.33 nmol/L
Italy	6 months				NR	
Home, 2007 ¹²⁴	Start year 2000	Run-in period but number of participants excluded was NR	>= 6 months	NR	7428/4458	Age <40 or >75 years, HbA1c <7% or >9%, BMI <25 kg/m ²
Multinational Europe, Australia and New Zealand	End year 2002				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Teramoto, 2007 ⁴¹	Neither year reported	Yes	NR	No	126/92	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), any medication affecting glucose metabolism, history of diabetic ketoacidosis, history of diabetic coma or pre-coma, Cushing's syndrome, history of allergy to thiazolidinediones, tumor therapy, receiving insulin for severe infection
Japan	24 weeks				NR	
Goldstein, 2007 ⁷⁵	Neither year reported	Run-in period but number of participants excluded was NR	NR	Yes	3544/1091	Age <18 or >78 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), patient with less than 75% compliance during placebo run in period, patient with HbA1c <7.5% or >11 % after diet/exercise run in/wash-out period, patients with fasting glucose >280 mg/dl after run-in period, no Type 2 DM, Type 1 DM
Multicontinent	24 weeks				NR	
Davies, 2007 ¹⁴⁷	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	NR/82	Age <30 or >80 years, history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), contraindication or history of intolerance to metformin, HbA1c >7.0%, BMI >43 kg/m ² , not using adequate contraception, history of previous insulin use for >2 weeks, duration of Type 2 DM <12 months, c-peptide levels <0.33, severe concurrent disease, serum Cr >150umol/l
United Kingdom	4 months				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Lund, 2007 ¹⁹⁷ Denmark	Start year 2001 End year 2002 8 months	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	127/96 Outpatient subspecialty care setting	Age <40 years for onset of diabetes diagnosis, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c >9.5% with ongoing ODMs prior to study start; 10.5 on 2 visits with >1m interval, HbA1c <6.5% after run-in period, BMI >27 kg/m ² , pregnant, insulin treated Type 2 DM, secondary DM, Factor II, VII, X <0.7, ongoing co-existing illness with life shortening prognosis, mental retardation or reduced intellectual behavior, history of drug abuse, weight loss of >5kg in past 6 months prior to study start, fasting C-peptide <300 of non fasting glucagon stimulated C-peptide <600, ketonuria, ketoacidosis
Nauck, 2007 ¹³³ U.S., multinational Europe, multi-continent	Neither year reported 52 weeks	Yes	< 6 months	Yes	2141/1172 NR	Age <18 or >78 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), FPG >15 mmol/L, insulin use within 8 weeks of screening, history of Type 1 DM, other treatments for hypoglycemia
Kim, 2007 ⁴² South Korea	Neither year reported 12 weeks	Fewer than 10% of participants were excluded during run-in	< 6 months	No	NR/120 Outpatient primary care, Outpatient subspecialty care setting	Age <30 or >70 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), duration of diabetes >5 years, not on a stable medication with a SU and/or alpha glucosidase inhibitor for at least 3 months, episodes of ketonuria or ketoacidosis, current malignancy, tuberculosis, rheumatic disease, thyroid disease, corticosteroid treatment, previous TZD or metformin treatment

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Raskin, 2007 ¹⁴⁶	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	N/NR	Age <18 or >75 years, HbA1c ≤8.0%, BMI >40 kg/m ² or weight >125 kg (275lbs), pregnant, nursing, not using adequate contraception, if not on metformin ≥1,000mg /day as a single agent or in ODM combination therapy for at least 3 months before the trial, history of insulin use
US	28 weeks				NR	
Hanefeld, 2007 ¹⁰⁰	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	NR/598	Age <40 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), BMI <22 kg/m ² or >38 kg/m ² , pregnant, patient on insulin therapy, patient with diabetic complications requiring treatment, hematologic impairment, FPG < 7mmol/l or >15 mmol/l, C peptide <0.27 nmol/l
Multinational Europe	52 weeks				NR	
Scott, 2007 ¹¹¹	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	2186/743	Age <21 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), Type 1 DM, gall bladder disease, elevated CK
U.S.	12 weeks				NR	
Kahn, 2006 ³⁸	Start year 2000 End year 2006	No run-in period	NR	Yes	6676/4360	Age <30 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), uncontrolled hypertension, FPG <126 or >180 mg/dL, history of lactic acidosis
Multicontinent	6 years				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Charbonnel, 2006 ⁹⁴	Neither year reported	Run-in period but number of participants excluded was NR	NR	Yes	1464/701	Age <18 or >78 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), HbA1c <7% or >10%, Type 1 DM, insulin use within 8 weeks of screening, FPG >14.4mmol/l
Multicontinent	24 weeks				NR	
Rosenstock, 2006 ⁴⁹	Start year 2003 to 2004	Yes	< 6 months	Yes	1252/468	Age <18 or >70 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <7% or >11%, FPG >15 mmol/l, hematological disease, uncontrolled hypertension while on antihypertensive treatment, intermittent or chronic use of oral or intravenous corticosteroids, investigators discretion, use of investigational agent within 30 days of the study (or five half lives of the investigational drug if longer than 30 days), previous history of severe edema or medically serious fluid related event associated with TZD, acute or chronic metabolic acidosis, history of diabetic ketoacidosis
Multicontinent	32 weeks				multicenter	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Jain, 2006 ¹⁰¹	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	NR/502	Age <18 or >80 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., failed initial treatment), HbA1c <7.5% or >11.5%, pregnant, nursing, duration of diabetes > than 2 years, intolerance to rosiglitazone, pioglitazone, or troglitazone, drug or alcohol abuse, previous treatment with meglitinide analog, alpha glucosidase inhibitor, metformin, insulin, SU for 3 months or more, use of hydrochlorothiazide, joint injections, niacin greater than 250 mg /day, oral anti-diabetic drugs, concurrent participation in another investigational study, serum creatinine level >1.5 mg/dl for men, 1.4 mg/dl for women, 1+ proteinuria, anemia (<10 g/dl women, <12 g/dl men), BMI ≤20 kg/m ² or >45 kg/m ² ; hypertension, chronic pulmonary disease, history of cancer not in remission for at least 5 years
U.S., Puerto Rico	56 weeks				NR	
Stewart, 2006 ¹⁵⁶	Start year 2003 to 2004	Yes	< 6 months	Yes	1397/526	Age < 18 or > 70 years, history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c < 7% or >9%, drug naive patients with FPG <7 mmol/l or >9 mmol/l, patient on monotherapy with FPG <6.0 mmol/l or >8 mmol/l, prior history of exposure to TZDs within previous 6 months, use of insulin anytime in the past, uncontrolled hypertension
Multinational Europe	32 weeks				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Bakris, 2006 ¹²⁵	Neither year reported	Yes	< 6 months	Yes	560/514	Age <40 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), BMI <22 kg/m ² , use of any TZD in the 3 months prior to screening, use of insulin for ≥ 6 months at any time prior to screening, anemia, severe angina, SBP >159 mm Hg (can't adjust the BP meds during the trial), DBP >99 mm Hg
U.S., multi-continent, South America, Europe	32 weeks				NR	
Umpierrez, 2006 ¹²⁶	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	538/210	Age <18 or >79 years, HbA1c <7.5% and >10%, BMI <24 kg/m ² , diagnosis of Type 2 DM <6 months, no taking stable doses of metformin (1-2.5g/day) or extended-release metformin (0.5 -2.0g/day) as their only ODM for at least 2months prior to the study, C-peptide <0.27nmol/L, subjects treated with insulin, TZDs or SU within 3months prior to study enrollment, history of substance abuse, severe hypoglycemia, acute metabolic complications, clinically significant abnormal baseline laboratory values including hematology, blood chemistry or urinalysis
U.S.	28 Weeks				Outpatient primary care, Outpatient subspecialty care setting	
Nakamura, 2006 ¹⁰⁸	Neither year reported	No run-in period	< 6 months	NR	NR/68	HbA1c >6.5%, history of ketoacidosis, treatment other than by diet alone, fasting C-peptide level of less than 0.33 mmol/l, hematuria, non-diabetic renal disease, microalbuminuria defined as a median urinary albumin excretion of 20 to 200 ug/min
Japan	12 weeks				NR	
Kvapil, 2006 ¹³⁸	Neither year reported	No run-in period	< 6 months	NR	NR/341	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), retinopathy, recurrent severe hypoglycemia, anemia, change in dose of meds known to interfere with glucose metabolism, inclusion criteria is not adequately controlled on metformin
Multinational Europe	16 weeks				NR	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Jibrán, 2006 ¹¹²	Start year 2000 End year 2001	NA	< 6 months	NR	NR/100	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), poorly controlled on prior treatments (e.g., failed initial treatment), no Type 2 DM, on insulin
Pakistan	12 months				Outpatient subspecialty care setting	
Derosa, 2006 ¹⁵⁷	Neither year reported	No run-in period	< 6 months	NR	NR/99	History of ketoacidosis, background retinopathy, nephropathy, neuropathy, impaired liver or kidney function, anemia, CVD or cerebrovascular conditions, pregnant, lactating, of child bearing potential while not taking adequate contraceptive
Italy	12 months				Outpatient primary care, Outpatient subspecialty care setting	
Garber, 2006 ¹²⁸	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <20 or >78 years, any liver disease, any kidney disease, history of CVD, HbA1c ≤7% or ≥12% no Type 2 DM, other
U.S.	24 weeks (planned duration)					
Derosa, 2005 ¹⁵¹	Neither year reported	No run-in period	< 6 months	NR	NR/99	Age ≤18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), poorly controlled on prior treatments (e.g., failed initial treatment), neuropathy, retinopathy, HbA1c <7.5%, BMI ≤25.3 kg/m ² , pregnant, nursing, not using adequate contraception, if no Type 2 DM for minimum 6 months based on ADA criteria, if no metabolic syndrome based on NCEP ATP III, if no hypertension, triglycerides ≤150mg/dl, C-peptide ≤1.0ng/ml, history of ketoacidosis, anemia, receiving lipid-lowering meds, anticoagulation, glimepiride, or a TZD
Italy	12 months				case-report forms or computerized clinic registers	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Gerich, 2005 ¹³⁶	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	908/428	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), neuropathy, retinopathy, HbA1c <7% or >11%, BMI < 22 kg/m ² and >45 kg/m ² , not using adequate contraception, FPG ≥15 mmol/l, if Type 1 DM, symptomatic hypoglycemia with >10% weight loss in previous 8 weeks, history of lactic acidosis or CHF requiring meds, other medical conditions that could interfere with interpretation of results or pose sig risk to the subject, had to be drug naive
U.S.	2 Years				NR	
Derosa, 2005 ¹²⁷	Neither year reported	No run-in period	< 6 months	NR	NR/99	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., failed initial treatment), neuropathy, retinopathy, HbA1c < 7%, pregnant, nursing, not using adequate contraception, no type 2 DM by ADA criteria for at least 6 mo, fasting c-peptide <1.0ng/ml, no metabolic syndrome with at least 3 components (based on NCEP ATP III), ketoacidosis, anemia, cerebrovascular conditions within 6 months, consumption of glimepiride or TZDs or prior intolerance to these medications
Italy	12 months				case notes and/or clinic registers	
Leiter, 2005 ⁸³	Neither year reported	No run-in period	< 6 months	Yes	720/613	Age <20 or >80 years, HbA1c <9.5%, no Type 2 DM, FBG <7 and >14 mmol/l
Canada	32 weeks				Outpatient primary care	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Weissman, 2005 ⁸⁶	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <18 or >75 years, any liver disease, any kidney disease, history of CVD, HbA1c <6.5% or >8.5% for patients having received prior combination treatment, HbA1c <7% or >10% prior monotherapy or drug naive patients, no Type 2 DM, other
U.S.	24 weeks (planned duration)					
Bailey, 2005 ⁸⁷	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <18 or >70 years, history of CVD, no Type 2 DM, other
U.K., 14 European countries	24 weeks (planned duration)					
Betteridge, 2005 ²⁸⁹	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <35 or >75 years, HbA1c <7.5% or >11%, no Type 2 DM
U.K.	104 weeks (planned duration)					
Yamanouchi, 2005 ⁵⁰	Not extracted	Not extracted	Not extracted	NR	Not extracted	Any liver disease, any kidney disease, history of CVD, treatment experienced, neuropathy, retinopathy, HbA1c <7.0%, no Type 2 DM, other
Japan	12 months (planned duration)					
Goldberg, 2005 ⁹⁸	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <35 years, any liver disease, any kidney disease, history of CVD, treatment experienced, HbA1c <7% or >11.5%, if naive to ODM therapy, HbA1c <7% or >9.5% if previously treated with ODM, no Type 2 DM, other
U.S., Puerto Rico, Mexico, and Columbia	24 weeks (planned duration)					
Pfutzner, 2005 ¹⁰⁵	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <40 or >75 years, any liver disease, any kidney disease, history of CVD, HbA1c <6.6% or >9.9%, other
Germany	26 weeks (planned duration)					
Derosa, 2005 ¹⁵⁹	Not extracted	Not extracted	Not extracted	NR	Not extracted	Age <18 years, any liver disease, any kidney disease, history of CVD, neuropathy, retinopathy, HbA1c <7.5%, no Type 2 DM, other
Italy	12 months (planned duration)					

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Langenfeld, 2005 ²⁹⁰	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <40 or >75 years, any liver disease, any kidney disease, history of CVD, HbA1c <6.6% or >9.9%, no Type 2 DM, other
Germany	24 weeks (planned duration)					
Feinglos, 2005 ⁹¹	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <30 or >81 years, any liver disease, any kidney disease, history of CVD, HbA1c <7.0% or >8.5%, no Type 2 DM, other
U.S.	16 weeks (planned duration)					
Smith, 2004 ²⁹¹	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	NR/598	Age <36 or >81 years, BMI <22 or >38 kg/m ² , FPG <126 or >270 mg/dL, fasting C-peptide >0.79 ng/ml
U.S., Multinational Europe	52 weeks				NR	
Hallsten, 2004 ¹⁵³	Neither year reported	Run-in period but number of participants excluded was NR	>= 6 months	Yes	NR/44	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, retinopathy, diabetes meds, oral corticosteroid treatment, BP >160/100 mm Hg
Finland	26 weeks				NR	
Nakamura, 2004 ¹⁰²	Neither year reported	No run-in period	>= 6 months	NR	NR/45	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c >6.5%, BP <140/90 mm Hg, controlled on diet alone, C-peptide <0.33 mmol/l, creatinine <1.5 mg/dL, no antihypertensive medications, malignancy, no microalbuminuria, collagen vascular disease, non-diabetic renal disease
Japan	12 months				Inpatient/hospital	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Horton, 2004 ⁸⁰	Neither year reported	Yes	< 6 months	Yes	701/401	Age <30 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), neuropathy, retinopathy, HbA1c <6.8% or >11%, Type 1 or secondary DM, diabetes >3 month duration, FPG <15 mmol/l, diabetic complication, on corticosteroids, non treatment naive
NR	24 Weeks				NR	
Ramachandran, 2004 ⁵¹	Not extracted	Not extracted	Not extracted	NR	Not extracted	Age <30 or >60 years, treatment experienced, HbA1c >11%, no Type 2 DM, other
India	14 weeks (planned duration)					
Schernthaner, 2004 ⁵²	Not extracted	Not extracted	Not extracted	NR	Not extracted	Age <35 or >75 years, treatment experienced, HbA1c <7.5% or >11%, no Type 2 DM
Europe	12 months (planned duration)					
Derosa, 2004 ⁶⁰	Not extracted	Not extracted	Not extracted	NR	Not extracted	Age <46 or >67 years, any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other
Italy	12 months (planned duration)					
Tan, 2004 ¹⁰⁶	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Treatment experienced, HbA1c <7.5% or >11% for patients not receiving ODM, <7.5 or >9.5 for patients receiving ODM, no Type 2 DM, other
Denmark, Finland, Norway, and Sweden	52 weeks (planned duration)					
Tan, 2004 ¹⁰⁷	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, HbA1c <7.5% or >11% in patients who were not receiving ODMs, and <7.5 or >9.5 in patients who were receiving ODM monotherapy, no Type 2 DM, other
Mexico	NR					

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Natali, 2004 ¹⁴⁸	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <40 or >80 years, any liver disease, any kidney disease, history of CVD, neuropathy, retinopathy, HbA1c >10% after washout, other
London and Italy	16 weeks (planned duration)					
Raskin, 2004 ¹⁰⁹	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <18 years, HbA1c <7% or >12% during previous monotherapy with SU or metformin at 50% or more of maximal recommended dose for at least 3 months, no Type 2 DM, other
U.S.	12 titration and 12 maintenance weeks (planned duration)					
Jovanovic, 2004 ¹¹⁰	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <18 years, HbA1c <7% or >12%, no Type 2 DM, other
U.S.	12 titration and 12 maintenance weeks (planned duration)					
Hanefeld, 2004 ¹⁴⁰	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <35 or >75 years, history of CVD, HbA1c <7.5% or >11%, no Type 2 DM, other
Canada, U.K., Hungary, Finland, Slovak Republic, Belgium, Estonia, Lithuania, Denmark, Italy, Greece, Sweden, and the Netherlands	NR					

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Lawrence, 2004 ⁵³ U.K.	Not extracted 12 titration and 12 maintenance weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <45 or >80 years, any liver disease, any kidney disease, history of CVD, HbA1c for diet treated diabetes <7% or >10% and for low-dose ODM >7.5%, no Type 2 DM, other
Madsbad, 2004 ¹²⁰ Multinational Europe	Start year 2000 End year 2001 12 weeks	No run-in period	< 6 months	Yes	311/193 Outpatient Primary Care setting	Age <30 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., "failed initial treatment"), HbA1c < 7.5% or >10% on diet treatment, BMI >40 kg/m ² , pregnant, nursing, not using adequate contraception, no Type 2 DM, no treatment for DM with ODM or diet, HbA1c >9.5% on ODM, history of CHF, NYHA class III, IV, use of TZDs or other investigational drugs
Malone, 2003 ¹³⁷ 14 countries not specified	Neither year reported 16 Weeks	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	NR/597 subgroup completing test	Age <30 or >75 years, HbA1c <125% of upper limit of normal by local lab within 4 weeks prior to entry, BMI >40 kg/m ² , not Type 2 DM, not use of single oral agent (metformin or SU) for 3 months prior to study at maximum clinically effective dose for previous 30 days
Yang, 2003 ¹³⁹ China	Neither year reported 12 Weeks	Run-in period but number of participants excluded was NR	< 6 months	Yes	NR/211 NR	Age <35 or >70 years, poorly controlled on prior treatments (e.g., failed initial treatment), no Type 2 DM as defined by WHO, not treated with diet and SU for 6-months
Garber, 2003 ⁶¹ U.S.	Not extracted 16 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <20 or >79 years, any liver disease, any kidney disease, treatment experienced, HbA1c >7% or <12%, no Type 2 DM, other

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Tosi, 2003 ^{36*}	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, treatment experienced, HbA1c <6.3%, no Type 2 DM, other
Italy	6 months (planned duration)					
Goldstein, 2003 ⁶²	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, HbA1c <7.5% and >12.0%, other
U.S.	18 weeks (planned duration)					
Derosa, 2003 ⁸¹	Not extracted	Not extracted	Not extracted	NR	Not extracted	Any kidney disease, history of CVD, treatment experienced, HbA1c <7%, no Type 2 DM, other
Italy	12 months (planned duration)					
Derosa, 2003 ¹¹³	Not extracted	Not extracted	Not extracted	NR	Not extracted	Any kidney disease, history of CVD, HbA1c <7.0%, no Type 2 DM, other
Italy	12 months (planned duration)					
Pavo, 2003 ⁵⁴	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <40 years, any liver disease, any kidney disease, history of CVD, treatment experienced, HbA1c <7.5% or >11.0%, no Type 2 DM, other
Russia and Hungary	32 weeks (planned duration)					
Bakris, 2003 ¹⁰⁴	Not extracted	Not extracted	Not extracted	Yes	Not extracted	NR
U.S. and U.K.	52 weeks (planned duration)					
Virtanen, 2003 ¹⁵⁴	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <45 or >75 years, any liver disease, any kidney disease, history of CVD, treatment experienced, neuropathy, retinopathy, no Type 2 DM, other
Finland	26 weeks (planned duration)					

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Marre, 2002 ⁹⁶	Neither year reported	Yes	< 6 months	Yes	680/467	Age <30 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <6.8% or >11%, BMI <20 or >35 kg/m ² , DM at least 6 months, FPG >15 mmol/l, gastroparesis, change in body weight during run-in, treated with diabetes meds other than metformin 3 months before study
Multicontinent	24 weeks				NR	
Vakkilainen, 2002 ¹¹⁹	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	NR/48	Age <18 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), HbA1c <6.5% or >10%, BMI >33 kg/m ² , FPG >15 mmol/l, total cholesterol >6.5 mmol/l, triglycerides >4.5 mmol/l, thyroid disease, smoking, nicotine therapy, use of lipid lowering agents, insulin, hormone replacement therapy
Finland	12 weeks (planned duration)				NR	
Hallsten, 2002 ⁵⁵	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, no Type 2 DM, other
Finland	26 weeks (planned duration)					
Blonde, 2002 ⁶³	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <30 or >75 years, any liver disease, any kidney disease, history of CVD, HbA1c <7.4%, no Type 2 DM, other
U.S.	16 weeks (planned duration)					

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
St John Sutton, 2002 ¹⁴⁹	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <40 or >80 years, any liver disease, any kidney disease, history of CVD, no Type 2 DM, other
U.S	52 weeks (planned duration)					
Marre, 2002 ⁶⁴	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <18 years, any liver disease, any kidney disease, history of CVD, other
Netherlands, Denmark, Portugal, France, Belgium	4 months (planned duration)					
Garber, 2002 ⁶⁵	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, treatment experienced, HbA1c <7% or >11%, no Type 2 DM, other
U.S.	20 weeks (planned duration)					
Gomez-Perez, 2002 ⁸⁸	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <40 or >80 years, any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other
Mexico	26 weeks (planned duration)					
Khan, 2002 ⁹⁷	Not extracted	Not extracted	Not extracted	NR	Not extracted	Any liver disease, other
U.S.	16 weeks (planned duration)					
Charpentier, 2001 ⁷¹	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age ≤34 or ≥71 years, any kidney disease, history of CVD, no Type 2 DM, other
France	20 weeks (planned duration)					
Madsbad, 2001 ¹¹⁴	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age ≤39 or ≥76 years, any liver disease, any kidney disease, HbA1c <6.5% or >10%, no Type 2 DM, other
Denmark and Scandinavia	12 months (planned duration)					

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Amador-Licona, 2000 ⁶⁶	Not extracted	Not extracted	Not extracted	NR	Not extracted	Age >65 years, any liver disease, history of CVD, other
Mexico	12 weeks (planned duration)					
Einhorn, 2000 ⁸⁹	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, neuropathy, retinopathy, HbA1c <8.0%, no Type 2 DM, other
U.S.	16 weeks (planned duration)					
Fonseca, 2000 ⁹⁰	Not extracted	Not extracted	Not extracted	NR	Not extracted	Age <40 or >80 years, any liver disease, any kidney disease, history of CVD, treatment experienced, neuropathy, no Type 2 DM, other
U.S.	26 weeks (planned duration)					
Nakamura, 2000 ¹⁰³	Not extracted	Not extracted	Not extracted	NR	Not extracted	Any liver disease, history of CVD, treatment experienced, HbA1c <6.5%, no Type 2 DM, other
Japan	3 months (planned duration)					
Horton, 2000 ⁹	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <30 years, any kidney disease, HbA1c <6.8% or >11%, no Type 2 DM, other
U.S.	24 weeks (planned duration)					
Turner, 1999 ³⁷	Start year 1977 End year 1991	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	NR/4075	Age <25 or >65 years, FPG<6 mmol/l x 2, individuals on diet only therapy who maintained their blood sugars <6 mmol/l on followup visits
U.K.	9 Years				23 UKPDS centers	

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Moses, 1999 ⁸²	Neither year reported	No run-in period	NR	NR	108/83	Age <40 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), contraindication or history of intolerance to metformin, HbA1c < 7.1%, BMI <21 kg/m ² , no Type 2 DM, not on metformin for more than 6 months, alcohol abuse, drug use, intention to become pregnant, history of lactic acidosis, vitamin B12 <150 pmol/l with anemia
Australia	4 to 5 months				NR	
Landgraf, 1999 ¹¹⁵	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other
Germany, Austria, and Netherlands	14 weeks (planned duration)					
Marbury, 1999 ¹¹⁷	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Age <37 or >75 years, any liver disease, any kidney disease, history of CVD, treatment experienced, retinopathy, HbA1c <6.5% or >14.6%, no Type 2 DM, other
US and Canada	12 months (planned duration)					
Wolffenbittel, 1999 ¹¹⁶	Not extracted	Not extracted	Not extracted	NR	Not extracted	Age <40 or >75 years, any liver disease, any kidney disease, history of CVD, treatment experienced, HbA1c <6.5% if treated with diet only, >12% if treated with diet plus ODM, other
Germany, Austria, and Netherlands	12 months (planned duration)					
DeFronzo, 1995 ⁷⁰	Not extracted	Not extracted	Not extracted	NR	Not extracted	Age <40 or >70 years, any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other
U.S.	29 weeks (planned duration)					

Table 2. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Enrollment period				Number screened/enrolled	
Country	Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Source population	Exclusion criteria
Hermann, 1994 ⁶⁸	Not extracted	Not extracted	Not extracted	Yes	Not extracted	No Type 2 DM, other
Sweden	6 months (planned duration)					
Campbell, 1994 ⁶⁷	Not extracted	Not extracted	Not extracted	NR	Not extracted	Age <40 or >69 years, any liver disease, any kidney disease, history of CVD, no Type 2 DM, other
U.K.	52 weeks (planned duration)					
Wolffenbuttel, 1993 ¹¹⁸	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, HbA1c <7.0% or >12.0%, no Type 2 DM, other
Netherlands	12 (4 week titration, 8 week treatment) (planned duration)					
Hermann, 1991 ⁶⁹	Not extracted	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, no Type 2 DM, other
Sweden	6 months (planned duration)					
Hermann, 1991 ¹⁵⁵	Not extracted	Not extracted	Not extracted	NR	Not extracted	No Type 2 DM, other
Sweden	6 months (planned duration)					

*Crossover study, no washout period

ACEI = angiotensin-converting enzyme inhibitors; ADA = American Diabetes Association; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; BP = blood pressure; CAD = coronary artery disease; CHF = congestive heart failure; CK = creatine phosphokinase; CVD = cardiovascular diseases; DBP = diastolic blood pressure; DM = diabetes mellitus; FBG = fasting blood glucose; FPG = fasting plasma glucose; g/day = grams per day; g/dl = grams per deciliter; GFR = glomerular filtration rate; GI disorder = gastrointestinal disorders; HbA1c = hemoglobin A1c; kg = kilogram; kg/m² = kilograms per meter squared; lbs = pounds; LDL = low density lipoprotein; LVEF = left ventricular ejection fraction; met = metformin; mg = milligram; mg/d = milligrams per day; mg/dL = milligrams per deciliter; mm Hg = millimeters of mercury; mmol/l = millimoles per liter; NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III; ng/ml = nanograms per milliliter; nmol/l = nanomoles per liter; NR = not reported; NYHA = New York Heart Association; ODM = oral diabetes medications; pmol/l = picomoles per liter; SBP = systolic blood pressure; SGOT = serum glutamyl

oxaloacetic transaminase; SGPT = serum glutamyl pyruvic transaminase; SU = sulfonylurea; TZD = thiazolidinedione; U/kg = units per kilogram; UKPDS = The UK Prospective Diabetes Study; US = United States; WHO = World Health Organization; yrs = years

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Seino, 2010 ¹²¹	Glibenclamide, 132	58.5	65	Asian: 100	24.4	8.978	8.5	12
	Liraglutide, 268	58.2	68	NR	24.5	8.92	8.1	22
Derosa, 2010 ⁴⁴	Metformin + glibenclamide, 65	NR	51	NR	28.5	8.9	NR	8
	Metformin + exenatide, 45	NR	67	NR	28.7	8.8	NR	4
DeFronzo, 2010 ¹³²	Metformin + rosiglitazone, 45	NR	NR	NR	NR	7.9	NR	11
	Metformin + exenatide, 45	NR	NR	NR	NR	7.8	NR	12
Aschner, 2010 ⁷⁷	Metformin, 439	55.7	44	NR	30.9	7.2	2.1	75
	Sitagliptin, 455	56.3	48	NR	30.7	7.2	2.6	61
Seck, 2010 ¹³⁴	Metformin + sitagliptin, 248	57.6	57.3	AA: 3.6, Asian: 9.3, C: 77.4, H: 5.6, Other: 4	30.9	7.3	5.8	231
	Metformin + glipizide, 584	57	62.9	AA: 5.1, Asian: 8.2, C: 78.5, H: 5.1, Other: 3.1	31.3	7.3	5.7	328
Pratley, 2010 ¹⁴³	Metformin + sitagliptin, 219	55	55	AA: 5, Asian: 1, C: 91, H: 16, Other: 4	32.6	8.5	6.3	25
	Metformin + liraglutide, 221	55.9	52	AA: 10, Asian: 3, C: 82, H: 17, Other: 5	32.6	8.4	6	27
	Metformin + liraglutide, 221	55	52	AA: 7, Asian: 2, C: 87, H: 15, Other: 4	33.1	8.4	6.4	52

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Home, 2009 ¹⁶	Metformin + rosiglitazone, 1117	57	53.8	C: 98.9	NR 93.5kg	7.8	6.1	NR
	Metformin + sulfonylurea, 1105	57.2	52.9	C: 98.4	NR 93.3 kg	7.8	6.3	NR
	Metformin + sulfonylurea, 1122	59.7	50.6	C: 99.1	NR 84.3kg	8	7.9	NR
	Metformin + sulfonylurea, 2227	58.5	51.7	C: 98.7	NR 31.5	7.9	7.1	233
	Rosiglitazone, 2220	58.4	51.4	C: 99.1	NR 31.6	7.9	7	218
	Rosiglitazone + sulfonylurea, 1103	59.8	49	NR	NR 85.0kg	8	7.9	NR
Raskin, 2009 ¹³¹	Metformin + repaglinide, 187	54.8 (20 to 87)	58	AA: 16, Asian: 4, C: 75, American Indian: 1, Other: 4	NR 32.9	8.45	7.4	62
	Metformin + repaglinide, 187	54.5	59	AA: 13, Asian: 5, C: 80, American Indian: 1, Other: 2	NR 32.5	8.29	7.3	58
	Metformin + rosiglitazone, 187	55.5 (28 to 83)	51	AA: 13, Asian: 2, C: 79, American Indians: 1, Others: 4	NR 32.2	8.46	7.1	58
Derosa, 2009 ⁴⁶	Metformin, 67	55 (50 to 60)	51	C: 100	NR 27.2 77.7 kg	9.1	NR	7
	Metformin + glimepiride, 66	57.7 (51.7-64.7)	48	C: 100	NR 27.1 77.4 kg	9	NR	6
	Metformin + pioglitazone, 69	57 (50 to 64)	49	C: 100	NR 27.4 76.4 kg	9.3	NR	9
	Pioglitazone, 69	54 (48 to 60)	46	C: 100	NR 27.5 76.7 kg	9.2	NR	9
van der Meer, 2009 ¹⁴¹	Metformin + glimepiride, 39	56.4	100	NR	NR 29.3	7	3	2
	Pioglitazone + glimepiride, 39	56.8	100	NR	NR 28.2 NR	7.1	4	5

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Kaku, 2009 ⁸⁴	Metformin, 86	53	57	NR	25.4	7.55	5.6	7
	Metformin + pioglitazone, 83	52	66	NR	NR	7.58	4.5	9
Gupta, 2009 ⁴⁷	Metformin, 17	56.9	37.5	C: 62.5	36.4	6.0	NR	1
	Pioglitazone, 16	59.2	25	C: 78.5	97.8 kg	6.2	NR	2
	Pioglitazone, 18	55.7	33	C: 50	98.5 kg	6.4	NR	0
Williams-Herman, 2009 ⁷⁶	Metformin, 182	54.2	45	NR	34.3	8.5	4.1	46
	Metformin, 182	53.7	48	NR	95.3 kg	8.7	4.1	56
	Metformin + sitagliptin, 182	53.6	41	NR	32	8.7	4.6	41
	Metformin + sitagliptin, 190	53.7	53	NR	NR	8.8	4.1	42
	Sitagliptin, 179	53.5	52	NR	32	8.7	3.9	57
Derosa, 2009 ¹³⁵	Metformin + glibenclamide, 114	56 (52 to 60)	51	NR	31	8.2	4	5
	Metformin + nateglinide, 119	55 (50 to 60)	49	NR	26.5	8.1	4	5
Nauck, 2009 ⁹²	Metformin, 122	56	60	AA: 3, Asian: 7, C: 88, Other: 3	26.4	8.4	8	48
	Metformin + glimepiride, 244	57	57	AA: 2, Asian: 9, C: 89, Other: 1	NR	8.4	8	34
	Metformin + liraglutide, 242	57	59	AA: 2, Asian: 7, C: 88, Other: 2	31.6	8.4	8	51
	Metformin + liraglutide, 241	57	54	AA: 4, Asian: 8, C: 88, Other: 1	NR	8.3	7	44
Vijay, 2009 ⁹⁹	Rosiglitazone, 20	47.75	NR	NR	31.1	9.10	15.40	NR
					82.46 kg			

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Pioglitazone, 20	48.1	NR	NR	32.26	9.27	16.55	NR
Kiyici, 2009 ⁴⁵	Metformin, 16	52.4	NR	NR	81.90 kg 31.6	6.7	NR	NR
	Rosiglitazone, 19	50.7	NR	NR	NR 31.2	7.1	NR	NR
Jonker, 2009 ¹⁶⁰	Metformin + glimepiride, 39	56.4	100	NR	NR 29.1	7	NR	NR
	Pioglitazone + glimepiride, 39	56.8	100	NR	NR 28	7.1	NR	NR
Perez, 2009 ⁵⁶	Metformin, 210	53.7	46.7	AA: 6.7, Asian: 2.4, C: 88.1, H: 26.2	NR 30.8	8.65	NR	68
	Metformin + pioglitazone, 201	54.7	44.8	AA: 6, Asian: 1.5, C: 91.5, H: 24.4	NR 30.8	8.89	NR	44
	Pioglitazone, 189	54	34.9	AA: 6.9, Asian: 2.6, C: 87.3, H: 25.9	NR 31.2	8.69	NR	64
Rigby, 2009 ¹³⁰	Metformin + rosiglitazone, 56	54.7	41	AA: 3.6, Asian: 0, C: 28.6, H: 67.9	NR 81.1 kg	8.06	7.57	5
	Metformin + sitagliptin, 56	54.8	35.7	AA: 1.8, Asian: 0, C: 23.2, H: 73.2	NR 79.6 kg	8.17	8.35	11
Tolman, 2009 ¹⁵⁰	Pioglitazone, 1063	54 (20-82)	57.2	AA: 14.5, Asian: 3.4, C: 59.8, H: 19.1	NR 32.5	9.5	5.86	649
	Glibenclamide, 1057	55 (19-81)	55.5	AA: 13.2, Asian: 2.5, C: 62.1, H: 18.7	NR 32.5	9.5	5.61	641
Jadzinsky, 2009 ⁷⁸	Metformin + saxagliptin, 320	52.4	51.6	AA: 2.2, Asian: 15.9, C: 76.9, Other: 5	NR 29.9	9.4	2	58
	Metformin + saxagliptin, 323	52.1	45.2	AA: 2.2, Asian: 16.7, C: 75.2, Other: 5.9	NR 30.3	9.5	1.4	62
	Metformin, 328	51.8	49.7	AA: 1.2, Asian: 15.9, C: 76.5, Other: 6.4	NR 30.2	9.4	1.7	85
	Saxagliptin, 335	52	50.4	AA: 1.8, Asian: 16.7, C: 76.1, Other: 5.4	NR 30.2	9.6	1.7	110
DeFronzo, 2009 ⁹⁵	Metformin + saxagliptin, 192	54.7	43.2	AA: 3.9, Asian: 4.2, C: 79.7, Other: 12	NR 31.7	8.1	6.7	44

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Metformin + saxagliptin, 191	54.7	53.9	AA: 5.8, Asian: 1.6, C: 83.2, Other: 9.4	31.2 NR	8.1	6.4	48
	Metformin + saxagliptin, 181	54.2	52.5	AA: 7.7, Asian: 2.8, C: 79.6, Other: 9.9	31.1 NR	8.0	6.3	41
	Metformin, 179	54.8	53.6	AA: 3.9, Asian: 2.2, C: 83.8, Other: 10.1	31.6 NR	8.1	6.7	40
Bunck, 2009 ¹⁴⁴	Metformin + exenatide, 36	58.4	63.9	NR	30.9 90.6 kg	7.6	5.7	6
	Metformin + glargine, 33	58.3	66.7	NR	30.1 92.4 kg	7.4	4	3
Garber, 2009 ¹²²	Glimepiride, 248	53.4	54	AA: 12, Asian: 4, C: 77, H: 38, Other: 7	33.2 93.4 kg	8.4	5.6	96
	Liraglutide, 247	52	49	AA: 12, Asian: 6, C: 75, H: 35, Other: 7	32.8 92.8 kg	8.3	5.3	74
	Liraglutide, 251	53.7	47	AA: 14, Asian: 2, C: 80, H: 32, Other: 5	32.3 92.5 kg	8.3	5.2	89
Kato, 2009 ⁵⁷	Metformin, 25	58.6	56	NR	27.5 NR	7.1	NR	NR
	Pioglitazone, 25	51.4	48	NR	28.4 NR	7.4	NR	NR
Erdem, 2008 ³⁹	Metformin, 27	55.09	33	NR	31.41 NR	6.74	NR	4
	Pioglitazone, 26	54.9	31	NR	30.41 NR	6.34	NR	5
Iliadis, 2007 ⁴⁸	Metformin, 16	57.8	NR	NR	30.8 80.8 kg	7.8	20.9 months	1
	Rosiglitazone, 16	56.3	NR	NR	31 83.2 kg	7.2	30.7 months	2
Scott, 2008 ⁸⁵	Metformin, 92	55.3	59	Asian: 39, C: 61	30 84.6 kg	7.7	5.4	9
	Metformin + rosiglitazone, 87	54.8	63	Asian: 38, C: 59, Others: 3	30.4 84.9 kg	7.7	4.6	2
	Metformin + sitagliptin, 94	55.2	55	Asian: 38, C: 61, Others: 1	30.3 83.1 kg	7.8	4.9	9

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Seufert, 2008 ¹⁴²	Metformin + sulfonylurea, 320	60	54.7	NR	30 NR	8.8	7.1	58
	Pioglitazone + sulfonylurea, 319	60	53.6	NR	30.2 NR	8.81	7	38
Robbins, 2007 ¹⁴⁵	Metformin + glargine, 159	58.1	49.4	AA: 5.7, Asian: 14.6, C: 63.3, H: 16.4	32 88.1kg	7.8	12.5	22
	Metformin + insulin lispro 50/50, 158	57.4	50.3	AA: 5.7, Asian: 14, C: 65, H: 15.3	32.1 89.1kg	7.8	11.3	15
Hamann, 2008 ¹²³	Metformin + rosiglitazone, 294	58.5	53	C: 94	33 91.4kg	8	6.3	61
	Metformin + sulfonylurea, 302	59.3	52	C: 95	32.2 88.9kg	8	6.4	71
Chien, 2007 ⁵⁹	Glyburide, 25	63	53	NR	25.3 63.7 kg	8.69	8.6	6
	Metformin, 25	59	41	NR	25.7 65.6 kg	8.88	6.4	8
	Metformin + glyburide, 26	60	71	NR	24.2 63.8 kg	8.71	9	5
	Metformin + glyburide, 26	57	62	NR	24.2 61.3 kg	8.85	6.6	5
Derosa, 2007 ²⁸⁸	Metformin + glibenclamide, 114	56	51	NR	26.5 NR	8.2	4	10
	Metformin + nateglinide, 119	55	49	NR	26.4 NR	8.1	5	5
Schwarz, 2008 ¹⁵²	Metformin + glyburide, 40	70.4	50	AA: 11.1, C: 77.8, Other: 11	33.5 NR	7.7	2.5	18
	Metformin + nateglinide, 35	70.1	51.5	AA: 9.1, C: 78.8, Other: 12.1	30.4 NR	7.8	1.7	14
Comaschi, 2008 ¹⁵⁸	Metformin + glibenclamide, 80	59.9	55	NR	29.85 81.9 kg	8.57	NR	13
	Metformin + pioglitazone, 103	57	45.63	NR	32.2 85.8 kg	8.4	NR	27
	Pioglitazone + sulfonylurea, 67	62.2	56.72	NR	28.9 78.8kg	8.7	NR	15

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Turkmen Kemal, 2007 ⁵⁸	Metformin, 16	56.8 (40 to 70)	25	NR	34.5 NR	6.3	1.5	0
	Rosiglitazone, 13	55.92 (42 to 68)	30	NR	30.8 75 kg	6.2	2.75	1
Comaschi, 2007 ¹²⁹	Metformin + pioglitazone, 103	57	45.63	NR	32.2 85.8 kg	8.4	NR	27
	Metformin + sulfonylurea, 80	59.9	55	NR	29.9 81.9 kg	8.6	NR	13
	Pioglitazone + sulfonylurea, 67	62.2	56.72	NR	28.9 78.8 kg	8.7	NR	14
Home, 2007 ¹²⁴	Metformin + rosiglitazone, 259	57	54	NR	32.7 93kg	7.9	6.1	52
	Metformin + sulfonylurea, 265	57	52	NR	NR 91kg	7.8	7	22
	Metformin + sulfonylurea, 284	60	52	NR	NR 83kg	8	8.1	54
	Rosiglitazone + sulfonylurea, 311	61	49	NR	NR 84kg	8	7.9	74
Teramoto, 2007 ⁴¹	Glibenclamide, 46	56.4	76	NR	25.2 NR	8.36	NR	5
	Pioglitazone, 46	57	72	NR	24.7 NR	8.01	NR	7
Goldstein, 2007 ⁷⁵	Metformin, 182	53.4	48.9	AA: 6.6, Asian: 7.7, C: 47.8, H: 30.2, not specified: 7.7	32.1 NR	8.9	4.5	29
	Metformin, 182	53.2	45.1	AA: 4.9, Asian: 5.5, C: 58.2, H: 21.4, not specified: 9.9	32.2 NR	8.7	4.4	182
	Metformin + sitagliptin, 182	53.3	42.3	AA: 7.7, Asian: 6, C: 52.2, H: 26.9, not specified: 7.1	32.4 NR	8.7	4.4	18
	Metformin + sitagliptin, 190	54.1	55.3	AA: 6.8, Asian: 4.7, C: 53.7, H: 28.9, not specified: 5.8	32.1 NR	8.8	4.5	26

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Sitagliptin, 179	53.3	52	AA: 6.1, Asian: 3.4, C: 52, H: 29.1, not specified: 9.5	31.2 NR	8.9	4.4	37
Lund, 2007 ¹⁹⁷	Metformin, 48	59.45	77	C: 100	24.71 74.81 kg	7.34	(Median: 3 years)	12*
	Repaglinide, 48	63.31	75	C: 100	24.82 75.57 kg	7.57	(Median: 5 years)	8†
Nauck, 2007 ¹³³	Metformin + glipizide, 584	56.6	61.3	AA: 6, Asian: 8.4, C: 74.3, H: 7.9, Other: 3.4	31.3 89.7 kg	7.6	6.2	172
	Metformin + sitagliptin, 588	56.8	57.1	AA: 7, Asian: 8.5, C: 73.5, H: 7.3, Other: 3.7	31.2 89.5 kg	7.7	6.5	202
Kim, 2007 ⁴²	Metformin + glimepiride, 60	57.6	50	NR	25.8 66.7 kg	7.7	3.4	4
	Rosiglitazone + glimepiride, 60	56.5	52.63	NR	25.7 68.1 kg	8.1	3.5	3
Raskin, 2007 ¹⁴⁶	Metformin + aspart 70/30, 79	52	52	AA: 13, Asian: 3, C: 52, H: 32, Other: 1	31.2 88.7kg	9.9	NR	12
	Metformin + glargine, 78	51.7	54	AA: 15, Asian: 4, C: 47, H: 32, Other: 1	30.8 86.2kg	9.9	NR	6
Hanefeld, 2007 ¹⁰⁰	Glibenclamide, 203	60.1	70	AA: 0, C: 99, Other: 1	28.7 NR	8.2	6.4	13
	Rosiglitazone, 189	60.6	58	AA: 0, C: 97, Other: 3	28.8 NR	8.2	6	9
	Rosiglitazone, 195	60.4	68	AA: 0, C: 8, Other: 2	28.7 NR	8.1	5.9	12
Scott, 2007 ¹¹¹	Glipizide, 123	54.7 (21 to 76)	56.9	AA: 3.3, Asian: 4.9, C: 61, Other: 24.4, Multiracial: 6.5	30.6 NR	7.9	4.7	23
	Sitagliptin, 123	56.2 (34 to 75)	48	AA: 4.9, Asian: 4.9, C: 63.4, multiracial: 5.7, Other: 21.1	30.5 NR	7.9	4.9	7

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Sitagliptin, 123	55.6 (34 to 76)	57.7	AA: 8.9, Asian: 4.9, C: 61, Multiracial: 6.5, Other: 18.7	31.4 NR	7.9	5	15
	Sitagliptin, 124	55.1 (28 to 75)	52.4	AA: 4.8, Asian: 2.4, C: 69.4, Multiracial: 7.3, Other: 16.1	30.4 NR	7.8	4.2	12
	Sitagliptin, 125	55.1 (30 to 76)	49.6	AA: 6.4, Asian: 7 5.6, C: 68.8, multiracial: 6.4, Other: 12.8	30.8 NR	7.9	4.3	18
Davies, 2007 ¹⁴⁷	Metformin + NPH, 29	57.9	48.28	AA: 0, Asian: 21, C: 66	32.6 90.4 kg	10	7.3	5
	Metformin + BHI 70/30, 27	57.4	80	AA: 4, Asian: 22, C: 70	30.2 82.2 kg	9	9.1	0
Kahn, 2006 ³⁸	Glyburide, 1441	56.4	58	AA: 4.2, Asian: 2.2, C: 89, H: 4.2, Other: 0.3	32.2 92 kg	7.35	(<1: 44, 1-2: 52, >2: 4)	634
	Metformin, 1454	57.9	59.4	AA: 3.7, Asian: 2.4, C: 89.1, H: 3.8, Other: 1	32.1 91.6 kg	7.36	(<1: 46, 1-2: 50, >2: 4)	551
	Rosiglitazone, 1456	56.3	55.7	AA: 4.2, Asian: 2.7, C: 87.2, H: 76 5.2, Other: 0.7	32.2 91.5 kg	7.36	(<1: 45, 1-2: 52, >2: 3)	539
Charbonnel, 2006 ⁹⁴	Metformin, 237	54.7	59.5	AA: 5.9, Asian: 11, C: 67.1, H: 11.8, Other: 4.2	31.5 NR	(<8: 54, 8 -8.9: 30, ≥9: 15)	6.6	45
	Metformin + sitagliptin, 464	54.4	55.8	AA: 6.7, Asian: 10.6, C: 63.1, H: 15.5	30.9 NR	(<8: 55, 8 -8.9: 31, ≥9: 14)	6	48
Rosenstock, 2006 ⁴⁹	Metformin, 154	51.5	56	AA: 5, Asian: 14, C: 58, H: 21, Other: <1	32.5 NR	8.8	2.9	31
	Metformin + rosiglitazone, 155	50.1	57	AA: 6, Asian: 12, C: 54, H: 26	33.2 NR	8.9	2.3	19
	Rosiglitazone, 159	50.6	58	AA: 5, Asian: 14, C: 59, H: 19, Other: 3	32.8 NR	8.8	2.7	22

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Jain, 2006 ¹⁰¹	Glyburide, 251	52.1	56.2	AA: 13.5, Asian: 0, C: 65.7, H: 19.9, Native American: 0.4, Other: 0.4	32.8	9.2	0.78	123
	Pioglitazone, 251	52.1	53	AA: 15.9, Asian: 1.6, C: 61, H: 20.7, Other: 0.4, Native American: 1 0.4	32.5	9.2	0.8	117
Stewart, 2006 ¹⁵⁶	Metformin, 272	59	56	AA: <1, Asian: <1, C: 99, H: <1, Native Hawaiian/Other Pacific Islander: <1	30.6	7.2	3.7	54
	Metformin + rosiglitazone, 254	58.8	55	AA: 0, Asian: 1, C: 98, H: <1, Native Hawaiian /Other pacific islander: 0	30.9	7.2	3.7	50
Bakris, 2006 ¹²⁵	Metformin + glyburide, 185	58.8	69	C: 76	31.8	8.3	7.6	5
	Metformin + rosiglitazone, 204	60	63	C: 78	90.3 kg	8.5	8	10
Umpierrez, 2006 ¹²⁶	Metformin + glimepiride, 96	51.6	55.2	AA: 13.5, Asian: 1.0, C: 79.2, H: 5.2, Other: 1.0	31.6	8.4	4.9	11
	Metformin + pioglitazone, 109	55.7	52.3	AA: 15.9, Asian: 3.7, C: 78.5, H: 1.9, Other: 0	89.2 kg	8.31	5.9	17
Kvapil, 2006 ¹³⁸	Metformin + aspart 70/30, 116	56.4	46	NR	34.54	9.	6.7	11
	Metformin + glibenclamide, 114	58.1	46	NR	30.4	9.4	8.1	5
Derosa, 2005 ¹⁵¹	Metformin + glimepiride, 49	52	47	NR	85.1 kg	7.9	4	2
	Metformin + rosiglitazone, 50	54	50	NR	30.5	8.0	5	2

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Gerich, 2005 ¹³⁶	Metformin + glyburide, 209	53.5	48	AA: 16.7, Asian: 0.5, C: 65.2, Other: 17.7	33.5	8.3	2.0	87
	Metformin + nateglinide, 219	52.6	51	AA: 13, Asian: 2.4, C: 64.4, Other: 20.2	NR	8.4	1.5	78
Derosa, 2005 ¹²⁷	Metformin + glimepiride, 49	52	47	NR	26.8	7.9	4	2
	Metformin + rosiglitazone, 50	54	50	NR	NR	8.0	5	2
Smith, 2004 ²⁹¹	Glyburide, 203	60	70	NR	28.7	8.2	6.4	0
	Rosiglitazone, 384	61	33	NR	NR	8.1	6	NR
Hallsten, 2004 ¹⁵³	Metformin, 9	54	56	NR	29.9	6.8	NR	2
	Rosiglitazone, 14	59.4	79	NR	NR	6.6	NR	NR
Nakamura, 2004 ¹⁰²	Glibenclamide, 15	55	53	NR	NR	7.8	19.2	0
	Pioglitazone, 15	57	60	NR	NR	7.9	17.5	NR
Horton, 2004 ⁸⁰	Metformin, 104	55.4	67.3	NR	NR	8.3	3.7	NR
	Metformin + nateglinide, 89	57.7	65.2	NR	29.9	8.2	3.4	NR
	Nateglinide, 104	57.9	56.7	NR	NR	8.1	4.7	NR
Malone, 2003 ¹³⁷	Metformin + glibenclamide, 301	59	49	AA: 1, C: 89, H: 6, Other: 4	29.6	9.27	7.4	29
	Metformin + lispro 75/25, 296	58	57	AA: 0.7, C: 88.9, H: 7.4, Other: 3	81.7 kg	9.17	8.0	25
Yang, 2003 ¹³⁹	Metformin + sulfonylurea	NR	NR	NR	29.8	8.59	NR	NR
	Rosiglitazone + sulfonylurea	NR	NR	NR	NR	8.61	NR	NR

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Marre, 2002 ⁹⁶	Metformin, 152	56.4	55.3	AA: 3.3, Asian: 2.6, C: 90.8	29.6 NR	8.25	6.5	16
	Metformin + nateglinide, 155	57.9	61.3	AA: 4.5, Asian: 3.2, C: 90.3	29.4 NR	7.99	7.2	18
	Metformin + nateglinide, 160	57.3	61.3	AA: 3.8, Asian: 3.1, C: 91.3	29.3 NR	8.18	6.8	15
Turner, 1999 ³⁷	Any in the Sulfonylurea class, 1305	NR	NR	NR	NR NR	NR	NR	NR
	Metformin, 340	NR	NR	NR	NR NR	NR	NR	NR
	Total, 4075	53	NR	AA: 9, Asian: 10, C: 81	29 NR	(median: 9.1)	NR	4 loss to followup
Moses, 1999 ⁸²	Metformin, 27	57.8	63	Asian: 7, C: 85, Not specified: 7	31.8 NR	8.6	8	0
	Metformin + repaglinide, 27	57.2	67	C: 96, Not specified: 4	33.2 NR	8.3	5.9	0
	Repaglinide, 28	60.3	54	Asian: 7, C: 93	31.3 NR	8.6	7	0
Jibrán, 2006 ¹¹²	Glibenclamide, 50	45.8	20	NR	30.4 72.7 kg	10.2	0	0
	Repaglinide, 50	46.6	32	NR	27.1 65.8 kg	9.9	0	0
Leiter, 2005 ⁸³	Metformin, 78	60	56	C: 78, Other: 22	32.2 NR	7.5	5.7	13
	Metformin + rosiglitazone, 158	58	65	C: 76, Other: 24	33 NR	7.5	5.3	18
Derosa, 2006 ¹⁵⁷	Metformin + rosiglitazone, 48	54	52	NR	26.6 NR	8	5	4 from both groups
	Metformin + glimepiride, 47	52	49	NR	26.8 NR	7.9	4	4 from both groups
Garber, 2006 ¹²⁸	Metformin + rosiglitazone, 158	56 (24 - 78)	65	AA: 6, C: 79, Asian: 3, H: 10, O: 3	32 94 kg	8.4	6	Not extracted
	Metformin + glibenclamide, 160	56 (31 - 78)	56	AA: 5, C: 80, Asian: 3, H: 11, O: 2	32 93 kg	8.5	5	Not extracted

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Nakamura, 2006 ¹⁰⁸	Pioglitazone, 17	56	53	NR	NR	8	16	NR
	Glibenclamide, 18	53.5	56	NR	NR	7.8	16.5	NR
	Nateglinide, 16	53.5	56	NR	NR	7.7	16.6	NR
Weissman, 2005 ⁸⁶	Metformin + rosiglitazone, 358	55.5	NR	NR	34.4 98.2 kg	8.05	NR	Not extracted
	Metformin, 351	55.7	NR	NR	33.8 96.7 kg	7.97	NR	Not extracted
Bailey, 2005 ⁸⁷	Metformin + rosiglitazone, 288	58.1	58	AA: 1, C: 97, Asian: 1, H: 0, O: 1	32.2 90.9 kg	7.4	6	Not extracted
	Metformin, 280	57.6	57	AA: <1, C: 98, Asian: 1, H: 0, O: 1	32.1 89.5 kg	7.5	6.1	Not extracted
Betteridge, 2005 ²⁸⁹	Metformin + pioglitazone, 317	NR	NR	NR	NR	NR	NR	Not extracted
	Metformin + unspecified sulfonylurea, 320	NR	NR	NR	NR	NR	NR	Not extracted
	Pioglitazone + unspecified sulfonylurea, 319	NR	NR	NR	NR	NR	NR	Not extracted
Yamanouchi, 2005 ⁵⁰	Pioglitazone, 38	55.2	47	AA: 0, C: 0, Asian: 0, H: 0, O: 100	25.8 NR	10.2	3.2 months	Not extracted
	Glimepiride, 37	55.6	51	AA: 0, C: 0, Asian: 0, H: 0, O: 100	25.6 NR	9.8	3.3 months	Not extracted
	Metformin, 39	54.7	20	AA: 0, C: 0, Asian: 0, H: 0, O: 100	26.2 NR	9.9	3 months	Not extracted
Goldberg, 2005 ⁹⁸	Pioglitazone, 369	55.9	53.9	AA: 2.4, C: 64.8, Asian: 2.7, H: 28.5, O: 1.6	33.7 93.7 kg	7.6	3.9	Not extracted
	Rosiglitazone, 366	56.3	54.9	AA: 2.7, C: 59.8, Asian: 3.3, H: 32.2, O: 1.9	32.6 92.5 kg	7.5	4	Not extracted
Pfutzner, 2005 ¹⁰⁵	Glimepiride, 84	63	61.9	AA: 0, C: 96.4, Asian: 0, H: 0, O: 3.7	31.8 NR	7.44	6.9	Not extracted

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Langenfeld, 2005 ²⁹⁰	Pioglitazone, 89	62.2	61.8	AA: 0, C: 98.8, Asian: 0, H: 0, O: 1.1	31.7	7.52	7.4	Not extracted
	Pioglitazone, 89	62	61.8	AA: 0; C: 98.9; Asian: 0; H: 0; O: 1.1	NR	7.52	7.4	Not extracted
Derosa, 2005 ¹⁵⁹	Glimepiride, 84	63	61.9	AA: 0; C: 96.4; Asian: 0; H: 0; O: 3.6	31.8	7.44	6.9	Not extracted
	Metformin + glimepiride, 47	52	49	NR	26.8	7.9	4	Not extracted
Feinglos, 2005 ⁹¹	Metformin + glipizide, 61	57.7 (30-80)	46	AA: 8.2, C: 78.7, Asian: 3.3, H: 8.2, O: 1.6	31.7	7.45	6.5	Not extracted
	Metformin, 61	58.8 (40-81)	41	AA: 16.4, C: 68.9, Asian: 3.3, H: 8.2, O: 3.3	90 kg	7.64	4.6	Not extracted
Ramachandran, 2004 ⁵¹	Glimepiride, 18	45.3	50	AA: 0, C: 0, Asian: 0, H: 0, O: 100	24.6	10.2	0	Not extracted
	Metformin, 21	44.4	71	AA: 0, C: 0, Asian: 0, H: 0, O: 100	65.7 kg	9.6	0	Not extracted
	Pioglitazone, 23	45.1	74	AA: 0, C: 0, Asian: 0, H: 0, O: 100	67.7 kg	9.3	0	Not extracted
Scherthaner, 2004 ⁵²	Metformin, 597	56	57.8	NR	31.4	8.7	3.1	Not extracted
	Pioglitazone, 597	57	52.6	NR	89.7 kg	8.7	3.4	Not extracted
Derosa, 2004 ⁶⁰	Glimepiride, 81	56	47	NR	31.2	8.5	NR	Not extracted
	Metformin, 83	58	51	NR	88.2 kg	8.4	NR	Not extracted
Tan, 2004 ¹⁰⁶	Glibenclamide, 109	57.9	73	AA: 0, C: 100, Asian: 0, H: 0, O: 0	28.1	8.5	62.6 months	Not extracted
					NR			Not extracted
					29.6			Not extracted
					89 kg			Not extracted

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Tan, 2004 ¹⁰⁷	Pioglitazone, 91	60	62	AA: 0, C: 99, Asian: 0, H: 0, O: 1	30.2 88.4 kg	8.4	57.1 months	Not extracted
	Glimepiride, 123	55.7	53	AA: 0, C: 1, Asian: 0, H: 99, O: 0	28.8 74.5 kg	8.45	81.2 months	Not extracted
	Pioglitazone, 121	55.1	45	AA: 0, C: 0, Asian: 0, H: 100, O: 0	29.3 74.2 kg	8.54	77.8 months	Not extracted
Natali, 2004 ¹⁴⁸	Metformin, 28	58	79	NR	28 NR	7.8	6.3	Not extracted
	Rosiglitazone, 24	59	92	NR	27.6 NR	7.7	6.5	Not extracted
Raskin, 2004 ¹⁰⁹	Repaglinide + rosiglitazone, 127	57.5	51	AA: 17, C: 65, Asian: 0, H: 3, O: 15	NR NR	NR	7.3	Not extracted
	Repaglinide, 63	58.5	62	AA: 16, C: 63, Asian: 0, H: 2, O: 19	NR NR	NR	7.2	Not extracted
	Rosiglitazone, 62	56.6	53	AA: 13, C: 68, Asian: 0, H: 0, O: 19	NR NR	NR	7.4	Not extracted
Jovanovic, 2004 ¹¹⁰	Pioglitazone, 62	56.2	50	AA: 11, C: 82, Asian: 0, H: 3, O: 3	32.1 NR	9.1	6.1	Not extracted
	Repaglinide, 61	57.8	59	AA: 11, C: 75, Asian: 0, H: 5, O: 8	31.2 NR	9	6.9	Not extracted
Hanefeld, 2004 ¹⁴⁰	Metformin + unspecified Sulfonylurea, 320	60	54.7	AA: 0.9, C: 98.4, Asian: 0, H: 0, O: 0.6	30 84.9 kg	8.8	7.1	Not extracted
	Unspecified sulfonylurea + pioglitazone, 31	60	53.6	AA: 0.6, C: 99.4, Asian: 0, H: 0, O: 0	30.2 85.3 kg	8.82	7	Not extracted
Lawrence, 2004 ⁵³	Metformin, 20	59.5	60	NR	(Median 29.2) NR	8.04	NR	Not extracted
	Pioglitazone, 20	60.4	70	NR	(Median 30.6) NR	7.43	NR	Not extracted
Madsbad, 2004 ¹²⁰	Glimepiride, 27	57	59	NR	30.2 NR	7.8	3.8	0
	Liraglutide, 26	53	85	NR	30.2 NR	7.4	4.1	3

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Liraglutide, 25	58	60	NR	32 NR	7.9	4.4	3
	Liraglutide, 27	57	67	NR	30.1 NR	7.7	4.5	7
	Liraglutide, 30	57	67	NR	30.4 NR	7.4	4.6	2
	Liraglutide, 29	58	55	NR	31.9 NR	7.4	6.1	2
Garber, 2003 ⁶¹	Glyburide, 151	55.3	43.7	AA: 7.3, C: 81.5, Asian: 0, H: 7.9, O: 3.3	31.1 91 kg	8.7	3	Not extracted
	Metformin + glyburide, 171	55.6	44	AA: 10.5, C: 77.2, Asian: 0, H: 8.8, O: 3.5	31.4 91.9 kg	8.8	3	Not extracted
	Metformin, 164	54.7	43.3	AA: 6.7, C: 80.5, Asian: 0, H: 9.1, O: 3.7	31.4 92.8 kg	8.5	2.6	Not extracted
Tosi, 2003 ³⁶	Glibenclamide, 20	NR	NR	NR	NR NR	NR	NR	Not extracted
	Glibenclamide, 21	NR	NR	NR	NR NR	NR	NR	Not extracted
	Metformin + glibenclamide, 39	NR	NR	NR	NR NR	NR	NR	Not extracted
	Metformin + glibenclamide, 41	NR	NR	NR	NR NR	NR	NR	Not extracted
	Metformin, 19	NR	NR	NR	NR NR	NR	NR	Not extracted
	Metformin, 20	NR	NR	NR	NR NR	NR	NR	Not extracted
Goldstein, 2003 ⁶²	Glipizide, 84	57.4	64.3	AA: 11.9, C: 71.4, Asian: 2.4, H: 14.3, O: 0	30.6 89.9 kg	8.9	6.5	Not extracted
	Metformin + glipizide, 87	54.6	58.6	AA: 11.5, C: 72.4, Asian: 0, H: 16.1, O: 0	31.7 94 kg	8.7	5.9	Not extracted

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Metformin, 76	56.6	61.8	AA: 15.8, C: 65.8, Asian: 1.3, H: 17.1, O: 0	31.6 93.8 kg	8.7	7.3	Not extracted
Derosa, 2003 ⁸¹	Metformin, 56	52	58	NR	24.7 72.3 kg	7.4	5	Not extracted
	Repaglinide, 56	55	52	NR	25.2 70.2 kg	7.6	4	Not extracted
Derosa, 2003 ¹¹³	Glimepiride, 62	54	48	NR	26.4 77.1 kg	7.8	NR	Not extracted
	Repaglinide, 62	56	50	NR	26.1 76.4 kg	8	NR	Not extracted
Pavo, 2003 ⁵⁴	Metformin, 100	55.8	56	NR	31.1 88.9 kg	8.6	0.53	Not extracted
	Pioglitazone, 105	54.2	43.8	NR	31.3 86.6 kg	8.6	0.47	Not extracted
Bakris, 2003 ¹⁰⁴	Rosiglitazone, 57	5.1	75	NR	NR NR	9.1	NR	Not extracted
	Glyburide, 64	56.1	71	NR	NR NR	9.5	NR	Not extracted
Virtanen, 2003 ¹⁵⁴	Metformin, 13	58	62	NR	29.9 88.8 kg	6.9	NR	Not extracted
	Rosiglitazone, 14	58	71	NR	29.1 83.7 kg	6.8	NR	Not extracted
Vakkilainen, 2002 ¹¹⁹	Glibenclamide, 20	63	NR	NR	28.8 NR	7.6	NR	Not extracted
	Nateglinide, 23	63	NR	NR	27.8 NR	7.6	NR	Not extracted
Hallsten, 2002 ⁵⁵	Metformin, 13	57.8	62	NR	29.9 NR	6.9	NR	Not extracted
	Rosiglitazone, 14	58.6	71	NR	29.3 NR	6.8	NR	Not extracted
Blonde, 2002 ⁶³	Glyburide, 164	55.8	57.3	AA: 12.2, C: 66.5, Asian: 0, H: 17.1, O: 4.3	30.3 88 kg	9.64	7.01	Not extracted

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Metformin + glyburide, 160	55.4	55.6	AA: 12.5, C: 70, Asian: 0, H: 15.6, O: 1.9	30.7 89.4 kg	9.41	7.36	Not extracted
	Metformin + glyburide, 162	55.6	63.6	AA: 9.3, C: 67.9, Asian: 0, H: 19.1, O: 3.7	30.6 89.6 kg	9.42	6.97	Not extracted
	Metformin, 153	57.6	62.1	AA: 10.5, C: 69.3, Asian: 0, H: 17, O: 3.3	30.6 89.5 kg	9.51	8.18	Not extracted
St John Sutton, 2002 ¹⁴⁹	Glyburide, 99	56.1 (40 - 76)	71	AA: 3, C: 76, Asian: 0, H: 0, O: 21	(BMI ≥27: 65.7) NR	9.5	6.2	Not extracted
	Rosiglitazone, 104	55.1 (40 - 77)	75	AA: 5, C: 73, Asian: 0, H: 0, O: 22	(BMI ≥27: 67.3) NR	9.1	5.3	Not extracted
Marre, 2002 ⁶⁴	Glibenclamide, 103	58.7	55	NR	29.3 82.5 kg	7.88	6.6	Not extracted
	Metformin + glibenclamide, 101	58	50	NR	30.1 84.7 kg	7.89	5.9	Not extracted
	Metformin + glibenclamide, 103	60.7	54	NR	29.7 83.1 kg	7.62	6.7	Not extracted
	Metformin, 104	57.5	60	NR	29.9 84.9 kg	8.09	5.4	Not extracted
Garber, 2002 ⁶⁵	Glyburide, 161	56.5	50.9	AA: 9.3, C: 78.3, Asian: 0, H: 8.7, O: 3.7	30.3 87.2 kg	8.21	2.81	Not extracted
	Metformin + glyburide, 158	56.9	57.6	AA: 12.7, C: 74.1, Asian: 0, H: 11.4, O: 1.9	30.1 88.8 kg	8.25	3.52	Not extracted
	Metformin + glyburide, 165	58.1	58.2	AA: 6.1, C: 79.4, Asian: 0, H: 9.7, O: 4.9	29.6 86.7 kg	8.18	3.3	Not extracted
	Metformin, 161	56	57.8	AA: 4.3, C: 80.7, Asian: 0, H: 12.4, O: 2.5	30.4 88.6 kg	8.26	2.98	Not extracted

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
Gomez-Perez, 2002 ⁸⁸	Metformin + rosiglitazone, 35	51.7 (40 - 73)	29	AA: 0, C: 0, Asian: 0, H: 80, O: 20	28 NR	NR	11.1	Not extracted
	Metformin + rosiglitazone, 36	54.2 (42 - 76)	19	AA: 0, C: 11, Asian: 0, H: 72, O: 17	27.6 NR	NR	10.7	Not extracted
	Metformin, 34	53.4 (40 - 68)	29	AA: 0, C: 3, Asian: 0, H: 76, O: 21	28.5 NR	NR	9.1	Not extracted
Khan, 2002 ⁹⁷	Pioglitazone, 67	57.8	52	NR	35.2 NR	8	NR	Not extracted
	Rosiglitazone, 60	57.1	45	NR	35.6 NR	7.9	NR	Not extracted
Charpentier, 2001 ⁷¹	Metformin + glimepiride, 147	56.8 (36 - 70)	59	NR	29.5 81.2 kg	6.4	5.6	Not extracted
	Glimepiride, 150	55.4 (35 - 70)	58	NR	29.3 81 kg	6.5	5.3	Not extracted
	Metformin, 75	56.7 (36 - 69)	60	NR	29.2 82.2 kg	6.8	7	Not extracted
Madsbad, 2001 ¹¹⁴	Glipizide, 81	62	64	NR	28 83.6 kg	7.2	7	Not extracted
	Repaglinide, 175	60.2	61	NR	28 82.9 kg	7.3	8.1	Not extracted
Amador-Licona, 2000 ⁶⁶	Glibenclamide, 23	48.2	30	NR	30.4 73.2 kg	8.4	4	Not extracted
	Metformin, 28	49.3	39	NR	26.8 70.7 kg	8.5	4.5	Not extracted
Einhorn, 2000 ⁸⁹	Metformin + pioglitazone, 168	55.5	54.8	AA: 8.3, C: 81, Asian: 0, H: 10.1, O: 0.6	32.11 NR	9.86	NR	Not extracted
	Metformin, 160	55.7	60	AA: 6.3, C: 86.9, Asian: 0, H: 3.8, O: 3.1	32.12 NR	9.75	NR	Not extracted
Fonseca, 2000 ⁹⁰	Metformin + rosiglitazone, 113	58.3	68.2	AA: 10, C: 77.3, Asian: 0, H: 0, O: 12.7	29.8 NR	8.9	8.3	Not extracted

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Metformin + rosiglitazone, 119	57.5	62.1	AA: 6.9, C: 80.2, Asian: 0, H: 0, O: 12.9	30.2 NR	8.9	7.5	Not extracted
	Metformin, 116	58.8	74.3	AA: 3.5, C: 81.4, Asian: 0, H: 0, O: 15	30.3 NR	8.6	7.3	Not extracted
Nakamura, 2000 ¹⁰³	Glibenclamide, 15	61	53	NR	NR NR	7.8	14	Not extracted
	Pioglitazone, 15	60	47	NR	NR NR	7.7	16	Not extracted
Horton, 2000 ⁹	Metformin + nateglinide, 172	58.4	59	AA: 11.6, C: 82.6, Asian: 0.6, H: 0, O: 5.2	30 NR	8.4	4.5	Not extracted
	Metformin, 178	56.8	68	AA: 9.6, C: 79.2, Asian: 2.2, H: 0, O: 9	29.6 NR	8.4	7.5	Not extracted
	Nateglinide, 179	58.6	61	AA: 9.5, C: 82.1, Asian: 2.8, H: 0, O: 5.6	29.6 NR	8.3	4.7	Not extracted
Landgraf, 1999 ¹¹⁵	Glibenclamide, 100	63	57	AA: 6, C: 93, Asian: 0, H: 0, O: 1	27.5 79 kg	8	10	Not extracted
	Repaglinide, 94	61	60	AA: 0, C: 96, Asian: 0, H: 0, O: 4	27.6 80 kg	7.8	10	Not extracted
Marbury, 1999 ¹¹⁷	Glyburide, 182	58.7	66	AA: 9, C: 79, Asian: 0, H: 0, O: 12	29.1 NR	8.9	8.3	Not extracted
	Repaglinide, 362	58.3	67	AA: 9, C: 77, Asian: 0, H: 0, O: 14	29.4 NR	8.7	7.2	Not extracted
Wolffenbuttel, 1999 ¹¹⁶	Placebo + glyburide, 139	61	68	NR	28 81.3 kg	7	(Median 6)	Not extracted
	Repaglinide, 286	61	62	NR	28.4 81.5 kg	7.1	(Median 6)	Not extracted
DeFronzo, 1995 ⁷⁰	Metformin + glyburide, 213	55	46	NR	29 92.1 kg	8.8	7.8	Not extracted
	Metformin, 143	53	43	NR	29.9 94.4 kg	8.4	6	Not extracted

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Glyburide, 209	56	49	NR	29.1 92.6 kg	8.5	8.7	Not extracted
	Metformin, 210	55	46	NR	29.4 92.6 kg	8.9	8.4	Not extracted
Hermann, 1994 ⁶⁸	Glibenclamide, 21	NR	NR	NR	NR 82.6 kg	6.7	NR	Not extracted
	Metformin + glibenclamide, 13	NR	NR	NR	NR 84.6 kg	7.8	NR	Not extracted
	Metformin + glibenclamide, 13	NR	NR	NR	NR 76 kg	7.8	NR	Not extracted
	Metformin + glibenclamide, 18	NR	NR	NR	NR 83.2 kg	8.4	NR	Not extracted
	Metformin + glibenclamide, 54	NR	NR	NR	NR 80.2 kg	6.8	NR	Not extracted
	Metformin, 25	60 (34 - 74)	NR	NR	NR 78.6 kg	6.9	4	Not extracted
Campbell, 1994 ⁶⁷	Glipizide, 24	57	33	NR	31.2 82.2 kg	11.8	2.8	Not extracted
	Metformin, 24	57	33	NR	29.6 78.2 kg	11.5	2.3	Not extracted
Wolffenbuttel, 1993 ¹¹⁸	Glibenclamide, 15	62 (45 - 75)	25	NR	26.1 70.9 kg	(Range 7.0 - 12.0)	9	Not extracted
	Repaglinide, 29	62 (45 - 75)	25	NR	26.1 74 kg	(Range 7.0 - 12.0)	9	Not extracted
Hermann, 1991 ⁶⁹	Metformin, 16	60 overall (38 - 73 overall)	64 overall	NR	27 76.5 kg	6.7	NR	Not extracted
	Glibenclamide, 17	60 overall (38 - 73 overall)	64 overall	NR	29.2 84.1 kg	6.6	NR	Not extracted
	Metformin + glibenclamide, 11	60 overall (38 - 73 overall)	64 overall	NR	26.1 74.4 kg	7.8	NR	Not extracted

Table 3. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on intermediate outcomes (KQ1) (continued)

Author, year	Group, N	Mean age (age range)	Male, %	Race, %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
					Mean weight in kg	Mean HbA1c in %		
	Metformin + glibenclamide, 12	60 overall (38 - 73 overall)	64 overall	NR	30	7.7	NR	Not extracted
Hermann, 1991 ¹⁵⁵	Glibenclamide, 34	NR	NR	NR	NR	NR	NR	Not extracted
	Metformin + glibenclamide, 72	60 (34 - 74)	79	NR	28.4	NR	NR	Not extracted
	Metformin, 38	NR	NR	NR	82.3 kg	NR	NR	Not extracted
					NR	NR	NR	Not extracted

AA = African American; BHI = biphasic human insulin; C = Caucasian; H = Hispanic; kg = kilogram; NPH = neutral protamine Hagedorn; NR = not reported; sd = standard deviation

* 5 while on metformin prior to second crossover; 2 during washout period; and 5 while on repaglinide after crossover

† 2 excluded on repaglinide prior to first crossover; 1 during washout, and 5 after first crossover while on metformin

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)	
Metformin versus thiazolidinedione							
Kiyici, 2009 ⁴⁵	Grp1: Metformin Fixed Mean: 850 mg Grp2: Rosiglitazone Fixed Mean: 4 mg	Grp1 B: 6.7 (0.9) F: 6.4 (0.6) p:> 0.05 F-B: -0.3 Grp2 B: 7.1 (0.9) F: 6.4 (0.6) p:0.008 F-B: -0.7 Grp1-Grp2: 0.4	Grp1 B: 136.5 (27.3) F: 128.7 (31.2) p:> 0.05 F-B: -7.8 Grp2 B: 120.9 (27.3) F: 117 (39) p:> 0.05 F-B: -3.9 Grp1-Grp2: -3.9	Grp1 B: 46.8 (3.9) F: 46.8 (7.8) p:> 0.05 F-B: 0 Grp2 B: 42.9 (3.9) F: 50.7 (11.7) p:0.018 F-B: 7.8 Grp1-Grp2: -7.8	Grp1 B: 124.6 (71.2) F: 115.7 (62.3) p: > 0.05 F-B: -8.9 Grp2 B: 142.4 (53.4) F: 124.6 (71.2) p: > 0.05 F-B: -17.8 Grp1-Grp2: 8.9		
Perez, 2009 ⁵⁶	Grp1: Metformin Fixed Start: 850 mg Grp2: Pioglitazone Fixed	Grp1 F-B: -0.99 Grp2 F-B: -0.96 Grp1-Grp2: -0.03 (0.17)				Grp1 F-B: -1.28 Grp2 F-B: 1.64 Grp1-Grp2: -2.92	
Kato, 2009 ⁵⁷	Grp1: Metformin Fixed Max: 500 mg Grp2: Pioglitazone Fixed Max: 15 mg	Grp1 B: 7.14 (1.4) F: 6.31 (0.9) p:<0.01 F-B: -0.83 Grp2 B: 7.37 (1.8) F: 6.32 (1.2) p:<0.01 F-B: -1.05 Grp1-Grp2: 0.22	Grp1 B: 134.94 (32.37) F: 133.38 (33.93) F-B: -1.56 Grp2 B: 127.14 (28.6) F: 127.53 (26.52) F-B: 0.39 Grp1-Grp2: -1.95	Grp1 B: 54.6 (12.09) F: 60.45 (14.43) F-B: 5.85 Grp2 B: 57.72 (19.5) F: 67.08 (21.06) F-B: 9.36 Grp1-Grp2: -3.51	Grp1 B: 145.07 (61.41) F: 134.39 (74.76) F-B: -10.68 Grp2 B: 143.29 (96.12) F: 125.49 (66.75) p: <0.05 F-B: -17.8 Grp1-Grp2: 7.12		

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Derosa, 2009 ⁴⁶	Grp1: Metformin Varied, prespecified target dose Start: 1000 mg, Max: 3000 mg D: 3 mos Grp2: Pioglitazone Varied Start: 15 mg, Max: 45 mg D: 3 mos	Grp1 B: 9.1 (1.2) F: 7.9 (0.5) p: <0.01 F-B: -1.1 (0.5) p: <0.01 Grp2 B: 9.2 (1.3) F: 8.2 (0.7) p: <0.01 F-B: -1 (0.7) p: <0.01 Grp1-Grp2: -0.1 (SE: 0.33)				
Gupta, 2009 ⁴⁷	Grp1: Metformin + ADA diet Varied, prespecified target dose Start: 500 mg, Max: 2000 mg D: every 1 wk increment by 500 mg Grp2: Pioglitazone + ADA diet Varied, glucose: FPG > 100 mg, HbA1c: 7.0% Start: 30 mg, Max: 45 mg D: 8 wks	Grp1 F-B: -0.24 (0.14) Grp2 F-B: -0.09 (0.13) Grp1-Grp2: -0.15 (SE: 0.22)	Grp1 F-B: -2.54 (5.36) Grp2 F-B: 14.3 (4.43) Grp1-Grp2: -16.84 (SE: 6.95)	Grp1 F-B: 1.67 (0.91) Grp2 F-B: 6.2 (1.94) Grp1-Grp2: -4.53 (SE: 2.14)	Grp1 F-B: -23.7 (14.7) Grp2 F-B: -72.8 (38.8) Grp1-Grp2: 49.1	Grp1 F-B: -3.21 (0.7) Grp2 F-B: 2.15 (1.09) Grp1-Grp2: -5.36
Gupta, 2009 ⁴⁷	Grp1: Metformin + ADA diet Varied, prespecified target dose Start: 500 mg/day, Max: 2000 mg/day D: every 1 wk increment by 500 mg Grp2: Pioglitazone + PC diet Varied, glucose: FPG > 100 mg, HbA1c: 7% Start: 30 mg, Max: 45 mg D: 8 wks	Grp1 F-B: -0.24 (0.14) Grp2 F-B: -0.42 (0.17) Grp1-Grp2: 0.18 (SE: 0.23)	Grp1 F-B: -2.54 (5.36) Grp2 F-B: 8.85 (6.45) Grp1-Grp2: -11.39 (SE: 1.42)	Grp1 F-B: 1.67 (0.91) Grp2 F-B: 8.11 (1.7) Grp1-Grp2: -6.44 (SE: 0.67)	Grp1 F-B: -23.7 (14.7) Grp2 F-B: -155.6 (95.6) Grp1-Grp2: 131.9	Grp1 F-B: -3.21 (0.7) Grp2 F-B: -2.59 (1.25) Grp1-Grp2: -0.62

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Erdem, 2008 ³⁹	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	
	Varied, glucose: 110 mg/dL	B: 6.74 (1.3)	B: 132.42 (30.9)	B: 48.31 (13.1)	B: 166.05 (81.8)	
	Start: 1000 mg, Max: 2000 mg	F: 6.15 (0.53) p:	F: 112.57 (27.8)	F: 49.37 (11.8)	F: 150.05 (67.3)	
	D: every 2 wks until goal	0.02	F-B: -19.85 p:	F-B: 1.06 p:	p:0.32	
	Grp2: Pioglitazone	F-B: -0.59	<0.001	0.39	Grp2	
	Varied, glucose: 110 mg/dL	Grp2	Grp2	Grp2	B: 183.95 (105.04) p:	
	Start: 15 mg, Max: 45 mg	B: 6.34 (1.2) p: 0.31	B: 132.66 (35.6)	B: 48.04 (9.4) p:	0.54	
	D: every 2 wks until goal	F: 5.6 (0.7) p: 0.01	p: 0.98	0.94	F: 162.23 (84.6) p:	
		F-B: -0.74	F: 128.62 (30.51)	F: 53.25 (10.7)	0.29	
		Grp1-Grp2: 0.15 (SE: 0.50)	F-B: -4.04 p: 0.76	F-B: 5.21 p:	Grp1-Grp2: 5.72 (SE: 44.9)	
		Grp1-Grp2: -15.81 (SE: 16.4)	0.01			
			Grp1-Grp2: -4.15 (SE: 5.89)			
Iliadis, 2007 ⁴⁸	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied, glucose: euglycemia	F-B: -1.7 (1.1) p:	F-B: 1 (17) p:	F-B: 1 (3) p:	F-B: -29 (101) p: NSG	F-B: -2.5
	Max: 1700 mg	<0.001	NSG	NSG	Grp2	(3.5) p:
	Grp2: Rosiglitazone	Grp2	Grp2	Grp2	F-B: 22 (73) p: NSG	<0.05
	Varied, glucose: euglycemia	F-B: -1 (0.7) p:	F-B: 3 (24) p:	F-B: 0.8 (5) p:	Grp1-Grp2: -51 (SE: 5.7)	Grp2
	Max: 8 mg	<0.01	NSG	NSG		F-B: -0.3
	Grp1-Grp2: -0.7 (SE: 0.59)	Grp1-Grp2: -2 (SE: 2.76)	Grp1-Grp2: 0.2 (SE: 1.22)		Grp1-Grp2: -2.2	
Turkmen Kemal, 2007 ⁵⁸	Grp1: Metformin	Grp1	Grp1		Grp1	
	Fixed	B: 5.95 Range: 5.6	B: Median: 3.4		B: Median: 4.27	
	Start: 1700 mg	F: 5.85 Range: 1.9	range: 2.69		range: 5.93	
	D: 6 mos	Grp2	mmol/l		F: Median: 3.36	
	Grp2: Rosiglitazone	B: 6 Range: 2.4	F: Median: 2.62		range: 5.36	
	Fixed	F: 5.95 Range: 1.9	range: 1.78		Grp2	
	Start: 8 mg		mmol/l		B: Median: 3.17	
			Grp2		range: 3.96	
			B: Median: 2.88		F: Median: 3.28	
			range: 2.48		range: 3.31	
		mmol/l				
		F: Median: 2.48				
		range: 1.81				
		mmol/l				

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Kahn, 2006 ³⁸	Grp1: Metformin Varied, glucose: <140 mg Start: 500 mg, Max: 2000 mg Grp2: Rosiglitazone Varied, glucose: <140 mg Start: 4 mg, Max: 8 mg	Grp1: Annualized slope: 0.14 (CI: 0.13, 0.16) Grp2: Annualized slope: 0.07 (CI: 0.06, 0.09) Grp2-Grp1: -0.13 (CI: -0.22, -0.05) p: 0.002				Grp1: Annualized slope: -0.3 (CI: -0.4, -0.2) Grp2: Annualized slope: 0.7 (CI: 0.6, 0.8) Grp1-Grp2: 6.9 (CI: 6.3, 7.4) p: <0.001
Rosenstock, 2006 ⁴⁹	Grp1: Metformin Varied, glucose: Mean daily glucose <= 6.1 mmol/l Start: 500 mg, Max: 2000 mg, Mean: 1847 mg D: 32 wks Grp2: Rosiglitazone Varied, glucose: Mean daily glucose <= 6.1 mmol/l Start: 4 mg, Max: 8 mg, Mean: 7.7 mg D: 32 wks	Grp1 B: 8.8 (1.0) F: 7.0 (1.0) F-B: -1.8 Grp2 B: 8.8 (1.0) F: 7.2 (1.0) F-B: -1.6 Grp1-Grp2: -0.2 (SE 0.20)	Grp1 B: 116 (CV: 33.9) F: 103.6 (CV: 35.5) F-B: -12.4 Grp2 B: 114.6 (CV: 40.5) F: 119.7 (CV: 58) F-B: 5.1 Grp1-Grp2: -17.5 (SE: 10.79)	Grp1 B: 42.9 (CV: 23.8) F: 43 (CV: 23) F-B: 0.1 Grp2 B: 42.8 (CV: 24.5) F: 44.1 (CV: 27) F-B: 1.3 Grp1-Grp2: -1.2 (SE: 2.35)	Grp1 B: 175.7 (CV: 62.3) F: 148.7 (CV: 58.3) Grp2 B: 166.6 (CV: 67.6) F: 158.5 (CV: 74.8) Grp1-Grp2: -18.9 (SE: 23.7)	Grp1 F-B: Median: -2.2 (IQR: -5.5, -0.5) Grp2 F-B: Median: 1.7 (IQR: -1.2, -4.5)
Hallsten, 2004 ¹⁵³	Grp1: Metformin Varied Start: 500 mg bid, Max: 1 g bid D: 2 wks Grp2: Rosiglitazone Varied Start: 2 mg bid, Max: 4 mg bid D: 2 wks			Grp1 F-B: 3.9 (SE: 3.9) p: >0.05 Grp2 F-B: 3.9 (SE: 3.9) p: >0.05 Grp1-Grp2: 0 (SE: 5.52)	Grp1 F-B: 0.2 (0.2) p: >0.05 Grp2 F-B: -0.2 (0.2) p: >0.05 Grp1-Grp2: 35.6 (SE: 25.1)	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Yamanouchi, 2005 ⁵⁰	Grp1: Metformin Fixed Start: 750 mg	Grp1 B: 9.9 (0.7) F: 7.8 (1.0)		Grp1 B: 53.82 (4.68) F: 58.11 (3.51)	Grp1 B: 219.83 (112.14) F: 185.12 (96.12)	
	Grp2: Pioglitazone Fixed Start: 30 mg for women and 45 mg for men	F-B: -2.1 p: <0.005 Grp2 B: 10.2 (0.8) F: 7.9 (1.0) F-B: -2.3 p: <0.005 Grp1-Grp2: 0.2		F-B: 4.29 p: NSG Grp2 B: 51.87 (3.51) F: 51.48 (4.68) F-B: -0.39 p: NSG Grp1-Grp2: 4.68	F-B: -39.16 p: NSG Grp2 B: 205.59 (101.46) F: 197.58 (94.34) F-B: -8.01 p: NSG Grp1-Grp2: -31.15	
Ramachandran, 2004 ⁵¹	Grp1: Metformin Varied Start: 250 mg, Max: 850 mg	Grp1 B: 9.6 (2.4) F: 8.2 (2.5)		Grp1 B: 38.22 (5.85) F: 42.9 (7.8)	Grp1 B: 258.1 (213.6) F: 195.8 (124.6)	Grp1 B: 68.9 (9.1) F: 67.8 (7.9)
	Grp2: Pioglitazone Varied Start: 15 mg, Max: 30 mg	F-B: -1.4 p: 0.05 Grp2 B: 9.3 (1.8) F: 6.7 (1.3) F-B: -2.6 p: 0.01 Grp1-Grp2: 1.2		F-B: 4.68 p: <0.01 Grp2 B: 39 (7.8) F: 42.9 (11.7) F-B: 3.9 Grp1-Grp2: 0.78	F-B: -62.3 p: <0.05 Grp2 B: 249.2 (222.5) F: 222.5 (160.2) F-B: -26.7 Grp1-Grp2: -35.6	F-B: -1.1 Grp2 B: 67.7 (11.5) F: 67 (11.4) F-B: -0.7 Grp1-Grp2: -0.4
Scherthaner, 2004 ⁵²	Grp1: Metformin Varied Start: 850 mg up to 3 times/day, Max: 2550 mg	Grp1 B: 8.68 (0.98) F: 7.18	Grp1 B: 138.84 F: 134.16	Grp1 B: 44.07 F: 50.31	Grp1 B: 234.96 F: 180.67	Grp1 F-B: 1.9
	Grp2: Pioglitazone Varied Start: 30 mg, Max: 45 mg	F-B: -1.5 Grp2 B: 8.69 (1.02) F: 7.28 F-B: -1.41 Grp1-Grp2: -0.09	F-B: -4.68 Grp2 B: 138.84 F: 149.37 F-B: 10.53 Grp1-Grp2: -15.21	F-B: 6.24 Grp2 B: 44.07 F: 47.19 F-B: 3.12 Grp1-Grp2: 3.12 p: 0.001	F-B: -54.29 Grp2 B: 232.29 F: 205.59 F-B: -26.7 Grp1-Grp2: -27.59 p: 0.001	F-B: -2.5 Grp1-Grp2: 4.4

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Lawrence, 2004 ⁵³	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	
	Varied	B: 8.04 (0.9)	B: 200.5 (42.6)	B: 49.6 (11.8)	B: 203 (149)	
	Start: 500 mg bid, Max: 1000 mg tid	F: 6.9 (0.5)	F: 200.9 (50.5)	F: 52.7 (11.1)	F: 176 (115)	
		F-B: -1.12 (0.84) p:	F-B: 0.4	F-B: 3.1 p:	F-B: -27 p: NSG	
	Grp2: Pioglitazone	<0.01	Grp2	<0.05	Grp2	
	Varied	Grp2	B: 194.2 (43.2)	Grp2	B: 202 (110)	
	Start: 30 mg, Max: 45 mg	B: 7.43 (0.9)	F: 202.4 (46.9)	B: 48.7 (9.4)	F: 175.6 (114.4)	
	F: 6.62 (0.5)	F-B: 8.2	F: 46.8 (8.5)	F-B: -26.4		
	F-B: -0.81 (0.63) p:	Grp1-Grp2: -7.8	F-B: -1.9 p:	Grp1-Grp2: -0.6		
	<0.01		NSG			
	Grp1-Grp2: -0.31 p:		Grp1-Grp2: 5			
	NSG					
Pavo, 2003 ⁵⁴	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied	B: 8.6	F-B: -7.02 p: 0.04	F-B: 8.58	F-B: -80.99 p: 0.001	B: 86.1
	Start: 850 mg, Max: 2550 mg	F: 7.1	Grp2	Grp2	Grp2	(15.6)
	Grp2: Pioglitazone	F-B: -1.5 p: <0.0001	F-B: 6.24 p:	F-B: 5.07	F-B: -56.07 p: 0.03	F: 86.8
	Varied	Grp2	0.055	Grp1-Grp2: 3.51	Grp1-Grp2: -24.92	F-B: -0.7
	Start: 30 mg, Max: 45 mg	B: 8.6	Grp1-Grp2:	p: 0.02		(0.4)
		F: 7.3	-13.26 p: 0.003			Grp2
	F-B: -1.3 p: <0.0001				B: 88.9	
	Grp1-Grp2: -0.2 p:				(15.9)	
	0.28				F: 90.2	
					F-B: 2.4	
					Grp1-Grp2:	
					-3.1 p:	
					<0.0001	
Hallsten, 2002 ⁵⁵	Grp1: Metformin	Grp1				Grp1
	Varied	B: 6.9 (0.2)				B: 83.7 (7.9)
	Start: 500 mg bid, Max: 1000 mg bid	F: 6.2 (0.2)				F: 84.3 (3.5)
		F-B: -0.7 p: <0.0001				F-B: 0.6 p:
	Grp2: Rosiglitazone	Grp2				NSG
	Varied	B: 6.8 (0.2)				Grp2
	Start: 2 mg bid, Max: 4 mg bid	F: 6.5 (0.2)				B: 88.8
	F-B: -0.3 p: <0.05				(10.8)	
	Grp1-Grp2: -0.4 p:				F: 86.8	
	NSG				F-B: -2 p:	
					<0.05	
					Grp1-Grp2:	
					-2.6	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Natali, 2004 ¹⁴⁸	Grp1: Metformin Fixed Start: 500 mg tid Grp2: Rosiglitazone Fixed Start: 4 mg bid	Grp1	Grp1	Grp1	Grp1	Grp1
		B: 118 (SE: 25)	B: 46 (SEM: 9)	B: 142 (SEM 7.3)	B: 80.4	
		F: 120	F: 50	F: 178	(SEM 10.1)	
		F-B: 2	F-B: 4	F-B: 36 (32)	F: 80.9	
		Grp2	Grp2	Grp2	F-B: 0.5	
		B: 120 (SE: 29)	B: 46 (SEM: 15)	B: 196 (SEM 251)	(0.5) p: NSG	
		F: 131	F: 49	F: 152	Grp2	
		F-B: 11	F-B: 3	F-B: -44 (41)	B: 77.3	
		Grp1-Grp2: -10	Grp1-Grp2: 0.4	Grp1-Grp2: 47 p:	(SEM 12.5)	
		(CI: -23, 4)	(CI: -5, 6) p:	NSG	F: 76.7	
	NSG		F-B: -0.6			
			(0.4) p: NSG			
			Grp1-Grp2:			
			1.1 p: NSG			
Virtanen, 2003 ¹⁵⁴	Grp1: Metformin Varied Start: 500 mg bid, Max: 1000 mg bid Grp2: Rosiglitazone Varied Start: 2 mg bid, Max: 4 mg bid	Grp1	Grp1	Grp1	Grp1	Grp1
		B: 109.2 (SE: 7.8)	B: 42.9 (SE: 3.9)	B: 151.3 (SE: 17.8)	B: 80.4	
		F: 101.4 (SE: 7.8)	F: 46.8 (SE: 3.9)	F: 133.5 (SE: 17.8)	(SEM 10.1)	
		F-B: -7.8	F-B: 3.9 p: NSG	F-B: -17.8	F: 80.9	
		Grp2	Grp2	Grp2	F-B: 0.5	
		B: 113.1 (SE: 7.8)	B: 42.9 (SE: 3.9)	B: 106.8 (SE: 8.9)	(0.5) p: NSG	
		F: 136.5 (SE: 7.8)	F: 46.8 (SE: 3.9)	F: 115.7 (SE: 17.8)	Grp2	
		F-B: 23.4	F-B: 3.9 p: NSG	F-B: 8.9	B: 77.3	
		Grp1-Grp2: -31.2	Grp1-Grp2: 0	Grp1-Grp2: -26.7 p:	(SEM 12.5)	
				NSG	F: 76.7	
			F-B: -0.6			
			(0.4) p: NSG			
			Grp1-Grp2:			
			1.1 p: NSG			

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Metformin versus sulfonylurea						
Chien, 2007 ⁵⁹	Grp1: Metformin Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Final mean dose: 1910 mg D: 4 wks Grp2: Glyburide Varied, glucose: <140 mg/dL Start: 10 mg, Max: 20 mg, Final mean dose: 19 mg D: 4 wks	Grp1 B: 8.88 (1.08) F: 8.98 F-B: 0.09 (SE: 0.37) p: NS Grp2 B: 8.69 (0.94) F: 9.21 F-B: 0.52 (SE: 0.24) p: 0.018 Grp1-Grp2: -0.43 (SE: 0.44)				
Kahn, 2006 ³⁸	Grp1: Metformin Varied, glucose: <140 mg/dL Start: 500 mg, Max: 2000 mg Grp2: Glyburide Varied, glucose: <140 mg/dL Start: 2.5 mg, Max: 15 mg	Grp1: Annualized slope: 0.14 (CI: 0.13, 0.16) Grp2: Annualized slope: 0.24 (CI: 0.23, 0.26)				Grp1: Annualized slope: -0.3 (CI: -0.4, - 0.2) Grp2: Annualized slope: -0.2 (CI: -0.3, 0.0)
Turner, 1999 ³⁷	Grp1: Metformin Varied, glucose: FPG <6 mmol/L Max: 2550 mg/day D: 9 yrs Grp2: Any in the Sulfonylurea class Varied, glucose: 6 mmol/L Max: Chlorpropramide-500 mg; Glyburide 20 mg D: 9 yrs	Grp1 Proportion achieving HbA1c<7% at 3 yrs: 44 (CI: 42, 46) 6 yrs: 34 (CI: 32, 37) 9 yrs: (CI: 11, 15) Grp2 Proportion achieving HbA1c<7% at 3 yrs: 45 (CI: 43, 48) 6 yrs: 28 (CI: 26, 30) 9 yrs: (CI: 19, 23)				

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Yamanouchi, 2005 ⁵⁰	Grp1: Metformin Fixed Start: 750 mg	Grp1 B: 9.9 (0.7) F: 7.8 (1.0)		Grp1 B: 51.87 (3.51) F: 51.48 (4.68)	Grp1 B: 205.59 (101.46) F: 197.58 (94.34)	
	Grp2: Glimepiride Varied Start: 1 mg, Max: 2 mg	F-B: -2.1 p: <0.005 Grp2 B: 9.8 (0.7) F: 7.7 (0.9) F-B: -2.1 p: <0.005 Grp1-Grp2: 0		F-B: -0.39 p: NSG Grp2 B: 52.65 (4.29) F: 52.26 (4.29) F-B: -0.39 p: NSG Grp1-Grp2: 0	F-B: -8.01 p: NSG Grp2 B: 234.07 (121.93) F: 229.62 (112.14) F-B: -4.45 p: NSG Grp1-Grp2: -3.56	
Ramachandran, 2004 ⁵¹	Grp1: Metformin Varied Start: 250 mg, Max: 850 mg	Grp1 B: 9.6 (2.4) F: 8.2 (2.5)		Grp1 B: 39 (7.8) F: 42.9 (11.7)	Grp1 B: 249.2 (222.5) F: 222.5 (160.2)	Grp1 B: 67.7 (11.5)
	Grp2: Glimepiride Varied Start: 1 mg, Max: 2 mg	F-B: -1.4 p: <0.05 Grp2 B: 10.2 (2.2) F: 7.7 (1.7) F-B: -2.5 p: <0.01 Grp1-Grp2: 1.1		F-B: 3.9 p: NSG Grp2 B: 37.05 (11.7) F: 42.9 (7.8) F-B: 5.85 p: NSG Grp1-Grp2: -1.95	F-B: -26.7 Grp2 B: 195.8 (124.6) F: 151.3 (80.1) F-B: -44.5 p: <0.05 Grp1-Grp2: 17.8	F: 67 (11.4) F-B: -0.7 Grp2 B: 65.7 (9.1) F: 67.5 (9.2) F-B: 1.8 p: <0.05 Grp1-Grp2: -2.5
Derosa, 2004 ⁶⁰	Grp1: Metformin Varied Start: 1000 mg, Max: 1000 mg tid	Grp1 B: 8.4 (1.0) F: 7 (0.9)	Grp1 B: 144 (20) F: 130 (25)	Grp1 B: 43 (5) F: 45 (4)	Grp1 B: 180 (25) F: 165 (25)	
	Grp2: Glimepiride Varied Start: 1 mg, Max: 2 mg bid	F-B: -1.4 (CI: -5.7, -0.51) p: 0.01 Grp2 B: 8.5 (1.2) F: 6.9 (0.7) F-B: -1.6 (CI: -6.4, -0.47) p: 0.01 Grp1-Grp2: 0.2	F-B: -14 (CI: -42, -8) Grp2 B: 135 (20) F: 130 (15) F-B: -5 (CI: 2.8, 9.6) Grp1-Grp2: -9 p: <0.05	F-B: 2 p: NSG Grp2 B: 42 (4) F: 44 (6) F-B: 2 p: NSG Grp1-Grp2: 0	F-B: -15 p: NSG Grp2 B: 160 (20) F: 145 (25) F-B: -15 p: NSG Grp1-Grp2: 0	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Garber, 2003 ⁶¹	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied	B: 8.42 (1.4)	B: 122.7 (3.2)	B: 42.3 (0.9)	B: 256.8 (26.7)	B: 92.8 (15.6)
	Start: 500 mg, Max: 2000 mg	F: 7.01	F: 117	F: 41.9	F: 217.2	F: 91.7
	Grp2: Glyburide	F-B: -1.53	F-B: -5.7 p:<0.05	F-B: -0.4 p:	F-B: -39.6 p: NSG	F-B: -1.1 p:
	Varied	Grp2	Grp2	NSG	Grp2	<0.001
	Start: 2.5 mg, Max: 10 mg	B: 8.67 (1.4)	B: 122.2 (3.2)	Grp2	B: 236.3 (19.1)	Grp2
		F: 6.75	F: 124.5	B: 41.6 (1)	F: 221.2	B: 91 (16.0)
	F-B: -1.9	F-B: 2.3 p: NSG	F: 42.1	F-B: -15.1 p: NSG	B: 93	
	Grp1-Grp2: 0.37	Grp1-Grp2: -8	F-B: 0.5 p: NSG	Grp1-Grp2: -24.5	F-B: 2 p:	
			Grp1-Grp2: -0.9		NSG	
					Grp1-Grp2:	
					-3.1	
Tosi, 2003 ³⁶	Grp1: Metformin	Grp1				
	Varied	B: 7.7 (1.4)				
	Start: 500 mg, Max: 3000 mg	F: 7.3				
	Grp2: Glibenclamide	F-B: -0.4				
	Varied	Grp2				
Start: 5 mg, Max: 15 mg	B: 7.85 (1.4)					
	F: 7.4					
	F-B: -0.45					
	Grp1-Grp2: 0.05					
Goldstein, 2003 ⁶²	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied	B: 8.6 (1.2)	B: 109.7 (35.2)	B: 42.3 (9.7)	B: 218.7 (120.2)	B: 94.2 (16.7)
	Start: 500 mg, Max: 2000 mg	F: 8.4 (0.1)	F: 102.5	F: 42.7	F: 217.1	F: 91.5
	Grp2: Glipizide	F-B: -0.2	F-B: -7.2 (CI: -15, 0.6)	F-B: 0.4 p: NSG	F-B: -1.6 (-25.3 to 22)	F-B: -2.7 (SE: 0.3)
	Fixed	Grp2	Grp2	Grp2	Grp2	Grp2
	Start: 15 mg bid	B: 8.9 (1.1)	B: 111.2 (34.6)	B: 43.5 (9.8)	B: 213.8 (127.2)	B: 90 (17.4)
		F: 8.5 (0.1)	F: 110.8	F: 43.9	F: 273.6	F: 89.6
	F-B: -0.4	F-B: -0.4 (CI: -6.7, 5.8)	F-B: 0.4 p: NSG	F-B: 59.8 (22.5 to 97.1) p: <0.05	F-B: -0.4 (SE: 0.3)	
	Grp1-Grp2: 0.2	Grp1-Grp2: -6.8	Grp1-Grp2: 0	Grp1-Grp2: -60.4	Grp1-Grp2:	
					-2.3	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Blonde, 2002 ⁶³	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Glyburide Fixed Start: 10 mg bid	Grp1 B: 9.51 (1.34) F: 9.7 F-B: 0.39 Grp2 B: 9.64 (1.44) F: 9.5 F-B: -0.11 Grp1-Grp2: 0.5		Grp1-Grp2: p: NSG	Grp1 F-B: p: NSG Grp2 F-B: p: NSG	Grp1 B: 89.5 (16.9) F: 87.5 F-B: -2 Grp2 B: 88 (15.9) F: 88.5 F-B: 0.5 Grp1-Grp2: -2.5
Marre, 2002 ⁶⁴	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Glibenclamide Varied Start: 5 mg, Max: 20 mg	Grp1 B: 8.09 (1.84) F: 7.89 F-B: -0.2 Grp2 B: 7.88 (1.65) F: 7.58 F-B: -0.3 Grp1-Grp2: 0.1 p: NSG	Grp1 B: 148.2 (SE: 39) F: 136.5 F-B: -11.7 (SE: 31.2) Grp2 B: 152.1 (SE: 42.9) F: 148.2 F-B: -3.9 (SE: 39) Grp1-Grp2: -7.8 p: NSG	Grp1 B: 46.8 (11.7) F: 47.97 F-B: 1.17 p: NSG Grp2 B: 46.8 (11.7) F: 47.19 F-B: 0.39 p: NSG Grp1-Grp2: 0.78	Grp1 B: 204.7 (169.1) F: 186.9 F-B: -17.8 (89) Grp2 B: 204.7 (151.3) F: 204.7 (133.5) F-B: 0 Grp1-Grp2: -17.8 p: NSG	Grp1 B: 84.9 (17.6) F: 84.1 F-B: -0.8 Grp2 B: 82.5 (15.4) F: 83.4 F-B: 0.9 Grp1-Grp2: -1.7
Garber, 2002 ⁶⁵	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Glyburide Varied Start: 2.5 mg, Max: 10 mg	Grp1 B: 8.26 (1.08) F: 7.23 F-B: -1.03 Grp2 B: 8.21 (1.09) F: 6.97 F-B: -1.24 Grp1-Grp2: 0.21				Grp1 F-B: -0.6 p: <0.05 Grp2 F-B: 1.7 Grp1-Grp2: -2.3

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Amador-Licona, 2000 ⁶⁶	Grp1: Metformin	Grp1		Grp1	Grp1	Grp1
	Varied	B: 8.5 (1.5)		B: 31.98 (8.97)	B: 195.8 (81.88)	B: 70.7
	Start: 850 mg, Max: NR	F: 7.6 (0.8)		F: 35.49 (8.97)	F: 178 (65.86)	(14.8)
	Grp2: Glibenclamide	F-B: -0.9 p: 0.003		F-B: 3.51 p: 0.0001	F-B: -17.8 p: 0.04	F: 69.6
	Varied	Grp2		Grp2	Grp2	(14.3)
	Start: 5 mg, Max: NR	B: 8.4 (1.4)		B: 36.66 (7.02)	B: 174.44 (81.88)	F-B: -0.9 p: 0.07
		F: 7.6 (0.8)		F: 39 (10.92)	F: 166.43 (97.9)	Grp2
		F-B: -0.8 p: 0.009		F-B: 2.34 p: 0.01	F-B: -8.01 p: 0.67	B: 73.2
		Grp1-Grp2: -0.1		Grp1-Grp2: 1.17	Grp1-Grp2: -10.68	(11.8)
						F: 74.1
					(12.6)	
					F-B: 0.9 p: 0.1	
					Grp1-Grp2: -1.7	
Campbell, 1994 ⁶⁷	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied	B: 11.46 (1.92)	B: 4.65 (1.07)	B: 35.88 (11.31)	B: 191.35 (130.83)	B: 78.2
	Start: 500 mg bid, Max: 3000 mg	F: 8.64 (1.21)	F: 4.58 (1.19)	F: 37.05 (11.31)	F: 202.92 (163.76)	(15.7)
	Grp2: Glipizide	F-B: -2.57	F-B: -0.07	F-B: 1.17	F-B: 11.57 p: NSG	F: 76.23
	Varied	Grp2	Grp2	Grp2	Grp2	F-B: -1.97
	Start: 5 mg, Max: 30 mg	B: 11.75 (2.11)	B: 4.51 (1.26)	B: 36.27 (8.58)	B: 183.34 (61.41)	Grp2
		F: 9.72 (1.91)	F: 4.99 (1.16)	F: 36.27 (8.58)	F: 205.59 (108.58)	B: 82.2
		F-B: -1.93	F-B: 0.48	F-B: 0	F-B: 22.25	(16.8)
		Grp1-Grp2: -0.64 p: <0.05	Grp1-Grp2: -0.55 p: NSG	Grp1-Grp2: 1.17 p: NSG	Grp1-Grp2: -10.68	F: 84.8
						F-B: 2.67
					Grp1-Grp2: -4.57 p: <0.001	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Hermann, 1994 ⁶⁸	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg Grp2: Glyburide Varied Start: 3.5 mg, Max: 10.5 mg	Grp1	Grp1	Grp1	Grp1	Grp1
		B: 6.9 (SE: 0.3)	B: 142.74 (SE: 9.75)	B: 31.59 (SE: 2.34)	B: 179.78 (SE: 18.69)	B: 78.6 (SE: 2.9)
		F: 5.8 (SE: 0.2)	F: 131.82 (SE: 8.97)	F: 30.03 (SE: 1.56)	F: 173.55 (SE: 14.24)	F: 78.8 (SE: 2.9)
		F-B: -0.9 (SE: 0.2) p: 0.001	F-B: -5.85 (SE: 2.73) p: 0.052	F-B: -0.78 (SE: 0.78) p: >0.1	F-B: -6.23 (SE: 12.46)	F-B: -0.8 (SE: 0.5) p: >0.1
		Grp2	Grp2	Grp2	Grp2	Grp2
		B: 6.7 (SE: 0.3)	B: 153.27 (SE: 5.46)	B: 34.71 (SE: 1.95)	B: 178.89 (SE: 32.93)	B: 82.6 (SE: 2.7)
		F: 5.3 (SE: 0.1)	F: 157.56 (SE: 5.07)	F: 35.88 (SE: 1.95)	F: 186.9 (SE: 31.15)	F: 86.2 (SE: 3.3)
		F-B: -1.3 (SE: 0.2) p: 0.001	F-B: 4.68 (SE: 3.51) p: >0.1	F-B: 1.17 (SE: 0.78) p: >0.1	F-B: 8.01 (SE: 11.57)	F-B: 2.8 (SE: 0.7) p: 0.001
		Grp1-Grp2: 0.4	Grp1-Grp2: -10.53	Grp1-Grp2: -0.39	Grp1-Grp2: -14.24 p: >0.1	Grp1-Grp2: -3.6
		Hermann, 1991 ⁶⁹	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg Grp2: Glibenclamide Varied Start: 3.5 mg, Max: 10.5 mg	Grp1	Grp1	
B: 6.7 (1.3)	F-B: 0.78 (SE: 3.9)					B: 76.5 (11.5)
F: 5.8 (0.7)	Grp2					F: 76.1 (11.1)
F-B: -0.9 p: <0.01	F-B: 5.07 (SE: 7.41)					F-B: -0.4 p: NSG
Grp2	Grp1-Grp2: -5.85					Grp2
B: 6.6 (1.3)						B: 84.1 (13.2)
F: 5.3 (0.5)						F: 87.4 (14.8)
F-B: -1.3 p: <0.001				F-B: 3.3 p: <0.01		
Grp1-Grp2: 0.4				Grp1-Grp2: 3.7		

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
DeFronzo, 1995 ⁷⁰	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied	B: 8.9	B: 134 (SE: 3)	B: 37 (SE: 1)	B: 231 (SE: 12)	B: 92.6
	Start: 500 mg, Max: 2500 mg	F: 8.5	F: 129 (SE: 3)	F: 38 (SE: 1)	F: 221 (SE: 13)	(14.5)
	Grp2: Glyburide	F-B: -0.4 (SE: 0.1)	F-B: -6 (SE: 2)	F-B: 1	F-B: -16 (SE: 7)	F: 87.8
	Varied	Grp2	Grp2	Grp2	Grp2	F-B: -3.8
	Start: 5 mg bid, Max: 10 mg bid	B: 8.5	B: 136 (SE: 3)	B: 39 (SE: 1)	B: 210 (SE: 8)	(SE: 0.2) p:
		F: 8.7	F: 141 (SE: 3)	F: 40 (SE: 1)	F: 227 (SE: 11)	<0.001
	F-B: 0.2 (SE: 0.1)	F-B: 5 (SE: 2)	F-B: 0	F-B: 21 (SE: 9)	Grp2	
	Grp1-Grp2: -0.6 p:	Grp1-Grp2: -11	Grp1-Grp2: 1	Grp1-Grp2: -37 p:	F-B: -0.3	
	<0.001	p: 0.009	(SE: 1.41)	0.001	(SE: 0.2) p:	
					NSG	
					Grp1-Grp2:	
					-3.5	
Charpentier, 2001 ⁷¹	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Fixed	B: 6.79 (1.17)	B: 46.41 (13.65)	B: 171.77 (119.26)	B: 82.2	
	Start: 850 mg tid	F: 6.86 (1.45)	F: 48.36	F: 185.12	F: 81.46	
	Grp2: Glimepiride	F-B: 0.07 (SE: 0.14)	F-B: 1.95	F-B: 13.35 (104.13)	F-B: -0.74	
	Varied	Grp2	Grp2	Grp2	(2.58)	
	Start: 1 mg, Max: 6 mg	B: 6.52 (1.13)	B: 45.24 (12.87)	B: 189.57 (143.29)	Grp2	
		F: 6.79 (1.43)	F: 45.63	F: 200.25	B: 81	
	F-B: 0.27 (SE: 0.09)	F-B: 0.39	F-B: 10.68 (108.58)	F: 81.78		
	Grp1-Grp2: -0.12 p:	Grp1-Grp2: 1.56	Grp1-Grp2: 2.67 p:	F-B: 0.78		
	0.369	p: 0.14 across	0.029 across all	(2.98)		
		all treatment	treatment groups	Grp1-Grp2:		
		groups		-1.52		

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Metformin versus DPP-IV inhibitors						
Jadzinsky, 2009 ⁷⁸	Grp1: Metformin Varied Start: 500 mg, Max: 1000 mg D: 1 Weeks Grp2: Saxagliptin Fixed	Grp1 F-B: -2 p: <0.0001 Grp2 F-B: -1.7 Grp1-Grp2: -0.3	Grp1 B: 126.7 F: 118.5 F-B: -4 (SE: 1.44) (CI: -6.8, -1.1) Grp2 B: 125.8 F: 121.7 F-B: -0.5 (SE: 1.48) (CI: -3.4, -2.4) Grp1-Grp2: -3.5	Grp1 B: 43.6 (SE: 0.66) F: 46.6 (SE: 0.71) F-B: 8.9 (SE: 1.36) (CI: 6.2, 11.5) Grp2 B: 43.4 (SE: 0.63) F: 44.4 (SE: 0.67) F-B: 3.9 (SE: 1.19) (CI: 1.6, 6.3) Grp1-Grp2: -3.5	Grp1 B: 228.1 (SE: 13.92) F: 207.2 (SE: 14.71) F-B: -1.5 (SE: 2.72) (CI: -6.8, 3.9) Grp2 B: 213.2 (SE: 9.91) F: 180 (SE: 7.06) F-B: -3 (SE: 2.93) (CI: -8.8, 2.8) Grp1-Grp2: 1.5	Grp1 F-B: -1.6 Grp2 F-B: -1.1 Grp1-Grp2: -0.5
Aschner, 2010 ⁷⁷	Grp1: Metformin Varied, prespecified target dose Start: 500 mg, Max: 2000 mg, Mean: 1903 D: 5 Weeks Grp2: Sitagliptin Fixed Mean: 100 mg	Grp1 F-B: -0.55 (CI: - 0.61, -0.5) Grp2 F-B: -0.38 (CI: - 0.43, -0.32) Grp1-Grp2: -0.18 (CI: -0.25, -0.1)	Grp1 F-B: 2.5 (CI: -0.8, 5.8) Grp2 F-B: 11.2 (CI: 8, 14.5) Grp1-Grp2: -8.7 (CI: 4.1, 13.3)	Grp1 F-B: 7 (CI: 5.4, 8.6) Grp2 F-B: 6.2 (CI: 4.7, 7.8) Grp1-Grp2: 0.8 (CI: -1.4, 3)	Grp1 F-B: -1.2 (CI: -5.2, 2.7) Grp2 F-B: -3.7 (CI: -7.2, -0.2) Grp1-Grp2: 3.8 (CI: -0.5, 8.2)	Grp1 F-B: -1.9 (CI: -2.2, -1.7) Grp2 F-B: -0.6 (CI: -0.9, -0.4) Grp1-Grp2: -1.3 p: <0.001
Williams-Herman, 2009 ⁷⁶	Grp1: Metformin Fixed Mean: 2000 mg Grp2: Sitagliptin Fixed Mean: 100 mg	Grp1 F-B: -1.3 (CI: -1.5, -1.2) Grp2 F-B: -0.8 (CI: -1, -0.6) Grp1-Grp2: -0.5	Grp1 B: 105.3 (32.3) F: 102.3 (33.6) F-B: -3 Grp2 B: 115.1 (35.1) F: 113.5 (34.5) F-B: -1.6 Grp1-Grp2: -1.4 (SE: 8.25)	Grp1 B: 43.2 (9.4) F: 44.6 (10.4) F-B: 1.4 Grp2 B: 42.7 (9.5) F: 43.2 (10.1) F-B: 0.5 Grp1-Grp2: 0.9 (SE: 1.94)	Grp1 B: Median: 172 (113.5) F: Median: 179 (107) Grp2 B: Median: 149 (97.7) F: Median: 155 (113.5)	Grp1 F-B: -1.5 (CI: -2.2, -0.8) Grp2 F-B: 0.6 (CI: -0.2, 1.4)

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Williams-Herman, 2009 ⁷⁶	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Fixed	F-B: -1 (CI: -1.2, -0.8)	B: 106.8 (34.2) F: 103.6 (31.5)	B: 42.7 (10.5) F: 45 (12.4)	B: Median: 167 (104.2)	F-B: -1 (CI: -1.7, -0.3)
	Mean: 1000 mg		F-B: -3.2	F-B: 2.3	F: Median: 173 (120)	Grp2
	Grp2: Sitagliptin	Grp2	Grp2	Grp2	Grp2	F-B: 0.6 (CI: -0.2, 1.4)
	Fixed	F-B: -0.8 (CI: -1, -0.6)	B: 111.4 (35.1) F: 113 (35.3)	B: 42.7 (9.5) F: 43.2 (10.1)	B: Median 147.5 (87.4)	
	Mean: 100 mg	Grp1-Grp2: -0.2	F-B: 1.6 Grp1-Grp2: -4.8 (SE: 6.73)	F-B: 0.5 Grp1-Grp2: 1.8 (SE: 2.09)	F: Median: 162.5 (94)	
Goldstein, 2007 ⁷⁵	Grp1: Metformin	Grp1				Grp1
	Varied, prespecified target dose	F-B: -1.13 (CI: -1.29, -0.97)				F-B: significant reduction relative to baseline
	Start: 500 mg, Max: 2000 mg					Grp2
	D: 3 wks	Grp2				F-B: 0
Goldstein, 2007 ⁷⁵	Grp2: Sitagliptin	F-B: -0.66 (CI: -0.83, -0.5)				Grp2
	Varied, prespecified target dose	Grp1-Grp2: -0.47				F-B: 0
	Start: 50 mg, Max: 100 mg					Grp1
	D: 1 wk	Grp1				F-B: significant reduction relative to baseline
Goldstein, 2007 ⁷⁵	Grp1: Metformin	F-B: -0.82 (CI: -0.98, -0.66)				Grp2
	Varied, prespecified target dose	Grp2				F-B: 0
	Start: 500 mg, Max: 100 mg	F-B: -0.66 (CI: -0.83, -0.5)				Grp1
	D: 1 wk	Grp1-Grp2: -0.16				F-B: 0

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Metformin versus meglitinides						
Lund, 2007 ¹⁹⁷	Grp1: Metformin Varied, prespecified target dose Start: 500 mg, Max: 2000 mg, Mean: 1629 mg D: 12 dys Grp2: Repaglinide Varied, prespecified target dose Start: 1 mg, Max: 6 mg, Mean: 4.72 mg D: 12 dys					Grp1 B: 74.81 (10.1) F: 73.94 (9.88) F-B: -0.88 (CI: -1.45, -0.3) Grp2 B: 75.57 (9.85) F: 75.47 (10.08) F-B: 0.7 (CI: 0.12, 1.28) Grp1-Grp2: -1.58 (CI: -2.17, -0.99) p: <0.001
Horton, 2004 ⁸⁰	Grp1: Metformin Fixed Start: 500 mg tid Grp2: Nateglinide Fixed Start: 120 mg qac	Grp1 F-B: -0.8 (SE: 0.1) p: <0.001 Grp2 F-B: -0.8 (SE: 0.1) p: <0.001 Grp1-Grp2: -0.8 (SE: 0.1) p: <0.005				
Moses, 1999 ⁸²	Grp1: Metformin NR Grp2: Repaglinide Fixed Start: 0.5 mg, Max: 4.0 mg D: 12 to 28 days	Grp1 F-B: -0.33 (SE: 0.24; CI: -0.8, -0.5) Grp2 F-B: -0.38 (SE: 0.23; CI: -0.84, -0.08) Grp1-Grp2: 0.05 (SE: 0.33)				Grp1 F-B: -0.86 (SE: 0.5) Grp2 F-B: 2.98 (SE: 0.49) p: <0.05 Grp1-Grp2: -3.84

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Derosa, 2003 ⁸¹	Grp1: Metformin Varied Start: 500 mg bid, Max: 2500 mg Grp2: Repaglinide Varied Start: 0.5 mg bid, Max: 4 mg	Grp1	Grp1	Grp1	Grp1	Grp1
		B: 7.4 (0.9)	B: 132.21 (26.13)	B: 46.41 (8.19)	B: 176.22 (4.806)	B: 72.3 (7.1)
		F: 6.5	F: 117	F: 45.224	F: 152.19	F: 70.3
		F-B: -0.9 p: <0.01	F-B: -15.21 (CI: -34.32 to -8.19)	F-B: -1.17	F-B: -24.03 (-55.18 to -15.13) p: <0.05	F-B: -2 (CI: -6, 4) p: 0.14
		Grp2	Grp2	Grp2	Grp2	Grp2
		B: 7.6 (0.9)	B: 127.14 (25.35)	B: 42.51 (7.02)	B: 156.64 (52.51)	B: 70.0 (6.5)
		F: 6.8	F: 115.05	F: 45.63	F: 140.62	F: 69.6
		F-B: -0.8 p: <0.01	F-B: -12.09 (CI: -29.05 to 20.28)	F-B: 3.12	F-B: -16.02 (-38.27 to 17.8) p: 0.065	F-B: -0.4 (CI: -0.8, 0.28) p: >0.2
		Grp1-Grp2: -0.1 p: NSG	Grp1-Grp2: -3.12	Grp1-Grp2: -4.29 p: NSG	Grp1-Grp2: -8.01	Grp1-Grp2: -1.6 p: NSG
		Horton, 2000 ⁹	Grp1: Metformin Fixed Start: 500 mg tid Grp2: Nateglinide Fixed Start: 120 mg tid	Grp1 B: 8.4 (1.2) F: 7.6 F-B: -0.8 (SE: 0.1) p: 0.0001 Grp2 B: 8.3 (1.0) F: 7.8 F-B: -0.5 (SE: 0.1) p: 0.0001 Grp1-Grp2: -0.3 p: NSG		
Metformin versus metformin + thiazolidinedione						
Perez, 2009 ⁵⁶	Grp1: Metformin Fixed Start: 850 mg Grp2: Metformin + pioglitazone Fixed	Grp1 F-B: -0.99 Grp2 F-B: -1.83 p: <0.0001 Grp1-Grp2: 0.84 (SE: 0.17)				Grp1 F-B: -1.28 Grp2 F-B: 0.69 Grp1-Grp2: -1.97

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Derosa, 2009 ⁴⁶	Grp1: Metformin Varied, prespecified target dose Start: 1000 mg, Max: 3000 mg D: 3 mos Grp2: Metformin + pioglitazone Varied, prespecified target dose Start: 850 mg, Max: 2550 mg; Start: 15 mg, Max: 45 mg D: 3 mos	Grp1 B: 9.1 (1.2) F: 7.9 (0.5) p: <0.01 F-B: -1.1 (0.5) p: <0.01 Grp2 B: 9.3 (1.4) F: 7.2 (0.3) p: >0.001 F-B: -2.1 (0.3) p: <0.01 Grp1-Grp2: 1.0 (SE: 0.27)				BMI Grp1 B: 27.2 (1.5) F: 26.7 (1.2) F-B: -1.8% Grp2 B: 27.4 (1.6) F: 26.9 (1.3) F-B: -1.8% Grp1-Grp2: 0
Rosenstock, 2006 ⁴⁹	Grp1: Metformin Varied, mean daily glucose <= 6.1 mmol/l Start: 500 mg, Max: 2000 mg, Mean: 1847 D: 32 wks Grp2: Metformin + rosiglitazone Varied, mean daily glucose <= 6.1 mmol/l Start: 500 mg, Max: 2000 mg, Mean: 1799 mg; Start: 2 mg, Max: 8 mg, Mean: 7.2 mg D: 32 wks	Grp1 B: 8.8 (1.0) F: (1.0) F-B: -1.8 Grp2 B: 8.9 (1.1) F: 6.6 (1.0) F-B: -2.3 Grp1-Grp2: 0.5 (SE: 0.20) p: 0.008	Grp1 B: 116 (CV: 33.9) F: 103.6 (CV: 35.5) F-B: -12.4 Grp2 B: 113.8 (CV: 32.5) F: 113.5 (CV: 30.4) F-B: -0.3 Grp1-Grp2: -12.1 (SE: 8.1)	Grp1 B: 42.9 (CV: 23.8) F: 43 (CV: 23) F-B: 0.1 Grp2 B: 42.6 (CV: 21.8) F: 45 (CV: 25.5) F-B: 2.4 Grp1-Grp2: -2.3 (SE: 2.25)	Grp1 B: 175.7 (CV: 62.3) F: 148.7 (CV: 58.3) F-B: -27 Grp2 B: 180.3 (CV: 67.7) F: 146.6 (CV: 68.6) F-B: -33.7 Grp1-Grp2: 6.7	Grp1 F-B: Median: -2.2 (IQR: -5.5, -0.5) Grp2 F-B: Median: 0.05 (IQR: -3.45, 3)
Leiter, 2005 ⁸³	Grp1: Metformin Varied, glucose: <7.0 mmol/L Start: 1500 mg, Max: 2500 mg D: 8 wks Grp2: Metformin + rosiglitazone Fixed; Varied, glucose: < 7 mmol/L Start: 1500 mg, Max: 1500 mg; Start: 4 mg, Max: 8 mg D: 8 wks	Grp1 F-B: -0.14 p: 0.93 Grp2 F-B: p: <0.001 Grp1-Grp2: -0.36 CI: 0.15 - 0.56				Grp1 F-B: no significant weight change Grp2 F-B: 1.6 (CI: 0.9, 2.3)

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Kaku, 2009 ⁸⁴	Grp1: Metformin Varied Start: 500 mg, Max: 750 mg D: Unclear	Grp1 F-B: 0.25 (0.92) (CI: 0.06, 0.45) p: 0.012	Grp1 F-B: 0.9 (20; CI: -3.34, 5.23) p: 0.6632	Grp1 F-B: -1.1 (8.5; CI: -2.96, 0.68) p: 0.2175	Grp1 F-B: -15.4 (93.8) (CI: -35.5, 4.7) p: 0.1316	Grp1 F-B: -0.47
	Grp2: Metformin + pioglitazone Varied Start: 500 mg, Max: 750 mg; Start: 15 mg, Max: 30 mg D: Unclear; 16 wks	Grp2 F-B: -0.67 (0.8) (CI: -0.84, -0.49) p: <0.0001 Grp1-Grp2: 0.92 (SE: 0.13)	Grp2 F-B: 3.5 (23.2; CI: -1.59, 8.62) p: 0.1746 Grp1-Grp2: -2.6 (SE: 3.4)	Grp2 F-B: 5.3 (8.1; CI: 3.52, 7.09) p: <0.0001 Grp1-Grp2: -6.4 (SE: 1.30)	Grp2 F-B: -9.3 (76.3) (CI: -26.1, 7.4) p: 0.2714 Grp1-Grp2: -6.1	Grp2 F-B: 1.68 Grp1-Grp2: -2.15
Scott, 2008 ⁸⁵	Grp1: Metformin Fixed Start: >1500 mg	Grp1 B: 7.68 (0.88) F: 7.47 (1.05)	Grp1 B: 95.6 (30.8) F: 108.4 (33.6)	Grp1 B: 43.5 (10.5) F: 44.1 (12.1)	Grp1 B: 171.1 (73.3) F: 191.5 (111.1)	Grp1 F-B: -0.8 (CI: -1.2, -0.4)
	Grp2: Metformin + rosiglitazone Fixed Start: >1500 mg; Start: 8 mg, Mean: 8 mg	F-B: -0.22 (CI: -0.36, -0.08) Grp2 B: 7.73 (0.88) F: 6.94 (0.75) F-B: -0.79 (CI: -0.92, -0.65) Grp1-Grp2: 0.57 (CI: 0.37, 0.76)	F-B: mean % change: 16.7 (CI: 10.2, 23.3) Grp2 B: 99.2 (29.4) F: 119.6 (37.6) F-B: mean % change: 26.2 (CI: 19.7, 32.7) Grp1-Grp2: -7.6 (SE: 8.8)	F-B: mean % change: 1.8 (CI: -1.3, 4.9) Grp2 B: 42.2 (10) F: 45.7 (10.5) F-B: mean % change: 9.2 (CI: 6.1, 12.2) Grp1-Grp2: -2.9 (SE: 2.89)	F-B: mean % change from baseline: 11.9 (CI: 3.9, 19.9) Grp2 B: 201.6 (126.2) F: 199.8 (108.4) F-B: mean % change from baseline: 13.1 (CI: 5.2 - 21.1) Grp1-Grp2: 1.2 (CI: -10.1, 12.6)	Grp2 F-B: 1.5 (CI: 1.0, 1.9) Grp2-Grp1: 2.3 (CI: 1.7, -2.9)
Stewart, 2006 ¹⁵⁶	Grp1: Metformin Varied, prespecified target dose Start: 500 mg, Max: 3000 mg, Mean: 2627.9 mg D: 20 wks	Grp1 B: 122.46 (CV: 34.53) F: 113.88 (CV: 35.66)	Grp1 B: 45.63 (CV: 24.3) F: 46.41 (CV: 25.01)	Grp1 B: 177.1 (CV: 55.39) F: 161.98 (CV: 55.08)	Grp1 F-B: -15.1	Grp1 F-B: -15.1
	Grp2: Metformin + rosiglitazone Varied, prespecified target dose Start: 500 mg, Max: 2000 mg, Mean: 1812.2 mg; Start: 4 mg, Max: 8 mg, Mean: 6.8 mg D: 18 wks	Grp2 F-B: -8.58 B: 122.85 (CV: 37.08) F: 128.31 (CV: 34.06) F-B: 5.46 Grp1-Grp2: -14.0 (SE: 8.1)	Grp2 F-B: 0.78 B: 45.63 (CV: 23.03) F: 48.75 (CV: 27.97) F-B: 3.12 Grp1-Grp2: -2.34 (SE: 0.05)	Grp2 B: 170.88 (CV: 53.65) F: 170.88 (CV: 57.35) F-B: Grp1-Grp2: -15.1 (SE: 16.9)	Grp2 F-B: 170.88 (CV: 57.35) F-B: Grp1-Grp2: -15.1 (SE: 16.9)	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Weissman, 2005 ⁸⁶	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	
	Varied	B: 7.97 (1.2)	B: 105.1 (CI: 103.4, 106.8)	B: 43.7	B: 179.2	
	Start: 1000 mg, Max: 2000 mg	F: 7.26	F: 103.4, 106.8)	F: 45.3	F: 176.8 (170.9 to 182.9)	
	Grp2: Metformin + rosiglitazone	F-B: -0.71	F: 101.6 (CI: 99.7, 103.6)	F-B: 1.6	F-B: -2.4 p: NSG	
	Fixed; Varied	Grp2	Grp2	Grp2	Grp2	
	Start: 1000 mg; Start: 4 mg, Max: 8 mg	B: 8.05 (1.2)	F-B: -3.5	B: 45	B: 184.8	
		F: 7.12	Grp2	F: 49.1	F: 196.6 (189.2 to 204.2) p: NSG	
		F-B: -0.93	B: 106.3 (CI: 104.5, 108.2)	F-B: 4.1	F-B: 11.8	
		Grp1-Grp2: 0.2	F: 118.5 (CI: 116.3, 120.7)	Grp1-Grp2: -2.5	Grp1-Grp2: -14.2	
			F-B: 12.2	Grp1-Grp2: -15.7		
Bailey, 2005 ⁸⁷	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied	B: 7.5 (1.0)	B: 111.9 (CI: 109.7, 114.1)	B: 47.2	B: 180.8 (175.5 to 186.3)	B: 89.5 (14.4)
	Start: 2500 mg, Max: 3000 mg	F: 7.4 (1.1)	F: 114.9 (CI: 112.6, 117.2)	F: 46.4	F: 167.5 (161.8 to 173.4) p: <0.05	F: 88.6 (SE: 0.9)
	Grp2: Metformin + rosiglitazone	F-B: -0.13	F-B: 3	F-B: -0.8 p: <0.05	F-B: -13.3	F-B: -0.9 (SE: 0.2)
	Fixed; Varied	Grp2	Grp2	Grp2	Grp2	Grp2
	Start: 2000 mg; Start: 4 mg, Max: 8 mg	B: 7.4 (1.0)	F-B: 3	B: 45.3	B: 189.3 (183.5 to 195.2)	B: 90.9 (15.6)
		F: 7.1 (1.1)	Grp2	F: 47.1	F: 189.4 (183.1 to 195.2) p: NSG	F: 92.2 (SE: 0.22)
		F-B: -0.33	B: 109.5 (CI: 107.1, 111.8)	F-B: 1.8 p: <0.05	F-B: 0.1	F-B: 1.3 (SE: 0.22)
		Grp1-Grp2: 0.22 p: 0.001	F: 125.9 (CI: 122.9, 128.9)	Grp1-Grp2: -2.6	Grp1-Grp2: -13.4	Grp1-Grp2: -2.2
			F-B: 16.4	Grp1-Grp2: -13.4		
Gomez-Perez, 2002 ⁸⁸	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	
	Fixed	B: 9.8 (SE: 0.3)	B: 116 (27.7)	B: 49.4 (11.9)	B: 227.2 (126.8)	
	Start: 2500 mg	F: 10.2 (SE: 0.3)	F: 115	F: 48.9	F: 233.4	
	Grp2: Metformin + rosiglitazone	F-B: 0.3 p: 0.2651	F-B: -1 (20.9)	F-B: -0.5 (7.2)	F-B: 6.2	
	Fixed	Grp2	Grp2	Grp2	Grp2	
	Start: 2500 mg; Start: 2 mg bid	B: 10.2 (SE: 0.2)	B: 106.9 (25.7)	B: 51.5 (10)	B: 204.4 (113.3)	
		F: 9.5 (SE: 0.3)	F: 123.5	F: 56.7	F: 199.9	
	F-B: -0.7 p: 0.052	F-B: 16.6 (24.7)	F-B: 5.2 (7)	F-B: -4.5		
	Grp1-Grp2: 1 p: 0.0132	Grp1-Grp2: -15.9 (CI: -4.73, -27)	Grp1-Grp2: -5.7 p: <0.05	Grp1-Grp2: 10.7		

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Gomez-Perez, 2002 ⁸⁸	Grp1: Metformin Fixed Start: 2500 mg	Grp1 B: 9.8 (SE: 0.3) F: 10.2 (SE: 0.3)	Grp1 B: 116 (27.7) F: 115	Grp1 B: 49.4 (11.9) F: 48.9	Grp1 B: 227.2 (126.8) F: 233.4	
	Grp2: Metformin + rosiglitazone Fixed Start: 2500 mg; Start: 4 mg bid	F-B: 0.3 p: 0.2651 Grp2 B: 9.75 (SE: 0.2) F: 8.6 (SE: 0.4) F-B: -1.2 p: 0.008 Grp1-Grp2: 1.5 p: 0.0002	F-B: -1 (20.9) Grp2 B: 108.2 (30) F: 114.3 F-B: 6.1 (22.5) Grp1-Grp2: -7.1 p: NSG	F-B: -0.5 (7.2) Grp2 B: 51.5 (10.9) F: 57.9 F-B: 6.4 (7) Grp1-Grp2: -6.9 p: <0.05	F-B: 6.2 Grp2 B: 199.6 (133.2) F: 193.8 F-B: -5.8 Grp1-Grp2: 12	
	Grp1: Metformin NR	Grp1 B: 9.75 (SE: 1.3) F-B: p: <0.05	Grp1 B: 119.3 (3.07) F: 128.5	Grp1 B: 42.9 (0.95) F: 53.1	Grp1 B: 298.9 (24.9) F: 289.2	Grp1 F-B: -1.36
	Grp2: Metformin + pioglitazone NR; Fixed NR; Start: 30 mg	Grp2 B: 9.86 (SE: 1.4) F-B: p: <0.05 Grp1-Grp2: -0.83 p: <0.05	F-B: 7.7% p: <0.05 Grp2 B: 118 (6.9) F: 132 F-B: 11.9% Grp1-Grp2: 4.20%	F-B: 10.2 Grp2 B: 42.1 (1) F: 43.6 F-B: 1.5 Grp1-Grp2: 8.7 p: ≤0.05	F-B: -9.7 Grp2 B: 300.4 (25.86) F: 308.9 F-B: 8.5 Grp1-Grp2: -18.2 p: 0.05	Grp2 F-B: 0.95 Grp1-Grp2: -2.31
	Grp1: Metformin Fixed Start: 2500 mg	Grp1 B: 8.6 (1.3) F: 9.05	Grp1 B: 118.17 (34.32) F: 122.07 (37.83)	Grp1 B: 44.46 (10.92) F: 46.8 (11.31)	Grp1 B: 246.53 (194.91) F: 247.42 (159.31)	Grp1 F-B: -1.2
	Grp2: Metformin + rosiglitazone Fixed Start: 2500 mg; Start: 8 mg	F-B: 0.45 Grp2 B: 8.9 (1.5) F: 8.12 F-B: -0.78 Grp1-Grp2: 1.2 p: <0.001	F-B: 3.9 Grp2 B: 116.61 (30.42) F: 134.94 (33.54) F-B: 18.33 Grp1-Grp2: -14.04	F-B: 2.34 Grp2 B: 46.8 (14.43) F: 53.04 (16.38) F-B: 6.24 Grp1-Grp2: -3.9 p: 0.0002	F-B: 0.89 Grp2 B: 228.73 (184.23) F: 228.73 (166.43) F-B: 0 Grp1-Grp2: 0.89 p: 0.56	Grp2 F-B: 0.7 Grp1-Grp2: -1.9 p: 0.0001

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Fonseca, 2000 ⁹⁰	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Fixed	B: 8.6 (1.3)	B: 118.17 (34.32)	B: 44.4 (10.92)	B: 246.53 (194.91)	F-B: -1.2
	Start: 2500 mg	F: 9.05	F: 122.07 (37.83)	F: 46.8 (11.31)	F: 247.42 (159.31)	Grp2
	Grp2: Metformin + rosiglitazone	F-B: 0.45	F-B: 3.9	F-B: 2.4	F-B: 0.89	F-B: 1.9
	Fixed	Grp2	Grp2	Grp2	Grp2	Grp1-Grp2:
	Start: 2500 mg; Start: 4 mg	B: 8.9 (1.3)	B: 113.49 (32.76)	B: 46.02 (11.31)	B: 226.06 (138.84)	-3.1 p:
		F: 8.34	F: 134.55 (40.56)	F: 51.48 (13.26)	F: 233.18 (139.73)	0.0001
	F-B: -0.56	F-B: 21.06	F-B: 5.46	F-B: 7.12		
	Grp1-Grp2: -1 p:	Grp1-Grp2:	Grp1-Grp2:	Grp1-Grp2: -6.23 p:		
	<0.001	-17.16 p:	-3.06 p: 0.0002	0.73		
		<0.0001				
Metformin versus metformin + sulfonylurea						
Derosa, 2009 ⁴⁶	Grp1: Metformin	Grp1				BMI
	Varied, prespecified target dose	B: 9.1 (1.2)				Grp1
	Start: 1000 mg, Max: 3000 mg	F: 7.9 (0.5)				B: 27.2 (1.5)
	D: 3 mos	F-B: -1.1 (0.5) p:				F: 26.7 (1.2)
	Grp2: Metformin + glimepiride	<0.01				F-B: -1.8%
	Fixed	Grp2				Grp2
	Start: 850 mg, Max: 850 mg;	B: 9 (1.1)				B: 27.1 (1.4)
Start: 2 mg, Max: 6 mg	F: 7.8 (0.4)				F: 28.4 (2.2)	
D: NR; 3 mos	F-B: -1.2 (0.4) p:				F-B: 4.8% p:	
	<0.01				<0.05	
	Grp1-Grp2: 0.1 (SE:				Grp1-Grp2:	
	0.29)				-1.8	
Nauck, 2009 ⁹²	Grp1: Metformin	Grp1				Grp1
	Varied	F-B: 0.1 (SE: 0.1)				F-B: -1.5
	Start: 2000 mg, Max: 2000 mg	Grp2				(SE: 0.3)
	Grp2: Metformin + glimepiride	F-B: -1 (SE: 0.1)				Grp2
	Varied; Fixed	Grp1-Grp2: 1.1 (SE:				F-B: 1 (SE:
	Start: 2000 mg, Max: 2000 mg;	0.14)				0.2)
Start: 1 mg, Max: 4 mg					Grp1-Grp2:	
D: NR; 3 wks					-2.5	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Chien, 2007 ⁵⁹	Grp1: Metformin Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Final mean: 1910 mg D: 4 wks Grp2: Metformin + glyburide Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Final mean: 1723 mg; Start: 10 mg, Max: 20 mg, Final mean: 17.2 mg D: 4 wks	Grp1-Grp2: -1.3 p: 0.005				
Chien, 2007 ⁵⁹	Grp1: Metformin Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Final mean: 1910 mg D: 4 wks Grp2: Metformin + glyburide Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Final mean: 1680 mg; Start: 5mg, Max: 10 mg, Final mean: 8.4 mg D: 4 wks	Grp1-Grp2: -1.34 p: 0.002				
Feinglos, 2005 ⁹¹	Grp1: Metformin Fixed Start: at least 1000 mg Grp2: Metformin + glipizide Fixed Start: at least 1000 mg; Start: 2.5 mg	Grp1 B: 7.64 F: 7.46 (SE: 0.1) F-B: -0.19 Grp2 B: 7.45 F: 6.8 (SE: 0.1) F-B: -0.66 Grp1-Grp2: 0.47 p: <0.0002		Grp1 F-B: p: NSG Grp2 F-B: p: NSG	Grp1 F-B: p: NSG Grp2 F-B: p: NSG	Grp1 B: 90.8 (18.4) Grp2 F: 89.1 F-B: -1.7 Grp2 B: 90 (18.7) F: 90.4 F-B: 0.4 Grp1-Grp2: -2.1 p: < 0.0001

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Garber, 2003 ⁸¹	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied	B: 8.42 (1.4)	B: 122.7 (3.2)	B: 42.3 (0.9)	B: 256.8 (26.7)	B: 92.8 (15.6)
	Start: 500 mg, Max: 2000 mg	F: 7.01	F: 115	F: 41.9	F: 217.2	F: 91.7
	Grp2: Metformin + glyburide	F-B: -1.53	F-B: -5.7 p:<0.05	F-B: -0.4 p:	F-B: -39.6 p: NSG	F-B: -1.1 p:
	Varied	Grp2	Grp2	NSG	Grp2	<0.001
	Start: 250 mg, Max: 1000 mg;	B: 8.78 (1.5)	B: 118.3 (3.5)	Grp2	B: 248.4 (26.2)	Grp2
	Start: 1.25 mg, Max: 5 mg	F: 6.43	F: 122.8	B: 41.3 (0.9)	F: 196.4	Grp2
		F-B: -2.27	F-B: 4.5 p:<0.05	F: 42.1	F-B: -52 p: <0.05	B: 91.9 (17.4)
		Grp1-Grp2: -0.74 p: 0.0003	Grp1-Grp2: -10.2	F-B: 0.8 p: NSG	Grp1-Grp2: 12.4	F: 93.5
				Grp1-Grp2: -1.2		F-B: 1.6 p: NSG
					Grp1-Grp2: -2.7	
Tosi, 2003 ³⁶	Grp1: Metformin	Grp1				
	Varied	B: 7.8 (1.4)				
	Start: 500 mg, Max: 3000 mg	F: 7.3				
	Grp2: Metformin + glibenclamide	F-B: -0.5				
	Varied	Grp2				
Start: 400 mg, Max: 2400 mg;	B: 7.8 (1.0)					
Start: 2.5 mg, Max: 15 mg	F: 5.9					
	F-B: -1.9					
	Grp1-Grp2: 1.4					
Goldstein, 2003 ⁶²	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied	B: 8.6 (1.2)	B: 109.7 (35.2)	B: 42.3 (9.7)	B: 218.7 (120.2)	B: 94.2 (16.7)
	Start: 500 mg, Max: 2000 mg	F: 8.4 (0.1)	F: 102.5	F: 42.7	F: 217.1	F: 91.5
	Grp2: Metformin + glipizide	F-B: -0.2	F-B: -7.2 (CI: -15, 0.6)	F-B: 0.4 p: NSG	F-B: -1.6 (-25.3 to 22)	F-B: -2.7 (SE: 0.3)
	Varied	Grp2	Grp2	Grp2	p: NSG	Grp2
	Start: 500 mg, Max: 2000 mg;	B: 8.7 (1.2)	B: 119.7 (29.5)	B: 43.2 (10.0)	B: 237.5 (192.2)	Grp2
	Start: 5 mg, Max: 20 mg	F: 7.4 (0.1)	F: 119.5	F: 44.1	B: 256	Grp2
		F-B: -1.3	F: 119.5	F-B: 0.9 p: NSG	F: 256	B: 95.1 (17.8)
		Grp1-Grp2: 1.06 p: <0.001	F-B: -0.2 (CI: -6.7, 6.3)	Grp1-Grp2: -0.5	F-B: 18.5 (-16.8 to 53.7) p: NSG	F: 94.8
			Grp1-Grp2: -7		Grp1-Grp2: -20.1	F-B: -0.3 (SE: 0.3)
					Grp1-Grp2: -2.4 p: <0.001	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Blonde, 2002 ⁶³	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 2000 mg; Start: 5 mg, Max: 20 mg	Grp1 B: 9.51 (1.34) F: 9.7 F-B: 0.39 Grp2 B: 9.42 (1.24) F: 7.9 F-B: -1.38 Grp1-Grp2: 1.77 p: <0.001	Grp1-Grp2: p: NSG	Grp1-Grp2: p: NSG	Grp1-Grp2: p: NSG	
Blonde, 2002 ⁶³	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 2000 mg; Start: 2.5 mg, Max: 10 mg	Grp1 B: 9.51 (1.34) F: 9.7 F-B: 0.39 Grp2 B: 9.41 (1.47) F: 7.9 F-B: -1.64 Grp1-Grp2: 2.03 p: <0.001	Grp1-Grp2: p: NSG	Grp1-Grp2: p: NSG	Grp1-Grp2: p: NSG	
Marre, 2002 ⁶⁴	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glibenclamide Varied Start: 500 mg, Max: 2000 mg; Start: 2.5 mg, Max: 10 mg	Grp1 B: 8.09 (1.84) F: 7.89 F-B: -0.2 Grp2 B: 7.89 (1.62) F: 6.69 F-B: -1.2 Grp1-Grp2: 1 p: <0.05	Grp1 B: 148.2 (39) F: 136.5 F-B: -11.7 (31.2) p: NSG Grp2 B: 152.1 (42.9) F: 144.3 F-B: -7.8 (27.3) p: NSG Grp1-Grp2: -3.9	Grp1 B: 46.8 (11.7) F: 47.97 F-B: 1.17 p: NSG Grp2 B: 46.8 (15.6) F: 47.19 F-B: 0.39 p: NSG Grp1-Grp2: 0.78	Grp1 B: 204.7 (169.1) F: 186.9 F-B: -17.8 (89) Grp2 B: 213.6 (160.2) F: 195.8 F-B: -17.8 (151.3) Grp1-Grp2: 0 p: NSG	Grp1 B: 84.9 (17.6) F: 84.1 F-B: -0.8 Grp2 B: 84.7 (15.1) F: 85.3 F-B: 0.6 Grp1-Grp2: -1.4

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Marre, 2002 ⁶⁴	Grp1: Metformin	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied	B: 8.09 (1.84)	B: 148.2 (39)	B: 46.8 (11.7)	B: 204.7 (169.1)	B: 84.9
	Start: 500 mg, Max: 2000 mg	F: 7.89	F: 136.5	F: 58.5	F: 186.9	(17.6)
	Grp2: Metformin + glibenclamide	F-B: -0.2	F-B: -11.7 (31.2)	F-B: 1.17 p:	F-B: -17.8 (89)	F: 84.1
	Varied	Grp2	p:NSG	NSG	Grp2	F-B: -0.8
	Start: 500 mg, Max: 2000 mg;	B: 7.62 (1.61)	Grp2	Grp2	B: 222.5 (284.8)	Grp2
	Start: 5 mg, Max: 10 mg	F: 6.72	B: 152.1 (35.1)	B: 50.7 (11.7)	F: 178	B: 83.1
	F-B: -0.9	F: 144.3	F: 50.7	F-B: -44.5 (186.9)	(13.3)	
	Grp1-Grp2: 0.7 p:	F-B: -7.8 (27.3)	F-B: 0 p: NSG	Grp1-Grp2: 26.7 p:	F: 84.1	
	<0.05	p:NSG	Grp1-Grp2: 1.17	NSG	F-B: 1	
		Grp1-Grp2: -3.9			Grp1-Grp2:	
					-1.8	
Garber, 2002 ⁶⁵	Grp1: Metformin	Grp1				Grp1
	Varied	B: 8.26 (1.08)				F-B: -0.6
	Start: 500 mg, Max: 2000 mg	F: 7.23				Grp2
	Grp2: Metformin + glyburide	F-B: -1.03				F-B: 1.4 p:
	Varied	Grp2				<0.05
	Start: 500 mg, Max: 2000 mg;	B: 8.18 (1.14)				Grp1-Grp2:
	Start: 2.5 mg, Max: 10 mg	F: 6.65				-2
	F-B: -1.53					
	Grp1-Grp2: 0.5 p:					
	<0.001					
Garber, 2002 ⁶⁵	Grp1: Metformin	Grp1				Grp1
	Varied	B: 8.26 (1.08)				F-B: -0.6
	Start: 500 mg, Max: 2000 mg	F: 7.23				Grp2
	Grp2: Metformin + glyburide	F-B: -1.03				F-B: 1.9 p:
	Varied	Grp2				<0.05
	Start: 250 mg, Max: 1000 mg;	B: 8.25 (1.11)				Grp1-Grp2:
	Start: 1.25 mg, Max: 5 mg	F: 6.77				-2.5
	F-B: -1.48					
	Grp1-Grp2: 0.45 p:					
	<0.001					

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Hermann, 1994 ⁶⁸	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg	Grp1 B: 6.9 (SE: 0.3) F: 5.8 (SE: 0.2)	Grp1 B: 142.74 (SE: 9.75)	Grp1 B: 31.59 (SE: 2.34)	Grp1 B: 179.78 (SE: 18.69) F: 173.55 (SE: 14.24)	Grp1 B: 78.6 (SE: 2.9)
	Grp2: Metformin + glyburide Varied Start: 1000 mg, Max: 3000 mg; Start: 10.5 mg, Max: 14.0 mg	F-B: -0.9 (SE: 0.2) p: 0.001 Grp2 B: 7.8 (SE: 0.3) F: 5.7 (SE: 0.3) F-B: -2.0 (SE: 0.4) p: 0.001 Grp1-Grp2: 1.1 p: >0.1 across all treatment groups	F: 131.82 (SE: 8.97) F-B: -5.85 (SE: 2.73) Grp2 B: 143.13 (SE: 5.46) F: 139.62 (SE: 4.68) F-B: -2.73 (SE: 2.34) Grp1-Grp2: -3.12	F: 30.03 (SE: 1.56) F-B: -0.78 (SE: 0.78) p: >0.1 Grp2 B: 35.49 (SE: 1.56) F: 37.05 (SE: 1.95) F-B: 1.56 (SE: 1.17) p: >0.1 Grp1-Grp2: -0.78	F-B: 8.01 (SE: 12.46) p: >0.1 Grp2 B: 175.33 (SE: 20.47) F: 168.21 (SE: 17.8) F-B: 5.34 (SE: 11.57) p: >0.1 Grp1-Grp2: 2.67	F: 78.8 (SE: 2.9) F-B: -0.2 (SE: 0.5) p: >0.1 Grp2 B: 80.2 (SE: 2.4) F: 81 (SE: 2.5) F-B: 0.7 (SE: 0.4) p: >0.1 Grp1-Grp2: -0.9
Hermann, 1994 ⁶⁸	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg	Grp1 B: 6.9 (SE: 0.3) F: 5.8 (SE: 0.2)	Grp1 B: 142.74 (SE: 9.75)	Grp1 B: 31.59 (SE: 2.34)	Grp1 B: 179.78 (SE: 18.69) F: 173.55 (SE: 14.24)	Grp1 B: 78.6 (SE: 2.9)
	Grp2: Metformin + glyburide Fixed; Varied Start: 3000 mg; Start: 3.5 mg, Max: 14.0 mg	F-B: -0.9 (SE: 0.2) p: 0.001 Grp2 B: 7.8 (SE: 0.3) F: 5.4 (SE: 0.3) F-B: -2.3 (SE: 0.4) p: 0.001 Grp1-Grp2: 1.4 p: >0.1 across all treatment groups	F: 131.82 (SE: 8.97) F-B: -5.85 (SE: 2.73) Grp2 B: 143.13 (SE: 5.46) F: 139.62 (SE: 4.68) F-B: -2.73 (SE: 2.34) Grp1-Grp2: -3.12	F: 30.03 (SE: 1.56) F-B: -0.78 (SE: 0.78) p: >0.1 Grp2 B: 35.49 (SE: 1.56) F: 37.05 (SE: 1.95) F-B: 1.56 (SE: 1.17) p: >0.1 Grp1-Grp2: -0.78	F-B: 8.01 (SE: 12.46) p: >0.1 Grp2 B: 175.33 (SE: 20.47) F: 168.21 (SE: 17.8) F-B: 5.34 (SE: 11.57) p: >0.1 Grp1-Grp2: 2.67	F: 78.8 (SE: 2.9) F-B: -0.2 (SE: 0.5) p: >0.1 Grp2 B: 80.2 (SE: 2.4) F: 81 (SE: 2.5) F-B: 0.7 (SE: 0.4) p: >0.1 Grp1-Grp2: -0.9

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Hermann, 1994 ⁶⁸	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg Grp2: Metformin + glyburide Varied Start: 2000 mg, Max: 3000 mg; Start: 7.0 mg, Max: 14.0 mg	Grp1 B: 6.9 (SE: 0.3) F: 5.8 (SE: 0.2) F-B: -0.9 (SE: 0.2) p: 0.001 Grp2 B: 8.4 (SE: 0.4) F: 6.2 (SE: 0.3) F-B: -2.2 (SE: 0.4) p: 0.001 Grp1-Grp2: 1.3 p: >0.1 across all treatment groups				
Hermann, 1994 ⁶⁸	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 1500 mg; Start: 1.75 mg, Max: 5.25 mg	Grp1 B: 6.9 (SE: 0.3) F: 5.8 (SE: 0.2) F-B: -0.9 (SE: 0.2) p: 0.001 Grp2 B: 6.8 (SE: 0.1) F: 5.6 (SE: 0.1) F-B: -1.2 (SE: 0.1) p: 0.001 Grp1-Grp2: 0.3 p: >0.1 across all treatment groups				

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Hermann, 1991 ¹⁵⁵	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg	Grp1 B: 6.7 (1.3) F: 5.8 (0.7)	Grp1 F-B: 0.78 (SE: 3.9)			Grp1 B: 76.5 (11.5)
	Grp2: Metformin + glibenclamide Fixed; Varied Start: 3000 mg; Start: 3.5 mg, Max: 14 mg	F-B: -0.9 p: <0.01 Grp2 B: 7.7 (1.1) F: 5.4 (0.9) F-B: -2.3 p: <0.001 Grp1-Grp2: 1.4	Grp2 F-B: -6.24 (SE: 2.34) Grp1-Grp2: 7.02 p:<0.05			F: 76.1 (11.1) F-B: -0.4 p: NSG Grp2 B: 87.3 (15.6) F: 87.3 (15.9) F-B: 0 p: NSG Grp1-Grp2: -0.4
Hermann, 1991 ¹⁵⁵	Grp1: Metformin + diet Varied Start: 1000 mg, Max: 3000 mg	Grp1 B: 6.7 (1.3) F: 5.8 (0.7)				Grp1 B: 76.5 (11.5)
	Grp2: Metformin + glibenclamide Varied Start: 1000 mg, Max: 3000 mg; Start: 10.5 mg, Max: 14 mg	F-B: -0.9 p: <0.01 Grp2 B: 7.8 (1.4) F: 5.7 (0.8) F-B: -2.2 p: <0.001 Grp1-Grp2: 1.3				F: 76.1 (11.1) F-B: -0.4 p: NSG Grp2 B: 74.4 (11.4) F: 76 (11.8) F-B: 1.6 p: <0.001 Grp1-Grp2: -2

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Charpentier, 2001 ⁷¹	Grp1: Metformin Fixed Start: 850 mg tid Grp2: Metformin + glimepiride Fixed; Varied Start: 850 mg tid; Start: 1 mg, Max: 6 mg	Grp1 B: 6.79 (1.17) F: 6.86 (1.45) F-B: 0.07 (SE: 0.14) Grp2 B: 6.42 (1.08) F: 5.68 (0.99) F-B: -0.74 (SE: 0.8) Grp1-Grp2: 0.92 p: <0.001	Grp1 B: 134 (SE: 3) F: 129 (SE: 3) F-B: -6 (SE: 2) Grp2 B: 137 (SE: 3) F: 128 (SE: 3) F-B: -8 (SE: 2) Grp1-Grp2: 2 p: NSG	Grp1 B: 46.41 (13.65) F: 48.36 F-B: 1.95 (9.36) Grp2 B: 46.41 (12.09) F: 45.24 F-B: -1.17 (9.87) Grp1-Grp2: 3.12 p: 0.14 across all treatment groups	Grp1 B: 171.77 (119.26) F: 185.12 F-B: 13.35 (104.13) Grp2 B: 169.99 (110.36) F: 167.32 F-B: -2.67 (93.45) Grp1-Grp2: 16.02 p: 0.029 across all treatment groups	Grp1 B: 82.2 F: 81.46 F-B: -0.74 (2.58) Grp2 B: 81.2 F: 81.8 F-B: 0.6 (2.86) Grp1-Grp2: -1.34
DeFronzo, 1995 ⁷⁰	Grp1: Metformin Varied Start: 500 mg, Max: 2500 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 2500 mg; Start: 10 mg, Max: 20 mg	Grp1 B: 8.9 F: 8.5 F-B: -0.4 (SE: 0.1) Grp2 B: 8.8 F: 7.1 F-B: -1.7 (SE: 0.1) Grp1-Grp2: 1.3 p: <0.001	Grp1 B: 134 (SE: 3) F: 129 (SE: 3) F-B: -6 (SE: 2) Grp2 B: 137 (SE: 3) F: 128 (SE: 3) F-B: -8 (SE: 2) Grp1-Grp2: 2 p: NSG	Grp1 B: 231 (SE: 12) F: 221 (SE: 13) F-B: -16 (SE: 7) Grp2 B: 216 (SE: 10) F: 194 (SE: 9) F-B: -20 (SE: 7) Grp1-Grp2: 4	Grp1 B: 228.1 (SE: 13.92) F: 207.2 (SE: 14.71) F-B: -1.5 (SE: 2.72) Grp2 B: 225.5 (SE: 13.92) F: 184.4 (SE: 9.17) F-B: -4.5 (SE: 2.82) (CI: -10.1, 1) Grp1-Grp2: 0.2	Grp1 F-B: -3.8 (SE: 0.2) p: <0.001 Grp2 F-B: 0.4 (SE: 0.2) p: NSG Grp1-Grp2: -4.2
Metformin versus metformin + DPP-IV inhibitor						
Jadzinsky, 2009 ⁷⁸	Grp1: Metformin Varied Start: 500 mg, Max: 1000 mg D: 1 Weeks Grp2: Metformin + saxagliptin Varied, prespecified target dose Start: 500 mg, Max: 1000 mg; Start: 5mg D: 1 Weeks	Grp1 F-B: -2 p: <0.0001 Grp2 F-B: -2.5 p: <0.0001 Grp1-Grp2: 0.5 p: <0.0001	Grp1 B: 126.7 F: 118.5 F-B: -4 (SE: 1.44) (CI: -6.8, -1.1) Grp2 B: 124.4 F: 114.8 F-B: -3.8 (SE: 1.85) (CI: -7.4, -0.1) Grp1-Grp2: 1.4	Grp1 B: 43.6 F: 46.6 F-B: 8.9 (SE: 1.36) (CI: 6.2, 11.5) Grp2 B: 43.9 F: 46 F-B: 6.2 (SE: 1.15) (CI: 3.9, 8.5) Grp1-Grp2: 0.9	Grp1 B: 228.1 (SE: 13.92) F: 207.2 (SE: 14.71) F-B: -1.5 (SE: 2.72) Grp2 B: 225.5 (SE: 13.92) F: 184.4 (SE: 9.17) F-B: -4.5 (SE: 2.82) (CI: -10.1, 1) Grp1-Grp2: 0.2	Grp1 F-B: -1.6 Grp2 F-B: -1.8 Grp1-Grp2: 0.2

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Jadzinsky, 2009 ⁸	Grp1: Metformin Varied Start: 500 mg, Max: 1000 mg D: 1 Weeks	Grp1 F-B: -2 p: <0.0001	Grp1 B: 126.7 F: 118.5	Grp1 B: 43.6 F: 46.6	Grp1 B: 228.1 (SE: 13.92) F: 207.2 (SE: 14.71)	Grp1 F-B: -1.6
	Grp2: Metformin + saxagliptin Varied, prespecified target dose Start: 500 mg, Max: 1000 mg; Mean: 10 mg D: 1 Weeks	Grp2 F-B: -2.5 p: <0.0001 Grp1-Grp2: 0.8 p: <0.0001	Grp2 F-B: -4 (SE: 1.44) (CI: -6.8, -1.1) Grp2 B: 124.6 F: 114.2 F-B: -4.6 (SE: 1.73) (CI: -8.1, -1.2) Grp1-Grp2: 2.2	Grp2 F-B: 8.9 (SE: 1.36) (CI: 6.2, 11.5) Grp2 B: 43.7 F: 45.6 F-B: 6.7 (SE: 1.26) (CI: 4.2, 9.2) Grp1-Grp2: 1.1	Grp2 F-B: -1.5 (SE: 2.72) (CI: -6.8, 3.9) Grp2 B: 217.9 (SE: 10.23) F: 181.7 (SE: 8.86) F-B: -5.8 (SE: 3.55) (CI: -12.8, 1.2) Grp1-Grp2: 15.3	Grp2 F-B: -1.4 Grp1-Grp2: -0.2
DeFronzo, 2009 ⁹⁵	Grp1: Metformin Fixed	Grp1 F-B:				
	Grp2: Metformin + Saxagliptin Fixed NR; Mean: 2.5 mg	Grp2 0 F-B: -0.59 (SE: 0.07) p: <0.0001 Grp1-Grp2: 0.73 (SE: 0.1) (CI: 0.53, 0.92) p: <0.0001				
DeFronzo, 2009 ⁹⁵	Grp1: Metformin Fixed	Grp1 F-B: 0				
	Grp2: Metformin + Saxagliptin Fixed NR; Mean: 5 mg	Grp2 F-B: -0.69 (SE: 0.07) p: <0.0001 Grp1-Grp2: 0.83 (SE: 0.1) (CI: 0.63, 1.02) p: <0.0001				
DeFronzo, 2009 ⁹⁵	Grp1: Metformin Fixed	Grp1 F-B: 0				
	Grp2: Metformin+ Saxagliptin Fixed NR; Mean: 10 mg	Grp2 F-B: -0.58 (SE: 0.07) p: <0.0001 Grp1-Grp2: 0.72 (SE: 0.1) (CI: 0.52, 0.91) p: <0.0001				

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Williams-Herman, 2009 ⁷⁶	Grp1: Metformin Fixed Mean: 2000 mg	Grp1 F-B: -1.3 (CI: -1.5, -1.2)	Grp1 B: 105.3 (32.3) F: 102.3 (33.6)	Grp1 B: 42.8 (9) F: 45.2 (11)	Grp1 B: 150 (92.1) F: 174.5 (124.7)	Grp1 F-B: -1.5 (CI: -2.2, -0.8)
	Grp2: Metformin + sitagliptin Fixed Mean: 2000 mg; Mean: 100 mg	Grp2 F-B: -1.8 (CI: -2, -1.7)	Grp2 B: 115.1 (39.1) F: 110.1 (37.1)	Grp2 B: 43.9 (11.1) F: 46.6 (13.5)	F-B: Median % change: 8.4 (CI: 0.5, 16.4)	Grp2 F-B: -1.7 (CI: -2.4, -1.1)
	Grp1-Grp2: 0.5	F-B: -5	Grp1-Grp2: 2 (SE: 7.8)	F-B: 2.7 Grp1-Grp2: -0.3 (SE: 2.40)	Grp2 B: 158 (97.7) F: 143 (94) F-B: Median % change: -7.1 (CI: -13.9, -0.2)	Grp1-Grp2: 39.5
Williams-Herman, 2009 ⁷⁶	Grp1: Metformin Fixed Mean: 2000 mg	Grp1 F-B: -1.3 (CI: -1.5, -1.2)	Grp1 B: 107.3 (33.4) F: 102.5 (36.7)	Grp1 B: 43.3 (10.8) F: 46.4 (12)	Grp1 B: 150 (92.1) F: 174.5 (124.7)	Grp1 F-B: -1.5 (CI: -2.2, -0.8)
	Grp2: Metformin + sitagliptin Fixed Mean: 1000 mg; Mean: 100 mg	Grp2 F-B: -1.4 (CI: -1.6, -1.3)	Grp2 B: 115.1 (39.1) F: 110.1 (37.1)	Grp2 B: 43.7 (9.3) F: 45.4 (11.3)	F-B: Median % change: 8.4 (CI: 0.5, 16.4)	Grp2 F-B: -0.7 (CI: -1, 0)
	Grp1-Grp2: 0.1	F-B: -5	Grp1-Grp2: 0.2 (SE: 7.8)	F-B: 1.7 Grp1-Grp2: 1.4 (SE: 2.31)	Grp2 B: 155 (104.2) F: 147 (95.8) F-B: Median % change: -4.6 (CI: -11.9, 2.7)	Grp1-Grp2: -0.8
Williams-Herman, 2009 ⁷⁶	Grp1: Metformin Fixed Mean: 1000 mg	Grp1 F-B: -1 (CI: -1.2, -0.8)	Grp1 B: 106.8 (34.2) F: 103.6 (31.5)	Grp1 B: 43.2 (9.4) F: 44.6 (10.4)	Grp1 B: 167 (104.2) F: 173 (120)	Grp1 F-B: -1 (CI: -1.7, -0.3)
	Grp2: Metformin + sitagliptin Fixed Mean: 2000 mg; Mean: 100 mg	Grp2 F-B: -1.8 (CI: -2, -1.7)	Grp2 B: 114.7 (37.1) F: 111 (32.4)	Grp2 B: 43.1 (9.2) F: 44.3 (10.4)	F-B: Median % change: 4.9 (CI: -3.3, 13)	Grp2 F-B: -1.7 (CI: -2.4, -1.1)
	Grp1-Grp2: 0.8	F-B: -3.7	Grp1-Grp2: 0.5 (SE: 6.5)	F-B: 1.2 Grp1-Grp2: 0.2 (SE: 1.88)	Grp2 B: 158 (97.7) F: 143 (94) F-B: Median % change: -7.1 (CI: -13.9, -0.2)	Grp1-Grp2: 0.7
					Grp1-Grp2: 21	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Williams-Herman, 2009 ⁷⁶	Grp1: Metformin Fixed Mean: 1000 mg	Grp1 F-B: -1 (CI: -1.2, -0.8)	Grp1 B: 108.2 (34.4) F: 104.6 (33.8)	Grp1 B: 43.2 (9.4) F: 44.6 (10.4)	Grp1 B: 167 (104.2) F: 173 (120)	Grp1 F-B: -1 (CI: -1.7, -0.3)
	Grp2: Metformin + sitagliptin Fixed Mean: 1000 mg; Mean: 100 mg	Grp2 F-B: -1.4 (CI: -1.6, -1.3) Grp1-Grp2: 0.4	Grp2 B: 114.7 (37.1) F: 111 (32.4) F-B: -3.7 Grp1-Grp2: 0.1 (SE: 6.6)	Grp2 B: 44.2 (10.9) F: 46 (12.2) F-B: 1.8 Grp1-Grp2: -0.4 (SE: 2.06)	Grp2 F-B: Median % change: 4.9 (CI: -3.3, 13) Grp2 B: 155 (104.2) F: 147 (95.8) F-B: Median % change: -4.6 (CI: -11.9, 2.7) Grp1-Grp2: 14	Grp2 F-B: -0.7 (CI: -1, 0) Grp1-Grp2: -0.3
Raz, 2008 ⁹³	Grp1: Metformin Fixed NR	Grp1 F-B: 0 (CI: -0.2, 0.3)				Grp1 F-B: -0.5
	Grp2: Metformin + sitagliptin Fixed Max: 2550 mg; Mean: 100 mg	Grp2 F-B: -1 (CI: -1.3, -0.7) p: <0.001 Grp1-Grp2: -1 (CI: -1.4, -0.6) p: <0.001				Grp2 F-B: -0.5 Grp1-Grp2: 0
Goldstein, 2007 ⁷⁵	Grp1: Metformin Varied, prespecified target dose Start: 500 mg, Max: 100 mg D: 1 wk	Grp1 F-B: -0.82 (CI: -0.98, -0.66)				Grp1 F-B: significant reduction relative to baseline
	Grp2: Metformin + sitagliptin Varied, prespecified target dose Start: 500 mg, Max: 1000 mg; Start: 50 mg, Max: 100 mg D: 1 wk	Grp2 F-B: -1.4 (CI: -1.56, -1.24) Grp1-Grp2: 0.58				Grp2 F-B: significant reduction relative to baseline

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Goldstein, 2007 ⁶⁵	Grp1: Metformin Varied, prespecified target dose Start: 500 mg, Max: 100 mg D: 1 wk Grp2: Metformin + sitagliptin Varied, prespecified target dose Start: 500 mg, Max: 2000 mg; Start: 50 mg, Max: 100 mg D: 3 wks; 1wk	Grp1 F-B: -0.82 (CI: -0.98, -0.66) Grp2 F-B: -1.9 (CI: -2.06, -1.74) Grp1-Grp2: 1.08				Grp1 F-B: significant reduction relative to baseline Grp2 F-B: significant reduction relative to baseline
Goldstein, 2007 ⁶⁵	Grp1: Metformin Fixed Start: 500 mg, Max: 2000 mg D: 3 wks Grp2: Metformin + sitagliptin Varied, prespecified target dose Start: 500 mg, Max: 1000 mg; Start: 50 mg, Max: 100 mg D: 1 wk	Grp1 F-B: -1.13 (CI: -1.29, -0.97) Grp2 F-B: -1.4 (CI: -1.56, -1.24) Grp1-Grp2: 0.27				Grp1 F-B: significant reduction relative to baseline Grp2 F-B: significant reduction relative to baseline
Goldstein, 2007 ⁷⁵	Grp1: Metformin Fixed Start: 500 mg, Max: 2000 mg D: 3 wks Grp2: Metformin + sitagliptin Varied, prespecified target dose Start: 500 mg, Max: 2000 mg; Start: 50 mg, Max: 100 mg D: 3 wks; 1 wk	Grp1 F-B: -1.13 (CI: -1.29, -0.97) Grp2 F-B: -1.9 (CI: -2.06, -1.74) Grp1-Grp2: 0.77 (SE: 0.12)				Grp1 F-B: significant reduction relative to baseline Grp2 F-B: significant reduction relative to baseline

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Charbonnel, 2006 ⁹⁴	Grp1: Metformin Varied, glucose: , HbA1c: 7% - 10% Start: >=1500 mg D: 19 wks	Grp1 B: 8.03 (0.82) F: 7.95 (1.1) F-B: -0.02 (CI: -0.15, 0.1)	Grp1 B: 102.18 (31.6) F: 104.13 (32.8) F-B: 1.95	Grp1 B: 44.85 (10.92) F: 45.63 (11.7) F-B: 0.78	Grp1 F-B: 24.6 (CI: 16.8, 32.3) Grp2 F-B: 7.7 (CI: 1.5, 14)	Grp1 F-B: 0.6-0.7 p: <0.05 Grp2 F-B: 0.6-0.7 p: <0.05 Grp1-Grp2: p=0.835
	Grp2: Metformin + sitagliptin Varied; Fixed Start: >=1500 mg; Mean: 100 mg D: 19 wks	Grp2 B: 7.96 (0.81) F: 7.26 (0.97) F-B: -0.67 (CI: -0.77, -0.57) Grp1-Grp2: 0.65 (SE 0.08)	Grp2 B: 98.67 (30.8) F: 100.62 (32.0) F-B: 1.95 Grp1-Grp2: 0 (SE: 4.7)	Grp2 B: 45.63 (10.92) F: 46.8 (11.31) F-B: 1.17 Grp1-Grp2: -0.39 (SE: 1.65)	Grp1-Grp2: 16.9	
Scott, 2008 ⁸⁵	Grp1: Metformin Fixed Total starting dose: > 1500 mg	Grp1 B: 7.68 (0.88) F: 7.47 (1.05) F-B: -0.22 (CI: -0.36, -0.08)	Grp1 B: 95.6 (30.8) F: 108.4 (33.6) F-B: Mean % change: 16.7 (CI: 10.2, 23.3)	Grp1 B: 43.5 (10.5) F: 44.1 (12.1) F-B: Mean % change: 1.8 (CI: -1.3, 4.9)	Grp1 B: 171.1 (73.3) F: 191.5 (111.1) F-B: Mean % change from baseline: 11.9 (CI: 3.9, 19.9)	Grp1 F-B: -0.8 (CI: -1.2, -0.4) Grp2 F-B: -0.4 (CI: -0.8, 0) Grp1-Grp2: -0.4
	Grp2: Metformin + sitagliptin Fixed Total starting dose: > 1500 mg; Start: 100 mg, Mean: 100 mg	Grp2 B: 7.75 (0.99) F: 7.01 (0.86) F-B: -0.73 (CI: -0.87, -0.6) Grp1-Grp2: -0.51 (CI: -0.7, -0.32) p: <0.001	Grp2 B: 95.4 (30.8) F: 104.6 (35.1) F-B: Mean % change: 11.4 (CI: 5, 17.8) Grp1-Grp2: 3.6 (SE: 8.7)	Grp2 B: 43.9 (11.6) F: 45.7 (13.4) F-B: Mean % change: 4.3 (CI: 1.2, 7.3) Grp1-Grp2: -1.2 (SE: 3.18)	Grp2 B: 177.8 (80.7) F: 163.3 (74) F-B: Mean % change from baseline: -4.8 (CI: -12.7, 3.1)	
Metformin versus metformin + meglitinides						
Horton, 2004 ⁸⁰	Grp1: Metformin Fixed Start: 500 mg tid Grp2: Metformin + nateglinide Fixed Start: 500 mg qac; Start: 120 mg qac	Grp1 F-B: -0.8 (SE: 0.1) p: <0.001 Grp2 F-B: -1.6 (SE: 0.1) p: <0.001 Grp1-Grp2: 0.8 (SE: 0.14)				

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Marre, 2002 ⁹⁶	Grp1: Metformin Fixed Start: 1000 mg bid Grp2: Metformin + nateglinide Fixed Start: 1000 mg bid; Start: 60 mg qac	Grp2-Grp1: -0.36 (CI: -0.59, -0.13) p: 0.003	Grp1-Grp2: 0.0 (CI: -3.9, 7.8) p: NSG	Grp1-Grp2: 0.0 (CI: -0.0, 3.9) p: NSG	Grp1-Grp2: -3.9 (CI: -11.7, 7.8) p: NSG	Grp1 F-B: 0.1 Grp2 F-B: 0.4 Grp1-Grp2: -0.3 (CI: -0.8, 0.2) p: >0.05
Marre, 2002 ⁹⁶	Grp1: Metformin Fixed Start: 1000 mg bid Grp2: Metformin + nateglinide Fixed Start: 1000 mg bid; Start: 120 mg qac	Grp2-Grp1: -0.51 (CI: -0.82, -0.36) p: <0.001	Grp1-Grp2: 3.9 (CI: -0.0, 11.7) p: NSG	Grp1-Grp2: 0.0 (CI: -0.0, 3.9) p: NSG	Grp1-Grp2: -7.8 (CI: -15.6, -0.0) p: <0.05	Grp1 F-B: 0.1 Grp2 F-B: 1 Grp1-Grp2: -0.9 (CI: - 1.4, 0) p: <0.001
Moses, 1999 ⁸²	Grp1: Metformin NR Grp2: Metformin + repaglinide NR NR; Start: 0.5 mg tid, Max: 4.0 mg tid D: NR; 12 to 28 days	Grp1 F-B: -0.33 (SE: 0.24, CI: -0.8, -0.5) Grp2 F-B: -1.41 (SE: 0.23, CI: -1.87, -0.95) Grp1-Grp2: -1.08 (SE: 0.33, CI: -1.84, -0.33) p: 0.05				Grp1 F-B: -0.86 (SE: 0.51) Grp2 F-B: 2.41 (SE: 0.5) p: <0.05 Grp1-Grp2: -3.27
Horton, 2000 ⁹	Grp1: Metformin Fixed Start: 500 mg tid Grp2: Metformin + nateglinide Fixed Start: 500 mg qac; Start: 120 mg qac	Grp1 B: 8.4 (1.2) F: 7.6 F-B: -0.8 p: ≤0.0001 Grp2 B: 8.4 (1.1) F: 7.1 F-B: -1.3 p: ≤0.0001 Grp1-Grp2: 0.5				

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Thiazolidinedione versus thiazolidinedione						
Vijay, 2009 ⁹⁹	Grp1: Rosiglitazone Varied Start: 4 mg daily, Max: 4 mg bid D: NR Grp2: Pioglitazone Varied Start: 30 mg, Max: 45 mg D: NR	Grp1 F-B: -1.26 (SD: 0.72) p: 0 Grp2 F-B: -1.27 (SD: 0.17) p: 0 Grp1-Grp2: 0.01	Grp1 F-B: 5.39 p: 0.39 Grp2 F-B: -13.66 (6.7) p: 0 Grp1-Grp2: 19.05	Grp1 F-B: 3.25 p: 0.01 Grp2 F-B: 4.7 (1.4) p: 0 Grp1-Grp2: -1.45	Grp1 F-B: -25.3 p: 0.013 Grp2 F-B: -33 (8.7) p: 0 Grp1-Grp2: 7.7	Grp1 F-B: 0.7 (0.3) p: 0.8 Grp2 F-B: 1.15 (0.4) p: 0 Grp1-Grp2: -0.45
Goldberg, 2005 ⁹⁸	Grp1: Rosiglitazone Varied Start: 4 mg, Max: 8 mg Grp2: Pioglitazone Varied Start: 30 mg, Max: 45 mg	Grp1 B: 7.5 (SE: 0.1) F: 6.9 F-B: -0.6 (SE: 0.1) p:<.05 Grp2 B: 7.6 (SE: 0.1) F: 6.9 F-B: -0.7 (SE: 0.1) p: <.05 Grp1-Grp2: 0.1	Grp1 B: 109.1 (SE: 1.4) F: 130.4 F-B: 21.3 (SE: 1.6) p: <0.05 Grp2 B: 107.1 (SE: 1.3) F: 119.4 F-B: 12.3 (SE: 1.6) p: <0.05 Grp1-Grp2: 9	Grp1 B: 39.8 (SE: 0.6) F: 42.2 F-B: 2.4 (SE: 0.5) Grp2 B: 38.8 (SE: 0.5) F: 44 F-B: 5.2 (SE: 0.5) p: <0.001 Grp1-Grp2: -2.8	Grp1 B: 235.3 (SE: 6.6) F: 248.4 F-B: 13.1 (SE: 7.8) p: NSG Grp2 B: 257.8 (SE: 8.2) F: 205.9 F-B: -51.9 (SE: 7.8) p: <0.05 Grp1-Grp2: 65	
Khan, 2002 ⁹⁷	Grp1: Rosiglitazone Fixed Start: 2-8 mg Grp2: Pioglitazone Fixed Start: 15-45 mg	Grp1 B: 7.9 (1.9) F: 7.6 F-B: -0.3 Grp2 B: 8.0 (1.7) F: 7.8 F-B: -0.2 (SE: 0.1) Grp1-Grp2: -0.1 p: NSG	Grp1 B: 105.9 (29.7) F: 103.9 F-B: -2 p: NSG Grp2 B: 116.2 (38) F: 98.2 F-B: -18 p: <0.01 Grp1-Grp2: 16	Grp1 B: 45.3 (15.2) F: 48.6 F-B: 1.5 p: NSG Grp2 B: 44.7 (15.6) F: 46.7 F-B: 2.0 p: NSG Grp1-Grp2: -0.5	Grp1 B: 236 (222) F: 242 F-B: 6 p: NSG Grp2 B: 181 (110.1) F: 166 F-B: -15 p: NSG Grp1-Grp2: 21	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Thiazolidinedione versus sulfonylurea						
Nakamura, 2006 ¹⁰⁸	Grp1: Pioglitazone Fixed Mean: 30 mg D: 12 Months Grp2: Glibenclamide Fixed Mean: 5 mg D: 12 Months	Grp1 B: 8 (1.4) F: 6.4 (1.2) p:<0.01 F-B: -1.6 Grp2 B: 7.8 (1.3) F: 7 (6.2) p:<0.01 F-B: -0.8 Grp1-Grp2: -0.8		Grp1 B: 32 (10) F: 40 (12) p:<0.05 F-B: 8 Grp2 B: 34 (8) F: 34 (10) p:NSG F-B: 0 Grp1-Grp2: 8	Grp1 B: 148 (42) F: 118 (28) p:<0.01 F-B: -30 Grp2 B: 144 (38) F: 146 (38) p: NSG F-B: 2 Grp1-Grp2: -32	
Teramoto, 2007 ⁴¹	Grp1: Pioglitazone Varied, glucose: <= 126 mg/dL Start: 15 mg, Max: 30 mg D: 15 wks Grp2: Glibenclamide Varied, glucose: <= 126 mg/dL Start: 1.25 mg, Max: 2.5 mg D: 15 wks	Grp1 F-B: -0.8 (1.14) p: <0.05 Grp2 F-B: -1.43 (1.09) p: <0.05 Grp1-Grp2: 0.63 (SE: 0.48)	Grp1 F-B: 8.65 (23.47) Grp2 F-B: -1.31 (24.94) Grp1-Grp2: 9.96 (SE: 2.25)	Grp1 F-B: 3.8 (8.2) p: <0.05 Grp2 F-B: -1.2 (6.3) Grp1-Grp2: 5 (SE: 1.23)	Grp1 F-B: -57.7 (111.5) p: <0.05 Grp2 F-B: 7.3 (112.7) Grp1-Grp2: -65 (SE: 4.8)	
Hanefeld, 2007 ¹⁰⁰	Grp1: Rosiglitazone Fixed Mean: 4 mg Grp2: Glibenclamide Varied Start: 2.5 mg, Max: 15 mg D: 12 wks	Grp1 F-B: -0.3 p: 0.0003 Grp2 F-B: -0.7 p: <0.0001 Grp1-Grp2: 0.4	Grp1 F-B: 7.8 (27.3) Grp2 F-B: -3.9 (27.3) Grp1-Grp2: 11.7 (SE: 1.66)	Grp1 F-B: Median: 0.12 CI: 0.09 - 0.15 p: <0.0001 Grp2 F-B: Median: 0.08 CI: 0.05 - 0.12 p: <0.0001	Grp1 F-B: -10 (351) p: NSG Grp2 F-B: -3 (86) p: NSG Grp1-Grp2: -7	Grp1 F-B: 1.75 Grp2 F-B: 1.9 Grp1-Grp2: -0.15
Hanefeld, 2007 ¹⁰⁰	Grp1: Rosiglitazone Fixed Mean: 8 mg Grp2: Glibenclamide Varied Start: 2.5 mg, Max: 15 mg D: 12 wks	Grp1 F-B: -0.5 p: <0.0001 Grp2 F-B: -0.7 p: <0.0001 Grp1-Grp2: 0.2 (SE: 0.24)	Grp1 F-B: 15.6 (35.1) Grp2 F-B: -3.9 (27.3) Grp1-Grp2: 19.5 (SE: 1.78)	Grp1 F-B: Median: 0.17 CI: 0.12 - 0.22 p: <0.0001 Grp2 F-B: Median: 0.08 CI: 0.05 - 0.12 p: <0.0001	Grp1 F-B: 12 (92) p: NSG Grp2 F-B: -3 (86) p: NSG Grp1-Grp2: 15	Grp1 F-B: 2.95 Grp2 F-B: 1.9 Grp1-Grp2: 1.05 p: 0.01

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Kahn, 2006 ³⁸	Grp1: Rosiglitazone Varied, glucose: <140 mg/dL Start: 4 mg, Max: 8 mg Grp2: Glyburide Varied, glucose: <140 mg/dL Start: 2.5 mg, Max: 15 mg	Grp1-Grp2: -0.42 (CI: -0.5, -0.33) p: <0.001				Grp1-Grp2: -2.5 (CI: -3.1, -2) p: <0.001
Jain, 2006 ¹⁰¹	Grp1: Pioglitazone Varied, glucose: FPG: 69-141 mg/dL Start: 15 mg, Max: 45 mg, Median: 45 mg D: 16 wks Grp2: Glyburide Varied, glucose: FPG: 69-141 mg/dL Start: 5 mg, Max: 15 mg, Median: 10 mg D: 16 wks	Grp1 B: 9.2 (1.26) F: 7.13 (1.26) F-B: -2.07 Grp2 B: 9.2 (1.20) F: 7.18 (1.20) F-B: -2.02 Grp1-Grp2: -0.05 p: 0.669				Grp1 F-B: 3.66 (6.14) p: <0.001 Grp2 F-B: 1.95 (5.35) Grp1-Grp2: 1.71
Smith, 2004 ²⁹¹	Grp1: Rosiglitazone Varied Start: 8 mg Grp2: Glyburide Varied Median: 7.5 mg D: 12 wks	Grp1 F-B: -0.4 Grp2 F-B: 0.72 Grp1-Grp2: -1.1 p: >0.05				
Nakamura, 2004 ¹⁰²	Grp1: Pioglitazone Fixed Start: 30 mg Grp2: Glibenclamide Fixed Start: 5 mg	Grp1 F-B: 1.7 (1) p: <0.05 Grp2 F-B: 1.5 (1.1) p: <0.05 Grp1-Grp2: 0.2 (SE: 0.62)				

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Yamanouchi, 2005 ⁵⁰	Grp1: Pioglitazone Fixed Start: 30 mg for women and 45 mg for men	Grp1 B: 10.2 (0.8) F: 7.9 (1.0) F-B: -2.3 p: <0.005		Grp1 B: 53.82 (4.68) F: 58.11 (3.51) F-B: 4.29 p: NSG	Grp1 B: 219.83 (112.14) F: 185.12 (96.12) F-B: -34.71 p: NSG	
	Grp2: Glimepiride Varied Start: 1.0 mg, Max: 2.0 mg	Grp2 B: 9.8 (0.7) F: 7.7 (0.9) F-B: -2.1 p: <0.005 Grp1-Grp2: -0.2		NSG Grp2 B: 52.65 (4.29) F: 52.26 (4.29) F-B: -0.39 p: NSG Grp1-Grp2: 4.68	Grp2 B: 234.07 (121.93) F: 229.62 (112.14) F-B: -4.45 p: NSG Grp1-Grp2: -30.26	
Pfutzner, 2005 ¹⁰⁵	Grp1: Pioglitazone Fixed Start: 45 mg	Grp1 B: 7.52 (0.85) F: 6.71 (0.89) F-B: -0.81 p: <0.05	Grp1 B: 136 (29) F: 133 (31) F-B: -3	Grp1 B: 46 (11) F: 54 (13) F-B: 8	Grp1 B: 190 (109) F: 168 (102) F-B: -22 p: <0.005	
Langenfeld, 2005 ²⁹⁰	Grp2: Glimepiride Varied Start: 1 mg, Max: 6 mg	Grp2 B: 7.44 (0.89) F: 6.83 (0.85) F-B: -0.61 p: <0.05 Grp1-Grp2: -0.2	Grp2 B: 137 (25) F: 129 (27) F-B: -8 Grp1-Grp2: 5 p: NSG	Grp2 B: 46 (14) F: 47 (12) F-B: 1 Grp1-Grp2: 7 p: 0.001	Grp2 B: 202 (111) F: 185 (106) F-B: -17 p: <0.001 Grp1-Grp2: -5	
Ramachandran, 2004 ⁵¹	Grp1: Pioglitazone Varied Start: 15 mg, Max: 30 mg	Grp1 B: 9.3 (1.8) F: 6.7 (1.3) F-B: -2.6 p: <0.01		Grp1 B: 38.22 (5.85) F: 42.9 (7.8) F-B: 4.68 p: <0.01	Grp1 B: 258.1 (213.6) F: 195.8 (124.6) F-B: -62.3 p: <0.05	Grp1 B: 68.9 (9.1) F: 67.8 (7.9) F-B: -1.1
	Grp2: Glimepiride Varied Start: 1 mg, Max: 2 mg	Grp2 B: 10.2 (2.2) F: 7.7 (1.7) F-B: -2.5 p: <0.01 Grp1-Grp2: -0.1		NSG e Grp2 B: 37.05 (11.7) F: 42.9 (7.8) F-B: 5.85 p: NSG e Grp1-Grp2: -1.17	Grp2 B: 195.8 (124.6) F: 151.3 (80.1) F-B: -44.5 p: <0.05 Grp1-Grp2: -17.8	Grp2 B: 65.7 (9.1) F: 67.5 (9.2) F-B: 1.8 p: <0.05 Grp1-Grp2: -2.9

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Tan, 2004 ¹⁰⁶	Grp1: Pioglitazone Varied Start: 30 mg, Max: 45 mg	Grp1 B: 8.4 (0.7) F: 7.9	Grp1 B: 141.18 F: 146.64		Grp1 B: 182.45 F: 150.45	Grp1 B: 88.7 (17.4)
	Grp2: Glibenclamide Varied Start: 1.75 mg, Max: 10.5 mg	F-B: -0.5 p: <0.005 Grp2 B: 8.5 (0.8) F: 8.1 F-B: -0.4 p: <0.005 Grp1-Grp2: -0.1	F-B: 5.46 p: NSG Grp2 B: 135.72 F: 134.55 F-B: -1.17 p: NSG Grp1-Grp2: 6.63		F-B: -32.04 p: <0.05 Grp2 B: 202.03 F: 199.36 F-B: -2.67 p: NSG Grp1-Grp2: -29.37	F: 91.7 F-B: 3 p: <0.001 Grp2 B: 89.1 (16) F: 90.2 F-B: 1.1 p: 0.008 Grp1-Grp2: 1.9 p: 0.002
Tan, 2004 ¹⁰⁶	Grp1: Pioglitazone Varied Start: 15 mg, Max: 45 mg	Grp1 B: 8.54 (0.903) F: 7.76		Grp1 B: 46.02 F: 54.21		
	Grp2: Glimepiride Varied Start: 2 mg, Max: 8 mg	F-B: -0.78 (0.162) p: <0.001 Grp2 B: 8.45 (1.02) F: 7.77 F-B: -0.68 (0.169) p: <0.001 Grp1-Grp2: -0.1 p: 0.638		F-B: 8.19 p: <0.001 Grp2 B: 43.68 F: 44.85 F-B: 1.17 p: NSG Grp1-Grp2: 7.02		
Bakris, 2003 ¹⁰⁴	Grp1: Rosiglitazone Fixed Start: 4 mg bid	Grp1 B: 9.1 (1.68) F: 8.2				
	Grp2: Glyburide Varied Start: NR, Max: 20 mg	F-B: -0.9 (1.38) Grp2 B: 9.5 (1.59) F: 8.6 F-B: -0.9 (1.39) Grp1-Grp2: 0 p: NSG				

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Nakamura, 2000 ¹⁰³	Grp1: Pioglitazone Fixed Start: 30 mg Grp2: Glibenclamide Fixed Start: 5 mg	Grp1 B: 7.7 (1.2) F: 6.8 (1.0) F-B: -0.9 p: <0.05 Grp2 B: 7.8 (1.1) F: 6.9 (1.2) F-B: -0.9 p: <0.05 Grp1-Grp2: 0				
St John Sutton, 2002 ¹⁴⁹	Grp1: Rosiglitazone Fixed Start: 4 mg bid Grp2: Glyburide Varied Start: NR, Max: 20 mg		Grp1 B: 140.2 F: 146.5 F-B: 6.3 to 7.7 Grp2 B: 135.4 F: 126.5 F-B: -8.9 Grp1-Grp2: 15.2	Grp1 F-B: Median: 7.7 p: <0.05 Grp2 NR	Grp1 B: 226.6 F: 223.8 F-B: -2.8 p: NSG Grp2 B: 189.6 F: 175.8 F-B: -13.8 p: NSG Grp1-Grp2: 11	Grp1 B: 86.2 (15.6) F: 91.2 F-B: 5 (CI: 3.7, 6.2) p: <0.05 Grp2 B: 85.1 (13.6) F: 88.5 F-B: 3.4 (CI: 2.7, 4.1) p: <0.05 Grp1-Grp2: 1.6
Thiazolidinedione versus meglitinides						
Nakamura, 2006 ¹⁰⁸	Grp1: Pioglitazone Fixed Mean: 30 mg D: 12 Months Grp2: Nateglinide Fixed Mean: 270 mg D: 12 Months	Grp1 B: 8 (1.4) F: 6.4 (1.2) p:<0.01 F-B: -1.6 Grp2 B: 7.7 (1.2) F: 6.3 (1.3) p:<0.01 F-B: -1.4 Grp1-Grp2: -0.2		Grp1 B: 32 (10) F: 40 (12) p:<0.05 F-B: 8 Grp2 B: 35 (6) F: 36 (6) p:NSG F-B: 1 Grp1-Grp2: 7	Grp1 B: 148 (42) F: 118 (28) p:<0.01 F-B: -30 Grp2 B: 146 (40) F: 148 (36) p: NSG F-B: 2 Grp1-Grp2: -32	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Raskin, 2004 ¹⁰⁹	Grp1: Rosiglitazone Varied Start: 2 mg bid, Max: 4 mg bid Grp2: Repaglinide Varied Start: 0.5 mg tid if HbA1c <8% and 1 mg tid if HbA1c >8%, Max: 4 mg tid	Grp1 B: 9 F: 8.5 F-B: -0.56 (SE: 0.14) Grp2 B: 9.3 F: 9.1 F-B: -0.17 (SE: 0.14) Grp1-Grp2: -0.39	Grp1 B: 125 (23.5) F: 139 (34.3) F-B: 14 Grp2 B: 124 (33.8) F: 123 (32.3) F-B: -1 Grp1-Grp2: 15	Grp1 B: 39.9 (10.6) F: 42.5 (11.3) F-B: 2.6 Grp2 B: 39.2 (10.5) F: 40.5 (11.5) F-B: 1.3 Grp1-Grp2: 1.3	Grp1 B: 245 (211) F: 246 (174) F-B: 1 Grp2 B: 306 (246) F: 284 (211) F-B: -22 Grp1-Grp2: 23	Grp1 F-B: 2.3 Grp2 F-B: 1.6 Grp1-Grp2: 0.7
Jovanovic, 2004 ¹¹⁰	Grp1: Pioglitazone Fixed Start: 30 mg Grp2: Repaglinide Varied Start: 0.5 mg tid if HbA1c <8% and 1 mg tid if HbA1c >8%, Max: 4 mg tid	Grp1 B: 9.1 F: 9.5 F-B: 0.32 (SE: 0.16) Grp2 B: 9 F: 8.9 F-B: -0.18 (SE: 0.17) Grp1-Grp2: 0.5 p: NSG	Grp1 B: 106 (37) F: 116 (42) F-B: 10 Grp2 B: 124 (36) F: 118 (38) F-B: -6 Grp1-Grp2: 16	Grp1 B: 41 (8.8) F: 47.2 (9.4) F-B: 6.2 Grp2 B: 45.4 (12.5) F: 44.6 (11.8) F-B: -0.8 Grp1-Grp2: 7	Grp1 B: 291 (232) F: 200 (99) F-B: -91 Grp2 B: 174 (80) F: 179 (78) F-B: 5 Grp1-Grp2: -96	Grp1 F-B: 2 p: <0.05 Grp2 F-B: 0.3 Grp1-Grp2: 1.7
Sulfonylurea versus DPP-IV inhibitor						
Scott, 2007 ¹¹¹	Grp1: Glipizide Varied, glucose: <160 mg/dl Start: 5 mg, Max: 20 mg D: 6 wks Grp2: Sitagliptin Fixed Start: 100 mg, Max: 100 mg	Grp1 B: 7.82 (0.95) F: 7.11 (0.91) F-B: -0.76 (CI: -0.9, -0.62) Grp2 B: 7.83 (0.95) F: 7.34 (1.01) F-B: -0.54 (CI: -0.68, -0.4) Grp1-Grp2: -0.22	Grp1 B: 115.05 (39.39) F: 114.27 (35.1) F-B: -0.78 Grp2 B: 115.44 (30.42) F: 115.44 (31.2) F-B: 0 Grp1-Grp2: -0.78	Grp1 B: 44.46 (9.75) F: 45.24 (10.92) F-B: 0.78 Grp2 B: 45.24 (10.53) F: 45.63 (11.31) F-B: 0.38 Grp1-Grp2: 0.4	Grp1 B: 171.77 (85.44) F: 174.44 (83.66) F-B: 2.67 Grp2 B: 179.78 (98.79) F: 192.24 (129.94) F-B: 12.46 Grp1-Grp2: -9.79	Grp1 F-B: 0.9 (CI: 0.5, 1.3) Grp2 F-B: no significant weight change

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Scott, 2007 ¹¹¹	Grp1: Glipizide	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied, glucose: <160 mg/dl	B: 7.82 (0.95)	B: 115.05 (39.39)	B: 44.46 (9.75)	B: 171.77 (85.44)	F-B: 0.9 (CI: 0.5, 1.3)
	Start: 5 mg, Max: 20 mg	F: 7.11 (0.91)	F: 114.27 (35.1)	F: 45.24 (10.92)	F: 174.44 (83.66)	Grp2
	D: 6 wks	F-B: -0.76 (CI: -0.9, -0.62)	F-B: -0.78	F-B: 0.78	F-B: 2.67	F-B: no significant weight change
	Grp2: Sitagliptin	Grp2	Grp2	Grp2	Grp2	
	Fixed	B: 7.89 (0.94)	B: 118.95 (31.98)	B: 45.24 (10.53)	B: 177.11 (105.91)	
	Start: 50 mg, Max: 50 mg	F: 7.5 (1.14)	F: 119.73 (32.76)	F: 46.02 (10.14)	F: 164.65 (88.11)	
		F-B: -0.43 (CI: -0.56, -0.29)	F-B: 0.78	F-B: 0.78	F-B: -12.46	
		Grp1-Grp2: -0.33	Grp1-Grp2: -1.56	Grp1-Grp2: 0	Grp1-Grp2: 15.13	
Scott, 2007 ¹¹¹	Grp1: Glipizide	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied, glucose: <160 mg/dl	B: 7.82 (0.95)	B: 115.05 (39.39)	B: 44.46 (9.75)	B: 171.77 (85.44)	F-B: 0.9 (CI: 0.5, 1.3)
	Start: 5 mg, Max: 20 mg	F: 7.11 (0.91)	F: 114.27 (35.1)	F: 45.24 (10.92)	F: 174.44 (83.66)	Grp2
	D: 6 wks	F-B: -0.76 (CI: -0.9, -0.62)	F-B: -0.78	F-B: 0.78	F-B: 2.67	F-B: no significant weight change
	Grp2: Sitagliptin	Grp2	Grp2	Grp2	Grp2	
	Fixed	B: 7.85 (0.88)	B: 115.44 (31.2)	B: 43.68 (9.75)	B: 177.11 (85.44)	
	Start: 25 mg, Max: 25 mg	F: 7.48 (0.98)	F: 115.44 (33.15)	F: 45.24 (10.14)	F: 174.44 (83.66)	
		F-B: -0.41 (CI: -0.55, -0.27)	F-B: 0	F-B: 1.56	F-B: -2.67	
		Grp1-Grp2: -0.35	Grp1-Grp2: -0.78	Grp1-Grp2: -0.78	Grp1-Grp2: 5.34	
Scott, 2007 ¹¹¹	Grp1: Glipizide	Grp1	Grp1	Grp1	Grp1	Grp1
	Varied, glucose: <160mg/dl	B: 7.82 (0.95)	B: 115.05 (39.39)	B: 44.46 (9.75)	B: 171.77 (85.44)	F-B: 0.9 (CI: 0.5, 1.3)
	Start: 5mg, Max: 20mg	F: 7.11 (0.91)	F: 114.27 (35.1)	F: 45.24 (10.92)	F: 174.44 (83.66)	Grp2
	D: 6 wks	F-B: -0.76 (CI: -0.9, -0.62)	F-B: -0.78	F-B: 0.78	F-B: 2.67	F-B: no significant weight change
	Grp2: Sitagliptin	Grp2	Grp2	Grp2	Grp2	
	Fixed	B: 7.89 (0.94)	B: 117 (38.22)	B: 45.24 (8.97)	B: 161.09 (88.11)	
	Start: 10, Max: 10	F: 7.77 (1.22)	F: 119.73 (37.83)	F: 46.8 (9.36)	F: 161.09 (88.11)	
		F-B: -0.15 (CI: -0.29, -0.01)	F-B: 2.73	F-B: 1.56	F-B: 0	
		Grp1-Grp2: -0.61	Grp1-Grp2: -3.51	Grp1-Grp2: -0.78	Grp1-Grp2: 2.67	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Sulfonylurea versus meglitinides						
Nakamura, 2006 ¹⁰⁸	Grp1: Glibenclamide Fixed Mean: 5 mg D: 12 Months Grp2: Nateglinide Fixed Mean: 270 mg D: 12 Months	Grp1 B: 7.8 (1.3) F: 7 (6.2) p:<0.01 F-B: -0.8 Grp2 B: 7.7 (1.2) F: 6.3 (1.3) p:<0.01 F-B: -1.4 Grp1-Grp2: 0.6		Grp1 B: 34 (8) F: 34 (10) p:NSG F-B: 0 Grp2 B: 35 (6) F: 36 (6) p:NSG F-B: 1 Grp1-Grp2: -1	Grp1 B: 144 (38) F: 146 (38) p: NSG F-B: 2 Grp2 B: 146 (40) F: 148 (36) p: NSG F-B: 2 Grp1-Grp2: 0	
Jibran, 2006 ¹¹²	Grp1: Glibenclamide Varied, glucose: fasting < 130 mg/dl, PP < 175 mg/dl Start: 5 mg, Max: 15 mg, Mean: 8.8 mg Grp2: Repaglinide Varied, glucose: fasting < 130 mg/dl, PP < 175 mg/dl Start: 0.5 mg tid, Max: 1.5 mg tid, Mean: 4.27 mg/day	Grp1 B: 10.2 (1.6) F: 9.4 (1.5) F-B: -0.7 (0.5) Grp2 B: 9.9 (1.6) F: 8.8 (1.7) F-B: -1.1 (0.3) Grp1-Grp2: 0.3 p: 0.001				Grp1 B: 72.7 (17.4) F: 71.7 (15.2) F-B: -1 Grp2 B: 65.8 (9.4) F: 66 (8.8) F-B: 0.2 Grp1-Grp2: -1.2
Derosa, 2003 ¹¹³	Grp1: Glimpiride Varied Start: 1 mg, Mean: 3 mg Grp2: Repaglinide Varied Start: 1 mg, Mean: 2.5 mg	Grp1 B: 7.8 (1.2) F: 6.7 (0.9) F-B: -1.1 (CI: -5.6, -0.54) p: <0.01 Grp2 B: 8 (1.1) F: 6.8 (0.8) F-B: -1.2 (CI: -6.2, -0.48) p: <0.01 Grp1-Grp2: 0.1 p: NSG	Grp1 B: 142 (24) F: 136 (25) F-B: -6 Grp2 B: 139 (22) F: 132 (18) F-B: -7 Grp1-Grp2: 1 p: NSG	Grp1 B: 44 (5) F: 43 (6) F-B: -1 Grp2 B: 43 (7) F: 45 (7) F-B: 2 Grp1-Grp2: -3 p: NSG	Grp1 B: 170 (36) F: 155 (39) F-B: -15 Grp2 B: 153 (32) F: 135 (36) F-B: -18 Grp1-Grp2: 3 p: NSG	Grp1 B: 77.1 (5.9) F: 76.6 (5.3) F-B: -0.5 Grp2 B: 76.4 (5.2) F: 76.5 (5.3) F-B: 0.1 Grp1-Grp2: -0.6 p: NSG

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Madsbad, 2001 ¹¹⁴	Grp1: Glipizide Varied Start: 5 mg, Max: 15 mg Grp2: Repaglinide Varied Start: 0.5 mg, Max: 4 mg	Grp1 B: 7.2 (1.4) F: 7.7 (SE: 0.2) F-B: 0.78 (CI: 0.46, 1.1) Grp2 B: 7.3 (1.2) F: 7.4 (SE: 0.15) F-B: 0.19 (-0.02, 0.4) Grp1-Grp2: 0.59 p: <0.05		Grp1 F-B: 0.78 p: NSG Grp2 F-B: 0 p: NSG Grp1-Grp2: 1.17 (1.56 to 3.5)	Grp1 F-B: 3.56 (-23.14 to 29.37) Grp2 F-B: 3.56 (-14.24 to 20.47) Grp1-Grp2: 0 (-31.15 to 31.15) p: NSG	
Landgraf, 1999 ¹¹⁵	Grp1: Glibenclamide Varied Start: 1.75 mg, 3.5 mg, 7.0 mg, 10.5 mg, Max: 10.5 mg Grp2: Repaglinide Varied Start: 0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg tid, Max: 4 mg tid	Grp1 B: 8 F: 7.6 (SE: 0.1) F-B: -0.4 Grp2 B: 7.8 F: 7.5 (SE: 0.1) F-B: -0.3 Grp1-Grp2: -0.1		Grp1 F-B: 1.11 (SE: 0.03) Grp2 F-B: 1.15 (SE: 0.03) Grp1-Grp2: -0.04 p: 0.005		Grp1 B: 78.9 (12.8) F: 77.5 F-B: -1.4 p: NSG Grp2 B: 79.6 (10.3) F: 78.9 F-B: -0.7 p: NSG Grp1-Grp2: -0.7 p: NSG

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Wolffenbittel, 1999 ¹¹⁶	Grp1: Glyburide Varied Start: 1.75 mg, Max: 10.5 mg Grp2: Repaglinide Varied Start: 1.5 mg, Max: 12 mg	Grp1 B: 7 (1.2) F: 7.45 F-B: 0.45 (CI: 0.22, 0.69) Grp2 B: 7.1 (1.4) F: 7.68 F-B: 0.58 (CI: 0.41, 0.7) Grp1-Grp2: -0.13 p: NSG		Grp1 B: 45.63 (12.48) F: 45.63 (12.48) F-B: 0 p: NSG Grp2 B: 44.85 (14.82) F: 46.02 (14.43) F-B: 1.17 p: NSG Grp1-Grp2: -1.17	Grp1 B: 163.76 F: 174.44 F-B: 10.68 p: NSG Grp2 B: 170.88 F: 178 F-B: 7.12 p: NSG Grp1-Grp2: 3.56	Grp1 B: 81.3 (12.2) F: 82 (11.9) F-B: 0.7 p: NSG Grp2 B: 81.5 (13.4) F: 81.5 (13.5) F-B: 0 p: NSG Grp1-Grp2: 0.7
Wolffenbittel, 1993 ¹¹⁸	Grp1: Glyburide Varied Start: 5 mg, Max: 15 mg Grp2: Repaglinide Varied Start: 0.5 mg, Max: 4 mg	Grp1 B: 8.7 (1.8) F: 8.5 (2.0) F-B: -0.2 Grp2 B: 9 (1.9) F: 8.8 (2.0) F-B: -0.2 Grp1-Grp2: 0				Grp1 B: 70.9 (10.8) F: 70.5 (10.2) F-B: -0.4 p: NSG Grp2 B: 74 (9.6) F: 72.3 (9.4) F-B: -1.7 p: <0.05 Grp1-Grp2: 1.3
Marbury, 1999 ¹¹⁷	Grp1: Glyburide Varied Start: 2.5 mg, Max: 15 mg Grp2: Repaglinide Varied Start: 0.5 mg, Max: 12 mg	Grp1 B: 8.9 (1.6) F: 9.0 F-B: 0.1 (0.11) Grp2 B: 8.7 (1.7) F: 8.78 F-B: 0.08 (0.07) Grp1-Grp2: -0.02	Grp1 F-B: -6.51 Grp2 F-B: -5.03 Grp1-Grp2: -1.48 (CI: -6.499, 3.532) p: NSG	Grp1 F-B: -0.13 p: NSG Grp2 F-B: -0.81 p: NSG e Grp1-Grp2: 0.68 (CI: -0.8, 2.15)	Grp1 F-B: -6.45 Grp2 F-B: 6.57 Grp1-Grp2: -13.02 (CI: -31.24, 57.28) p: NSG	Grp1 F-B: 0.05 (SE: 0.5) Grp2 F-B: -0.22 (SE: 0.5) Grp1-Grp2: 0.27 p: NSG

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Vakkilainen, 2002 ¹¹⁹	Grp1: Glibenclamide Varied Start: 5 mg, Max: 10 mg Grp2: Nateglinide Fixed Start: 120 mg tid	Grp1 B: 7.6 (7.2 to 8.1) F: 6.9 (6.5 to 7.3) F-B: -0.7 p: <0.001 Grp2 B: 7.6 (7.2 to 8.0) F: 7.4 (7.0 to 7.9) F-B: -0.2 Grp1-Grp2: -0.5 p: NSG	Grp1 F-B: p: NSG Grp2 F-B: p: NSG	Grp1 F-B: p: NSG Grp2 F-B: p: NSG	Grp1 F-B: p: NSG Grp2 F-B: p: NSG	
Sulfonylurea versus GLP-1 agonist						
Seino, 2010 ¹²¹	Grp1: Glibenclamide Varied, prespecified target dose Start: 1.25 mg, Max: 2.5 mg D: 4 Weeks Grp2: Liraglutide Varied, prespecified target dose Start: 0.3 mg, Max: 0.9 mg D: 2 Weeks	Grp1 F-B: -1.88 (SE: 0.07) p: <0.0001 Grp2 F-B: -1.38 (SE: 0.09) p: <0.0001 Grp1-Grp2: 0.5 (CI: 0.3, 0.7) p<0.0001	Grp1-Grp2: 0.07 (CI: -0.04, 0.17) p: 0.2107	Grp1-Grp2: 0.01 (CI: -0.03, 0.05) p: 0.529	Grp1-Grp2: 0.05 (CI: -0.11, 0.21) p: 0.5434	Grp1 F-B: -0.92 (2.15) p: p<0.0001 Grp2 F-B: 0.99 (1.84) p: p<0.0001 Grp1-Grp2: 1.91 (CI: 1.48, 2.34) p: <0.0001
Garber, 2009 ¹²²	Grp1: Glimepiride Varied, prespecified target dose Start: 2 mg, Max: 8 mg D: 2 Weeks Grp2: Liraglutide Varied, prespecified target dose Start: 0.6 mg, Max: 1.2 mg D: 2 Weeks	Grp1 F-B: 0.51 (SD: 1.2) Grp2 F-B: 0.84 (SD: 1.23) Grp1-Grp2: 0.62 (CI: 0.42, 0.83) p<0.0001				Grp1 F-B: 1 (0.5) Grp2 F-B: -2 (0.5) Grp1-Grp2: 3
Garber, 2009 ¹²²	Grp1: Glimepiride Varied, prespecified target dose Start: 2 mg, Max: 8 mg D: 2 Weeks Grp2: Liraglutide Varied, prespecified target dose Start: 0.6 mg, Max: 1.8 mg D: 2 Weeks	Grp1 F-B: 0.51 (SD: 1.2) Grp2 F-B: 1.14 (SD: 1.24) Grp1-Grp2: 0.33 (CI: 0.13, 0.53) p: 0.0014				Grp1 F-B: 1 (0.5) Grp2 F-B: -2.5 (0.5) Grp1-Grp2: 3.5

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Madsbad, 2004 ¹²⁰	Grp1: Glimepiride Varied, fasting glucose < 7mmol/L Start: 1 mg, Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.75 mg	Grp1 F-B: -0.74 p: 0.0001 Grp2 F-B: -0.75 p: <0.0001 Grp1-Grp2: 0.01				Grp1 F-B: 0.94 p: 0.0622 Grp2 F-B: -0.74 p: 0.1544 Grp1-Grp2: 1.68
Madsbad, 2004 ¹²⁰	Grp1: Glimepiride Varied, fasting glucose < 7mmol/L Start: 1 mg, Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.045 mg	Grp1 F-B: -0.74 p: 0.0001 Grp2 F-B: 0.25 p: 0.1905 Grp1-Grp2: -0.49				Grp1 F-B: 0.94 p: 0.0622 Grp2 F-B: -0.03 p: 0.9602 Grp1-Grp2: 0.97
Madsbad, 2004 ¹²⁰	Grp1: Glimepiride Varied, fasting glucose < 7mmol/L Start: 1 mg, Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.225 mg	Grp1 F-B: -0.74 p: 0.0001 Grp2 F-B: -0.34 p: 0.0877 Grp1-Grp2: -0.4				Grp1 F-B: 0.94 p: 0.0622 Grp2 F-B: -1.2 p: 0.0184 Grp1-Grp2: 2.14
Madsbad, 2004 ¹²⁰	Grp1: Glimepiride Varied, fasting glucose < 7mmol/L Start: 1 mg, Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.45 mg	Grp1 F-B: -0.74 p: 0.0001 Grp2 F-B: -0.3 p: 0.1131 Grp1-Grp2: -0.44				Grp1 F-B: 0.94 p: 0.0622 Grp2 F-B: 0.27 p: 0.5838 Grp1-Grp2: 0.67
Madsbad, 2004 ¹²⁰	Grp1: Glimepiride Varied, fasting glucose < 7mmol/L Start: 1 mg, Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.60 mg	Grp1 F-B: -0.74 p: 0.0001 Grp2 F-B: -0.7 p: 0.0002 Grp1-Grp2: -0.04				Grp1 F-B: 0.94 p: 0.0622 Grp2 F-B: -0.39 p: 0.4391 Grp1-Grp2: 1.33

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Metformin + thiazolidinedione versus metformin + sulfonylurea						
Home, 2009 ¹⁶	Grp1: Metformin + rosiglitazone Varied, HbA1c: <=7.0% Max: 2550 mg; Start: 4 mg, Max: 8 mg D: 8 wks; NR Grp2: Metformin + sulfonylurea Varied, HbA1c: <=7.0% Max: 2550 mg; Unclear D: 8 wks	Grp1 F-B: -0.28 (SE: 0.03) Grp2 F-B: 0.01 (SE: 0.04) Grp1-Grp2: -0.29 (SE: 0.05) p: <0.0001	Grp1 F-B: -12.87 (SE: 1.56) Grp2 F-B: -20.67 (SE: 1.17) Grp1-Grp2: 7.8 (SE: 1.95)	Grp1 F-B: 4.68 (SE: 0.39) Grp2 F-B: 2.73 (SE: 0.39) Grp1-Grp2: 1.95 (SE: 0.55)	Grp1 F-B: -0.14 (SE: 0.04) Grp2 F-B: -0.14 (SE: 0.04) Grp1-Grp2: 0	Grp1 F-B: 3.8 (SE: 0.24) Grp2 F-B: 0 (SE: 0.2) and -1.5 (SE: 0.2) Grp1-Grp2: 3.8
Derosa, 2009 ⁴⁶	Grp1: Metformin + Pioglitazone Varied, prespecified target dose Start: 850 mg, Max: 2550 mg; Start: 15 mg, Max: 45 mg D: 3 mos Grp2: Metformin + glimepiride Fixed; Varied, prespecified target dose Start: 850 mg, Max: 850 mg; Start: 2 mg, Max: 6 mg D: NA; 3 mos	Grp1 B: 9.3 (1.4) F: 7.2 (0.3) p: >0.001 F-B: -2.1 (0.3) p: <0.01 Grp2 B: 9 (1.1) F: 7.8 (0.4) p: <0.01 F-B: -1.2 (0.4) p: <0.01 Grp1-Grp2: -0.9 (SE: 0.25)	Grp1 B: 111.15 (CV: 33.29) F: 116.22 (CV: 35.93) F-B: 5.07 Grp2 B: 114.27 (CV: 37.68) F: 108.03(CV: 37.3) F-B: -6.24 Grp1-Grp2: 11.31 (SE: 7.22)	Grp1 B: 46.8 (CV: 23.99) F: 51.48 (CV: 30.1) F-B: 4.68 Grp2 B: 46.41 (CV: 21.6) F: 47.58 (CV: 21.76) F-B: 1.17 Grp1-Grp2: 3.51 (SE: 2.02)	Grp1 B: 189.57 (CV: 56.4) F: 171.77 (CV: 65.97) F-B: -17.8 Grp2 B: 180.67 (CV: 47.72) F: 157.53 (CV: 42.82) F-B: -23.14 Grp1-Grp2: 5.34	Grp1 F-B: 2.7 (SE: 0.3) Grp2 F-B: 1.6 (SE: 0.3) Grp1-Grp2: 1.1 p: 0.0016
Hamann, 2008 ¹²³	Grp1: Metformin + rosiglitazone Varied, glucose: 6.1 mmol/l Max: 2 g; Unclear D: 12 wks Grp2: Metformin + sulfonylurea Varied, glucose: 6.1 mmol/l Max: 2 g; Unclear D: 12 wks	Grp1 F-B: -0.78 (SE: 0.06) Grp2 F-B: -0.86 (SE: 0.06) Grp1-Grp2: 0.09 (CI: -0.08, 0.25)	Grp1 B: 111.15 (CV: 33.29) F: 116.22 (CV: 35.93) F-B: 5.07 Grp2 B: 114.27 (CV: 37.68) F: 108.03(CV: 37.3) F-B: -6.24 Grp1-Grp2: 11.31 (SE: 7.22)	Grp1 B: 46.8 (CV: 23.99) F: 51.48 (CV: 30.1) F-B: 4.68 Grp2 B: 46.41 (CV: 21.6) F: 47.58 (CV: 21.76) F-B: 1.17 Grp1-Grp2: 3.51 (SE: 2.02)	Grp1 B: 189.57 (CV: 56.4) F: 171.77 (CV: 65.97) F-B: -17.8 Grp2 B: 180.67 (CV: 47.72) F: 157.53 (CV: 42.82) F-B: -23.14 Grp1-Grp2: 5.34	Grp1 F-B: 2.7 (SE: 0.3) Grp2 F-B: 1.6 (SE: 0.3) Grp1-Grp2: 1.1 p: 0.0016

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Comaschi, 2007 ¹²⁹	Grp1: Metformin + pioglitazone Varied Max: 3 g; Start: 15 mg, Max: 30 mg D: NR; 22 wks Grp2: Metformin + sulfonyleurea Varied, HbA1c: 7.50% Start: 400 mg, Max: 3 g; Start: 2.5 mg D: 22 wks	Grp1 F-B: -0.99 p: <0.001 Grp2 F-B: -1.29 p: 0.192 Grp1-Grp2: 0.31 p: 0.054				
Comaschi, 2008 ¹⁵⁸	Grp1: Metformin + pioglitazone Varied Max: 3 g; Start: 15 mg, Max: 30 mg D: NR; 22 wks Grp2: Metformin + sulfonyleurea Varied, HbA1c: 7.50%; Fixed Start: 400 mg; Start: 2.5 mg D: 22 wks			Grp1 B: 42.51 (SE: 12.09) F: 44.85 (SE: 10.92) F-B: 2.34 p: 0.009 Grp2 B: 45.63 (SE: 13.26) F: 42.12 (SE: 12.87) p: <0.001 F-B: -3.51 p: <0.001 Grp1-Grp2: 5.85 p: <0.001	Grp1 B: 189.57 (SE: 97.9) F: 171.77 (SE: 101.46) F-B: -17.8 p: 0.067 Grp2 B: 178.89 (SE: 114.81) F: 181.56 (SE: 120.15) F-B: 2.67 p: 0.733 Grp1-Grp2: 2.67	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Home, 2007 ¹²⁴	Grp1: Metformin + rosiglitazone Varied, HbA1c: <=7% Max: 2550 mg; Start: 4 mg, Max: 8 mg	Grp1 F-B: -0.48 (CI: -0.59, -0.36)	Grp1 F-B: 1.56 (CI: -2.73, 5.85)	Grp1 F-B: 3.12 (CI: 1.95, 4.29)	Grp1 F-B: 35.6	Grp1 F-B: 2.3 (CI: 1.7, 2.9)
	Grp2: Metformin + sulfonylurea Varied, HbA1c: <=7.0% Max: 2550 mg; Unclear D: 8 wks; NR	Grp2 F-B: -0.55 (CI: -0.66, -0.44) Grp1-Grp2: 0.07 (CI: -0.09, 0.23)	Grp2 F-B: -10.14 (CI: -14.04, -6.24) Grp1-Grp2: 11.7 (SE: 2.89) p: 0.01	Grp2 F-B: 0.78 (CI: -0.39, 1.94) Grp1-Grp2: 2.34 (SE: 0.99) p: 0.016	Grp2 F-B: 13.35 Grp1-Grp2: 23.14	Grp2 F-B: 1.1 (CI: 0.6, 1.6) (cohort1), -0.9 (CI: -1.4, -0.4) (cohort2) Grp1-Grp2 (cohort 1): 1.2 (CI: 0.4, 2) p: 0.003; Grp1-Grp2 (cohort 2): 4.3 (CI: 3.6, 5.1) p: <0.001
Bakris, 2006 ¹²⁵	Grp1: Metformin + rosiglitazone Varied; Varied, glucose: <=6.6 mmol/L Unclear; Start: 4 mg D: 3 wks Grp2: Metformin + glyburide Varied; Glucose: <=6.6 mmol/L Unclear; Start: 5 mg D: 3 wks; NR	Grp1 F-B: 0.72 (SE: 0.1) Grp2 F-B: 0.92 (SE: 0.08) Grp1-Grp2: -0.2 (SE: 0.12)				Grp1 F-B: 1.94 (4.63) Grp2 F-B: 1.5 (3.53) Grp1-Grp2: 0.44
Umpierrez, 2006 ¹²⁶	Grp1: Metformin + pioglitazone NR; Varied, glucose: <120 mg/dL, HbA1c: <8.0% Start: 1.54 g, Max: 1.57g; Start: 30 mg, Max: 45 mg D: NR; Unclear Grp2: Metformin + glimepiride NR; Glucose: <120 mg/dL Start: 1.47 g, Max: 1.49 g; Start: 2 mg, Max: 8 mg D: NR; 6 wks	Grp1 F-B: -1.23 (SE: 0.073) p: 0.4825 Grp2 F-B: -1.3 (SE: 0.077) Grp1-Grp2: 0.07 (SE: 0.11)	Grp1 F-B: 8.5 (SE: 2.81) Grp2 F-B: -0.1 (SE: 2.87) Grp1-Grp2: 8.5 (SE: 4.01) p: 0.0001	Grp1 F-B: 4.8 (SE: 0.66) Grp2 F-B: -0.6 (SE: 0.7) p: 0.0001 Grp1-Grp2: 10 (SE: 9.53) p: 0.2953	Grp1 F-B: -14.2 (SE: 6.57) Grp2 F-B: -4.2 (SE: 7.06) p: 0.2953 Grp1-Grp2: -10 (SE: 9.6)	Grp1 F-B: 1.85 (SE: 0.38) Grp2 F-B: 1.74 (SE: 0.41) Grp1-Grp2: 0.11

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Derosa, 2005 ¹²⁷	Grp1: Metformin + rosiglitazone Fixed Start: 500 mg tid, Max: 500 mg tid; Start: 4 mg, Max: 4 mg Grp2: Metformin + glimepiride Fixed Start: 500 mg tid, Max: 500 mg tid; Start: 2 mg, Max: 2 mg	Grp1 B: 8 (0.7) F: 6.8 (0.6) p: <0.01 F-B: -1.2 Grp2 B: 7.9 (0.6) F: 7 (0.7) p: <0.05 F-B: -0.9 Grp1-Grp2: -0.3 (SE: 0.23)				
Derosa, 2005 ¹⁵¹	Grp1: Metformin + rosiglitazone Fixed Start: 500 mg tid; Start: 2 mg Grp2: Metformin + glimepiride Fixed Start: 500mg tid; Start: 4mg qday					Grp1 B: 74.2 (3.6) F: 68.3 (3) p: <0.01 F-B: -5.9 Grp2 B: 75.6 (4.2) F: 71.1 (3.2) p: <0.05 F-B: -4.5 Grp1-Grp2: -1.4
Derosa, 2006 ¹⁵⁷	Grp1: Metformin + rosiglitazone Fixed Start: 500 mg tid, Max: 500 mg tid; Start: 4 mg, Max: 4 mg Grp2: Metformin + glimepiride Fixed Start: 500 mg tid, Max: 500 mg tid; Start: 2 mg qday, Max: 2 mg qday		Grp1 B: 116 (15) F: 120 (17) F-B: 4 Grp2 B: 118 (13) F: 102 (11) F-B: -16 p: <0.05 Grp1-Grp2: 20 p: <0.05	Grp1 B: 42 (4) F: 44 (3) F-B: 2 Grp2 B: 43 (5) F: 43 (4) F-B: 0 Grp1-Grp2: 2 p: NSG		

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Garber, 2006 ¹²⁸	Grp1: Metformin + rosiglitazone Varied Start: 1500-2000 mg, Max: 2000 mg; Start: 4 mg, Max: 8 mg		Grp1 B: 116 F: 125 F-B: 9 (35)	Grp1 B: 45 F: 48 F-B: 3 (10)	Grp1 B: 218 F: 238 F-B: 21 (113)	Grp1 B: 94 F: 95.4 F-B: 1.4
	Grp2: Metformin + glibenclamide Varied Start: 1000 mg, Max: 2000 mg; Start: 5 mg, Max: 10 mg		Grp2 B: 119 F: 115 F-B: -4 (26) Grp1-Grp2: -14 (CI: -6, 22) p: NSG	Grp2 B: 47 F: 45 F-B: -2 (10) Grp1-Grp2: 4 (CI: 1, 7) p: <0.05	Grp2 B: 226 F: 238 F-B: 12 (133) Grp1-Grp2: 9 (CI: -22, 40) p: NSG	Grp2 B: 92 F: 95 F-B: 3 Grp1-Grp2: -1.5 p: <0.001
Derosa, 2005 ¹⁵⁹	Grp1: Metformin + rosiglitazone Fixed Start: 1500 mg; Start: 4 mg Grp2: Metformin + glimepiride Fixed Start: 1500 mg, Start: 2 mg				Grp1 B: 186 (28) F: 129 (18) F-B: -57 Grp2 B: 178 (23) F: 137 (20) F-B: -41 Grp1-Grp2: -16 p: NSG	
Metformin + thiazolidinedione versus metformin + meglitinides						
Raskin, 2009 ¹³¹	Grp1: Metformin + rosiglitazone Varied, prespecified target dose; Varied Start: 1000 mg, Max: 2500 mg; Start: 4 mg, Max: 8 mg D: 4 wks Grp2: Metformin + repaglinide Varied Start: 1000 mg, Max: 2500 mg; Start: 4 mg, Max: 10 mg D: 4 wks	Grp1-Grp2: -0.21 (CI: -0.452, 0.031)	Grp1 B: 111.9 (SE: 2.88) F: 121.2 (SE: 3.51) F-B: 9.576 p:0.0008 Grp2 B: 108.2 (SE: 2.87) F: 104.6 (SE: 2.89) F-B: -2.604 p: 0.4637 Grp1-Grp2: 12.9	Grp1 B: 44.8 (SE: 0.85) F: 49.4 (SE: 1.05) F-B: 4.479 p: <0.0001 Grp2 B: 44.3 (SE: 0.91) F: 44.2 (SE: 1.05) F-B: -0.151 p: NSG Grp1-Grp2: 4.63 p: <0.001	Grp1 B: 208.8 (SE: 21.88) F: 208.2 (SE: 16.20) F-B: -0.6 p: 0.9493 Grp2 B: 190.3 (SE: 10.77) F: 194.9 (SE: 10.66) F-B: 4.6 p: 0.8607 Grp1-Grp2: -5.2 p: 0.6007	Grp1-Grp2: not clinically relevant

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Metformin + thiazolidinedione versus metformin + DPP-IV inhibitor						
Scott, 2008 ⁸⁵	Grp1: Metformin + rosiglitazone NR; Fixed Start: >=1500 mg; Mean: 8 mg D: 10 wks; NA Grp2: Metformin + sitagliptin Fixed Start: > 1500 mg; Start: 100 mg, Mean: 100 mg	Grp1-Grp2: -0.06 (CI: -0.25, 0.14)	Grp1 B: 99.2 (29.4) F: 119.6 (37.6) F-B: Mean % change: 26.2 (CI: 19.7, 32.7) Grp2 B: 95.4 (30.8) F: 104.6 (35.1) F-B: Mean % change: 11.4 (CI: 5, 17.8) Grp1-Grp2: 11.2 (SE: 8.8)	Grp1 B: 42.2 (10) F: 45.7 (10.5) F-B: Mean % change: 9.2 (CI: 6.1, 12.2) Grp2 B: 43.9 (11.6) F: 45.7 (13.4) F-B: Mean % change: 4.3 (CI: 1.2, 7.3) Grp1-Grp2: 1.7 (SE: 3.03)	Grp1 B: 201.6 (126.2) F: 199.8 (108.4) F-B: Mean % change: 13.1 (CI: 5.2, 21.1) Grp2 B: 177.8 (80.7) F: 163.3 (74) F-B: Mean % change: -4.8 (CI: -12.7, 3.1) Grp1-Grp2: 12.7	Grp1 F-B: 1.5 (CI: 1, 1.9) Grp2 F-B: -0.4 (CI: -0.8, 0) Grp1-Grp2: 1.9 (CI: 1.3, 2.5)
Rigby, 2009 ¹³⁰	Grp1: Metformin + rosiglitazone Fixed Mean: 4 mg Grp2: Metformin + sitagliptin Fixed Mean: 100 mg	Grp1 B: 8.09 F: 7.53 F-B: -0.6 (CI: -0.83, -0.32) p: <0.0001 Grp2 B: 8.19 F: 7.79 F-B: -0.4 (CI: -0.64, -0.13) p: 0.0087 Grp1-Grp2: -0.2				Grp1 F-B: 0.26 p: 0.5935 Grp2 F-B: -1.15 p: 0.0008 Grp1-Grp2: 1.41
Metformin + thiazolidinedione versus metformin + GLP-1 agonist						
Defronzo, 2010 ¹³²	Grp1: Metformin + rosiglitazone Varied NR; Start: 4 mg, Max: 8 mg D: NR Grp2: Metformin + exenatide Varied Start: 0.010 mg, Max: 0.02 mg D: NR	Grp1 F-B: -1 (SD: 0.1) p: <0.05 Grp2 F-B: -0.9 (SD: 0.1) p: <0.05 Grp1-Grp2: -0.1 p: 0.72	Grp1 F-B: 12.87 (3.9) p: <0.05 Grp2 F-B: -1.95 (3.9) p: >0.05 Grp1-Grp2: 14.82 p: 0.008	Grp1 F-B: 2.34 (1.17) p: >0.05 Grp2 F-B: 0.78 (1.17) p: >0.05 Grp1-Grp2: 1.56 p: 0.445	Grp1 F-B: 2.73 (6.63) p: >0.05 Grp2 F-B: -13.26 (6.63) p: <0.05 Grp1-Grp2: 15.99 p: 0.079	Grp1 F-B: 1.5 (0.5) p: <0.05 Grp2 F-B: -2.8 (0.5) p: <0.05 Grp1-Grp2: 4.3 p: <0.001

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Metformin + thiazolidinedione versus thiazolidinedione + sulfonylurea						
Home, 2009 ¹⁶	Grp1: Metformin + rosiglitazone Varied, HbA1c: <=7.0% Max: 2550 mg; Start: 4 mg, Max: 8 mg D: 8 wks; NR Grp2: Rosiglitazone + sulfonylurea Varied, HbA1c: <=7.0% Start: 4 mg, Max: 8 mg; NR D: Unclear; NR	Grp1 F-B: -0.28 (SE: 0.03) Grp2 F-B: -0.44 (SE: 0.03) Grp1-Grp2: 0.16 (SE: 0.04) p: <0.0001	Grp1 F-B: -12.87 (SE: 1.56) Grp2 F-B: -8.58 (SE: 1.56) Grp1-Grp2: -4.29 (SE: 2.21)	Grp1 F-B: 4.68 (SE: 0.39) Grp2 F-B: 4.29 (SE: 0.39) Grp1-Grp2: 0.39 (0.55)	Grp1 F-B: -0.14 (SE: 0.04) Grp2 F-B: -0.13 (SE: 0.04) Grp1-Grp2: -0.01 p: 0.82	Grp1 F-B: 3.8 (SE: 0.24) Grp2 F-B: 4.1 (SE: 0.2) Grp1-Grp2: -0.3
Comaschi, 2008 ¹⁵⁸	Grp1: Metformin + pioglitazone Varied, HbA1c: NR Max: 3 g; Start: 15 mg, Max: 30 mg Grp2: Pioglitazone + sulfonylurea Varied, HbA1c: <=7.5% Start: 15 mg, Max: 30 mg; NR D: 22wks		Grp1-Grp2: p: 0.28	Grp1 B: 42.51 (SE: 12.09) F: 44.85 (SE: 10.92) F-B: 2.34 p: 0.009 Grp2 B: 41.73 (SE: 12.87) F: 42.51 (SE: 13.26) F-B: 0.39 p: 0.617 Grp1-Grp2: 1.95	Grp1 B: 189.57 (SE: 97.9) F: 171.77 (SE: 101.46) F-B: -17.8 p: 0.067 Grp2 B: 186.01 (SE: 120.15) F: 157.53 (SE: 83.66) F-B: -28.48 p: 0.017 Grp1-Grp2: 10.68 p: <0.05	
Comaschi, 2007 ¹²⁹	Grp1: Metformin + pioglitazone Varied Max: 3 g; Start: 15 mg, Max: 30 mg D: NR; 22 wks Grp2: Pioglitazone + sulfonylurea Varied, HbA1c: 7.50%; Varied, NR Start: 15 mg, Max: 30 mg; Unclear D: 22 wks; NR	Grp1 F-B: -0.99 p: <0.001 Grp2 F-B: -1.29 p: <0.001 Grp1-Grp2: 0.3 p: 0.043				

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Home, 2007 ¹²⁴	Grp1: Metformin + rosiglitazone Varied, HbA1c: <=7% Max: 2550 mg; Start: 4 mg, Max: 8 mg	Grp1 F-B: -0.48 (CI: -0.59, -0.36)	Grp1 F-B: 1.56 (CI: -2.73, 5.85)	Grp1 F-B: 3.12 (CI: 1.95, 4.29)	Grp1 F-B: 35.6 (CI: 22.25, 48.95)	Grp1 F-B: 2.3 (CI: 1.7, 2.9)
	Grp2: Rosiglitazone + sulfonylurea Varied, HbA1c: <=7.0% Start: 4 mg, Max: 8 mg; Unclear D: 8 wks	Grp2 F-B: -0.55 (CI: -0.67, -0.44) Grp1-Grp2: 0.06 (CI: -0.09, 0.2)	Grp2 F-B: 7.41 (CI: 3.12, 11.7) Grp1-Grp2: -18.72 (CI: -24.96, -12.48)	Grp2 F-B: 3.9 (CI: 2.73, 5.07) Grp1-Grp2: -0.78	Grp2 F-B: 21.36 (CI: 5.34, 37.38) Grp1-Grp2: 5.34 (CI: -17.8, 28.48)	Grp2 F-B: 3.4 (CI: 2.9, 4) Grp1-Grp2: -1.1
Metformin + sulfonylurea versus metformin + meglitinides						
Dimic, 2009 ¹⁹⁹	Grp1: Metformin + glimepiride Fixed	Grp1 F-B: -1.04 p: <0.001	Grp1 F-B: -0.55 p: <0.05	Grp1 F-B: 0.01 p:>0.05	Grp1 F-B: -0.4 p:>0.05	
	Grp2: Metformin + repaglinide Fixed Mean: 2000 mg; Mean: 6 mg daily	Grp2 F-B: -1.54 p: <0.001 Grp1-Grp2: 0.5	Grp2 F-B: -0.66 p: <0.05 Grp1-Grp2: 0.11	Grp2 F-B: -0.66 p:<0.05 Grp1-Grp2: 0.67	Grp2 F-B: -0.66 p:<0.05 Grp1-Grp2: 0.26	
Derosa, 2009 ¹³⁵	Grp1: Metformin + glibenclamide Fixed Start: 1500 mg, Max: 3000 mg, Mean: 2500 mg; Start: 7.5 mg, Max: 15 mg, Mean: 12.5 mg D: 6 mos	Grp1 B: 8.2 (1.1) F: 7.3 (0.6) F-B: -0.9 p: <0.05	Grp1 B: Median: 119 (12) F: Median: 104 (10)	Grp1 B: Median: 42 (5) F: Median: 41 (4)	Grp1 B: 161 (42) F: 140 (31) p: NSG F-B: -21	BMI Grp1 B: 26.5 (1.5) F: 26.9 (1.7) F-B: 0.4
	Grp2: Metformin + nateglinide Fixed Start: 1500 mg, Max: 3000 mg, Mean: 2500 mg; Start: 180 mg, Max: 360 mg, Mean: 300 mg D: 6 mos	Grp2 B: 8.1 (1.0) F: 6.4 (0.4) F-B: -1.7 p: <0.01 Grp1-Grp2: 0.8 (SE: 0.18) p: 0.05	Grp2 B: Median: 121 (13) F: Median: 113 (11)	Grp2 B: Median: 42 (5) F: Median: 43 (6)	Grp2 B: 156 (40) F: 141 (33) p: NSG F-B: -15 Grp1-Grp2: -6	Grp2 B: 26.4 (1.4) F: 26.8 (1.6) F-B: 0.4 Grp1-Grp2: 0
Schwarz, 2008 ¹⁵²	Grp1: Metformin + glyburide Varied, glucose: <120 mg/dL Start: 500 mg, Max: 2000 mg; Start: 1.25 mg, Max: 10 mg D: 12 wks Grp2: Metformin + nateglinide Varied, glucose: <120 mg/dL Start: 500 mg, Max: 2000 mg; Start: 360 mg, Max: 360 mg D: 12 wks	Grp1 F-B: -1.2 (SE: 0.1) p: <0.001 Grp2 F-B: -1.2 (SE: 0.2) p: <0.001 Grp1-Grp2: 0 (SE: 0.22)				Grp1-Grp2: no clinically relevant difference in weight

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Gerich, 2005 ¹³⁶	Grp1: Metformin + glyburide Varied, glucose: FPG >=6.7 mmol/L; Fixed Start: 500 mg, Max: 2000 mg, Mean: 1459 mg; Start: 120 mg, Mean: 357 mg D: 12 wks; NA Grp2: Metformin + nateglinide Varied, glucose: FPG >=6.7 mmol/L Start: 500 mg, Max: 2000 mg, Mean: 1105 mg; Start: 1.25 mg, Max: 10 mg, Mean: 5.1 mg D: 12 wks	Grp1 B: 8.4 (1.2) F: 6.4 p: <0.0001 F-B: -1.5 (SE: 0.1) p: <0.0001 Grp2 B: 8.3 (1.1) F: 6.7 p: <0.0001 F-B: -1.2 (SE: 0.1) p: <0.0001 Grp1-Grp2: -0.3 (SE: 0.14) p: 0.173	Grp1 F-B: 5% decrease Grp2 F-B: 5% decrease	Grp1 F-B: 5% increase Grp2 F-B: 5% increase	Grp1 F-B: 10% decrease Grp2 F-B: 10% decrease	Grp1 F-B: -0.4 (0.4) p: 0.8143 Grp2 F-B: 0.8 (0.5) p: 0.0011 Grp1-Grp2: -1.2 p: 0.0115
Metformin + sulfonylurea versus metformin + DPP-IV inhibitor						
Seck, 2010 ¹³⁴	Grp1: Metformin + glipizide Fixed NR; Start: 5, Max: 20, Mean: 9.2 mg D: 2 Years Grp2: Metformin + sitagliptin Fixed NR D: 2 Years	Grp1 F-B: -0.35 (CI: -0.44, -0.26) Grp2 F-B: -0.33 (CI: -42, -0.25) Grp1-Grp2: -0.01 (CI: -0.1, 0.08)				Grp1 F-B: 0.7 (CI: 0, 1.3) p: NSG Grp2 F-B: -1.6 (CI: -2.3, -1) p: NS Grp1-Grp2: 2.3 (1.6, 3) p: NSG
Nauck, 2007 ¹³³	Grp1: Metformin + glipizide Varied; Varied, glucose: <6.1 mmol/l NR; Start: 5 mg, Max: 20 mg D: Unclear; 18 wks Grp2: Metformin + sitagliptin Varied; Fixed NR	Grp1-Grp2: -0.01 (CI: -0.09, 0.08)				Grp1-Grp2: -2.5 (CI: -3.1, -2) p: <.001

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Metformin + sulfonylurea versus metformin + GLP-1 agonist						
Derosa, 2010 ⁴⁴	Grp1: Metformin + glibenclamide NR Mean: 1500 mg; Start: 7.5 mg, Max: 15 mg D: NR Grp2: Metformin + exenatide NR NR; Start: 10 mcg, Max: 20 mcg D: NR	Grp1 B: 8.9 (0.8) F: 7.1 (0.2) p:NSG F-B: -1.8 p: <0.001 Grp2 B: 8.8 (0.7) F: 7.3 (0.3) F-B: -1.5 p: <0.001 Grp1-Grp2: -0.3 p: NSG				Grp1 B: 82.4 (9.1) F: 86.7 (11.2) p: <0.05 F-B: 4.3 p: <0.05 Grp2 B: 82 (8.3) F: 74 (4.1) F-B: -8 p: <0.001 Grp1-Grp2: 12.3
Nauck, 2009 ⁹²	Grp1: Metformin + glimepiride Varied Start: 2000 mg, Max: 2000 mg; Start: 1 mg, Max: 4 mg Grp2: Metformin + liraglutide Fixed NR; Start: 0.6, Max: 1.2	Grp1-Grp2: 1.1 (CI: 0.9, 1.3)				Grp1 F-B: 1 (SE: 0.2) Grp2 F-B: -2.6 (SE: 0.2) Grp1-Grp2: 3.6 p: <0.01
Nauck, 2009 ⁹²	Grp1: Metformin + glimepiride Varied Start: 2000 mg, Max: 2000 mg; Start: 1 mg, Max: 4 mg Grp2: Metformin + liraglutide Fixed NR; Start: 0.6 mg, Max: 1.8 mg	Grp1-Grp2: 1.1 (CI: 0.9, 1.3)				Grp1 F-B: 1 (SE: 0.2) Grp2 F-B: -2.8 (SE: 0.2) Grp1-Grp2: 3.8 p: <0.01

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Pratley, 2010 ¹⁴³	Grp1: Metformin + sitagliptin Varied NR; Max: 100 mg D: NR	Grp1 F-B: -0.9 (CI: -1.03, -0.77)	Grp1 F-B: 0.13 (CI: 0.04, 0.22)	Grp1 F-B: 0 (CI: -0.02, 0.02)	Grp1 F-B: -0.4 (CI: -0.58, -0.22)	Grp1 F-B: -0.96 (CI: -1.5, -0.42)
	Grp2: Metformin + liraglutide Varied, HbA1c: 7.5-10% NR; Start: 0.6 mg, Max: 1.2 mg D: NR	Grp2 F-B: -1.24 (CI: -1.37, -1.11) Grp1-Grp2: 0.34 (CI: 0.16, 0.51) p<0.0001	Grp2 F-B: 0.05 (CI: -0.04, 0.17) Grp1-Grp2: 0.08 (CI: -0.04, 0.2) p: 0.2055	Grp2 F-B: 0 (CI: -0.02, 0.03) Grp1-Grp2: 0 (CI: -0.03, 0.03) p:0.9225	Grp2 F-B: -0.43 (CI: -0.61, -0.25) Grp1-Grp2: 0.03 (CI: -0.21, 0.28) p: 0.8021	Grp2 F-B: -3.38 (CI: -3.91, -2.84) Grp1-Grp2: 2.42 (CI: 1.7, 3.14)
Pratley, 2010 ¹⁴³	Grp1: Metformin + sitagliptin Varied NR; Max: 100 mg D: NR	Grp1 F-B: -0.9 (CI: -1.03, -0.77)	Grp1 F-B: 0.13 (CI: 0.04, 0.22)	Grp1 F-B: 0 (CI: -0.02, 0.02)	Grp1 F-B: -0.4 (CI: -0.58, -0.22)	Grp1 F-B: -0.96 (CI: -1.5, -0.42)
	Grp2: Metformin + liraglutide Varied, HbA1c: 7.5-10% Unclear; Start: 0.6 mg, Max: 1.8 mg D: NR	Grp2 F-B: -1.5 (CI: -1.63, -1.37) Grp1-Grp2: 0.6 (CI: 0.43, 0.77) p<0.0001	Grp2 F-B: 0.08 (CI: -0.01, 0.17) Grp1-Grp2: 0.05 (CI: -0.07, 0.17) p: 0.4414	Grp2 F-B: 0 (CI: -0.02, 0.02) Grp1-Grp2: 0 (CI: -0.03, 0.03) p:0.9507	Grp2 F-B: -0.19 (CI: -0.38, 0) Grp1-Grp2: -0.21 (CI: -0.46, 0.04) p: 0.0962	Grp2 F-B: -2.86 (CI: -3.39, -2.32) Grp1-Grp2: 1.9 (CI: 1.18, 2.61)
Metformin + sulfonyleurea versus thiazolidinedione + sulfonyleurea						
Jonker, 2009 ¹⁶⁰	Grp1: Metformin + glimepiride Fixed Start: 500 mg BD, Max: 1000 mg BD; NR D: 2 Weeks	Grp1 B: 7 (0.1) F: 6.3 (SE: 0.1) p:0.146 F-B: -0.7			Grp1 B: Median: 1.5 (IQR: 0.9, 2.1) F: Median: 1.7 (IQR: 0.9, 2.3) p: 0.596	
	Grp2: Pioglitazone + glimepiride Fixed Start: 15 mg OD, Max: 30 mg OD; NR D: 2 Weeks	Grp2 B: 7.1 (0.2) F: 6.5 (SE: 0.1) F-B: -0.6 Grp1-Grp2: -0.1			Grp2 B: Median: 1.4 (IQR: 1, 2.2) F: Median: 1.4 (IQR: 0.9, 2.3)	

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Seufert, 2008 ¹⁴²	Grp1: Metformin + sulfonylurea Fixed Max: 2550 mg, Mean: 2081 mg; NR D: 12 wks Grp2: Pioglitazone + sulfonylurea Fixed Max: 45 mg, Mean: 37 mg; NR D: 12 wks	Grp1 B: 8.8 F: 7.64 F-B: -1.16 Grp2 B: 8.82 F: 7.79 F-B: -1.03 Grp1-Grp2: 0.13 (CI: -0.06 - 0.31) p: 0.173				Grp1 F-B: -1.7 (4.5) Grp2 F-B: 3.2 (4.7) Grp1-Grp2: -4.9
Home, 2009 ¹⁶	Grp1: Metformin + sulfonylurea Varied, HbA1c: <=7.0% Max: 2550 mg Grp2: Rosiglitazone + sulfonylurea Varied, HbA1c: <=7.0% Start: 4 mg, Max: 8 mg; NR D: Unclear; NR	Grp1 F-B: -0.18 (SE: 0.04) Grp2 F-B: -0.44 (SE: 0.03) Grp1-Grp2: 0.26 (SE: 0.05) p: <0.0001	Grp1 F-B: -20.67 (SE: 1.17) Grp2 F-B: -8.58 (SE: 1.56) Grp1-Grp2: -12.09 (SE: 1.95)	Grp1 F-B: 2.73 (SE: 0.39) Grp2 F-B: 4.29 (SE: 0.39) Grp1-Grp2: 1.56 (SE: 0.55)	Grp1 F-B: -12.46 (SE: 3.56) Grp2 F-B: -11.57 (SE: 3.56) Grp1-Grp2: -0.89 (SE: 5.0) p: 0.82	Grp1 F-B: -1.5 (SE: 0.2) Grp2 F-B: 4.1 (SE: 0.2) Grp1-Grp2: -5.6 p: <0.001
van der Meer, 2009 ¹⁴¹	Grp1: Metformin + glimepiride Fixed; Varied Start: 1000 mg, Max: 2000 mg; NR D: NR; 8 wks Grp2: Pioglitazone + glimepiride Fixed; Varied Start: 15 mg, Max: 30 mg; NR D: 2 wks; NR	Grp1 B: 7 (SE: 0.1) F: 6.3 (SE: 0.1) p: <0.001 F-B: -0.7 Grp2 B: 7.1 (SE: 0.2) F: 6.5 (SE: 0.1) p: <0.001 F-B: -0.6 Grp1-Grp2: -0.1 (SE: 0.32) p: 0.146	Grp1 B: 113.1 (SE: 3.9) F: 101.4 (SE: 7.8) p: 0.001 F-B: -11.7 Grp2 B: 97.5 (SE: 3.9) F: 97.5 (SE: 3.9) p: 0.38 F-B: 0 Grp1-Grp2: -11.7 (SE: 12.33)	Grp1 B: Median: 44.07 (IQR: 35.1, 55.38) F: Median: 39.78 (IQR: 33.54, 49.14) Grp2 B: Median: 41.73 (IQR: 36.66, 49.92) F: Median: 47.97 (IQR: 38.61, 56.94)	Grp1 B: Median: 133.5 (IQR: 80.1, 186.9) F: Median: 151.3 (IQR: 80.1, 204.7) p: 0.519 Grp2 B: Median: 124.6 (IQR: 89, 195.8) F: Median: 124.6 (IQR: 80.1, 204.7) p: 0.926 Grp1-Grp2: p:0.596	Grp1 B: 92 (2) F: 92 (3) F-B: 0 Grp2 B: 91 (2) F: 94 (4) F-B: 3 Grp1-Grp2: -3 p: <0.001

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Comaschi 2007 ¹²⁹	Grp1: Metformin + sulfonylurea Varied, HbA1c: 7.50% Start: 400 mg, Max: 3g; Start: 2.5 mg D: 22 wks Grp2: Pioglitazone + sulfonylurea Varied, HbA1c: 7.50%; Varied Start: 15 mg, Max: 30 mg; Unclear D: 22 wks; NR	Grp1 F-B: -1.29 p: 0.192 Grp2 F-B: -1.29 p: <0.001 Grp1-Grp2: 0.01 (SE: 0.27) p: 0.975				
Comaschi, 2008 ¹⁵⁸	Grp1: Metformin + glibenclamide Varied, HbA1c: 7.50% Start: 400 mg; Start: 2.5 mg D: 22 wks Grp2: Pioglitazone + sulfonylurea Varied, HbA1c: 7.50% Start: 15 mg, Max: 30 mg; Unclear D: 22 wks			Grp1 B: 45.63 (SE: 13.26) F: 42.12 (SE: 12.87) p: <0.001 F-B: -3.51 p: <0.001 Grp2 B: 41.73 (SE: 12.87) F: 42.51 (SE: 13.26) F-B: 0.39 p: 0.617 Grp1-Grp2: -3.9	Grp1 B: 178.89 (SE: 114.81) F: 181.56 (SE: 120.15) F-B: 2.67 p: 0.733 Grp2 B: 186.01 (SE: 120.15) F: 157.53 (SE: 83.66) F-B: -28.48 p: 0.017 Grp1-Grp2: 31.15 p: <0.05	
Home, 2007 ¹²⁴	Grp1: Metformin + sulfonylurea Varied, HbA1c: <=7.0% Max: 2550 mg; Unclear D: 8 wks Grp2: Rosiglitazone + sulfonylurea Varied, HbA1c: <=7.0% Start: 4 mg, Max: 8 mg; Unclear	Grp1 F-B: -0.61 (CI: -0.7, -0.51) Grp2 F-B: -0.55 (CI: -0.67, -0.44) Grp1-Grp2: 0.06 (CI: -0.09, 0.2)	Grp1 F-B: -11.31 (CI: -15.6, -7.41) Grp2 F-B: 7.41 (CI: 3.12, 11.7) Grp1-Grp2: -18.72 (SE: 3.18)	Grp1 F-B: 3.12 (CI: 1.95, 4.29) Grp2 F-B: 3.9 (CI: 0.73, 5.07) Grp1-Grp2: -0.39 (CI: -1.95, 0.78)	Grp1 F-B: 15.13 (CI: -1.78, 32.04) Grp2 F-B: 21.36 (CI: 5.34, 37.68) Grp1-Grp2: 5.34 (CI: -17.8, 28.48)	Grp1 F-B: -0.9 (CI: -1.4, -0.4) Grp2 F-B: 3.4 (CI: 2.9, 4) Grp1-Grp2: 4.3 (CI: 3.6, 5.1) p: <0.001

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Kim, 2007 ⁴²	Grp1: Metformin + glimepiride Fixed; Varied, glucose: 7.2 - 9.4 mmol/L Max: 1000 mg; Start: 2 mg, Max: 7 mg	Grp1 F-B: -1.1 (CI: -1.4, -0.8) p: <0.001	Grp1 F-B: -6.24 (CI: -12.87,-0.78) p: 0.082	Grp1 F-B: -1.56 (CI: -0.39, 1.17) p: 0.246	Grp1 F-B: -8.9 (CI: -29.37, 11.57) p: 0.389	Grp1 F-B: -0.5 (CI: -1.2, -0.2) p: 0.187
	Grp2: Rosiglitazone + glimepiride Fixed; Varied, glucose: 7.2 - 9.4 mmol/L Max: 4 mg; Start: 2 mg, Max: 7 mg	Grp2 F-B: -1.1 (CI: -1.5, -0.8) p: <0.001	Grp2 F-B: -8.97 (CI: -15.6, 19.11) p: 0.158	Grp2 F-B: -4.29 (CI: -10.53, 1.56) p: 0.158	Grp2 F-B: -23.97 (CI: -47.17, -11.57) p: 0.002	Grp2 F-B: 1.3 (CI: 0.8, 1.9) p: <0.00
		Grp1-Grp2: 0 (SE: 0.24) p: 0.615	Grp1-Grp2: 2.73 (SE: 6.11)	Grp1-Grp2: 2.73 p: 0.868	Grp1-Grp2: 20.47	Grp1-Grp2: -1.8 p: <0.001
Yang, 2003 ¹³⁹	Grp1: Metformin + sulfonylurea Fixed; NR Start: 1000 mg; NR	Grp1 B: 8.59 (1.78) F: 7.61 (1.47) p: <0.01				
	Grp2: Rosiglitazone + sulfonylurea Fixed Start: 4 mg; NR	Grp2 F-B: -0.95 (1.5) p: <0.01				
		Grp1-Grp2: 0.14 (SE: 0.48)				
Hanefeld, 2004 ¹⁴⁰	Grp1: Metformin + sulfonylurea Varied; NR Start: 850 mg, Max: 850 mg tid; NR	Grp1 B: 8.8 (0.97) F: 7.45 (0.06) F-B: -1.36	Grp1 B: 139.23 (33.54) F: 142.74 (1.56) F-B: 3.12	Grp1 B: 42.51 (9.36) F: 48.75 (0.39) F-B: 6.24	Grp1 B: 219.83 (150.41) F: 178.89 (5.34) F-B: -40.94	Grp1 B: 85.3 (15.1) F: 88.1
	Grp2: Pioglitazone + sulfonylurea Varied; NR Start: 15 mg, Max: 45 mg; NR	Grp2 B: 8.82 (0.98) F: 7.61 (0.06) F-B: -1.2	Grp2 B: 139.62 (35.58) F: 132.99 (1.56) F-B: -6.24	Grp2 B: 43.29 (10.53) F: 46.41 (0.39) F-B: 3.12	Grp2 B: 211.82 (153.08) F: 191.35 (5.34) F-B: -20.47	Grp2 F-B: 2.8
		Grp1-Grp2: -0.16 p: 0.065	Grp1-Grp2: 9.36 p: 0.0002	Grp1-Grp2: 3.12 p: <0.0001	Grp1-Grp2: -20.47 p: 0.008	Grp1-Grp2: F: 84.9 (14.5) F: 83.9 F-B: -1 Grp1-Grp2: 3.8

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Metformin + GLP-1 agonist versus metformin + basal insulin						
Bunck, 2009 ¹⁴⁴	Grp1: Metformin + exenatide Fixed Mean: 2058 mg; Start: 5 ug b.i.d., Max: 20 micro g t.i.d.	Grp1 B: 7.6 (0.1) F: 6.8 F-B: -0.8 (SD: 0.1)				Grp1-Grp2: -4.6 (1.1) p: 0.0001
	Grp2: Metformin + glargine Fixed Mean: 1798 mg; Start: 10 Units, Mean: 33.6	Grp2 B: 7.4 (0.1) F: 6.8 F-B: -0.7 (SD: 0.2) p: 0.55 Grp1-Grp2: -0.1				
Metformin + long-acting insulin versus metformin + premixed insulin						
Robbins, 2007 ¹⁴⁵	Grp1: Metformin + glargine Fixed; Varied, glucose: <6.7 mmol/l Start: 500 mg tid, Max: 1000 mg tid, Mean: 1636 mg; Mean: 0.6 U/kg Start: QD, Final: QD	Grp1 F-B: -0.4 (0.9) Grp2 F-B: -0.7 (0.9) p: <0.001 Grp1-Grp2: 0.3 (SE: 0.32) p: <0.001				Grp1 B: 88.1 (19) F: 87.6 (19.3) p: 0.04 F-B: -0.5 Grp2 B: 89.1 (20.4) F: 90 (20.5) p: <0.001 F-B: 0.9 Grp1-Grp2: -1.4 p: <0.001
	Grp2: Metformin + insulin lispro 50/50 Fixed; Varied, glucose: <6.7 mmol/L Start: 500 mg tid, Max: 1000 mg tid, Mean: 1641 mg; Mean: 0.7 U/kg Start freq: NR, Final freq: tid					
Raskin, 2007 ¹⁴⁶	Grp1: Metformin + glargine Fixed; Varied, glucose: 4.4 - 6.1 mmol/L before breakfast and dinner NR; Start: 12 U/day, Mean: 0.57 IU/kg Start freq: QD, Final freq: QD	Grp1 F-B: -2.46 (SE: 1.6) Grp2 F-B: -2.89 (SE: 1.6) Grp1-Grp2: 0.43 (SE: 2.26) p: 0.035				Grp1 F-B: 3 (4.3) Grp2 F-B: 5.6 (4.6) Grp1-Grp2: -2.6 p: 0.0004
	Grp2: Metformin + aspart 70/30 Fixed; Varied, glucose: 4.4 - 6.1 mmol/L NR; Start: 12 IU/day, Mean: 0.91 IU/kg Start freq: BID, Final freq: BID					

Table 4. Comparative effectiveness of diabetes medications on intermediate outcomes (KQ1): baseline, final, and mean difference from baseline values for hemoglobin A1c, weight and lipids (continued)

Author, year	Intervention	Hemoglobin A1c, mean (SD)	LDL, mean (SD)	HDL, mean (SD)	Triglycerides, mean (SD)	Weight, mean (SD)
Davies, 2007 ¹⁴⁷	Grp1: Metformin + NPH Varied NR; Start: 10, Mean: 0.58 IU/kg D: NR Grp2: Metformin + BHI 70/30 Varied NR; Start: 10 IU, Mean: 0.63 IU/kg D: NR	Grp1 B: 10 (2.2) F: 9.2 (1.4) F-B: -0.8 Grp2 B: 9 (1.1) F: 7.9 (1.1) F-B: -1.1 Grp1-Grp2: 0.3				Grp1-Grp2: 0.7
Metformin + premixed insulin versus metformin + sulfonylurea						
Kvapil, 2006 ¹³⁸	Grp1: Metformin + aspart 70/30 Fixed; Varied, glucose: 5 - 8 mmol/L Mean: 1660 mg; Start: 0.2 U/kg, Mean: 0.30 U/kg Start freq: BID, Final freq: BID D: NA; Unclear Grp2: Metformin + glibenclamide Fixed; Varied Mean: 1660 mg; Start: 1.75 mg, Max: 10.5 mg, Mean: 6.58 mg D: NA; Unclear	Grp1 F-B: -1.7 Grp2 F-B: -1.7 Grp1-Grp2: 0.2 (SE: 0.15) p: >0.05		Grp1-Grp2: -1.95 (SE: 1.17)	Grp1 F: 204.7 (SE: 133.5) Grp2 F: 178 (SE: 97.9) F-B: 17.8 Grp1-Grp2: -13.35 (SE: 12.46)	Grp1 F-B: 0.8 Grp2 F-B: 0.1 Grp1-Grp2: -0.66 (0.41) p: 0.1
Malone, 2003 ¹³⁷	Grp1: Metformin + lispro 75/25 Varied; Varied, glucose: fasting and premeal glucose <7 mmol/L and 2-h post-prandial glucose <10 mmol/L Max: 2550 mg; Mean: 0.19U/kg in am and 0.14 U/kg in evening D: 4 wks; titrated throughout study period Grp2: Metformin + glibenclamide Varied; Varied, glucose: fasting and pre-meal goal <7mmol/L, 2-hour post-prandial goal <10 mmol/L Max: 2550 mg, Mean: 1968 mg; Mean: 14.2 mg D: 4 wks; titrated throughout study period	Grp2 B: 9.17 (1.5) F: 7.29 (1) F-B: -1.87 (1.35) p: <0.001 Grp1 B: 9.27 (1.55) p: 0.181 F: 7.33 (1.14) p: 0.661 F-B: -1.98 (1.28) p: <0.001 Grp1-Grp2: 0.11 (SE: 0.33) p: 0.288				Grp1 B: 83 (15.2) F: 84 (15.1) F-B: 1 Grp2 B: 81.7 (15.7) F: 82.2 (15.4) p: 0.33 F-B: 0.5 Grp1-Grp2: 0.5

ac or qac=before each meal ; ADA= American Diabetes Association; B=baseline; bid= twice a day; BMI=body mass index; CI=confidence interval; cv=coefficient of variation; D=duration of dose titration; dl=deciliter; F=final; F-B=mean difference from baseline to final; FPG=fasting plasma glucose; GLP-1 agonist = glucagon-like peptide-1 agonist; Grp1-Grp2=mean difference between the two groups; HDL=high density lipoprotein; IQR=inter quartile range; LDL=low density lipoprotein; Max=maximum; mg=milligram; mmol/l=millimoles per liter; mos=months; NA=not applicable; NR=not reported; NSG=not significant; PC= portion control; po=per oral; qday or qd=daily; SD=standard deviation; SE or SEM =standard error of the mean; tid= thrice a day; wks= weeks
All values for LDL, HDL, and triglycerides are reported in mg/dL. To convert to mmol/L, divide by 39 for LDL and HDL and divide by 89 for triglycerides.

Table 5. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence (KQ2). Outcome: All-cause mortality

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness	Precision	Magnitude and Direction of Effect	
Met vs. TZD							
4 RCTs	4457	Low	Consistent	Direct	Imprecise	Unclear	Low
Met vs. SU							
5 RCTs, 8 obs	50498	Medium	Inconsistent	Direct	Precise	Small, favors metformin	Low
Met vs. DPP-4 Inhibitor							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met vs. Meg							
1 RCT	357	Low	NA	Direct	Imprecise	Unclear	Low
Met vs. Met + TZD							
5 RCTs	2554	Low	Consistent	Direct	Imprecise	Unclear	Low
Met vs. Met + SU							
4 RCTs, 6 obs	30211	Medium	Consistent	Direct	Precise	Small, neither favored	Low
Met vs. Met + DPP-4 Inhibitor							
1 RCT	190	Medium	NA	Direct	Imprecise	Unclear	Low
Met vs. Met + Meg							
1 RCT	350	Low	NA	Direct	Imprecise	Unclear	Low
TZD vs. TZD							
0	NA	NA	NA	NA	NA	NA	Insufficient
TZD vs. SU							
3 RCTs	3986	Low	Consistent	Direct	Imprecise	Unclear	Low
TZD vs. DPP-4 Inhibitor							
0	NA	NA	NA	NA	NA	NA	Insufficient
TZD vs. Meg							
0	NA	NA	NA	NA	NA	NA	Insufficient
SU vs. DPP-4 Inhibitor							
0	NA	NA	NA	NA	NA	NA	Insufficient
SU vs. Meg							
1 RCT	576	Medium	NA	Direct	Imprecise	Unclear	Low
Sitagliptin vs. Meg							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and TZD vs. Met and SU							
2 RCTs	970	Low	Consistent	Direct	Imprecise	Unclear	Low
Met and SU vs. Met and Meg							
2 RCTs, 1 obs	4432	Low	Consistent	Direct	Imprecise	Unclear	Low
Met and SU vs. Met and DPP-4 Inhibitor							
1 RCT	1172	Low	NA	Direct	Imprecise	Unclear	Low
Met and Meg vs. Met and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and DPP-4 Inhibitor vs. Met and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Exenatide vs. Met and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Basal Insulin vs. Met and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient

Table 5. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence (KQ2). Outcome: All-cause mortality (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness	Precision	Magnitude and Direction of Effect	
Met and Premixed Insulin vs. Met and SU							
2 RCTs	819	Low	Consistent	Direct	Imprecise	Unclear	Low
Met and TZD vs. TZD and SU							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and SU vs. TZD and SU							
1 RCT	639	Medium	NA	Direct	Imprecise	Unclear	Low
Met and Meg vs. TZD and Met							
1 RCT	374	Medium	NA	Direct	Imprecise	Unclear	Low
Met and Sitagliptin vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Exenatide vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Basal Insulin vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Premixed Insulin vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient

Meg = meglitinides; Met = metformin; Nateg = nateglinide; Pio = pioglitazone; RCT, randomized controlled trial;

Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione

All other comparisons were graded as insufficient since there were no studies of those comparisons.

The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate.

Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

Table 5. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Cardiovascular disease mortality

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness	Precision	Magnitude and Direction of Effect	
Met vs. TZD							
2 RCTs	2950	Medium	Consistent	Direct	Imprecise	Small. Neither favored.	Low
Met vs. SU							
1 RCT 4 obs	16788	Medium	Consistent	Direct	Imprecise	Small. Met favored.	Low
Met vs. DPP-4 inhibitor							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met vs. Meg							
1 RCT	357	Low	NA	Direct	Imprecise	Unclear	Low
Met vs. GLP-1 agonist							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met vs. Met + TZD							
3 RCTs	1479	Low	Consistent	Direct	Imprecise	Small. Unclear.	Low
Met vs. Met + SU							
2 obs	4968	Medium	Consistent	Direct	Imprecise	Unclear	Low
Met vs. Met + DPP-4 inhibitor							
1	190	Low	NA	Direct	Imprecise	Unclear.	Low
Met vs. Met + Meg							
1	350	Low	NA	Direct	Imprecise	Unclear	Low
TZD vs. TZD							
0	NA	NA	NA	NA	NA	NA	Insufficient
TZD vs. SU							
1	2897	Low	NA	Direct	Imprecise	Unclear	Low
TZD vs. DPP-4 inhibitor							
0	NA	NA	NA	NA	NA	NA	Insufficient
TZD vs. Meg							
0	NA	NA	NA	NA	NA	NA	Insufficient
TZD vs. GLP-1 agonist							
0	NA	NA	NA	NA	NA	NA	Insufficient
SU vs. DPP-4 inhibitor							
0	NA	NA	NA	NA	NA	NA	Insufficient
SU vs. Meg							
1	576	Low	NA	Direct	Imprecise	Unclear	Low
SU vs. GLP-1 agonist							
0	NA	NA	NA	NA	NA	NA	Insufficient
DPP-4 inhibitor vs. Meg							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and TZD vs. Met and Another Agent							
1 RCT	561	Low	NA	Direct	Imprecise	Unclear	Low
Met and SU vs. Met and Another Agent							
2 RCTs	4447	Low	Inconsistent	Direct	Imprecise	Unclear	Low
Met and Meg vs. Met and Another Agent							
None							Insufficient
Met and DPP-4 inhibitor vs. Met and Another Agent							
1 RCT	1172	Low	NA	Direct	Imprecise	Unclear	Low
Met and GLP-1 agonist vs. Met and Another Agent							
1 RCT	1172	Low	NA	Direct	Imprecise	Unclear	Low

Table 5. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Cardiovascular disease mortality (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness	Precision	Magnitude and Direction of Effect	
Met and Basal Insulin vs. Met and Another Agent							
1 RCT	91	Low	NA	Direct	Imprecise	Unclear	Low
Met and Premixed Insulin vs. Met and Another Agent							
2	438	Low	Consistent	Direct	Imprecise	Unclear	Low
Met and TZD vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and SU vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Meg vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Sitagliptin vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Exenatide vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Basal Insulin vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Premixed Insulin vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient

Meg = meglitinides; Met = metformin; Nateg = nateglinide; Pio = pioglitazone; RCT, randomized controlled trial;

Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione

All other comparisons were graded as insufficient since there were no studies of those comparisons.

The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate.

Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

Table 5. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Cardiovascular and cerebrovascular disease morbidity

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness	Precision	Magnitude and Direction of effect	
Met vs. TZD							
4 RCTs 9 obs	640, 910	Low	Inconsistent	Direct	Imprecise	Unclear	Low
Met vs. SU							
2 RCTs, 5 obs	609, 436	Low	Inconsistent	Direct	Imprecise	Unclear.	Low
Met vs. DPP-4 inhibitor							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met vs. Meg							
1 RCT	701	Low	NA	Indirect	Imprecise	Unclear	Low
Met vs. Met + TZD							
6 RCTs 1 obs	486,27 6	Low	Consistent	Direct	Imprecise	Small. Met favored.	Low
Met vs. Met + SU							
1 RCT, 1 obs	10449	Medium	Inconsistent	Direct	Imprecise	Small. Met favored.	Low
Met vs. Met + DPP-4 inhibitor							
2 RCTs	376	Low	Consistent	Direct	Imprecise	Unclear.	Low
Met vs. Met + Meg							
1	350	Low	NA	Indirect	Imprecise	Unclear	Low
TZD vs. TZD							
3 obs	585,45 4	High	Inconsistent	Direct	Imprecise	Unclear	Low
TZD vs. SU							
3 RCTs 5 obs	518914	Low	Inconsistent	Direct	Imprecise	Unclear.	Low
TZD vs. DPP-4 inhibitor							
0	NA	NA	NA	NA	NA	NA	Insufficient
TZD vs. Meg							
0	NA	NA	NA	NA	NA	NA	Insufficient
SU vs. DPP-4 inhibitor							
0	NA	NA	NA	NA	NA	NA	Insufficient
SU vs. Meg							
2 RCTs	969	Low	Inconsistent	Direct	Imprecise	Unclear	Low
SU vs. GLP-1 agonist							
1 RCT	411	Low	NA	Direct	Imprecise	Unclear	Low
DPP-4 Inhibitor vs. Meg							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and TZD vs. Met and Another Agent							
4 RCTs 1 obs	474,64 4	Low	Inconsistent	Direct	Imprecise	Unclear	Low
Met and SU vs. Met and Another Agent							
3 RCTs	6791	Low	Inconsistent	Direct	Precise	Unclear	Low
Met and Meg vs. Met and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and DPP-4 inhibitor vs. Met and Another Agent							
1 RCT	665	Low	NA	Indirect	Imprecise	Unclear	Low
Met and GLP-1 agonist vs. Met and Another Agent							
1 RCT	665	Low	NA	Indirect	Imprecise	Unclear	Low

Table 5. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Cardiovascular and cerebrovascular disease morbidity (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness	Precision	Magnitude and Direction of effect	
Met and Basal Insulin vs. Met and Another Agent							
1 cross-over	105	Medium	NA	Direct	Imprecise	Unclear	Low
Met and Premixed Insulin vs. Met and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and TZD vs. TZD and Another Agent							
2 RCTs, 2 obs	488,535	Low	Inconsistent	Direct	Imprecise	Unclear	Low
Met and SU vs. TZD and Another Agent							
1 RCT	639	Low	NA	Indirect	Imprecise	Unclear	Low
Met and Meg vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and DPP-4 inhibitor vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and GLP-1 agonist vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Basal Insulin vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient
Met and Premixed Insulin vs. TZD and Another Agent							
0	NA	NA	NA	NA	NA	NA	Insufficient

Meg = meglitinides; Met = metformin; Nateg = nateglinide; Pio = pioglitazone; RCT, randomized controlled trial;

Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione

All other comparisons were graded as insufficient since there were no studies of those comparisons.

The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

Table 5. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Nephropathy

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias:	Consistency	Directnes s	Precision	Magnitude and Direction of effect	
Met vs. TZD							
2 RCT's	1715	Low	Consistent	Indirect	Precise	Small. Favors pioglitazone	Moderate
Met vs. SU							
1 RCT's	51	High	NA	Indirect	Imprecise	Unclear	Low
TZD vs. SU							
5 RCT's	375	High	Inconsistent	Indirect	Imprecise	Unclear	Low
TZD vs. Meg							
1 RCT	68	Low	NA	Indirect	Imprecise	Unclear	Low
Met and TZD vs. Met and Another Agent							
1 RCT's	389	Low	NA	Indirect	Imprecise	Unclear	Low

Meg = meglitinides; Met = metformin; Nateg = nateglinide; Pio = pioglitazone; RCT, randomized controlled trial;

Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione

All other comparisons were graded as insufficient since there were no studies of those comparisons.

The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate.

Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

Table 5. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Neuropathy

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias:	Consistency	Directness	Precision	Magnitude and Direction of effect	
Met vs. Met and TZD							
1 RCT's	105	Moderate	NA	Indirect	Imprecise	Unclear	Low
Met vs. Met and sitagliptin							
1 RCT's	190	High	NA	Indirect	Imprecise	Unclear	Low
Met and TZD vs. Met and Another Agent							
1 RCT's	183	High	NA	Indirect	Imprecise	Unclear	Low

Meg = meglitinides; Met = metformin; Nateg = nateglinide; Pio = pioglitazone; RCT, randomized controlled trial; Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Seino, 2010 ¹²¹	RCT	Neither year reported	Yes	<6 months	Yes	NR/464	Age <20 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), retinopathy, HbA1c < 7% or >10%, BMI >35 kg/m ² , treated with insulin within 12 weeks of the start of the study, receiving or expecting to receive systemic corticosteroids, known hypoglycemia unawareness or recurrent major hypoglycemia, no Type 2 DM, treated with diet therapy for less than 8 weeks, on more than 1/2 of the recommended maximum dose of an SU (e.g., on more than 2.5 mg of glibenclamide)
Japan		24 weeks				NR	
Aschner, 2010 ⁷⁷	RCT	Neither year reported	Run-in period but number of participants excluded not reported	NR	Yes	2068/1050	Age <18 or >78 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <6.5% or >9%, treatment naive, no Type 2 DM, FPG <120 or >250 mg/dL, triglycerides >600 mg/dL, CK > 2x upper limit normal
Multi-continent		24 weeks				NR	

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Seck, 2010 ¹³⁴ NR	RCT	Neither year reported 2 years	Run-in period but number of participants excluded not reported	< 6 months	Yes	2141/1172 NR	Age <17 or >78 years
Pratley, 2010 ¹⁴³ Multi-continent, Europe, USA and Canada	RCT	Neither year reported 2 years	No run-in period	>= 6 months	Yes	1302/665 "office based"-possibly outpatient	Age <18 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c >7.5% or <10%, BMI >45 kg/m ² , no Type 2 DM, cancer, contraindication to trial drugs, recurrent hypoglycemia or hypoglycemia unawareness, not on metformin for at least 3 months, on any non-metformin ODM in past 3 months
Brownstein, 2010 ¹⁸² United States	Cohort	Start year: 2000 End year: 2006 7 years	NA	NA	No	NA/34252 Inpatient/hospital, Outpatient: primary care, Outpatient: subspecialty care setting	Age ≤18 years, HbA1c ≤ 6.0%, no diagnosis of DM with ICD-9 code of 250.XX

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Pantalone, 2009 ¹⁷⁴ United States	Cohort	Start year: 1998 End year: 2006 8 years	NA	NA	Yes	NA/20450 Inpatient/hospital, Outpatient: primary care, Outpatient: subspecialty care setting	Age <18 years, history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), on dialysis, on combination ODM, on insulin or other injectable antidiabetics, history of CHF
Hsiao, 2009 ¹⁷³ Taiwan	Cohort	Start year: 2000 End year: 2005 6 years	NA	NA	NR	NA/20450 Inpatient/hospital, Outpatient: primary care, Outpatient: subspecialty care setting	Type 1 DM, prescribed insulin only during study period, new diagnosis of Type 2 DM during the year before index date, switch between rosiglitazone and pioglitazone or combined use of both drugs during study period, prescribed ODM less than three times during study period
Tzoulaki, 2009 ¹⁷¹ United Kingdom	Cohort	Start year: 1990 End year: 2005 7.1 years (mean)	NA	NA	No	NA/91521 Inpatient/hospital, Outpatient: primary care, Outpatient: subspecialty care setting	Age <35 or >90 years, no diabetes, multiple or missing dates of death, missing information, no treatment with medications

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Rigby, 2009 ¹³⁰ United States, Multi-continent	RCT	Start year: 2007 End year: 2008 16 weeks	No run-in period	< 6 months	Yes	356/169 NR	Age <18 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c >10% (9.5% if on metformin combination therapy), HbA1c < 7% (6.5% if on metformin combination therapy), BMI > 40 kg/m ² , LDL<50mg/dl or TG > = 500 mg/dL, weight loss program with ongoing weight loss or starting an intensive exercise program within 4 weeks of screening, need for oral corticosteroids, bile acid sequestrants, or any antidiabetes medications other than metformin, >2 months insulin, not on metformin for >=3 months (1500-2550 mg/day, Type 1 DM and/or ketoacidosis, dysphagia/swallowing disorders, intestinal motility disorders, pancreatitis, HIV/AIDS, drug/alcohol abuse within 2 years, any serious disorder including pulmonary, hepatic, gastrointestinal, uncontrolled endocrine/metabolic, hematologic/oncologic (within 5 years), neurologic, or psychiatric diseases, current treatment with TZD/combo with metformin/colesevelam/fixed-dose combination product including metformin, hospitalization within 14 days of screening

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year		Enrollment period		Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country	Study design	Followup duration	Run-in period				
Juurlink, 2009 ²¹⁰ Canada	Cohort	Start year: 2002 End year: 2008 3 years	NA	NA	No	NA/39736 Outpatient: Primary care	Age <66 years, patients on rosiglitazone or pioglitazone before the index date, patients on insulin before the index date
Jadzinsky, 2009 ⁷⁸ Multi-continent	RCT	Start year: 2006 End year: 2007 24 weeks	Fewer than 10% participants excluded	<6 months	Yes	2936/1394 Outpatient: primary care, Outpatient: subspecialty care	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g. "failed initial treatment"), HbA1c < 8% or >12%, BMI >40 kg/m ² , prior treatment, diabetic ketoacidosis or nonketotic hyperosmolar coma, CVD events 6 months prior, LVEF <40%, psychiatric history, alcohol or drug abuse, abnormal metabolic or hematologic test
Home, 2009 ¹⁶ Multinational Europe	RCT	Start year: 2001 End year: 2003 7.5 years	Run-in period but number of participants excluded was NR	>= 6 months	Yes	7428/4458 Outpatient: primary care	Age <40 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), contraindication or history of intolerance to metformin, HbA1c < 7% or >9%, BMI <25 kg/m ² , pregnant, nursing, not using adequate contraception, recent CAD event, heart failure

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Raskin, 2009 ¹³¹	RCT	Neither year reported	No run-in period	< 6 months	Yes	1093/383	Age <18 years, pregnant, nursing, currently not under monotherapy at least 2 months or dual therapy, FBG >260 mg/dL, any disease of abnormality as judged by the investigator, treatment with the investigational drug for 4 weeks, allergy to study drugs or related compounds, history of hypoglycemia unawareness or recurrent severe hyperglycemia
NR		26 weeks				Outpatient: primary care	
Scott, 2008 ⁸⁵	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	486/273	Age <18 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), HbA1c < 7% or >11%, not on 10 weeks on stable dose of metformin, insulin use, Type 1 DM, glucose > 270 mg/dL
Multi-continent		18 weeks				NR	
Raz, 2008 ⁹³	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	544/190	Age <18 or >78 years, HbA1c <8% after run-in or HbA1c >11% after run-in, BMI <20 kg/m ² or >43 kg/m ² , pregnant, nursing, insulin within 8 weeks prior to screening, PPAR-G or incretin mimetics within 12 weeks prior to screening, Type 1 DM, FPG <7.2 mmol/l or >15.6 mmol/L consistently during run-in, no Type 2 DM
Multi-continent		30 weeks				NR	

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Hamann, 2008 ¹²³	RCT	Neither year reported	Yes	< 6 months	NR	818/596	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <7% or >10%, BMI <25 kg/m ² , used any ODM other than metformin in the prior 12 weeks, or insulin at any time other than during pregnancy or for emergency treatment, history of metabolic acidosis, edema requiring pharmacological treatment (either ongoing or within the prior 12 months), anemia (hemoglobin < 11.0 g/dl for men and < 10.0 g/dl for women), C-peptide <0.5nmol/L, SBP >170 mmHg, DBP >100 mmHg
Multinational Europe, Mexico		52 weeks				NR	
Schwarz, 2008 ¹⁵²	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	75/69	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), contraindication or history of intolerance to metformin, HbA1c <7.0% or >11.0%, BMI <22 or >45 kg/m ² , FBG >270 mg/dL, history of lactic acidosis, congestive cardiac failure requiring pharmacologic treatment, Type 1 DM or secondary forms of DM
US		104 weeks				NR	

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled Source population	Exclusion criteria
Monami, 2008 ¹⁸⁰ Italy	Cohort	Start year: 1993 End year: 2001 28 months	NA	NR	NR	NA (for cohort studies, claims data, etc)/1108 Outpatient: primary care, Geriatric clinic	Insulin treatment was an exclusion, not Type 2 DM by WHO 1985 criteria
Hanefeld, 2007 ¹⁰⁰ Multinational Europe	RCT	Neither year reported 52 weeks	Run-in period but number of participants excluded was NR	< 6 months	Yes	NR/598 NR	Age <40 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), BMI <22 kg/m ² or >38 kg/m ² , pregnant, patient on insulin therapy, patient with diabetic complications requiring treatment, hematologic impairment, FPG: <7 mmol/l or >15 mmol/l, C-peptide <0.27 nmol/l
Comaschi, 2007 ¹²⁹ Italy	RCT	Neither year reported 6 Months	Run-in period but number of participants excluded was NR	< 6 months	Yes	398/250 NR	Age <35 years, HbA1c <7.5% or >11%, had not received SU or metformin as a monotherapy at a stable dose for at least 3 months, fasting C-peptide <0.33 nmol/L
Nauck, 2007 ¹³³ US, Multinational Europe, Multi-continent	RCT	Neither year reported 52 weeks	Yes	< 6 months	Yes	2141/1172 NR	Age <18 or >78 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), FPG >15 mmol/L, insulin use within 8 weeks of screening, history of Type 1 DM, other treatments for hypoglycemia

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Kahler, 2007 ¹⁷⁵	Cohort	Start year: 1998 End year: 2001 3 years	NA	NA	No	> 1500000/39721 VHA Medical facilities	Age <18 years, non-respondents to 1999 LHSVE survey, medical facilities that do not have assays certified by the National Glycohemoglobin Standardization Program, less than 15 month window period after 1 year exposure to drug, alive as of 31 December 2000, fixed one year window of drug exposure
US							
McAfee, 2007 ¹⁸¹	Cohort	Start year: 2000 to 2004 End year: 2005 NR	NA	NA	Yes	NA (for cohort studies, claims data, etc)/31075 Ingenix research claims database	Age >18 years, less than 6 months in insurance plan, insulin or study drug given within 6 months prior to study, insulin or other drug given within 30 days after monotherapy initiation, no medical or pharmacy benefits
US							
Nakamura, 2006 ¹⁰⁸	RCT	Neither year reported 12 months	No run-in period	< 6 months	NR	NR/68 NR	HbA1c >6.5%, history of ketoacidosis, treatment other than by diet alone, fasting C-peptide level < 0.33 mmol/L, hematuria, non-diabetic renal disease, microalbuminuria defined as a median urinary albumin excretion of 20 to 200 ug/min
Japan							
Kahn, 2006 ³⁸	RCT	Start year: 2000 End year: 2006 6 Years	No run-in period	NR	Yes	6676/4360 NR	Age <30 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), uncontrolled hypertension, FPG <126 or > 180 mg/dL, history of lactic acidosis
Multi-continent							

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Rosenstock, 2006 ⁴⁹	RCT	Start year: 2003 to 2004	Yes	< 6 months	Yes	1252/468 multicenter	Age <18 or >70 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c < 7% or > 11%, FPG >15 mmol/l, hematological disease, uncontrolled hypertension while on antihypertensive treatment, intermittent or chronic use of oral or intravenous corticosteroids, investigators discretion, use of investigational agent within 30 days of the study (or five half live of the investigational drug if longer than 30 days), previous history of severe edema or medically serious fluid related event associated with TZD, acute or chronic metabolic acidosis, history of diabetic ketoacidosis
Multi-continent		32 weeks					

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Jain, 2006 ¹⁰¹	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	NR/502	Age <18 or >80 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g. failed initial treatment), HbA1c < 7.5% or >11.5%, pregnant, nursing, duration of DM > than 2 years, intolerance to Rosi, Pio or Troglitazone, drug or alcohol abuse, previous treatment with meglitinide analog, alpha glucosidase inhibitor, metformin, insulin, SU for 3 months or more, use of hydrochlorothiazide, joint injections, niacin greater than 250 mg/day, oral antidiabetic drugs, concurrent participation in another investigational study, serum creatinine level > 1.5mg/dl of men, 1.4 mg/dl for women, 1 + proteinuria, anemia (< 10g/dl women, < 12g/dl men), BMI ≤20kg/m ² or >45kg/m ² , hypertension, chronic pulmonary disease, history of cancer not in remission for at least 5 years
US, Puerto Rico		56 weeks				NR	
Bakris, 2006 ¹²⁵	RCT	Neither year reported	Yes	< 6 months	Yes	560/514	Age <40 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), BMI < 22 kg/m ² , use of any TZD in the 3 months prior to screening, use of insulin for ≥6 months at any time prior to screening, anemia, severe angina, SBP >159 mm Hg (can't adjust the BP meds during the trial), DBP >99 mm Hg
US, Multi-continent, South America, Europe		32 weeks				NR	

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Kvapil, 2006 ¹³⁸	RCT	Neither year reported	No run-in period	< 6 months	NR	NR/341	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), retinopathy, recurrent severe hypoglycemia, anemia, change in dose of meds known to interfere with glucose metabolism, inclusion criteria includes not adequately controlled on metformin
Multinational Europe		16 weeks				NR	
Stewart, 2006 ¹⁵⁶	RCT	Start year: 2003 to 2004	Yes	< 6 months	Yes	1397/526	Age <18 or >70 years, history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c < 7% or > 9%, drug naive patients with FPG <7 mmol/l or >9 mmol/l, patient on monotherapy with FPG < 6.0 mmol/l or > 8 mmol/l, prior history of exposure to thiazolidinediones within previous 6 months, use of insulin anytime in the past, uncontrolled hypertension
Multinational Europe		32 weeks				NR	
Simpson, 2006 ¹⁶⁶	Cohort	Start year: 1991 End year: 1999	NA	NA	No	12272/5795	Age <30 years, patients on insulin, patients on two or more ODM
Canada		8 years				Saskatchewan health databases	
Rosak, 2006 ¹⁸³	Cohort	Neither year reported	NA	< 6 months	Yes	NR/22808	Not all treated with rosiglitazone
Germany		6 months				Outpatient: primary care, Outpatient: subspecialty care setting	

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Malone, 2005 ¹⁶⁵ Multinational Europe	RCT	Neither year reported 32 weeks	Yes	< 6 months	Yes	119/97 NR	Age <30 or >75 years, HbA1c >2.0 times the upper limit of normal, HbA1c <1.3 times the upper limit of normal, used glitazones within 30 days prior to the study, used NPH QD or BID 30-days prior to entry, expected to benefit from prandial control
Weissman, 2005 ⁸⁶ US	RCT	Neither year reported 24 weeks (planned duration)	Run-in period but number of participants excluded was NR	< 6 months	Yes	1270/766 NR	Age <18 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <6.5% for subjects having received prior combination treatment (metformin + SU), HbA1c >8.5% for subjects having received prior combination treatment (Metformin + SU), BMI <27 kg/m ² , HbA1c < 7% for drug naive or prior monotherapy subjects, HbA1c > 10% for drug naive or prior monotherapy subjects, FPG < 126 mg/dL or >270 mg/dL, anemia, severe edema, prior insulin use within 3 months of study start, non-compliant patient with metformin up-titration
Bailey, 2005 ⁸⁷ UK, 14 European countries	RCT	24 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <18 or >70 years, history of CVD, no Type 2 DM, other

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Gerich, 2005 ¹³⁶	RCT	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	908/428	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), neuropathy, retinopathy, HbA1c < 7% or >11%, BMI <22kg/m ² and >45 kg/m ² , not using adequate contraception, FPG ≥15mmol/L, if Type 1 DM, symptomatic hypoglycemia with >10% weight loss in previous 8 weeks, history of lactic acidosis or CHF requiring meds, other medical conditions that could interfere with interpretation of results or pose sig risk to the subject, had to be drug naive
US		2 Years				NR	
Johnson, 2005 ¹⁶⁷	Cohort	Median followup periods for each group ranged from 4.6 to 5.6 years	Not extracted	Not extracted	No	Not extracted	Age < 30 years, no Type 2 DM, other
Canada							
Eurich, 2005 ¹⁶⁹	Cohort	2.1 years (mean followup)	Not extracted	Not extracted	No	Not extracted	History of CVD, treatment experienced, other
Canada							
Evans, 2005 ¹⁷⁶	Cohort	Neither year reported	Not extracted	NA	NR	6089/5730	Diagnosed under the age of 35 years, requirement for insulin within 90 days of diagnosis or their first ODM prescription, ODM users before January 1994
Scotland		8 Years				NR	

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Agarwal, 2005 ¹⁸⁴	RCT	Start year: 2001 End year: 2003 16 Weeks	No run-in period	< 6 months	Yes	102/54 Outpatient: subspecialty care setting	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), BMI >40 kg/m ² , class III or IV heart failure, NSAID use
Scherthaner, 2004 ⁵²	RCT	12 months (planned duration)	Not extracted	Not extracted	No	Not extracted	Age <35 or >75 years, treatment experienced, HbA1c <7.5% or >11%, no Type 2 DM
Lawrence, 2004 ⁵³	RCT	12 titration, 12 week maintenance (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <45 or >80 years, any liver disease, any kidney disease, history of CVD, HbA1c for diet treated diabetes: <7% or >10% for low-dose ODM: >7.5%, no Type 2 DM, other
Nakamura, 2004 ¹⁰²	RCT	Neither year reported 12 Months	No run-in period	>= 6 months	NR	NR/45 Inpatient/hospital	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c > 6.5%, BP <140/90 mm Hg, controlled on diet alone, no history ketoacidosis, c peptide <0.33mmol/L, creatinine <1.5, no BP meds, malignancy, no microalbuminuria, collagen vascular disease, non-diabetic renal disease

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled Source population	Exclusion criteria
Hanefeld, 2004 ¹⁴⁰	RCT	NR	Not extracted	Not extracted	Yes	Not extracted	Age <35 or >75 years, history of CVD, HbA1c <7.5% or >11%, no Type 2 DM, other
Canada, U.K., Hungary, Finland, Slovak Republic, Belgium, Estonia, Lithuania, Denmark, Italy, Greece, Sweden, and Netherlands							
Malone, 2004 ¹⁶⁴	RCT	Neither year reported	Yes	< 6 months	Yes	145/111	Age <30 or >80 years, HbA1c <1.3 or >2.0 times normal, BMI >40 kg/m ² , HbA1c value that is less than or greater than 1.3 and 2.0 times the ULN within 30 days before the study, while using 1 or more ODM without insulin for 30 or more days before study start
U.S.		32 weeks				NR	
Gulliford, 2004 ¹⁷⁰	Cohort	Median followup for each group ranged from 1.67 to 3.49 years	Not extracted	Not extracted	No	Not extracted	Treatment experienced, no Type 2 DM, other,
U.K., Wales, Scotland, and Ireland							
Garber, 2003 ⁶¹	RCT		Not extracted	Not extracted	Yes	Not extracted	Age < 20 or >79 years, any liver disease, any kidney disease, treatment experienced, HbA1c >7% or <12%, no Type 2 DM, other
U.S.		16 weeks (planned duration)					

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled Source population	Exclusion criteria
Goldstein, 2003 ⁶² U.S.	RCT	18 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, HbA1c <7.5% or >12.0%, other
Bakris, 2003 ¹⁰⁴ likely U.S. and U.K.	RCT	52 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	NR
Malone, 2003 ¹³⁷ 14 countries not specified	randomized, open-label, 2 arm parallel prospective study	Neither year reported 16 weeks	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	NR/597 subgroup completing test meals	Age <30 or >75 years, HbA1c <125% of upper limit of normal by local lab within 4 weeks prior to entry, BMI >40 kg/m ² , not Type 2 DM, not use of single oral agent (metformin or SU) for 3 months prior to study at maximum clinically effective dose for previous 30 days
Jones, 2003 ¹⁷⁹ U.S.	RCT	Neither year reported 6 months	Run-in period but number of participants excluded was NR	< 6 months	NR	NR	Age <40 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, CHF, history chronic insulin, FPG <140 or >300 mg/dL, prior rosiglitazone study, use on any investigational drug within 30 days
Hallsten, 2002 ⁵⁵ Finland	RCT	26 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, no Type 2 DM, other

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled Source population	Exclusion criteria
Gomez-Perez, 2002 ⁸⁸	RCT	26 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <40 or >80 years, any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other
Mexico							
St John Sutton, 2002 ¹⁴⁹	RCT	52 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <40 or age >80 years, any liver disease, any kidney disease, history of CVD, no Type 2 DM, other
US							
Johnson, 2002 ¹⁶⁸	Cohort	5.1 years (mean followup)	Not extracted	Not extracted	No	Not extracted	Age <30 years, other
Canada							
Fisman, 2001 ¹⁷⁷	Cohort	7.7 years (mean followup)	Not extracted	Not extracted	No	Not extracted	Age < 45 or >74 years, any liver disease, any kidney disease, other
Israel							
Amador-Licona, 2000 ⁶⁶	RCT	12 weeks (planned duration)	Not extracted	Not extracted	No	Not extracted	Age >65 years, any liver disease, history of CVD, other
Mexico							
Horton, 2000 ⁷⁹	RCT	24 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <30 years, any kidney disease, HbA1c <6.8% or >11%, no Type 2 DM, other
US							
Fonseca, 2000 ⁹⁰	RCT	26 weeks (planned duration)	Not extracted	Not extracted	No	Not extracted	Age <40 or >80 years, any liver disease, any kidney disease, history of CVD, treatment experienced, neuropathy, no Type 2 DM, other
US							

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period Followup duration	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled Source population	Exclusion criteria
Nakamura, 2000 ¹⁰³ Japan	RCT	3 months (planned duration)	Not extracted	Not extracted	No	Not extracted	Any liver disease, history of CVD, treatment experienced, HbA1c <6.5%, no Type 2 DM, other
Wolffenbuttel, 1999 ¹¹⁶ Germany, Austria, and Netherlands	RCT	12 months (planned duration)	Not extracted	Not extracted	No	Not extracted	Age <40 or >75 years, any liver disease, any kidney disease, history of CVD, treatment experienced, HbA1c <6.5% if treated with diet only, HbA1c >12% if treated with diet plus oral, other
Marbury, 1999 ¹¹⁷ US and Canada	RCT	12 months (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age >37 or <75 years, any liver disease, any kidney disease, history of CVD, treatment experienced, retinopathy, HbA1c <6.5% or >14.6%, no Type 2 DM, other
Fisman, 1999 ¹⁷⁸ NR	Cohort	Neither year reported 6 years	NA	NA	NR	NR/14440 Community	Age < 45 and > 75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), pacemaker, hepatitis, renal disease, malignancy, insulin, estrogen replacement
DeFronzo, 1995 ⁷⁰ U.S.	RCT	29 weeks (planned duration)	Not extracted	Not extracted	No	Not extracted	Age <40 or >70 years, any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other

Table 6. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on long term outcomes (KQ2) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of followup	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Hermann, 1994 ⁶⁸	RCT	6 months (planned duration)	Not extracted	Not extracted	Yes	Not extracted	No Type 2 DM, other
Sweden							

ALT = alanine aminotransferase; AST = aspartate aminotransferase; BID = twice a day; BMI = body mass index; BP = blood pressure; CAD = coronary artery disease; CHF = congestive heart failure; CK = creatine kinase; CVD = cardiovascular diseases; DBP = diastolic blood pressure; DM = diabetes mellitus; FBG = fasting blood glucose; FPG = fasting plasma glucose; g/dl = grams per deciliter; GFR = glomerular filtration rate; HbA1c = hemoglobin A1c; ICD-9 = International Statistical Classification of Diseases and Related Health Problems-9; kg = kilogram; kg/m² = kilogram per meter squared; LDL = low density lipoprotein; LHSVE = Large Health Survey of Veteran Enrollees; LVEF = left ventricular ejection fraction; mg/d = milligrams per day; mg/dl = milligrams/deciliter; mmHg = millimeters of mercury; mmol/L = millimoles per liter; NA = not applicable; nmol/L = nanomoles per liter; NPH = neutral protamine Hagedorn; NR = not reported; NSAID = non-steroidal anti-inflammatory drugs; ODM = oral diabetes medication; PPAR- γ = peroxisome proliferator-activated receptor gamma; QD = once a day; RCT = randomized controlled trial; SBP = systolic blood pressure; SGOT = glutamyl oxaloacetic transaminase; SGPT = serum glutamyl pyruvic transaminase; SU = sulfonylurea; TG = triglycerides; TZD = thiazolidinedione; VHA = Veterans Health Administration; WHO = World Health Organization

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2)

Author, year	Group, N	Mean age (age range),			Mean BMI in kg/m ²			N of withdrawals
		Age categories(n;) in years	Male, %	Race, n %	Mean weight in kg	Mean HbA1c (other measure)	Mean duration of diabetes in years	
Brownstein, 2010 ¹⁸²	Pioglitazone, 806	63.7	52	NR	NR	8.1	NR	NR
	Rosiglitazone, 1879	64	51.7	NR	NR	8	NR	NR
	Metformin, 12490	61.7	49.9	NR	NR	7.8	NR	NR
	Any in the Sulfonylurea class, 11200	65.8	57.5	NR	NR	7.7	NR	NR
Seino, 2010 ¹²¹	Glibenclamide, 132	58.5	65	Asian: 100	24.4 NR	8.978	8.5	12
	Liraglutide, 268	58.2	68	NR	24.5 NR	8.92	8.1	22
Aschner, 2010 ¹⁷⁷	Metformin, 439	55.7	44	NR	30.9 NR	7.2	2.1	75
	Sitagliptin, 455	56.3	48	NR	30.7 NR	7.2	2.6	61
Seck, 2010 ¹³⁴	Metformin + sitagliptin, 248	57.6	57.3	AA: 3.6, Asian: 9.3, C: 77.4, H: 5.6, Other: 4	30.9 88.5 kg	7.3	5.8	231
	Metformin + glipizide, 584	57	62.9	AA: 5.1, Asian: 8.2, C: 78.5, H: 5.1, Other: 3.1	31.3 90.3 kg	7.3	5.7	328
Pratley, 2010 ¹⁴³	Metformin + sitagliptin, 219	55	55	AA: 5, Asian: 1, C: 91, H: 16, Other: 4	32.6 93.1 kg	8.5	6.3	25
	Metformin + liraglutide, 221	55.9	52	AA: 10, Asian: 3, C: 82, H: 17, Other: 5	32.6 93.7 kg	8.4	6	27
	Metformin + liraglutide, 221	55	52	AA: 7, Asian: 2, C: 87, H: 15, Other: 4	33.1 94.6 kg	8.4	6.4	52

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, n %	Mean BMI in kg/m ²	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years			Mean weight in kg			
Pantalone, 2009 ¹⁷⁴	Rosiglitazone, 1079	61.4	45.5	C: 86.8	32.7 NR	7.3	NR	NR
	Any in the Sulfonylurea Class, 7427	66.1	49.5	C: 78	31.1 NR	7.6	NR	NR
	Pioglitazone, 1508	61.6	48.3	C: 83.5	33 NR	7.4	NR	NR
	Metformin, 10436	56.8	41.18	C: 76.9	33.8 NR	7.7	NR	NR
Hsiao, 2009 ¹⁷³	Metformin, 46444	59	48.22	NR	NR NR	NR	NR	NR
	Rosiglitazone, 2093	61.24	53.46	NR	NR NR	NR	NR	NR
	Pioglitazone, 495	60.75	52.02	NR	NR NR	NR	NR	NR
	Any in the Sulfonylurea class, 97651	60.71	54.1	NR	NR NR	NR	NR	NR
	Metformin + sulfonylurea, 267754	57.17	54.45	NR	NR NR	NR	NR	NR
	Metformin + rosiglitazone, 2408	57.3	49.8	NR	NR NR	NR	NR	NR
Tzoulaki, 2009 ¹⁷¹	Metformin, 68181	66.3	50.6	NR	31.47 NR	8.13	5.59	NR
	Rosiglitazone, 8442	65.7	50.5	NR	31.7 NR	8.4	6.7	NR
	Any in the Sulfonylurea class, 58095	70.4	52.6	NR	28.5 NR	8.2	6.6	NR
Rigby, 2009 ¹³⁰	Metformin + rosiglitazone, 56	54.7	41.1	AA: 3.6, Asian: 0, C: 28.6, H: 67.9, Other: 0	NR 81.1 kg	8.06	7.57	5
	Metformin + sitagliptin, 56	54.8	35.7	AA: 1.8, Asian: 0, C: 23.2, H: 73.2, Unspecified: 1.8	NR 79.6 kg	8.17	8.35	11

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, n %	Mean BMI in kg/m ²	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years			Mean weight in kg			
Juurink, 2009 ²¹⁰	Rosiglitazone, 22785	66-75 (69%) 76-85 (28%) >=86 (3%)	53.1	NR	NR NR	NR	NR	NR
	Pioglitazone, 16951	66-75 (69%) 76-85 (28%) >=86 (3%)	52.1	NR	NR NR	NR	NR	NR
Jadzinsky, 2009 ⁸	Metformin + saxagliptin, 320	52.4	51.6	AA: 2.2, Asian: 15.9, C: 76.9, Other: 5	29.9 NR	9.4	2	NR
	Metformin + saxagliptin, 323	52.1	45.2	AA: 2.2, Asian: 16.7, C: 75.2, Other: 5.9	30.3 NR	9.5	1.4	NR
	Metformin, 328	51.8	49.7	AA: 1.2, Asian: 15.9, C: 76.5, Other: 6.4	30.2 NR	9.4	1.7	NR
	Saxagliptin, 335	52	50.4	AA: 1.8, Asian: 16.7, C: 76.1, Other: 5.4	30.2 NR	9.6	1.7	NR
Home, 2009 ¹⁶	Rosiglitazone, 2220	58.4	51.4	C: 99.1	31.6 NR	7.9	7	218
	Rosiglitazone + sulfonylurea, 1103	59.8	49	NR	30.3 85.0 kg	8	7.9	NR
	Metformin + sulfonylurea, 1122	59.7	50.6	C: 99.1	NR 84.3 kg	8	7.9	NR
	Metformin + sulfonylurea, 1105	57.2	52.9	C: 98.4	NR 93.3 kg	7.8	6.3	NR
	Metformin + rosiglitazone, 1117	57	53.8	C: 98.9	NR 93.5 kg	7.8	6.1	NR
	Metformin + sulfonylurea, 2227	58.5	51.7	C: 98.7	31.5 NR	7.9	7.1	233
Raskin, 2009 ¹³¹	Metformin + repaglinide, 187	54.5	58.8	AA: 13.4, Asian: 4.8, C: 78.8, American Indian and Alaskan Native: .5, Other: 1.6	32.5 NR	8.29	7.3	58
	Metformin + rosiglitazone, 187	55.5	50.8	AA: 13.4, Asian: 2, C: 79.1, American Indian and Alaskan Native: 1.1, Others: 4.3	32.2 NR	8.46	7.1	58

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),		Race, n %	Mean BMI in kg/m ²			N of withdrawals
		Age categories(n;) in years	Male, %		Mean weight in kg	Mean HbA1c (other measure)	Mean duration of diabetes in years	
	Metformin + repaglinide, 187	54.8	57.8	AA: 16, Asian: 4.3, C: 74.9, American Indian and Alaskan Native: 0.5, Others: 4.3	32.9 NR	8.45	7.4	62
Scott, 2008 ⁸⁵	Metformin + rosiglitazone, 87	54.8	63	Asian: 38, C: 59, Others: 3	30.4 84.9 kg	7.7	4.6	2
	Metformin + sitagliptin, 94	55.2	55	Asian: 38, C: 61, Others: 1	30.3 83.1 kg	7.8	4.9	9
	Metformin, 92	55.3	59	Asian: 39, C: 61	30 84.6 kg	7.7	5.4	9
Raz, 2008 ⁹³	Metformin + sitagliptin, 96	53.6	51	AA: 3, C: 42, H: 32, Multiracial: 22, Not Specified: 1	30.1 81.5 kg	9.3	8.4	18
	Metformin, 94	56.1	41.5	AA: 1, C: 47, H: 25, Multiracial: 25, Not Specified: 2	30.4 81.2 kg	9.1	7.3	16
Hamann, 2008 ¹²³	Metformin + rosiglitazone, 294	58.5	53	C: 94	33 91.4 kg	8	6.3	61
	Metformin + sulfonylurea, 302	59.3	52	C: 95	32.2 88.9 kg	8	6.4	71
Chien, 2007 ⁵⁹	Metformin + glyburide, 26	60	71	NR	24.2 63.8 kg	8.71	9	5
	Metformin + glyburide, 26	57	62	NR	24.2 61.3 kg	8.85	6.6	5
	Metformin, 25	59	41	NR	25.7 65.6 kg	8.88	6.4	8
	Glyburide, 25	63	53	NR	25.3 63.7 kg	8.69	8.6	6
Schwarz, 2008 ¹⁵²	Metformin + glyburide, 40	70.4	50	AA: 11.1, C: 77.8, Other: 11	33.5 NR	7.7	2.5	18
	Metformin + nateglinide, 35	70.1	51.5	AA: 9.1, C: 78.8, Other: 12.1	30.4 NR	7.8	1.7	14
Comaschi, 2007 ¹²⁹	Metformin + pioglitazone, 103	57	45.63	NR	32.2 85.8 kg	8.4	NR	27

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, n %	Mean BMI in kg/m ²	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years			Mean weight in kg			
McAfee, 2007 ¹⁸¹	Metformin + sulfonylurea, 80	59.9	55	NR	29.9 81.9 kg	8.6	NR	13
	Pioglitazone + sulfonylurea, 67	62.2	56.72	NR	28.9 78.8 kg	8.7	NR	14
	Any in the Sulfonylurea class, 8977	52	56	NR	NR NR	NR	NR	NR
	Rosiglitazone + sulfonylurea, 1362	52	59	NR	NR NR	NR	NR	NR
	Metformin + rosiglitazone, 1362	52	59	NR	NR NR	NR	NR	NR
	Rosiglitazone, 8977	52	55	NR	NR NR	NR	NR	NR
	Metformin, 8977	52	55	NR	NR NR	NR	NR	NR
Monami, 2008 ¹⁸⁰	Metformin + sulfonylurea, 1362	51	61	NR	NR NR	NR	NR	NR
	Metformin + repaglinide	NR	NR	NR	NR NR	NR	NR	0
	Metformin + sulfonylurea	NR	NR	NR	NR NR	NR	NR	0
Kahler, 2007 ¹⁷⁵	Any in the Sulfonylurea class, 19053	68.2	NR	AA: 12.6, C: 78.6, Other: 8.8	29.6 NR	7.2	(<1: 12.8, 1-3: 32.2, 4-10: 33.4, >11: 20)	NR
	Metformin, 2988	64.9	96.9	AA: 12.7, C: 78.7, Other: 8.7	30.4 NR	7	(<1: 20.5, 1-3: 41.5, 4-10: 25.1, >11: 11.6)	NR
	Metformin + sulfonylurea, 13820	65.6	98.1	AA: 13.2, C: 77.5, Other: 9.3	30.3 NR	8	(<1: 4.5, 1-3: 21.2, 4-10: 43.3, >11: 29.1)	NR

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),		Race, n %	Mean BMI in kg/m ²		Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years	Male, %		Mean weight in kg	Mean HbA1c (other measure)		
	TZD, 675	67.1	97.5	AA: 8.7, C: 80.9, Other: 10.4	30.7 NR	7.9	(<1: 3.3, 1-3: 18.2, 4-10: 39.9, >11: 37.5)	NR
Nauck, 2007 ¹³³	Metformin + sitagliptin, 588	56.8	57.1	AA: 7, Asian: 8.5, C: 73.5, H: 7.3, Other: 3.7	NR NR	7.7	6.5	202
	Metformin + glipizide, 584	56.6	61.3	AA: 6, Asian: 8.4, C: 74.3, H: 7.9, Other: 3.4	31.3 89.7 kg	7.6	6.2	172
Hanefeld, 2007 ¹⁰⁰	Rosiglitazone, 189	60.6	57.7	AA: 0, C: 97, Other: 3	28.8 NR	8.2	6	9
	Glibenclamide, 203	60.1	70.4	AA: 0, C: 99, Other: 0.5	28.7 NR	8.2	6.4	13
	Rosiglitazone, 195	60.4	68.2	AA: 0, C: 98.5, Other: 1.5	28.7 NR	8.1	5.9	12
Nakamura, 2006 ¹⁰⁸	Pioglitazone, 17	56	52.9	NR	NR NR	8.0	16	NR
	Glibenclamide, 18	53.5	55.6	NR	NR NR	7.8	16.5	NR
	Nateglinide, 16	53.5	56.3	NR	NR NR	7.7	16.6	NR
Kahn, 2006 ³⁸	Rosiglitazone, 1456	56.3	55.7	AA: 4.2, Asian: 2.7, C: 87.2, H: 5.2, Other: 0.7	32.2 91.5 kg	7.36	(<1: 651, 1-2: 758, >2: 47)	539
	Glyburide, 1441	56.4	58	AA: 4.2, Asian: 2.2, C: 89, H: 4.2, Other: 0.3	32.2 92 kg	7.35	(<1 year: 637, 1-2: 751, >2: 53)	634
	Metformin, 1454	57.9	59.4	AA: 3.7, Asian: 2.4, C: 89.1, H: 3.8, Other: 1	32.1 91.6 kg	7.36	(< 1 year: 673, 1-2: 724, >2: 57)	551
Rosenstock, 2006 ⁴⁹	Rosiglitazone, 159	50.6	58	AA: 5, Asian: 14, C: 59, H: 19, Other: 3	32.8 NR	8.8	2.7	22
	Metformin + rosiglitazone, 155	50.1	57	AA: 6, Asian: 12, C: 54, H: 26	33.2 NR	8.9	2.3	19

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, n %	Mean BMI in kg/m ²	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years			Mean weight in kg			
Jain, 2006 ¹⁰¹	Metformin, 154	51.5	56	AA: 5, Asian: 14, C: 58, H: 21, Other: <1	32.5 NR	8.8	2.9	31
	Pioglitazone, 251	52.1	53	AA: 15.9, Asian: 1.6, C: 61, H: 20.7, Other: 0.4, Native American: 0.4	32.5 93.9 kg	9.2	0.8	117
	Glyburide, 251	52.1	56.2	AA: 13.5, Asian: 0, C: 65.7, H: 19.9, Native American: 0.4, Other: 0.4	32.8 94.3 kg	9.2	0.78	123
Stewart, 2006 ¹⁵⁶	Metformin, 272	59	56	AA: <1, Asian: <1, C: 99, H: <1, Native Hawaiian/Other Pacific Islander: <1	30.6 87.2 kg	7.2	3.7	54
	Metformin + rosiglitazone, 254	58.8	55	AA: 0, Asian: 1, C: 98, H: <1, Native Hawaiian/Other Pacific Islander: 0	30.9 88.1 kg	7.2	3.7	50
Bakris, 2006 ¹²⁵	Metformin + glyburide, 185	58.8	69	C: 76	31.8 90.3 kg	8.3	7.6	5
	Metformin + rosiglitazone, 204	60	63	C: 78	31.6 89.2 kg	8.5	8	10
Rosak, 2006 ¹⁸³	Metformin + rosiglitazone, 7705	60	50.2	NR	29.3 87.2 kg	8.1	3.9	545
	Rosiglitazone + sulfonyleurea, 5511	65	48.2	NR	NR 81.3 kg	8.3	5.3	478
	Rosiglitazone, 1559	62.0	47.7	NR	28.7 83.8 kg	8.1 (median)	4.5	542
Simpson, 2006 ¹⁶⁶	Metformin, 768	64.6	53	NR	NR NR	NR	NR	NR
	Glyburide, 2067	67.8	60	NR	NR NR	NR	NR	NR
Kvapil, 2006 ¹³⁸	Metformin + glibenclamide, 114	58.1	45.6	NR	30.5 84.0 kg	9.4	8.1	5
	Metformin + aspart 70/30, 116	56.4	45.7	NR	30.4 85.1 kg	9.3	6.7	11

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),			Mean BMI in kg/m ²	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years	Male, %	Race, n %	Mean weight in kg			
Malone, 2005 ¹⁶⁵	Metformin + lispro 75/25, 50	59.18	50	NR	29.41 77.82 kg	8.5	13.52	3
	Metformin + glargine, 47	59.63	38	NR	29.64 77.21 kg	8.48	11.9	10
Gerich, 2005 ¹³⁶	Metformin + glyburide, 209	53.5	48	AA: 16.7, Asian: 0.5, C: 65.2, Other: 17.7	33.5 NR	8.3	2.0	87
	Metformin + nateglinide, 219	52.6	51	AA: 13, Asian: 2.4, C: 64.4, Other: 20.2	33.3 NR	8.4	1.5	78
Agarwal, 2005 ¹⁸⁴	Pioglitazone, 22	67	100	AA: 14, C: 86	32 97 kg	7.7	16	1
	Glipizide, 22	64	100	AA: 27, C: 73	34 102 kg	7.7	14	3
Malone, 2004 ¹⁶⁴	Pooled arms		63	NR	30.9 91.5 kg	8.7	9	NR
	Metformin + lispro 75/25	NR	NR	NR	NR NR	NR	NR	3 during this arm
	Metformin + glargine	NR	NR	NR	NR NR	NR	NR	7
Nakamura, 2004 ¹⁰²	Pioglitazone, 15	57	60	NR	NR NR	7.9	17.5	NR
	Glibenclamide, 15	55	53.3	NR	NR NR	7.8	19.2	0
Malone, 2003 ¹³⁷	Metformin + lispro 75/25, 296	58	57	AA: 0.7, C: 88.9, H: 7.4, Other: 3	29.8 83.0 kg	9.17	8.0	25
	Metformin + glibenclamide, 301	59	49	AA: 1, C: 89, H: 6, Other: 4	29.6 81.7 kg	9.27	7.4	29
Jones, 2003 ¹⁷⁹	Metformin, 82	60	74	NR	28 NR	8.8	6	NR
	Metformin, 22	64	9	NR	23 NR	8.6	6.5	NR
	Metformin + rosiglitazone, 35	62	71	NR	23 NR	9.3	8	NR
	Metformin + rosiglitazone, 141	58	69	NR	28 NR	8.8	6	NR

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),			Mean BMI in kg/m ²			
		Age categories(n;) in years	Male, %	Race, n %	Mean weight in kg	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
	Metformin + rosiglitazone, 142	57	57	NR	34 NR	8.8	5	NR
	Metformin, 121	58	70	NR	34 NR	8.7	5	0
Fisman, 1999 ¹⁷⁸	Any in the Sulfonylurea class, 1041	60.5	76	NR	27 76 kg	NR	NR	NR
	Metformin + sulfonylurea, 266	60.9	66	NR	27 75 kg	NR	NR	0
	Metformin, 78	59.5	65	NR	29 80 kg	NR	NR	NR
Evans, 2005 ¹⁷⁶	Metformin, 2286	60.2	51.20	NR	32.9 NR	7.7	2.7	NR
	Sulfonylurea, 3331	65.9	56.30	NR	28.6 NR	7.8	4.6	NR
	Metformin + sulfonylurea, 985	61.2	47.00	NR	33.2 NR	8.1	4.4	NR
	Metformin + sulfonylurea, 1252	63.6	55.10	NR	30.2 NR	8.2	4.8	NR
	Metformin + sulfonylurea, 113	64	49.60	NR	30 NR	8	8.8	NR
Weissman, 2005 ⁸⁶	Metformin, 384	55.7	NR	NR	33.8 96.7 kg	7.97	NR	95
	Metformin + rosiglitazone, 382	55.5	NR	NR	34.4 98.2 kg	8.05	NR	76
Bailey, 2005 ⁸⁷	Metformin, 280	57.6	57	AA: <1, Asian: 1, C: 98, Other: 1	32.1 89.5 kg	7.5	6.1	44
	Metformin + rosiglitazone, 288	58.1	58	AA: 1, C: 97, Asian: 1, H: 0, Other: 1	32.2 90.9 kg	7.4	6	30
Eurich, 2005 ¹⁶⁹	Unspecified Sulfonylurea, 773	74.8	58	NR	NR NR	NR	NR	NR
	Metformin, 208	72.5	59	NR	NR NR	NR	NR	NR
	Metformin + unspecified Sulfonylurea, 852	70	55	NR	NR NR	NR	NR	NR

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, n %	Mean BMI in kg/m ²	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years			Mean weight in kg			
Johnson, 2005 ¹⁶⁷	Unspecified Sulfonylurea, 2138	67.8	59	NR	NR NR	NR	NR	NR
	Metformin, 923	64.3	52	NR	NR NR	NR	NR	NR
	Metformin + unspecified Sulfonylurea, 1081	62	54	NR	NR NR	NR	NR	NR
Scherthner, 2004 ⁵²	Placebo + diet + Metformin, 597	56	57.8	NR	31.4 89.7 kg	8.7	3.1	96
	Placebo + diet + pioglitazone, 597	57	52.6	NR	31.2 88.2 kg	8.7	3.4	98
Gulliford, 2004 ¹⁷⁰	Unspecified Sulfonylurea, 6620	67	55	NR	NR NR	NR	NR	NR
	Metformin + unspecified Sulfonylurea, 1868	61	51	NR	NR NR	NR	NR	NR
	Metformin, 2232	61	50	NR	NR NR	NR	NR	NR
	Metformin + unspecified Sulfonylurea, 867	58	45	NR	NR NR	NR	NR	NR
Hanefeld, 2004 ¹⁴⁰	Placebo + unspecified Sulfonylurea + pioglitazone, 319	60	53.6	AA: 0.6, C: 99.4, Asian: 0, H: 0, Other: 0	30.2 85.3 kg	8.82	7	259
	Placebo + Metformin + unspecified Sulfonylurea, 320	60	54.7	AA: 0.9, C: 98.4, Asian: 0, H: 0 Other: 0.6	30 84.9 kg	8.8	7.1	279
Lawrence, 2004 ⁵³	Metformin, 20	59.5	60	NR	29.2 NR	NR	NR	NR
	Pioglitazone, 20	60.4	70	NR	30.6 NR	NR	NR	NR
Garber, 2003 ⁶¹	Metformin + glyburide, 171	55.6	44	AA: 10.5, C: 77.2, Asian: 0, H: 8.8, Other: 3.5	31.4 91.9 kg	8.8	3	NR

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, n %	Mean BMI in kg/m ²	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years			Mean weight in kg			
	Glyburide, 151	55.3	43.7	AA: 7.3, C: 81.5, Asian: 0, H: 7.9, Other: 3.3	31.1 91 kg	8.7	3	NR
	Metformin, 164	54.7	43.3	AA: 6.7, C: 80.5, Asian: 0, H: 9.1, Other: 3.7	31.4 92.8 kg	8.5	2.6	NR
Goldstein, 2003 ⁶²	Metformin + glipizide, 87	54.6	58.60	AA: 11.5, C: 72.4, Asian: 0, H: 16.1, Other: 0	31.7 94 kg	8.7	5.9	NR
	Glipizide, 84	57.4	64.30	AA: 11.9, C: 71.4, Asian: 2.4, H: 14.3, Other: 0	30.6 89.9 kg	8.9	6.5	NR
	Metformin, 76	56.6	61.80	AA: 15.8, C: 65.8, Asian: 1.3, H: 17.1, Other: 0	31.6 93.8 kg	8.7	7.3	NR
Bakris, 2003 ¹⁰⁴	Rosiglitazone, 104	55.1	72.1	NR	NR NR	9.1	NR	NR
	Glyburide, 99	56.1	71.7	NR	NR NR	9.5	NR	NR
Johnson, 2002 ¹⁶⁸	Unspecified Sulfonylurea, 3033	67.2	59	NR	NR NR	NR	NR	NR
	Metformin, 1150	63.8	54	NR	NR NR	NR	NR	NR
	Metformin + unspecified Sulfonylurea, 4683	62.1	54.3	NR	NR NR	NR	NR	NR
Hallsten, 2002 ⁵⁵	Diet + rosiglitazone, 14	58.6	71.4	NR	29.3 NR	6.8	NR	NR
	Placebo + diet, 14	57.7	71.4	NR	30.3 NR	6.3	NR	NR
	Diet + Metformin, 13	57.8	61.5	NR	29.9 NR	6.9	NR	NR
St John Sutton, 2002 ¹⁴⁹	Rosiglitazone, 104	55.1	75	AA: 5, C: 73, Asian: 0, H: 0, Other: 22	67.3% >=27kg/m ² 86.2 kg	9.1	5.3	NR

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, n %	Mean BMI in kg/m ²	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years			Mean weight in kg			
	Glyburide, 99	56.1	71	AA: 3, C: 76, Asian: 0, H: 0, Other: 21	65.7% >=27 kg/m ²	9.5	6.2	NR
					85.1 kg			
Gomez-Perez, 2002 ⁸⁸	Placebo + Metformin, 34	53.4	29.4	C: 2.9, H: 76.5, Mestizo: 20.6	28.5 NR	NR	9.1	NR
	Metformin + rosiglitazone, 35	51.7	28.6	C: 0, H: 80, Mestizo: 20	28 NR	NR	11.1	NR
	Metformin + rosiglitazone, 36	54.2	19.4	C: 11.1, H: 72.2, Mestizo: 16.7	27.6 NR	NR	10.7	NR
Fisman, 2001 ¹⁷⁷	Glyburide, 953	59.8	76	NR	27 77 kg	NR	NR	NR
	Metformin, 79	59.5	66	NR	29 81 kg	NR	NR	NR
	Metformin + glyburide, 253	60.7	66	NR	27 75 kg	NR	NR	NR
Amador-Licona, 2000 ⁶⁶	Glibenclamide, 23	48.2	30.4	NR	30.4 73.2 kg	8.4	4	NR
	Metformin, 28	49.3	39.3	NR	26.8 70.7 kg	8.5	4.5	NR
Fonseca, 2000 ⁹⁰	Metformin + rosiglitazone, 113	58.3	68.2	AA: 10, C: 77.3, Asian: 0, H: 0, Other: 12.7	29.8 NR	8.9	8.3	18
	Placebo + Metformin, 116	58.8	74.3	AA: 3.5, C: 81.4, Asian: 0, H: 0, O: 15	30.3 NR	8.6	7.3	22
	Metformin + rosiglitazone, 119	57.5	62.1	AA: 6.9, C: 80.2, Asian: 0, H: 0, Other: 12.9	30.2 NR	8.9	7.5	18
Nakamura, 2000 ¹⁰³	Pioglitazone, 15	60	46.7	NR	NR NR	7.7	16	NR
	Glibenclamide, 15	61	53.3	NR	NR NR	7.8	14	NR
Horton, 2000 ⁷⁹	Nateglinide, 179	58.6	61.5	AA: 9.5, C: 82.1, Asian: 2.8, H: 0, Other: 5.6	29.6 NR	8.3	4.7	NR

Table 7. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on long-term outcomes (KQ2) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, n %	Mean BMI in kg/m ²	Mean HbA1c (other measure)	Mean duration of diabetes in years	N of withdrawals
		Age categories(n;) in years			Mean weight in kg			
	Metformin, 178	56.8	68	AA: 9.6, C: 79.2, Asian: 2.2, H: 0, Other: 9	29.6 NR	8.4	7.5	NR
	Metformin + nateglinide, 172	58.4	58.7	AA: 11.6, C: 82.6, Asian: 0.6, H: 0, Other: 5.2	30 NR	8.4	4.5	NR
Wolffenbittel, 1999 ¹¹⁶	Repaglinide, 286	61	62	NR	28.4 81.5 kg	7.1	Median 6	NR
	Placebo + glyburide, 139	61	68	NR	28 81.3 kg	7	Median 6	NR
DeFronzo, 1995 ⁷⁰	Metformin, 143	53	43.4	NR	29.9 94.4 kg	8.4	6	NR
	Metformin + glyburide, 213	55	46.0	NR	29 92.1 kg	8.8	7.8	NR
	Placebo + glyburide, 209	56	49.3	NR	29.1 92.6 kg	8.5	8.7	NR
	Placebo + Metformin, 210	55	45.7	NR	29.4 92.6 kg	8.9	8.4	NR
Hermann, 1994 ⁶⁸	Diet + Metformin, 25	60	63	NR	NR 78.6 kg	6.9	4	NR
	Diet + glibenclamide, 21	NR	NR	NR	NR NR	NR	NR	NR
	Diet + Metformin + glibenclamide + Other, 54	NR	80.2	NR	NR NR	NR	NR	NR
Marbury, 1999 ¹¹⁷	Repaglinide, 362	58.3	67	AA: 9, C: 77, Asian: 0, H: 0, Other: 14	29.4 NR	8.7	7.2	NR
	Placebo + glyburide, 182	58.7	66	AA: 9, C: 79, Asian: 0, H: 0, Other: 12	29.1 NR	8.9	8.3	NR

AA= African American; C= Caucasian; H=Hispanic; Kg=kilogram; Met=Metformin; NR=Not reported; Repa=Repaglinide; Rosi=Rosiglitazone; Sita=Sitagliptin; SU=Sulfonylurea

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Metformin versus thiazolidinedione						
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Metformin NS Grp2: Pioglitazone NS			Def: Angina pectoris defined by ICD-9-CM diagnostic codes for hospitalization Grp1: 1367 (2.97) Grp2: 22 (4.51) HR: 1.15 (CI: 0.6 to 2.21) p: 0.6753 Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 484 (1.02) Grp2: 44 (8.89) HR: 1.0 (CI: 0.26 to 3.89) p: 0.9954	Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 116 (0.25) Grp2: 2 (0.41) Def: TIA defined by ICD-9-CM diagnostic codes of hospitalization Grp1: 285 (0.63) Grp2: 5 (1.03)
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Metformin NS Grp2: Rosiglitazone NS			Def: Angina pectoris defined by ICD-9-CM diagnostic codes for hospitalization Grp1: 1367 (2.97) Grp2: 154 (7.52) HR: 1.79 (CI: 1.39 to 2.3) Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 484 (1.02) Grp2: 266 (12.71) HR: 2.09 (CI: 1.36 to 3.24) p: 0.0007	Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 116 (0.25) Grp2: 16 (0.8) Def: TIA defined by ICD-9-CM diagnostic codes of hospitalization Grp1: 285 (0.63) Grp2: 23 (1.14)
Brownstein, 2010 ¹⁸²	Cohort	Grp1: Metformin NS Grp2: Rosiglitazone NS			Def: Hospitalization for acute MI Grp1: ref Grp2: HR: 3.0 (CI: 2.4-3.7)	
Tzoulaki, 2009 ¹⁷¹	Cohort	Grp1: Metformin NS Grp2: Rosiglitazone NS	Grp1: ref Grp2: 34 (<1) HR: 1.07 (CI: 0.77 to 1.49) p: 0.74		Def: Incident MI Grp1: ref Grp2: 9 (<1) HR: 0.79 (CI: 0.41 to 1.53) p: 0.485	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Metformin NR Grp2: Rosiglitazone NR	Grp1: ref Grp2: HR: 1.33 (CI: 0.93 to 1.91) p: 0.11		Def: CABG, PTCA, MI, or diagnosis of CAD by ICD-9 after baseline Grp1: ref Grp2: HR: 0.96 (CI: 0.76 to 1.21) p: 0.74	
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Metformin NR Grp2: Pioglitazone NR	Grp1: ref Grp2: HR: 1.08 (CI: 0.78 to 1.51) p: 0.64		Def: CABG, PTCA, MI, or diagnosis of CAD by ICD-9 after baseline Grp1: ref Grp2: HR: 1.11 (CI: 0.91 to 1.34) p: 0.32	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin NR Grp2: Rosiglitazone NR			Def: Inpatient MI and coronary revascularization using ICD-9 and CPT codes Grp1: 149 (2) Grp2: 152 (2)	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin NR Grp2: Rosiglitazone NR			Def: MI based on ICD-9 diagnosis codes (could be fatal or nonfatal MI since not specified but likely nonfatal mostly) Grp1: 62 (1) Grp2: 70 (1)	
Lawrence, 2004 ⁵³	RCT	Grp1: Metformin Varied Start: 500 mg bid, Max: 1000 mg tid Grp2: Pioglitazone Varied Start: 30 mg, Max: 45 mg	Grp1: 1 (5) Grp2: 0 (0)	Def: CVD mortality/Fatal MI Grp1: 1 (5) Grp2: 0 (0)	Def: CVD morbidity/MI (non-fatal) Grp1: 0 (0) Grp2: 0 (0)	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Rosenstock, 2006 ⁴⁹	RCT	Grp1: Metformin Varied, glucose: 6.1 mmol/l Start: 500 mg, Mean: 1847 mg, Max: 2000 mg D: 32 wks Grp2: Rosiglitazone Varied, glucose: 6.1 mmol/l Start: 4 mg, Mean: 7.7 mg, Max: 8 mg D: 32 wks	Grp1: 0 (0) Grp2: 0 (0)		Def: Not defined ischemic heart disease Grp1: 2 (1) Grp2: 2 (1)	
Kahn, 2006 ³⁸	RCT	Grp1: Metformin Varied, glucose: 140 mg/dL Start: 500 mg, Max: 2000 mg Grp2: Rosiglitazone Varied, glucose: 140 mg/dL Start: 4 mg, Max: 8 mg	Grp1: 31 (2) Grp2: 34 (2)	Def: Fatal MI Grp1: 2 (0.1) Grp2: 2 (0.1)	Grp1: 21 (1.4) Grp2: 25 (1.7)	Def: Stroke not defined Grp1: 19 (1.3) Grp2: 16 (1.1)
Scherthaner, 2004 ⁵²	RCT	Grp1: Metformin Varied Max: 850 mg tid Grp2: Pioglitazone Varied Start: 30 mg, Max: 45 mg	Grp1: 2 (0.3) Grp2: 3 (0.5)			
Metformin versus sulfonylurea						
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Metformin NS Grp2: Sulfonylurea NS			Def: Angina pectoris defined by ICD-9-CM diagnostic codes for hospitalization Grp1: 1367 (2.97) Grp2: 3721 (3.87) Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 484 (1.02) Grp2: 1678 (1.76)	Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 116 (0.25) Grp2: 318 (0.34) Def: TIA defined by ICD-9-CM diagnostic codes of hospitalization Grp1: 285 (0.63) Grp2: 940 (0.99)
Tzoulaki, 2009 ¹⁷¹	Cohort	Grp1: Metformin NS Grp2: Sulfonylurea NS	Grp1: ref Grp2: 1379 (2) HR: 1.24 (CI: 1.14 to 1.35) p: <0.001		Def: Incident MI Grp1: ref Grp2: 365 (1) HR: 1.09 (CI: 0.94 to 1.27) p: 2.66	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR	Grp1: HR: 0.54 (CI: 0.46 to 0.64) p: <0.001 Grp2: ref		Def: CABG, PTCA, MI, or diagnosis of CAD by ICD-9 after baseline Grp1: HR: 0.94 (CI: 0.85 to 1.05) p: 0.23 Grp2: ref	
Simpson, 2006 ¹⁶⁶	Cohort	Grp1: Metformin NR Grp2: Glyburide NR	Grp1: 39.6/1000 person-years Grp2: 61.4/1000 person-years	Def: Fatal MI Grp1: 11.5/1000 person-years Grp2: 17.6/1000 person-years		
Eurich, 2005 ¹⁶⁹	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR	Grp1: 69 (33) Adjusted HR 0.70 Grp2: 404 (52)			
Fisman, 2001 ¹⁷⁷	Cohort	Grp1: Metformin NR Grp2: Glyburide NR	Grp1: 25 (32) Grp2: 324 (34)	Def: CVD mortality/CVD mortality + ICD-9 codes 410-414 + matched the patients ID number with their life status in the population registry + ischemic heart disease Grp1: Age-adjusted IR 30/1000 person-years Grp2: Age-adjusted IR 24.5/1000 person-years		

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Johnson, 2005 ¹⁶⁷	Cohort	Grp1: Metformin Varied Min: 250 mg Grp2: Sulfonylurea Varied		Def: CVD mortality/CVD mortality registry + CVD mortality + ICD-9 codes 410, 411-414, 420-427, 429, 428, 430-432, 433-434, 436-438, 440 Grp1: 14.4/1000 patient-years Grp2: 25.5/1000 patient-years	Def: Non-fatal cardiovascular hospitalization/used ICD-9 codes 410-414, 420-427, 429, 428, 440, 430-432, 433-434, 436-438 Grp1: 53.7/1000 patient-years Grp2: 75.3/1000 patient-years	
Johnson, 2002 ¹⁶⁸	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR	Grp1: 159 (14) Grp2: 750 (25)	Def: CVD mortality/Fatal MI + fatal stroke + CVD mortality + ICD-9 codes 390-398, 401-417, 420-438, 440-444, 446-448, 451-459 Grp1: 80 (7) Grp2: 351 (11.6)		
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR			Def: Inpatient MI and coronary revascularization using ICD-9 and CPT codes Grp1: 149 (2) Grp2: 152 (2)	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR			Def: MI based on ICD-9 diagnosis codes (could be fatal or nonfatal MI since not specified but likely nonfatal mostly) Grp1: 62 (1) Grp2: 94 (1)	
Evans, 2006 ¹⁷⁶	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR	Grp1: (4.7) Adjusted RR: 1.43 Grp2: (17.9)	Grp1: Adjusted HR: 1.7 Grp2: ref		

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Kahler, 2007 ¹⁷⁵	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR	Grp1: 82 (2.7) Grp2: 1005 (5.3)			
Hermann, 1994 ⁶⁸	RCT	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg Grp2: Glyburide Varied Start: 3.5 mg, Max: 10.5 mg			Def: CVD morbidity/unclear CHD Grp1: 2 (5) Grp2: 3 (9)	
Goldstein, 2003 ⁶²	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Glipizide Fixed Start: 15mg bid	Grp1: 0 (0) Grp2: 0 (0)			
Garber, 2003 ⁶¹	RCT	Grp1: Metformin Varied Start: 500 mg, max: 2000 mg Grp2: Glyburide Varied Start: 2.5 mg, max: 10 mg	Grp1: 0 (0) Grp2: 0 (0)			
DeFronzo, 1995 ⁷⁰	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2500 mg Grp2: Glyburide Varied Start: 5 mg bid, Max: 10 mg bid	Grp1: 1 (0.5) Grp2: 0 (0)	Def: CVD mortality/Fatal MI Grp1: 1 (0.5) Grp2: 0 (0)		

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Chien, 2007 ⁵⁹	RCT	Grp1: Metformin Varied, glucose: 140 mg/dL Start: 1000mg, Mean: 1910 mg, Max: 2000 mg D: 4 wks Grp2: Glyburide Varied, glucose: 140 Start: 10 mg, Mean: 19 mg, Max: 20 mg D: 4 wks	Grp1: 0 (0) Grp2: 0 (0)			
Kahn, 2006 ³⁸	RCT	Grp1: Metformin Varied, glucose: 140 mg/dL Start: 500 mg, Max: 2000 mg Grp2: Glyburide Varied, glucose: 140 mg/dL Start: 2.5 mg, Max: 15 mg	Grp1: 31 (2) Grp2: 31 (2)	Def: Fatal MI Grp1: 2 (0.1) Grp2: 3 (0.2)	Def: Not defined Grp1: 21 (1.4) Grp2: 15 (1)	Def: Stroke not defined Grp1: 19 (1.3) Grp2: 17 (1.2)
Gulliford, 2004 ¹⁷⁰	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR	Grp1: 144 (7) Grp2: 1030 (16)			
Fisman, 1999 ¹⁷⁸	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR	Grp1: 78 (26) Grp2: 234 (23)			
Metformin versus DPP-4 inhibitors						
Aschner, 2010 ⁷⁷	RCT	Grp1: Metformin Varied, prespecified target dose Start: 500 mg, Max: 2000 mg, Mean: 1903 D: 5 weeks Grp2: Sitagliptin Fixed Mean: 100 mg	Grp1: 0 (0) Grp2: 1 (<1)			
Jadzinsky, 2009 ⁸	RCT	Grp1: Metformin Varied, NS Start: 500 mg, Max: 1000 mg D: 1 week Grp2: Saxagliptin Fixed	Grp1: 3 (1) Grp2: 0 (0)			

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Metformin versus meglitinide						
Horton, 2000 ⁷⁹	RCT	Grp1: Metformin Fixed Start: 500 mg tid Grp2: Nateglinide Fixed Start: 120 mg tid	Grp1: 1 (0.6) Grp2: 0 (0)	Def: CVD mortality/due to arteriolosclerotic and hypertensive heart disease + unclear CHD Grp1: 1 (0.6) Grp2: 0 (0)	Def: CVD morbidity/electrocardiogram abnormalities Grp1: 0 (0) Grp2: 0 (0)	
Metformin versus metformin + thiazolidinedione						
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Metformin NS Grp2: Metformin + rosiglitazone NS			Def: Angina pectoris defined by ICD-9-CM diagnostic codes for hospitalization Grp1: 1367 (2.97) Grp2: 103 (4.26) Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 484 (1.02) Grp2: 25 (1.03)	Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 116 (0.25) Grp2: 12 (0.49) Def: TIA defined by ICD-9-CM diagnostic codes of hospitalization Grp1: 285 (0.63) Grp2: 11 (0.45)
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin NR Grp2: Metformin + rosiglitazone NR			Def: Composite outcome Grp1: 149 (2) Grp2: 24 (2)	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin NR Grp2: Metformin + rosiglitazone NR			Def: Non-fatal MI Grp1: 62 (1) Grp2: 6 (<1)	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin NR Grp2: Metformin + rosiglitazone NR			Def: Inpatient MI and coronary revascularization using ICD-9 and CPT codes Grp1: OR: 6.1 Grp2: ref	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Weissman, 2005 ⁸⁶	RCT	Grp1: Metformin Varied Start: 1000mg, Max: 2000mg Grp2: Metformin + rosiglitazone Fixed; Varied Start: 1000 mg; Start: 4 mg, Max: 8 mg	Grp1: 0 (0) Grp2: 1 (<1)		Def: CVD morbidity/MI (non-fatal) Grp1: 0 (0) Grp2: 2 (1)	
Weissman, 2005 ⁸⁶	RCT	Grp1: Metformin Varied Start: 1000mg, Max: 2000mg Grp2: Metformin + rosiglitazone Fixed; Varied Start: 1000 mg; Start: 4 mg, Max: 8 mg			Def: CVD morbidity/MI (non-fatal) + pulmonary edema with MI Grp1: 3 + 1 withdrew (1) Grp2: 5 (1)	
Gomez-Perez, 2002 ⁸⁸	RCT	Grp1: Metformin Fixed Start: 2500 mg Grp2: Metformin + rosiglitazone Fixed Start: 2500 mg; Start: 2 mg bid			Def: CVD morbidity/ischemic heart disease + bundle branch block + tachycardia Grp1: 1 (3) Grp2: 1 (3)	
Gomez-Perez, 2002 ⁸⁸	RCT	Grp1: Metformin Fixed Start: 2500 mg Grp2: Metformin + rosiglitazone Fixed Start: 2500 mg; Start: 4 mg bid			Def: CVD morbidity/ischemic heart disease + bundle branch block + tachycardia Grp1: 1 (3) Grp2: 2 (5)	
Fonseca, 2000 ⁹⁰	RCT	Grp1: Metformin Fixed Start: 2500 mg Grp2: Metformin + rosiglitazone Fixed Start: 2500 mg; Start: 8 mg	Grp1: 0 (0) Grp2: 1 (1)	Def: CVD mortality/unclear mortality + Fatal MI Grp1: 0 (0) Grp2: 0 (0)		

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Bailey, 2005 ⁸⁷	RCT	Grp1: Metformin Varied Start: 2500 mg, Max: 3000 mg Grp2: Metformin + rosiglitazone Fixed; Varied Start: 2500mg; Start: 4 mg, Max: 8 mg	Grp1: 0 (0) Grp2: 1 (<1)	Def: CVD mortality/sudden cardiac death Grp1: 0 (0) Grp2: 1 (<1)	Def: CVD morbidity/MI (non-fatal) + pulmonary edema with MI Grp1: 0 (0) Grp2: 1 (<1)	
Stewart, 2006 ¹⁵⁶	RCT	Grp1: Metformin Varied Start: 500 mg, Mean: 2627.9 mg, Max: 3000 mg D: 20wks Grp2: Metformin + rosiglitazone Varied Start: 500 mg, Mean: 1812.9 mg, Max: 2000 mg D: 18 wks			Def: MI, angina pectoris, myocardial ischemic, coronary artery insufficiency Grp1: 0 (0) Grp2: 4 (2)	
Rosenstock, 2006 ⁴⁹	RCT	Grp1: Metformin Varied, glucose: 6.1 mmol/l Start: 500 mg, Max: 2000 mg, Mean: 1847 mg D: 32 wks Grp2: Metformin + rosiglitazone Varied, glucose: 6.1 mmol/l Start: 500 mg, Mean: 1799 mg, Max: 2000 mg; Start: 2 mg, Max: 8 mg, Mean: 7.2mg D: 32 wks	Grp1: 0 (0) Grp2: 0 (0)		Def: Not defined ischemic heart disease Grp1: 2 (1) Grp2: 1 (1)	
Jones, 2003 ¹⁷⁹	RCT	Grp1: Metformin Fixed Start: 2.5 g Grp2: Metformin + rosiglitazone Fixed; Varied, NS Start: 2.5 g; Max: 8 mg	Grp1: 0 (0) Grp2: 1 (1)			

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Metformin versus metformin + sulfonylurea						
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Metformin NS Grp2: Metformin + sulfonylurea NS			Def: Angina pectoris defined by ICD-9-CM diagnostic codes for hospitalization Grp1: 1367 (2.97) Grp2: 5910 (2.2) Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 484 (1.02) Grp2: 11435 (4.27)	Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 116 (0.25) Grp2: 588 (0.22) Def: TIA defined by ICD-9-CM diagnostic codes of hospitalization Grp1: 285 (0.63) Grp2: 1637 (0.61)
Fisman, 1999 ¹⁷⁸	Cohort	Grp1: Metformin NR Grp2: Metformin + sulfonylurea NR	Grp1: 20 (26) Grp2: 84 (32)	Def: Fatal MI Grp1: 39.3/1000 person-years Grp2: 35.3/1000 person-years	Def: CVD mortality/CVD mortality + ICD-9 codes 410-414 + matched the patients ID number with their life status in the population registry + ischemic heart disease Grp1: IR: 30/1000 person-years Grp2: IR: 31.2/1000 person-years	
Gulliford, 2004 ¹⁷⁰	Cohort	Grp1: Metformin NR Grp2: Metformin + sulfonylurea NR	Grp1: 144 (5) Grp2: 159 (6)			
Kahler, 2007 ¹⁷⁵	Cohort	Grp1: Metformin NR Grp2: Metformin + sulfonylurea NR	Grp1: 82 (2.7) Grp2: 468 (3.4)			
Evans, 2006 ¹⁷⁶	Cohort	Grp1: Metformin NR Grp2: Metformin + later addition of sulfonylurea NR		Def: Cardiovascular mortality Grp1: Adjusted RR 2.29 (CI: 1.45-3.61) Grp2: ref		

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Evans, 2006 ¹⁷⁶	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea + later addition of metformin NR		Def: Cardiovascular mortality Grp1: Adjusted RR 2.43 (CI: 1.61-3.66) Grp2: ref		
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin NR Grp2: Metformin + sulfonylurea NR			Def: Inpatient MI and coronary revascularization using ICD-9 and CPT codes Grp1: 149 (2) Grp2: 36 (3)	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin NR Grp2: Metformin + sulfonylurea NR			Def: MI based on ICD-9 diagnosis codes (could be fatal or nonfatal MI since not specified but likely nonfatal mostly) Grp1: 62 (1) Grp2: 17 (1)	
Garber, 2003 ⁶¹	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 2000 mg; Start: 1.25 mg, Max: 20 mg	Grp1: 0 (0) Grp2: 2 (1)			
Goldstein, 2003 ⁶²	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glipizide Varied Start: 500 mg, Max: 2000 mg; Start: 5 mg, Max: 20 mg	Grp1: 0 (0) Grp2: 0 (0)			

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
DeFronzo, 1995 ⁷⁰	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2500 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 2500 mg; Start: 10 mg, Max: 20 mg	Grp1: 1 (1) Grp2: 0 (0)			
Hermann, 1994 ⁶⁸	RCT	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 1500 mg; Start: 1.75mg, Max: 5.25 mg			Def: CVD morbidity/unclear CHD Grp1: 2(5) Grp2: 10 (14)	
Chien, 2007 ⁵⁹	RCT	Grp1: Metformin Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Final mean: 1910 mg D: 4 wks Grp2: Metformin + glyburide Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Final mean: 1680 mg; Start: 5 mg, Max: 10 mg, Final mean: 8.4 mg D: 4 wks	Grp1: 0 (0) Grp2: 0 (0)			
Johnson, 2002 ¹⁶⁸	Cohort	Grp1: Metformin NR Grp2: Metformin + sulfonylurea NR	Grp1: 159 (14) Grp2: 635 (14)			
Eurich, 2005 ¹⁶⁹	Cohort	Grp1: Metformin NR Grp2: Metformin + sulfonylurea NR	Grp1: 69 (33) Grp2: 263 (31)			

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Fisman, 2001 ¹⁷⁷	Cohort	Grp1: Metformin NR Grp2: Metformin + Glyburide NR	Grp1: 25 (32) Grp2: 111 (44)			
Metformin versus metformin + DPP-IV inhibitor						
Raz, 2008 ⁹³	RCT	Grp1: Metformin Fixed Grp2: Metformin + sitagliptin Fixed Max: 2550 mg; Mean: 100 mg	Grp1: 1 (1) Grp2: 0 (0)	Def: Fatal MI Grp1: 1 (1) Grp2: 0 (0)		
Jadzinsky, 2009 ⁷⁸	RCT	Grp1: Metformin + saxagliptin Varied, prespecified target dose; Fixed Start: 500 mg, Max: 1000 mg; Mean: 10 mg D: 1 week Grp2: Metformin Varied, NS Start: 500 mg, Max: 1000 mg D: 1 week	Grp1: 0 (0) Grp2: 3 (1)			
Jadzinsky, 2009 ⁷⁸	RCT	Grp1: Metformin + saxagliptin Varied, prespecified target dose; Fixed Start: 500 mg, Max: 1000 mg; Mean: 5 mg Grp2: Metformin Varied, NS Start: 500 mg, Max: 1000 mg D: 1 week	Grp1: 0 (0) Grp2: 3 (1)			

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Thiazolidinedione versus thiazolidinedione						
Juurlink, 2009 ²¹⁰	Cohort	Grp1: Rosiglitazone Varied, NS Grp2: Pioglitazone Varied, NS	Grp1: 645 (3) Grp2: 377 (2) HR: 0.86 (CI: 0.75 to 0.98)	Def: Death or admission to hospital Grp1: 1563 events Grp2: 895 events HR: 0.83 (CI: 0.76 to 0.9)	Def: Acute MI Grp1: 425 events Grp2: 273 events HR: 0.95 (CI: 0.81 to 1.11) Def: Hospitalization Grp1: 869 events Grp2: 461 events HR: 0.77 (CI: 0.69 to 0.87)	
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Rosiglitazone NS Grp2: Pioglitazone NS			Def: Angina pectoris defined by ICD-9-CM diagnostic codes for hospitalization Grp1: 154 (7.52) Grp2: 22 (4.51) Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 266 (12.71) Grp2: 44 (8.89)	Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 16 (0.8) Grp2: 2 (0.41) Def: TIA defined by ICD-9-CM diagnostic codes of hospitalization Grp1: 23 (1.14) Grp2: 5 (1.03)
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Rosiglitazone NR Grp2: Pioglitazone NR	Grp1: ref Grp2: HR: 0.81 (CI: 0.52 to 1.27) p: 0.36		Def: CABG, PTCA, MI, or diagnosis of CAD by ICD-9 after baseline Grp1: ref Grp2: HR: 1.15 (CI: 0.87 to 1.53) p: 0.32	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Thiazolidinedione versus sulfonylurea						
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Pioglitazone NS Grp2: Sulfonylurea NS			Def: Angina pectoris defined by ICD-9-CM diagnostic codes for hospitalization Grp1: 22 (4.51) Grp2: 3721 (3.87) Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 44 (8.89) Grp2: 1678 (1.76)	Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 2 (0.41) Grp2: 318 (0.34) Def: TIA defined by ICD-9-CM diagnostic codes of hospitalization Grp1: 5 (1.03) Grp2: 940 (0.99)
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Rosiglitazone NS Grp2: Sulfonylurea NS			Def: Angina pectoris defined by ICD-9-CM diagnostic codes for hospitalization Grp1: 154 (7.52) Grp2: 3721 (3.87) Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 266 (12.71) Grp2: 1678 (1.76)	Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 16 (0.8) Grp2: 318 (0.34) Def: TIA defined by ICD-9-CM diagnostic codes of hospitalization Grp1: 23 (1.14) Grp2: 940 (0.99)
Brownstein, 2010 ¹⁸²	Cohort	Grp1: Rosiglitazone NS Grp2: Sulfonylurea			Def: Hospitalization for acute MI Grp1: HR: 1.3 (CI: 1.0-1.7) Grp2: ref	
Tzoulaki, 2009 ¹⁷⁴	Cohort	Grp1: Rosiglitazone NS Grp2: Sulfonylurea NS	Grp1: 34 (<1) Grp2: 1379 (2)		Def: Incident MI Grp1: 9 (<1) Grp2: 365 (1)	
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Rosiglitazone NR Grp2: Sulfonylurea NR	Grp1: HR: 0.73 (CI: 0.51 to 1.02) p: 0.08 Grp2: ref		Def: CABG, PTCA, MI, or diagnosis of CAD by ICD-9 after baseline Grp1: HR: 0.90 (CI: 0.71 to 1.14) p: 0.41 Grp2: ref	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Pioglitazone NR Grp2: Sulfonylurea NR	Grp1: HR: 0.59 (CI: 0.43 to 0.81) p: <0.001 Grp2: ref		Def: CABG, PTCA, MI, or diagnosis of CAD by ICD-9 after baseline Grp1: HR: 1.04 (CI: 0.86 to 1.26) p: 0.69 Grp2: ref	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Rosiglitazone NR Grp2: Sulfonylurea NR			Def: Inpatient MI and coronary revascularization using ICD-9 and CPT codes Grp1: 152 (2) Grp2: 191 (2)	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Rosiglitazone NR Grp2: Sulfonylurea NR			Def: MI based on ICD -9 diagnosis codes (could be fatal or nonfatal MI since not specified but likely nonfatal mostly) Grp1: 70 (1) Grp2: 94 (1)	
Hanefeld, 2007 ¹⁰⁰	RCT	Grp1: Rosiglitazone Fixed Start: 4 mg D: 12 wks Grp2: Glibenclamide Varied Start: 2.5 mg, Max: 15 mg D: 12 wks	Grp1: 0 (0) Grp2: 0 (0)			

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Hanefeld, 2007 ¹⁰⁰	RCT	Grp1: Rosiglitazone Fixed Start: 8 mg D: 12 wks Grp2: Glibenclamide Varied Start: 2.5 mg, Max: 15 mg D: 12 wks	Grp1: 0 (0) Grp2: 0 (0)			
Kahn, 2006 ³⁸	RCT	Grp1: Rosiglitazone Varied, glucose: 140 mg/dL Start: 4 mg, Max: 8 mg Grp2: Glyburide Varied, glucose: 140 mg/dL Start: 2.5 mg, Max: 15 mg	Grp1: 34 (2) Grp2: 31 (2)	Def: Fatal MI Grp1: 2 (0.1) Grp2: 3 (0.2)	Def: Non-fatal MI Grp1: 25 (1.7) Grp2: 15 (1)	Def: Stroke not defined Grp1: 16 (1.1) Grp2: 17 (1.2)
Jain, 2006 ¹⁰¹	RCT	Grp1: Pioglitazone Varied, glucose: 69-141 mg/dL Start: 15 mg, Median: 45 mg, Max: 45 mg D: 12 wks Grp2: Glyburide Varied, glucose: 69-141 mg/dL Start: 5 mg, Median: 10 mg, Max: 15 mg D: 12 wks	Grp1: 0 (0) Grp2: 2 (0.8)		Def: Non-fatal MI Grp1: 2 (0.8) Grp2: 2 (0.8)	
St John Sutton, 2002 ¹⁴⁹	RCT	Grp1: Rosiglitazone Fixed Start: 4 mg bid Grp2: Glyburide Varied Max: 20 mg			Def: CVD morbidity/heart disease Grp1: 9 (9) Grp2: 5 (5)	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Sulfonylurea versus meglitinide						
Marbury, 1999 ¹¹⁷	RCT	Grp1: Glyburide Varied Start: 2.5 mg, Max: 4 mg bid Grp2: Repaglinide Varied Start: 0.5 mg, Max: 12 mg	Grp1: 1 (1) Grp2: 3 (1)		Def: CVD morbidity/unclear CHD Grp1: 4 (2) Grp2: 19 (5)	
Wolffenbuttel, 1999 ¹¹⁶	RCT	Grp1: Glyburide Varied Start: 1.75 mg, Max: 10.5 mg bid Grp2: Repaglinide Varied Start: 1.5 mg, Max: 12 mg			Def: Cardiac events NOS Authors stated similar frequencies in each group but no data given	
Sulfonylurea versus GLP-1 agonists						
Seino, 2010 ¹²¹	RCT	Grp1: Glibenclamide Varied, prespecified target dose Start: 1.25 mg, Max: 2.5 mg D: 4 weeks Grp2: Liraglutide Varied, prespecified target dose Start: 0.3 mg, Max: 0.9 mg D: 2 weeks	Grp1: 0 (0) Grp2: 1 (<1)		Grp1: 9 (6.8) Grp2: 9 (3.4)	
Metformin + thiazolidinedione versus metformin + sulfonylurea						
Hsiao, 2009 ¹²³	Cohort	Grp1: Metformin + rosiglitazone NS Grp2: Metformin + sulfonylurea NS			Def: Angina pectoris defined by ICD-9-CM diagnostic codes for hospitalization Grp1: 103 (4.26) Grp2: 5910 (2.2)	Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 12 (0.49) Grp2: 588 (0.22)
					Def: ICD-9-CM diagnostic codes of hospitalization Grp1: 25 (1.03) Grp2: 11435 (4.27)	Def: TIA defined by ICD-9-CM diagnostic codes of hospitalization Grp1: 11 (0.45) Grp2: 1637 (0.61)

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin + rosiglitazone NR Grp2: Metformin + sulfonylurea NR			Def: Inpatient MI and coronary revascularization using ICD-9 and CPT codes Grp1: 24 (2) HR: 0.61 (0.37 to 1.03) Grp2: 36 (3)	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin + rosiglitazone NR Grp2: Metformin + sulfonylurea NR			Def: MI based on ICD -9 diagnosis codes (could be fatal or nonfatal MI since not specified but likely nonfatal mostly) Grp1: 6 (<1) Grp2: 17 (1)	
Hamann, 2008 ¹²³	RCT	Grp1: Metformin + rosiglitazone Varied, glucose: 6.1 mmol/l Start: 2 g; Start: 4 mg D: 12 wks Grp2: Metformin + sulfonylurea Varied, glucose: 6.1 mmol/l Start: 2 g; Start: 5 mg D: 12 wks	Grp1: 2 (1) Grp2: 2 (1)			
Bakris, 2006 ¹²⁵	RCT	Grp1: Metformin + rosiglitazone Varied, NS; Varied, glucose: ≤ 6.6 mmol/L Unclear; Start: 4mg D: 3 wks Grp2: Metformin + glyburide Varied, NS; Varied, glucose: ≤ 6.6mmol/L Unclear; Start: 5 mg D: 3 wks	Grp1: 1 (1) Grp2: 0 (0)			

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Metformin + thiazolidinediones versus metformin + DPP-4 inhibitors						
Rigby, 2009 ¹³⁰	RCT	Grp1: Metformin + rosiglitazone Fixed NS; Mean: 4 mg Grp2: Metformin + sitagliptin NS; Mean: 100 mg			Def: Transient ischemic cerebrovascular accident Grp1: 1 (2) Grp2: 0 (0)	
Metformin + thiazolidinediones versus metformin + meglitinides						
Raskin, 2009 ¹³¹	RCT	Grp1: Metformin + rosiglitazone Varied, prespecified target dose Start: 1000 mg, Max: 2500 mg; Start: 4 mg, Max: 8 mg D: 4 wks Grp2: Metformin + repaglinide Varied Start: 1000 mg, Max: 2500 mg; Start: 4 mg, Max: 10 mg D: 4 wks	Grp1: 0 (0) Grp2: 1 (1)	Def: Sudden cardiac death Grp1: 0 (0) Grp2: 1 (1)		
Metformin + thiazolidinedione versus thiazolidinedione + sulfonylurea						
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin + rosiglitazone NR Grp2: Rosiglitazone + sulfonylurea NR			Def: Inpatient MI and coronary revascularization using ICD -9 and CPT codes Grp1: 24 (2) HR: 0.61 (0.37 to 1.03) Grp2: 6 (<1)	
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin + rosiglitazone NR Grp2: Rosiglitazone + sulfonylurea NR			Def: MI based on ICD -9 diagnosis codes (could be fatal or nonfatal MI since not specified but likely nonfatal mostly) Grp1: 6 (<1) Grp2: 21 (2)	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Rosak, 2006 ¹⁸³	RCT	Grp1: Metformin + rosiglitazone Varied Grp2: Rosiglitazone + sulfonyleurea Varied NS; Start: 4 mg, Max: 8 mg			Def: Not defined Grp1: 0.08/100 patient-years (0.04) Grp2: 0.22/100 patient-years (0.11)	Def: Not defined Grp1: 0.03/100 patient years (0.36) Grp2: 0.01/100 patient-years (0.18)
Metformin + sulfonyleurea versus metformin + meglitinide						
Monami, 2008 ¹⁸⁰	Cohort	Grp1: Metformin + sulfonyleurea NR Grp2: Metformin + repaglinide NR	Grp1: 35/6344 person-months Grp2: 5/2013 person-months			
Schwarz, 2008 ¹⁵²	RCT	Grp1: Metformin + glyburide Varied, glucose: 6.7mmol/l Start: 500 mg, Max: 2000 mg D: 12 wks Grp2: Metformin + nateglinide Varied, glucose: 6.7mmol/l Start: 500 mg; Max: 2000 mg D: 12 wks	Grp1: 1 (3) Grp2: 0 (0)			
Gerich, 2005 ¹³⁶	RCT	Grp1: Metformin + glyburide Varied, glucose: 6.7 mmol/l Start: 500 mg, Max: 2000 mg, Mean: 1105mg D: 12 wks Grp2: Metformin + nateglinide Varied, glucose: 6.7 mmol/l Start: 500 mg, Max: 2000 mg, Mean: 1459 mg D: 12 wks	Grp1: 1 (1) Grp2: 1 (1)			

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Metformin + sulfonyleurea versus metformin + DPP-IV inhibitors						
Seck, 2010 ¹³⁴	RCT	Grp1: Metformin + sitagliptin Fixed Grp2: Metformin + glipizide Fixed; Varied, glucose > 110 mg/dl NR; Start: 5 mg, Max: 20 mg, Mean: 9.2 mg	Grp1: 8 (1.4) Grp2: 1 (0.2)	Def: Sudden cardiac death Grp1: 2 (<1) Grp2: 0 (0)		
Nauck, 2007 ¹³³	RCT	Grp1: Metformin + glipizide NR Grp2: Metformin + sitagliptin NR	Grp1: 2 (0.3) Grp2: 1 (0.2)	Def: Fatal MI Grp1: 1 (0.2) Grp2: 0 (0)		
Metformin + sulfonyleurea versus metformin + GLP-1 agonists						
Pratley, 2010 ¹⁴³	RCT	Grp1: Metformin + sitagliptin NS; Max: 100 mg Grp2: Metformin + liraglutide Varied, HgbA1c: 7.5-10% NS; Start: 0.6 mg, Max: 1.8 mg		Def: Fatal cardiac arrest Grp1: 1 (<1) Grp2: 0 (0)		
Pratley, 2010 ¹⁴³	RCT	Grp1: Metformin + sitagliptin NS; Max: 100 mg Grp2: Metformin + liraglutide Varied, HgbA1c: 7.5-10% NS; Start: 0.6 mg, Max: 1.2 mg		Def: Fatal cardiac arrest Grp1: 1 (<1) Grp2: 0 (0)		
Metformin + sulfonyleurea versus thiazolidinedione + sulfonyleurea						
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin + sulfonyleurea NR Grp2: Rosiglitazone + sulfonyleurea NR			Def: Inpatient MI and coronary revascularization using ICD -9 and CPT codes Grp1: 36/1852 person-years Grp2: 39/1474 person-years	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
McAfee, 2007 ¹⁸¹	Cohort	Grp1: Metformin + sulfonyleurea NR Grp2: Rosiglitazone + sulfonyleurea NR			Def: MI based on ICD -9 diagnosis codes (could be fatal or nonfatal MI since not specified but likely nonfatal mostly) Grp1: 17/1865 person-years Grp2: 21/1495 person-years	
Hanefeld, 2004 ¹⁴⁰	RCT	Grp1: Metformin + sulfonyleurea Varied; NR Start: 850 mg, Max: 850 mg tid; NR Grp2: Pioglitazone + sulfonyleurea Varied; NR Start: 15 mg, Max: 45 mg; NR	Grp1: 2 (1) Grp2: 1 (<1)		Def: Coronary heart diseases/cardiac disorders Grp1: (3.1) Grp2: (4.1)	
van der Meer, 2009 ¹⁴¹	RCT	Grp1: Metformin + glimepiride Fixed Start: 1000 mg, Max: 2000 mg; Start: 15 mg, Max: 30 mg D: 8 wks Grp2: Pioglitazone + glimepiride Varied Not specified D: 8 weeks		Def: CVD event Grp1: 0 (0) Grp2: 0 (0)		

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Metformin + sulfonylurea versus metformin + premixed insulin						
Kvapil, 2006 ¹³⁸	RCT	Grp1: Metformin + sulfonylurea Fixed; Varied Start: 1660 mg; Start: 1.75 mg, Max: 10.5, Mean: 6.58 Grp2: Metformin + aspart 70/30 Fixed; Varied Start: 1660 mg; Start: 0.2 U/kg BID, Mean: 0.3 BID	Grp1: 0 (0) Grp2: 1	Def: Fatal MI Grp1: 0 (0) Grp2: 1		
Malone, 2003 ¹³⁷	RCT	Grp1: Metformin + glibenclamide Varied; Varied, fasting and pre-meal goal <7mmol/L, 2-hour post-prandial goal <10mmol/L Max: 2550 mg, Mean: 1968 mg; Mean: 14.2 mg D: 4 wks; 16 wks Grp2: Metformin + lispro 75/25 Varied; Varied, fasting and pre-meal goal <7mmol/L, 2-hour post-prandial goal <10mmol/L Max: 2550 mg; Mean: 0.19 U/kg in am and 0.14 U/kg in evening D: 4 wks; 16 wks	Grp1: 0 (0) Grp2: 1 (<1)			

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Overall mortality, n (%)	CVD mortality, n (%)	CVD morbidity, n (%)	Cerebrovascular disease, n (%)
Metformin + sulfonylureas versus metformin or sulfonylureas + thiazolidinediones						
Home, 2009 ¹⁶	RCT	Grp1: Metformin + sulfonylurea Varied, HgbA1c: ≤7.0% Max: 2550 mg; Glibenclamide, Max: 15 mg, Glimepiride, Max: 4 mg D: 8 wks Grp2: Rosiglitazone + metformin or sulfonylurea Varied, HgbA1c: ≤7.0% Start: 4 mg, Max: 8 mg; Metformin, Max: 2550 mg, Glibenclamide, Max: 15 mg, Glimepiride, Max: 4 mg D: 8 wks	Grp1: 157 Grp2: 136 HR: 0.86 (CI: 0.68 to 1.08), p: 0.19	Grp1: 71 Grp2: 60 HR: 0.84 (CI: 0.59 to 1.18), p: 0.32	Def: Fatal and non-fatal MI Grp1: 56 Grp2: 64 HR: 1.14 (CI: 0.80 to 1.63), p: 0.47	Def: Fatal and nonfatal stroke Grp1: 63 Grp2: 46 HR: 0.72 (CI: 0.49 to 1.06), p: 0.10
Metformin + basal insulin versus metformin + premixed insulin						
Malone, 2005 ¹⁶⁵	RCT	Grp1: Metformin + lispro 75/25 Varied, premeal glucose 90-126 mg/dL; 2-hr postprandial 144-180 mg/dL Start: 1500 mg, Max: 2550 mg, Mean: 2146 mg; Mean: 0.42 U/kg BID D: 4 wks, 16 wks Grp2: Metformin + glargine Varied, pre-meal glucose 90-126 mg/dL Start: 1500 mg, Max: 2500 mg, Mean: 2146 mg; Mean: 0.36 U/Kg QD D: 4 wks, 16 wks	Grp1: 1 (2) Grp2: 1 (2)	Grp1: 1 (2) Grp2: 0 (0)		

bid= twice; CHD= coronary heart disease; CPT=current procedural terminology; CVD=cardiovascular disease; Def=definition; D=duration of titration; g = grams per day; Grp= group; HbA1c = hemoglobin A1c; HR= hazard ratio; ICD=International Classification of Diseases; ID= identification; IR= incidence ratio; Met= metformin; mg = milligram; MI= myocardial infarction; mmol/l = millimoles/liter; NOS= not otherwise specified; NR= not reported; OR= odds ratio; RCT= randomized controlled trial; RR=risk ratio; SU= sulfonylurea; tid = thrice; U/kg = unit per kilogram; wks = weeks

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2)

Author, year	Study design	Intervention	Nephropathy, n (%)	Neuropathy, n (%)
Metformin versus thiazolidinedione				
Scherthauer, 2004 ⁵²	RCT	Grp1: Metformin Varied Start: 850 mg, Max: 2550 mg Grp2: Pioglitazone Varied Start: 30 mg, Max: 45 mg	Def: urinary albumin/creatinine ratio Grp1: 1% Grp2: 19%, p: 0.002 vs. Grp2	
Metformin versus sulfonylurea				
Amador-Licona, 2000 ⁶⁶	RCT	Grp1: Metformin Varied Start: 850mg, Max: NR Grp2: Glibenclamide Varied Start: 5mg, Max: NR	Def: change in glomerular filtration rate Grp1: B: 138 mL/min F: 134 mL/min, p=0.46 vs. baseline Grp2: B: 136 mL/min F: 151 mL/min, p=0.04 vs. baseline	
Amador-Licona, 2000 ⁶⁶	RCT	Grp1: Metformin Varied Start: 850 mg, Max: NR Grp2: Glibenclamide Varied Start: 5 mg, Max: NR	Def: change in microalbumin (mg/d) Grp1: B: 74 mg/d F: 49 mg/d, p=0.008 vs. baseline Grp2: B: 83 mg/d F: 102 mg/d, p=0.09 vs. baseline	
Metformin versus metformin + thiazolidinedione				
Gomez-Perez, 2002 ⁸⁸	RCT	Grp1: Metformin Fixed Start: 2500 mg Grp2: Metformin + rosiglitazone Fixed Start: 2500 mg; Start: 2 mg bid		Def: Unclear neuropathy Grp1: 1 Grp2: 0 (0)

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Nephropathy, n (%)	Neuropathy, n (%)
Gomez-Perez, 2002 ⁸⁸	RCT	Grp1: Metformin Fixed Start: 2500 mg Grp2: Metformin + rosiglitazone Fixed Start: 2500mg; Start: 4mg bid		Def: Unclear neuropathy Grp1: 1 Grp2: 0 (0)
Metformin versus metformin + DPP-IV inhibitors				
Raz, 2008 ⁹³	RCT	Grp1: Metformin Fixed NR Grp2: Metformin + sitagliptin Fixed Max: 2550 mg; Mean: 100 mg		Def: NR Grp1: 2 (2.1) Grp2: 4 (4.2)
Thiazolidinedione versus sulfonylurea				
Nakamura, 2006 ¹⁰⁸	RCT	Grp1: Pioglitazone Fixed Mean: 30 mg Grp2: Glibenclamide Fixed Mean: 5 mg	Def: Urine albumin excretion (microgram/min), mean (SD) Grp1: Baseline: 142.5 (46.5); 12 mos: 40.5 (20.5) p<0.001 Grp2: Baseline: 136.5 (40.8); 12 mos: 146.0 (48.8) Grp1-Grp2: -111.5	
Nakamura, 2004 ¹⁰²	RCT	Grp1: Pioglitazone Fixed Start: 30 mg Grp2: Glibenclamide Fixed Start: 5 mg	Def: Urine albumin excretion (microgram/min), mean (SD) Grp1: 6 mos: 86.5 (24.5); 12 mos: 44.5 (16.4) Grp2: 6 mos: 142.5 (42.5); 12 mos: 146.8 (38.5) Grp1-Grp2: 6 mos, p: <0.05; 12 mos: <0.01	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Nephropathy, n (%)	Neuropathy, n (%)
Agarwal, 2005 ¹⁸⁴	RCT	<p>Grp1: Pioglitazone Varied, glucose: 140 mg/dL, HgbA1c: 8% Start: 15 mg, Mean: 33 mg, Max: 41 mg D: 3.8 mos</p> <p>Grp2: Glipizide Varied, glucose: 140 mg/dL, HgbA1c: 8% Start: 5 mg, Mean: 16 mg, Max: 19 mg D: 3.7 mos</p>	<p>Def: Proteinuria Grp1: % mean reduction: 7.2, CI: -24.9 - 10.6</p> <p>Grp2: % mean increase: 6.1, CI: -11.7-23.8</p> <p>Grp1-Grp2: % reduction: 13.2, CI: -38.4 -11.9, p: 0.294</p>	
Bakris, 2003 ¹⁰⁴	RCT	<p>Grp1: Rosiglitazone Fixed Start: 4 mg bid</p> <p>Grp2: Glyburide Varied Start: NR, Max: 20 mg</p>	<p>Def: n (%) with normal albuminuria at baseline who progressed to microalbuminuria by study end Grp1: 3 (7)</p> <p>Grp2: 5 (10.6)</p>	
Bakris, 2003 ¹⁰⁴	RCT	<p>Grp1: Rosiglitazone Fixed Start: 4 mg bid</p> <p>Grp2: Glyburide Varied Start: NR, Max: 20 mg</p>	<p>Def: albumin/creatinine ratio Grp1: (-45 to -4) p: NSG vs. Grp2</p> <p>Grp2: (-22 to 4)</p>	
Nakamura, 2000 ¹⁰³	RCT	<p>Grp1: Pioglitazone Fixed Start: 30 mg bid</p> <p>Grp2: Glibenclamide Fixed Start: 5 mg</p>	<p>Def: urinary albumin excretion Grp1: B: 142.8 ug/min F: 48.4 ug/min, p: < 0.05</p> <p>Grp2: B: NR F: NR, p: > 0.05</p>	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Nephropathy, n (%)	Neuropathy, n (%)
Thiazolidinedione versus meglitinide				
Nakamura, 2006 ¹⁰⁸	RCT	Grp1: Pioglitazone Fixed Mean: 30 mg Grp2: Nateglinide Fixed Mean: 270 mg	Def: Urine albumin excretion (microgram/min), mean (SD) Grp1: Baseline: 142.5 (46.5); 12 mos: 40.5 (20.5) p<0.001 Grp2: Baseline: 134.6 (42.8); 12 mos: 140.8 (44.4) Grp1-Grp2: -108.2	
Metformin + thiazolidinedione versus metformin + sulfonyleurea				
Bakris, 2006 ¹²⁵	RCT	Grp1: Metformin + rosiglitazone Varied; Varied, glucose: ≤ 6.6 mmol/L NS; Start: 4mg D: 3 wks Grp2: Metformin + Glyburide Varied; Varied, glucose: ≤6.6 NR; Start: 5 mg D: 3 wks	Def: % change in UACR (urine albumin: creatinine ratio >=30), Mean (SD) Grp1: -22.7 (15), p: <0.01 Grp2: -5.5 (14.5), p: NSG Grp1-Grp2: -15.5%, p: 0.07	
Comaschi, 2007 ¹²⁹	RCT	Grp1: Metformin + pioglitazone Varied, NR Max: 3 g; Start: 15 mg, Max: 30 mg D: NR; 22 wks Grp2: Metformin + glibenclamide Varied, HgbA1c: 7.50% Start: 400mg, Max: 3g; Start: 2.5mg D: 22 wks		Grp1: 1 Grp2: 0 (0)
Metformin + sulfonyleurea versus thiazolidinedione + sulfonyleurea				
Hanefeld, 2004 ¹⁴⁰	RCT	Grp1: Metformin + unspecified sulfonyleurea + placebo Varied Start: 850 mg, Max: 2550 mg; NR Grp2: Pioglitazone + unspecified sulfonyleurea + placebo Varied Start: 15 mg, Max: 45 mg; NR	Def: albumin/ creatinine ratio Grp1: Grp2: CI: 0.73-0.97, p: 0.017 vs. Grp1	

Table 8. Comparative effectiveness of diabetes medications on long-term clinical outcomes (KQ2) (continued)

Author, year	Study design	Intervention	Nephropathy, n (%)	Neuropathy, n (%)
Hanefeld, 2004 ¹⁴⁰	RCT	Grp1: Metformin + unspecified sulfonylurea + placebo Varied Start: 850 mg, Max: 2550 mg; NR Grp2: Pioglitazone + unspecified sulfonylurea + placebo Varied Start: 15 mg, Max: 45 mg; NR	Def: microalbuminuria resolved Grp1: 7.7% Grp2: 10.2%	

B=Baseline; bid=twice; CI= Confidence interval; Def=Definition; D= Duration of titration; F=Final; Grp=Group; HgbA1c = hemoglobin A1c; mos=Months; mg = milligram; mL/min = milliliter per minute; mmol/l = millimoles/liter; NR=Not reported; NSG=Not significant; RCT = Randomized controlled trial; ug/min= micrograms per minute; UACR= Urine albumin: creatinine ratio; wks=weeks

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Hypoglycemia

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met vs. TZD							
1 trial	2910	Medium	Unknown	Direct	Precise	Small, No favorite	Moderate
Met vs. SU							
11 RCTs	6679	Medium	Consistent	Direct	Precise	Large, Favors metformin	High
Met vs. DPP-4 Inhibitor							
3 RCTs	1918	Medium	Consistent	Direct	Precise	Small, No favorite	High
Met vs. Meg							
5 RCTs	914	Medium	Consistent	Direct	Imprecise	Small, Favors Met	Moderate
Met vs. Met + TZD							
8 RCTs	3073	Medium	Consistent	Direct	Precise	Small, Favors Met alone	Moderate
Met vs. Met + SU							
9 RCTs	2141	Medium	Consistent	Direct	Imprecise	Large, Favors Met alone	Moderate
Met vs. Met + DPP-4 Inhibitor							
4 RCTs (in 5 reports)	1448	High	Consistent	Direct	Precise	Small, No favorite	Moderate
Met vs. Met + Meg							
3 RCTs	559	Medium	Inconsistent	Direct	Imprecise	Large, Favors Met alone	Low
Rosi vs. Pio							
1 obs.	202	High	Unknown	Direct	Imprecise	Small, Favors Rosi	Low
TZD vs. SU							
8 RCTs, 1 obs	10680	Medium	Consistent	Direct	Precise	Large, Favors TZD	High
TZD vs. Meg							
2 RCTs	248	High	Consistent	Direct	Precise	Small, Favors TZD	Low
SU vs. DPP-4 Inhibitor							
1 RCT	245	Low	Unknown	Direct	Precise	Large, Favors DPP-4 inhibitor	Moderate
SU vs. Meg							
8 RCTs	1846	Medium	Consistent	Direct	Precise	Small Favors Meg	Low
SU vs. GLP-1 Agonist							
3 RCTs	1310	Low	Consistent	Direct	Precise	Medium, Favors liraglutide	High
Met + TZD vs. Met + Another Agent (mostly SU)							
6 RCTs, 1 obs	2543	Medium	Consistent	Direct	Precise	Large, Favors Met + TZD	High
Met + TZD vs. TZD + SU							
1 obs	22808	High	Unknown	Direct	Precise	Large, Favors Met + TZD	Low
Met + SU vs. Met + Another Agent							
9 RCTs	3409	Low	Inconsistent	Direct	Imprecise	Small, Unclear, Depends on "other agent"	Low

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Hypoglycemia

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met + SU vs. TZD + SU							
1 RCT	441	High	Unknown	Direct	Precise	Small, Favors TZD + SU	Low
Met + GLP-1 Agonist vs. Met + Basal Insulin							
1 RCT	69	Low	Unknown	Direct	Imprecise	Large, Favors Met + exenatide`	Low
Met + Basal Insulin vs. Met + Another Insulin							
5 RCTs	826	Medium	Consistent	Direct	Precise	Medium, Favors Met + basal insulin	Moderate

DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; Meg = meglitinides; Met = metformin; NA = not applicable; Nateg = nateglinide; obs = observational study; Pio = pioglitazone; RCT = randomized controlled trial; Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Liver injury

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and direction of effect	
Met vs. TZD							
1 Rct 1 Obs	1194	Low	Consistent	Direct	Precise	Small, no favorite	Moderate
Met vs. SU							
1 RCT	1194	Low	Unknown	Direct	Imprecise	Unclear.	Low
Rosi vs. Pio							
1 Obs	3694	Low	Unknown	Direct	Precise	Unclear	Low
TZD vs. SU							
1 Obs, 2 RCT	7764	Moderate	Consistent	Direct	Precise	Small, no favorite	High
Met + TZD vs. Met + Another agent							
1 RCT	95	Low	Unknown	Direct	Imprecise	No difference	Low
Met + SU vs. TZD + SU							
2 RCT	837	High	Unknown	Direct	Precise	No difference	Low

Met = metformin; obs = observational study; Pio = pioglitazone; RCT = randomized controlled trial; Rosi = rosiglitazone; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Congestive heart failure

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and Direction of Effect	
Met vs. TZD							
3 RCTs 4 Obs	1786 91	Medium	Inconsistent	Direct	Imprecise	Small. No favorite	Moderate
Met vs. SU							
5 Obs	1896 10	Medium	Consistent	Direct	Precise	Small. Increase risk with SU	Moderate
Rosi vs. Pio							
4 Obs	4511 4	High	Unknown	Direct	Imprecise	Unclear.	Low
TZD vs. SU							
4 RCTs 5 Obs	2748 80	Medium	Consistent	Direct	Imprecise	Small. Increase risk with TZD	Moderate
Met + TZD vs. TZD + SU							
1 Obs	1219 3	High	Unknown	Direct	Imprecise	Small. Increase risk with TZD + SU combination	Low
Met + SU vs. TZD + other							
1 RCT	2200	Low	Unknown	Direct	Imprecise	Favors SU + Met	Low
Met + Basal Insulin vs. Met + Another Insulin							
1 RCT	67	Low	Inconsistent	Direct	Imprecise	Unclear	Low

Met = metformin; obs = observational study; Pio = pioglitazone; RCT = randomized controlled trial; Rosi = rosiglitazone; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Lactic acidosis

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/ Quality	Consistency	Directness*	Precision	Magnitude and Direction of Effect	
Met vs. SU							
2 RCTs	160	Low	Consistent	Direct	Imprecise	Weak; no increased risk with Metformin	Moderate
Met vs. Met +SU							
2 RCTs	163	Low	Consistent	Direct	Imprecise	Weak; no favorite	Moderate

Met = metformin; RCT = randomized controlled trial; SU = sulfonylurea. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Cancer

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias: Design/Quality	Consistency	Directness*	Precision	Magnitude and Direction of Effect	
Met vs. SU							
1 Obs	38860	High	Unknown	Direct	Imprecise	Weak; favors Met	Low
Met vs. Meg							
1 RCT	96	Low	Unknown	Direct	Imprecise	Weak; favors Meg	Low
Met vs. Met + SU							
1 Obs	45303	High	Unknown	Direct	Imprecise	Weak; favors Met	Low
Met vs. Met +DPP-4 Inhibitor							
1 RCT	190	Low	Unknown	Direct	Imprecise	Weak; favors Met + DPP-4 inhibitor	Low
TZD vs. SU							
1 RCT	502	Low	Unknown	Direct	Imprecise	Weak; favors TZDs	Low

DPP-4 = dipeptidyl peptidase-4; Meg = meglitinides; Met = metformin; obs = observational study; RCT = randomized controlled trial; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Fractures

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and Direction of Effect	
Met vs. TZD							
1 RCT 1 Obs	7953 3	Medium	Unknown	Direct	Precise	Small. Favors metformin	High
Met vs. SU							
2 RCTs 1 Obs	1352 58	Medium	Consistent	Direct	Imprecise	Unclear	Low
Met vs. Met+ TZD							
1 RCT 2 Obs	7827 5	Medium	Unknown	Direct	Imprecise	Small, favors metformin	Low
Met vs. Met + SU							
1 RCT	59	Medium	Unknown	Direct	Imprecise	Unclear	Low
Met vs. Met + DPP-4 Inhibitor							
1 RCT	190	Medium	Unknown	Direct	Imprecise	Unclear	Low
TZD vs. SU							
2 RCT 1 Obs	8773 8	Medium	Unknown	Direct	Imprecise	Small, favors SU	High
Met + SU vs. TZD + Another agent							
1 RCT	3325	Low	Unknown	Direct	Precise	Small. Favors metformin + SU	High

DPP-4 = dipeptidyl peptidase-4; Met = metformin; obs = observational study; RCT = randomized controlled trial; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Pancreatitis

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and Direction of Effect	
Met vs. Met +SU							
1 RCT	366	Low	Unknown	Direct	Imprecise	Small, favors metformin	Low
DPP-4 Inhibitors vs. GLP-1 Agonists							
1 RCT	665	Low	Unknown	Direct	Imprecise	Unclear, no favorite	Low
Sulfonylureas vs. GLP-1 Agonists							
2 RCT	1156	Low	Unknown	Direct	Imprecise	Small, favors SU	Low

DPP-4 = dipeptidyl peptidase-4; GLP-1 agonist = glucagon-like peptide-1 agonist; Met = metformin; RCT = randomized controlled trial; SU = sulfonylurea. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Cholecystitis

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and Direction of Effect	
Met vs. TZD							
1 RCT	205	Low	Unknown	Direct	Imprecise	Small, favors metformin	Low
Met vs. Met + TZD							
1 RCT	569	Low	Unknown	Direct	Imprecise	Small, favors TZD	Low
TZD vs. SU							
1 RCT	2120	Low	Unknown	Direct	Imprecise	Small, no favorite	Low

Met = metformin; RCT = randomized controlled trial; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Macular edema

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and Direction of Effect	
Met + TZD vs. Met + Another agent							
1 RCT	561	Low	Unknown	Direct	Imprecise	Small, increased risk with metformin + TZD	Low

Met = metformin; RCT = randomized controlled trial; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Gastrointestinal effects

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and Direction of Effect	
Met vs. TZD							
5 RCTs	5021	Low	Consistent	Direct	Precise	Large; Favors TZD	High
Met vs. SU							
11 RCTs, 1 Obs.	10666	Medium	Consistent	Direct	Precise	Large; Favors SU	Moderate
Met vs. DPP-4 Inhibitor							
2 RCTs	1028	High	Unknown	Direct	Imprecise	Large; Favors Sitagliptin	Low
Met vs. Meg							
4 RCTs	776	Medium	Inconsistent	Direct	Imprecise	Small; Unclear for "any GI effect"; favors MEG for diarrhea	Low
Met vs. Met + TZD							
8 RCTs	2977	Medium	Consistent	Direct	Imprecise	Small; Unclear for "any GI effect"; favors Met+TZD for diarrhea	Moderate
Met vs. Met + SU							
10 RCTs	2786	Medium	Consistent	Direct	Imprecise	Small; Unclear favorite; favors combination arm when combination dose of metformin lower	Moderate
Met vs. Met + DPP-4 Inhibitor							
6 RCTs	3355	Medium	Consistent	Direct	Precise	Small; Unclear favorite	Low
Met vs. Met + Meg							
1 RCT	193	Low	Unknown	Direct	Imprecise	Small; Unclear favorite	Low
TZD vs. SU							
4 RCTs	6083	Low	Consistent	Direct	Precise	Small; Unclear favorite	High
TZD vs. Meg							
1 RCT	123	Medium	Unknown	Direct	Imprecise	Small; Unclear favorite	Low
SU vs. GLP-1 Agonist							
						Favors SU	Low
Met + TZD vs. Met + SU							
4 RCTs	1212	Low	Inconsistent	Direct	Imprecise	Small; Favors neither	Low
Met + TZD vs. Met + DPP-4 Inhibitor							
1 RCT	181	Low	Unknown	Direct	Imprecise	Small; Favors neither	Low
Met + TZD vs. Met + GLP-1 Agonist							
						Favors met + TZD	Low

Table 9. Number of studies, strength of evidence domains, magnitude of effect, and strength of evidence. Outcome: Gastrointestinal effects (continued)

Number of Studies	Total N	Domains Pertaining to Strength of Evidence					Strength of Evidence
		Risk of Bias Design/Quality	Consistency	Directness*	Precision	Magnitude and Direction of Effect	
Met + SU vs. Met + DPP-4 Inhibitor							
1 RCT	1172	Low	Unknown	Direct	Imprecise	Small; Favors neither	Low
Met + SU vs. Met + MEG							
1 RCT	66	Low	Unknown	Direct	Imprecise	Small; Unclear favorite for "any GI side effects"; Favors Met + MEG for abdominal dyspepsia	Low
Met + basal insulin vs. Met + another insulin							
1 RCT	317	Low	Unknown	Direct	Imprecise	Small; Unclear favorite	Low
Met + SU vs. TZD + SU							
2 RCTs	1591	Medium	Consistent	Direct	Precise	Small; Favors TZD combination arm	Moderate

DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; Meg = meglitinides; Met = metformin; NA = not applicable; Nateg = nateglinide; obs = observational study; Pio = pioglitazone; RCT = randomized controlled trial; Repag = repaglinide; Rosi = rosiglitazone; Sita = sitagliptin; SU = sulfonylurea; TZD = thiazolidinedione. All other comparisons were graded as insufficient since there were no studies of those comparisons. The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Seino, 2010 ¹²¹	RCT	Neither year reported	Yes	< 6 months	Yes	NR/464	Age <20 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), retinopathy, HbA1c <7% or >10%, BMI >35 kg/m ² , treated with insulin within 12 weeks of the start of the study, receiving or expecting to receive systemic corticosteroids, known hypoglycemia unawareness or recurrent major hypoglycemia unawareness or recurrent major hypoglycemia, no Type 2 DM, treated with diet therapy for less than 8 weeks, on more than 1/2 of the recommended maximum dose of an SU (e.g., on more than 2.5 mg of glibenclamide)
Japan		24 weeks				NR	
Derosa, 2010 ⁴⁴	RCT	Neither year reported	No run-in period	< 6 months	No	128/128	Age <18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, retinopathy, HbA1c < 8%, BMI <25 kg/m ² or ≥30 kg/m ² , pregnant, nursing, not using adequate contraception, history of ketoacidosis, severe anemia, not intolerant to metformin at maximum dosage (3,000 mg/day), not on metformin, diabetic neuropathy
Italy		12 months					

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
DeFronzo, 2010 ¹³²	RCT	Start year: 2006 End year: 2008 20 weeks	None	< 6 months	Yes	NR/137 NR	Age <18 or >75 years, HbA1c <6.8% or >10%, BMI <25 kg/m ² or >40 kg/m ² , not on stable dose of metformin for at least 6 weeks, body weight stable for past 6 months, islet cell auto-antibodies, treatment with any other antidiabetic medication (other than metformin)
United States							
Aschner, 2010 ⁷⁷	RCT	Neither year reported 24 weeks	Run-in period but number of participants excluded was NR	NR	Yes	2068/1050 NR	Age <18 and > 78 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c < 6.5% or >9%, treatment naive, no Type 2 DM, FPG <120 mg/dL or >250 mg/dL, triglycerides >600 mg/dL, CK > 2 times normal upper limit
Multicontinent							
Seck, 2010 ¹³⁴	RCT	Neither year reported 2 years	Run-in period but number of participants excluded was NR	< 6 months	Yes	2141/1172 NR	Age <17 years or >78 years
NR							

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Komajda, 2010 ²⁹²	RCT	Start year: 2001 End year: 2003 5.5 years	None	NR	Yes	NR/4447	Age <40 or > 75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c ≤7% or > 9%, BMI ≤25 kg/m ² , planned cardiovascular intervention, uncontrolled hypertension, no Type 2 DM, current use of other anti-DM medications, hospitalization within last 3 months for CVD event, heart failure
Pratley, 2010 ¹⁴³	RCT	Start year: 2008 End year: 2009 26 months	None	≥ 6 months	Yes	1302/665	Age <18 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <7.5% or >10%, BMI >45 kg/m ² , no Type 2 DM, cancer, contraindication to trial drugs, recurrent hypoglycemia or hypoglycemia unawareness, not on metformin for at least 3 months, on any non-metformin anti-hypoglycemic in past 3 months

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Pantalone, 2009 ¹⁷⁴	Prospective or retrospective cohort	Start year: 1998 End year: 2006 8 years	NA	NA	Yes	NR/20450 Inpatient/hospital, Outpatient: primary care, Outpatient: subspecialty care setting	Age <18 years, history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), on dialysis, on combination ODM, on insulin or other injectable antidiabetics, history of CHF
United States							
Currie, 2009 ¹⁷³	Prospective or retrospective cohort	Start year: 2000 End year: 2005 6 years	NA	NA	NR	1432850/473483 Inpatient/hospital, Outpatient: primary care, Outpatient: subspecialty care setting	Type 1 DM, prescribed insulin only during study period, new diagnosis of Type 2 DM during the year before index date, switch between rosiglitazone and pioglitazone or combined use of both drugs during study period, prescribed ODM less than three times during study period
Taiwan							
Currie, 2009 ²¹²	Prospective or retrospective cohort	Start year: 2000 5 years	NA	NA	No	170000/62809 Outpatient: primary care, General Practices	Age <40 years at diabetes onset, <6 sequential prescriptions of ODM, secondary causes of DM
United Kingdom							
Tzoulaki, 2009 ¹⁷¹	Prospective or retrospective cohort	Start year: 1990 End year: 2005 Mean 7.1 years	NA	NA	No	NR/91,521 Inpatient/hospital, Outpatient: primary care, Outpatient: subspecialty care setting	Age < 35 or > 90 years, no DM, multiple or missing dates of death, missing information, no treatment with medications
United Kingdom							

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Perez, 2009 ⁵⁶	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	1436/600	Age <18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g. "failed initial treatment"), contraindication or history of intolerance to metformin, HbA1c <7.5% or >10%, BMI >45 kg/m ² , pregnant, nursing, triglyceride level 500, if they were NOT discontinued metformin and TZD therapy due to lack of efficacy
United States, Multinational Europe		24 weeks				NR	
Juurlink, 2009 ²¹⁰	Prospective or retrospective cohort	Start year: 2002 End year: 2008 3 years	NA	NA	No	NA/ 39736 Outpatient: primary care	Age <66 years, patients on rosiglitazone or pioglitazone before the index date, patients on insulin before the index date
Dormuth, 2009 ²¹⁵	Prospective or retrospective cohort	Start year: 1998 End year: 2007 11 years	NA	NR	No	127581/ 84339 Community	Had received insulin or other ODMs besides metformin, SU or TZD, gestational DM, fractures, admitted to long term facility

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Rigby, 2009 ¹³⁰	RCT	Start year: 2007 End year: 2008	NA	< 6 months	Yes	169/356 NR	Age <18 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c >10% (9.5% if on metformin combination therapy), HbA1c <7% (6.5% if on metformin combination therapy), BMI > 40 kg/m ² , LDL <50mg/dl or TG ≥500 mg/dL, weight loss program with ongoing weight loss or starting an intensive exercise program within 4 weeks of screening, need for oral corticosteroids, bile acid sequestrants, or any antidiabetes medications other than metformin, >2 months insulin, not on metformin for ≥3 months (1500-2550 mg/day), Type 1 DM and/or ketoacidosis, dysphagia/swallowing disorders, intestinal motility disorders, pancreatitis, HIV/AIDS, drug/alcohol abuse within 2 years, any serious disorder including pulmonary, hepatic, gastrointestinal, uncontrolled endocrine/metabolic, hematologic/oncologic (within 5 years), neurologic, or psychiatric diseases, current treatment with TZD/combo with metformin/colesevelam/ fixed-dose combination product including metformin, hospitalization within 14 days of screening

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Mancini, 2009 ²¹⁴	Cross-sectional study	Neither year reported	NA	NA	Yes	65/65	History of significant trauma, neoplastic disorder or diseases affecting the bone, prolonged immobilization, use of anti-osteoporotic drug
Italy		NR				Outpatient: primary care, Outpatient: subspecialty care setting	
Tolman, 2009 ¹⁵⁰	RCT	Start year: 2000 End year: 2005 3 years	None	< 6 months	Yes	NR/2120 NR	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <7%, BMI <20kg/m ² or >48 kg/m ² , not taking metformin and/or SU, history of ketoacidosis, history of TZD use other than troglitazone before 4/00
United States							
Dimic, 2009 ¹⁹⁹	Non-randomized trial	Neither year reported	None	< 6 months	NR	NR/60 NR	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g. "failed initial treatment"), HbA1c <7.5%, glucocorticoids
Serbia		12 weeks					

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Jadzinsky, 2009 ⁷⁸	RCT	Start year: 2006 End year: 2007	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	2936/1394	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g. "failed initial treatment"), HbA1c < 8% >12%, BMI >40 kg/m ² , prior treatment, diabetic ketoacidosis or nonketotic hyperosmolar coma, CVD events 6 months prior, LVEF <40%, psychiatric history, alcohol or drug abuse, abnormal metabolic or hematologic test
Multi-continent		24 weeks				Outpatient: primary care, Outpatient: subspecialty care setting, Community	
DeFronzo, 2009 ⁹⁵	RCT	Neither year reported	Yes	< 6 months	Yes	1462/743	Age >18 and <77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g. "failed initial treatment"), contraindication or history of intolerance to metformin, neuropathy, retinopathy, HbA1c < 7% or >10%, BM >40 kg/m ² , pregnant, nursing, alcohol or drug abuse, NYHA III and IV, LVEF <40
NR		24 weeks				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Bunck, 2009 ¹⁴⁴	RCT	Start year: 2004 End year: 2007	None	< 6 months	Yes	150/69	Age <30 and >75 years, HbA1c<6.5% or >9.5%, BMI <25 kg/m ² or BMI >40 kg/m ² , metformin treatment not at a stable dose for at least 2 months, no other blood glucose lowering medications allowed in 3 months prior to study, no changes in other medications known to affect B cell function (ACEI, B Blockers)
Sweden, Finland, Netherlands		56 weeks				NR	
Garber, 2009 ¹²²	RCT	Start year: 2006 End year: 2007	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	NR/746	Age <18 or >80 years, HbA1c <7% or >11% if prior treatment was diet; >10% if prior treatment was drug, BMI >45 kg/m ² , either not treated with diet and exercise or up to half the highest dose of ODM monotherapy for at least 2 months prior to trial, insulin treatment during the previous 3 months (except short-term treatment for intercurrent illness), treatment with systemic corticosteroids, hypoglycemia unawareness or recurrent severe hypoglycemia, impaired liver function (aspartate aminotransferase or alanine aminotransferase concentrations 5 times upper normal range)
United States, Mexico		52 weeks				NR	
Derosa, 2009 ⁴⁶	RCT	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	NR	271/252	Age <18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, retinopathy, HbA1c < 6.5%, BMI <25 kg/m ² or >30 kg/m ² , pregnant, nursing, not using adequate contraception, no Type 2 DM, history of ketoacidosis, severe anemia
Italy		15 months				Outpatient: primary care, computerized clinic registry	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Williams-Herman, 2009 ⁷⁶	RCT	Neither year reported	Run-in period but number of participants excluded was NR	NR	Yes	3544/1091	Age <18 or >78 years, HbA1c ≤7.5% or ≥11% after screening diet/exercise run-in (which included a wash-out period), lack of adequate compliance (≥75% by tablet count) during 2-week single-blind placebo run-in period, no Type 2 DM
NR		54 weeks				NR	
Kaku, 2009 ⁸⁴	RCT	Start year: 2005	Yes	< 6 months	Yes	NR/236	Age ≤20 or ≥65 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g. failed initial treatment), HbA1c <6.5% or >10%, other pre-existing conditions that potentially require hospitalization such as cancer, severe lung, gastrointestinal, pancreatic and hematological disorders, history of lactic acidosis, ketoacidosis, diabetic coma, or pre coma within the preceding 26 weeks, if on any medications that might affect glycemic control, drug or alcohol dependency
Japan		40 weeks				NR	
Nauck, 2009 ⁹²	RCT	Neither year reported	Run-in period but number of participants excluded was NR	≥ 6 months	Yes	1662/1087	Age <18 or >80 years, HbA1c > 11% if on monotherapy; 10% if on combination therapy (both greater than 3 months), HbA1c < 7%, BMI >40 kg/m ² , used insulin in last 3 months
Multi-continent		26 weeks				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Raskin, 2009 ¹³¹	RCT	Neither year reported	No run-in period	< 6 months	Yes	1093/383	Age <18 years, pregnant, nursing, currently not under monotherapy at least 2 months or dual therapy, FBG >260 mg/dL, any disease of abnormality as judged by the investigator, treatment with the investigational drug for 4 weeks, allergy to study drugs or related compounds, history of hypoglycemia unawareness or recurrent severe hyperglycemia
NR		26 weeks				Outpatient: primary care	
van der Meer, 2009 ¹⁴¹	RCT	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	173/80	Age <45 or >65 years, female, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <6.5% or >8.5%, BMI <25 kg/m ² or >32 kg/m ² , SBP <150 mm Hg, DBP <85 mm Hg, prior TZD or insulin use
Netherlands		24 weeks				NR	
Scott, 2008 ⁸⁵	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	486/273	Age <18 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), HbA1c <7% or >11%, not on 10 weeks on stable dose of metformin, insulin use, Type 1 DM, glucose > 270 mg/dL
Multi-continent		18 weeks				NR	
Raz, 2008 ⁹³	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	544/190	Age <18 or >78 years, HbA1c <8% after run-in, HbA1c >11% after run-in, BMI <20 or >43 kg/m ² , pregnant, nursing, insulin within 8 weeks prior to screening, PPAR-G or incretin mimetics within 12 weeks prior to screening, Type 1 DM, FPG <7.2 or >15.6 mmol/L consistently during run-in, no Type 2 DM
Multicontinent		30 weeks				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Hamann, 2008 ¹²³	RCT	Neither year reported	Yes	< 6 months	NR	818/596	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <7% or >10%, BMI <25 kg/m ² , used any ODM other than metformin in the prior 12 weeks, or insulin at any time other than during pregnancy or for emergency treatment, history of metabolic acidosis, edema requiring pharmacological treatment (either ongoing or within the prior 12 months), anemia (hemoglobin < 11.0 g/ dl for men and < 10.0 g/ dl for women), C-peptide <0.5nmol/L, SBP >170mmHg, DBP >100mmHg
Multinational Europe, Mexico		52 weeks				NR	
Seufert, 2008 ¹⁴²	randomized but does not have control; comparative study	Neither year reported	No run-in period	NR	Yes	NR/1269	Age < 35 or >75 years, history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g. failed initial treatment), HbA1c < 7.5% or > 11%, pregnant, nursing, fasting c-peptide >1.5, ketoacidosis, symptomatic heart failure, acute malabsorption, chronic pancreatitis, familial polyposis coli, malignant disease in the previous 10 years
Multicontinent		104 weeks				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Schwarz, 2008 ¹⁵²	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	75/69	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), contraindication or history of intolerance to metformin, HbA1c <7.0% or >11.0%, BMI <22 or >45 kg/m ² , FBG >270 mg/dL, history of lactic acidosis, congestive cardiac failure requiring pharmacologic treatment, Type 1 DM or secondary forms of DM
US		104 weeks				NR	
Asche, 2008 ²⁰⁰	Cohort	Start year: 1996 End year: 2005 395 days NA	NA	NA	Yes	1129573/5438	Age <65 years, took any ODM within 395 days prior to first prescription for monotherapy with metformin, SU, or TZD, less than two HbA1c levels (first recorded within 90 days prior to index date or 30 days post-index date and the second level drawn either (longer of the two) 90 days after index date or baseline A1c), no Type 2 DM (defined by ICD-9 , FBG ≥125 mg/dL, on ODM, or prescription for injectable incretic mimetic)
US						General Electric Research Database	
McAlister, 2008 ²⁰⁸	Cohort	Start year: 1991 End year: 1996 9 years	NA	NA	No	NR/5631	Age <30 years, treatment with insulin, did not receive at least one new prescription for an oral antidiabetic medication (metformin or SU) between 01/01/1991 and 12/31/96, not eligible for prescription drug benefits, less than one year of coverage in the provincial health plan, history of heart failure (by ICD-9 for hospitalization for heart failure) in last 3 years prior to starting first ODM, receipt of more than one ODM at any time (concurrently or not)
Canada						Saskatchewan Health database	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Kahn, 2008 ²¹³	RCT	Neither year reported	No run-in period	NR	Yes	4360/4351	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), history of lactic acidosis, uncontrolled hypertension, corticosteroid use
U.S., Multinational Europe		4 years				NR	
Davies, 2007 ¹⁴⁷	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	82/NR	Age <30 or >80 years, history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), contraindication or history of intolerance to metformin, HbA1c <7.0%, BMI >43 kg/m ² , not using adequate contraception, history of previous insulin use for >2weeks, duration of Type 2 DM <12 months, C-peptide levels <0.33, severe concurrent disease, serum creatine >150umol/l
United Kingdom		4 months				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Chien, 2007 ⁵⁹	RCT	Neither year reported	No run-in period	< 6 months	Yes	166/100	Age <30 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), contraindication or history of intolerance to metformin, retinopathy, HbA1c >12% and FPG>250 mg/dL at screening visit, HbA1c <7% and FPG<140 mg/dL at screening visit, BMI <18.5 or >35 kg/m ² , current significant GI disorder, hyperosmolar nonketotic coma, hypersensitivity to glyburide or metformin, current infection, treatment with insulin in last 6 months, surgery in past 4 weeks, history of cancer in 5 years, on concurrent drugs affect sugar metabolism, FPG < 140 mg/dl at second visit, not on a stable dose of SU at baseline or dose of metformin>1000mg/day or SU dose too low (glyburide or glicazide<10 mg/day, glimepiride<4mg/d, glicazide<160mg/d)
Taiwan, Multi-center		16 weeks				5 medical centers. Does not specify inpatient or outpatient	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Goldstein, 2007 ⁷⁵	RCT	Neither year reported	Run-in period but number of participants excluded was NR	NR	Yes	3544/1091	Age <18 or >78 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), patient with < 75% compliance during placebo run in period, patient with HbA1c <7.5% or >11 % after diet/exercise run in/wash-out period, patients with fasting glucose > 280 mg/dl after run-in period, no Type 1 DM or Type 2 DM
Multicontinent		24 weeks				NR	
Hanefeld, 2007 ¹⁰⁰	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	NR/598	Age <40 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), BMI <22 kg/m ² or >38 kg/m ² , pregnant, patient on insulin therapy, patient with diabetic complications requiring treatment, hematologic impairment, FPG <7mmol/l or > 15mmol/l, C-peptide <0.27 nmol/l
Multinational Europe		52 weeks				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Scott, 2007 ¹¹¹	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	2186/743	Age <21 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), Type 1 DM, gall bladder disease, elevated CK
U.S.		12 weeks				NR	
Comaschi, 2007 ¹²⁹	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	398/250	Age <35 years, HbA1c <7.5% or >11%, had not received SU or metformin as a monotherapy at a stable dose for at least 3 months, fasting C-peptide <0.33nmol/L
Italy		6 months				NR	
Nauck, 2007 ¹³³	RCT	Neither year reported	Yes	< 6 months	Yes	2141/1172	Age <18 or >78 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), FPG >15 mmol/L, insulin use within 8 weeks of screening, history of Type 1 DM, other treatments for hypoglycemia
U.S., Multinational Europe, Multi-continent		52 weeks				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Robbins, 2007 ¹⁴⁵	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	433/317	Age <35 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), HbA1c <6.5% or >11%, pregnant, nursing, not using adequate contraception, patients who were receiving continuous SC insulin injections or a total daily insulin of >2.0 U/kg or who had a change in type or dose of lipid-altering medications or TZD use up to 3 months before the study, fasting triglyceride level >4.5 mmol/L, serum creatinine >134 micromol/L (men) or >109 micromol/L (women)
US, Multinational Europe, Multi-continent, India, Australia		24 weeks				NR	
Raskin, 2007 ¹⁴⁶	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	N:/NR	Age <18 or >75 years, HbA1c ≤8.0%, BMI >40 kg/m ² or weight >125 kg (275 lbs.), pregnant, nursing, not using adequate contraception, if not on metformin ≥1,000mg /day as a single agent or in ODM combination therapy for at least 3 months before the trial, history of insulin use
US		28 weeks				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Lund, 2007 ¹⁹⁷	RCT	Start year: 2001 End year: 2002 8 months	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	127/96 Outpatient: subspecialty care setting	Age <40 years for onset of diabetes diagnosis, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c >9.5% with ongoing ODMs prior to study start; 10.5 on 2 visits with >1 month interval, HbA1c <6.5% after run in period, BMI >27 kg/m ² , pregnant, insulin treated Type 2 DM, secondary DM, Factor II, VII, X <0.7, ongoing co-existing illness with life shortening prognosis, mental retardation or reduced intellectual behavior, history of drug abuse, weight loss of >5 kg in past 6 months prior to study start, fasting C peptide <300 of non fasting glucagon stimulated C peptide <600, ketonuria; ketoacidosis
Denmark							
Kahn, 2006 ³⁸	RCT	Start year: 2000 End year: 2006 6 years	No run-in period	NR	Yes	6676/4360 NR	Age < 30 or > 75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), uncontrolled hypertension, fasting plasma glucose <126 or > 180 mg/dL, history of lactic acidosis
Multi-continent							

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Rosenstock, 2006 ⁴⁹	RCT	Start year: 2003 to 2004	Yes	< 6 months	Yes	1252/468	Age <18 or >70 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c < 7% or > 11%, FPG >15mmol/l, hematological disease, uncontrolled hypertension while on antihypertensive treatment, intermittent or chronic use of oral or intravenous corticosteroids, investigators discretion, use of investigational agent within 30 days of the study (or five half lives of the investigational drug if longer than 30 days), previous history of severe edema or medically serious fluid related event associated with TZD, acute or chronic metabolic acidosis, history of diabetic ketoacidosis
Multi-continent		32 weeks				multicenter	
Charbonnel, 2006 ⁹⁴	RCT	Neither year reported	Run-in period but number of participants excluded was NR	NR	Yes	1464/701	Age < 18 or >78 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), HbA1c <7% or >10%, Type 1 DM, insulin use within 8 weeks of screening, FPG > 14.4mmol/l
Multi-continent		24 weeks				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Jain, 2006 ¹⁰¹	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	NR/502	Age <18 or >80 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g. failed initial treatment), HbA1c < 7.5% or >11.5%, pregnant, nursing, duration of DM > than 2 years, intolerance to rosiglitazone, pioglitazone or troglitazone, drug or alcohol abuse, previous treatment with meglitinide analog, alpha glucosidase inhibitor, metformin, insulin, SU for 3 months or more, use of hydrochlorothiazide, joint injections, niacin > 250 mg/day, ODM, concurrent participation in another investigational study, serum creatinine level > 1.5mg/dl of men, 1.4 mg/dl for women, 1 + proteinuria, anemia(< 10g/dl women, < 12g/dl men, BMI <20 kg/m ² or >45 kg/m ² ; hypertension, chronic pulmonary disease, history of cancer not in remission for at least 5 years
US, Puerto Rico		56 weeks				NR	
Jibrán, 2006 ¹¹²	Randomized, open-label, 2 arm parallel prospective study	Start year: 2000 End year: 2001 12 months	NA	< 6 months	NR	NR/100	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), poorly controlled on prior treatments (e.g. failed initial treatment), no Type 2 DM, on insulin
Pakistan						Outpatient: subspecialty care setting	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period		Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
		Followup duration	Run-in period				
Bakris, 2006 ¹²⁵	RCT	Neither year reported	Yes	< 6 months	Yes	560/514	Age <40 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), BMI < 22 kg/m ² , use of any TZD in the 3 months prior to screening, use of insulin for ≥ 6 months at any time prior to screening, anemia, severe angina, SBP >159 mm Hg (can't adjust the BP meds during the trial), DBP >99 mm Hg
U.S., Multi-continent, South America, Europe		32 weeks				NR	
Umpierrez, 2006 ¹²⁶	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	538/210	Age <18 or >79 years, HbA1c <7.5% or >10%, BMI <24 kg/m ² , diagnosis of Type 2 DM <6 months, no taking stable doses of metformin (1-2.5g/day) or extended-release metformin (0.5 -2.0g/day) as their only ODM for at least 2 months prior to the study, C-peptide <0.27nmol/L, subjects treated with insulin, TZDs or SU within 3 months prior to study enrollment, history of substance abuse, severe hypoglycemia, acute metabolic complications, clinically significant abnormal baseline laboratory values including hematology, blood chemistry or urinalysis
U.S.		28 weeks				Outpatient: primary care, Outpatient: subspecialty care setting	
Garber, 2006 ¹²⁸	RCT	24 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <20 or >78 years, any liver disease, any kidney disease, history of CVD, HbA1c ≤7.0% or ≥12.0%, no Type 2 DM, other
U.S.							

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Kvapil, 2006 ¹³⁸	RCT	Neither year reported	No run-in period	< 6 months	NR	NR/341	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), retinopathy, recurrent severe hypoglycemia, anemia, change in dose of meds known to interfere with glucose metabolism, adequately controlled on metformin
Multinational Europe		16 weeks				NR	
Stewart, 2006 ¹⁵⁶	RCT	Start year: 2003 to 2004	Yes	< 6 months	Yes	1397/526	Age <18 or >70 years, history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <7% or >9%, drug naive patients with FPG <7 mmol/l or >9mmol/l, patient on monotherapy with FPG < 6.0mmol/l or >8 mmol/l, prior history of exposure to TZDs within previous 6 months, use of insulin anytime in the past, uncontrolled hypertension
Multinational Europe		32 weeks				NR	
Rosak, 2006 ¹⁸³	Cohort	Neither year reported	NA	< 6 months	Yes	NR/22808	Not all treated with rosiglitazone
Germany		6 months				Outpatient: primary care, Outpatient: subspecialty care setting	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Wright, 2006 ¹⁹⁸ U.K.	RCT	Start year: 1977 End year: 1991 6 years	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	7616/4191 23 clinical Center	Age <25 or >65 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), FPG ≤6 mmol/l x2 after being diagnosed with diabetes, ketonuria> 3 mmol/l, mixed ethnicity, severe previous illness that would limit life expectancy or require systemic treatment, serum creatinine>175 umol/l, if on same treatment for <6 years
Hanefeld, 2006 ²⁰¹ Germany	Cohort	Neither year reported 42 months	NA	≥ 6 months	Yes	NR/500 Outpatient: primary care	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), pregnant, known hypersensitivity to pioglitazone, glibenclamide, or their metabolites, ketoacidosis, diabetic coma, pre-coma, Type 1 DM, serious impairment of adrenocortical function
Malone, 2005 ¹⁶⁵ Multinational Europe	RCT	Neither year reported 32 weeks	Yes	< 6 months	Yes	97/119 NR	Age <30 or >75 years, HbA1c >2.0 times the upper limit of normal, HbA1c <1.3 times the upper limit of normal, used glitazones within 30 days prior to the study, used NPH QD or BID 30-days prior to entry, expected to benefit from prandial control
Yamanouchi, 2005 ⁵⁰ Japan	RCT	12 months (Planned duration)	Not extracted	Not extracted	No	Not extracted	Any liver disease, any kidney disease, history of CVD, treatment experienced, neuropathy, retinopathy, HbA1c <7.0%, no Type 2 DM, other

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Leiter, 2005 ⁸³ Canada	RCT	Neither year reported 32 weeks	No run-in period	< 6 months	Yes	720/613 Outpatient: primary care	Age <20 or >80 years, HbA1c < 9.5%, no Type 2 DM, FBG <7 but >14mmol/L
Weissman, 2005 ⁸⁶ U.S.	RCT	Neither year reported 24 weeks (Planned duration)	Run-in period but number of participants excluded was NR	< 6 months	Yes	1270/766 NR	Age <18 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c <6.5% or >8.5% for subjects having received prior combination treatment (metformin + SU), HbA1c < 7% or > 10% for drug naive or prior monotherapy subjects, BMI <27 kg/m ² , FPG < 126mg/dL or >270mg/dL, anemia, severe edema, prior insulin use within 3 months of study start, non-compliant patient with metformin up-titration
Bailey, 2005 ⁸⁷ U.K., 14 European Countries	RCT	24 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <18 or >70 years, history of CVD, no Type 2 DM, other
Feinglos, 2005 ⁹¹ U.S.	RCT	16 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <30 or >81 years, any liver disease, any kidney disease, history of CVD, HbA1c <7.0% or >8.5%, no Type 2 DM, other

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Derosa, 2005 ¹²⁷	RCT	Neither year reported	No run-in period	< 6 months	NR	NR/99	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., failed initial treatment), neuropathy, retinopathy, HbA1c < 7%, pregnant, nursing, not using adequate contraception, no type 2 DM by ADA criteria for at least 6 mo, fasting c-peptide <1.0ng/ml, no metabolic syndrome with at least 3 components (based on NCEP ATP III), ketoacidosis, anemia, cerebrovascular conditions within 6 months, consumption of glimepiride or TZDs or prior intolerance to these medications
Italy		12 months				case notes and/or clinic registers	
Gerich, 2005 ¹³⁶	RCT	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	908/428	Age <18 or >77 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), neuropathy, retinopathy, HbA1c <7% or >11%, BMI < 22 kg/m2 or >45 kg/m2, not using adequate contraception, FPG ≥15mmol/L, if Type 1 DM, symptomatic hypoglycemia with >10% weight loss in previous 8 weeks, history of lactic acidosis or CHF requiring meds, other medical conditions that could interfere with interpretation of results or pose sign risk to the subject, had to be drug naive
US		2 years				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period		Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
		Followup duration	Run-in period				
Derosa, 2005 ¹⁵⁹	RCT	12 months (planned duration)	Not extracted	Not extracted	No	Not extracted	Age <18 years, any liver disease, any kidney disease, history of CVD, neuropathy, retinopathy, HbA1c <7.5%, no Type 2 DM, other
Italy							
Agarwal, 2005 ¹⁸⁴	RCT	Start year: 2001 End year: 2003 16 weeks	No run-in period	< 6 months	Yes	102/54 Outpatient: subspecialty care setting	Any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), BMI >40 kg/m ² <7.5 kg/m ² , class III or IV heart failure, NSAID use
Rajagopalan, 2005 ¹⁹⁴	Cohort		Not extracted	Not extracted	Yes	Not extracted	Age <18 years, any liver disease, no Type 2 DM, other
US							
Maru, 2005 ¹⁹⁵	Cohort	130 (mean followup)	Not extracted	Not extracted	Yes	Not extracted	Age <35, treatment experienced, no Type 2 DM, other
UK							
Nichols, 2005 ¹⁹⁶	Cohort		Not extracted	Not extracted	Yes	Not extracted	Other
US							
Rajagopalan, 2005 ²⁰⁶	Cohort	Start year: 1999 End year: 2001 Duration: NA	NA	NA	Yes	NA (for cohort studies, claims data, etc)/1123645 pharmacy database	Age <18 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), use of troglitazone, in cohort <12 months prior to study, follow up <3 months after study started, prior treated with rosiglitazone, metformin, pioglitazone, or SU, not continuously having insurance or medication coverage
Karter, 2005 ²⁰⁷	Cohort	Start year: 1999 End year: 2001 10 months	NA	NA	No	NA (for cohort studies, claims data, etc)/23440 managed care organization	CHF, no pharmacy benefit, Type 1 DM, >80% pill adherence, filled a refill of index medication, member of health plan >1 year, any utilization of the index therapy in the 12 months prior to initiation of the study
US							

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period		Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
		Followup duration	Run-in period				
Madsbad, 2004 ¹²⁰	RCT	Start year: 2000 End year: 2001	No run-in period	< 6 months	Yes	311/193	Age <30 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), poorly controlled on prior treatments (e.g., "failed initial treatment"), HbA1c < 7.5% or >10% on diet treatment, BMI >40 kg/m ² , pregnant, nursing, not using adequate contraception, no Type 2 DM, no treatment for DM with ODM or diet, HbA1c >9.5% on ODM, history of CHF, NYHA class III, IV, use of TZDs or other investigational drugs
Multinational Europe		12 weeks				Outpatient: primary care, Outpatient: subspecialty care setting, Community	
Scherthaner, 2004 ⁵²	RCT	12 months (planned duration)	Not extracted	Not extracted	No	Not extracted	Age <35 or >75 years, treatment experienced, HbA1c <7.5% or >11%, no Type 2 DM
Europe							
Derosa, 2004 ⁶⁰	RCT	12 months (planned duration)	Not extracted	Not extracted	No	Not extracted	Age <46 or >67 years, any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other
Italy							
Horton, 2004 ⁸⁰	RCT	Neither year reported	Yes	< 6 months	Yes	701/401	Age >30 years, any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), neuropathy, retinopathy, HbA1c < 6.8% or >11%, Type 1 or 2 DM, diabetes > 3 months duration, FPG <15mmol/L, diabetic complication, on corticosteroids, non treatment naive
NR		24 weeks				NR	

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Tan, 2004 ¹⁰⁶ Denmark, Finland, Norway, and Sweden.	RCT	52 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Treatment experienced, HbA1c <7.5% or >11% for patients not receiving ODM, <7.5% or > 9.5% for patients receiving ODM, no Type 2 DM, other
Raskin, 2004 ¹⁰⁹ U.S.	RCT	12 titration and 12 maintenance weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <18 years, HbA1c <7% or >12% during previous monotherapy with SU or metformin at 50% or more of maximal recommended dose for at least 3 months, no Type 2 DM, other
Jovanovic, 2004 ¹¹⁰ U.S.	RCT	12 week titration then 12 week maintenance (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <18 years, HbA1c <7% or >12%, no Type 2 DM, other
Hanefeld, 2004 ¹⁴⁰ Canada, U.K., Hungary, Finland, U.K., Slovak Republic, Belgium, Estonia, Lithuania, Denmark, Italy, Greece, Sweden, and the Netherlands	RCT	NR	Not extracted	Not extracted	Yes	Not extracted	Age <35 or >75 years, history of CVD, HbA1c <7.5% or >11%, no Type 2 DM, other

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Malone, 2004 ¹⁶⁴	RCT	Neither year reported	Yes	< 6 months	Yes	145/111	Age <30 OR >80 years, HbA1c <1.3 or >2.0 times normal, BMI >40 kg/m ² , HbA1c value that is less than or greater than 1.3 and 2.0 times the ULN within 30 days before the study, while using 1 or more ODM without insulin for 30 or more days before study start
US		32 weeks				NR	
Hussein, 2004 ²⁰²	Cohort	Start year: 2000 End year: 2002	NA	NA	No	2500/203	HbA1c < 8%, treated at Melbourne Hospital, treated with rosiglitazone or pioglitazone >2 months
Australia		30 months				Outpatient: subspecialty care setting	
Tosi, 2003 ³⁶	RCT, cross-over	6 months (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, treatment experienced, HbA1c <6.3%, no Type 2 DM, other
Italy							
Pavo, 2003 ⁵⁴	RCT	32 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <40 years, any liver disease, any kidney disease, history of CVD, treatment experienced, HbA1c <7.5% or >11.0%, no Type 2 DM, other
Russia and Hungary							
Garber, 2003 ⁶¹	RCT	16 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	NR
US							
Goldstein, 2003 ⁶²	RCT	18 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, HbA1c <7.5 and >12.0, other
US							
Derosa, 2003 ⁸¹	RCT	12 months (planned duration)	Not extracted	Not extracted	No	Not extracted	Any kidney disease, history of CVD, treatment experienced, HbA1c < 7%, no Type 2 DM, other
Italy							

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country		Followup duration				Source population	
Yang, 2003 ¹³⁹	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	Yes	NR/211	Age <35 or >70 years, poorly controlled on prior treatments (e.g. failed initial treatment), no Type 2 DM as defined by WHO, not treated with diet and sulfonylurea for 6-months
China		12 weeks				NR	
Malone, 2003 ¹³⁷	randomized, open-label, 2 arm parallel prospective study	Neither year reported	Fewer than 10% of participants were excluded during run-in	< 6 months	Yes	NR/597	Age < 30 or >75 years, HbA1c <125% of upper limit of normal by local lab within 4 weeks prior to entry, BMI >40 kg/m ² , not Type 2 DM, not use of single oral agent (metformin or SU) for 3 months prior to study at max clinically effective dose for previous 30 days
14 countries not specified		16 weeks				subgroup completing test meals	
Jones, 2003 ¹⁷⁹	RCT	Neither year reported	Run-in period but number of participants excluded was NR	< 6 months	NR	NR/N:	Age <40 or >80 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), neuropathy, CHF, history of chronic insulin, FPG <140 or >300 mg/dL, prior rosiglitazone study, use on any investigational drug within 30 days
US		6 months				NR	
Blonde, 2002 ⁶³	RCT	16 weeks (planned duration)	Not extracted	Not extracted	Yes		Age <30 or >75 years, any liver disease, any kidney disease, history of CVD, HbA1c <7.4%, no Type 2 DM, other
Marre, 2002 ⁶⁴	RCT	4 months (planned duration)	Not extracted	Not extracted	Yes		Age <18 years, any liver disease, any kidney disease, history of CVD, other
Netherlands, Denmark, Portugal, France, Belgium							

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Run-in period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Garber, 2002 ⁶⁵	RCT	20 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, treatment experienced, HbA1c <7% or >11%, no Type 2 DM, other
US							
Gomez-Perez, 2002 ⁸⁸	RCT	26 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <40 or >80 years, any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other
Mexico							
Marre, 2002 ⁹⁶	RCT	Neither year reported	Yes	< 6 months	Yes	680/467	Age < 30 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g. myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), HbA1c < 6.8% or >11%, BMI <20 kg/m ² or >35 kg/m ² , DM at least 6 months, FPG>15mmol/l, gastroparesis, change in body weight during run-in, treated with diabetes meds other than metformin 3 months before study
Multi-continent		24 weeks				NR	
Vakkilainen, 2002 ¹¹⁹	RCT	12 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <18 or >75 years, any liver disease, any kidney disease, HbA1c <6.5% or >10%, no Type 2 DM, other
Finland							
St John Sutton, 2002 ¹⁴⁹	RCT	52 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <40 or >80 years, any liver disease, any kidney disease, history of CVD, no type 2 DM, other
US							
Charpentier, 2001 ⁷¹	RCT	20 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age ≤34 or ≥71 years, any kidney disease, history of CVD, no Type 2 DM, other
France							

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria	
Country	Study design	Followup duration	Run-in period	Pharmaceutical support	Source population	Exclusion criteria	
Madsbad, 2001 ¹¹⁴ Denmark, Scandinavia	RCT	12 months (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age ≤39 or ≥76 years, any liver disease, any kidney disease, HbA1c <6.5% or >10%, no Type 2 DM, other
Amador-Licona, 2000 ⁶⁶ Mexico	RCT	12 weeks (planned duration)	Not extracted	Not extracted	No	Not extracted	Age >65 years, any liver disease, history of CVD, other
Horton, 2000 ⁷⁹ US	RCT	24 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Age <30 years, any kidney disease, HbA1c <6.8% or >11%, no Type 2 DM, other
Einhorn, 2000 ⁸⁹ US	RCT	16 weeks (planned duration)	Not extracted	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, neuropathy, retinopathy, HbA1c <8.0%, no Type 2 DM, other
Fonseca, 2000 ⁹⁰ US	RCT	26 weeks (planned duration)	Not extracted	Not extracted	No	Not extracted	Age <40 or >80 years, any liver disease, any kidney disease, history of CVD, treatment experienced, neuropathy, no type 2 DM, other
Moses, 1999 ⁸² Australia	RCT	Neither year reported 4 to 5 months	No run-in period	NR	NR	108/83 NR	Age <40 or >75 years, any liver disease (such as elevated aminotransferases (ALT, AST, SGOT, SGPT)), any kidney disease (such as microalbuminuria, macroalbuminuria or elevated creatinine, low GFR or creatinine clearance), history of cardiovascular disease (e.g., myocardial infarction, stroke, transient ischemic attack, coronary artery disease, angina), contraindication or history of intolerance to metformin, HbA1c < 7.1%, BMI <21 kg/m ² , no Type 2 DM, not on metformin for more than 6 months, alcohol abuse, drug use, intention to become pregnant, history of lactic acidosis, vitamin B12 <150 pmol/l with anemia

Table 10. Study design characteristics of studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Enrollment period	Planned interval of follow-up	Pharmaceutical support	Number screened/enrolled	Exclusion criteria
Country	Study design	Followup duration	Run-in period	Pharmaceutical support	Source population	Exclusion criteria
Landgraf, 1999 ¹¹⁵ Germany, Austria, and Netherlands	RCT	14 weeks (planned duration)	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other
Wolffenbittel, 1999 ¹¹⁶ Germany, Austria, Netherlands	RCT	12 months (planned duration)	Not extracted	No	Not extracted	Age <40 or >75 years, any liver disease, any kidney disease, history of CVD, treatment experienced, HbA1c <6.5% if treated with diet only, >12% if treated with diet plus oral, other
Marbury, 1999 ¹¹⁷ US, Canada	RCT	12 months (planned duration)	Not extracted	Yes	Not extracted	Age >37 or <75 years, any liver disease, any kidney disease, history of CVD, treatment experienced, retinopathy, HbA1c <6.5% or 14.6%, no Type 2 DM, other
DeFronzo, 1995 ⁷⁰ +US	RCT	29 weeks (planned duration)	Not extracted	No	Not extracted	Age <40 or >70 years, any liver disease, any kidney disease, history of CVD, treatment experienced, no Type 2 DM, other
Hermann, 1994 ⁶⁸ Sweden	RCT	6 months (planned duration)	Not extracted	Yes	Not extracted	No Type 2 DM, other
Wolffenbittel, 1993 ¹¹⁸ Netherlands	RCT	12 (4 week titration, 8 week treatment) (planned duration)	Not extracted	Yes	Not extracted	Any liver disease, any kidney disease, HbA1c <7.0% or >12.0%, no Type 2 DM, other

ACEI = angiotensin-converting enzyme inhibitors; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BID = twice a day; BMI = body mass index; CAD = coronary artery disease; CHF = congestive heart failure; CK = creatine kinase; CVD = cardiovascular diseases; DBP = diastolic blood pressure; DKA = diabetic ketoacidosis; DM = diabetes mellitus; FBG = fasting blood glucose; FPG = fasting plasma glucose; GFR = glomerular filtration rate; GI = gastrointestinal; HbA1c = hemoglobin A1c; HONK = hyper osmolar non ketotic; HTN = hypertension; ICD = International classification disease; kg/m² = kilograms per meters squared; LDL = low density lipoprotein; LVEF = left ventricular ejection fraction; mg/d = milligrams per day; mg/dl = milligrams/deciliter; MHS = Military health system; mmHg = millimeters of mercury; mmol = millimoles; mmol/L = millimoles per liter; NA = not applicable; NPH = neutral protamine Hagedorn; NR = not reported; NSAID = nonsteroidal antiinflammatory drug; NYHA = New York

Health Association; OAD = oral antidiabetic; OAM = oral antihyperglycemic medications; PPAR-G = peroxisome proliferator-activated receptors-gamma; PPG = postprandial glucose; QD = once a day; RCT = randomized controlled trial; SBP = systolic blood pressure; SC = subcutaneous; SGOT = serum glutamyl oxaloacetic transaminase; SGPT = serum glutamyl pyruvic transaminase; SU = sulfonylurea; TG = triglycerides; TZD = thiazolidinedione; U/kg = unit per kilogram; y = years

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Seino, 2010 ¹²¹	Glibenclamide, 132	58.5	65	Asian: 100	24.4 NR	8.978	8.5	12
	Liraglutide, 268	58.2	68	NR	24.5 NR	8.92	8.1	22
Derosa, 2010 ⁴⁴	Metformin + glibenclamide, 65	56	51	NR	28.5 NR	8.9	NR	8
	Metformin + exenatide, 63	57	48	NR	28.7 NR	8.8	NR	4
Defronzo, 2010 ¹³²	Metformin + rosiglitazone, 45	NR	NR	NR	NR NR	7.9	NR	11
	Metformin + exenatide, 45	NR	NR	NR	NR NR	7.8	NR	12
Aschner, 2010 ⁷⁷	Metformin, 439	55.7	44	NR	30.9 NR	7.2	2.1	75
	Sitagliptin, 455	56.3	48	NR	30.7 NR	7.2	2.6	61
Seck, 2010 ¹³⁴	Metformin + sitagliptin, 248	57.6	57.3	AA: 3.6, Asian: 9.3, C: 77.4, H: 5.6, Other: 4	30.9 88.5 kg	7.3	5.8	231
	Metformin + glipizide, 584	57	62.9	AA: 5.1, Asian: 8.2, C: 78.5, H: 5.1, other: 3.1	31.3 90.3 kg	7.3	5.7	328
Komajda, 2010 ²⁹²	Metformin + rosiglitazone, 2220	NR	NR	NR	NR NR	NR	NR	NR
	Metformin + sulfonylurea, 2227	NR	NR	NR	NR NR	NR	NR	NR
Pratley, 2010 ¹⁴³	Metformin + sitagliptin, 219	55	55	AA: 5, Asian: 1, C: 91, H: 16, Other: 4	32.6 93.1 kg	8.5	6.3	25
	Metformin + liraglutide, 221	55.9	52	AA: 10, Asian: 3, C: 82, H: 17, Other: 5	32.6 93.7 kg	8.4	6	27
	Metformin + liraglutide, 221	55	52	AA: 7, Asian: 2, C: 87, H: 15, Other: 4	33.1 94.6 kg	8.4	6.4	52

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Raskin, 2009 ¹³¹	Metformin + repaglinide, 187	54.8	58	AA: 16, Asian: 4, C: 75, American Indian/Alaska Native: 1, Other: 4	32.9 NR	8.45	7.4	62
	Metformin + repaglinide, 187	54.5	59	AA: 13, Asian: 5, C: 80, American Indian/Alaska Native: 1, Other: 2	32.5 NR	8.29	7.3	58
	Metformin + rosiglitazone, 187	55.5 (28 to 83)	51	AA: 13, Asian: 2, C: 79, American Indian/Alaska Native: 1, Other: 4	32.2 NR	8.46	7.1	58
Derosa, 2009 ⁴⁶	Metformin, 67	55	51	C: 100	27.2 77.7 kg	9.1	NR	7
	Metformin + glimepiride, 66	57.7	48	C: 100	27.1 77.4 kg	9	NR	6
	Metformin + pioglitazone, 69	57	49	C: 100	27.4 76.4	9.3	NR	9
	Pioglitazone, 69	54	46	C: 100	27.5 76.7 kg	9.2	NR	9
van der Meer, 2009 ¹⁴¹	Metformin + glimepiride, 39	56.4	100	NR	29.3 NR	7	3	2
	Pioglitazone + glimepiride, 39	56.8	100	NR	28.2 NR	7.1	4	5
Kaku, 2009 ⁸⁴	Metformin, 86	53	57	NR	25.4 NR	7.55	5.6	7
	Metformin + pioglitazone, 83	52	66	NR	25.6 NR	7.58	4.5	9

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Williams-Herman, 2009 ⁷⁶	Metformin, 182	54.2	45	NR	32 NR	8.5	4.1	46
	Metformin, 182	53.7	48	NR	32 NR	8.7	4.1	56
	Metformin + sitagliptin, 182	53.6	41	NR	32 NR	8.7	4.6	41
	Metformin + sitagliptin, 190	53.7	53	NR	32 NR	8.8	4.1	42
	Sitagliptin, 179	53.5	52	NR	31 NR	8.7	3.9	57
Pantalone, 2009 ¹⁷⁴	Rosiglitazone, 1079	61.4	45.5	C: 86.8, Non-Caucasian: 13.2	32.7 NR	7.3	NR	NR
	Any in the SU class, 7427	66.1	49.5	C: 78, Non-Caucasian: 22	31.1 NR	7.6	NR	NR
	Pioglitazone, 1508	61.6	48.3	C: 83.5, Non-Caucasian: 16.5	33 NR	7.3	NR	NR
	Metformin, 10436	56.8	41.8	C: 76.9, Non-Caucasian: 23.1	33.8 NR	7.7	NR	NR
Nauck, 2009 ⁹²	Metformin, 122	56	60	AA: 3, Asian: 7, C: 88, other: 3	31.6 NR	8.4	8	48
	Metformin + glimepiride, 244	57	57	AA: 2, Asian: 9, C: 89, other: 1	31.2 NR	8.4	8	34
	Metformin + liraglutide, 242	57	59	AA: 2, Asian: 7, C: 88, Other: 2	30.9 NR	8.4	8	51
	Metformin + liraglutide, 241	57	54	AA: 4, Asian: 8, C: 88, Other:1	31.1 NR	8.3	7	44

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Hsiao, 2009 ¹⁷³	Metformin, 46444	59	48.22	NR	NR NR	NR	NR	NR
	Rosiglitazone, 2093	61.24	53.46	NR	NR NR	NR	NR	NR
	Pioglitazone, 495	60.75	52.02	NR	NR NR	NR	NR	NR
	Any in the SU class, 97651	60.71	54.1	NR	NR NR	NR	NR	NR
	Metformin + sulfonylurea, 267754	57.17	54.45	NR	NR NR	NR	NR	NR
	Metformin + rosiglitazone, 2408	57.3	49.8	NR	NR NR	NR	NR	NR
Currie, 2009 ²¹²	Metformin + sulfonylurea, 13882	64.4	57.9	NR	NR 90.9 kg for men 79.7 kg for women	8.6	4.4	NA
	Metformin, 31421	58.6	51.1	NR	NR 95.9 kg for men 86.2 kg for women	8.4	1.5	NA
	Any in the SU class, 7439	70	54.9	NR	NR 80.4 kg for men 68 kg for women	8.4	1.9	NA
Tzoulaki, 2009 ¹⁷¹	Metformin, 68181	66.3	50.6	NR	31.47 NR	8.13	5.59	NR
	Rosiglitazone, 8442	65.7	50.5	NR	31.7 NR	8.4	6.7	NR
	Any in the SU class, 58095	70.4	52.6	NR	28.5 NR	8.2	6.6	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Perez, 2009 ⁵⁶	Metformin, 210	53.7	46.7	AA: 6.7, Asian: 2.4, C: 88.1, H: 26.2	30.8 NR	8.65	NR	68
	Metformin + pioglitazone, 201	54.7	44.8	AA: 6, Asian: 1.5, C: 91.5, H: 24.4	30.8 NR	8.89	NR	44
	Pioglitazone, 189	54	34.9	AA: 6.9, Asian: 2.6, C: 87.3, H: 25.9	31.2 NR	8.69	NR	64
Rigby, 2009 ¹³⁰	Metformin + rosiglitazone, 56	54.7	41	AA: 3.6, Asian: 0, C: 28.6, H: 67.9, other: 0	NR 81.1 kg	8.06	7.57	5
	Metformin + sitagliptin, 56	54.8	35.7	AA: 1.8, Asian: 0, C: 23.2, H: 73.2, unspecified: 1.8	NR 79.6 kg	8.17	8.35	11
Juurlink, 2009 ²¹⁰	Rosiglitazone, 22785	NR	53.1	NR	NR NR	NR	(<2 years: 6%, 2-5 years: 11%, >5 years: 83%)	NR
	Pioglitazone, 16951	NR	52.1	NR	NR NR	NR	(<2 years: 7%, 2-5 years: 11%, >5 years: 82%)	NR
Dormuth, 2009 ²¹⁵	TZD, 10476	56	48	NR NR	NR NR	NR	4.6	NR
	Rosiglitazone, 6880	56	48	NR NR	NR NR	NR	4.6	NR
	Pioglitazone, 3596	57	48	NR NR	NR NR	NR	4.7	NR
	Any in the SU class, 73863	60	47	NR NR	NR NR	NR	4	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Mancini, 2009 ²¹⁴	Metformin, 22	Median: 73 (61-78)	100	NR	Median: 30 (Range: 25-38) NR	Median: 7.2 (Range: 6.0-9.3)	Median: 15 (Range: 4-30)	NA
	Metformin + rosiglitazone, 21	Median: 69 (47-77)	100	NR	Median: 34 (Range: 27-40) NR	Median: 7.4 (Range: 5.8-10)	Median: 14 (Range: 5-30)	NA
Tolman, 2009 ¹⁵⁰	Pioglitazone, 1063	54 (20-82)	57.2	AA: 14.5, Asian: 3.4, C: 59.8, H: 19.1	32.5 NR	9.5	5.86	649
	Glibenclamide, 1057	55 (19-81)	55.5	AA: 13.2, Asian: 2.5, C: 62.1, H: 18.7	32.5 NR	9.5	5.61	641
Dimic, 2009 ¹⁹⁹	Metformin + glimepiride, 30	59	47	NR	29.21 NR	8.63	3.21	0
	Metformin + repaglinide, 30	57	43	NR	29.63 NR	8.67	3.63	0
Jadzinsky, 2009 ⁷⁸	Metformin + saxagliptin, 320	52.4	51.6	AA: 2.2, Asian: 15.9, C: 76.9, other: 5	29.9 NR	9.4	2	58
	Metformin + saxagliptin, 323	52.1	45.2	AA: 2.2, Asian: 16.7, C: 75.2, other: 5.9	30.3 NR	9.5	1.4	62
	Metformin, 328	51.8	49.7	AA: 1.2, Asian: 15.9, C: 76.5, other: 6.4	30.2 NR	9.4	1.7	85
	Saxagliptin, 335	52	50.4	AA: 1.8, Asian: 16.7, C: 76.1, other: 5.4	30.2 NR	9.6	1.7	110
DeFronzo, 2009 ⁹⁵	Metformin + saxagliptin, 192	54.7	43.2	AA: 3.9, Asian: 4.2, C: 79.7, other: 12	31.7 86 kg	8.1	6.7	44
	Metformin + saxagliptin, 191	54.7	53.9	AA: 5.8, Asian: 1.6, C: 83.2, other: 9.4	31.2 87.3 kg	8.1	6.4	48
	Metformin + saxagliptin, 181	54.2	52.5	AA: 7.7, Asian: 2.8, C: 79.6, other: 9.9	31.1 87.8 kg	8.0	6.3	41
	Metformin, 179	54.8	53.6	AA: 3.9, Asian: 2.2, C: 83.8, other: 10.1	31.6 87.1 kg	8.1	6.7	40
Bunck, 2009 ¹⁴⁴	Metformin + exenatide, 36	58.4	63.9	NR	30.9 90.6 kg	7.6	5.7	6
	Metformin + glargine, 33	58.3	66.7	NR	30.1 92.4 kg	7.4	4	3

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Garber, 2009 ¹²²	Glimepiride, 248	53.4	54	AA: 12, Asian: 4, C: 77, H: 38, other: 7	33.2 93.4 kg	8.4	5.6	96
	Liraglutide, 247	52	49	AA: 12, Asian: 6, C: 75, H: 35, other: 7	32.8 92.8 kg	8.3	5.3	74
	Liraglutide, 251	53.7	47	AA: 14, Asian: 2, C: 80, H: 32, Other: 5	33.2 92.5 kg	8.3	5.2	NR
Asche, 2008 ²⁰⁰	Any in the sulfonylurea class, 2117	NR	NR	NR	NR NR	NR	NR	NA
	Metformin, 2138	NR	NR	NR	NR NR	NR	NR	NA
	Thiazolidinedione, 702	NR	NR	NR	NR NR	NR	NR	NA
McAlister, 2008 ²⁰⁸	Any in the sulfonylurea class, 4162	66.59	58.1	NR	NR NR	NR	NR	0
	Metformin, 1469	63.37	53.8	NR	NR NR	NR	NR	0
Kahn, 2008 ²¹³	Glyburide, 1441	NR	58	NR	NR NR	NR	NR	0
	Metformin, 1454	NR	59.4	NR	NR NR	NR	NR	0
	Rosiglitazone, 1456	NR	56	NR	NR NR	NR	NR	0
Scott, 2008 ⁸⁵	Metformin, 92	55.3	59	Asian: 39, C: 61	30 84.6 kg	7.7	5.4	9
	Metformin + rosiglitazone, 87	54.8	63	Asian: 38, C: 59, Other: 3	30.4 84.9 kg	7.7	4.6	2
	Metformin + sitagliptin, 94	55.2	55	Asian: 38, C: 61, Other: 1	30.3 83.1	7.8	4.9	9
Raz, 2008 ⁹³	Metformin, 94	56.1 (36 to 77)	41	AA: 1, C: 47, H: 25, multiracial: 25, not specified: 2	30.4 81.2 kg	9.1	7.3	16
	Metformin + sitagliptin, 96	53.6 (29 to 73)	51	AA: 3, C: 42, H: 32, multiracial: 22, not specified: 1	30.1 81.5 kg	9.3	8.4	18

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Seufert, 2008 ¹⁴²	Metformin + sulfonylurea, 320	60	54.7	NR	30 NR	8.8	7.1	58
	Pioglitazone + sulfonylurea, 319	60	53.6	NR	30.2 NR	8.81	7	38
Robbins, 2007 ¹⁴⁵	Metformin + glargine, 159	58.1	49.4	AA: 5.7, Asian: 14.6, C: 63.3, H: 16.4	32 88.1kg	7.8	12.5	22
	Metformin + insulin lispro 50/50, 158	57.4	50.3	AA: 5.7, Asian: 14, C: 65, H: 15.3	32.1 89.1kg	7.8	11.3	15
Hamann, 2008 ¹²³	Metformin + rosiglitazone, 294	58.5	53	C: 94	33 91.4kg	8	6.3	61
	Metformin + sulfonylurea, 302	59.3	52	C: 95	32.2 88.9kg	8	6.4	71
Chien, 2007 ⁵⁹	Glyburide, 25	63	53	NR	25.3 63.7 kg	8.69	8.6	6
	Metformin, 25	59	41	NR	25.7 65.6 kg	8.88	6.4	8
	Metformin + glyburide, 26	60	71	NR	24.2 63.8 kg	8.71	9	5
	Metformin + glyburide, 26	57	62	NR	24.2 61.3 kg	8.85	6.6	5
Schwarz, 2008 ¹⁵²	Metformin + glyburide, 40	70.4	50	AA: 11.1, C: 77.8, Other: 11	33.5 NR	7.7	2.5	18
	Metformin + nateglinide, 35	70.1	51.5	AA: 9.1, C: 78.8, Other: 12.1	30.4 NR	7.8	1.7	14
Comaschi, 2007 ¹²⁹	Metformin + pioglitazone, 103	57	45.63	NR	32.2 85.8 kg	8.4	NR	27
	Metformin + sulfonylurea, 80	59.9	55	NR	29.9 81.9 kg	8.6	NR	13
	Pioglitazone + sulfonylurea, 67	62.2	56.72	NR	28.9 78.8 kg	8.7	NR	14

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Goldstein, 2007 ⁷⁵	Metformin, 182	53.4	48.9	AA: 6.6, Asian: 7.7, C: 47.8, H: 30.2, not specified: 7.7	32.1 NR	8.9	4.5	29
	Metformin, 182	53.2	45.1	AA: 4.9, Asian: 5.5, C: 58.2, H: 21.4, not specified: 9.9	32.2 NR	8.7	4.4	NR
	Metformin + sitagliptin, 182	53.3	42.3	AA: 7.7, Asian: 6, C: 52.2, H: 26.9, not specified: 7.1	32.4 NR	8.7	4.4	18
	Metformin + sitagliptin, 190	54.1	55.3	AA: 6.8, Asian: 4.7, C: 53.7, H: 28.9, not specified: 5.8	32.1 NR	8.8	4.5	26
	Sitagliptin, 179	53.3	52	AA: 6.1, Asian: 3.4, C: 52, H: 29.1, not specified: 9.5	31.2 NR	8.9	4.4	37
Davies, 2007 ¹⁴⁷	Metformin + NPH, 29	57.9	48.28	AA: 0, Asian: 21, C: 66	32.6 90.4kg	10	7.3	5
	Metformin + BHI 70/30, 27	57.4	80	AA: 4, Asian: 22, C: 70	30.2 82.2 kg	9	9.1	0
Lund, 2007 ¹⁹⁷	Metformin, 48	59.45	77	C: 100	24.71 74.81 kg	7.34	(Median: 3 years)	12*
	Repaglinide, 48	63.31	75	C: 100	24.82 75.57 kg	7.57	(Median: 5 years)	8†
Nauck, 2007 ¹³³	Metformin + glipizide, 584	56.6	61.3	AA: 6, Asian: 8.4, C: 74.3, H: 7.9, other: 3.4	31.3 89.7 kg	7.6	6.2	172
	Metformin + sitagliptin, 588	56.8	57.1	AA: 7, Asian: 8.5, C: 73.5, H: 7.3, other: 3.7	NR NR	7.7	6.5	202
Raskin, 2007 ¹⁴⁶	Metformin + aspart 70/30, 79	52	52	AA: 13, Asian: 3, C: 52, H: 32, Other: 1	31.2 88.7 kg	9.9	NR	12
	Metformin + glargine, 78	51.7	54	AA: 15, Asian: 4, C: 47, H: 32, other: 1	30.8 86.2 kg	9.9	NR	6

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Hanefeld, 2007 ¹⁰⁰	Glibenclamide, 203	60.1	70	AA: 0, C: 99, other: <1	28.7 NR	8.2	6.4	13
	Rosiglitazone, 189	60.6	58	AA: 0, C: 97, other: 3	28.8 NR	8.2	6	9
	Rosiglitazone, 195	60.4	68	AA: 0, C: 98, other: 2	28.7 NR	8.1	5.9	12
Scott, 2007 ¹¹¹	Glipizide, 123	54.7 (21 to 76)	56.9	AA: 3.3, Asian: 4.9, C: 61, other: 24.4, Multiracial: 6.5	30.6 NR	7.9	4.7	23
	Sitagliptin, 123	56.2 (34 to 75)	48	AA: 4.9, Asian: 4.9, C: 63.4, multiracial: 5.7, other: 21.1	30.5 NR	7.9	4.9	7
	Sitagliptin, 123	55.6 (34 to 76)	57.7	AA: 8.9, Asian: 4.9, C: 61, Multiracial: 6.5, Other: 18.7	31.4 NR	7.9	5	15
	Sitagliptin, 124	55.1 (28 to 75)	52.4	AA: 4.8, Asian: 2.4, C: 69.4, Multiracial: 7.3, Other: 16.1	30.4 NR	7.8	4.2	12
	Sitagliptin, 125	55.1 (30 to 76)	62 49.6	AA: 6.4, Asian: 5.6, C: 68.8, multiracial: 6.4, other: 12.8	30.8 NR	7.9	4.3	18
Kahn, 2006 ³⁸	Glyburide, 1441	56.4	58	AA: 4.2, Asian: 2.2, C: 89, H: 4.2, Other: 0.3	32.2 92 kg	7.35	(<1: 44, 1-2: 52, >2: 4)	634
	Metformin, 1454	57.9	59.4	AA: 3.7, Asian: 2.4, C: 89.1, H: 3.8, Other: 1	32.1 91.6 kg	7.36	(<1: 46, 1-2: 50, >2: 4)	551
	Rosiglitazone, 1456	56.3	55.7	AA: 4.2, Asian: 2.7, C: 87.2, H: 5.2, other: 0.7	32.2 91.5 kg	7.36	(<1: 45, 1-2: 52, >2: 3)	539

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Charbonnel, 2006 ⁹⁴	Metformin, 237	54.7	59.5	AA: 5.9, Asian: 11, C: 67.1, H: 11.8, other: 4.2	31.5 NR	(<8: 54, 8-8.9: 30, ≥9: 15)	6.6	45
	Metformin + sitagliptin, 464	54.4	55.8	AA: 6.7, Asian: 10.6, C: 63.1, H: 15.5	30.9 NR	(<8: 55, 8-8.9: 31, ≥9: 14)	6	48
Wright, 2006 ¹⁹⁸	Any in the sulfonylurea class, 1687	NR	NR	NR	NR NR	NR	NR	NR
	Metformin, 336	NR	NR	NR	NR NR	NR	NR	NR
	Total, 5063	52.4	59	AA: 8, Asian: 9, C: 83	27.5 NR	6.9	NR	NR
Rosenstock, 2006 ⁴⁹	Metformin, 154	51.5	56	AA: 5, Asian: 14, C: 58, H: 21, other: <1	32.5 NR	8.8	2.9	31
	Metformin + rosiglitazone, 155	50.1	57	AA: 6, Asian: 12, C: 54, H: 26	33.2 NR	8.9	2.3	19
	Rosiglitazone, 159	50.6	58	AA: 5, Asian: 14, C: 59, H: 19, Other: 3	32.8 NR	8.8	2.7	22
Jain, 2006 ¹⁰¹	Glyburide, 251	52.1	56.2	AA: 13.5, Asian: 0, C: 65.7, H: 19.9, Native American: 0.4, Other: 0.4	32.8 94.3kg	9.2	0.78	123
	Pioglitazone, 251	52.1	53	AA: 15.9, Asian: 1.6, C: 61, H: 20.7, Other: 0.4, Native American: 0.4	32.5 93.9kg	9.2	0.8	117
Stewart, 2006 ¹⁵⁶	Metformin, 272	59	56	AA: <1, Asian: <1, C: 99, H: <1, Native Hawaiian/other Pacific Islander: <1	30.6 87.2 kg	7.2	3.7	54
	Metformin + rosiglitazone, 254	58.8	55	AA: 0, Asian: 1, C: 98, H: <1, Native Hawaiian /other pacific islander: 0	30.9 88.1 kg	7.2	3.7	50

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Bakris, 2006 ¹²⁵	Metformin + glyburide, 185	58.8	69	C: 76	31.8 90.3 kg	8.3	7.6	5
	Metformin + rosiglitazone, 204	60	63	C: 78	31.6 89.2 kg	8.5	8	10
Rosak, 2006 ¹⁸³	Metformin + rosiglitazone, 7705	60	50.2	NR	29.3 87.2	8.1 (median)	3.9	545
	Rosiglitazone, 1559	62	47.7	NR	28.7 83.8	8.1 (median)	4.5	542
	Rosiglitazone + sulfonylurea, 5511	65	48.2	NR	27.7 81.3kg	8.3 (median)	5.3	478
Hanefeld, 2006 ²⁰¹	Metformin + glibenclamide, 250	61	55	NR	32 91.8kg	8.6	4.6	138
	Metformin + pioglitazone, 250	61	54	NR	32 90.2kg	8.5	4.8	55
Umpierrez, 2006 ¹²⁶	Metformin + glimepiride, 96	51.6	55.2	AA: 13.5, Asian: 1.0, C: 79.2, H: 5.2, Other: 1.0	34.54 NR	8.4	4.9	11
	Metformin + pioglitazone, 109	55.7	52.3	AA: 15.9, Asian: 3.7, C: 78.5, H: 1.9, Other: 0	33.81 NR	8.31	5.9	17
Kvapil, 2006 ¹³⁸	Metformin + aspart 70/30, 116	56.4	46	NR	30.4 85.1 kg	9.3	6.7	11
	Metformin + glibenclamide, 114	58.1	46	NR	30. 84.0 kg	9.4	8.1	5
Gerich, 2005 ¹³⁶	Metformin + glyburide, 209	53.5	48	AA: 16.7, Asian: 0.5, C: 65.2, other: 17.7	33.5 NR	8.3	2.0	87
	Metformin + nateglinide, 219	52.6	51	AA: 13, Asian: 2.4, C: 64.4, other: 20.2	33.3 NR	8.4	1.5	78
Karter, 2005 ²⁰⁷	Any in the sulfonylurea class, 5921	59.9	54.8	NR	NR NR	8.9	NR	0
	Metformin, 11937	59.9	52.5	NR	NR NR	9.6	NR	0
	Pioglitazone, 3556	60.2	51.1	NR	NR NR	9.6	NR	0

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Agarwal, 2005 ¹⁸⁴	Glipizide, 22	64	100	AA: 27, C: 73	34 102 kg	7.7	14	3
	Pioglitazone, 22	67	100	AA: 14, C: 86	32 97 kg	7.7	16	1
Derosa, 2005 ¹²⁷	Metformin + glimepiride, 49	52	47	NR	26.8 NR	7.9	4	2
	Metformin + rosiglitazone, 50	54	50	NR	26.6 NR	8.0	5	2
Malone, 2004 ¹⁶⁴	Metformin + glargine,	NR	NR	NR	NR NR	NR	NR	7
	Metformin + lispro 75/25,	NR	NR	NR	NR NR	NR	NR	3
	Pooled arms	NR	63	NR	30.9 91.5kg	8.7	9	NR
Malone, 2005 ¹⁶⁵	Metformin + lispro 75/25, 50	59.18	50	NR	29.41 77.82 kg	8.5	13.52	3
	Metformin + glargine, 47	59.63	38	NR	29.64 77.21 kg	8.48	11.9	10
Madsbad, 2004 ¹²⁰	Glimepiride, 27	57	59	NR	30.2 NR	7.8	3.8	0
	Liraglutide, 26	53	85	NR	30.2 NR	7.4	4.1	3
	Liraglutide, 25	58	60	NR	32 NR	7.9	4.4	3
	Liraglutide, 27	57	67	NR	30.1 NR	7.7	4.5	7
	Liraglutide, 30	57	67	NR	30.4 NR	7.4	4.6	2
	Liraglutide, 29	58	55	NR	31.9 NR	7.4	6.1	2

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Rajagopalan, 2005 ²⁰⁶	Any in the sulfonylurea class, 1474	54.5	52.9	NR	NR NR	NR	NR	NR
	Metformin, 1137	52.5	49.6	NR	NR NR	NR	NR	NR
	Pioglitazone, 1137	52.7	50	NR	NR NR	NR	NR	NR
	Pioglitazone, 1474	54.6	54.3	NR	NR NR	NR	NR	0
	Pioglitazone, 1847	54.3	52.4	NR	NR NR	NR	NR	0
	Rosiglitazone, 1847	54.3	51.8	NR	NR NR	NR	NR	0
Hussein, 2004 ²⁰²	Pioglitazone, 107	64.4 (36 to 86)	48	NR	NR 84.3	9.5	17	0
	Rosiglitazone, 96	64.6 (41 to 82)	55	NR	NR 82.3	9.6	14.5	0
Horton, 2004 ⁸⁰	Metformin, 104	55.4	67.3	NR	29.9 NR	8.3	3.7	NR
	Metformin + nateglinide, 89	57.7	65.2	NR	30.6 NR	8.2	3.4	NR
	Nateglinide, 104	57.9	56.7	NR	29.9 NR	8.1	4.7	NR
Malone, 2003 ¹³⁷	Metformin + glibenclamide, 301	59	49	AA: 1, C: 89, H: 6, other: 4	29.6 81.7 kg	9.27	7.4	29
	Metformin + lispro 75/25, 296	58	57	AA: 0.7, C: 88.9, H: 7.4, other: 3	29.8 83.0 kg	9.17	8.0	25
Yang, 2003 ¹³⁹	Metformin + sulfonylurea	NR	NR	NR	NR NR	8.59	NR	NR
	Rosiglitazone + sulfonylurea	NR	NR	NR	NR NR	8.61	NR	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Jones, 2003 ¹⁷⁹	Metformin, 121	58 (38 to 78)	70	NR	34 NR	8.7	5	0
	Metformin, 22	64 (46 to 81)	9	NR	23 NR	8.6	6.5	NR
	Metformin, 82	60 (40 to 81)	74	NR	28 NR	8.8	6	NR
	Metformin + rosiglitazone, 141	58 (36 to 82)	69	NR	28 NR	8.8	6	NR
	Metformin + rosiglitazone, 142	57 (39 to 80)	57	NR	34 NR	8.8	5	NR
	Metformin + rosiglitazone, 35	62 (42 to 78)	71	NR	23 NR	9.3	8	NR
Marre, 2002 ⁹⁶	Metformin, 152	56.4	55.3	AA: 3.3, Asian: 2.6, C: 30.8	29.6 NR	8.25	6.5	16
	Metformin + nateglinide, 155	57.9	61.3	AA: 4.5, Asian: 3.2, C: 90.3	29.4 NR	7.99	7.2	18
	Metformin + nateglinide, 160	57.3	61.3	AA: 3.8, Asian: 3.1, C: 91.3	29.3 NR	8.18	6.8	15
Moses, 1999 ⁸²	Metformin, 27	57.8	63	Asian: 7, C: 85, not specified: 7	31.8 NR	8.6	8	0
	Metformin + repaglinide, 27	57.2	67	C: 96, not specified: 4	33.2 NR	8.3	5.9	0
	Repaglinide, 28	60.3	54	Asian: 7, C: 93	31.3 NR	8.6	7	0
Jibrán, 2006 ¹¹²	Glibenclamide, 50	45.8	10	NR	30.4 72.7 kg	10.2	0	0
	Repaglinide, 50	46.6	16	NR	27.1 65.8 kg	9.9	0	0
Leiter, 2005 ⁸³	Metformin, 78	60	56	C: 86, Others: 22	32.2 NR	7.5	5.7	13
	Metformin + rosiglitazone, 158	58	65	C: 76, Others: 24	33 NR	7.5	5.3	18
Garber, 2006 ¹²⁸	Diet + metformin + glibenclamide, 160	56 (31-78)	56	AA: 5, C: 80, Asian: 3, H: 11, O: 2	32 93 kg	8.5	5	NR
	Diet + metformin + rosiglitazone, 158	56 (24-78)	65	AA: 6, C: 79, Asian: 3, H: 10, O: 3	32 94 kg	8.4	6	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Weissman, 2005 ⁸⁶	Metformin, 384	55.7	NR	NR	33.8 96.7kg	7.97	NR	95
	Metformin + rosiglitazone, 382	55.5	NR	NR	34.4 98.2kg	8.05	NR	76
	Metformin + rosiglitazone, 358	55.5	NR	NR	34.4 98.2kg	8.05	NR	95
	Metformin, 351	55.7	NR	NR	33.8 96.7kg	7.97	NR	76
Bailey, 2005 ⁸⁷	Metformin, 280	57.6	57	AA: <1, Asian: 1, C: 98, Other: 1	32.1 89.5kg	7.5	6.1	44
	Metformin + rosiglitazone, 289	58.1	58	AA: 1, C: 97, Asian: 1, H: 0, O: 1	32.2 90.9kg	7.4	6	30
	Metformin + rosiglitazone, 288	58.1	58	AA: 1, Asian: 1, C: 97, other: 1	32.2 90.9kg	7.4	6	30
Yamanouchi, 2005 ⁵⁰	Diet + exercise + glimepiride, 37	55.6 (46.3 - 64.9)	51	AA: 0, C: 0, Asian: 0, H: 0, O: 100	25.6 NR	9.8	3.3 months	3
	Diet + exercise + metformin, 39	54.7 (44.9 - 64.5)	51	AA: 0, C: 0, Asian: 0, H: 0, O: 100	26.2 NR	9.9	3 months	2
	Diet + exercise + pioglitazone, 38	55.2 (46 - 64.4)	47	AA: 0, C: 0, Asian: 0, H: 0, O: 100	25.8 NR	10.2	3.2 months	2
	Glimepiride, 37	55.6	51	NR	25.6 NR	9.8	3.3	3
	Metformin, 39	54.7	51	NR	26.2 NR	9.9	3	2
	Pioglitazone, 38	55.2	47	NR	25.8 NR	10.2	3.2	3
Derosa, 2005 ¹⁵⁹	Diet + exercise + behavioral therapy + metformin + glimepiride, 47	52 (47 -57)	49	NR	26.8 NR	7.9	4	NR
	Diet + exercise + behavioral therapy + metformin + rosiglitazone, 48	54 (50 -58)	52	NR	26.6 NR	8	5	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Rajagopalan, 2005 ¹⁹⁴	Metformin, 1137	52.5 (19-88)	49.6	NR	NR NR	NR	NR	NR
	Pioglitazone, 1847	54.3 (18-91)	52.4	NR	NR NR	NR	NR	NR
	Unspecified sulfonylurea, 1474	54.5 (19-94)	52.9	NR	NR NR	NR	NR	NR
	Pioglitazone, 1137	52.7 (18-90)	50	NR	NR NR	NR	NR	NR
	Pioglitazone, 1474	54.6 (18-91)	54.3	NR	NR NR	NR	NR	NR
	Rosiglitazone, 1847	54.3 (18-92)	51.8	NR	NR NR	NR	NR	NR
Feinglos, 2005 ⁹¹	Metformin + glipizide, 61	57.7 (30-80)	46	AA: 8.2, C: 78.7, Asian: 3.3, H: 8.2, O: 1.6	31.7 90 kg	7.45	6.5	NR
	Placebo + metformin, 61	58.8 (40-81)	41	AA: 16.4, C: 68.9, Asian: 3.3, H: 8.2, O: 3.3	32.1 90.8 kg	7.64	4.6	NR
Maru, 2005 ¹⁹⁵	Unspecified sulfonylurea, 11350	64	52.5	NR	(BMI) \geq 30: 21%) NR	NR	NR	NR
	Metformin, 4579	59	48.2	NR	(BMI) \geq 30: 48%) NR	NR	NR	NR
Schernthaner, 2004 ⁵²	Metformin, 597	56 (35 to 75)	58	NR	31.4 89.7kg	8.7	3.1	96
	Pioglitazone, 597	57 (35 to 75)	53	NR	31.2 88.2kg	8.7	3.4	98
	Placebo + diet + metformin, 597	56	57.8	NR	31.4 89.7kg	8.7	3.1	NR
	Placebo + diet + pioglitazone, 597	57	52.6	NR	31.2 88.2kg	8.7	3.4	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Nichols, 2005 ¹⁹⁶	Unspecified sulfonylurea, 1085	62	55.9	NR	NR NR	8	4	NR
	Metformin + unspecified sulfonylurea, 1834	61.1	52.4	NR	NR NR	8.3	5.8	NR
	Metformin, 272	60	51.1	NR	NR NR	7.8	4.3	NR
Derosa, 2004 ⁶⁰	Placebo + diet + exercise + glimepiride, 81	56	47	NR	27.6 NR	8.5	NR	NR
	Placebo + diet + exercise + metformin, 83	58	51	NR	28.1 NR	8.4	NR	NR
Tan, 2004 ¹⁰⁶	Glibenclamide, 109	57.9	73	AA: 0, C: 100, Asian: 0, H: 0, O: 0	29.6 89 kg	8.5	5.22	41
	Pioglitazone, 91	60	62	C: 99, Unspecified: 1	30.2 88.4 kg	8.4	4.76	36
Raskin, 2004 ¹⁰⁹	Repaglinide, 63	58.5	62	AA: 16, C: 63, H: 2, Unspecified: 19	30.4 NR	9.3	7.2	25
	Rosiglitazone, 62	56.6	53	AA: 13, C: 68, H: 0, Unspecified: 19	31.4 NR	9	7.4	25
Jovanovic, 2004 ¹¹⁰	Pioglitazone, 62	56.2	50	AA: 11, C: 82, H: 3, other: 3	32.1 NR	9.1	6.1	36
	Pioglitazone + repaglinide, 123	58.9	68.3	AA: 15, C: 82, H: 1, others: 2.4	32.3 NR	9.3	7.1	18
	Repaglinide, 61	57.8	58	AA: 11, C: 75, H: 4.9, other: 8.1	31.2 NR	9	6.9	25
Hanefeld, 2004 ¹⁴⁰	Metformin + sulfonylurea, 320	60 (36 to 75)	54.7	AA: 0.9, C: 98.4, other: 0.6	30 84.9 kg	8.8	7.1	279
	Pioglitazone + sulfonylurea, 319	60 (36 to 75)	53.6	AA: 0.6, C: 99.4, other: 0	30.2 85.3 kg	8.82	60	259
	Placebo + metformin + unspecified sulfonylurea, 320	60 (36 to 75)	54.7	AA: 0.9, C: 98.4, Asian: 0, H: 0, O: 0.6	30 84.9 kg	8.8	7.1	NR
	Placebo + unspecified sulfonylurea + pioglitazone, 31	60 (36 to 75)	53.6	AA: 0.6, C: 99.4, Asian: 0, H: 0, O: 0	30.2 85.3 kg	8.82	7	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Garber, 2003 ⁶¹	Metformin + glyburide, 171	55.6	44	AA: 10.5, C: 77.2, Asian: 0, H: 8.8, O: 3.5	31.4 91.9 kg	8.8	3	NR
	Metformin, 164	54.7	43.3	AA: 6.7, C: 80.5, Asian: 0, H: 9.1, O: 3.7	31.4 92.8 kg	8.5	2.6	NR
	Glyburide, 151	55.3	43.7	AA: 7.3, C: 81.5, Asian: 0, H: 7.9, O: 3.3	31.1 91 kg	8.7	3	NR
Tosi, 2003 ³⁶	Glibenclamide, 20	NR	NR	NR	NR NR	NR	NR	NR
	Metformin + glibenclamide, 41	NR	NR	NR	NR NR	NR	NR	NR
	Metformin, 19	NR	NR	NR	NR NR	NR	NR	NR
Goldstein, 2003 ⁶²	Metformin + glipizide, 87	54.6	58.6	AA: 11.5, C: 72.4, Asian: 0, H: 16.1, O: 0	31.7 94 kg	8.7	5.9	NR
	Glipizide, 84	57.4	64.3	AA: 11.9, C: 71.4, Asian: 2.4, H: 14.3, O: 0	30.6 89.9 kg	8.9	6.5	NR
	Metformin, 76	56.6	61.8	AA: 15.8, C: 65.8, Asian: 1.3, H: 17.1, O: 0	31.6 93.8 kg	8.7	7.3	NR
Derosa, 2003 ⁸¹	Diet + exercise + metformin, 56	52	48	NR	24.7 72.3 kg	7.4	5	NR
	Diet + exercise + repaglinide, 56	55	52	NR	25.2 70.2 kg	7.6	4	NR
Pavo, 2003 ⁵⁴	Metformin, 100	55.8	56	NR	31.1 88.9 kg	8.6	6.3	9
	Pioglitazone, 105	54.2	56.2	NR	31.3 86.6 kg	8.6	5.6	5
Vakkilainen, 2002 ¹¹⁹	Placebo + glibenclamide, 20	63	NR	AA: 0, C: 100, Asian: 0, H: 0, O: 0	28.8 NR	7.6	NR	NR
	Placebo + nateglinide, 23	63	NR	AA: 0, C: 100, Asian: 0, H: 0, O: 0	27.8 NR	7.6	NR	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Blonde, 2002 ⁶³	Metformin + glyburide, 162	55.6	63.6	AA: 9.3, C: 67.9, Asian: 0, H: 19.1, O: 3.7	30.6 89.6 kg	9.42	6.97	NR
	Glyburide, 164	55.8	57.3	AA: 12.2, C: 66.5, Asian: 0, H: 17.1, O: 4.3	30.3 88 kg	9.64	7.01	NR
	Metformin + glyburide, 160	55.4	55.6	AA: 12.5, C: 70, Asian: 0, H: 15.6, O: 1.9	30.7 89.4 kg	9.41	7.36	NR
	Metformin, 153	57.6	62.1	AA: 10.5, C: 69.3, Asian: 0, H: 17, O: 3.3	30.6 89.5 kg	9.51	8.18	NR
St John Sutton, 2002 ¹⁴⁹	Glyburide, 99	56.1	72	AA: 3, C: 76, others: 21	NR 85.1 kg	9.5	6.2	NR
	Rosiglitazone, 104	55.1	72	AA: 5, C: 73, others: 22	NR 82.6 kg	9.1	5.3	NR
Marre, 2002 ⁶⁴	Glibenclamide, 103	58.7	55	NR	29.3 82.5 kg	7.88	6.6	NR
	Metformin, 104	57.5	60	NR	29.9 84.9 kg	8.09	5.4	NR
	Metformin + glibenclamide, 101	58	50	NR	30.1 84.7 kg	7.89	5.9	NR
	Metformin + glibenclamide, 103	60.7	54	NR	29.7 83.1 kg	7.62	6.7	NR
Garber, 2002 ⁶⁵	Metformin + glyburide, 165	58.1	58	AA: 6, C: 79, Asian: 0, H: 10, O: 5	29.6 86.7 kg	8.18	3.3	NR
	Glyburide, 161	56.5	51	AA: 9, C: 78, Asian: 0, H: 9, O: 4	30.3 87.2 kg	8.21	2.81	NR
	Metformin + glyburide, 158	56.9	58	AA: 13, C: 74, Asian: 0, H: 11, O: 2	30.1 88.8 kg	8.25	3.52	NR
	Metformin, 161	56	58	AA: 4, C: 81, Asian: 0, H: 12, O: 2	30.4 88.6 kg	8.26	2.98	NR
Gomez-Perez, 2002 ⁸⁸	Metformin, 34	53.4 (40 - 68)	29.4	C: 2.9, H: 76.5, Mestizo: 20.6	28.5 NR	NR	9.1	NR
	Metformin + rosiglitazone, 35	51.7 (40 - 73)	28.6	C: 0, H: 80, Mestizo: 20	28.0 NR	NR	11.1	NR
	Metformin + rosiglitazone, 36	54.2 (42-76)	40	C: 11.1, H: 72.2, Mestizo: 16.7	27.6 NR	NR	10.7	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Charpentier, 2001 ⁷¹	Metformin + glimepiride, 147	56.8 (36-70)	59	NR	29.5 81.2 kg	6.4	5.6	NR
	Placebo + glimepiride, 150	55.4 (35-70)	58	NR	29.3 81 kg	6.5	5.3	NR
	Placebo + metformin, 75	56.7 (36-69)	60	NR	29.2 82.2 kg	6.8	7	NR
Madsbad, 2001 ¹¹⁴	Repaglinide, 175	60.2	61	NR	28 82.9 kg	7.3	8.1	NR
	Placebo + glipizide, 81	62	64	NR	28 83.6 kg	7.2	7	NR
Amador-Licona, 2000 ⁶⁶	Metformin, 28	49.3	39	NR	26.8 70.7 kg	8.5	4.5	NR
	Glibenclamide, 23	48.2	30	NR	30.4 73.2 kg	8.4	4	NR
Einhorn, 2000 ⁸⁹	Diet + metformin + pioglitazone, 168	55.5	54.8	AA: 8.3, C: 81, Asian: 0, H: 10.1, O: 0.6	32.11 NR	9.86	NR	NR
	Metformin, 160	55.7	60	AA: 6.3, C: 86.9, H: 3.8, Others: 3.1	32.12 NR	9.75	NR	37
	Metformin + pioglitazone, 168	55.5	54.8	AA: 8.3, C: 81, H: 10.1, Others: 0.6	32.11 NR	9.86	NR	21
	Placebo + diet + metformin, 160	55.7	60	AA: 6.3, C: 86.9, Asian: 0, H: 3.8, O: 3.1	32.12 NR	9.75	NR	NR
Fonseca, 2000 ⁹⁰	Metformin, 116	58.8	74.3	AA: 3.5, C: 81.4, other: 15	30.3 NR	8.6	7.3	22
	Metformin + rosiglitazone, 113	58.3	68.2	AA: 10, C: 77.3, others: 12.7	29.8 NR	8.9	8.3	18
	Metformin + rosiglitazone, 119	57.5	62.1	AA: 6.9, C: 80.2, others: 12.9	30.2 NR	8.9	7.5	18
Horton, 2000 ⁹	Metformin, 178	56.8	68	AA: 9.6, C: 79.2, Asian: 2.2, H: 0, O: 9	29.6 NR	8.4	7.5	NR
	Nateglinide, 179	58.6	61	AA: 9.5, C: 82.1, Asian: 2.8, H: 0, O: 5.6	29.6 NR	8.3	4.7	NR

Table 11. Population characteristics of the studies reporting on the comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Group, N	Mean age (age range),	Male, %	Race, %	Mean BMI in kg/m ² Mean weight in kg	Mean HbA1c in %	Mean duration of diabetes in years	N of withdrawals
Landgraf, 1999 ¹¹⁵	Repaglinide, 94	61	60	AA: 0, C: 96, Asian: 0, H: 0, O: 4	27.6 80 kg	7.8	10	NR
	Placebo + glibenclamide, 100	63	57	AA: 6, C: 93, Asian: 0, H: 0, O: 1	27.5 79 kg	8	10	NR
Marbury, 1999 ¹¹⁷	Placebo + glyburide, 182	58.7	66	AA: 9, C: 79, Asian: 0, H: 0, O: 12	29.1 NR	8.9	8.3	NR
	Repaglinide, 362	58.3	67	AA: 9, C: 77, Asian: 0, H: 0, O: 14	29.4 NR	8.7	7.2	NR
Wolffenbittel, 1999 ¹¹⁶	Placebo + glyburide, 139	61	68	NR	28 81.3 kg	7	Median: 6	NR
	Repaglinide, 286	61	62	NR	28.4 81.5 kg	7.1	Median: 6	NR
DeFronzo, 1995 ⁷⁰	Metformin, 143	53	43	NR	29.9 94.4 kg	8.4	6	NR
	Metformin + glyburide, 213	55	46	NR	29 92.1 kg	8.8	7.8	NR
	Placebo + glyburide, 209	56	49	NR	29.1 92.6 kg	8.5	8.7	NR
	Placebo + metformin, 210	55	46	NR	29.4 92.6 kg	8.9	8.4	NR
Hermann, 1994 ⁶⁸	Diet + metformin + glibenclamide, 54	NR	NR	NR	NR 80.2 kg	6.8	NR	NR
	Diet + metformin, 25	NR	NR	NR	NR 78.6 kg	6.9	NR	NR
	Diet + metformin + glibenclamide, 13	NR	NR	NR	NR 84.6 kg	7.8	NR	NR
	Diet + metformin + glibenclamide, 13	NR	NR	NR	NR 76 kg	7.8	NR	NR
	Diet + metformin + glibenclamide, 18	NR	NR	NR	NR 83.2 kg	8.4	NR	NR
	Diet + glibenclamide, 21	NR	NR	NR	NR 82.6 kg	6.7	NR	NR
Wolffenbittel, 1993 ¹¹⁸	Glibenclamide, 15	62 (45-75)	25	NR	26.1 70.9 kg	Range 7.0-12.0	9	NR
	Repaglinide, 29	62 (45-75)	25	NR	26.1 74 kg	Range 7.0-12.0	9	NR

AA=African American; C=Caucasian; H=Hispanic; kg=kilogram; NR=not reported; O = other

* 5 while on metformin prior to second crossover; 2 during washout period; and 5 while on repaglinide after crossover

† 2 excluded on repaglinide prior to first crossover; 1 during washout, and 5 after first crossover while on metformin

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Metformin versus thiazolidinediones								
Tzoulaki, 2009 ¹⁷¹	Cohort	Grp1: Metformin NR Grp2: Rosiglitazone NR			Def: First episode of CHF Grp1: ref Grp2: 0.61 (CI: 0.33 to 1.15)	Non-hip fractures Grp1: ref Grp2: HR: 1.09 (CI: 0.72 to 1.68)		
Tzoulaki, 2009 ¹⁷¹	Cohort	Grp1: Metformin NR Grp2: Pioglitazone NR			Def: First episode of CHF Grp1: ref Grp2: 1.17 (CI: 0.77 to 1.77)	Non-hip fractures Grp1: ref Grp2: HR: 1.28 (CI: 0.93 to 1.77)		
Perez, 2009 ^{5b}	RCT	Grp1: Metformin Fixed Mean: 850 mg Grp2: Pioglitazone Fixed				Def: Wrist fractures Coll: Active Timing: Specified ITT: NR Grp1: 1 (<1) Grp2: 0 (0)	Def: Diarrhea Coll: Active Timing: Specified ITT: NR Grp1: (15.3) Grp2: (2.6)	
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Metformin NR Grp2: Rosiglitazone NR			Def: ICD-9 codes Coll: NR Timing: NA ITT: NA Grp1: ref Grp2: HR: 1.16 (CI: 0.78 to 1.73)			
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Metformin NR Grp2: Pioglitazone NR			Def: ICD-9 codes Coll: NR Timing: NA ITT: NA Grp1: ref Grp2: HR: 1.38 (CI: 1.00 to 1.90)			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Metformin NR Grp2: Rosiglitazone NR			Def: ICD-9-CM diagnostic codes of hospitalization Coll: NR Timing: Unspecified ITT: NA Grp1: 578 (1.26); ref Grp2: 67 (3.33); HR: 1.30 (CI: 0.89 to 1.89)			
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Metformin NR Grp2: Pioglitazone NR			Def: ICD-9-CM diagnostic codes of hospitalization Coll: NR Timing: Unspecified ITT: NA Grp1: 578 (1.26); ref Grp2: 13 (2.66); HR: 1.54 (CI: 0.65 to 3.64)			
Karter, 2005 ²⁰⁷	Cohort	Grp1: Metformin NR Grp2: Pioglitazone NR			Def: ICD-9-CM codes for primary discharge diagnosis (HR relative to sulfonylurea use) Coll: Passive Timing: Unspecified ITT: NR Grp1: HR: 0.7 (CI: 0.49 - 0.99), p: 0.05 Grp2: HR: 1.28 (CI: 0.85 - 1.92), p: 0.2			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Asche, 2008 ²⁰⁰	Cohort	Grp1: Metformin NR Grp2: Thiazolidinediones NR			Def: NR Coll: NR Timing: Unspecified ITT: NR Grp1: NR Grp2: 18 (2.6)		Def: Nausea & vomiting; diarrhea; dyspepsia Coll: NR Timing: NR ITT: NR Grp1: (1.3%; 1.6%; 2.8%) Grp2: NR	Def: Lactic acidosis Coll: NR Timing: Unspecified ITT: NR Grp1: 6 (0.3) Grp2: NR
Kawai, 2008 ²²¹	Non-randomized	Grp1: Metformin NR Start: 500-750mg, Max: 750mg Grp2: Pioglitazone Fixed NR	Def: Mild, moderate and severe Coll: NR Timing: Unspecified ITT: Yes Grp1: 0 (0) Grp2: 0 (0)					
Rosenstock, 2006 ⁴⁹	RCT	Grp1: Metformin Varied, mean daily glucose \leq 6.1 mmol/l Start: 500 mg, Max: 2000 mg, Mean: 1847 mg D: 32 wks Grp2: Rosiglitazone Varied, mean daily glucose \leq 6.1 mmol/l Start: 4 mg, Max: 8 mg, Mean: 7.7 mg D: 32 wks	Def: Mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: 14 (9) Grp2: 13 (8)				Def: Diarrhea, nausea, vomiting, dyspepsia Coll: Active Timing: Specified ITT: Yes Grp1: (51) Grp2: (35)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Kahn, 2006 ³⁸	RCT	Grp1: Metformin Varied, glucose: <140 mg Start: 500 mg, Max: 2000 mg Grp2: Rosiglitazone Varied, glucose: <140 mg Start: 4 mg, Max: 8 mg	Def: Self reported Coll: NR Timing: Unspecified ITT: Yes Grp1: All: 168 (11.6), Severe: 1 (0.1) Grp2: All: 142 (9.8), Severe: 1 (0.1)		Def: Investigator reported Grp1: 19 (1.3) Grp2: 22 (1.5)		Def: Nausea, vomiting, diarrhea, abdominal discomfort Coll: NR Timing: Unspecified ITT: Yes Grp1: (38.3) Grp2: (23)	
Yamanouchi, 2005 ⁵⁰	RCT	Grp1: Metformin Fixed Start: 750 mg Grp2: Pioglitazone Fixed Start: 30 mg women, 45 mg men	Def: NR Grp1: 0 (0) Grp2: 0 (0)					
Pavo, 2003 ⁵⁴	RCT	Grp1: Metformin Varied, glucose: < 126 mg/dl Start: 850 mg, Max: 2550 mg, Mean: 2292 mg D: 8 wks Grp2: Pioglitazone Varied, glucose: < 126 mg/dl Start: 35 mg, Max: 45 mg, Mean: 41.5 mg D: 8 wks					Def: Diarrhea Grp1: (16) Grp2: (3)	Def: Cholecystitis Coll: Active Timing: Unspecified ITT: NR Grp1: 0 (0) Grp2: 1 (1)

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Schernthaner, 2004 ⁵²	RCT	Grp1: Metformin Varied Start: 850 mg, Max: 2550 mg Grp2: Pioglitazone Varied Start: 35 mg, Max: 45 mg					Def: Diarrhea; Nausea Grp1: (11.1); (4.2) Grp2: (3.2); (2.3)	
Leiter 2005 ⁸³	RCT	Grp1: Metformin Varied, glucose: <7.0 mmol/L Start: 1500 mg, Max: 2500 mg D: 8 wks Grp2: Rosiglitazone Varied, glucose: <7.0 mmol/L Start: 4 mg, Max: 8 mg D: 8 wks			Grp1: 0 (0) Grp2: 3 (1)			
Rajagopalan, 2005 ²⁰⁶	Cohort	Grp1: Metformin NR Grp2: Pioglitazone NR		Def: ICD9 code liver failure or hepatitis Coll: Passive Timing: Unspecified ITT: NR Grp1: 0.8% incidence Grp2: 0.5% incidence HR: 1.139 (CI: 0.439 - 2.96)				

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Rajagopalan, 2005 ²⁰⁶	Cohort	Grp1: Metformin NR Grp2: Rosiglitazone NR		Def: ICD9 code 'liver failure' or 'hepatitis' Coll: Passive Timing: Unspecified ITT: NR Grp1: 0.8% incidence Grp2: 0.4% incidence				
Kahn, 2008 ²¹³	RCT	Grp1: Metformin Varied, glucose: < 140 Start dose: 500g, Max: 2g Grp2: Rosiglitazone Varied, glucose: < 140 Start dose: 4mg, Max: 8mg				Def: Fractures (NS) Coll: NR Timing: Unspecified ITT: Yes Grp1: 1.2/ 100 patient- years Grp2: 1.86/ 100 patient- years HR: 1.57 (CI: 1.13 - 2.17), p: 0.0073		
Metformin versus sulfonylurea								
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR			Def: ICD-9 codes Coll: NR Timing: NA ITT: NA Grp1: HR: 0.76 (CI: 0.64 to 0.91) Grp2: ref			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Tzoulaki, 2009 ¹⁷¹	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR			Def: First episode of CHF Grp1: ref Grp2: 1.18 (CI: 1.04 to 1.34)	Non-hip fractures Grp1: ref Grp2: HR: 1.09 (CI: 0.97 to 1.23)		
Currie, 2009 ²¹²	Cohort	Grp1: Metformin NR Grp1: Sulfonylurea						Def: Cancer Coll: Passive Timing: Unspecified ITT: NA Grp1: ref Grp2: HR: 1.36 (CI: 1.19 to 1.54)
Asche, 2008 ²⁰⁰	Cohort	Grp1: Metformin NR Grp2: Any drug in the sulfonylurea class NR					Def: Nausea/vomiting; Diarrhea; Dyspepsia Coll: NR Timing: No ITT: NR Grp1: (1.3; 1.6; 2.8) Grp2: NR	Def: Lactic acidosis Coll: NR Timing: Unspecified ITT: NR Grp1: 6 (0.3) Grp2: NR
McAlister, 2008 ²⁰⁸	Cohort	Grp1: Metformin NR Median: 726 mg Grp2: Any sulfonylurea Varied Median: 4 mg for glyburide, 198 mg for chlorpropamide, 425 mg for tolbutamide			Def: Primary, secondary or most responsible diagnosis of HF using ICD-9 codes Coll: Passive ITT: NR Grp1: 3.3 cases/100yrs Grp2: 4.4 cases/100 yrs, aHR: 1.16 (CI: 0.96-1.41)			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Karter, 2005 ²⁰⁷	Cohort	Grp1: Metformin NR Grp2: Any sulfonylurea NR			Def: ICD-9-CM codes for primary discharge diagnosis Coll: Passive Timing: Unspecified ITT: NR Grp1: HR: 0.7 (CI: 0.49-0.99), p: 0.05 Grp2: ref			
Chien, 2007 ⁵⁹	RCT	Grp1: Metformin Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Mean: 1910 mg D: 4 wks Grp2: Glyburide Varied, glucose: <140 mg/dL Start: 10 mg, Max: 20 mg, Mean: 19 mg D: 4 wks	Def: Mild or moderate Coll: Passive Timing: Unspecified ITT: Yes Grp1: 0 (0) Grp2: 0 (0)				Def: Diarrhea, dry mouth, increased appetite, GI disease Coll: Passive Timing: Unspecified ITT: Yes Grp1: (32) Grp2: (13)	
Kahn, 2006 ³⁸	RCT	Grp1: Metformin Varied, glucose: <140 mg/dL Start: 500 mg, Max: 2000 mg Grp2: Glyburide Varied, glucose: <140 mg/dL Start: 2.5 mg, Max: 15 mg	Def: Self reported events Coll: NR Timing: Unspecified ITT: Yes Grp1: All: 168 (11.6), Severe: 1 (0.1) Grp2: All: 557 (38.7), Severe: 8 (0.6)		Def: Investigator reported events Coll: NR Timing: Unspecified ITT: Yes Grp1: All: 19 (1.3), Serious: 12 (0.8) Grp2: All: 9 (0.6), Serious: 3 (0.2)		Def: Nausea, vomiting, diarrhea, abdominal discomfort Coll: NR Timing: Unspecified ITT: Yes Grp1: (38.3) Grp2: (21.9)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Wright, 2006 ¹⁹⁸	RCT	Grp1: Metformin Varied, glucose: <6 mmol/L Max: 2550 mg Grp2: Sulfonylurea Varied, glucose: <6 mmol/L Max: glipizide 40 mg, chlorpropamide 500 mg, glibenclamide 20 mg	Def: Mean annual % Coll: Active Timing: Specified ITT: NR Grp1: Substantive hypo: 0.3, (CI: 0.1-1.1); Any: 1.7, (CI: 1-3) Grp2: Substantive hypo: 1.2, (CI: 0.4-3.4); Any: 7.9, (CI: 5.1-11.9)					
Yamanouchi, 2005 ⁵⁰	RCT	Grp1: Metformin Fixed 750 mg Grp2: Glimepiride Varied Start: 1.0 mg, Max: 2.0 after 1 month in 8 cases. Rest on 1 mg	Grp1: Severe: 0 (0); Mild/moderate: 0 (0) Grp2: Severe: 0 (0); Mild/moderate: 1 (2.7)					
Derosa, 2004 ⁶⁰	RCT	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg Grp2: Glimepiride Varied Start: 1 mg, Max: 4 mg	Grp1: 0 (0) Grp2: 0 (0)				Def: Nausea + diarrhea Grp1: 2 (2.4) Grp2: NR	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Garber, 2003 ⁶¹	RCT	Grp1: Metformin Varied Start: 500 mg (adjusted to patient response), Max: 2000 mg Grp2: Glyburide Varied Start: 2.5 (adjusted to patient response), Max: 10 mg	Def: Mild or moderate Grp1: Symptomatic: 29 (17.7), Fingerstick: 1 (0.6) Grp2: Symptomatic: 98 (57.6), Fingerstick: 16 (10.6)				Def: Abdominal pain; Nausea & Vomiting; Diarrhea Grp1: (6.1; 10.4; 18.3) Grp2: (4; 6.6; 5.3)	
Blonde, 2002 ⁶³	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Glyburide Fixed Start: 10 mg	Def: Mild or moderate, Fsg≤60mg/dl + symptomatic Grp1: 1 (<1) Grp2: 3 (1.8)				Def: Dyspepsia and heartburn; Nausea + vomiting; Flatulence Grp1: (4.6; (12.4); (2) Grp2: (3); (5.5); (0)	
Marre, 2002 ⁶⁴	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Glibenclamide Varied Start: 5 mg, Max: 20 mg	Def: Symptoms or labs Grp1: Serious: 1 (1.0), Mild or moderate: 0 (0) Grp2: Serious: 1 (1.0), Mild or moderate: 7 (7)					
Garber, 2002 ⁶⁵	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Glyburide Varied Start: 2.5 mg, Max: 10mg	Def: Mild or moderate Grp1: 0 (0) Grp2: 10 (6)				Def: Nausea + vomiting + diarrhea + dyspepsia Grp1: (43) Grp2: (24)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Charpentier, 2001 ⁷¹	RCT	Grp1: Metformin Fixed Start: 850 mg tid Grp2: Glimepiride Fixed or Varied 1 mg (either fixed or increased stepwise to 2, 4, 6 mg od depending on clinical symptoms of hypoglycemia)	Def: Clinical symptoms Grp1: Serious: 0 (0), Mild or moderate: 8 (11) Grp2: Serious: 3 (2), Mild or moderate: 17 (11)				Def: Diarrhea Grp1: (7) Grp2: (1)	
DeFronzo, 1995 ⁷⁰	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2500 mg Grp2: Glyburide Varied Start: 10 mg, Max: 20 mg	Def: Mild or moderate Grp1: 4 (2) Grp2: 6 (3)				Def: Nausea + diarrhea Grp1: (1.4) Grp2: (1)	
Hermann, 1994 ⁶⁸	RCT	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg Grp2: Glyburide Varied Start: 3.5 mg, Max: 10.5 mg	Def: Serious Grp1: 8 (21) Grp2: 12 (35)				Def: Nausea + diarrhea + dyspepsia and digestive Grp1: (63) Grp2: (32)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Maru, 2005 ¹⁹⁵	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR			Def: CHF/clinical diagnosis + validated a small sample via questionnaires to Grp to confirm the diagnosis + oxmis and read codes similar to ICD-9 codes Grp1: IR: 18.8/1000 person-years Grp2: IR: 26.6/1000 person-years			
Nichols, 2005 ¹⁹⁶	Cohort	Grp1: Metformin NR Grp2: Sulfonylurea NR			Def: Medical record for CHF + ICD-9 code for CHF + clinical diagnosis + first record Grp1: IR: 10.5 (6.7-16.2) Grp2: IR: 13.8 (11.4-16.6)			
Rajagopalan, 2005 ²⁰⁶	Cohort	Grp1: Metformin NR Grp2: Any drug in SU class NR		Def: ICD9 code liver failure or hepatitis Coll: Passive Timing: Unspecified ITT: NR Grp1: (0.8) Grp2: (1)				

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Kahn, 2008 ²¹³	RCT	Grp1: Metformin Varied, glucose: < 140 mg/dL Start dose: 500 mg, Max: 2 g Grp2: Glyburide Varied, glucose: < 140 mg/dL Start dose: 2.5 mg, Max: 15 mg				Def: Fractures (NS) Coll: NR Timing: Unspecified ITT: Yes Grp1: 1.2/100 patient-years Grp2: 1.15/100 patient-years		
Chien, 2007 ⁵⁹	RCT	Grp1: Metformin Varied, glucose: <140 mg/dL Start dose: 1000 mg, Max: 2000 mg, Mean: 1910 mg D: 4 wks Grp2: Glyburide Varied, glucose: <140 mg/dL Start dose: 10 mg, Max: 20 mg, Mean: 19 mg D: 4 wks				Def: Right metacarpal bone fracture Coll: passive Timing: Unspecified ITT: Yes Grp1: 0 Grp2: 1 (6)		
Amador-Licona, 2000 ⁶⁶	RCT	Grp1: Metformin Varied Start: 850 mg Grp2: Glibenclamide Varied Start: 5 mg					Def: Diarrhea + Diffuse abdominal pain Grp1: 4 (14.3) Grp2: NR	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Goldstein, 2003 ⁶²	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Glipizide Varied Start: 30 mg, Max: 30 mg					Def: Diarrhea Grp1: (17.3) Grp2: (13.1)	
Metformin versus DPP-IV inhibitors								
Aschner, 2010 ⁷⁷	RCT	Grp1: Metformin Varied, prespecified dose Start: 500 mg, Max: 2000 mg; Mean: 1903 mg D: 5 weeks Grp2: Sitagliptin Fixed Mean: 100 mg	Coll: Passive Timing: Unspecified ITT: No Grp1: Severe: 0 (0) Mild/moderate: 17 (3.3); 23 events Grp2: Severe: 2 (<1) Mild/moderate: 9 (1.7); 17 events				Def: Combined GI events; Nausea; Diarrhea; Vomiting; Abdominal pain Coll: NR Timing: Unspecified ITT: No Grp1: (20.7, 3.1, 10.9, 1.3, 3.8) Grp2: (11.6, 1.1, 3.6, 0.4, 2.1)	
Jadzinsky, 2009 ⁷⁸	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 1000 mg D: 1 week Grp2: Saxagliptin Fixed Mean: 10 mg	Coll: Active Timing: Unspecified ITT: Yes Grp1: Severe: 0 (0) Mild/moderate: 13 (4) Grp2: Severe: 0 (0) Mild/moderate: 5 (1)				Def: Diarrhea Coll: Active Timing: Unspecified ITT: Yes Grp1: 24 (7) Grp2: 10 (3)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Williams-Herman, 2009 ⁷⁶	RCT	Grp1: Metformin Fixed Mean: 1000 mg or 2000 mg Grp2: Sitagliptin Fixed Mean: 100 mg	Def: Coll: Active Timing: Unspecified ITT: No Grp1: 2 (1) Grp2: 2 (1)				Def: Nausea; Diarrhea; Abdominal pain; Vomiting; Nausea/ Vomiting Coll: NR Timing: Unspecified ITT: No Grp1: (3; 7; 4; 0; 20 for 1000 mg and 10; 12; 6; 3; 31 for 2000 mg) Grp2: (1; 4; 5; 1; 20)	
Goldstein, 2007 ⁷⁵	RCT	Grp1: Metformin Varied, prespecified target Start: 500 mg, Max: 2000 mg Grp2: Sitagliptin Varied, prespecified target Start: 50 mg, Max: 100 mg	Grp1: 3 (2) Grp2: 1 (1)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Metformin versus meglitinides								
Lund, 2007 ¹⁹⁷	RCT	Grp1: Metformin Varied, prespecified target Start: 500 mg, Max: 2000 mg, Mean: 1629 mg D: 12 days Grp2: Repaglinide Varied, prespecified target Start: 1 mg, Max: 6 mg, Mean: 4.72 mg D: 12 days	Coll: Active Timing: Specified ITT: Yes Grp1: Serious: 1 (1), Mild or moderate: 22 (23) Grp2: Serious: 1 (1), Mild or moderate: 45 (47)				Def: NR Coll: Active Timing: Specified ITT: Yes Grp1: (65.7) Grp2: (42.7)	Def: Cancer Grp1: 2 (2) Grp2: 0 (0)
Horton, 2004 ⁸⁰		Grp1: Metformin Fixed Start: 500 mg Grp2: Nateglinide Fixed Start: 120 qac	Def: Mild/ moderate, plasma glucose <2.8 mmol/l Coll: Active Timing: Specified ITT: Yes Grp1: 1 (1) Grp2: 2 (2)				Def: Diarrhea Coll: Active Timing: Specified ITT: Yes Grp1: (20.2) Grp2: (3.8)	
Moses, 1999 ⁸²	RCT	Grp1: Metformin NR Grp2: Repaglinide Fixed Start: 0.5 mg, Max: 4.0 mg D: 12-28 days	Def: Mild or moderate Coll: Passive Timing: Unspecified ITT: No Grp1: 1 (4) Grp2: 3 (11)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Derosa, 2003 ⁸¹	RCT	Grp1: Metformin Varied Start: 500 mg bid, Max: 2500 mg D: 8 weeks Grp2: Repaglinide Varied Start: 0.5 mg bid, Max: 4 mg tid D: 8 weeks	Def: Mild or moderate Grp1: 0 (0) Grp2: 0 (0)				Def: Nausea + diarrhea (withdrawn due to) Grp1: (3.6) Grp2: (0)	
Horton, 2000 ⁹	RCT	Grp1: Metformin Fixed Start: 500 mg Grp2: Nateglinide Fixed Start: 120 mg tid	Def: Mild or moderate Grp1: 19 (11) Grp2: 22 (12)				Def: Nausea + diarrhea (withdrawn due to) Grp1: (3.4) Grp2: (0.6)	
Metformin versus metformin + thiazolidinedione								
Mancini, 2009 ²¹⁴	Cross-sectional	Grp1: Metformin Median: 1700 mg Grp2: Metformin + rosiglitazone Median: 1850 mg; Median: 8 mg				Def: Vertebral fractures Coll: NR Timing: NA ITT: NA Grp1: ref Grp2: OR: 6.5 (CI: 1.3 to 38.1)		
Perez, 2009 ⁵⁶	RCT	Grp1: Metformin Fixed Mean: 850 mg Grp2: Metformin + pioglitazone Fixed				Def: Wrist fractures Coll: Active Timing: Specified ITT: NR Grp1: 1 (<1) Grp2: 1 (<1)	Def: Diarrhea Coll: Active Timing: Specified ITT: NR Grp1: (15.3) Grp2: (9)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Kawai, 2008 ²²¹	Non-randomized	Grp1: Metformin NR Start: 500-750 mg, Max: 750 mg Grp2: Metformin + pioglitazone NR; Fixed Start: 500-750 mg, Max: 750 mg; NR	Def: Mild, moderate and severe Coll: NR Timing: Unspecified ITT: No Grp1: 0 (0) Grp2: 0 (0)					
Kaku, 2009 ⁸⁴	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 750 mg Grp2: Metformin + pioglitazone Varied Start: 500 mg, Max: 750 mg; Start: 15 mg, Max: 30 mg D: NR; 16 wks	Def: Mild or moderate Grp1: 0 (0) Grp2: 1 (1)				Def: abdominal pain and constipation Grp1: (2.3) Grp2: (2.4)	
Scott, 2008 ⁸⁵	RCT	Grp1: Metformin Fixed Start: >1500 mg D: 10 wks Grp2: Metformin + rosiglitazone Fixed Start: >1500 mg; Start: 8 mg, Mean: 8 mg D: 10 wks	Def: Mild or moderate Coll: NR Timing: Unspecified Grp1: 2 (2) Grp2: 1 (1)				Def: Diarrhea, nausea, abdominal pain, vomiting Coll: NR Timing: Unspecified ITT: No Grp1: (9) Grp2: (7)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Rosenstock, 2006 ⁴⁹	RCT	Grp1: Metformin Varied, mean daily glucose \leq 6.1 mmol/l Start: 500 mg, Max: 2000 mg, Mean: 1847 mg D: 32 wks Grp2: Metformin + rosiglitazone Varied, mean daily glucose \leq 6.1 mmol/l Start: 500 mg, Max: 2000 mg, Mean: 1799 mg; Start: 2 mg, Max: 8 mg, Mean: 7.2 mg D: 32 wks	Def: Self reported mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: 14 (9) Grp2: 19 (12)				Def: Diarrhea, nausea, vomiting Dyspepsia Coll: Active Timing: Specified ITT: Yes Grp1: (51) Grp2: (47)	
Stewart, 2006 ¹⁵⁶	RCT	Grp1: Metformin Varied, prespecified Start: 500 mg, Max: 3000 mg, Mean: 2627.9 mg D: 20 wks Grp2: Metformin + rosiglitazone Varied, prespecified Start: 500 mg, Max: 2000 mg, Mean: 1812.2 mg; Start: 4 mg, Max: 8 mg, Mean: 6.8 mg D: 18 wks; 16 wks	Def: Mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: 10 (4) Grp2: 17 (7)				Def: Diarrhea Grp1: (18) Grp2: (8)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Jones, 2003 ¹⁷⁹	RCT	Grp1: Metformin Fixed Max: 2.5 g Grp2: Metformin + rosiglitazone Fixed; Varied, prespecified target Max: 2.5 g; Max: 8 mg	Def: Symptomatic hypoglycemia Grp1: All: (0.4), Obese: (1.7) Grp2: All: (2.1), Obese: (1.9)					
Weissman, 2005 ⁸⁶	RCT	Grp1: Metformin Varied Start: 500 mg bid, Max: 1000 mg bid Grp2: Metformin + rosiglitazone Fixed Start: 2500 mg; Start: 12 mg	Def: Mild or moderate Grp1: 4 (1) Grp2: 4 (1)				Def: Withdrawn due to GI Grp1: (6.8) Grp2: (3.1)	
Bailey, 2005 ⁸⁷	RCT	Grp1: Metformin Varied Start: 2500 mg, Max: 3000 mg D: 24 wks Grp2: Metformin + rosiglitazone Fixed; Varied Start: 2000 mg; Start: 4 mg, Max: 8 mg D: 24 wks	Grp1: Serious: 0, Mild or moderate: 1 (<1) Grp2: Serious: 0, Mild or moderate: 3 (1)				Def: diarrhea and abdominal pain Grp1: (5.4) Grp2: (3.2)	Def: acute cholecystitis, serious cholelithiasis and cholestatic jaundice Coll: Active Timing: Specified ITT: Yes Grp1: 1 (<1) Grp2: 0 (0)
Fonseca, 2000 ⁹⁰	RCT	Grp1: Metformin Fixed Start: 2500 mg Grp2: Metformin + rosiglitazone Fixed Start: 2500 mg; Start: 4-8 mg	Def: mild or moderate Grp1: 2 (2) Grp2: 5 (4)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Einhorn, 2000 ⁸⁹	RCT	Grp1: Metformin NR Grp2: Metformin + pioglitazone NR; Fixed NR; 30 mg	Grp1: 1 (0.6) Grp2: 1 (0.6)					
Gomez-Perez, 2002 ⁸⁸	RCT	Grp1: Metformin Fixed Start: 2.5 g Grp2: Metformin + rosiglitazone Fixed Start: 2.5 g; Start: 2-4 mg bid					Def: Nausea + vomiting + diarrhea + flatulence and abdominal pain Grp1: (15.4) Grp2: (16.8)	
Metformin versus metformin + sulfonylurea								
Currie, 2009 ²¹²	Cohort	Grp1: Metformin NR Grp1: Metformin + sulfonylurea						Def: Cancer Coll: Passive Timing: Unspecified ITT: NA Grp1: ref Grp2: HR: 1.8 (CI: 0.96 to 1.21)
Nauck, 2009 ⁹²	RCT	Grp1: Metformin Varied Start: 2000 mg, Max: 2000 mg Grp2: Metformin + glimepiride Varied; Fixed Start: 2000 mg, Max: 2000 mg; Start: 1 mg, Max: 4 mg D: NR; 3 wks	Def: Serious Coll: NR Timing: Unspecified ITT: NR Grp1: 0 (0) Grp2: 0 (0)				Def: nausea, vomiting, and diarrhea Coll: NR Timing: NR ITT: NR Grp1: (17) Grp2: (17)	Def: acute pancreatitis Coll: NR Timing: Unspecified ITT: NR Grp1: 0 (0) Grp2: 1 (<1)

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Feinglos, 2005 ⁹¹	RCT	Grp1: Metformin Fixed Start: ≥1000 mg Grp2: Metformin + glipizide Fixed Start: ≥1000 mg; 2.5 mg	Def: FSG <60 mg/dl w/ symptoms or FSG <50 mg/dl w/o symptoms or FPG<55 mg/dl w/o symptoms Grp1: Serious: 0, Mild or moderate: 2 (3.3) Grp2: Serious: 0, Mild or moderate: 9 (14.8)					
Garber, 2003 ⁶¹	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glyburide Varied Start: 250 mg, Max: 1000 mg; Start: 1.25 mg, Max: 5 mg	Def: Mild or moderate Grp1: Symptomatic: 29 (17.7), Fingerstick: 1 (0.6) Grp2: Symptomatic: 59 (39.1), Fingerstick: 19 (11.2)				Def: Abdominal pain; nausea + vomiting; Diarrhea Grp1: (6.1; 10.4; 18.3) Grp2: (4.1; 4.7; 7.6)	
Tosi, 2003 ³⁶	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 3000 mg Grp2: Metformin + glibenclamide Varied Start: 500 mg, Max: 2000; Start: 2.5 mg, Max: 10mg	Grp1: Severe: 2 (10.5), Mild or moderate: 1 (5) Grp2: NR				Def: Diarrhea + constipation + discomfort and abdominal pain and anorexia Grp1: (10.5) Grp2: (2.6)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Blonde, 2002 ⁶³	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 2000 mg; Start: 5 mg, Max: 20 mg	Def: FSG≤60mg/dl + symptomatic Grp1: Mild or moderate: 1 (<1) Grp2: Mild or moderate: 22 (6.8)				Def: Dyspepsia and heartburn; Nausea + vomiting; Flatulence Grp1: (4.6; 12.4; 2) Grp2: (3.7; 6.8; 2.5)	
Blonde, 2002 ⁶³	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 2000 mg; Start: 2.5 mg, Max: 10 mg	Def: FSG≤60mg/dl + symptomatic Grp1: Mild or moderate: 1 (<1) Grp2: Mild or moderate: 22 (6.8)				Def: Dyspepsia and heartburn; Nausea + vomiting; Flatulence Grp1: (4.6; 12.4; 2) Grp2: (5; 10; 6.3)	
Marre, 2002 ⁶⁴	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glibenclamide Varied Start: 500 mg, Max: 2000 mg; Start: 2.5 mg, Max: 10 mg	Def: Symptoms or labs Grp1: Serious: 1 (1.0), Mild or moderate: 0 Grp2: Serious: 0, Mild or moderate: 11 (10.9)				Def: Not specified Grp1: (14.4) Grp2: (6.9)	
Marre, 2002 ⁶⁴	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glibenclamide Varied Start: 500 mg, Max: 2000 mg; Start: 2.5 mg, Max: 10 mg	Def: Symptoms or labs Grp1: Serious: 1 (1.0), Mild or moderate: 0 Grp2: Serious: 2 (1.9), Mild or moderate: 12 (11.4)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Garber, 2002 ⁶⁵	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glyburide Varied Start: 250 mg; Start: 1.25 mg	Def: Mild or moderate Grp1: NR Grp2: 18 (11.4)				Def: Nausea + vomiting + diarrhea + dyspepsia Grp1: IR - 43 Grp2: IR - 32	
Garber, 2002 ⁶⁵	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glyburide Varied Start: 500 mg; Start: 2.5 mg	Def: Mild or moderate Grp1: NR Grp2: 61 (37.7)				Def: Nausea + vomiting + diarrhea + dyspepsia Grp1: IR - 43 Grp2: IR - 38	
Charpentier, 2001 ⁷¹	RCT	Grp1: Metformin Fixed Start: 850 mg tid Grp2: Metformin + glimepiride Fixed Start: 850 mg tid; Start: 1 mg	Def: Clinical symptoms Grp1: Serious: 0 (0), Mild or moderate: 8 (11) Grp2: Serious: 2 (1.4), Mild or moderate: 30 (21)				Def: diarrhea Grp1: (7) Grp2: (3)	
DeFronzo, 1995 ⁷⁰	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2500 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 2500 mg; Start: 10 mg, Max: 20mg	Def: Mild or moderate Grp1: 4 (2) Grp2: 38 (18)				Def: Nausea + diarrhea Grp1: (1.4) Grp2: (0.9)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Hermann, 1994 ⁶⁸	RCT	Grp1: Metformin Varied Start: 1000 mg, Max: 3000 mg Grp2: Metformin + glyburide Varied Start: 500 mg, Max: 3000 mg; Start: 1.75 mg, Max: 14 mg	Def: Mild or moderate Grp1: 8 (21) Grp2: 24 (33)					
Chien, 2007 ⁵⁹	RCT	Grp1: Metformin Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Mean: 1910 mg D: 4 wks Grp2: Metformin + glyburide Varied, glucose: <140 mg/dL Start: 1000 mg, Max: 2000 mg, Mean: 1680 mg; Start: 5 mg, Max: 10 mg, Mean: 8.4 mg D: 4 wks	Def: Mild or moderate Coll: Passive Timing: Unspecified ITT: Yes Grp1: 0 (0) Grp2: 0 (0)			Def: Right metacarpal bone fracture Coll: passive Timing: Unspecified ITT: Yes Grp1: 0 (0) Grp2: 0 (0)	Def: Diarrhea, dry mouth, increased appetite, GI disease Coll: Passive Timing: Unspecified ITT: NR Grp1: (32) Grp2: (13)	
Nichols, 2005 ¹⁹⁶	Cohort	Grp1: Metformin NR Grp2: Metformin + unspecified sulfonylurea NR			Def: Medical record for CHF + ICD-9 code for CHF + clinical diagnosis + first record Grp1: IR: 10.5 (CI: 6.7-16.2) Grp2: IR: 13.4 (CI: 11.6-15.5)			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Goldstein, 2003 ⁶²	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 2000 mg Grp2: Metformin + glipizide Varied Start: 500 mg, Max: 2000 mg; Start: 5 mg, Max: 20 mg					Def: Diarrhea Grp1: (17.3) Grp2: (13.1)	
Metformin versus metformin + DPP-IV inhibitors								
Jadzinsky, 2009 ⁷⁸	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 1000 mg D: 1 week Grp2: Metformin + saxagliptin Varied, prespecified dose Start: 500 mg, Max: 1000 mg; Start: 5 mg	Coll: Active Timing: Unspecified ITT: Yes Grp1: Severe: 0 (0) Mild/moderate: 13 (4) Grp2: Severe: 0 (0) Mild/moderate: 11 (3)				Def: Diarrhea Coll: Active Timing: Unspecified ITT: Yes Grp1: 24 (7) Grp2: 22 (7)	
Jadzinsky, 2009 ⁷⁸	RCT	Grp1: Metformin Varied Start: 500 mg, Max: 1000 mg D: 1 week Grp2: Metformin + saxagliptin Varied, prespecified dose Start: 500 mg, Max: 1000 mg; Start: 10 mg	Coll: Active Timing: Unspecified ITT: Yes Grp1: Severe: 0 (0) Mild/moderate: 13 (4) Grp2: Severe: 2 (1) Mild/moderate: 16 (5)				Def: Diarrhea Coll: Active Timing: Unspecified ITT: Yes Grp1: 24 (7) Grp2: 31 (10)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
DeFronzo, 2009 ⁹⁵	RCT	Grp1: Metformin Fixed Grp2: Metformin + saxagliptin Fixed NR; Mean: 10 mg	Grp1: Severe: 1 (1) Mild/moderate: 9 (5) Grp2: Severe: 1 (1) Mild/moderate: 7 (4)				Def: Diarrhea Coll: Active Timing: Unspecified ITT: Yes Grp1: 20 (11) Grp2: 10 (6)	
DeFronzo, 2009 ⁹⁵	RCT	Grp1: Metformin Fixed Grp2: Metformin + saxagliptin Fixed NR; Mean: 5 mg	Grp1: Severe: 1 (1) Mild/moderate: 9 (5) Grp2: Severe: 1 (1) Mild/moderate: 10 (5)				Def: Diarrhea Coll: Active Timing: Unspecified ITT: Yes Grp1: 20 (11) Grp2: 11 (6)	
DeFronzo, 2009 ⁹⁵	RCT	Grp1: Metformin Fixed Grp2: Metformin + saxagliptin Fixed NR; Mean: 2.5 mg	Grp1: Severe: 1 (1) Mild/moderate: 9 (5) Grp2: Severe: 1 (1) Mild/moderate: 15 (8)				Def: Diarrhea Coll: Active Timing: Unspecified ITT: Yes Grp1: 20 (11) Grp2: 19 (10)	
Williams-Herman, 2009 ⁷⁶	RCT	Grp1: Metformin Fixed Mean: 1000 mg bid Grp2: Metformin + sitagliptin Fixed Mean: 500 mg bid; Mean: 50 mg bid	Def: Mild or moderate Coll: Active Timing: Unspecified ITT: No Grp1: 2 (1) Grp2: 4 (2)				Def: Nausea; vomiting; diarrhea; abdominal pain; Nausea/Vomiting Coll: NR Timing: Unspecified ITT: No Grp1: (3; 0; 7; 4; 31) Grp2: (5; 2; 9; 3; 26)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Williams-Herman, 2009 ⁷⁶	RCT	Grp1: Metformin Fixed Mean: 1000 mg bid Grp2: Metformin + sitagliptin Fixed Mean: 1000 mg bid; Mean: 50 mg bid	Def: Mild or moderate Coll: Active Timing: Unspecified ITT: No Grp1: 2 (1) Grp2: 5 (3)				Def: Nausea; vomiting; diarrhea; abdominal pain; Nausea/Vomiting Coll: NR Timing: Unspecified ITT: No Grp1: (3; 0; 7; 4; 31) Grp2: (NR; 4; 13; 4; 29)	
Scott, 2008 ⁸⁵	RCT	Grp1: Metformin Fixed Start: ≥1500 mg Grp2: Metformin + sitagliptin Fixed Start: ≥1500 mg; Start: 100 mg	Def: Mild or moderate Coll: NR Timing: Unspecified ITT: No Grp1: 2 (2) Grp2: 1 (1)				Def: Diarrhea, nausea, abdominal pain, vomiting Coll: NR Timing: Unspecified ITT: No Grp1: (9) Grp2: (1)	
Raz, 2008 ⁹³	RCT	Grp1: Metformin Fixed Start: ≥1500 mg Grp2: Metformin + sitagliptin Fixed Start: ≥ 1500 mg; Start: 100 mg	Def: Mild or moderate Coll: NR Timing: Unspecified ITT: No Grp1: 0 (0) Grp2: 1 (1)			Def: Limb fracture Coll: NR Timing: Unspecified ITT: No Grp1: 1 (1) Grp2: 0 (0)	Def: abdominal pain, nausea, vomiting, or diarrhea Coll: NR Timing: Unspecified ITT: No Grp1: (7.4) Grp2: (10.4)	Def: Neoplasms Coll: NR Timing: Unspecified ITT: No Grp1: 3 (3) Grp2: 0 (0)

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Goldstein, 2007 ⁷⁵	RCT	Grp1: Metformin Fixed Start: 500 mg or 1000 mg bid Grp2: Metformin + sitagliptin Fixed Start: 500 mg or 1000 mg bid; Start: 50 mg bid	Def: Mild or moderate Grp1: 3 (2) Grp2: 6 (3)					
Charbonnel, 2006 ⁹⁴	RCT	Grp1: Metformin Varied, HbA1c: 7 - 10% Start: ≥1500 mg D: 19 wks Grp2: Metformin + sitagliptin Varied; Fixed Start: ≥1500 mg; Mean: 100 mg D: 19 wks	Def: Mild or moderate Grp1: 5 (2.1) Grp2: 6 (1.3)				Def: Abdominal pain, nausea, vomiting, or diarrhea Coll: NR Timing: Unspecified ITT: No Grp1: (10.5) Grp2: (11.9)	
Metformin versus metformin + meglitinides								
Horton, 2004 ⁸⁰	RCT	Grp1: Metformin Fixed Start: 500 mg tid Grp2: Metformin + nateglinide Fixed Start: 500 mg tid; Start: 120 mg ac	Def: Mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: Symptomatic: 11 (0.6), Confirmed ≤2.8 mmol/l: 1 (1.0) Grp2: Symptomatic: 26 (29.2), Confirmed ≤ 2.8mmol/l: 3 (3.4)				Def: Diarrhea Coll: Active Timing: Specified ITT: Yes Grp1: (20.2) Grp2: (16.9)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Marre, 2002 ⁹⁶	RCT	Grp1: Metformin Fixed Start: 1000 mg bid Grp2: Metformin + nateglinide Fixed Start: 1000 mg bid; Start: 60 mg ac	Def: Mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: Symptomatic: 6 (3.9), Confirmed: 1 (0.7) Grp2: Symptomatic: 13 (8.4), Confirmed: 0					
Marre, 2002 ⁹⁶	RCT	Grp1: Metformin Fixed Start: 1000 mg bid Grp2: Metformin + nateglinide Fixed Start: 1000 mg bid; Start: 120 mg ac	Def: Mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: Symptomatic: 6 (3.9), Confirmed: 1 (0.7) Grp2: Symptomatic: 25 (15.6), Confirmed: 5 (3.1)					
Moses, 1999 ⁸²	RCT	Grp1: Metformin NR Grp2: Metformin + repaglinide NR; Varied, glucose: 4.4-7.8 mmol/l NR; Start: 0.5 mg, Max: 4 mg	Def: Mild or moderate Coll: NR Timing: Unspecified ITT: NR Grp1: 0 Grp2: 9 (33.3)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Thiazolidinedione versus thiazolidinedione								
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Rosiglitazone NR Grp2: Pioglitazone NR			Def: ICD-9 codes Coll: NR Timing: NA ITT: NA Grp1: ref Grp2: HR: 1.19 (CI: 0.74 to 1.91)			
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Rosiglitazone NR Grp2: Pioglitazone NR			Def: ICD-9-CM diagnostic codes of hospitalization Coll: NR Timing: Unspecified ITT: NA Grp1: 67 (3.33) Grp2: 13 (2.66)			
Juurink, 2009 ²¹⁰	Cohort	Grp1: Rosiglitazone NR Grp2: Pioglitazone NR			Def: Congestive cardiac failure or heart failure hospitalization Coll: NR Timing: Unspecified ITT: NA Grp1: ref Grp2: HR: 0.77 (CI: 0.69 to 0.87)			
Hussein, 2004 ²⁰²	Cohort	Grp1: Rosiglitazone Fixed Start: 15-45 mg Grp2: Pioglitazone Fixed Start: 4-8 mg	Def: Mild or moderate Coll: Passive Timing: Unspecified Grp1: 11 (11) Grp2: 18 (17) Grp1-Grp2: p: NSG		Def: Pulmonary edema Coll: Passive Timing: Unspecified ITT: NR Grp1: 3 (3) Grp2: 2 (2)			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Rajagopalan, 2005 ²⁰⁶	Cohort	Grp1: Rosiglitazone NR Grp2: Pioglitazone NR		Def: ICD9 code liver failure or hepatitis Coll: Passive Timing: Unspecified ITT: NR Grp1: (0.4) Grp2: (0.5)				
Thiazolidinedione versus sulfonylurea								
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Rosiglitazone NR Grp2: Sulfonylurea NR			Def: ICD-9 codes Coll: NR Timing: NA ITT: NA Grp1: HR: 0.88 (CI: 0.60 to 1.31) Grp2: ref			
Pantalone, 2009 ¹⁷⁴	Cohort	Grp1: Pioglitazone NR Grp2: Sulfonylurea NR			Def: ICD-9 codes Coll: NR Timing: NA ITT: NA Grp1: HR: 1.05 (95% CI 0.77 to 1.43) Grp2: ref			
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Rosiglitazone NR Grp2: Sulfonylurea NR			Def: ICD-9-CM diagnostic codes of hospitalization Coll: NR Timing: Unspecified ITT: NA Grp1: 67 (3.33); Grp2: 1872 (1.97)			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Hsiao, 2009 ¹⁷³	Cohort	Grp1: Pioglitazone NR Grp2: Sulfonylurea NR			Def: ICD-9-CM diagnostic codes of hospitalization Coll: NR Timing: Unspecified ITT: NA Grp1: 13 (2.66) Grp2: 1872 (1.97)			
Dormuth, 2009 ²¹⁵	Cohort	Grp1: Thiazolidinedione NR Grp2: Sulfonylurea NR				Def: Hip fractures Coll: Passive Timing: Unspecified ITT: NA Grp1: HR: 1.28 (CI: 1.12 to 1.45) Grp2: ref		
Tolman, 2009 ¹⁵⁰	RCT	Grp1: Pioglitazone Varied, HbA1c < 7.5% Max: 45 mg Grp2: Glibenclamide Max: 15 mg	Coll: Active Timing: Specified ITT: Yes Grp1: 40 (4) Grp2: 119 (11)	Def: ALT > 3x ULN with repeat confirmation Coll: Active Timing: Specified ITT: Yes Grp1: 0 (0) Grp2: 4 (<1)	Coll: Active Timing: Specified ITT: Yes Grp1: 12 (1) Grp2: 11 (1)		Def: Diarrhea Coll: Active Timing: Specified ITT: Yes Grp1: 93 (9) Grp2: 80 (8)	Def: Cholecystitis Coll: Active Timing: Specified ITT: Yes Grp1: 4 (<1) Grp2: 4 (<1)

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Jain, 2006 ¹⁰¹	RCT	Grp1: Pioglitazone Varied, glucose: FPG (69-141 mg/dl) Start: 15 mg, Max: 45 mg, Median: 45 mg Grp2: Glyburide Varied, glucose: FPG: 69-141 mg/dl Start: 5 mg, Max: 15 mg, Median: 10 mg	Def: Mild or moderate Coll: Active Timing: Unspecified ITT: Yes Grp1: 11 (4.4) Grp2: 61 (24.3)			Def: Ankle Coll: Active Timing: No ITT: Yes Grp1: (0) Grp2: (0.8)	Def: diarrhea Coll: active Timing: Unspecified ITT: Yes Grp1: (6) Grp2: (6.4)	Def: stage IV colon ca Coll: active Timing: Unspecified ITT: Yes Grp1: 0 (0) Grp2: 2 (0.8)
Yamanouchi, 2005 ⁵⁰	RCT	Grp1: Pioglitazone Fixed Start: 30 mg for women and 45 mg for men Grp2: Glimepiride Varied Start: 1.0 mg, Max: 2.0	Grp1: Serious: 0 (0), Mild or moderate: 0 (0) Grp2: Serious: 0 (0), Mild or moderate: 1 (2.7)					
Tan, 2004 ¹⁰⁶	RCT	Grp1: Pioglitazone Varied Start: 30 mg, Max: 45 mg Grp2: Glibenclamide Varied Start: 1.75 mg, Max: 10.5 mg	Def: Symptoms or SMBG < 50 mg/dl Grp1: 4 (4) Grp2: 32 (29)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Hanefeld, 2007 ¹⁰⁰	RCT	Grp1: Rosiglitazone Fixed Start: 4 mg Grp2: Glibenclamide Varied Start: 2.5 mg, Max: 15 mg	Coll: NR Timing: Unspecified ITT: Yes Grp1: 1 (0.5) Grp2: Serious: 2 (<1), Mild or moderate: 23 (11)				Def: Unspecified Coll: NR Timing: Unspecified ITT: Yes Grp1: 11 (5.5) Grp2: 7 (3.4)	
Hanefeld, 2007 ¹⁰⁰	RCT	Grp1: Rosiglitazone Fixed Start: 8 mg Grp2: Glibenclamide Varied Start: 2.5 mg, Max: 15 mg D: 12 wks	Coll: NR Timing: Unspecified ITT: Yes Grp1: 3 (1.6) Grp2: Serious: 2 (<1), Mild or moderate: 23 (11)				Def: Unspecified Coll: NR Timing: Unspecified ITT: Yes Grp1: 5 (2.6) Grp2: 7 (3.4)	
St John Sutton, 2002 ¹⁴⁹	RCT	Grp1: Rosiglitazone Fixed Start: 4 mg Grp2: Glyburide Varied Start: NR, Max: 20 mg D: 8 weeks	Def: Signs and symptoms Grp1: (1.9) Grp2: (7.1)		Def: NR Grp1: 1 (1.0) Grp2: 0 (0)			
Asche, 2008 ²⁰⁰	Cohort	Grp1: Thiazolidinedione NR Grp2: Any in the Sulfonylurea class NR	Def: Mild or moderate Coll: NR Timing: Unspecified ITT: NR Grp1: 12 (1.7) Grp2: 55 (2.6)		Coll: NR Timing: Unspecified ITT: NR Grp1: 18 (2.6) Grp2: NR			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Kahn, 2006 ³⁸	RCT	Grp1: Rosiglitazone Varied, glucose: <140 mg/dl Start: 4 mg, Max: 8 mg Grp2: Glyburide Varied, glucose: <140 mg/dl Start: 2.5 mg, Max: 15 mg	Def: Self reported events Coll: NR Timing: Unspecified ITT: Yes Grp1: Serious events: 1 (0.1), Mild or moderate events: 142 (9.8) Grp2: Serious events: 8 (0.6), Mild or moderate events: 557 (38.7)		Def: Investigator reported events Coll: NR Timing: Unspecified ITT: Yes Grp1: All: 22 (1.5), Serious: 12 (0.8) Grp2: All: 9 (0.6), Serious: 3 (0.2), p: ≤ 0.05		Def: Nausea, vomiting, diarrhea, abdominal discomfort Grp1: (23) Grp2: (21.9)	
Agarwal, 2005 ¹⁸⁴	RCT	Grp1: Pioglitazone Varied, glucose: 140 mg/dL, HbA1c: 8% Start: 15 mg D: 16 wks Grp2: Glipizide Varied, glucose: 140 mg/dL, HbA1c: 8% Start: 5 mg D: 16 wks	Grp1: 2 events Grp2: 3 events		Grp1: 2 (2) Grp2: 2 (2)			
Karter, 2005 ²⁰⁷	Cohort	Grp1: Pioglitazone NR Grp2: Any sulfonylurea NR			Def: ICD-9-CM codes for primary discharge diagnosis Coll: Passive Timing: Unspecified ITT: NR Grp1: HR: 1.28 (CI: 0.85-1.92), p: 0.2 Grp2: ref			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Rajagopalan, 2005 ²⁰⁶	Cohort	Grp1: Rosiglitazone NR Grp2: Sulfonylurea NR		Def: ICD9 code liver failure or hepatitis Coll: Passive Timing: Unspecified ITT: NR Grp1: (0.4) Grp2: (1)				
Rajagopalan, 2005 ²⁰⁶	Cohort	Grp1: Pioglitazone NR Grp2: Sulfonylurea NR		Def: visit with ICD9 code liver failure or hepatitis Coll: Passive Timing: Unspecified ITT: NR Grp1: (0.5) Grp2: (1)				
Thiazolidinedione versus meglitinides								
Jovanovic, 2004 ¹¹⁰	RCT	Grp1: Pioglitazone Fixed Start: 30 mg Grp2: Repaglinide Varied Start: 0.5 mg if HbA1c<8% or 1 mg if HbA1c >8%, Max: 4 mg per meal D: 12 weeks	Def: Severe: needed assistance, Mild or moderate: <50mg/dl Grp1: Severe: 0, Mild or moderate: 2 (3) Grp2: Severe: 0, Mild or moderate: 5 (8)				Def: Diarrhea Grp1: (3) Grp2: (5)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Raskin, 2004 ¹⁰⁹	RCT	Grp1: Rosiglitazone Varied Start: 2 mg bid, Max: 4 mg bid D: 12 weeks Grp2: Repaglinide Varied Start: 0.5 mg per meal if HbA1c≤8% or 1 mg if >8%, Max: 4 mg per meal D: 12 weeks	Grp1: Severe: 0, Mild or moderate: 1 (2) Grp2: Severe: 0, Mild or moderate: 4 (6)					
Kahn, 2008 ²¹³	RCT	Grp1: Rosiglitazone Varied, glucose: <140 mg/dL Start dose: 4 mg, Max: 8 mg Grp2: Glyburide Varied, glucose: <140 mg/dL Start dose: 2.5 mg, Max: 15 mg				Def: Fractures (NS) Coll: NR Timing: Unspecified ITT: Yes Grp1: 1.86/100 patient-years HR: 1.61 (CI: 1.14-2.28), p: 0.0069 Grp2: 1.15/100 patient-years		

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Sulfonylurea versus DPP-IV inhibitors								
Scott, 2007 ¹¹¹	RCT	Grp1: Glipizide Varied, glucose: <160 mg/dl Start: 5 mg, Max: 20 mg D: 6 wks Grp2: Sitagliptin Fixed Start: 5 mg bid to 50 mg bid	Def: Mild or moderate Grp1: 21 (17.1) Grp2: 0 (0)					
Sulfonylurea versus meglitinides								
Jibrán, 2006 ¹¹²	RCT	Grp1: Glibenclamide Varied, FPG < 130 mg/dl, PPG < 175 mg/dl Start: 5 mg, Max: 15 mg Grp2: Repaglinide Varied, FPG < 130 mg/dl, PPG < 175 mg/dl Start: 0.5 mg TDS, Max: 1.5 mg TDS	Def: Mild, moderate or severe Grp1: 0 (0) Grp2: 0 (0)					
Vakkilainen, 2002 ¹¹⁹	RCT	Grp1: Glibenclamide Varied Start: 5 mg, Max: 10 mg Grp2: Nateglinide Fixed Start: 120 mg tid	Grp1: 3 (12.5) Grp2: 0 (0)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Madsbad, 2001 ¹¹⁴	RCT	Grp1: Glipizide Varied Start: 5 mg, Max: 15 mg Grp2: Repaglinide Varied Start: 0.5 mg, Max: 4.0 mg tid	Def: Severe Grp1: 0 (0) Grp2: 0 (0)					
Landgraf, 1999 ¹¹⁵	RCT	Grp1: Glibenclamide Varied Max: 10.5 mg Grp2: Repaglinide Varied Max: 4.0 mg tid	Def: Mild or moderate Grp1: 9 (9.0) Grp2: 9 (9.6)					
Marbury, 1999 ¹¹⁷	RCT	Grp1: Glyburide Varied Start: 2.5 mg, Max: 15mg Grp2: Repaglinide Varied Start: 0.5 mg, Max: 12 mg	Grp1: Severe: 2 (1), Mild or moderate: 35 (18) Grp2: Severe: 5 (1), Mild or moderate: 54 (14)					
Wolffenbuttel, 1999 ¹¹⁶	RCT	Grp1: Glyburide Varied Start: 1.75 mg, Max: 10.5 mg D: 6-8 weeks Grp2: Repaglinide Varied Start: 1.5 mg, Max: 12.0 mg D: 6-8 weeks	Def: Mild or moderate Grp1: 13 (9) Grp2: 26 (9)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Wolffenbuttel, 1993 ¹¹⁸	RCT	Grp1: Glibenclamide Varied Start: 5 mg, Max: 15 mg Grp2: Repaglinide Varied Start: 0.5 mg, Max: 4 mg tid	Grp1: Severe: 0 (0), Mild or moderate: 1 (7) Grp2: Severe: 0 (0), Mild or moderate: 0 (0)					
Sulfonylurea versus GLP-1 agonists								
Seino, 2010 ¹²¹	RCT	Grp1: Glibenclamide Varied, prespecified dose Start: 1.25 mg; Max: 2.5 mg D: 4 weeks Grp2: Liraglutide Varied, prespecified dose Start: 0.3 mg; Max: 0.9 mg D: 2 weeks	Coll: Passive Timing: Unspecified ITT: No Grp1: Symptoms: 45 (34.1); 228 events; IR: 3.927/year Severe: 0 (0) Grp2: Symptoms: 36 (13.4) 61 events; IR: 0.525/year Severe: 0 (0)				Def: Diarrhea; Constipation Coll: NR Timing: Unspecified ITT: No Grp1: (3.8; 3.8) Grp2: (6.3; 5.6)	Def: Pancreatitis Coll: NR Timing: Unspecified ITT: No Grp1: 0 (0) Grp2: 0 (0)
Garber, 2009 ¹²²	RCT	Grp1: Glimpiride Varied, prespecified dose Start: 2 mg, Max: 8 mg D: 2 weeks Grp2: Liraglutide Varied, prespecified dose Start: 0.6 mg, Max: 1.8 mg D: 2 weeks	Def: Not requiring assistance, PG < 3.1 mmol/L Coll: NR Timing: Unspecified ITT: No Grp1: 24 events Grp2: 8 events				Def: Total GI events; Nausea and vomiting Coll: Passive Timing: Unspecified ITT: No Grp1: (26, 51) Grp2: (12, 38)	Def: Pancreatitis Coll: Passive Timing: Unspecified ITT: No Grp1: 0 (0) Grp2: 1 (<1)

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Garber, 2009 ¹²²	RCT	Grp1: Glimpiride Varied, prespecified dose Start: 2 mg, Max: 8 mg D: 2 weeks Grp2: Liraglutide Varied, prespecified dose Start: 0.6 mg, Max 1.2 mg D: 2 weeks	Def: Not requiring assistance, PG < 3.1 mmol/L Coll: NR Timing: Unspecified ITT: No Grp1: 24 events Grp2: 12 events				Def: Total GI events; Nausea and vomiting Coll: Passive Timing: Unspecified ITT: No Grp1: (26, 49) Grp2: (12, 39)	Def: Pancreatitis Coll: Passive Timing: Unspecified ITT: No Grp1: 0 (0) Grp2: 1 (<1)
Madsbad, 2004 ¹²⁰	RCT	Grp1: Glimpiride Varied, FPG < 7 mmol/L Start: 1 mg; Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.75 mg	Def: Glucose < 2.8 mmol/L Coll: Active Timing: Specified ITT: Yes Grp1: 4 (15) Grp2: 0 (0)					
Madsbad, 2004 ¹²⁰	RCT	Grp1: Glimpiride Varied, FPG < 7 mmol/L Start: 1 mg; Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.60 mg	Def: Glucose < 2.8 mmol/L Coll: Active Timing: Specified ITT: Yes Grp1: 4 (15) Grp2: 1 (3)					
Madsbad, 2004 ¹²⁰	RCT	Grp1: Glimpiride Varied, FPG < 7 mmol/L Start: 1 mg; Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.45 mg	Def: Glucose < 2.8 mmol/L Coll: Active Timing: Specified ITT: Yes Grp1: 4 (15) Grp2: 0 (0)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Madsbad, 2004 ¹²⁰	RCT	Grp1: Glimpiride Varied, FPG < 7 mmol/L Start: 1 mg; Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.225 mg	Def: Glucose < 2.8 mmol/L Coll: Active Timing: Specified ITT: Yes Grp1: 4 (15) Grp2: 0 (0)					
Madsbad, 2004 ¹²⁰	RCT	Grp1: Glimpiride Varied, FPG < 7 mmol/L Start: 1 mg; Max: 4 mg D: 4 weeks Grp2: Liraglutide Fixed Mean: 0.045 mg	Def: Glucose < 2.8 mmol/L Coll: Active Timing: Specified ITT: Yes Grp1: 4 (15) Grp2: 0 (0)					
Metformin + thiazolidinedione versus metformin + sulfonylurea								
Hamann, 2008 ¹²³	RCT	Grp1: Metformin + rosiglitazone Varied, glucose: 6.1 mmol/l Max: 2 g; Start: 4 mg, Max: 8 mg D: 12 wks Grp2: Metformin + sulfonylurea Varied, glucose: 6.1 mmol/l Max: 2 g; Start: 5 mg, Max: 15 mg D: 12 wks	Def: Mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: 18 (6) Grp2: 90 (30)				Coll: Active Timing: Specified ITT: Yes Grp1: (13) Grp2: (18)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Comaschi, 2007 ¹²⁹	RCT	Grp1: Metformin + pioglitazone Varied Max: 3 g; Start: 15 mg, Max: 30 mg D: NR, 22 wks Grp2: Metformin + sulfonylurea Varied, HbA1c: 7.50% Start: 400 mg, Max: 3 g; Start: 2.5 mg D: 22 wks	Def: Mild or moderate Grp1: 0 (0) Grp2: 1 (1)					
Bakris, 2006 ¹²⁵	RCT	Grp1: Metformin + rosiglitazone Varied, glucose: ≤6.6 mmol/L Unclear; Start: 4 mg D: 3 wks Grp2: Metformin + glyburide Varied, glucose: ≤6.6 mmol/L Unclear; Start: 5 mg D: 3 wks	Def: Mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: 2 (1) Grp2: 22 (12)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Umpierrez, 2006 ¹²⁶	RCT	Grp1: Metformin + pioglitazone Varied, glucose: <120 mg/dl, HbA1c: <8.0% Start: 1.54 g, Max: 1.57 g; Start: 30 mg, Max: 45 mg Grp2: Metformin + glimepiride Varied, glucose: <120 mg/dL Start: 1.47 g, Max: 1.49 g; Start: 2 mg, Max: 8 mg D: NR, 6 wks	Def: mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: 10 (9) Grp2: 32 (33)				Def: Diarrhea Coll: Active Timing: Specified ITT: Yes Grp1: (4.7) Grp2: (6)	
Garber, 2006 ¹²⁸	RCT	Grp1: Metformin + rosiglitazone Varied Start: 1500 or 2000 mg, Max: 2000 mg; Start: 4 mg, Max: 8 mg Grp2: Metformin + glibenclamide Varied Start: 1000 mg, Max: 2000; Start: 5 mg, Max: 10 mg	Grp1: Severe: 0 (0), Mild or moderate: 2 (1) Grp2: Severe: 7 (4), Mild or moderate: 53 (33)				Def: Diarrhea + abdominal pain + other GI symptoms; Diarrhea; Abdominal pain Grp1: (10; 3; 4) Grp2: (11; 6; 6)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Hanefeld, 2006 ²⁰¹	RCT	Grp1: Metformin + pioglitazone Fixed; Varied Mean: 1900 mg; Start: 30 mg, Max: 45 mg Grp2: Metformin + glibenclamide NR; Varied Mean: 1900 mg; Start: 3.5 mg, Max: 5 mg	Def: Severe Coll: NR Timing: Unspecified ITT: NR Grp1: 5 (2) Grp2: 34 (14)					
Yang, 2003 ¹³⁹	RCT	Grp1: Metformin + sulfonylurea Fixed Grp2: Rosiglitazone + sulfonylurea Fixed		Def: AST or ALT 3 x ULN Coll: NR Timing: Unspecified ITT: NR Grp1: 0 (0) Grp2: 0 (0)				
Derosa, 2005 ¹⁵⁹	RCT	Grp1: Metformin + rosiglitazone Fixed Start: 1500 mg; Start: 4 mg Grp2: Metformin + glimepiride Fixed Start: 1500 mg; Start: 2 mg					Def: Transient flatulence Grp1: (4.2) Grp2: (2.1)	
Metformin + thiazolidinedione versus metformin + meglitinides								

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Raskin, 2009 ¹³¹	RCT	Grp1: Metformin + rosiglitazone Varied, prespecified target dose Start: 1000 mg, Max: 2500 mg; Start: 4, Max: 8 mg D: 4 wks Grp2: Metformin + repaglinide Varied Start: 1000 mg, Max: 2500 mg; Start: 4 mg, Max: 10 mg D: 4 wks	Coll: Active Timing: Specified ITT: NR Grp1: Severe: 0 (0), Mild or moderate: 1 (1) Grp2: Severe: 0 (0), Mild or moderate: 8 (4)					Def: Macular edema Grp1: 2 (1) Grp2: 0 (0)
Metformin + thiazolidinedione versus metformin + DPP-IV inhibitors								
Scott, 2008 ⁸⁵	RCT	Grp1: Metformin + rosiglitazone Fixed Start: > 1500 mg; Mean: 8 mg D: 10 wks Grp2: Metformin + sitagliptin Fixed Start: > 1500 mg; Mean: 100 mg D: 10 wks	Def: Mild or moderate Coll: NR Timing: Unspecified ITT: No Grp1: 1 (1) Grp2: 1 (1)				Def: Diarrhea, nausea, abdominal pain, vomiting Coll: NR Timing: Unspecified ITT: No Grp1: (7) Grp2: (1)	
Metformin + thiazolidinedione versus metformin + GLP-1 agonists								

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
DeFronzo, 2010 ¹³²	RCT	Grp1: Metformin + rosiglitazone Varied, prespecified dose NR: Start: 4 mg; Max: 8 mg Grp2: Metformin + exenatide Varied, prespecified dose NR: Start: 0.010 mg; Max: 0.02 mg BID D: 2 months	Coll: NR Timing: Unspecified ITT: No Grp1: Severe: 0 (0); Mild/moderate: 0 (0) Grp2: Severe: 0 (0); Mild/moderate: 2 (4)				Def: Vomiting; Diarrhea Coll: NR Timing: Unspecified ITT: No Grp1: (0; 9) Grp2: (49; 16)	
Metformin + thiazolidinedione versus thiazolidinedione + sulfonylurea								
Comaschi, 2007 ¹²⁹	RCT	Grp1: Metformin + pioglitazone Varied Max: 3 g; Start: 15 mg, Max: 30 mg D: NR; 22 wks Grp2: Pioglitazone + sulfonylurea Varied, HbA1c: 7.50% Start: 15 mg, Max: 30 mg; Unclear D: 22 wks; NR	Def: Mild or moderate Grp1: 0 (0) Grp2: 0 (0)					
Rosak, 2006 ¹⁸³	Cohort	Grp1: Metformin + rosiglitazone NR Unclear; Start: 4mg, Max: 8mg Grp2: Rosiglitazone + sulfonylurea Varied Start: 4mg, Max: 8mg; NR	Def: Hypoglycemic events Coll: Active Timing: Specified ITT: Yes Grp1: 0.05/100 patient-years Grp2: 0.47/100 patient-years		Def: Investigator reported Coll: Active Timing: Specified ITT: Yes Grp1: 0.13/100 patient-years Grp2: 0.47/100 patient-years			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Derosa, 2005 ¹²⁷	RCT	Grp1: Metformin + rosiglitazone Fixed Start dose: 500 mg tid, Max: 500 mg tid; Start dose: 4mg, Max: 4 mg Grp2: Metformin + glimepiride Fixed Start dose: 500 mg tid, Max: 500 mg tid; Start dose: 2 mg, Max: 2 mg		Def: Transiently elevated LFT to 1.5 times upper limit of normal Coll: NR Timing: Unspecified ITT: NR Grp1: 3 events out of 48 participants Grp2: NR				

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Metformin + sulfonylurea versus metformin + meglitinides								
Dimic, 2009 ¹⁹⁹	Non-randomized trial	Grp1: Metformin + glimepiride Fixed NR Grp2: Metformin + repaglinide Fixed Mean: 2000 mg; Mean: 6 mg	Coll: Active Timing: Specified ITT: NR Grp1: 7 (23) Grp2: 5 (17)					
Schwarz, 2008 ¹⁵²	RCT	Grp1: Metformin + glyburide Varied, glucose: <120 mg/dL Start: 500 mg, Max: 2000 mg; Start: 1.25 mg, Max: 10 mg D: 12 wks Grp2: Metformin + nateglinide Varied, glucose: <120 mg/dL Start: 500 mg, Max: 2000 mg; Start: 360 mg, Max: 360 mg D: 12 wks	Def: Severe Coll: Active Timing: Specified ITT: Yes Grp1: 1 (3) Grp2: 0 (0)				Def: Diarrhea Coll: Active Timing: Specified ITT: Yes Grp1: (20) Grp2: (22.9)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Gerich, 2005 ¹³⁶	RCT	Grp1: Metformin + glyburide Varied, glucose: FPG ≥6.7 mmol/L Start: 500 mg, Max: 2000 mg, Mean: 1105 mg; Start: 1.25 mg, Max: 10 mg, Mean: 5.1 mg D: 12 wks Grp2: Metformin + nateglinide Varied, glucose: FPG ≥6.7 mmol/L; Fixed Start: 500 mg, Max: 2000 mg, Mean: 1459 mg; Start: 120 mg, Mean: 357 mg D: 12 wks	Def: Severe Coll: NR Timing: Unspecified ITT: Yes Grp1: Mild or moderate:38 (18); Severe: 2 (1) Grp2: Mild or moderate:18 (8); Severe: 0 (0)					
Metformin + sulfonylurea versus metformin + DPP-IV inhibitors								
Seck, 2010 ¹³⁴	RCT	Grp1: Metformin + sitagliptin Fixed NR Grp2: Metformin + glipizide Fixed; Varied NR; Start: 5 mg, Max: 20 mg; Mean: 9.2 mg	Coll: Active Timing: Specified ITT: Yes Grp1: Severe: 18 (3) Mild/moderate: 31 (5.3) Grp2: Severe: 2 (<1) Mild/moderate: 199 (34.1)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Nauck, 2007 ¹³³	RCT	Grp1: Metformin + glipizide Varied; Varied, glucose: <6.1 mmol/l NR; Start: 5 mg, Max: 20 mg D: NR, 18 wks Grp2: Metformin + sitagliptin Varied; Fixed NR	Def: Severe Coll: Active Timing: Specified ITT: Yes Grp1: 7 (1) Grp2: 1 (<1)				Def: Diarrhea, abdominal pains, nausea, vomiting Coll: Active Timing: Specified ITT: Yes Grp1: 69 (12) Grp2: 70 (12)	
Metformin + sulfonylurea versus metformin + GLP-1 agonists								
Derosa, 2010 ⁴⁴	RCT	Grp1: Metformin + glibenclamide NR Mean: 1500 mg; Start: 7.5 mg; Max: 15 mg Grp2: Metformin + exenatide NR NR; Start: 10 mcg; Max: 20 mcg	Def: FPG < 60 mg/dL Coll: Active Timing: Specified ITT: No Grp1: 3 (5) Grp2: 0 (0)				Def: Vomiting; Diarrhea Coll: Active Timing: Specified ITT: No Grp1: (2; 2) Grp2: (2; 3)	
Nauck, 2009 ⁹²	RCT	Grp1: Metformin + glimepiride Fixed; Varied Mean: 2000 mg; Start: 1 mg; Max: 4 mg Grp2: Metformin + liraglutide Fixed; Varied Start: 0.6 mg; Max: 1.8 mg	Coll: Passive Timing: Unspecified ITT: Yes Grp1: Severe: 0 (0) Mild/moderate: (17) Grp2: Grp1: Severe: 0 (0) Mild/moderate: (3)				Def: Nausea, vomiting, and diarrhea Coll: Passive Timing: Unspecified ITT: Yes Grp1: (17) Grp2: (44)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Nauck, 2009 ⁹²	RCT	Grp1: Metformin + glimepiride Fixed; Varied Mean: 2000 mg; Start: 1 mg; Max: 4 mg Grp2: Metformin + liraglutide Fixed; Varied Start: 0.6 mg; Max: 1.2 mg	Coll: Passive Timing: Unspecified ITT: Yes Grp1: Severe: 0 (0) Mild/moderate: (17) Grp2: Grp1: Severe: 0 (0) Mild/moderate: (3)				Def: Nausea, vomiting, and diarrhea Coll: Passive Timing: Unspecified ITT: Yes Grp1: (17) Grp2: (40)	
Metformin + sulfonylurea versus metformin + premixed insulin								
Malone, 2003 ¹³⁷	RCT	Grp1: Metformin + glibenclamide Varied, glucose: fasting and pre-meal <7mmol.L, 2-hour post-prandial <10mmol/L Max: 2550 mg, Mean: 1968 mg; Mean: 14.2 mg D: 4 wks Grp2: Metformin + lispro 75/25 fasting and pre-meal <7mmol.L, 2-hour post-prandial <10mmol/L Max: 2550 mg; Mean: 0.19U/kg in am and 0.14 U/kg in evening D: 4 wks	Def: Symptomatic or BG <3.5mmol/l Timing: Unspecified ITT: NR Grp1: (1) Grp2: (1.3)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Kvapil, 2006 ¹³⁸	RCT	Grp1: Metformin + glibenclamide Fixed; Varied Mean: 1660 mg; Start: 1.75 mg, Max: 10.5 mg, Mean: 6.58 mg Grp2: Metformin + aspart 70/30 Fixed; Varied, glucose: 5 - 8 mmol/L Mean: 1660 mg; Start: 0.2 U/kg bid, Mean: 0.30 U/kg bid	Coll: NR Timing: Unspecified ITT: Yes Grp1: Severe: 0, Mild or moderate: 9 (8) Grp2: Severe: 0, Mild or moderate: 13 (12)					
Metformin + sulfonylurea versus thiazolidinedione + sulfonylurea								
van der Meer, 2009 ¹⁴¹	RCT	Grp1: Metformin + glimepiride Fixed; Varied Start: 1000 mg, Max: 2000 mg; NR D: NR; 8 wks Grp2: Pioglitazone + glimepiride Fixed, Varied Start: 15 mg, Max: 30 mg; NR D: 2 wks; NR			Grp1: 0 (0) Grp2: 0 (0)			

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Seufert, 2008 ¹⁴²	RCT	Grp1: Metformin + sulfonylurea Fixed Max: 2550 mg, Mean: 2081 mg; NR D: 12 wks Grp2: Pioglitazone + sulfonylurea Fixed Max: 45 mg, Mean: 37 mg; NR D: 12 wks	Coll: NR Timing: Unspecified ITT: NR Grp1: 50 (22) Grp2: 36 (17)				Def: Diarrhea Coll: NR Timing: Unspecified ITT: NR Grp1: (14.4) Grp2: (3.4)	
Hanefeld, 2004 ¹⁴⁰	RCT	Grp1: Metformin + sulfonylurea Varied; Fixed Start: 850 mg, Max: 2550 mg; NR D: 12 wks Grp2: Pioglitazone + sulfonylurea Varied; Fixed Start: 15 mg (Max: 45 mg; NR D: 12 wks	Def: Serious Grp1: 0 (0) Grp2: 0 (0)				Def: Diarrhea Grp1: (12.2) Grp2: (23.4)	
Yang, 2003 ¹³⁹	RCT	Grp1: Metformin + sulfonylurea Fixed Start: 1000 mg; NR Grp2: Rosiglitazone + sulfonylurea Fixed Start: 4mg; NR					Def: Diarrhea Grp1: NR Grp2: 2 cases	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Metformin + DPP-IV inhibitor versus metformin + GLP-1 agonist								
Pratley, 2010 ¹⁴³	RCT	Grp1: Metformin + sitagliptin Varied, HbA1c : 7.5% - 10% NS; Max: 100 mg Grp2: Metformin + liraglutide Varied, HbA1c: 7.5% - 10% NS; Start: 0.6 mg Max: 1.2 mg					Def: GI events Coll: NR Timing: Unspecified ITT: No Grp1: 4 (2) Grp2: 3 (1)	Def: Neoplasm Coll: NR Timing: Unspecified ITT: No Grp1: 1 (<1) Grp2: 0 (0) Def: Pancreatitis Grp1: 0 (0) Grp2: 0 (0)
Pratley, 2010 ¹⁴³	RCT	Grp1: Metformin + sitagliptin Varied, HbA1c : 7.5% - 10% NS; Max: 100 mg Grp2: Metformin + liraglutide Varied, HbA1c: 7.5% - 10% NS; Start: 0.6 mg Max: 1.8 mg					Def: GI events Coll: NR Timing: Unspecified ITT: No Grp1: 4 (2) Grp2: 3 (1)	Def: Neoplasm Coll: NR Timing: Unspecified ITT: No Grp1: 1 (<1) Grp2: 1 (<1) Def: Pancreatitis Grp1: 0 (0) Grp2: 0 (0)

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Metformin + GLP-1 agonist versus metformin + basal insulin								
Bunck, 2009 ¹⁴⁴	RCT	Grp1: Metformin + exenatide Fixed; Varied, HbA1c: 7.1%-7.5% Mean: 2058 mg; Start: 5 ug bid, 20 ug tid Grp2: Metformin + glargine Fixed; Varied, SMBG: 4.5-5.5 mmol/L Mean: 1798 mg; Start: 10 U, Mean: 33.6 U qd	Def: <3.3mmol/L Coll: Active Timing: Unspecified ITT: NR Grp1: (8.3) Grp2: (24.2)				Def: Mild to moderate nausea, vomiting, diarrhea Grp1: NR Grp2: (50)	Def: Pancreatitis Grp1: 1 (3) Grp2: 0 (0)
Metformin + basal insulin versus metformin + premixed insulin								
Davies, 2007 ¹⁴⁷	RCT	Grp1: Metformin + NPH Varied, glucose < 6.0 mmol/L NR; Start: 10 IU/kg; Mean: 0.58 IU/kg D: 6 weeks Grp2: Metformin + BHI 70/30 Varied, glucose < 6.0 mmol/L NR; Start: 10 IU bid, Mean: 0.63 IU bid	Def: Clinical hypoglycemia Coll: Active Timing: Specified ITT: NR Grp1: (25) Grp2: (29.6)					

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Raskin, 2007 ¹⁴⁶	RCT	Grp1: Metformin + glargine Fixed; Varied, premeal glucose: 4.4 - 6.1mmol/L NR; Start: 12 U/kg QD, Mean: 0.57 IU/kg QD Grp2: Metformin + aspart 70/30 Fixed; Varied, premeal glucose: 4.4 - 6.1mmol/L NR; Start: 12 IU/kg BID, Mean: 0.91 IU/kg	Def: mild or moderate Coll: Active Timing: Specified ITT: Yes Grp1: 11 (14) Grp2: 33 (42)					
Robbins, 2007 ¹⁴⁵	RCT	Grp1: Metformin + glargine Fixed; Varied, glucose: <6.7 mmol/l Start: 500 mg bid, Max: 1000 mg bid, Mean: 1636 mg; Mean: 0.6 U/kg QD Grp2: Metformin + insulin lispro 50/50 Fixed; Varied, glucose: <6.7 mmol/l Start: 500 mg bid, Max: 1000 mg bid, Mean: 1641 mg; Mean: 0.7 U/kg tid	Def: Coll: Active Timing: Specified ITT: Yes Grp1: Severe: 2 (1), Mild or moderate: 75 (47) Grp2: Severe: 3 (2), Mild or moderate: 79 (50)				Def: Diarrhea Coll: Active Timing: Specified ITT: Yes Grp1: (5.7) Grp2: (6.4)	

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Malone, 2005 ¹⁶⁵	RCT	<p>Grp1: Metformin + lispro 75/25 Varied, pre-meal glucose 90-126 mg/dL 2-hr PPG 144-180 mg/dL Start: 1500 mg; Max: 2550 mg; Mean: 2146 mg; Mean: 0.42 U/kg bid D: 4 weeks; 16 weeks</p> <p>Grp2: Metformin + glargine Varied, glucose 90-126 mg/dL Start: 1500 mg; Max: 2550 mg; Mean: 2146 mg; Mean: 0.36 U/kg qd D: 4 weeks; 16 weeks</p>	<p>Def: Overall Coll: Active Timing: Specified ITT: NR Grp1: 0.61 episodes/patient/30 days Grp2: 0.44 episodes/patient/30 days</p>					


Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3) (continued)

Author, year	Study design	Intervention	Hypoglycemia, n (%)	Liver failure, n (%)	Congestive heart failure, n (%)	Fractures, n (%)	GI side effects, n (%)	Other, n (%)
Malone, 2004 ¹⁶⁴	RCT	Grp1: Metformin + glargine Fixed; Varied, glucose: 90 – 126 mg/dL Start: 1500 mg, Max: 2550 mg; Mean: 0.57 U/kg qd Grp2: Metformin + lispro 75/25 Varied, glucose: 90 – 126 mg/dL Start: 1500 mg, Max: 2550 mg; Mean: 0.62 U/kg bid	Def: Coll: Active Timing: Specified ITT: Yes Grp1: Severe: 0 (0), Mild or moderate: 40 (40) Grp2: Severe: 0 (0), Mild or moderate: 57 (57)		Coll: Active Timing: Specified ITT: Yes Grp1: 0 (0) Grp2: 1 (1)			

D = duration; Def = definition; DPP-4 = dipeptidyl peptidase-4; dys = days; fsg = fasting serum glucose; GLP-1 = glucagon-like peptidase-1; Grp = group; HR = hazard ratio; ICD = International Classification Disease; IR = incident rates; ITT = intention to treat; mg/day = milligram per day; mg/dl = milligrams/deciliter; mg = milligram; mmol/l = millimoles per liter; NR = not reported; NSG = non significant; od = once a day; SU = sulfonylurea; tid = twice a day; wks = weeks

Appendix H. Summary of Updated Literature Search for Long-Term Clinical Trials (Number of Articles)

Table 12. Comparative effectiveness of diabetes medications on adverse events (KQ3)



* Total may exceed number in corresponding box, as articles could be excluded for more than one reason at this level.
 CENTRAL = Central Register of Controlled Trials; CINAHL = Cumulative Index to Allied Health and Nursing Literature; FDA = U.S. Food and Drug Administration